PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Messaoudi, I; Guevara-Patino, JA; Dyall, R; LeMaoult, J; Nikolich-Zugich, J				Messaoudi, I; Guevara-Patino, JA; Dyall, R; LeMaoult, J; Nikolich-Zugich, J			Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense	SCIENCE			English	Article							HERPES-SIMPLEX-VIRUS; CLASS-I; CTL RESPONSE; RECOGNITION; INFECTION; SITE; SPECIFICITY; ADVANTAGE; SELECTION; MICE	Major histocompatibility complex (mhc)-encoded molecules govern immune responses by presenting antigenic peptides to T cells. The extensive polymorphism of genes encoding these molecules is believed to enhance immune defense by broadening the array of antigenic peptides available for T cell recognition, but direct evidence supporting the importance of this mechanism in combating pathogens is limited. Here we link mhc polymorphism-driven diversification of the cytotoxic T lymphocyte (CTL) repertoire to the generation of high-avidity, protective antiviral T cells and to superior antiviral defense. Thus, much of the beneficial effect of the mhc polymorphism in immune defense may be due to its critical influence on the properties of the selected CTL repertoire.	Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA; Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon National Primate Research Center; Memorial Sloan Kettering Cancer Center	Nikolich-Zugich, J (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA.	nikolich@ohsu.edu	LeMaoult, Joel/E-9583-2011; Guevara, Jose/AAD-6707-2020	Nikolich-Zugich, Janko/0000-0001-5830-5323	NATIONAL CANCER INSTITUTE [R01CA086803] Funding Source: NIH RePORTER; NCI NIH HHS [CA-86803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bertoni R, 1997, J CLIN INVEST, V100, P503, DOI 10.1172/JCI119559; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BONNEAU RH, 1993, VIROLOGY, V195, P62, DOI 10.1006/viro.1993.1346; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Cose SC, 1997, EUR J IMMUNOL, V27, P2310, DOI 10.1002/eji.1830270927; COSE SC, 1995, J VIROL, V69, P5849, DOI 10.1128/JVI.69.9.5849-5852.1995; Dyall R, 1996, J EXP MED, V184, P253, DOI 10.1084/jem.184.1.253; Dyall R, 2000, J IMMUNOL, V164, P1695, DOI 10.4049/jimmunol.164.4.1695; Ehl S, 1997, EUR J IMMUNOL, V27, P3404, DOI 10.1002/eji.1830271240; FINK PJ, 1995, ADV IMMUNOL, V59, P99, DOI 10.1016/S0065-2776(08)60630-6; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Gallimore A, 1998, J EXP MED, V187, P1647; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; Goldsmith K, 1998, J EXP MED, V187, P341, DOI 10.1084/jem.187.3.341; HANKE T, 1991, J VIROL, V65, P1177, DOI 10.1128/JVI.65.3.1177-1186.1991; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; KAUFMAN J, 1995, IMMUNOL REV, V143, P63, DOI 10.1111/j.1600-065X.1995.tb00670.x; LAWLOR DA, 1990, ANNU REV IMMUNOL, V8, P23, DOI 10.1146/annurev.iy.08.040190.000323; Liu T, 2000, J EXP MED, V191, P1459, DOI 10.1084/jem.191.9.1459; Malherbe L, 2000, IMMUNITY, V13, P771, DOI 10.1016/S1074-7613(00)00075-3; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; Messaoudi I, 2001, J IMMUNOL, V167, P836, DOI 10.4049/jimmunol.167.2.836; MOSKOPHIDIS D, 1994, J IMMUNOL, V152, P4976; NASH AA, 1993, SEMIN VIROL, V4, P181, DOI 10.1006/smvy.1993.1013; NATHENSON SG, 1986, ANNU REV IMMUNOL, V4, P471, DOI 10.1146/annurev.iy.04.040186.002351; Penn DJ, 2002, P NATL ACAD SCI USA, V99, P11260, DOI 10.1073/pnas.162006499; POTTS WK, 1995, IMMUNOL REV, V143, P181, DOI 10.1111/j.1600-065X.1995.tb00675.x; ROUSE BT, 2000, HERPES S1, V8, pA2; SPEISER DE, 1992, J IMMUNOL, V149, P972; Turner SJ, 1998, MOL IMMUNOL, V35, P307, DOI 10.1016/S0161-5890(98)00051-0; Wallace ME, 1999, J VIROL, V73, P7619, DOI 10.1128/JVI.73.9.7619-7626.1999	32	252	255	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1797	1800		10.1126/science.1076064	http://dx.doi.org/10.1126/science.1076064			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459592				2022-12-28	WOS:000179494800048
J	Arseneault, L; Cannon, M; Poulton, R; Murray, R; Caspi, A; Moffitt, TE				Arseneault, L; Cannon, M; Poulton, R; Murray, R; Caspi, A; Moffitt, TE			Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study	BRITISH MEDICAL JOURNAL			English	Article									Kings Coll London, SGDP Res Ctr, London SE5 8AF, England; Kings Coll London, Div Psychol Med, London WC2R 2LS, England; Univ Otago, Dunedin Multidisciplinary Hlth & Dev Res Unit, Dunedin, New Zealand	University of London; King's College London; University of London; King's College London; University of Otago	Moffitt, TE (corresponding author), Kings Coll London, SGDP Res Ctr, London SE5 8AF, England.	t.moffitt@iop.kcl.ac.uk	Moffitt, Terrie E/D-5295-2011; caspi, avshalom/D-5294-2011; Young, Alexander/A-1523-2009; caspi, avshalom/AAJ-5874-2020; Arseneault, Louise/ABE-7205-2020; Cannon, Mary/D-8227-2012; murray, robin/F-8658-2012	Moffitt, Terrie E/0000-0002-8589-6760; caspi, avshalom/0000-0003-0082-4600; Young, Alexander/0000-0002-9367-9213; caspi, avshalom/0000-0003-0082-4600; Cannon, Mary/0000-0002-0910-299X; murray, robin/0000-0003-0829-0519; Arseneault, Louise/0000-0002-2938-2191	NIMH NIH HHS [MH49414, R01 MH045070, R01 MH049414, MH45070] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH049414, R01MH049414, R01MH045070] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREASSON S, 1987, LANCET, V2, P1483, DOI 10.1016/s0140-6736(87)92620-1; Fergusson DM, 1997, ADDICTION, V92, P279; Poulton R, 2000, ARCH GEN PSYCHIAT, V57, P1053, DOI 10.1001/archpsyc.57.11.1053; Silva P., 1996, CHILD ADULT DUNEDIN; Strang J, 2000, BMJ-BRIT MED J, V320, P108, DOI 10.1136/bmj.320.7227.108	5	876	894	10	227	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 23	2002	325	7374					1212	1213		10.1136/bmj.325.7374.1212	http://dx.doi.org/10.1136/bmj.325.7374.1212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	619YU	12446537	Bronze, Green Published			2022-12-28	WOS:000179506200020
J	Horng, T; Barton, GM; Flavell, RA; Medzhitov, R				Horng, T; Barton, GM; Flavell, RA; Medzhitov, R			The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors	NATURE			English	Article							INNATE IMMUNE-RESPONSE; NF-KAPPA-B; RECOGNITION; ACTIVATION; LIPOPROTEINS; ENDOTOXIN; PATHWAY; MICE; TLR4	Mammalian Toll-like receptors (TLRs) function as sensors of infection and induce the activation of innate and adaptive immune responses(1-3). Upon recognizing conserved pathogen-associated molecular products, TLRs activate host defence responses through their intracellular signalling domain, the Toll/interleukin-1 receptor (TIR) domain, and the downstream adaptor protein MyD88 (refs 1-3). Although members of the TLR and the interleukin-1 (IL-1) receptor families all signal through MyD88, the signalling pathways induced by individual receptors differ. TIRAP, an adaptor protein in the TLR signalling pathway, has been identified and shown to function downstream of TLR4 ( refs 4, 5). Here we report the generation of mice deficient in the Tirap gene. TIRAP-deficient mice respond normally to the TLR5, TLR7 and TLR9 ligands, as well as to IL-1 and IL-18, but have defects in cytokine production and in activation of the nuclear factor NF-kappaB and mitogen-activated protein kinases in response to lipopolysaccharide, a ligand for TLR4. In addition, TIRAP-deficient mice are also impaired in their responses to ligands for TLR2, TLR1 and TLR6. Thus, TIRAP is differentially involved in signalling by members of the TLR family and may account for specificity in the downstream signalling of individual TLRs.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University	Medzhitov, R (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.			Barton, Gregory/0000-0002-3793-0100				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459	20	642	703	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					329	333		10.1038/nature01180	http://dx.doi.org/10.1038/nature01180			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447442				2022-12-28	WOS:000179340400045
J	Schaefer, BF; Turner, S; Parkinson, I; Rogers, N; Hawkesworth, C				Schaefer, BF; Turner, S; Parkinson, I; Rogers, N; Hawkesworth, C			Evidence for recycled Archaean oceanic mantle lithosphere in the Azores plume	NATURE			English	Article							OS ISOTOPE SYSTEMATICS; MID-ATLANTIC RIDGE; ISLAND BASALTS; OSMIUM; GEOCHEMISTRY; HETEROGENEITY; COMPONENTS; LAVAS; HIMU	The compositional differences between mid-ocean-ridge and ocean-island basalts place important constraints on the form of mantle convection(1,2). Also, it is thought that the scale and nature of heterogeneities within plumes and the degree to which heterogeneous material endures within the mantle might be reflected in spatial variations of basalt composition observed at the Earth's surface. Here we report osmium isotope data on lavas from a transect across the Azores archipelago which vary in a symmetrical pattern across what is thought to be a mantle plume. Many of the lavas from the centre of the plume have lower Os-187/Os-188 ratios than most ocean-island basalts and some extend to subchondritic Os-187/Os-188 ratios-lower than any yet reported from ocean-island basalts. These low ratios require derivation from a depleted, harzburgitic mantle, consistent with the low-iron signature of the Azores plume. Rhenium-depletion model ages extend to 2.5 Gyr, and we infer that the osmium isotope signature is unlikely to be derived from Iberian subcontinental lithospheric mantle. Instead, we interpret the osmium isotope signature as having a deep origin and infer that it may be recycled, Archaean oceanic mantle lithosphere that has delaminated from its overlying oceanic crust. If correct, our data provide evidence for deep mantle subduction and storage of oceanic mantle lithosphere during the Archaean era.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Open Univ, Dept Earth Sci, Milton Keynes MK7 6AA, Bucks, England	University of Bristol; Open University - UK	Turner, S (corresponding author), Univ Bristol, Dept Earth Sci, Wills Mem Bldg, Bristol BS8 1RJ, Avon, England.		Parkinson, Ian/C-7398-2009; Rogers, Nick/A-5870-2009; Schaefer, Bruce F/C-8718-2018; Turner, Simon/0000-0002-6426-6495	Schaefer, Bruce F/0000-0002-7366-0152; Turner, Simon/0000-0002-6426-6495				Bennett VC, 1996, NATURE, V381, P221, DOI 10.1038/381221a0; BONATTI E, 1990, SCIENCE, V250, P107, DOI 10.1126/science.250.4977.107; BOYD FR, 1989, EARTH PLANET SC LETT, V96, P15, DOI 10.1016/0012-821X(89)90120-9; Campbell IH, 2002, GEOCHIM COSMOCHIM AC, V66, P1651, DOI 10.1016/S0016-7037(01)00856-0; Cohen AS, 1996, ANAL CHIM ACTA, V332, P269, DOI 10.1016/0003-2670(96)00226-7; Dosso L, 1999, EARTH PLANET SC LETT, V170, P269, DOI 10.1016/S0012-821X(99)00109-0; GAST PW, 1964, SCIENCE, V145, P1181, DOI 10.1126/science.145.3637.1181; Hauri EH, 1997, EARTH PLANET SC LETT, V153, P21, DOI 10.1016/S0012-821X(97)00158-1; Hauri EH, 1996, J GEOPHYS RES-SOL EA, V101, P11793, DOI 10.1029/95JB03346; HAURI EH, 1993, EARTH PLANET SC LETT, V114, P353, DOI 10.1016/0012-821X(93)90036-9; HAWKESWORTH CJ, 1979, NATURE, V280, P28, DOI 10.1038/280028a0; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; JORDAN TH, 1978, NATURE, V257, P745; Lassiter JC, 1998, EARTH PLANET SC LETT, V164, P483, DOI 10.1016/S0012-821X(98)00240-4; MARCANTONIO F, 1995, EARTH PLANET SC LETT, V133, P397, DOI 10.1016/0012-821X(95)00092-Q; MCKENZIE D, 1995, J PETROL, V36, P133, DOI 10.1093/petrology/36.1.133; PEARSON DG, 1995, EARTH PLANET SC LETT, V134, P341, DOI 10.1016/0012-821X(95)00125-V; REISBERG L, 1993, EARTH PLANET SC LETT, V120, P149, DOI 10.1016/0012-821X(93)90236-3; Schaefer BF, 2000, GEOLOGY, V28, P563; Schiano P, 1997, EARTH PLANET SC LETT, V150, P363, DOI 10.1016/S0012-821X(97)00098-8; Schiano P, 2001, EARTH PLANET SC LETT, V186, P527, DOI 10.1016/S0012-821X(01)00265-5; SCHILLING JG, 1983, AM J SCI, V283, P510, DOI 10.2475/ajs.283.6.510; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; SHIREY SB, 1995, ANAL CHEM, V67, P2136, DOI 10.1021/ac00109a036; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; Turner S, 1997, CHEM GEOL, V139, P145, DOI 10.1016/S0009-2541(97)00031-4; WHITE WM, 1993, J GEOPHYS RES-SOL EA, V98, P19533, DOI 10.1029/93JB02018; WHITE WM, 1979, CONTRIB MINERAL PETR, V69, P201, DOI 10.1007/BF00372322; Widom E, 1996, EARTH PLANET SC LETT, V142, P451, DOI 10.1016/0012-821X(96)00111-2; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	30	81	81	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					304	307		10.1038/nature01172	http://dx.doi.org/10.1038/nature01172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447437				2022-12-28	WOS:000179340400039
J	Koopman, J				Koopman, J			Controlling smallpox	SCIENCE			English	Editorial Material									Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Koopman, J (corresponding author), Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.							FOX JP, 1971, AM J EPIDEMIOL, V94, P179, DOI 10.1093/oxfordjournals.aje.a121310; Halloran ME, 2002, SCIENCE, V298, P1428, DOI 10.1126/science.1074674; Kaplan EH, 2002, P NATL ACAD SCI USA, V99, P10935, DOI 10.1073/pnas.162282799; Koopman JS, 2001, ANN NY ACAD SCI, V954, P268; Koopman JS, 2002, MATH BIOSCI, V180, P49, DOI 10.1016/S0025-5564(02)00124-4; Newman MEJ, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.016128; Rohani P, 2002, AM NAT, V159, P469, DOI 10.1086/339467; Wolfram S., 2002, NEW KIND SCI	8	25	25	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1342	1344						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434038				2022-12-28	WOS:000179223100026
J	Moy, CM; Seltzer, GO; Rodbell, DT; Anderson, DM				Moy, CM; Seltzer, GO; Rodbell, DT; Anderson, DM			Variability of El Nino/Southern Oscillation activity at millennial timescales during the Holocene epoch	NATURE			English	Article							SOUTHERN-OSCILLATION; TROPICAL PACIFIC; NINO; ECUADOR; PERU	The variability of El Nino/Southern Oscillation (ENSO) during the Holocene epoch, in particular on millennial timescales, is poorly understood. Palaeoclimate studies have documented ENSO variability for selected intervals in the Holocene, but most records are either too short or insufficiently resolved to investigate variability on millennial scales(1-3). Here we present a record of sedimentation in Laguna Pallcacocha, southern Ecuador, which is strongly influenced by ENSO variability, and covers the past 12,000 years continuously. We find that changes on a timescale of 2-8 years, which we attribute to warm ENSO events, become more frequent over the Holocene until about 1,200 years ago, and then decline towards the present. Periods of relatively high and low ENSO activity, alternating at a timescale of about 2,000 years, are superimposed on this long-term trend. We attribute the long-term trend to orbitally induced changes in insolation, and suggest internal ENSO dynamics as a possible cause of the millennial variability. However, the millennial oscillation will need to be confirmed in other ENSO proxy records.	Syracuse Univ, Dept Earth Sci, Heroy Geol Lab 204, Syracuse, NY 13244 USA; Union Coll, Dept Geol, Schenectady, NY 12308 USA; Univ Colorado, NOAA, Paleoclimatol Program, Boulder, CO 80305 USA; Univ Colorado, INSTAAR, Boulder, CO 80305 USA	Syracuse University; Union College; National Oceanic Atmospheric Admin (NOAA) - USA; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Moy, CM (corresponding author), Syracuse Univ, Dept Earth Sci, Heroy Geol Lab 204, Syracuse, NY 13244 USA.		anderson, david/E-6416-2011	Moy, Christopher/0000-0002-2177-5265				Bond GC, 1999, GEOPH MONOG SERIES, V112, P35; Clement AC, 1999, GEOPH MONOG SERIES, V112, P363; Clement AC, 2000, PALEOCEANOGRAPHY, V15, P731, DOI 10.1029/1999PA000466; Cole J, 2001, SCIENCE, V291, P1496, DOI 10.1126/science.1059111; GILMAN DL, 1963, J ATMOS SCI, V20, P182, DOI 10.1175/1520-0469(1963)020<0182:OTPSON>2.0.CO;2; HANSEN BCS, IN PRESS PALEOGEOGR; MARTIN L, 1993, QUATERNARY RES, V39, P338, DOI 10.1006/qres.1993.1040; Moy C.M., 2000, THESIS SYRACUSE U; Rodbell DT, 1999, SCIENCE, V283, P516, DOI 10.1126/science.283.5401.516; Rodbell DT, 2002, QUATERNARY RES, V57, P343, DOI 10.1006/qres.2002.2324; RODBELL DT, 1993, GEOL SOC AM BULL, V105, P923, DOI 10.1130/0016-7606(1993)105<0923:TTOTLD>2.3.CO;2; Sandweiss DH, 2001, GEOLOGY, V29, P603, DOI 10.1130/0091-7613(2001)029<0603:VIHENO>2.0.CO;2; STUIVER M, 1991, QUATERNARY RES, V35, P1, DOI 10.1016/0033-5894(91)90091-I; THOMPSON LG, 1992, EL NINO HIST PALEOCL, P295; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Tudhope AW, 2001, SCIENCE, V291, P1511, DOI 10.1126/science.1057969; Villalba, 2000, EL NINO SO OSCILLATI, P297; Vuille M, 2000, J CLIMATE, V13, P2520, DOI 10.1175/1520-0442(2000)013<2520:CVITAO>2.0.CO;2	18	1144	1211	5	286	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					162	165		10.1038/nature01194	http://dx.doi.org/10.1038/nature01194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432388				2022-12-28	WOS:000179200900041
J	McCarthy, M				McCarthy, M			Public-health research in Europe	LANCET			English	Editorial Material									UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	McCarthy, M (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	m.mccarthy@ucl.ac.uk	McCarthy, Mark/C-1117-2009					*EUR COMM, 2002, PUBL HLTH; European Commission, 2022, EUR HLTH UN EUR HLTH; HOLLAND WW, 1997, EUROPEAN COMMUNITY A; Mackenbach JP, 1997, LANCET, V349, P1655, DOI 10.1016/S0140-6736(96)07226-1; SCHERMER L, 2002, OVERVIEW PUBLIC HLTH	5	5	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1439	1439		10.1016/S0140-6736(02)11490-5	http://dx.doi.org/10.1016/S0140-6736(02)11490-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433508				2022-12-28	WOS:000179186000005
J	Neuberger, JS; Gesell, TF				Neuberger, JS; Gesell, TF			Childhood cancers, radon, and gamma radiation	LANCET			English	Editorial Material									Univ Kansas, Sch Med, Dept Prevent Med & Publ Hlth, Kansas City, KS 66160 USA; Idaho State Univ, Dept Phys, Pocatello, ID 83209 USA	University of Kansas; University of Kansas Medical Center; Idaho; Idaho State University	Neuberger, JS (corresponding author), Univ Kansas, Sch Med, Dept Prevent Med & Publ Hlth, Kansas City, KS 66160 USA.							Boulton A, 2000, BRIT J CANCER, V82, P1073; Cartwright RA, 2002, BRIT J CANCER, V86, P1721, DOI 10.1038/sj.bjc.6600276; Cartwright RA, 2002, BRIT J CANCER, V86, P1727, DOI 10.1038/sj.bjc.6600277; Neuberger JS, 2002, HEALTH PHYS, V83, P1, DOI 10.1097/00004032-200207000-00001	4	9	9	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1437	1438		10.1016/S0140-6736(02)11488-7	http://dx.doi.org/10.1016/S0140-6736(02)11488-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433506				2022-12-28	WOS:000179186000003
J	Wunsch, C				Wunsch, C			What is the thermohaline circulation?	SCIENCE			English	Editorial Material									MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Wunsch, C (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	cwunsch@mit.edu						BAINES WD, 1993, J FLUID MECH, V255, P621, DOI 10.1017/S0022112093002617; Ganachaud A, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2000GB001333; HUANG RX, UNPUB; Munk W, 1998, DEEP-SEA RES PT I, V45, P1977, DOI 10.1016/S0967-0637(98)00070-3; Paparella F, 2002, J FLUID MECH, V466, P205, DOI 10.1017/S0022112002001313; Samelson RM, 1997, J MAR RES, V55, P223, DOI 10.1357/0022240973224382; Sandstrom J.W., 1908, ANN HYDROGR MARIT ME, V36, P6; Stammer D, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2001JC000888; STOMMEL H, 1961, TELLUS, V13, P224, DOI 10.1111/j.2153-3490.1961.tb00079.x	9	162	178	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	2002	298	5596					1179	+		10.1126/science.1079329	http://dx.doi.org/10.1126/science.1079329			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424356				2022-12-28	WOS:000179080400025
J	James, A				James, A			Medicines, society, and industry	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		James, A (corresponding author), Lancet, London NW1 7BY, England.								0	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1346	1346		10.1016/S0140-6736(02)11416-4	http://dx.doi.org/10.1016/S0140-6736(02)11416-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423979				2022-12-28	WOS:000179081600006
J	Crawford, MJ; Rutter, D; Manley, C; Weaver, T; Bhui, K; Fulop, N; Tyrer, P				Crawford, MJ; Rutter, D; Manley, C; Weaver, T; Bhui, K; Fulop, N; Tyrer, P			Systematic review of involving patients in the planning and development of health care	BRITISH MEDICAL JOURNAL			English	Review							USER INVOLVEMENT; COMMUNITY CARE; STRATEGY	Objective To examine the effects of involving patients in the planning and development of health care. Data sources Published and grey literature. Study selection Systematic search for worldwide reports written in English between January 1966 and October 2000. Data extraction Qualitative review of papers describing the effects of involving patients in the planning and development of health care. Results Of 42 papers identified, 31 (74%) were case studies. Papers often described changes to services that were attributed to involving patients, including attempts to make services more accessible and producing information leaflets for patients. Changes in the attitudes of organisations to involving patients and positive responses from patients who took part in initiatives were also reported. Conclusions Evidence supports the notion that involving patients has contributed to changes in the provision of services across a range of different settings. An evidence base for the effects on use of services, quality of care, satisfaction, or health of patients does not exist.	Imperial Coll Sch Med, Dept Psychol Med, London W2 1PD, England; Univ London Imperial Coll Sci & Technol, Dept Social Sci & Med, Div Primary Care & Populat Hlth Sci, London W6 8RP, England; St Bartholomews & Royal London Med Sch, Inst Community Hlth Sci, London E1 2AD, England; Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England	Imperial College London; Imperial College London; University of London; Queen Mary University London; University of London; London School of Hygiene & Tropical Medicine	Crawford, MJ (corresponding author), Imperial Coll Sch Med, Dept Psychol Med, St Marys Campus, London W2 1PD, England.			Weaver, Tim/0000-0002-3437-3556; Crawford, Mike/0000-0003-3137-5772; Fulop, Naomi/0000-0001-5306-6140; Bhui, Kamaldeep/0000-0002-9205-2144				ATKINSON K, 1998, AUDIT TRENDS, V6, P24; Barker J., 1997, REFERENCE MANUAL PUB; BARNES C, 1993, DISABLING BARRIERS E; Barnes M., 1997, J MENTAL HLTH, V6, P289, DOI DOI 10.1080/09638239718824; BARNES M, 1994, J MENTAL HLTH, V3, P525, DOI DOI 10.3109/09638239409003827; Barnes M, 1999, PUBLIC EXPECTATIONS; Beresford P., 1993, CITIZEN INVOLVEMENT; Berger E, 1996, Aust N Z J Ment Health Nurs, V5, P131; Bowl R, 1996, INT J SOC PSYCHIATR, V42, P165, DOI 10.1177/002076409604200301; BRODERICK C, 1997, HLTH DIRECTOR, V1, P14; CARLSON A, 1990, Health Education Research, V5, P41, DOI 10.1093/her/5.1.41; CHECKOWAY B, 1982, J HEALTH POLIT POLIC, V7, P723, DOI 10.1215/03616878-7-3-723; Checkoway B, 1984, Policy Stud Rev, V3, P296; COOPER TL, 1979, AM J PUBLIC HEALTH, V69, P368, DOI 10.2105/AJPH.69.4.368; DIXON L, 1994, COMMUNITY MENT HLT J, V30, P615, DOI 10.1007/BF02188599; Donovan JL, 1996, PRIORITY SETTING HLT; ELIZABETH S, 1998, HLTH CARE RISK REP, V4, P16; Gummer T, 1998, HLTH MANAG, V2, P12; HARRIS B, 1989, ISLINGTON MENTAL HLT; Harrison S, 1998, SOC POLICY ADMIN, V32, P60, DOI 10.1111/1467-9515.00086; HEGINBOTHAM C, 1993, LISTENING LOCAL VOIC; HENDESSI M, 1994, GETTING BETTER ALL T; Kelson M, 1997, USER INVOLVEMENT GUI; Kirk S, 1997, HEALTH SOC CARE COMM, V5, P398, DOI 10.1111/j.1365-2524.1997.tb00137.x; Lord J, 1998, PSYCHIATR REHABIL J, V21, P327, DOI 10.1037/h0095291; Mays N., 2001, STUDYING ORG DELIVER; MCIVER S, 1991, OBTAINING VIEWS USER; Milewa T, 1997, HEALTH PROMOT INT, V12, P161, DOI 10.1093/heapro/12.2.161; Millett A., 1999, Health Expect, V2, P280; *NHS EX, 1994, INV LOC PEOPL EX GOO; *NHS EX, 1998, PAT PARTN; *NHS EX, 1996, PAT PARTN BUILD COLL; NHS Executive, 1999, PAT PUBL INV NEW NHS; NHS Executive, 2000, NHS PLAN PLAN INV PL; NUTT PC, 1976, ACAD MANAGE J, V19, P378, DOI 10.2307/255605; Pagett J., 1994, CCUFLINK B COMMUNITY; PECARCHIK R, 1976, PUBLIC HEALTH REP, V91, P72; Pilgrim D., 1998, J MENT HEALTH, V7, P95, DOI [10.1080/09638239818373, DOI 10.1080/09638239818373]; Pool PE, 2000, TELECOMMUNICATIONS, V34, P14; PRITCHARD P, 1993, PARTNERSHIP PATIENTS; RICHARDSON A, 1987, PROMOTING HLTH PARTI; Sheahan M, 1999, J Qual Clin Pract, V19, P139, DOI 10.1046/j.1440-1762.1999.00317.x; SHEPPARD B, 2000, VOICE OLDER LONDONER; SILVA EL, 1990, NEW DIR MENT HLTH SE, V46, P57; SMITH H, 1988, COLLABORATION CHANGE; SMITH MK, 1984, PSYCHOSOC REHABIL J, V8, P35; Summers A, 1996, PUBLIC HEALTH, V110, P145, DOI 10.1016/S0033-3506(96)80067-9; TAYLOR P, 1994, CCUFLINK, V4, P19; TISCHLER GL, 1971, AM J ORTHOPSYCHIAT, V41, P501, DOI 10.1111/j.1939-0025.1971.tb01136.x; Todd S, 2000, J INTELL DISABIL RES, V44, P31, DOI 10.1046/j.1365-2788.2000.00248.x; WILLIAMS D, 1994, CCUFLINK, V4, P10; WISTOW G, 1993, PUBLIC ADMIN, V71, P279, DOI 10.1111/j.1467-9299.1993.tb00975.x; WOODS T, 1994, CCUFLINK, V4, P7; YOUNG TK, 1975, MED CARE, V13, P897, DOI 10.1097/00005650-197511000-00002; [No title captured]	55	552	558	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1263	1265		10.1136/bmj.325.7375.1263	http://dx.doi.org/10.1136/bmj.325.7375.1263			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	623HB	12458240	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000179696300013
J	Goldsmith, I; Turpie, AGG; Lip, GYH				Goldsmith, I; Turpie, AGG; Lip, GYH			ABC of antithrombotic therapy - Valvar heart disease and prosthetic heart valves	BRITISH MEDICAL JOURNAL			English	Review							GUIDELINES; MANAGEMENT		Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B15 2TT, W Midlands, England; McMaster Univ, Hamilton Hlth Sci Corp, Hamilton, ON, Canada	University of Birmingham; McMaster University	Goldsmith, I (corresponding author), Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B15 2TT, W Midlands, England.							Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; Gohlke-Barwolf C, 2000, HEART, V84, P567, DOI 10.1136/heart.84.5.567; GOHLKEBARWOLF C, 1995, EUR HEART J, V16, P1320	3	23	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 23	2002	325	7374					1228	1231		10.1136/bmj.325.7374.1228	http://dx.doi.org/10.1136/bmj.325.7374.1228			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446543	Green Published			2022-12-28	WOS:000179506200027
J	Maury, E; Lemant, J; Dussaule, JC; Vedrine, AP; Offenstadt, G				Maury, E; Lemant, J; Dussaule, JC; Vedrine, AP; Offenstadt, G			A reversible paralysis	LANCET			English	Editorial Material							SECONDARY		Assistance Publ Hop Paris, St Antoine UFR, Intens Care Unit, F-75571 Paris 12, France; Assistance Publ Hop Paris, St Antoine UFR, Dept Physiol, F-75571 Paris, France	Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Maury, E (corresponding author), Hop St Antoine, Intens Care Unit, Assistance Publ Hop Paris, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.							Charytan D, 2000, ARCH INTERN MED, V160, P1605, DOI 10.1001/archinte.160.11.1605; Evers S, 1998, J NEUROL NEUROSUR PS, V64, P249, DOI 10.1136/jnnp.64.2.249; Halperin ML, 1998, LANCET, V352, P135; LIVINGSTONE IR, 1979, LANCET, V2, P963; Patel P, 2001, POSTGRAD MED J, V77, P50, DOI 10.1136/pmj.77.903.50	5	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 23	2002	360	9346					1660	1660		10.1016/S0140-6736(02)11604-7	http://dx.doi.org/10.1016/S0140-6736(02)11604-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457790				2022-12-28	WOS:000179393900012
J	Poulton, R; Caspi, A; Milne, BJ; Thomson, WM; Taylor, A; Sears, MR; Moffitt, TE				Poulton, R; Caspi, A; Milne, BJ; Thomson, WM; Taylor, A; Sears, MR; Moffitt, TE			Association between children's experience of socioeconomic disadvantage and adult health: a life-course study	LANCET			English	Article							CARDIOVASCULAR-DISEASE; RISK-FACTORS; CHILDHOOD; DETERMINANTS; INEQUALITIES; MORTALITY	Background Research into social inequalities in health has tended to focus on low socioeconomic status in adulthood. We aimed to test the hypothesis that children's experience of socioeconomic disadvantage is associated with a wide range of health risk factors and outcomes in adult life. Methods We studied an unselected cohort of 1000 children (born in New Zealand during 1972-73) who had been assessed at birth and ages 3, 5, 7, 9, 11, 13, and 15 years. At age 26 years, we assessed these individuals for health outcomes including body-mass index, waist:hip ratio, blood pressure, cardiorespiratory fitness, dental caries, plaque scores, gingival bleeding, periodontal disease, major depression, and tobacco and alcohol dependence, and tested for associations between these variables and childhood and adult socioeconomic status. Findings Compared with those from high socioeconomic status backgrounds, children who grew up in low socioeconomic status families had poorer cardiovascular health. Significant differences were also found on all dental health measures, with a threefold increase in adult periodontal disease (31.1% vs 11.9%) and caries level (32.2% vs 9.9%) in low versus high childhood socioeconomic status groups. Substance abuse resulting in clinical dependence was related in a similar way to childhood socioeconomic status (eg, 21.5% vs 12.1% for adult alcohol dependence). The longitudinal associations could not be attributed to life-course continuity of low socioeconomic status, and upward mobility did not mitigate or reverse the adverse effects of low childhood socioeconomic status on adult health. Interpretation Protecting children against the effects of socioeconomic adversity could reduce the burden of disease experienced by adults. These findings provide strong impetus for policy makers, practitioners, and researchers to direct energy and resources towards childhood as a way of improving population health.	Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin Multidisciplinary Hlth & Dev Res Unit, Dunedin, New Zealand; Kings Coll London, Inst Psychiat, London WC2R 2LS, England; Univ Wisconsin, Madison, WI USA; Univ Otago, Sch Dent, Dept Oral Hlth, Dunedin, New Zealand; McMaster Univ, Dept Med, Hamilton, ON, Canada	University of Otago; University of London; King's College London; University of Wisconsin System; University of Wisconsin Madison; University of Otago; McMaster University	Poulton, R (corresponding author), Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin Multidisciplinary Hlth & Dev Res Unit, POB 913, Dunedin, New Zealand.	richiep@gandalf.otago.ac.nz	caspi, avshalom/AAJ-5874-2020; Moffitt, Terrie E/D-5295-2011; caspi, avshalom/D-5294-2011; Thomson, William Murray/AAC-8575-2019; Thomson, William Murray/A-4971-2008	caspi, avshalom/0000-0003-0082-4600; Moffitt, Terrie E/0000-0002-8589-6760; caspi, avshalom/0000-0003-0082-4600; Thomson, William Murray/0000-0003-0588-6843	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045070, R29MH049414, R01MH049414] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH045070, R01 MH049414, MH49414, MH45070] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 2002, MERITOCRACY EC INEQU; Barker DJP, 1998, MOTHERS BABIES HLTH; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; Brunner E, 1997, BMJ-BRIT MED J, V314, P1472, DOI 10.1136/bmj.314.7092.1472; Conley D, 2000, AM SOCIOL REV, V65, P458, DOI 10.2307/2657467; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; GREENE JC, 1964, J AM DENT ASSOC, V68, P7, DOI 10.14219/jada.archive.1964.0034; Hertzman C, 1996, SOC SCI MED, V43, P1083, DOI 10.1016/0277-9536(96)00028-7; Kuh D, 1997, LIFE COURSE APPROACH TO CHRONIC DISEASE EPIDEMIOLOGY, P169; LEON D, 1999, POVERTY INEQUALITY H; LOOKER ED, 1989, SOCIOL EDUC, V62, P257, DOI 10.2307/2112830; Marmot M, 2001, J EPIDEMIOL COMMUN H, V55, P301, DOI 10.1136/jech.55.5.301; Marmot M, 2006, SOCIAL DETERMINANTS; Miech RA, 1999, AM J SOCIOL, V104, P1096, DOI 10.1086/210137; Power C, 1998, LANCET, V351, P1009, DOI 10.1016/S0140-6736(97)11082-0; Power C, 1997, BRIT MED BULL, V53, P210; Rosenthal Robert., 1985, CONTRAST ANAL FOCUSE; Silva P., 1996, CHILD ADULT DUNEDIN; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411; Thomson WM, 2000, J PERIODONTOL, V71, P1840, DOI 10.1902/jop.2000.71.12.1840; Wadsworth MEJ, 1997, SOC SCI MED, V44, P859, DOI 10.1016/S0277-9536(96)00187-6; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; Wolfe B, 1996, J AM STAT ASSOC, V91, P970, DOI 10.2307/2291716	30	674	689	2	155	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2002	360	9346					1640	1645		10.1016/S0140-6736(02)11602-3	http://dx.doi.org/10.1016/S0140-6736(02)11602-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	618AE	12457787	Green Accepted			2022-12-28	WOS:000179393900009
J	Feng, Q; Zhang, YJ; Hao, P; Wang, SY; Fu, G; Huang, YC; Li, Y; Zhu, JJ; Liu, YL; Hu, X; Jia, PX; Zhang, Y; Zhao, Q; Ying, K; Yu, SL; Tang, YS; Weng, QJ; Zhang, L; Lu, Y; Mu, J; Lu, YQ; Zhang, LS; Yu, Z; Fan, DL; Liu, XH; Lu, TT; Li, C; Wu, YR; Sun, TG; Lei, HY; Li, T; Hu, H; Guan, JP; Wu, M; Zhang, RQ; Zhou, B; Chen, ZH; Chen, L; Jin, ZQ; Wang, R; Yin, HF; Cai, Z; Ren, SX; Lv, G; Gu, WY; Zhu, GF; Tu, YF; Jia, J; Zhang, Y; Chen, J; Kang, H; Chen, XY; Shao, CY; Sun, Y; Hu, QP; Zhang, XL; Zhang, W; Wang, LJ; Ding, CW; Sheng, HH; Gu, JL; Chen, ST; Ni, L; Zhu, FH; Chen, W; Lan, LF; Lai, Y; Cheng, ZK; Gu, MH; Jiang, JM; Li, JY; Hong, GF; Xue, YB; Han, B				Feng, Q; Zhang, YJ; Hao, P; Wang, SY; Fu, G; Huang, YC; Li, Y; Zhu, JJ; Liu, YL; Hu, X; Jia, PX; Zhang, Y; Zhao, Q; Ying, K; Yu, SL; Tang, YS; Weng, QJ; Zhang, L; Lu, Y; Mu, J; Lu, YQ; Zhang, LS; Yu, Z; Fan, DL; Liu, XH; Lu, TT; Li, C; Wu, YR; Sun, TG; Lei, HY; Li, T; Hu, H; Guan, JP; Wu, M; Zhang, RQ; Zhou, B; Chen, ZH; Chen, L; Jin, ZQ; Wang, R; Yin, HF; Cai, Z; Ren, SX; Lv, G; Gu, WY; Zhu, GF; Tu, YF; Jia, J; Zhang, Y; Chen, J; Kang, H; Chen, XY; Shao, CY; Sun, Y; Hu, QP; Zhang, XL; Zhang, W; Wang, LJ; Ding, CW; Sheng, HH; Gu, JL; Chen, ST; Ni, L; Zhu, FH; Chen, W; Lan, LF; Lai, Y; Cheng, ZK; Gu, MH; Jiang, JM; Li, JY; Hong, GF; Xue, YB; Han, B			Sequence and analysis of rice chromosome 4	NATURE			English	Article							PLANT ARABIDOPSIS-THALIANA; GENOME SEQUENCE; DRAFT SEQUENCE; PHYSICAL MAP; GENETIC-MAP; EXPRESSION; PROJECT; CLONING; TOOL; DNA	Rice is the principal food for over half of the population of the world. With its genome size of 430 megabase pairs ( Mb), the cultivated rice species Oryza sativa is a model plant for genome research(1). Here we report the sequence analysis of chromosome 4 of O. sativa, one of the first two rice chromosomes to be sequenced completely(2). The finished sequence spans 34.6 Mb and represents 97.3% of the chromosome. In addition, we report the longest known sequence for a plant centromere, a completely sequenced contig of 1.16 Mb corresponding to the centromeric region of chromosome 4. We predict 4,658 protein coding genes and 70 transfer RNA genes. A total of 1,681 predicted genes match available unique rice expressed sequence tags. Transposable elements have a pronounced bias towards the euchromatic regions, indicating a close correlation of their distributions to genes along the chromosome. Comparative genome analysis between cultivated rice subspecies shows that there is an overall syntenic relationship between the chromosomes and divergence at the level of single-nucleotide polymorphisms and insertions and deletions. By contrast, there is little conservation in gene order between rice and Arabidopsis.	Chinese Acad Sci, Shanghai Inst Biol Sci, Natl Ctr Gene Res, Shanghai 200233, Peoples R China; Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China; Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China; Yangzhou Univ, Yangzhou 225009, Jiangsu, Peoples R China; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; Yangzhou University; University of Wisconsin System; University of Wisconsin Madison	Han, B (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Natl Ctr Gene Res, 500 Caobao Rd, Shanghai 200233, Peoples R China.	bhan@ncgr.ac.cn	Yin, Haifeng/E-8787-2012; Jiang, Jiming/V-6060-2019; Jiang, Jiming/A-9614-2009; chen, zehua/H-1260-2011; Chen, Zehua/E-6356-2011	Jiang, Jiming/0000-0002-6435-6140; Jiang, Jiming/0000-0002-6435-6140; Lan, Lefu/0000-0002-5551-5496; Hao, Pei/0000-0002-1498-7059				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chen MS, 2002, PLANT CELL, V14, P537, DOI 10.1105/tpc.010485; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; Dong FG, 1998, P NATL ACAD SCI USA, V95, P8135, DOI 10.1073/pnas.95.14.8135; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Harushima Y, 1998, GENETICS, V148, P479; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Khush GS, 1997, PLANT MOL BIOL, V35, P25, DOI 10.1023/A:1005810616885; KNUTZON DS, 1995, PLANT PHYSIOL, V109, P999, DOI 10.1104/pp.109.3.999; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Maugenest S, 1999, PLANT MOL BIOL, V39, P503, DOI 10.1023/A:1006131506193; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Messing J, 1998, P NATL ACAD SCI USA, V95, P2017, DOI 10.1073/pnas.95.5.2017; Oka H. I., 1991, Rice biotechnology., P55; Paterson AH, 1996, NAT GENET, V14, P380, DOI 10.1038/ng1296-380; Saji S, 2001, GENOME, V44, P32, DOI 10.1139/gen-44-1-32; Sasaki T, 2000, CURR OPIN PLANT BIOL, V3, P138, DOI 10.1016/S1369-5266(99)00047-3; Sasaki T, 2002, NATURE, V420, P312, DOI 10.1038/nature01184; Wu JZ, 2002, PLANT CELL, V14, P525, DOI 10.1105/tpc.010274; Yoshimura S, 1998, P NATL ACAD SCI USA, V95, P1663, DOI 10.1073/pnas.95.4.1663; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; Zhao Q, 2002, GENOME RES, V12, P817, DOI 10.1101/gr.48902	30	387	930	3	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					316	320		10.1038/nature01183	http://dx.doi.org/10.1038/nature01183			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447439				2022-12-28	WOS:000179340400042
J	Seddon, AM				Seddon, AM			The long and the short of it	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2002	288	19					2377	2378		10.1001/jama.288.19.2377	http://dx.doi.org/10.1001/jama.288.19.2377			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FB	12435237				2022-12-28	WOS:000179292300001
J	Waters, DD; Alderman, EL; Hsia, J; Howard, BV; Cobb, FR; Rogers, WJ; Ouyang, P; Thompson, P; Tardif, JC; Higginson, L; Bittner, V; Steffes, M; Gordon, DJ; Proschan, M; Younes, N; Verter, JI				Waters, DD; Alderman, EL; Hsia, J; Howard, BV; Cobb, FR; Rogers, WJ; Ouyang, P; Thompson, P; Tardif, JC; Higginson, L; Bittner, V; Steffes, M; Gordon, DJ; Proschan, M; Younes, N; Verter, JI			Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN-REPLACEMENT; HEART-DISEASE; ARTERY DISEASE; CARDIOVASCULAR-DISEASE; E CONSUMPTION; PROGRESSION; RISK; PREVENTION; SIMVASTATIN; PROGESTIN	Context Hormone replacement therapy (HRT) and antioxidant vitamins are widely used for secondary prevention in postmenopausal women with coronary disease, but no clinical trials have demonstrated benefit to support their use. Objective To determine whether HRT or antioxidant vitamin supplements, alone or in combination, influence the progression of coronary artery disease in postmenopausal women, as measured by serial quantitative coronary angiography. Design, Setting, and Patients The Women's Angiographic Vitamin and Estrogen (WAVE) Trial, a randomized, double-blind trial of 423 postmenopausal women with at least one 15% to 75% coronary stenosis at baseline coronary angiography. The trial was conducted from July 1997 to January 2002 in 7 clinical centers in the United States and Canada. Interventions Patients were randomly assigned in a 2 x 2 factorial design to receive either 0.625 mg/d of conjugated equine estrogen (plus 2.5 mg/d of medroxyprogesterone acetate for women who had not had a hysterectomy), or matching placebo, and 400 IU of vitamin E twice daily plus 500 mg of vitamin C twice daily, or placebo. Main Outcome Measure Annualized mean (SD) change in minimum lumen diameter (MLD) from baseline to concluding angiogram of all qualifying coronary lesions averaged for each patient. Patients with intercurrent death or myocardial infarction (MI) were imputed the worst rank of angiographic outcome. Results The mean (SD) interval between angiograms was 2.8 (0.9) years. Coronary progression, measured in mean (SD) change, worsened with HRT by 0.047 (015) mm/y and by 0.024 (0.15) mm/y with HRT placebo (P=.17); and for antioxidant vitamins by 0.044 (0.15) mm/y and with vitamin placebo by 0.028 (0.15) mm/y (P=32). When patients with intercurrent death or MI were included, the primary outcome showed an increased risk for women in the active HRT group (P=.045), and suggested an increased risk in the active vitamin group (P=.09). Fourteen patients died in the HRT group and 8 in the HRT placebo group (hazard ratio [HR], 1.8; 95% confidence interval [CI], 0.75-4.3), and 16 in the vitamin group and 6 in the vitamin placebo group (HR, 2.8; 95% CI, 1.1-7.2). Death, nonfatal MI, or stroke occurred in 26 HRT patients vs 15 HRT controls (HR, 1.9; 95% CI, 0.97-3.6) and in 26 vitamin patients and 18 vitamin controls (HR, 1.5; 95% CI, 0.80-2.9). There was no interaction between the 2 treatment interventions. Conclusion In postmenopausal women with coronary disease, neither HRT nor antioxidant vitamin supplements provide cardiovascular benefit. Instead, a potential for harm was suggested with each treatment.	San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Stanford Univ, Div Cardiovasc Med, Stanford, CA 94305 USA; George Washington Univ, Dept Med, Washington, DC USA; George Washington Univ, Dept Stat, Washington, DC 20052 USA; Medstar Res Inst, Dept Cardiol, Washington, DC USA; Duke Univ, Duke Ctr Living, Durham, NC USA; Univ Alabama, Div Cardiol, Birmingham, AL USA; Johns Hopkins Bayview Med Ctr, Div Cardiol, Baltimore, MD USA; Hartford Hosp, Div Cardiol, Hartford, CT 06115 USA; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; Univ Ottawa, Inst Heart, Ottawa, ON, Canada; Univ Minnesota, Cent Biochem Lab, Minneapolis, MN USA; NHLBI, NIH, Bethesda, MD 20892 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Stanford University; George Washington University; George Washington University; Duke University; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins Medicine; Hartford Hospital; Universite de Montreal; University of Ottawa; University of Ottawa Heart Institute; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Waters, DD (corresponding author), San Francisco Gen Hosp, Div Cardiol, Room 5G1,1001 Potrero Ave, San Francisco, CA 94110 USA.			Bittner, Vera/0000-0001-9456-850X	NCRR NIH HHS [M01 RR02715] Funding Source: Medline; NHLBI NIH HHS [N01-HV-68170, N01-HV-68165] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV068170, N01HV068165] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S14RR002715] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Azen SP, 1996, CIRCULATION, V93, P34, DOI 10.1161/01.CIR.93.1.34; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; Cheung MC, 2001, ARTERIOSCL THROM VAS, V21, P1320, DOI 10.1161/hq0801.095151; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; CONOVER WJ, 1971, PRACTICAL NONPARAMET, P318; DAGENAIS DR, 2000, CURR CARDIOL REP, V2, P293; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GAZIANO JM, 1992, ANN NY ACAD SCI, V669, P249; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; HODIS HN, 1995, JAMA-J AM MED ASSOC, V273, P1849, DOI 10.1001/jama.273.23.1849; HSIA J, IN PRESS CONTROL CLI; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; LEUNG WH, 1991, CATHETER CARDIO DIAG, V24, P121, DOI 10.1002/ccd.1810240211; Lynch S M, 1996, Subcell Biochem, V25, P331; Manson JE, 2001, NEW ENGL J MED, V345, P34, DOI 10.1056/NEJM200107053450106; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Newton KM, 1997, AM J EPIDEMIOL, V145, P269; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; Sullivan JM, 1997, AM J CARDIOL, V79, P847, DOI 10.1016/S0002-9149(97)00001-5; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; Waters DD, 2002, J AM COLL CARDIOL, V39, P238, DOI 10.1016/S0735-1097(01)01735-1; Yusuf S, 2000, NEW ENGL J MED, V342, P145	34	417	432	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2002	288	19					2432	2440		10.1001/jama.288.19.2432	http://dx.doi.org/10.1001/jama.288.19.2432			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FB	12435256	Bronze			2022-12-28	WOS:000179292300026
J	Wong, MD; Shapiro, MF; Boscardin, WJ; Ettner, SL				Wong, MD; Shapiro, MF; Boscardin, WJ; Ettner, SL			Contribution of major diseases to disparities in mortality.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	24th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 02-05, 2001	SAN DIEGO, CALIFORNIA	Soc Gen Internal Med			FACTOR INTERVENTION TRIAL; SOCIOECONOMIC DIFFERENTIALS; CIGARETTE-SMOKING; UNITED-STATES; RISK FACTOR; EDUCATIONAL STATUS; COMPETING RISKS; LIFE EXPECTANCY; BLACK; RACE	Background: Mortality from all causes is higher for persons with fewer years of education and for blacks, but it is unknown which diseases contribute most to these disparities. Methods: We estimated cause-specific risks of death from data from the National Health Interview Survey conducted from 1986 through 1994 and from linked vital statistics. Using these risk estimates, we calculated potential years of life lost and potential gains in life expectancy related to specific causes, with stratification according to education level and race. Results: Persons without a high-school education lost 12.8 potential life-years per person in the population, as compared with 3.6 for persons who graduated from high school (ratio, 3.5; P<0.001). Ischemic heart disease contributed most (11.7 percent) to the difference according to education in potential life-years lost (with all cardiovascular diseases accounting for 35.3 percent). All cancers accounted for 26.5 percent, including 7.7 percent due to lung cancer; other lung diseases and pneumonia contributed 10.1 percent of the total, whereas human immunodeficiency virus (HIV) disease accounted for none of the difference according to education. The pattern of disparities according to level of income was similar to that according to level of education. Blacks and whites lost 7.0 and 5.2 potential life-years per person, respectively, as a result of deaths from any cause (ratio, 1.35; P<0.001). Cardiovascular diseases accounted for one third of this disparity, in large part because of hypertension (15.0 percent); HIV disease (11.2 percent) contributed almost as much as ischemic heart disease (5.5 percent), stroke (2.8 percent), and cancer (3.4 percent) combined; trauma and diabetes mellitus accounted for 10.7 percent and 8.5 percent, respectively. Conclusions: Although many conditions contribute to socioeconomic and racial disparities in potential life-years lost, a few conditions account for most of these disparities -- smoking-related diseases in the case of mortality among persons with fewer years of education, and hypertension, HIV, diabetes mellitus, and trauma in the case of mortality among black persons. These findings have important implications for targeting efforts to reduce existing disparities in mortality rates.	Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Wong, MD (corresponding author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Plaza, Los Angeles, CA 90095 USA.			Wong, Mitchell/0000-0002-4800-8410	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS010858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG017265] Funding Source: NIH RePORTER; AHRQ HHS [5PO1 HS10858] Funding Source: Medline; NIA NIH HHS [P30-AG17265] Funding Source: Medline; BHP HRSA HHS [6 T32 PE-190001-13 R] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); BHP HRSA HHS		Alexander M, 1999, AM HEART J, V137, P919, DOI 10.1016/S0002-8703(99)70417-5; BOTMAN SL, 1995, STAT MED, V14, P669, DOI 10.1002/sim.4780140523; *CDCP, 2001, HIV AIDS SURVEILLANC, V13, P1; Chiang C., 1968, INTRO STOCHASTIC PRO; CHIANG CL, 1991, ANNU REV PUBL HEALTH, V12, P281, DOI 10.1146/annurev.pu.12.050191.001433; COUGHLIN SS, 1994, J NATL MED ASSOC, V86, P583; CURTIS JR, 1993, AM J PUBLIC HEALTH, V83, P1425, DOI 10.2105/AJPH.83.10.1425; Davison AC, 1997, BOOTSTRAP METHODS TH; *DEP HHS, 2000, HLTH PEOPL 2010; Edwards MJ, 1998, J CLIN ONCOL, V16, P2693, DOI 10.1200/JCO.1998.16.8.2693; Feldman RHL, 1999, J HEALTH CARE POOR U, V10, P45; Gardner J W, 1990, Epidemiology, V1, P322, DOI 10.1097/00001648-199007000-00012; GOODALL C, 1990, MODERN METHODS DATA, P126; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; HOWARD G, 1995, STROKE, V26, P1759, DOI 10.1161/01.STR.26.10.1759; Howard G, 2000, ANN EPIDEMIOL, V10, P214, DOI 10.1016/S1047-2797(00)00038-7; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; Kallan J, 1997, SOC BIOL, V44, P294; Klein JP., 2003, SURVIVAL ANAL TECHNI; Kressin NR, 2001, ANN INTERN MED, V135, P352, DOI 10.7326/0003-4819-135-5-200109040-00012; Lai DJ, 1999, INT J EPIDEMIOL, V28, P894, DOI 10.1093/ije/28.5.894; Madison T, 1998, CANCER-AM CANCER SOC, V83, P1546, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1546::AID-CNCR9>3.0.CO;2-M; MARMOT MG, 1984, LANCET, V1, P1003; Minino A M, 2001, Natl Vital Stat Rep, V49, P1; Mundt AJ, 1998, GYNECOL ONCOL, V71, P151, DOI 10.1006/gyno.1998.5203; *NAT CTR HLTH STAT, 1994, NAT HLTH INT SURV 1; *NAT CTR HLTH STAT, 1997, NAT HLTH INT SURV 19; Nilsson PM, 1998, DIABETIC MED, V15, P213, DOI 10.1002/(SICI)1096-9136(199803)15:3<213::AID-DIA569>3.3.CO;2-R; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P56, DOI 10.1001/jama.261.1.56; Robinson N, 1998, DIABETIC MED, V15, P205, DOI 10.1002/(SICI)1096-9136(199803)15:3<205::AID-DIA519>3.0.CO;2-#; ROGOT E, 1992, PUBLIC HEALTH REP, V107, P457; Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P497, DOI 10.2105/AJPH.86.4.497; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; WAGENKNECHT LE, 1990, PREV MED, V19, P158, DOI 10.1016/0091-7435(90)90017-E; Wilkins R, 1989, Health Rep, V1, P137	40	602	610	2	40	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2002	347	20					1585	1592		10.1056/NEJMsa012979	http://dx.doi.org/10.1056/NEJMsa012979			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	614KL	12432046				2022-12-28	WOS:000179187800007
J	Zielasek, J; Bender, G; Schlesinger, S; Friedl, P; Kenn, W; Allolio, B; Lauer, M				Zielasek, J; Bender, G; Schlesinger, S; Friedl, P; Kenn, W; Allolio, B; Lauer, M			A woman who gained weight and became schizophrenic	LANCET			English	Editorial Material									Univ Wurzburg, Dept Psychiat, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Med, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Dermatol, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Radiol, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg	Zielasek, J (corresponding author), Univ Wurzburg, Dept Psychiat, D-97080 Wurzburg, Germany.							BARNETT IG, 1970, P ROY SOC MED, V63, P338, DOI 10.1177/003591577006300404; FRIEDLAND RP, 1978, MT SINAI J MED, V45, P509; GERSON SN, 1985, CAN J PSYCHIAT, V30, P223, DOI 10.1177/070674378503000312; Hirsch D, 2000, ISRAEL J PSYCHIAT, V37, P46; JOHNSON J, 1975, PSYCHOL MED, V5, P165, DOI 10.1017/S0033291700056427	5	11	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1392	1392		10.1016/S0140-6736(02)11404-8	http://dx.doi.org/10.1016/S0140-6736(02)11404-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	612ND	12423986				2022-12-28	WOS:000179081600013
J	Marchand, AP				Marchand, AP			Diamondoid hydrocarbons - Delving into nature's bounty	SCIENCE			English	Editorial Material									Univ N Texas, Dept Chem, Denton, TX 76203 USA	University of North Texas System; University of North Texas Denton	Marchand, AP (corresponding author), Univ N Texas, Dept Chem, Denton, TX 76203 USA.							BRAGG WH, 1913, NATURE, V91, P554; CUPAS C, 1965, J AM CHEM SOC, V87, P917, DOI 10.1021/ja01082a042; Dahl J. E., 2002, [No title captured], Patent No. [WO 0258139, 0258139]; Dahl JE, 2003, SCIENCE, V299, P96, DOI 10.1126/science.1078239; DAHL JE, 2002, Patent No. 0257202; Fort R. C., 1976, ADAMANTANE CHEM DIAM; Olah G., 1990, CAGE HYDROCARBONS, P103; SCHLEYER PV, 1957, J AM CHEM SOC, V79, P3292; SCHNEIDE.A, 1966, J ORG CHEM, V31, P1617, DOI 10.1021/jo01343a070; SCHNEIDER A, Patent No. 3356751; SCHNEIDER A, Patent No. 3382288; Shakespeare William, HAMLET; WILLIAMS VZ, 1966, J AM CHEM SOC, V88, P3362	13	69	77	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 3	2003	299	5603					52	53		10.1126/science.1079630	http://dx.doi.org/10.1126/science.1079630			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	631JZ	12459550				2022-12-28	WOS:000180165800023
J	Ko, HW; Jiang, J; Edery, I				Ko, HW; Jiang, J; Edery, I			Role for Slimb in the degradation of Drosophila Period protein phosphorylated by Doubletime	NATURE			English	Article							CASEIN-KINASE-I; DOUBLE-TIME; CLOCK-GENE; CYCLIN-E; F-BOX; LIGHT; UBIQUITINATION; EXPRESSION; MUTATION	Protein phosphorylation has a key role in modulating the stabilities of circadian clock proteins in a manner specific to the time of day(1). A conserved feature of animal clocks is that Period (Per) proteins undergo daily rhythms in phosphorylation and levels(2,3), events that are crucial for normal clock progression(4-7). Casein kinase Iepsilon (CKIepsilon) has a prominent role in regulating the phosphorylation and abundance of Per proteins in animals(8). This was first shown in Drosophila with the characterization of Doubletime (Dbt), a homologue of vertebrate casein kinase Iepsilon(4,6). However, it is not clear how Dbt regulates the levels of Per. Here we show, using a cell culture system, that Dbt promotes the progressive phosphorylation of Per, leading to the rapid degradation of hyperphosphorylated isoforms by the ubiquitin-proteasome pathway. Slimb, an F-box/WD40-repeat protein functioning in the ubiquitin-proteasome pathway(9,10) interacts preferentially with phosphorylated Per and stimulates its degradation. Overexpression of slimb or expression in clock cells of a dominant-negative version of slimb disrupts normal rhythmic activity in flies. Our findings suggest that hyperphosphorylated Per is targeted to the proteasome by interactions with Slimb.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Grad Program Physiol & Neurobiol, Piscataway, NJ 08854 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75390 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Edery, I (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Mol Biol & Biochem, 679 Hoes Lane, Piscataway, NJ 08854 USA.	edery@cabm.rutgers.edu		KO, HYUK WAN/0000-0003-1753-1900	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061269] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061269] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Bae K, 2000, J NEUROSCI, V20, P1746; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; Bocca SN, 2001, BIOCHEM BIOPH RES CO, V286, P357, DOI 10.1006/bbrc.2001.5394; BRAND AH, 1993, DEVELOPMENT, V118, P401; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Edery I, 1999, CHRONOBIOL INT, V16, P377, DOI 10.3109/07420529908998716; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Eide EJ, 2001, CHRONOBIOL INT, V18, P389, DOI 10.1081/CBI-100103963; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kaneko M, 2000, J NEUROBIOL, V43, P207, DOI 10.1002/(SICI)1097-4695(20000605)43:3<207::AID-NEU1>3.0.CO;2-0; Kim EY, 2002, NEURON, V34, P69, DOI 10.1016/S0896-6273(02)00639-6; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kloss B, 2001, NEURON, V30, P699, DOI 10.1016/S0896-6273(01)00320-8; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rothenfluh A, 2000, CURR BIOL, V10, P1399, DOI 10.1016/S0960-9822(00)00786-7; Sidote D, 1998, MOL CELL BIOL, V18, P2004, DOI 10.1128/MCB.18.4.2004; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Worby C A, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.95.pl1; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301	30	258	261	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	2002	420	6916					673	678		10.1038/nature01272	http://dx.doi.org/10.1038/nature01272			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	624GK	12442174				2022-12-28	WOS:000179751800047
J	Conner, JK				Conner, JK			Genetic mechanisms of floral trait correlations in a natural population	NATURE			English	Article							DROSOPHILA-MELANOGASTER; WILD RADISH; SELECTION; CHARACTERS; EVOLUTION; ARCHITECTURE; COVARIANCES; LINKAGE; FITNESS	Genetic correlations among traits are important in evolution, as they can constrain evolutionary change or reflect past selection for combinations of traits(1,2). Constraints and integration depend on whether the correlations are caused by pleiotropy or linkage disequilibrium(3), but these genetic mechanisms underlying correlations remain largely unknown in natural populations(4). Quantitative trait locus (QTL) mapping studies do not adequately address the mechanisms of within-population genetic correlations because they rely on crosses between distinct species, inbred lines or selected lines (see ref. 5), and they cannot distinguish moderate linkage disequilibrium from pleiotropy because they commonly rely on only one or two episodes of recombination(6). Here I report that after nine generations of enforced random mating (nine episodes of recombination), correlations between six floral traits in wild radish plants are unchanged, showing that pleiotropy generates the correlations. There is no evidence for linkage disequilibrium despite previous correlational selection acting on one functionally integrated pair of traits(7). This study provides direct evidence of the genetic mechanisms underlying correlations between quantitative traits in a natural population and suggests that there may be constraints on the independent evolution of pairs of highly correlated traits.	Michigan State Univ, Kellogg Biol Stn, Hickory Corners, MI 49060 USA; Michigan State Univ, Dept Plant Biol, Hickory Corners, MI 49060 USA	Michigan State University; Michigan State University	Conner, JK (corresponding author), Michigan State Univ, Kellogg Biol Stn, 3700 E Gull Lake Dr, Hickory Corners, MI 49060 USA.	conner@kbs.msu.edu	Conner, Jeffrey/F-3188-2011	Conner, Jeffrey/0000-0003-1613-5826				BULMER MG, 1974, GENET RES, V23, P281, DOI 10.1017/S0016672300014920; Bulmer MG, 1985, MATH THEORY QUANTITA; Clark A., 1987, GENETIC CONSTRAINTS, P25, DOI DOI 10.1007/978-3-642-72770-2_3; CONNER J, 1993, EVOLUTION, V47, P704, DOI 10.1111/j.1558-5646.1993.tb02128.x; Conner JK, 1997, INT J PLANT SCI, V158, pS108, DOI 10.1086/297511; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; Deng HW, 1999, EVOLUTION, V53, P1592, DOI 10.1111/j.1558-5646.1999.tb05422.x; Falconer DS, 1996, INTRO QUANTITATIVE G; Futuyma D. J., 1998, EVOLUTIONARY BIOL; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; Houle D, 2002, EVOLUTION, V56, P433; Kearsey MJ, 1998, HEREDITY, V80, P137, DOI 10.1046/j.1365-2540.1998.00500.x; LANDE R, 1984, GENET RES, V44, P309, DOI 10.1017/S0016672300026549; LANDE R, 1980, GENETICS, V94, P203; Lynch M., 1998, GENETICS ANAL QUANTI; Maynard Smith J., 1985, Q REV BIOL, V60, P265, DOI DOI 10.1086/414425); MitchellOlds T, 1996, EVOLUTION, V50, P1849, DOI 10.1111/j.1558-5646.1996.tb03571.x; Morgan MT, 2001, EVOLUTION, V55, P272, DOI 10.1111/j.0014-3820.2001.tb01292.x; Nuzhdin SV, 1999, GENETICS, V153, P1317; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; Phillips PC, 1999, EVOLUTION, V53, P1506, DOI 10.2307/2640896; Roff DA, 1999, J EVOLUTION BIOL, V12, P361, DOI 10.1046/j.1420-9101.1999.00036.x; SAS Institute, 1999, SAS STAT US GUID VER; Shabalina SA, 1997, P NATL ACAD SCI USA, V94, P13034, DOI 10.1073/pnas.94.24.13034; Shaw FH, 1995, EVOLUTION, V49, P1260, DOI 10.1111/j.1558-5646.1995.tb04452.x; SHAW RG, 1991, EVOLUTION, V45, P143, DOI 10.1111/j.1558-5646.1991.tb05273.x; Snedecor G.W., 1989, AMES IOWA STATE U PR; WHITLOCK MC, 1995, ANNU REV ECOL SYST, V26, P601, DOI 10.1146/annurev.es.26.110195.003125; WILLIS JH, 1991, EVOLUTION, V45, P441, DOI 10.1111/j.1558-5646.1991.tb04418.x; Wright S., 1969, THEORY GENE FREQUENC, V2, P520	30	139	142	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	2002	420	6914					407	410		10.1038/nature01105	http://dx.doi.org/10.1038/nature01105			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459781				2022-12-28	WOS:000179494700037
J	Zeng, H; Li, J; Liu, JP; Wang, ZL; Sun, SH				Zeng, H; Li, J; Liu, JP; Wang, ZL; Sun, SH			Exchange-coupled nanocomposite magnets by nanoparticle self-assembly	NATURE			English	Article							MULTILAYERS	Exchange-spring magnets are nanocomposites that are composed of magnetically hard and soft phases that interact by magnetic exchange coupling(1). Such systems are promising for advanced permanent magnetic applications, as they have a large energy product-the combination of permanent magnet field and magnetization-compared to traditional, single-phase materials(1-3). Conventional techniques, including melt-spinning(4-6), mechanical milling(7-9) and sputtering(10-12), have been explored to prepare exchange-spring magnets. However, the requirement that both the hard and soft phases are controlled at the nanometre scale, to ensure efficient exchange coupling, has posed significant preparation challenges. Here we report the fabrication of exchange-coupled nanocomposites using nanoparticle self-assembly. In this approach, both FePt and Fe3O4 particles are incorporated as nanometre-scale building blocks into binary assemblies. Subsequent annealing converts the assembly into FePt-Fe3Pt nanocomposites, where FePt is a magnetically hard phase and Fe3Pt a soft phase. An optimum exchange coupling, and therefore an optimum energy product, can be obtained by independently tuning the size and composition of the individual building blocks. We have produced exchange-coupled isotropic FePt-Fe3Pt nanocomposites with an energy product of 20.1 MG Oe, which exceeds the theoretical limit of 13 MG Oe for non-exchange-coupled isotropic FePt by over 50 per cent.	IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA; Louisiana Tech Univ, Inst Micromfg, Ruston, LA 71272 USA; Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA	International Business Machines (IBM); University of Louisiana System; Louisiana Technical University; University System of Georgia; Georgia Institute of Technology	Sun, SH (corresponding author), IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA.		Zeng, Hao/E-1994-2012; Zeng, Hao/AAD-8060-2021; wang, jie/GRS-0942-2022; Wang, Zhong Lin/E-2176-2011	Wang, Zhong Lin/0000-0002-5530-0380				COEHOORN R, 1989, J MAGN MAGN MATER, V80, P101, DOI 10.1016/0304-8853(89)90333-8; Fullerton EE, 1998, APPL PHYS LETT, V72, P380, DOI 10.1063/1.120743; GONG W, 1994, J APPL PHYS, V75, P6649; Kiely CJ, 1998, NATURE, V396, P444, DOI 10.1038/24808; KLEMMER T, 1995, SCRIPTA METALL MATER, V33, P1793, DOI 10.1016/0956-716X(95)00413-P; KNELLER EF, 1991, IEEE T MAGN, V27, P3588, DOI 10.1109/20.102931; Kobayashi T, 2000, J APPL PHYS, V87, P6579, DOI 10.1063/1.372776; Liu JP, 1999, J APPL PHYS, V85, P4812, DOI 10.1063/1.370490; Liu JP, 1998, APPL PHYS LETT, V72, P483, DOI 10.1063/1.120793; McCormick PG, 1998, J APPL PHYS, V83, P6256, DOI 10.1063/1.367772; O'Handley R C, 2000, MODERN MAGNETIC MAT, P469; Ping DH, 1998, J APPL PHYS, V83, P7769, DOI 10.1063/1.367951; PODGORNY M, 1991, PHYS REV B, V43, P13700; Schrelfl T., 1993, J MAGN MAGN MATER, V127, P273; SKOMSKI R, 1993, PHYS REV B, V48, P15812, DOI 10.1103/PhysRevB.48.15812; Sun SH, 2001, IEEE T MAGN, V37, P1239, DOI 10.1109/20.950807; Sun SH, 2002, J AM CHEM SOC, V124, P8204, DOI 10.1021/ja026501x; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; Weller D, 2000, IEEE T MAGN, V36, P10, DOI 10.1109/20.824418; Zeng H, 2002, APPL PHYS LETT, V80, P2583, DOI 10.1063/1.1467976; Zhang J, 2001, J APPL PHYS, V89, P2857, DOI 10.1063/1.1344219	21	1408	1445	14	919	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					395	398		10.1038/nature01208	http://dx.doi.org/10.1038/nature01208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459779				2022-12-28	WOS:000179494700033
J	Dukes, MNG				Dukes, MNG			Accountability of the pharmaceutical industry	LANCET			English	Article							DISEASES; POOR	The pharmaceutical industry is accountable on the one hand to its shareholders and on the other to the community at large. These two obligations can, in principle, be met. However, the industry has developed practices that do not consider society, including excessive or inappropriate pricing of drugs, an indifference to the needs and limitations of the developing world, an imbalance between true innovation and promotional activity, interference with clinical investigations, and efforts to mould medical thinking and priorities as a means to enlarge the market. In such respects, the pharmaceutical industry must now be called to order. The industry has shown itself to be sufficiently resilient to adapt to change if society insists on it. However, to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent society's public-health interests.	Univ Oslo, Inst Pharmacotherapy, N-0778 Oslo, Norway	University of Oslo	Dukes, MNG (corresponding author), Univ Oslo, Inst Pharmacotherapy, Trosterudveien 19, N-0778 Oslo, Norway.							Abraham J., 2000, REGULATING MED EUROP; BOSELEY S, 2001, GUARDIAN        1010, P18; Cragg G. M., 1996, Progress in new crops: Proceedings of the Third National Symposium, Indianapolis, Indiana, USA, 22-25 October, 1996., P554; Dukes M.N.G., 1985, EFFECTS DRUG REGULAT; Eaton L, 2001, BRIT MED J, V323, P827, DOI 10.1136/bmj.323.7317.827; *GEN ACC OFF, 1990, FDA DRUG REV POST AP; *GIP, 2002, STAT PHARM SERV NETH; Guyatt G, 2002, CAN MED ASSOC J, V167, P36; HODGKIN C, 1996, HAI LIGHTS, V1, P2; Horton R, 2002, LANCET, V359, P1605, DOI 10.1016/S0140-6736(02)08523-9; Laing RD, 2001, WHO WTO SECR WORKSH; MARSH P, 1909, NEW SCI         1118; McNeil DG, 2000, NY TIMES, P1; MCNEIL DG, 2000, NY TIMES        0521, P6; MOSS L, 2001, CUTTER IT J, V14, P1; *MSF, 2001, MATT LIF DEATH; *MSF, 2001, DRUG DON WONT SOLV A, P3; *MSF, 2001, PRESCR ACT; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Richter J., 2001, HOLDING CORPORATIONS; SAUNDERS C, 2001, WHO WTO SECR WORKSH; TEIXEIRA PK, 2001, WHO WTO WORKSH DIFF; Trouiller P, 1999, LANCET, V354, P164, DOI 10.1016/S0140-6736(05)75299-5; *UN SUBC PREV DISC, 1998, 1998 RES CALL EST WO; *WHO, 2001, WHO WTO SECR WORKSH; 1966, CAI FORUM        JUN; 1997, SCRIP, V2287, P2	27	25	27	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 23	2002	360	9346					1682	1684		10.1016/S0140-6736(02)11599-6	http://dx.doi.org/10.1016/S0140-6736(02)11599-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457804				2022-12-28	WOS:000179393900026
J	Adam, D				Adam, D			Cambridge-MIT Institute probed	NATURE			English	News Item																		1999, NATURE, V402, P111	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					256	256		10.1038/420256b	http://dx.doi.org/10.1038/420256b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447404	Bronze			2022-12-28	WOS:000179340400005
J	Dolan, RJ				Dolan, RJ			Emotion, cognition, and behavior	SCIENCE			English	Review							SKIN-CONDUCTANCE RESPONSES; HUMAN AMYGDALA; NEURAL ACTIVITY; TIME-COURSE; DECLARATIVE MEMORY; SPATIAL ATTENTION; EPISODIC MEMORY; DECISION-MAKING; BRAIN ACTIVITY; STIMULI	Emotion is central to the quality and range of everyday human experience. The neurobiological substrates of human emotion are now attracting increasing interest within the neurosciences motivated, to a considerable extent, by advances in functional neuroimaging techniques. An emerging theme is the question of how emotion interacts with and influences other domains of cognition, in particular attention, memory, and reasoning. The psychological consequences and mechanisms underlying the emotional modulation of cognition provide the focus of this article.	Inst Neurol, Wellcome Dept Imaging Neurosci, London WC1N 3BG, England	University of London; University College London	Dolan, RJ (corresponding author), Inst Neurol, Wellcome Dept Imaging Neurosci, Queen Sq, London WC1N 3BG, England.	r.dolan@fil.ion.ucl.ac.uk		Dolan, Ray/0000-0001-9356-761X				Adolphs R, 1997, LEARN MEMORY, V4, P291, DOI 10.1101/lm.4.3.291; Adolphs R, 1998, NATURE, V393, P470, DOI 10.1038/30982; Amaral D.G., 1992, AMYGDALA NEUROBIOLOG; Anderson AK, 2001, NATURE, V411, P305, DOI 10.1038/35077083; Anderson AK, 2002, J COGNITIVE NEUROSCI, V14, P709, DOI 10.1162/08989290260138618; Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Armony JL, 2002, NEUROPSYCHOLOGIA, V40, P817, DOI 10.1016/S0028-3932(01)00178-6; Babinsky R, 1993, Behav Neurol, V6, P167, DOI 10.3233/BEN-1993-6310; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Buchel C, 1998, NEURON, V20, P947, DOI 10.1016/S0896-6273(00)80476-6; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; Cahill L, 1996, P NATL ACAD SCI USA, V93, P8016, DOI 10.1073/pnas.93.15.8016; Canli T, 2000, J NEUROSCI, V20; Critchley HD, 2001, NAT NEUROSCI, V4, P207, DOI 10.1038/84048; Critchley HD, 2000, J NEUROSCI, V20, P3033; Critchley HD, 2001, BRAIN, V124, P1003, DOI 10.1093/brain/124.5.1003; Critchley HD, 2001, NEURON, V29, P537, DOI 10.1016/S0896-6273(01)00225-2; Critchley HD, 2002, NEURON, V33, P653, DOI 10.1016/S0896-6273(02)00588-3; Damasio A., 1995, DESCARTES ERROR; Damasio A.R., 2000, FEELING WHAT HAPPENS; Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871; Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591; de Gelder B, 1999, NEUROREPORT, V10, P3759, DOI 10.1097/00001756-199912160-00007; Dolan RS, 2000, NEUROIMAGE, V11, P203, DOI 10.1006/nimg.2000.0538; Drevets WC, 2000, PROG BRAIN RES, V126, P413; Eimer M, 2002, NEUROREPORT, V13, P427, DOI 10.1097/00001756-200203250-00013; ESTEVES F, 1994, PSYCHOPHYSIOLOGY, V31, P375, DOI 10.1111/j.1469-8986.1994.tb02446.x; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; Halgren E, 2000, CEREB CORTEX, V10, P69, DOI 10.1093/cercor/10.1.69; Hamann SB, 1997, LEARN MEMORY, V4, P301, DOI 10.1101/lm.4.3.301; Hamann SB, 1999, NAT NEUROSCI, V2, P289, DOI 10.1038/6404; James W., 1890, PRINCIPLES PSYCHOL, P449, DOI [https://doi.org/10.1037/11059-009, DOI 10.1037/11059-009]; Johnsrude IS, 2000, J NEUROSCI, V20, P2649; Katkin ES, 2001, PSYCHOL SCI, V12, P366, DOI 10.1111/1467-9280.00368; Kawasaki H, 2001, NAT NEUROSCI, V4, P15, DOI 10.1038/82850; LABAR KS, 1995, J NEUROSCI, V15, P6846; LaBar KS, 1998, NEURON, V20, P937, DOI 10.1016/S0896-6273(00)80475-4; LeDoux J., 1998, EMOTIONAL BRAIN; Maratos EJ, 2001, NEUROPSYCHOLOGIA, V39, P910, DOI 10.1016/S0028-3932(01)00025-2; Mayberg HS, 2000, BIOL PSYCHIAT, V48, P830, DOI 10.1016/S0006-3223(00)01036-2; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Mogg K, 1997, BEHAV RES THER, V35, P297, DOI 10.1016/S0005-7967(96)00109-X; Morris JS, 2001, BRAIN, V124, P1241, DOI 10.1093/brain/124.6.1241; Morris JS, 1998, NATURE, V393, P467, DOI 10.1038/30976; Morris JS, 1998, BRAIN, V121, P47, DOI 10.1093/brain/121.1.47; O'Doherty JP, 2002, NEURON, V33, P815, DOI 10.1016/S0896-6273(02)00603-7; Ohman A, 2001, J EXP PSYCHOL GEN, V130, P466, DOI 10.1037/0096-3445.130.3.466; Ohman A, 1998, J EXP PSYCHOL GEN, V127, P69, DOI 10.1037/0096-3445.127.1.69; Phelps EA, 1997, BRAIN COGNITION, V35, P85, DOI 10.1006/brcg.1997.0929; Pourtois G, 2000, NEUROREPORT, V11, P1329, DOI 10.1097/00001756-200004270-00036; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Rotshtein P, 2001, NEURON, V32, P747, DOI 10.1016/S0896-6273(01)00513-X; Thiel CM, 2002, NEURON, V35, P567, DOI 10.1016/S0896-6273(02)00801-2; Vuilleumier P, 2002, NEUROPSYCHOLOGIA, V40, P2156, DOI 10.1016/S0028-3932(02)00045-3; Vuilleumier P, 2001, NEURON, V30, P829, DOI 10.1016/S0896-6273(01)00328-2; Vuilleumier P, 2001, NEUROLOGY, V56, P153, DOI 10.1212/WNL.56.2.153; Vuilleumier P, 2001, NEUROREPORT, V12, P1119, DOI 10.1097/00001756-200105080-00014; Weinberger NM, 1998, NEUROBIOL LEARN MEM, V70, P226, DOI 10.1006/nlme.1998.3850; Whalen PJ, 1998, J NEUROSCI, V18, P411; Winston JS, 2002, NAT NEUROSCI, V5, P277, DOI 10.1038/nn816	63	1107	1157	18	350	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	2002	298	5596					1191	1194		10.1126/science.1076358	http://dx.doi.org/10.1126/science.1076358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	612MQ	12424363				2022-12-28	WOS:000179080400032
J	Burrone, J; O'Byrne, M; Murthy, VN				Burrone, J; O'Byrne, M; Murthy, VN			Multiple forms of synaptic plasticity triggered by selective suppression of activity in individual neurons	NATURE			English	Article							GLUTAMATE RECEPTORS; NEUROMUSCULAR-JUNCTION; PRESYNAPTIC RELEASE; HIPPOCAMPAL-NEURONS; EXCITATORY SYNAPSES; SILENT SYNAPSES; NMDA RECEPTOR; EXPRESSION; BLOCKADE; MEMBRANE	The rules by which neuronal activity causes long-term modification of synapses in the central nervous system are not fully understood. Whereas competitive or correlation-based rules result in local modification of synapses, homeostatic modifications allow neuron-wide changes in synaptic strength, promoting stability(1,2). Experimental investigations of these rules at central nervous system synapses have relied generally on manipulating activity in populations of neurons(1,3-6). Here, we investigated the effect of suppressing excitability in single neurons within a network of active hippocampal neurons by overexpressing an inward-rectifier potassium channel. Reducing activity in a neuron before synapse formation leads to a reduction in functional synaptic inputs to that neuron; no such reduction was observed when activity of all neurons was uniformly suppressed. In contrast, suppressing activity in a single neuron after synapses are established results in a homeostatic increase in synaptic input, which restores the activity of the neuron to control levels. Our results highlight the differences between global and selective suppression of activity, as well as those between early and late manipulation of activity.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Murthy, VN (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.		Burrone, Juan/C-5654-2009	Burrone, Juan/0000-0003-1233-668X; O'Byrne, Michael/0000-0001-6023-1634; Murthy, Venkatesh/0000-0003-2443-4252				Abbott LF, 2000, NAT NEUROSCI, V3, P1178, DOI 10.1038/81453; Bacci A, 2001, J NEUROSCI, V21, P6588, DOI 10.1523/JNEUROSCI.21-17-06588.2001; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; Bi GQ, 2001, ANNU REV NEUROSCI, V24, P139, DOI 10.1146/annurev.neuro.24.1.139; Cottrell JR, 2000, J NEUROPHYSIOL, V84, P1573, DOI 10.1152/jn.2000.84.3.1573; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; Crowley JC, 1999, NAT NEUROSCI, V2, P1125, DOI 10.1038/16051; Davis GW, 2001, ANNU REV PHYSIOL, V63, P847, DOI 10.1146/annurev.physiol.63.1.847; Gomperts SN, 2000, J NEUROSCI, V20, P2229; Holt JR, 1999, J NEUROPHYSIOL, V81, P1881, DOI 10.1152/jn.1999.81.4.1881; Hubener M, 1999, NAT NEUROSCI, V2, P1043, DOI 10.1038/15964; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Johns DC, 1999, J NEUROSCI, V19, P1691; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Li ZY, 2001, NEURON, V31, P593, DOI 10.1016/S0896-6273(01)00398-1; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lin DM, 2000, NEURON, V26, P69, DOI 10.1016/S0896-6273(00)81139-3; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; OBrien RJ, 1997, J NEUROSCI, V17, P7339; Paradis S, 2001, NEURON, V30, P737, DOI 10.1016/S0896-6273(01)00326-9; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Turrigiano GG, 2000, CURR OPIN NEUROBIOL, V10, P358, DOI 10.1016/S0959-4388(00)00091-X; Xia ZG, 1996, J NEUROSCI, V16, P5425; Zhao HQ, 2001, CELL, V104, P651, DOI 10.1016/S0092-8674(02)01107-8; Zheng C, 2000, NEURON, V26, P81, DOI 10.1016/S0896-6273(00)81140-X	30	349	358	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					414	418		10.1038/nature01242	http://dx.doi.org/10.1038/nature01242			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459783				2022-12-28	WOS:000179494700039
J	Guallar, E; Sanz-Gallardo, MI; van't Veer, P; Bode, P; Aro, A; Gomez-Aracena, J; Kark, JD; Riemersma, RA; Martin-Moreno, JM; Kok, FJ				Guallar, E; Sanz-Gallardo, MI; van't Veer, P; Bode, P; Aro, A; Gomez-Aracena, J; Kark, JD; Riemersma, RA; Martin-Moreno, JM; Kok, FJ		Heavy Metals and Myocardial Infarc	Mercury, fish oils, and the risk of myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; N-3 FATTY-ACIDS; ADIPOSE-TISSUE; DIETARY-INTAKE; LIPID-PEROXIDATION; CONSUMPTION; MORTALITY; DEATH; METHYLMERCURY; BIOMARKERS	Background: It has been suggested that mercury, a highly reactive heavy metal with no known physiologic activity, increases the risk of cardiovascular disease. Because fish intake is a major source of exposure to mercury, the mercury content of fish may counteract the beneficial effects of its n-3 fatty acids. Methods: In a case-control study conducted in eight European countries and Israel, we evaluated the joint association of mercury levels in toenail clippings and docosahexaenoic acid (C22:6n-3, or DHA) levels in adipose tissue with the risk of a first myocardial infarction among men. The patients were 684 men with a first diagnosis of myocardial infarction. The controls were 724 men selected to be representative of the same populations. Results: The average toenail mercury level in controls was 0.25 microg per gram. After adjustment for the DHA level and coronary risk factors, the mercury levels in the patients were 15 percent higher than those in controls (95 percent confidence interval, 5 to 25 percent). The risk-factor-adjusted odds ratio for myocardial infarction associated with the highest as compared with the lowest quintile of mercury was 2.16 (95 percent confidence interval, 1.09 to 4.29; P for trend = 0.006). After adjustment for the mercury level, the DHA level was inversely associated with the risk of myocardial infarction (odds ratio for the highest vs. the lowest quintile, 0.59; 95 percent confidence interval, 0.30 to 1.19; P for trend = 0.02). Conclusions: The toenail mercury level was directly associated with the risk of myocardial infarction, and the adipose-tissue DHA level was inversely associated with the risk. High mercury content may diminish the cardioprotective effect of fish intake.	Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21205 USA; Natl Sch Publ Hlth, Inst Hlth Carlos III, Dept Epidemiol & Biostat, Madrid, Spain; Hosp 12 Octubre, Serv Prevent Med, E-28041 Madrid, Spain; Univ Wageningen & Res Ctr, Div Human Nutr & Epidemiol, Wageningen, Netherlands; Delft Univ Technol, Interfac Reactor Inst, NL-2629 JB Delft, Netherlands; Natl Publ Hlth Inst, Dept Hlth & Funct Capac, Helsinki, Finland; Univ Malaga, Dept Prevent Med, E-29071 Malaga, Spain; Hebrew Univ Jerusalem, Hadassah Sch Publ Hlth & Community Med, Jerusalem, Israel; Hadassah Med Org, Dept Social Med, Epidemiol Unit, Jerusalem, Israel; Univ Edinburgh, Cardiovasc Res Unit, Edinburgh, Midlothian, Scotland; Univ Tromso, Dept Med Physiol, Tromso, Norway; Univ Autonoma Madrid, Dept Prevent Med, Madrid, Spain	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Hospital Universitario 12 de Octubre; Wageningen University & Research; Delft University of Technology; Finland National Institute for Health & Welfare; Universidad de Malaga; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Edinburgh; UiT The Arctic University of Tromso; Autonomous University of Madrid	Guallar, E (corresponding author), Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-639, Baltimore, MD 21205 USA.	eguallar@jhsph.edu	Martin-Moreno, Jose M./S-7733-2016; Guallar, Eliseo/D-3807-2014	Martin-Moreno, Jose M./0000-0002-8648-5541; Guallar, Eliseo/0000-0002-4471-9565				Albert CM, 2002, NEW ENGL J MED, V346, P1113, DOI 10.1056/NEJMoa012918; ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BARREGARD L, 1990, BRIT J IND MED, V47, P99; Bode P, 2000, J RADIOANAL NUCL CH, V245, P127, DOI 10.1023/A:1006777230207; Boffetta P, 2001, OCCUP ENVIRON MED, V58, P461, DOI 10.1136/oem.58.7.461; BURR ML, 1989, LANCET, V2, P757; Clarkson TW, 1997, CRIT REV CL LAB SCI, V34, P369, DOI 10.3109/10408369708998098; Committee on the Toxicological Effects of Methylmercury Board on Environmental Studies and Toxicology National Research Council, 2000, TOX EFF METH; Connor WE, 2000, AM J CLIN NUTR, V71, p171S, DOI 10.1093/ajcn/71.1.171S; *CTR FOOD SAF APPL, 2001, CONS ADV IMP MESS PR; CUVINARALAR MLA, 1991, ECOTOX ENVIRON SAFE, V21, P348, DOI 10.1016/0147-6513(91)90074-Y; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DOROZYNSKI A, 1975, NATURE, V254, P549, DOI 10.1038/254549a0; GARLAND, 1994, CANCER EPIDEM BIOMAR, V3, P523; GARLAND M, 1993, CANCER EPIDEM BIOMAR, V2, P493; Gillum RF, 2000, J CLIN EPIDEMIOL, V53, P237, DOI 10.1016/S0895-4356(99)00149-3; *GISSI PREV INV, 2001, LANCET, V357, P642; Guallar E, 1999, ARTERIOSCL THROM VAS, V19, P1111, DOI 10.1161/01.ATV.19.4.1111; GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6; Hu FB, 2002, JAMA-J AM MED ASSOC, V287, P1815, DOI 10.1001/jama.287.14.1815; InSug O, 1997, TOXICOLOGY, V124, P211, DOI 10.1016/S0300-483X(97)00153-4; JANSSON G, 1993, FREE RADICAL RES COM, V18, P87, DOI 10.3109/10715769309147345; Kardinaal AFM, 1997, AM J EPIDEMIOL, V145, P373, DOI 10.1093/oxfordjournals.aje.a009115; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; Keating MH, 1997, EPA452R97003; KISHIMOTO T, 1995, ARCH TOXICOL, V69, P357, DOI 10.1007/s002040050184; KOSTKA B, 1992, Journal of Trace Elements in Experimental Medicine, V5, P1; Krauss RM, 2000, STROKE, V31, P2751, DOI 10.1161/01.STR.31.11.2751; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; MacIntosh DL, 1997, CANCER EPIDEM BIOMAR, V6, P1043; Magos L, 1997, MET IONS BIOL SYST, V34, P321; MARCKMANN P, 1995, AM J CLIN NUTR, V62, P956, DOI 10.1093/ajcn/62.5.956; Marckmann P, 1999, EUR J CLIN NUTR, V53, P585, DOI 10.1038/sj.ejcn.1600832; Mathsoft, 1999, S PLUS 2000 US GUID; MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615; NAGANUMA A, 1980, TOXICOL APPL PHARM, V54, P405, DOI 10.1016/0041-008X(80)90167-2; Rissanen T, 2000, CIRCULATION, V102, P2677, DOI 10.1161/01.CIR.102.22.2677; RUNGBY J, 1992, PHARMACOL TOXICOL, V70, P205, DOI 10.1111/j.1600-0773.1992.tb00458.x; Salonen JT, 2000, ATHEROSCLEROSIS, V148, P265, DOI 10.1016/S0021-9150(99)00272-5; SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; TUOMILEHTO J, 1989, INT J EPIDEMIOL, V18, pS38; *UN FAO, 2001, FAOSTAT 2001 CD ROM; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Von Burg R., 1991, METALS THEIR COMPOUN, P1045; Wierzbicki R, 2002, J TRACE ELEM EXP MED, V15, P21, DOI 10.1002/jtra.1055; WOOD DA, 1987, LANCET, V1, P177; Yoshizawa K, 2002, NEW ENGL J MED, V347, P1755, DOI 10.1056/NEJMoa021437	50	515	529	3	82	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1747	1754		10.1056/NEJMoa020157	http://dx.doi.org/10.1056/NEJMoa020157			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456850	Bronze			2022-12-28	WOS:000179468600004
J	Krusell, L; Madsen, LH; Sato, S; Aubert, G; Genua, A; Szczyglowski, K; Duc, G; Kaneko, T; Tabata, S; de Bruijn, F; Pajuelo, E; Sandal, N; Stougaard, J				Krusell, L; Madsen, LH; Sato, S; Aubert, G; Genua, A; Szczyglowski, K; Duc, G; Kaneko, T; Tabata, S; de Bruijn, F; Pajuelo, E; Sandal, N; Stougaard, J			Shoot control of root development and nodulation is mediated by a receptor-like kinase	NATURE			English	Article							LOTUS-JAPONICUS; SYMBIOTIC MUTANTS; WILD-TYPE; CLAVATA1; ARABIDOPSIS; INFECTION; MERISTEM; GENES	In legumes, root nodule organogenesis is activated in response to morphogenic lipochitin oligosaccharides that are synthesized by bacteria, commonly known as rhizobia(1). Successful symbiotic interaction results in the formation of highly specialized organs called root nodules, which provide a unique environment for symbiotic nitrogen fixation. In wild-type plants the number of nodules is regulated by a signalling mechanism integrating environmental and developmental cues to arrest most rhizobial infections within the susceptible zone of the root(2-7). Furthermore, a feedback mechanism controls the temporal and spatial susceptibility to infection of the root system. This mechanism is referred to as autoregulation of nodulation, as earlier nodulation events inhibit nodulation of younger root tissues(3,4,8). Lotus japonicus plants homozygous for a mutation in the hypernodulation aberrant root (har1) locus escape this regulation and form an excessive number of nodules(9-11). Here we report the molecular cloning and expression analysis of the HAR1 gene and the pea orthologue, Pisum sativum, SYM29. HAR1 encodes a putative serine/threonine receptor kinase, which is required for shoot-controlled regulation of root growth, nodule number, and for nitrate sensitivity of symbiotic development.	Aarhus Univ, Dept Mol Biol, Gene Express Lab, DK-8000 Aarhus C, Denmark; Kazusa DNA Res Inst, Chiba 2920812, Japan; INRA, URGAP, F-21065 Dijon, France; Agr & Agri Food Canada, SPFRC, London, ON N5V 4T3, Canada; Lab Biol Mol Relat Plantes Microorganismes, F-31326 Castanet Tolosan, France	Aarhus University; Kazusa DNA Research Institute; INRAE; Agriculture & Agri Food Canada	Stougaard, J (corresponding author), Aarhus Univ, Dept Mol Biol, Gene Express Lab, Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.		Han, Liqi/K-6127-2013; Sato, Shusei/A-3616-2015; Aubert, Gregoire/AAC-4035-2019	Sato, Shusei/0000-0002-0293-5366; Aubert, Gregoire/0000-0002-1867-5730; pajuelo, Eloisa/0000-0002-1084-5301; Stougaard, Jens/0000-0002-9312-2685; Genua, Aratz/0000-0003-0437-1119				CAETANOANOLLES G, 1991, ANNU REV MICROBIOL, V45, P345, DOI 10.1146/annurev.mi.45.100191.002021; Carroll B. J., 1990, Molecular biology of symbiotic nitrogen fixation., P159; CARROLL BJ, 1985, P NATL ACAD SCI USA, V82, P4162, DOI 10.1073/pnas.82.12.4162; Clark SE, 2001, NAT REV MOL CELL BIO, V2, P276, DOI 10.1038/35067079; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; DELVES AC, 1986, PLANT PHYSIOL, V82, P588, DOI 10.1104/pp.82.2.588; HANDBERG K, 1992, PLANT J, V2, P487, DOI 10.1111/j.1365-313X.1992.00487.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Kawaguchi M, 2000, J PLANT RES, V113, P507, DOI 10.1007/PL00013961; KOSSLAK RM, 1984, PLANT PHYSIOL, V75, P125, DOI 10.1104/pp.75.1.125; MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828, DOI 10.1073/pnas.88.21.9828; Nakamura Y, 2002, DNA RES, V9, P63, DOI 10.1093/dnares/9.2.63; NUTMAN PS, 1952, ANN BOT, V16, P81; Penmetsa RV, 1997, SCIENCE, V275, P527, DOI 10.1126/science.275.5299.527; PIERCE M, 1983, PLANT PHYSIOL, V73, P286, DOI 10.1104/pp.73.2.286; Sagan M, 1996, SYMBIOSIS, V20, P229; Sandal N, 2002, GENETICS, V161, P1673; Sato S, 2001, DNA RES, V8, P311, DOI 10.1093/dnares/8.6.311; Schauser L, 1998, MOL GEN GENET, V259, P414, DOI 10.1007/s004380050831; Sheng CX, 1997, PLANT PHYSIOL, V113, P825, DOI 10.1104/pp.113.3.825; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; Spaink HP, 2000, ANNU REV MICROBIOL, V54, P257, DOI 10.1146/annurev.micro.54.1.257; Szczyglowski K, 1998, MOL PLANT MICROBE IN, V11, P684, DOI 10.1094/MPMI.1998.11.7.684; Torii KU, 2000, CURR OPIN PLANT BIOL, V3, P361, DOI 10.1016/S1369-5266(00)00097-2; Trotochaud AE, 1999, PLANT CELL, V11, P393, DOI 10.1105/tpc.11.3.393; VASSE J, 1993, PLANT J, V4, P555, DOI 10.1046/j.1365-313X.1993.04030555.x; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; Wopereis J, 2000, PLANT J, V23, P97, DOI 10.1046/j.1365-313x.2000.00799.x; Yamamoto E, 2000, BBA-GENE STRUCT EXPR, V1491, P333, DOI 10.1016/S0167-4781(00)00061-0	29	411	442	3	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					422	426		10.1038/nature01207	http://dx.doi.org/10.1038/nature01207			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12442170				2022-12-28	WOS:000179494700041
J	McDowell, N				McDowell, N			Britain failing to bar risky students	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					349	349		10.1038/420349b	http://dx.doi.org/10.1038/420349b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459748	Bronze			2022-12-28	WOS:000179494700007
J	Hu, FB; Willett, WC				Hu, FB; Willett, WC			Optimal diets for prevention of coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TRANS-FATTY-ACIDS; ALPHA-LINOLENIC ACID; DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED TRIAL; ACUTE MYOCARDIAL-INFARCTION; WHOLE-GRAIN CONSUMPTION; CARDIOVASCULAR-DISEASE; SERUM-CHOLESTEROL; VEGETABLE INTAKE; GLYCEMIC INDEX	Context Coronary heart disease (CHD) remains the leading cause of mortality in industrialized countries and is rapidly becoming a primary cause of death worldwide. Thus, identification of the dietary changes that most effectively prevent CHD is critical. Objective To review metabolic, epidemiologic, and clinical trial evidence regarding diet and CHD prevention. Data Sources and Study Selection We searched MEDLINE through May 2002 for epidemiologic and clinical investigations of major dietary factors (fat, cholesterol, omega-3 fatty acids, trans-fatty acids, carbohydrates, glycemic index, fiber, folate, specific foods, and dietary patterns) and CHD. We selected 147 original investigations and reviews of metabolic studies, epidemiologic studies, and dietary intervention trials of diet and CHD. Data Extraction Data were examined for relevance and quality and extracted by 1 of the authors. Data Synthesis Compelling evidence from metabolic studies, prospective cohort studies, and clinical trials in the past several decades indicates that at least 3 dietary strategies are effective in preventing,CHD: substitute nonhydrogenated unsaturated fats for saturated and trans-fats; increase consumption of omega-3 fatty acids from fish, fish oil supplements, or plant sources; and consume a diet high in fruits, vegetables, nuts, and whole grains and low in refined grain products. However, simply lowering the percentage of energy from total fat in the diet is unlikely to improve lipid profile or reduce CHD incidence. Many issues remain unsettled, including the optimal amounts of monounsaturated and polyunsaturated fats, the optimal balance between omega-3 and omega-6 polyunsaturated fats, the amount and sources of protein, and the effects of individual phytochemicals, antioxidant vitamins, and minerals. Conclusions Substantial evidence indicates that diets using nonhydrogenated unsaturated fats as the predominant form of dietary fat, whole grains as the main form of carbohydrates, an abundance of fruits and vegetables, and adequate omega-3 fatty acids can offer significant protection against CHD. Such diets, together with regular physical activity, avoidance of smoking, and maintenance of a healthy body weight, may prevent the majority of cardiovascular disease in Western populations.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	frank.hu@channing.harvard.edu	Hu, Frank/C-1919-2013		NHLBI NIH HHS [HL60712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CM, 2002, NEW ENGL J MED, V346, P1113, DOI 10.1056/NEJMoa012918; Albert CM, 2002, ARCH INTERN MED, V162, P1382, DOI 10.1001/archinte.162.12.1382; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; Anitschkow N, 1967, COWDRYS ARTERIOSCLER, P21; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Aro A, 1997, AM J CLIN NUTR, V65, P1419, DOI 10.1093/ajcn/65.5.1419; Ascherio A, 1999, NEW ENGL J MED, V340, P1994, DOI 10.1056/NEJM199906243402511; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; Baba NH, 1999, INT J OBESITY, V23, P1202, DOI 10.1038/sj.ijo.0801064; Bazzano LA, 2002, AM J CLIN NUTR, V76, P93; Bazzano LA, 2002, STROKE, V33, P1183, DOI 10.1161/01.STR.0000014607.90464.88; Berry Elliot M., 1997, American Journal of Clinical Nutrition, V66, p991S, DOI 10.1093/ajcn/66.4.991S; Bostom AG, 2001, ANN INTERN MED, V135, P133, DOI 10.7326/0003-4819-135-2-200107170-00014; BROWN L, 1999, FASEB J, V13, pA4332; BURR ML, 1989, LANCET, V2, P757; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Connor SL, 1997, AM J CLIN NUTR, V66, P1020; DAYTON S, 1969, CIRCULATION       S2, V40, P1; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; de Roos NM, 2001, BRIT J NUTR, V86, P181, DOI 10.1079/BJN2001365; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; Ellsworth JL, 2001, NUTR METAB CARDIOVAS, V11, P372; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; Fraser GE, 1997, ARCH INTERN MED, V157, P2249, DOI 10.1001/archinte.157.19.2249; Fung TT, 2001, ARCH INTERN MED, V161, P1857, DOI 10.1001/archinte.161.15.1857; GARCIAPALMIERI MR, 1980, AM J CLIN NUTR, V33, P1818, DOI 10.1093/ajcn/33.8.1818; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; Geleijnse JM, 2002, AM J CLIN NUTR, V75, P880, DOI 10.1093/ajcn/75.5.880; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; GORDON T, 1988, AM J EPIDEMIOL, V127, P220, DOI 10.1093/oxfordjournals.aje.a114798; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Hertog MGL, 1997, AM J CLIN NUTR, V65, P1489, DOI 10.1093/ajcn/65.5.1489; HILL EG, 1982, P NATL ACAD SCI-BIOL, V79, P953, DOI 10.1073/pnas.79.4.953; HJERMANN I, 1981, LANCET, V2, P1303; Hu FB, 2000, AM J CLIN NUTR, V72, P912; Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802; Hu FB, 1999, AM J CLIN NUTR, V70, P1001; Hu FB, 1999, AM J CLIN NUTR, V69, P890; Hu FB, 2002, JAMA-J AM MED ASSOC, V287, P1815, DOI 10.1001/jama.287.14.1815; Hu FB, 1999, JAMA-J AM MED ASSOC, V281, P1387, DOI 10.1001/jama.281.15.1387; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Hu FB, 1999, AM J CLIN NUTR, V70, P221; Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Hu FB, 2001, J AM COLL NUTR, V20, P5, DOI 10.1080/07315724.2001.10719008; Hu FB, 2001, DIABETOLOGIA, V44, P805, DOI 10.1007/s001250100547; HU FB, 2002, CARDIOVASCULAR HLTH, P71; Jacobs DR, 2000, J AM COLL NUTR, V19, p326S, DOI 10.1080/07315724.2000.10718968; Jacobs DR, 1998, AM J CLIN NUTR, V68, P248, DOI 10.1093/ajcn/68.2.248; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; Jenkins DJA, 2002, AM J CLIN NUTR, V76, p266S, DOI 10.1093/ajcn/76.1.266S; Jeppesen J, 1997, AM J CLIN NUTR, V65, P1027, DOI 10.1093/ajcn/65.4.1027; Joshipura KJ, 1999, JAMA-J AM MED ASSOC, V282, P1233, DOI 10.1001/jama.282.13.1233; Joshipura KJ, 2001, ANN INTERN MED, V134, P1106, DOI 10.7326/0003-4819-134-12-200106190-00010; Judd JT, 2002, LIPIDS, V37, P123, DOI 10.1007/s11745-002-0871-9; JUDD JT, 1994, AM J CLIN NUTR, V59, P861, DOI 10.1093/ajcn/59.4.861; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI [10.1146/annurev.nu.15.070195.002353, 10.1146/annurev.nutr.15.1.473]; KATO H, 1973, AM J EPIDEMIOL, V97, P372, DOI 10.1093/oxfordjournals.aje.a121518; KEYS A, 1966, AM J CLIN NUTR, V19, P175; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KINSELLA JE, 1981, AM J CLIN NUTR, V34, P2307, DOI 10.1093/ajcn/34.10.2307; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; Krauss RM, 2000, CIRCULATION, V102, P2284; Kris-Etherton PM, 2001, NUTR REV, V59, P103, DOI 10.1111/j.1753-4887.2001.tb06996.x; KROMHOUT D, 1995, PREV MED, V24, P308, DOI 10.1006/pmed.1995.1049; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KROMHOUT D, 1984, AM J EPIDEMIOL, V119, P733, DOI 10.1093/oxfordjournals.aje.a113794; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; Law M, 2000, BMJ-BRIT MED J, V320, P861, DOI 10.1136/bmj.320.7238.861; Leaf A, 2002, CIRCULATION, V105, P1874, DOI 10.1161/01.CIR.0000015344.46176.99; Lemaitre RN, 2002, CIRCULATION, V105, P697, DOI 10.1161/hc0602.103583; LEREN P, 1966, ACTA MED SCAND, VS, P5; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; Lichtenstein AH, 1999, NEW ENGL J MED, V340, P1933, DOI 10.1056/NEJM199906243402501; LICHTENSTEIN AH, 1993, ARTERIOSCLER THROMB, V13, P154, DOI 10.1161/01.ATV.13.2.154; Liu S, 2000, AM J CLIN NUTR, V72, P922; Liu SM, 2000, JAMA-J AM MED ASSOC, V284, P1534, DOI 10.1001/jama.284.12.1534; Liu SM, 1999, AM J CLIN NUTR, V70, P412; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Liu SM, 2002, J AM COLL CARDIOL, V39, P49, DOI 10.1016/S0735-1097(01)01695-3; Liu SM, 2001, AM J CLIN NUTR, V73, P560; Liu W, 2001, COMMUN STAT-THEOR M, V30, P135, DOI 10.1081/STA-100001563; Loria CM, 2000, ARCH INTERN MED, V160, P3258, DOI 10.1001/archinte.160.21.3258; Lovejoy J C, 1999, Curr Atheroscler Rep, V1, P215, DOI 10.1007/s11883-999-0035-5; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; Marckmann P, 1999, EUR J CLIN NUTR, V53, P585, DOI 10.1038/sj.ejcn.1600832; MCGEE DL, 1984, AM J EPIDEMIOL, V119, P667, DOI 10.1093/oxfordjournals.aje.a113788; MCGILL HC, 1979, AM J CLIN NUTR, V32, P2664, DOI 10.1093/ajcn/32.12.2664; McManus K, 2001, INT J OBESITY, V25, P1503, DOI 10.1038/sj.ijo.0801796; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Meyer KA, 2001, DIABETES CARE, V24, P1528, DOI 10.2337/diacare.24.9.1528; MIETTINEN TA, 1992, ANN MED, V24, P85, DOI 10.3109/07853899209148332; NESTEL P, 1992, J LIPID RES, V33, P1029; Oomen CM, 2001, LANCET, V357, P746, DOI 10.1016/S0140-6736(00)04166-0; Oomen CM, 2000, AM J EPIDEMIOL, V151, P999, DOI 10.1093/oxfordjournals.aje.a010144; Oomen CM, 2001, AM J CLIN NUTR, V74, P457; Ornish D, 1998, JAMA-J AM MED ASSOC, V280, P2001, DOI 10.1001/jama.280.23.2001; Pietinen P, 1997, AM J EPIDEMIOL, V145, P876, DOI 10.1093/oxfordjournals.aje.a009047; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; PIROZZO S, 2002, ADVICE LOW FAT DIETS; Pruthi S, 2001, MAYO CLIN PROC, V76, P1131, DOI 10.4065/76.11.1131; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rimm EB, 1996, ANN INTERN MED, V125, P384, DOI 10.7326/0003-4819-125-5-199609010-00005; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; Rissanen T, 2000, CIRCULATION, V102, P2677, DOI 10.1161/01.CIR.102.22.2677; ROBERTS TL, 1995, LANCET, V345, P278, DOI 10.1016/S0140-6736(95)90274-0; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545; Salmeron J, 2001, AM J CLIN NUTR, V73, P1019; Schnyder G, 2002, JAMA-J AM MED ASSOC, V288, P973, DOI 10.1001/jama.288.8.973; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; Singh RB, 1997, CARDIOVASC DRUG THER, V11, P485, DOI 10.1023/A:1007757724505; Skov AR, 1999, INT J OBESITY, V23, P528, DOI 10.1038/sj.ijo.0800867; Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103; Summers LKM, 2002, DIABETOLOGIA, V45, P369, DOI 10.1007/s00125-001-0768-3; Sundram K, 1997, J NUTR, V127, pS514, DOI 10.1093/jn/127.3.514S; Tavani A, 2001, CIRCULATION, V104, P2269, DOI 10.1161/hc4401.099450; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; *USDA US DHHS, 2000, HOM CARD B USDA US D, V232; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Vermeulen EGJ, 2000, LANCET, V355, P517, DOI 10.1016/S0140-6736(99)07391-2; Voutilainen S, 2001, CIRCULATION, V103, P2674, DOI 10.1161/01.CIR.103.22.2674; Voutilainen S, 2000, EUR J CLIN NUTR, V54, P424, DOI 10.1038/sj.ejcn.1600991; Willett W., 1998, NUTR EPIDEMIOL, V122, P101; Willett W C, 2002, Obes Rev, V3, P59, DOI 10.1046/j.1467-789X.2002.00060.x; WOLEVER TMS, 1991, AM J CLIN NUTR, V54, P846, DOI 10.1093/ajcn/54.5.846; WOLFE BM, 1995, CAN J CARDIOL, V11, pG127; Wolk A, 1999, JAMA-J AM MED ASSOC, V281, P1998, DOI 10.1001/jama.281.21.1998; Yochum L, 1999, AM J EPIDEMIOL, V149, P943, DOI 10.1093/oxfordjournals.aje.a009738; YU SM, 1995, AM J CLIN NUTR, V61, P1129, DOI 10.1093/ajcn/61.5.1129; Zemel MB, 2002, J AM COLL NUTR, V21, p146S, DOI 10.1080/07315724.2002.10719212; Zock PL, 1998, AM J CLIN NUTR, V68, P142, DOI 10.1093/ajcn/68.1.142; ZOCK PL, 1992, J LIPID RES, V33, P399	147	977	1009	7	232	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2002	288	20					2569	2578		10.1001/jama.288.20.2569	http://dx.doi.org/10.1001/jama.288.20.2569			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AL	12444864				2022-12-28	WOS:000179394500024
J	Delva, MD; Kirby, JR; Knapper, CK; Birtwhistle, RV				Delva, MD; Kirby, JR; Knapper, CK; Birtwhistle, RV			Postal survey of approaches to learning among Ontario physicians: implications for continuing medical education	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREFERENCES; STUDENTS	Objectives To understand the approaches to learning of practising physicians in their workplace and to assess the relation of these approaches to their motivation for, preferred methods of, and perceived barriers to continuing medical education. Design Postal survey of 800 Ontario physicians. Participants 373 physicians who responded. Main outcome measures Correlations of approaches to learning and perceptions of workplace climate with methods, motives, and barriers to continuing medical education. Results Perceived heavy workload was significantly associated with the surface disorganised (r=0.463, P < 0.01) and surface rational approach (r=0.135, P < 0.05) to learning. The deep approach to learning was significantly correlated with a perception of choice-independence and a supportive-receptive climate at work (r=0.341 and 0.237, P < 0.01). Physicians who adopt a deep approach to learning seem to be internally motivated to learn, whereas external motivation is associated with surface approaches to learning. Heavy workload and a surface disorganised approach to learning were correlated with every listed barrier to continuing medical education. The deep approach to learning was associated with independent learning activities and no barriers. Conclusions Perception of the workplace climate affects physicians' approaches to learning at work and their motivation for and perceived barriers to continuing medical education. Younger, rural, family physicians may be most vulnerable to feeling overworked and adopting less effective approaches to learning. Further work is required to determine if changing the workplace environment will help physicians learn more effectively.	Queens Univ, Dept Family Med, Kingston, ON K71 5E9, Canada; Queens Univ, Fac Educ, Kingston, ON K7L 3N6, Canada; Queens Univ, Instruct Dev Ctr, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Family Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada	Delva, MD (corresponding author), Queens Univ, Dept Family Med, Kingston, ON K71 5E9, Canada.	mdd2@post.queensu.ca		Kirby, John/0000-0002-8874-1641				[Anonymous], 1978, MAIL TELEPHONE SURVE; Biggs J. B, 1987, STUDENT APPROACHES L; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; ENTWISTLE N, 1990, HIGH EDUC, V19, P169, DOI 10.1007/BF00137106; Entwistle Noel., 1983, UNDERSTANDING STUDEN, V1st ed., DOI [10.4324/9781315718637/UNDERSTANDING-STUDENT-LEARNING-ROUTLEDGE-REVIVALS-NOEL-ENTWISTLE-PAUL-RAMSDEN, DOI 10.4324/9781315718637/UNDERSTANDING-STUDENT-LEARNING-ROUTLEDGE-REVIVALS-NOEL-ENTWISTLE-PAUL-RAMSDEN]; FOX RD, 1989, CHANGE LEARNING LIVE; KIRBY JR, IN PRESS INT J TRAIN; KNAPPER CK, 1995, IMPROVING STUDENTS L; MARTENSON DF, 1986, MED EDUC, V20, P532, DOI 10.1111/j.1365-2923.1986.tb01395.x; McManus IC, 1999, BRIT MED J, V319, P542, DOI 10.1136/bmj.319.7209.542; Miller J, 1998, BRIT J GEN PRACT, V48, P1429; NORRIS S, 1998, THESIS QUEENS U KING; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; Parboosingh J, 2000, J Contin Educ Health Prof, V20, P188, DOI 10.1002/chp.1340200309; PREMI J, 1994, ACAD MED, V69, P800, DOI 10.1097/00001888-199410000-00002; Ramsden P., 1986, LEARNING STYLES STRA, P159; Smith LFP, 2000, BRIT J GEN PRACT, V50, P293; *SOUTH CO, 2000, SOUTH MED LISTS; TAN CM, 1993, MED EDUC, V27, P143, DOI 10.1111/j.1365-2923.1993.tb00245.x; TOOTH D, 1989, MED EDUC, V23, P416, DOI 10.1111/j.1365-2923.1989.tb00896.x	20	26	26	2	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	2002	325	7374					1218	1220A		10.1136/bmj.325.7374.1218	http://dx.doi.org/10.1136/bmj.325.7374.1218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446540	Green Published, Bronze			2022-12-28	WOS:000179506200023
J	Hawton, K; Rodham, K; Evans, E; Weatherall, R				Hawton, K; Rodham, K; Evans, E; Weatherall, R			Deliberate self harm in adolescents: self report survey in schools in England	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SUICIDE; OXFORD	Objective To determine die prevalence of deliberate self harm in adolescents and the factors associated with it. Design Cross sectional survey using anonymous self report questionnaire. Setting 41 schools in England. Participants 6020 pupils aged 15 and 16 years. Main outcome measure Deliberate self harm. Results 398 (6.9%) participants reported an act of deliberate self harm in the previous year that met study criteria. Only 12.6% of episodes had resulted in presentation to hospital. Deliberate self harm was more common in females than it was in males (11.2% v 3.2%; odds ratio 3.9, 95% confidence interval 3.1 to 4.9). In females the factors included in a multivariate logistic regression for deliberate self harm were recent self harm by friends, self harm by family members, drug misuse, depression, anxiety, impulsivity, and low self esteem. In males the factors were suicidal behaviour in friends and family members, drug use, and low self esteem. Conclusions Deliberate self harm is common in adolescents, especially females. School based mental health initiatives are needed. These could include approaches aimed at educating school pupils about mental health problems and screening for those at risk.	Univ Oxford, Warneford Hosp, Dept Psychiat, Ctr Suicide Res, Oxford OX3 7JX, England; Inst Hlth Sci, Ctr Stat Med, Oxford OX3 7LF, England	University of Oxford; University of Oxford	Hawton, K (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Ctr Suicide Res, Oxford OX3 7JX, England.	keith.hawton@psychiatry.ox.ac.uk		Rodham, Karen/0000-0002-5377-1998				[Anonymous], 1994, ADOLESCENTS ENQUETE; BJARNASON T, 1994, SUICIDE LIFE-THREAT, V24, P350; BRENT DA, 1993, J AM ACAD CHILD PSY, V32, P521, DOI 10.1097/00004583-199305000-00006; Brent DA, 1996, ARCH GEN PSYCHIAT, V53, P1145; British Educational Research Association, 1992, ETH GUID ED RES; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P633; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Dean AG, 1994, EPIINFO VERSION 6 WO; DEWILDE EJ, 1994, ATTEMPTED SUICIDE EU, P263; GOULD MS, 1989, SUICIDE LIFE-THREAT, V19, P17; Hawton K, 1996, BRIT J PSYCHIAT, V169, P202, DOI 10.1192/bjp.169.2.202; Hawton K, 2000, J ADOLESCENCE, V23, P47, DOI 10.1006/jado.1999.0290; HAZELL P, 1991, J ADOLESCENCE, V14, P335, DOI 10.1016/0140-1971(91)90002-9; Kerfoot M, 1996, BRIT J PSYCHIAT, V168, P38, DOI 10.1192/bjp.168.1.38; Malmberg A, 1999, BRIT J PSYCHIAT, V175, P103, DOI 10.1192/bjp.175.2.103; MELTZER H., 2001, CHILDREN ADOLESCENTS; PLUTCHIK R, 1989, PSYCHIAT RES, V27, P71, DOI 10.1016/0165-1781(89)90011-5; RABASH J, 2000, USERS GUIDE MLWIN VE; ROBSON P, 1989, PSYCHOL MED, V19, P513, DOI 10.1017/S003329170001254X; Shaffer D, 1996, ARCH GEN PSYCHIAT, V53, P339; SHAFFER D, 2000, INT HDB SUICIDE ATTE, P645, DOI DOI 10.1002/9780470698976.CH37; *SPSS, 1999, SPSS BAS 9 0 US GUID; Statacorp, 2001, STAT STAT SOFTW REL; White D, 1999, BRIT J PSYCHIAT, V175, P452, DOI 10.1192/bjp.175.5.452	24	661	680	2	91	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	2002	325	7374					1207	1211		10.1136/bmj.325.7374.1207	http://dx.doi.org/10.1136/bmj.325.7374.1207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	619YU	12446536	Green Published, Bronze			2022-12-28	WOS:000179506200019
J	Bever, T; Montalbetti, M				Bever, T; Montalbetti, M			Noam's ark	SCIENCE			English	Editorial Material									Univ Arizona, Dept Linguist, Tucson, AZ 85721 USA; Univ Arizona, Dept Spanish & Portuguese, Tucson, AZ 85721 USA	University of Arizona; University of Arizona	Bever, T (corresponding author), Univ Arizona, Dept Linguist, Tucson, AZ 85721 USA.							CHOMSKY N, 1986, KNOWLEDGE LANGAUGE; Chomsky N., 1999, MIT WORKING PAPERS L, V18; Chomsky N., 2002, JANUA LINGUARUM; Chomsky Noam, 1998, MIT WORKING PAPERS L, V15; CHOMSKY Noam, 1986, KNOWLEDGE LANGUAGE I; Freud S., 1965, INTERPRETATION DREAM; Hauser MD, 2002, SCIENCE, V298, P1569, DOI 10.1126/science.298.5598.1569; HERDER JGV, 1966, ESSAY ORIGIN LANGUAG; Jakobson Roman, 1956, 2 ASPECTS LANGUAGE 2; Lacan Jacques, 1993, PSYCHOSES, VIII; Rousseau Jean Jacques, 1781, ESSAY ORIGIN LANGUAG	11	5	5	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1565	1566		10.1126/science.1079320	http://dx.doi.org/10.1126/science.1079320			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446896				2022-12-28	WOS:000179361600035
J	Dundr, M; Hoffmann-Rohrer, U; Hu, QY; Grummt, I; Rothblum, LI; Phair, RD; Misteli, T				Dundr, M; Hoffmann-Rohrer, U; Hu, QY; Grummt, I; Rothblum, LI; Phair, RD; Misteli, T			A kinetic framework for a mammalian RNA polymerase in vivo	SCIENCE			English	Article							TRANSCRIPTION; COMPONENTS; PROMOTER	We have analyzed the kinetics of assembly and elongation of the mammalian RNA polymerase I complex on endogenous ribosomal genes in the nuclei of living cells with the use of in vivo microscopy. We show that components of the RNA polymerase I machinery are brought to ribosomal genes as distinct subunits and that assembly occurs via metastable intermediates. With the use of computational modeling of imaging data, we have determined the in vivo elongation time of the polymerase, and measurements of recruitment and incorporation frequencies show that incorporation of components into the assembling polymerase is inefficient. Our data provide a kinetic and mechanistic framework for the function of a mammalian RNA polymerase in living cells.	NCI, NIH, Bethesda, MD 20892 USA; German Canc Res Ctr, D-69120 Heidelberg, Germany; Weis Ctr Res, Danville, PA 17821 USA; BioInformat Serv, Rockville, MD 20854 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Helmholtz Association; German Cancer Research Center (DKFZ)	Misteli, T (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.	mistelit@mail.nih.gov						Aprikian P, 2001, MOL CELL BIOL, V21, P4847, DOI 10.1128/MCB.21.15.4847-4855.2001; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; CAVANAUGH AH, 2002, J BIOL CHEM; Chen DY, 2001, J CELL BIOL, V153, P169, DOI 10.1083/jcb.153.1.169; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; DUNDR M, IN PRESS J STRUCT BI; DUNDR M, UNPUB; GONZALEZ IL, 1995, GENOMICS, V27, P320, DOI 10.1006/geno.1995.1049; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; GRUMMT I, UNPUB; HAAF T, 1991, EXP CELL RES, V193, P78, DOI 10.1016/0014-4827(91)90540-B; Hannan RD, 1999, NUCLEIC ACIDS RES, V27, P3720, DOI 10.1093/nar/27.18.3720; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; MILLER OL, 1972, ACTA ENDOCRINOL-COP, P155; Panov KI, 2001, MOL CELL BIOL, V21, P2641, DOI 10.1128/MCB.21.8.2641-2649.2001; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Phair RD, 2001, NAT REV MOL CELL BIO, V2, P898, DOI 10.1038/35103000; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Scheer U, 1997, CHROMOSOMA, V105, P470, DOI 10.1007/s004120050209; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; ZEEVI M, 1982, MOL CELL BIOL, V2, P517, DOI 10.1128/MCB.2.5.517	22	336	342	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1623	1626		10.1126/science.1076164	http://dx.doi.org/10.1126/science.1076164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446911				2022-12-28	WOS:000179361600050
J	Jensen, MH				Jensen, MH			Per Bak (1947-2002) - Obituary	NATURE			English	Biographical-Item									Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark	University of Copenhagen; Niels Bohr Institute	Jensen, MH (corresponding author), Univ Copenhagen, Niels Bohr Inst, Blegdamsvej 17, DK-2100 Copenhagen, Denmark.		Jensen, Mogens H./U-5510-2017	Jensen, Mogens H./0000-0001-8104-4299				BAK P, PUBLICATION LIST	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					284	284		10.1038/420284a	http://dx.doi.org/10.1038/420284a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447430	Bronze			2022-12-28	WOS:000179340400031
J	Sarrao, JL; Morales, LA; Thompson, JD; Scott, BL; Stewart, GR; Wastin, F; Rebizant, J; Boulet, P; Colineau, E; Lander, GH				Sarrao, JL; Morales, LA; Thompson, JD; Scott, BL; Stewart, GR; Wastin, F; Rebizant, J; Boulet, P; Colineau, E; Lander, GH			Plutonium-based superconductivity with a transition temperature above 18 K	NATURE			English	Article								Plutonium is a metal of both technological relevance and fundamental scientific interest. Nevertheless, the electronic structure of plutonium, which directly influences its metallurgical properties(1), is poorly understood. For example, plutonium's 5f electrons are poised on the border between localized and itinerant, and their theoretical treatment pushes the limits of current electronic structure calculations(2). Here we extend the range of complexity exhibited by plutonium with the discovery of superconductivity in PuCoGa5. We argue that the observed superconductivity results directly from plutonium's anomalous electronic properties and as such serves as a bridge between two classes of spin-fluctuation-mediated superconductors: the known heavy-fermion superconductors and the high-T-c copper oxides. We suggest that the mechanism of superconductivity is unconventional; seen in that context, the fact that the transition temperature, T-c approximate to 18.5 K, is an order of magnitude greater than the maximum seen in the U- and Ce-based heavy-fermion systems may be natural. The large critical current displayed by PuCoGa5, which comes from radiation-induced self damage that creates pinning centres, would be of technological importance for applied superconductivity if the hazardous material plutonium were not a constituent.	Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Univ Florida, Dept Phys, Gainesville, FL 32611 USA; European Commiss, JRC, Inst Transuranium Elements, D-76125 Karlsruhe, Germany	United States Department of Energy (DOE); Los Alamos National Laboratory; State University System of Florida; University of Florida; European Commission Joint Research Centre; EC JRC Institute for Transuranium Elements (ITU)	Sarrao, JL (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	sarrao@lanl.gov	Scott, Brian/D-8995-2017; stewart, greg/AAL-9267-2020; BOULET, Pascal/D-6494-2011	Scott, Brian/0000-0003-0468-5396; BOULET, Pascal/0000-0003-0684-4397				BEAN CP, 1962, PHYS REV LETT, V8, P250, DOI 10.1103/PhysRevLett.8.250; CAMPBELL AM, 1972, ADV PHYS, V21, P199, DOI 10.1080/00018737200101288; GRIN YN, 1986, J LESS-COMMON MET, V121, P497, DOI 10.1016/0022-5088(86)90568-0; Hecker SS, 2001, MRS BULL, V26, P672, DOI 10.1557/mrs2001.176; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; Nagamatsu J, 2001, NATURE, V410, P63, DOI 10.1038/35065039; Petrovic C, 2001, J PHYS-CONDENS MAT, V13, pL337, DOI 10.1088/0953-8984/13/17/103; Savrasov SY, 2001, NATURE, V410, P793, DOI 10.1038/35071035; STEWART GR, 1981, 12441 LBL, P206; Tokiwa Y, 2002, J PHYS SOC JPN, V71, P845, DOI 10.1143/JPSJ.71.845; WERTHAME.NR, 1966, PHYS REV, V147, P295, DOI 10.1103/PhysRev.147.295; WICK OJ, 1980, PLUTONIUM HDB GUIDE, P33; Wolfer W.G., 2000, LOS ALAMOS SCI, V26, P274	14	445	450	5	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	2002	420	6913					297	299		10.1038/nature01212	http://dx.doi.org/10.1038/nature01212			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447434				2022-12-28	WOS:000179340400036
J	Sabin, CA; Griffioen, A; Yee, TT; Emery, VC; Herrero-Martinez, E; Phillips, AN; Lee, CA				Sabin, CA; Griffioen, A; Yee, TT; Emery, VC; Herrero-Martinez, E; Phillips, AN; Lee, CA			Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; WOMENS INTERAGENCY HIV; INFECTED PATIENTS; NATURAL-HISTORY; VIRAL LOAD; SERUM-ALBUMIN; LYMPHOCYTE COUNTS; MORTALITY; AIDS	Background Low serum albumin concentration is associated with short-term survival in individuals with HIV-1. However, few investigators have assessed whether individuals with a low serum albumin concentration have delayed progression to AIDS, or survive in the long term. We aimed to assess the relation between markers of liver function and progression to AIDS and death in individuals with haemophilia infected with HIV-1 and hepatitis C virus. Methods We measured markers of liver function and took CD4 counts every 3 months in 111 patients registered at the Royal Free Hospital Haemophilia Centre, London, UK. HIV RNA concentrations were measured yearly and then every 3-6 months from 1996. We used Cox's regression models to assess the independent prognostic value of these markers for AIDS and death. Findings As a fixed covariate, albumin concentrations measured shortly after HIV-1 seroconversion were associated with risk of AIDS (relative hazard 0.91 [95% Cl 0.84-1.00], p=0.04) and death (0.89 [0.82-0.96], p=0.004) over a 15-year period. These findings were independent of the CD4 count and HIV-1 RNA concentration. As a time-updated covariate, after adjustment for CD4 count and HIV-1 RNA concentrations, albumin was not associated with progression to AIDS (0.96 [0.90-1.01], p=0.13), but was strongly associated with death (0.88 [0.84-0.93], p<0.0001) in the short term. Interpretation Low concentrations of albumin in individuals infected with HIV-1 could indicate a poor outlook and should therefore prompt concern at any stage of infection.	UCL Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, Dept Primary Care & Populat Sci, London NW3 2PF, England; UCL Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, Dept Virol, London NW3 2PF, England; UCL Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, Haemophilia Ctr, London NW3 2PF, England; UCL Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, Haemostasis Unit, London NW3 2PF, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Sabin, CA (corresponding author), UCL Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, Dept Primary Care & Populat Sci, Rowland Hill St, London NW3 2PF, England.	c.sabin@pcps.ucl.ac.uk	Phillips, Andrew N/B-4427-2008; Yee, Thynn Thynn/H-5862-2012; Sabin, Caroline/C-2464-2008; Emery, Vincent/G-8928-2013	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760; Emery, Vincent/0000-0001-5893-9756				Anastos K, 1999, AIDS, V13, P1717, DOI 10.1097/00002030-199909100-00016; BAUM MK, 1995, AIDS, V9, P1051, DOI 10.1097/00002030-199509000-00010; BIRD G, 1994, AIDS, V8, P911; BLATT SP, 1995, J INFECT DIS, V171, P847; Daar ES, 2001, J INFECT DIS, V183, P589, DOI 10.1086/318539; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; DORRUCCI M, 1995, J INFECT DIS, V172, P1503, DOI 10.1093/infdis/172.6.1503; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; Feldman JG, 2000, AIDS, V14, P863, DOI 10.1097/00002030-200005050-00013; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Goldwasser P, 1997, J CLIN EPIDEMIOL, V50, P693, DOI 10.1016/S0895-4356(97)00015-2; Hoover DR, 1996, AM J EPIDEMIOL, V143, P943; JUSTICE AC, 1989, NEW ENGL J MED, V320, P1388, DOI 10.1056/NEJM198905253202106; KERNOFF PBA, 1985, BRIT J HAEMATOL, V60, P469, DOI 10.1111/j.1365-2141.1985.tb07444.x; Khan MH, 2000, HEPATOLOGY, V31, P513, DOI 10.1002/hep.510310236; Kim S, 2000, AIDS RES HUM RETROV, V16, P645, DOI 10.1089/088922200308873; Kvale D, 1999, AIDS, V13, P195, DOI 10.1097/00002030-199902040-00007; Landau A, 2001, AIDS, V15, P2149, DOI 10.1097/00002030-200111090-00010; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; Levy S, 1997, AIDS, V11, P1399; Melchior JC, 1999, NUTRITION, V15, P865, DOI 10.1016/S0899-9007(99)00210-5; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Miller V, 2000, AIDS, V14, P2129, DOI 10.1097/00002030-200009290-00009; Mocroft A, 1999, AIDS, V13, P943, DOI 10.1097/00002030-199905280-00010; PHILLIPS A, 1989, LANCET, V2, P1434; PHILLIPS AN, 1993, AIDS, V7, P975, DOI 10.1097/00002030-199307000-00011; Piroth L, 1998, AIDS, V12, P381, DOI 10.1097/00002030-199804000-00006; Prins M, 2000, AIDS, V14, P1829, DOI 10.1097/00002030-200008180-00019; Sabin CA, 2000, J ACQ IMMUN DEF SYND, V23, P172; Sabin CA, 2000, AIDS, V14, P1001, DOI 10.1097/00002030-200005260-00012; SABIN CA, 1994, BRIT J HAEMATOL, V86, P366, DOI 10.1111/j.1365-2141.1994.tb04741.x; Yee TT, 2000, GUT, V47, P845, DOI 10.1136/gut.47.6.845; Zimmermann J, 1999, KIDNEY INT, V55, P648, DOI 10.1046/j.1523-1755.1999.00273.x	34	28	28	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1546	1551		10.1016/S0140-6736(02)11519-4	http://dx.doi.org/10.1016/S0140-6736(02)11519-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443592				2022-12-28	WOS:000179292400010
J	Dobson, DP; Meredith, PG; Boon, SA				Dobson, DP; Meredith, PG; Boon, SA			Simulation of subduction zone seismicity by dehydration of serpentine	SCIENCE			English	Article							DEEP-FOCUS EARTHQUAKES; SYSTEM MGO-SIO2-H2O; HIGH-PRESSURE; MANTLE; GENERATION; TRANSPORT; STABILITY; ROCKS; WATER; CRUST	We measured acoustic emission energy during antigorite dehydration in a multianvil press from 1.5 to 8.5 gigapascals and 300degrees to 900degrees C. There was a strong acoustic emission signal on dehydration, and analysis of recovered samples revealed brittle deformation features associated with high pore-fluid pressures. These results demonstrate that intermediate depth (50 to 200 kilometers) seismicity can be generated by dehydration reactions in the subducting slab.	Univ Bayreuth, Bayer Geoinst, D-95440 Bayreuth, Germany; UCL, Dept Earth Sci, London WC1E 6BT, England	University of Bayreuth; University of London; University College London	Dobson, DP (corresponding author), Univ Bayreuth, Bayer Geoinst, POB 101251, D-95440 Bayreuth, Germany.	d.dobson@ucl.ac.uk		Meredith, Philip/0000-0003-2193-5342; Dobson, David/0000-0002-0890-0121				BONATTI E, 1989, EARTH PLANET SC LETT, V91, P297, DOI 10.1016/0012-821X(89)90005-8; Bose K, 1998, J GEOPHYS RES-SOL EA, V103, P9713, DOI 10.1029/98JB00506; BRACE WF, 1980, INT J ROCK MECH MIN, V17, P241, DOI 10.1016/0148-9062(80)90807-4; DAVIES JH, 1992, J GEOPHYS RES-SOL EA, V97, P2037, DOI 10.1029/91JB02571; FROHLICH C, 1989, ANNU REV EARTH PL SC, V17, P227, DOI 10.1146/annurev.ea.17.050189.001303; GREEN HW, 1990, NATURE, V348, P720, DOI 10.1038/348720a0; HACKER BR, 1990, GEOPHYS MONOGR SER, V56, P127; HOOGERDUIJNSTRA.EH, 1991, TECTONOPHYSICS, V200, P187; Jiao WJ, 2000, J GEOPHYS RES-SOL EA, V105, P28125, DOI 10.1029/2000JB900314; KAWAI N, 1970, REV SCI INSTRUM, V41, P1178, DOI 10.1063/1.1684753; Kirby S. H., 1996, GEOPHYS MONOGR SER, V96, P195, DOI DOI 10.1029/GM096P0195; KIRBY SH, 1991, SCIENCE, V252, P216, DOI 10.1126/science.252.5003.216; KUSHIRO I, 1990, J GEOPHYS RES-SOLID, V95, P15929, DOI 10.1029/JB095iB10p15929; MEADE C, 1991, SCIENCE, V252, P68, DOI 10.1126/science.252.5002.68; MURRELL SAF, 1976, TECTONOPHYSICS, V31, P207, DOI 10.1016/0040-1951(76)90120-7; Obara K, 2002, SCIENCE, V296, P1679, DOI 10.1126/science.1070378; Peacock SM, 2001, GEOLOGY, V29, P299, DOI 10.1130/0091-7613(2001)029<0299:ATLPOD>2.0.CO;2; RALEIGH CB, 1965, J GEOPHYS RES, V70, P3965, DOI 10.1029/JZ070i016p03965; RUTTER EH, 1988, J GEOPHYS RES-SOLID, V93, P4907, DOI 10.1029/JB093iB05p04907; Seno T., 1996, SUBDUCTION TOP BOTTO, DOI [10.1029/GM096p0347, DOI 10.1029/GM096P0347]; Tibi R, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000361; ULMER P, 1995, SCIENCE, V268, P858, DOI 10.1126/science.268.5212.858; Watson EB, 1997, CONTRIB MINERAL PETR, V130, P66, DOI 10.1007/s004100050350; Wong TF, 1997, J GEOPHYS RES-SOL EA, V102, P841, DOI 10.1029/96JB02484; Wunder B, 1997, LITHOS, V41, P213, DOI 10.1016/S0024-4937(97)82013-0	25	166	186	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1407	1410		10.1126/science.1075390	http://dx.doi.org/10.1126/science.1075390			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434056				2022-12-28	WOS:000179223100047
J	Ohmura, A; Wild, M				Ohmura, A; Wild, M			Is the hydrological cycle accelerating?	SCIENCE			English	Editorial Material							CLIMATE-CHANGE; EVAPORATION		Swiss Fed Inst Technol, Inst Atmospher & Climate Sci, CH-8057 Zurich, Switzerland; Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 060, Japan	Swiss Federal Institutes of Technology Domain; ETH Zurich; Hokkaido University	Ohmura, A (corresponding author), Swiss Fed Inst Technol, Inst Atmospher & Climate Sci, CH-8057 Zurich, Switzerland.		Wild, Martin/J-8977-2012					Brutsaert W, 1998, NATURE, V396, P30, DOI 10.1038/23845; Budyko M.I., 1963, ATLAS HEAT BALANCE E; Callendar GS, 1938, Q J ROY METEOR SOC, V64, P223, DOI 10.1002/qj.49706427503; FLOHN H, 1990, CLIM DYNAM, V4, P237; Karl TR, 1996, B AM METEOROL SOC, V77, P279, DOI 10.1175/1520-0477(1996)077<0279:IOCCFT>2.0.CO;2; MITCHELL JM, 1961, ANN NY ACAD SCI, V95, P235, DOI 10.1111/j.1749-6632.1961.tb50036.x; Ohmura A, 1989, CURRENT PROBLEMS ATM, P298; PETERSON TC, 1995, NATURE, V377, P687, DOI 10.1038/377687b0; Roderick ML, 2002, SCIENCE, V298, P1410; ROSSOW W, 2002, NASA GEWEX RAD PAN M; RUSSAK V, 1994, AMBIO, V23, P160; TOKIOKA T, 1987, WORKSH JAP COMM WORL; Wild M, 1997, J CLIMATE, V10, P3093, DOI 10.1175/1520-0442(1997)010<3093:GSSEFI>2.0.CO;2; WILLETT HC, 1950, CENTENARY P ROYAL ME, P195; XU J, 2002, P ANN C JAP SOC HYDR, P112	15	184	249	10	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1345	1346		10.1126/science.1078972	http://dx.doi.org/10.1126/science.1078972			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434040				2022-12-28	WOS:000179223100028
J	Yamamoto, H; Esaki, M; Kanamori, T; Tamura, Y; Nishikawa, S; Endo, T				Yamamoto, H; Esaki, M; Kanamori, T; Tamura, Y; Nishikawa, S; Endo, T			Tim50 is a subunit of the TIM23 complex that links protein translocation across the outer and inner mitochondrial membranes	CELL			English	Article							INTERMEMBRANE-SPACE DOMAIN; IMPORT PATHWAY; PREPROTEIN TRANSLOCASE; TARGETING SEQUENCES; YEAST MITOCHONDRIA; CONTACT SITES; BINDING-SITE; PRESEQUENCE; RECEPTOR; CHANNEL	Based on the results of site-specific photocrosslinking of translocation intermediates, we have identified Tim50, a component of the yeast TIM23 import machinery, which mediates translocation of presequence-containing proteins across the mitochondrial inner membrane. Tim50 is anchored to the inner mitochondrial membrane, exposing the C-terminal domain to the intermembrane space. Tim50 interacts with the N-terminal intermembrane space domain of Tim23. Functional defects of Tim50 either by depletion of the protein or addition of anti-Tim50 antibodies block the protein translocation across the inner membrane. A translocation intermediate accumulated at the TOM complex is crosslinked to Tim50. We suggest that Tim50, in cooperation with Tim23, facilitates transfer of the translocating protein from the TOM complex to the TIM23 complex.	Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nippon Med Coll, Inst Gerontol, Dept Biochem & Cell Biol, Nakahara Ku, Kanagawa 2118533, Japan	Nagoya University; Nippon Medical School	Endo, T (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Yasushi, TAMURA/I-7122-2014; Tamura, Yasushi/H-8270-2017; Esaki, Masatoshi/L-6591-2017; Esaki, Masatoshi/ABS-6645-2022	Tamura, Yasushi/0000-0002-8462-0607; 				Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; Bomer U, 1997, J BIOL CHEM, V272, P30439, DOI 10.1074/jbc.272.48.30439; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Court DA, 1996, MOL CELL BIOL, V16, P4035; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Diehn M, 2000, NAT GENET, V25, P58, DOI 10.1038/75603; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8; Esaki M, 1999, P NATL ACAD SCI USA, V96, P11770, DOI 10.1073/pnas.96.21.11770; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; James P, 1996, GENETICS, V144, P1425; Kanamori T, 1997, P NATL ACAD SCI USA, V94, P485, DOI 10.1073/pnas.94.2.485; Kanamori T, 1999, P NATL ACAD SCI USA, V96, P3634, DOI 10.1073/pnas.96.7.3634; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Rose MD., 1990, METHODS YEAST GENETI; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; Siniossoglou S, 2000, J BIOL CHEM, V275, P19352, DOI 10.1074/jbc.M001314200; Siniossoglou S, 1998, EMBO J, V17, P6449, DOI 10.1093/emboj/17.22.6449; Sirrenberg C, 1997, J BIOL CHEM, V272, P29963, DOI 10.1074/jbc.272.47.29963; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726	35	189	193	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 15	2002	111	4					519	528		10.1016/S0092-8674(02)01053-X	http://dx.doi.org/10.1016/S0092-8674(02)01053-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437925	Bronze			2022-12-28	WOS:000179346900005
J	de Gans, J; van de Beek, D				de Gans, J; van de Beek, D		European Dexamethasone Adulthood B	Dexamethasone in adults with bacterial meningitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBROSPINAL-FLUID; STREPTOCOCCUS-PNEUMONIAE; PNEUMOCOCCAL MENINGITIS; CHILDREN; THERAPY; GLUCOCORTICOIDS	Background: Mortality and morbidity rates are high among adults with acute bacterial meningitis, especially those with pneumococcal meningitis. In studies of bacterial meningitis in animals, adjuvant treatment with corticosteroids has beneficial effects. Methods: We conducted a prospective, randomized, double-blind, multicenter trial of adjuvant treatment with dexamethasone, as compared with placebo, in adults with acute bacterial meningitis. Dexamethasone (10 mg) or placebo was administered 15 to 20 minutes before or with the first dose of antibiotic and was given every 6 hours for four days. The primary outcome measure was the score on the Glasgow Outcome Scale at eight weeks (a score of 5, indicating a favorable outcome, vs. a score of 1 to 4, indicating an unfavorable outcome). A subgroup analysis according to the causative organism was performed. Analyses were performed on an intention-to-treat basis. Results: A total of 301 patients were randomly assigned to a treatment group: 157 to the dexamethasone group and 144 to the placebo group. The base-line characteristics of the two groups were similar. Treatment with dexamethasone was associated with a reduction in the risk of an unfavorable outcome (relative risk, 0.59; 95 percent confidence interval, 0.37 to 0.94; P=0.03). Treatment with dexamethasone was also associated with a reduction in mortality (relative risk of death, 0.48; 95 percent confidence interval, 0.24 to 0.96; P=0.04). Among the patients with pneumococcal meningitis, there were unfavorable outcomes in 26 percent of the dexamethasone group, as compared with 52 percent of the placebo group (relative risk, 0.50; 95 percent confidence interval, 0.30 to 0.83; P=0.006). Gastrointestinal bleeding occurred in two patients in the dexamethasone group and in five patients in the placebo group. Conclusions: Early treatment with dexamethasone improves the outcome in adults with acute bacterial meningitis and does not increase the risk of gastrointestinal bleeding.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	de Gans, J (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol H2, POB 22660, NL-1100 DD Amsterdam, Netherlands.		van de beek, diederik/A-2935-2010; van de Beek, Diederik/Y-2713-2019	van de Beek, Diederik/0000-0002-4571-044X				Aronin SI, 1998, ANN INTERN MED, V129, P862, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00004; BOHR V, 1983, J INFECTION, V7, P21, DOI 10.1016/S0163-4453(83)90894-0; Coyle PK, 1999, ARCH NEUROL-CHICAGO, V56, P796, DOI 10.1001/archneur.56.7.796; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Enting RH, 1996, J ANTIMICROB CHEMOTH, V38, P777; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004; Hasbun R, 2001, NEW ENGL J MED, V345, P1727, DOI 10.1056/NEJMoa010399; JENNETT B, 1981, MANAGEMENT HEAD INJU, V20; KLUGMAN KP, 1995, ANTIMICROB AGENTS CH, V39, P1988, DOI 10.1128/AAC.39.9.1988; McIntyre PB, 1997, JAMA-J AM MED ASSOC, V278, P925, DOI 10.1001/jama.278.11.925; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; Saez-Llorens X, 1999, INFECT DIS CLIN N AM, V13, P619, DOI 10.1016/S0891-5520(05)70097-0; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; SCHAAD UB, 1993, LANCET, V342, P457, DOI 10.1016/0140-6736(93)91592-A; SCHELD WM, 1980, J CLIN INVEST, V66, P243, DOI 10.1172/JCI109850; SPANOS A, 1989, JAMA-J AM MED ASSOC, V262, P2700, DOI 10.1001/jama.262.19.2700; SYROGIANNOPOULOS GA, 1994, J INFECT DIS, V169, P853, DOI 10.1093/infdis/169.4.853; TAUBER MG, 1985, J INFECT DIS, V151, P528, DOI 10.1093/infdis/151.3.528; van Crevel H, 2002, J NEUROL, V249, P129, DOI 10.1007/PL00007855; van de Beek D, 2002, J INFECT DIS, V186, P1047, DOI 10.1086/344229; van de Beek D, 2002, J ANTIMICROB CHEMOTH, V49, P661, DOI 10.1093/jac/49.4.661; VILADRICH PF, 1991, ANTIMICROB AGENTS CH, V35, P2467, DOI 10.1128/AAC.35.12.2467; Wade DT., 1992, MEASUREMENT NEUROLOG; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	26	624	634	1	19	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2002	347	20					1549	1556		10.1056/NEJMoa021334	http://dx.doi.org/10.1056/NEJMoa021334			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614KL	12432041	Green Published			2022-12-28	WOS:000179187800002
J	Ibarra, RU; Edwards, JS; Palsson, BO				Ibarra, RU; Edwards, JS; Palsson, BO			Escherichia coli K-12 undergoes adaptive evolution to achieve in silico predicted optimal growth	NATURE			English	Article							IN-SILICO; METABOLIC NETWORKS; GENOME SEQUENCE; RECONSTRUCTION; CAPABILITIES; DEFINITION	Annotated genome sequences(1,2) can be used to reconstruct whole-cell metabolic networks(3-6). These metabolic networks can be modelled and analysed (computed) to study complex biological functions(7-11). In particular, constraints-based in silico models(12) have been used to calculate optimal growth rates on common carbon substrates, and the results were found to be consistent with experimental data under many but not all conditions(13,14). Optimal biological functions are acquired through an evolutionary process. Thus, incorrect predictions of in silico models based on optimal performance criteria may be due to incomplete adaptive evolution under the conditions examined. Escherichia coli K-12 MG1655 grows sub-optimally on glycerol as the sole carbon source. Here we show that when placed under growth selection pressure, the growth rate of E. coli on glycerol reproducibly evolved over 40 days, or about 700 generations, from a sub-optimal value to the optimal growth rate predicted from a whole-cell in silico model. These results open the possibility of using adaptive evolution of entire metabolic networks to realize metabolic states that have been determined a priori based on in silico analysis.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Delaware, Dept Chem Engn, Newark, DE 19716 USA	University of California System; University of California San Diego; University of Delaware	Palsson, BO (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Palsson, Bernhard/0000-0003-2357-6785				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bonarius HPJ, 1997, TRENDS BIOTECHNOL, V15, P308, DOI 10.1016/S0167-7799(97)01067-6; Covert MW, 2001, TRENDS BIOCHEM SCI, V26, P179, DOI 10.1016/S0968-0004(00)01754-0; Drell Daniel, 2002, OMICS A Journal of Integrative Biology, V6, P3, DOI 10.1089/15362310252780799; Edwards J., 1999, METABOLIC ENG; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Edwards JS, 2002, BIOTECHNOL BIOENG, V77, P27, DOI 10.1002/bit.10047; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; FELL D, 1996, UNDERSTANDING CONTRO; Gombert AK, 2000, CURR OPIN BIOTECH, V11, P180, DOI 10.1016/S0958-1669(00)00079-3; Karp PD, 2002, NUCLEIC ACIDS RES, V30, P56, DOI 10.1093/nar/30.1.56; Overbeek R, 2000, NUCLEIC ACIDS RES, V28, P123, DOI 10.1093/nar/28.1.123; Palsson B, 2000, NAT BIOTECHNOL, V18, P1147, DOI 10.1038/81125; Schilling CH, 2002, J BACTERIOL, V184, P4582, DOI 10.1128/JB.184.16.4582-4593.2002; Schilling CH, 2000, BIOTECHNOL BIOENG, V71, P286, DOI 10.1002/1097-0290(2000)71:4<286::AID-BIT1018>3.0.CO;2-R; Schuster S, 2000, NAT BIOTECHNOL, V18, P326, DOI 10.1038/73786; Selkov E, 1997, GENE, V197, pGC11, DOI 10.1016/S0378-1119(97)00307-7; Tomita M, 1999, BIOINFORMATICS, V15, P72, DOI 10.1093/bioinformatics/15.1.72; VARMA A, 1994, BIO-TECHNOL, V12, P994, DOI 10.1038/nbt1094-994; VARMA A, 1994, APPL ENVIRON MICROB, V60, P3724, DOI 10.1128/AEM.60.10.3724-3731.1994; Weikert C, 1997, MICROBIOL-UK, V143, P1567, DOI 10.1099/00221287-143-5-1567; Wiechert W, 2002, J BIOTECHNOL, V94, P37, DOI 10.1016/S0168-1656(01)00418-7	22	607	658	1	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					186	189		10.1038/nature01149	http://dx.doi.org/10.1038/nature01149			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432395				2022-12-28	WOS:000179200900048
J	Khogali, SS; Townend, JN				Khogali, SS; Townend, JN			Coronary-artery calcification.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Khogali, SS (corresponding author), Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England.			Townend, Jonathan/0000-0002-5881-5806					0	1	1	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2002	347	20					1584	1584		10.1056/NEJMicm010843	http://dx.doi.org/10.1056/NEJMicm010843			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614KL	12432045				2022-12-28	WOS:000179187800006
J	Harris, B				Harris, B			Child murders in Central America	LANCET			English	Editorial Material																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1508	1508		10.1016/S0140-6736(02)11481-4	http://dx.doi.org/10.1016/S0140-6736(02)11481-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433538				2022-12-28	WOS:000179186000035
J	Rabkin, M; El-Sadr, W; Katzenstein, DA; Mukherjee, J; Masur, H; Mugyenyi, P; Munderi, P; Darbyshire, J				Rabkin, M; El-Sadr, W; Katzenstein, DA; Mukherjee, J; Masur, H; Mugyenyi, P; Munderi, P; Darbyshire, J			Antiretroviral treatment in resource-poor settings: clinical research priorities	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION; CD4 CELL COUNT; VIRAL LOAD; DISEASE PROGRESSION; CONTROLLED TRIAL; THERAPY; ADHERENCE; INDINAVIR; AIDS		Columbia Univ, Dept Med, New York, NY 10027 USA; Columbia Univ, Harlem Hosp, Mailman Sch Publ Hlth, New York, NY USA; Columbia Univ, Harlem Hosp, Div Infect Dis, New York, NY USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA; NIH, Dept Crit Care Med, Bethesda, MD 20892 USA; Joint Clin Res Ctr, Kampala, Uganda; WHO, Dept Essential Drugs & Med, CH-1211 Geneva, Switzerland; Med Res Ctr, Clin Trials Unit, London, England	Columbia University; Columbia University; Columbia University; Stanford University; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; Joint Clinic Research Center - United Arab Emirates; World Health Organization; Medical Research Council Clinical Trials Unit	Rabkin, M (corresponding author), Columbia Univ, Dept Med, New York, NY 10027 USA.			katzenstein, david/0000-0002-8593-4560				Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; BEDELL R, 2001, 1 IAS C HIV PATH TRE; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; CHAPMAN K, 2001, UNAIDS0193E; Deeks SG, 2002, AIDS, V16, P201, DOI 10.1097/00002030-200201250-00009; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; DIDER JM, 2001, J ACQ IMMUN DEF SYND, V26, P193; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrington M, 2000, LANCET, V355, P2147, DOI 10.1016/S0140-6736(00)02388-6; Henry K, 2000, ANN INTERN MED, V132, P306, DOI 10.7326/0003-4819-132-4-200002150-00009; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Janossy G, 2000, BRIT J HAEMATOL, V111, P1198, DOI 10.1046/j.1365-2141.2000.02433.x; KITYO C, 2002, 14 INT AIDS C BARC; LAURENT C, 2002, 9 C RETR OPP INF SEA; Ledergerber B, 2000, J INFECT DIS, V181, P1280, DOI 10.1086/315366; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; Post FA, 1996, QJM-MON J ASSOC PHYS, V89, P505; SCHECHTER M, 1994, J ACQ IMMUN DEF SYND, V7, P163; Sterling TR, 2001, AIDS, V15, P2251, DOI 10.1097/00002030-200111230-00006; *US DEP HHS HJ KAI, 2002, GUID US ANT AG HIV 1; *WHO, 2002, SCAL ANT THER RES LI; Zwerner RK, 1997, J ACQ IMMUN DEF SYND, V14, P31, DOI 10.1097/00042560-199701010-00006	26	38	39	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1503	1505		10.1016/S0140-6736(02)11478-4	http://dx.doi.org/10.1016/S0140-6736(02)11478-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433534				2022-12-28	WOS:000179186000031
J	Wiesli, P; Spinas, GA; Pfammatter, T; Krahenbuhl, L; Schmid, C				Wiesli, P; Spinas, GA; Pfammatter, T; Krahenbuhl, L; Schmid, C			Glucose-induced hypoglycaemia	LANCET			English	Editorial Material									Univ Zurich Hosp, Div Endocrinol & Diabet, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Inst Diagnost Radiol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Clin Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Wiesli, P (corresponding author), Univ Zurich Hosp, Div Endocrinol & Diabet, CH-8091 Zurich, Switzerland.			Schmid, Christoph/0000-0003-2080-4439				DOPPMAN JL, 1995, ANN INTERN MED, V123, P269, DOI 10.7326/0003-4819-123-4-199508150-00004; SERVICE FJ, 1995, NEW ENGL J MED, V332, P1144, DOI 10.1056/NEJM199504273321707	2	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1476	1476		10.1016/S0140-6736(02)11475-9	http://dx.doi.org/10.1016/S0140-6736(02)11475-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433516				2022-12-28	WOS:000179186000013
J	Chuck, G; Muszynski, M; Kellogg, E; Hake, S; Schmidt, RJ				Chuck, G; Muszynski, M; Kellogg, E; Hake, S; Schmidt, RJ			The control of spikelet meristem identity by the branched silkless1 gene in maize	SCIENCE			English	Article							FLOWER DEVELOPMENT; ARABIDOPSIS; INITIATION; FIMBRIATA; TASSEL; FAMILY	Most of the world's food supply is derived from cereal grains that are borne in a unique structure called the spikelet, the fundamental unit of inflorescence architecture in all grasses. branched silkless1 ( bd1) is a maize mutation that alters the identity of the spikelet meristem, causing indeterminate branches to form in place of spikelets. We show that bd1 encodes a putative ERF transcription factor that is conserved in different grasses and is expressed in a distinct domain of the spikelet meristem. Its expression pattern suggests that signaling pathways regulate meristem identity from lateral domains of the spikelet meristem.	ARS, Ctr Plant Gene Express, USDA, Albany, CA 94710 USA; Pioneer HiBred Int Inc, Johnston, IA 50131 USA; Univ Missouri, St Louis, MO 63121 USA; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	United States Department of Agriculture (USDA); DuPont; University of Missouri System; University of Missouri Saint Louis; University of California System; University of California San Diego	Chuck, G (corresponding author), ARS, Ctr Plant Gene Express, USDA, 800 Buchanan St, Albany, CA 94710 USA.	gchuck@nature.berkeley.edu	Kellogg, Elizabeth/M-2845-2013; Muszynski, Michael G./L-2843-2016	Kellogg, Elizabeth/0000-0003-1671-7447; Muszynski, Michael G./0000-0002-0817-7594				Banno H, 2001, PLANT CELL, V13, P2609, DOI 10.1105/tpc.13.12.2609; BARKAN A, 1991, P NATL ACAD SCI USA, V88, P3502, DOI 10.1073/pnas.88.8.3502; CHENG PC, 1983, AM J BOT, V70, P450, DOI 10.2307/2443252; Chuck G, 1998, GENE DEV, V12, P1145, DOI 10.1101/gad.12.8.1145; CHUCK G, UNPUB; Clayton WD., 1990, REPROD VERSATILITY G, P32; Colombo L, 1998, PLANT J, V16, P355, DOI 10.1046/j.1365-313x.1998.00300.x; Fujimoto SY, 2000, PLANT CELL, V12, P393, DOI 10.1105/tpc.12.3.393; HELENTJARIS T, 1988, GENETICS, V118, P353; INGRAM GC, 1995, PLANT CELL, V7, P1501, DOI 10.1105/tpc.7.9.1501; Irish EE, 1997, AM J BOT, V84, P1502, DOI 10.2307/2446611; Kempton JH, 1934, J HERED, V25, P29, DOI 10.1093/oxfordjournals.jhered.a103835; Laudencia-Chingcuanco D, 2002, DEVELOPMENT, V129, P2629; Lee I, 1997, CURR BIOL, V7, P95, DOI 10.1016/S0960-9822(06)00053-4; LEVIN JZ, 1995, PLANT CELL, V7, P529, DOI 10.1105/tpc.7.5.529; Mathews S, 2002, INT J PLANT SCI, V163, P441, DOI 10.1086/339155; McSteen P, 2000, TRENDS PLANT SCI, V5, P61, DOI 10.1016/S1360-1385(99)01541-1; Mena M, 1996, SCIENCE, V274, P1537, DOI 10.1126/science.274.5292.1537; Mena M, 1995, PLANT J, V8, P845, DOI 10.1046/j.1365-313X.1995.8060845.x; Riechmann JL, 1998, BIOL CHEM, V379, P633; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; van der Graaff E, 2000, DEVELOPMENT, V127, P4971; Wilson K, 1996, PLANT CELL, V8, P659, DOI 10.1105/tpc.8.4.659	23	210	237	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	2002	298	5596					1238	1241		10.1126/science.1076920	http://dx.doi.org/10.1126/science.1076920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424380				2022-12-28	WOS:000179080400052
J	Joint, I; Tait, K; Callow, ME; Callow, JA; Milton, D; Williams, P; Camara, M				Joint, I; Tait, K; Callow, ME; Callow, JA; Milton, D; Williams, P; Camara, M			Cell-to-cell communication across the prokaryote-eukaryote boundary	SCIENCE			English	Article							LACTONE		Plymouth Marine Lab, Plymouth PL1 3DH, Devon, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden; Univ Nottingham, Sch Pharmaceut Sci, Inst Infect & Immun, Nottingham NG7 2RD, England	Plymouth Marine Laboratory; University of Birmingham; Umea University; University of Nottingham	Joint, I (corresponding author), Plymouth Marine Lab, Prospect Pl, Plymouth PL1 3DH, Devon, England.		Williams, Paul/P-5224-2019; Williams, Paul/A-5629-2011	Williams, Paul/0000-0002-1920-5036; Tait, Karen/0000-0001-8137-6998				Callow ME, 1997, J PHYCOL, V33, P938, DOI 10.1111/j.0022-3646.1997.00938.x; Joint I, 2000, BIOFOULING, V16, P151, DOI 10.1080/08927010009378440; Milton DL, 1997, J BACTERIOL, V179, P3004, DOI 10.1128/jb.179.9.3004-3012.1997; Milton DL, 2001, J BACTERIOL, V183, P3537, DOI 10.1128/JB.183.12.3537-3547.2001; Swift S, 2001, ADV MICROB PHYSIOL, V45, P199, DOI 10.1016/S0065-2911(01)45005-3; Withers H, 2001, CURR OPIN MICROBIOL, V4, P186, DOI 10.1016/S1369-5274(00)00187-9	6	208	218	3	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1207	1207		10.1126/science.1077075	http://dx.doi.org/10.1126/science.1077075			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424372				2022-12-28	WOS:000179080400041
J	Dixon, J				Dixon, J			Uses of error - Pattern recognition	LANCET			English	Editorial Material									Coach House, London NW3 2UT, England		Dixon, J (corresponding author), Coach House, London NW3 2UT, England.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1418	1418		10.1016/S0140-6736(02)11396-1	http://dx.doi.org/10.1016/S0140-6736(02)11396-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12424007				2022-12-28	WOS:000179081600033
J	Bracey, MH; Hanson, MA; Masuda, KR; Stevens, RC; Cravatt, BF				Bracey, MH; Hanson, MA; Masuda, KR; Stevens, RC; Cravatt, BF			Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling	SCIENCE			English	Article							ACID AMIDE HYDROLASE; MOLECULAR CHARACTERIZATION; FAMILY	Cellular communication in the nervous system is mediated by chemical messengers that include amino acids, monoamines, peptide hormones, and lipids. An interesting question is how neurons regulate signals that are transmitted by membrane-embedded lipids. Here, we report the 2.8 angstrom crystal structure of the integral membrane protein fatty acid amide hydrolase ( FAAH), an enzyme that degrades members of the endocannabinoid class of signaling lipids and terminates their activity. The structure of FAAH complexed with an arachidonyl inhibitor reveals how a set of discrete structural alterations allows this enzyme, in contrast to soluble hydrolases of the same family, to integrate into cell membranes and establish direct access to the bilayer from its active site.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Stevens, RC (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	stevens@scripps.edu; cravatt@scripps.edu	Stevens, Raymond/K-7272-2015	Stevens, Raymond/0000-0002-4522-8725	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013173] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA013173-02] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boger DL, 2000, P NATL ACAD SCI USA, V97, P5044, DOI 10.1073/pnas.97.10.5044; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Egertova M, 1998, P ROY SOC B-BIOL SCI, V265, P2081, DOI 10.1098/rspb.1998.0543; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; GOMI K, 1991, GENE, V108, P91, DOI 10.1016/0378-1119(91)90491-S; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lichtman AH, 2002, J PHARMACOL EXP THER, V302, P73, DOI 10.1124/jpet.302.1.73; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P14125, DOI 10.1021/bi991876p; Patricelli MP, 2001, BIOCHEMISTRY-US, V40, P6107, DOI 10.1021/bi002578r; Patricelli MP, 1998, BIOCHEMISTRY-US, V37, P15177, DOI 10.1021/bi981733n; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P9804, DOI 10.1021/bi990637z; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Shin S, 2002, EMBO J, V21, P2509, DOI 10.1093/emboj/21.11.2509; Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799; Tieleman DP, 1998, BIOPHYS J, V74, P2786, DOI 10.1016/S0006-3495(98)77986-X; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545	26	418	448	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1793	1796		10.1126/science.1076535	http://dx.doi.org/10.1126/science.1076535			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459591				2022-12-28	WOS:000179494800047
J	Dubertret, B; Skourides, P; Norris, DJ; Noireaux, V; Brivanlou, AH; Libchaber, A				Dubertret, B; Skourides, P; Norris, DJ; Noireaux, V; Brivanlou, AH; Libchaber, A			In vivo imaging of quantum dots encapsulated in phospholipid micelles	SCIENCE			English	Article							CDSE NANOCRYSTALS; PHASE-BEHAVIOR; MIXTURES; DNA	Fluorescent semiconductor nanocrystals (quantum dots) have the potential to revolutionize biological imaging, but their use has been limited by difficulties in obtaining nanocrystals that are biocompatible. To address this problem, we encapsulated individual nanocrystals in phospholipid block-copolymer micelles and demonstrated both in vitro and in vivo imaging. When conjugated to DNA, the nanocrystal-micelles acted as in vitro. fluorescent probes to hybridize to specific complementary sequences. Moreover, when injected into Xenopus embryos, the nanocrystal-micelles were stable, nontoxic (<5 x 10(9) nanocrystals per cell), cell autonomous, and slow to photobleach. Nanocrystal fluorescence could be followed to the tadpole stage, allowing lineage-tracing experiments in embryogenesis.	Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA; Rockefeller Univ, Mol Embryol Lab, New York, NY 10021 USA; NEC Res Inst, Princeton, NJ 08540 USA; Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	Rockefeller University; Rockefeller University; NEC Corporation; University of Minnesota System; University of Minnesota Twin Cities	Dubertret, B (corresponding author), CNRS, UPRA0005, 10 Rue Vauquelin, F-75005 Paris, France.		Norris, David J/F-4022-2010	Norris, David J/0000-0002-3765-0678; noireaux, vincent/0000-0002-5213-273X; Skourides, Paris/0000-0003-3502-5729				Aldana J, 2001, J AM CHEM SOC, V123, P8844, DOI 10.1021/ja016424q; Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Belsito S, 2000, BIOPHYS J, V78, P1420, DOI 10.1016/S0006-3495(00)76695-1; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Dahan M, 2001, OPT LETT, V26, P825, DOI 10.1364/OL.26.000825; Gerion D, 2002, J AM CHEM SOC, V124, P7070, DOI 10.1021/ja017822w; Gerion D, 2001, J PHYS CHEM B, V105, P8861, DOI 10.1021/jp0105488; Golander C. G., 1992, POLYETHYLENE GLYCOL, P221, DOI DOI 10.1007/978-1-4899-0703-5_15.; Goldman ER, 2002, ANAL CHEM, V74, P841, DOI 10.1021/ac010662m; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; HRISTOVA K, 1995, MACROMOLECULES, V28, P991, DOI 10.1021/ma00108a029; Johnsson M, 2001, J PHYS CHEM B, V105, P8420, DOI 10.1021/jp011088l; Jones MC, 1999, EUR J PHARM BIOPHARM, V48, P101, DOI 10.1016/S0939-6411(99)00039-9; KATAOKA K, 1993, J CONTROL RELEASE, V24, P119; LASIC DD, 1991, PERIOD BIOL, V93, P287; Leatherdale CA, 2002, J PHYS CHEM B, V106, P7619, DOI 10.1021/jp025698c; Mattoussi H, 2000, J AM CHEM SOC, V122, P12142, DOI 10.1021/ja002535y; Mikulec F. V., 1999, THESIS MIT; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Parak WJ, 2002, ADV MATER, V14, P882, DOI 10.1002/1521-4095(20020618)14:12<882::AID-ADMA882>3.0.CO;2-Y; Pathak S, 2001, J AM CHEM SOC, V123, P4103, DOI 10.1021/ja0058334; Rosenthal SJ, 2002, J AM CHEM SOC, V124, P4586, DOI 10.1021/ja003486s; Torchilin VP, 2002, ADV DRUG DELIVER REV, V54, P235, DOI 10.1016/S0169-409X(02)00019-4; Winter JO, 2001, ADV MATER, V13, P1673, DOI 10.1002/1521-4095(200111)13:22<1673::AID-ADMA1673>3.0.CO;2-6	28	2662	2906	19	864	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1759	1762		10.1126/science.1077194	http://dx.doi.org/10.1126/science.1077194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459582				2022-12-28	WOS:000179494800036
J	Prusiner, SB				Prusiner, SB			Historical essay - Discovering the cause of AIDS	SCIENCE			English	Editorial Material							RETROVIRUSES HTLV-III; IMMUNE-DEFICIENCY SYNDROME; KAPOSIS-SARCOMA; IMMUNODEFICIENCY; LYMPHOCYTES; PATIENT		Univ Calif San Francisco, Dept Neurol, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Prusiner, SB (corresponding author), Univ Calif San Francisco, Dept Neurol, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA.							BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Centers for Disease Control (CDC), 1981, MMWR-MORBID MORTAL W, V30, P250; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COFFIN J, 1986, SCIENCE, V232, P697, DOI 10.1126/science.3008335; EHRENKRANZ NJ, 1982, MMWR-MORBID MORTAL W, V31, P365; ESSEX M, 1986, AIDS PAPERS SCI 1982, P3; FRANCIS DP, 1983, J NATL CANCER I, V71, P1; GALLO RC, 1987, NATURE, V326, P435; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GALLO RC, 1988, SCI AM, V259, P40, DOI 10.1038/scientificamerican1088-40; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; Karon J M, 1992, MMWR Recomm Rep, V41, P1; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SAFAI B, 1984, LANCET, V1, P1438, DOI 10.1016/S0140-6736(84)91933-0; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937	20	5	8	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1726	1727						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459574				2022-12-28	WOS:000179494800026
J	Bolger, PM; Schwetz, BA				Bolger, PM; Schwetz, BA			Mercury and health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US FDA, College Pk, MD 20740 USA	US Food & Drug Administration (FDA)	Bolger, PM (corresponding author), US FDA, College Pk, MD 20740 USA.								0	92	96	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1735	1736		10.1056/NEJMp020139	http://dx.doi.org/10.1056/NEJMp020139			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456847				2022-12-28	WOS:000179468600001
J	Nishimura, R; Hayashi, M; Wu, GJ; Kouchi, H; Imaizumi-Anraku, H; Murakami, Y; Kawasaki, S; Akao, S; Ohmori, M; Nagasawa, M; Harada, K; Kawaguchi, M				Nishimura, R; Hayashi, M; Wu, GJ; Kouchi, H; Imaizumi-Anraku, H; Murakami, Y; Kawasaki, S; Akao, S; Ohmori, M; Nagasawa, M; Harada, K; Kawaguchi, M			HAR1 mediates systemic regulation of symbiotic organ development	NATURE			English	Article							SPLIT-ROOT SYSTEM; LOTUS-JAPONICUS; RECEPTOR KINASE; WILD-TYPE; LINKAGE MAP; NODULATION; MUTANT; SHOOT; CLAVATA1; SUPPRESSION	Symbiotic root nodules are beneficial to leguminous host plants; however, excessive nodulation damages the host because it interferes with the distribution of nutrients in the plant. To keep a steady balance, the nodulation programme is regulated systemically in leguminous hosts(1),(2). Leguminous mutants that have lost this ability display a hypernodulating phenotype. Through the use of reciprocal and self-grafting studies using Lotus japonicus hypernodulating mutants, har1 (also known as sym78)(3), we show that the shoot genotype is responsible for the negative regulation of nodule development. A map-based cloning strategy revealed that HAR1 encodes a protein with a relative molecular mass of 108, 000, which contains 21 leucine-rich repeats, a single transmembrane domain and serine/threonine kinase domains. The har1 mutant phenotype was rescued by transfection of the HAR1 gene. In a comparison of Arabidopsis receptor-like kinases, HAR1 showed the highest level of similarity with CLAVATA1 (CLV1)(4). CLV1 negatively regulates formation of the shoot and floral meristems through cell-cell communication involving the CLV3 peptide(5). Identification of hypernodulation genes thus indicates that genes in leguminous plants bearing a close resemblance to CLV1 regulate nodule development systemically, by means of organ-organ communication.	Niigata Univ, Fac Sci, Dept Environm Sci, Niigata 9502181, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1638902, Japan; Chiba Univ, Fac Hort, Chiba 2718510, Japan; Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058602, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	Niigata University; University of Tokyo; Chiba University; National Institute of Agrobiological Sciences - Japan; Japan Science & Technology Agency (JST)	Kawaguchi, M (corresponding author), Niigata Univ, Fac Sci, Dept Environm Sci, Niigata 9502181, Japan.	masayosi@env.sc.niigata-u.ac.jp	Han, Liqi/K-6127-2013	Kawaguchi, Masayoshi/0000-0002-1032-6261				AKAO S, 1992, SOIL SCI PLANT NUTR, V38, P183, DOI 10.1080/00380768.1992.10416966; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; DELVES AC, 1986, PLANT PHYSIOL, V82, P588, DOI 10.1104/pp.82.2.588; DeYoung BJ, 2001, PLANT MOL BIOL, V46, P505, DOI 10.1023/A:1010672910703; Flemetakis E, 2000, MOL PLANT MICROBE IN, V13, P987, DOI 10.1094/MPMI.2000.13.9.987; GRESSHOFF PM, 1992, CURRENT TOPICS PLANT, P87; HAMAGUCHI H, 1992, SOIL SCI PLANT NUTR, V38, P771, DOI 10.1080/00380768.1992.10416710; Hayashi M, 2001, DNA RES, V8, P301, DOI 10.1093/dnares/8.6.301; Kawaguchi M, 2002, MOL PLANT MICROBE IN, V15, P17, DOI 10.1094/MPMI.2002.15.1.17; Kawaguchi M, 2001, MOL GENET GENOMICS, V266, P157, DOI 10.1007/s004380100540; Kawasaki S, 2000, J PLANT RES, V113, P497, DOI 10.1007/PL00013960; KOSSLAK RM, 1984, PLANT PHYSIOL, V75, P125, DOI 10.1104/pp.75.1.125; Kouchi H, 1999, PLANT J, V18, P121, DOI 10.1046/j.1365-313X.1999.00432.x; Matsubayashi Y, 2002, SCIENCE, V296, P1470, DOI 10.1126/science.1069607; Nishimura R, 2002, PLANT CELL PHYSIOL, V43, P853, DOI 10.1093/pcp/pcf098; NUTMAN PS, 1952, ANN BOT-LONDON, V16, P79, DOI 10.1093/oxfordjournals.aob.a083304; OLSSON JE, 1989, PLANT PHYSIOL, V90, P1347, DOI 10.1104/pp.90.4.1347; Penmetsa RV, 1997, SCIENCE, V275, P527, DOI 10.1126/science.275.5299.527; PIERCE M, 1983, PLANT PHYSIOL, V73, P286, DOI 10.1104/pp.73.2.286; Sagan M, 1996, SYMBIOSIS, V20, P229; Schauser L, 1998, MOL GEN GENET, V259, P414, DOI 10.1007/s004380050831; Scheer JM, 2002, P NATL ACAD SCI USA, V99, P9585, DOI 10.1073/pnas.132266499; Sheng CX, 1997, PLANT PHYSIOL, V113, P825, DOI 10.1104/pp.113.3.825; Solaiman MZ, 2000, J PLANT RES, V113, P443, DOI 10.1007/PL00013953; Stiller J, 1997, J EXP BOT, V48, P1357, DOI 10.1093/jxb/48.7.1357; Szczyglowski K, 1998, MOL PLANT MICROBE IN, V11, P684, DOI 10.1094/MPMI.1998.11.7.684; van Brussel AAN, 2002, MOL PLANT MICROBE IN, V15, P341, DOI 10.1094/MPMI.2002.15.4.341; Wopereis J, 2000, PLANT J, V23, P97, DOI 10.1046/j.1365-313x.2000.00799.x; Yamamoto E, 2000, BBA-GENE STRUCT EXPR, V1491, P333, DOI 10.1016/S0167-4781(00)00061-0; Yamanaka N, 2001, DNA RES, V8, P61, DOI 10.1093/dnares/8.2.61	30	393	422	1	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	2002	420	6914					426	429		10.1038/nature01231	http://dx.doi.org/10.1038/nature01231			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12442172				2022-12-28	WOS:000179494700042
J	Hampp, N				Hampp, N			Analytes ante portas	SCIENCE			English	Editorial Material							DNA		Univ Marburg, Inst Phys Chem, D-35032 Marburg, Germany	Philipps University Marburg	Hampp, N (corresponding author), Univ Marburg, Inst Phys Chem, D-35032 Marburg, Germany.		Hampp, Norbert/AAA-9150-2019					Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038; Das G, 2002, SCIENCE, V298, P1600, DOI 10.1126/science.1077353; Gu LQ, 2001, SCIENCE, V291, P636, DOI 10.1126/science.291.5504.636; Howorka S, 2001, NAT BIOTECHNOL, V19, P636, DOI 10.1038/90236; Meller A, 2001, PHYS REV LETT, V86, P3435, DOI 10.1103/PhysRevLett.86.3435	5	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1561	1562						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446893				2022-12-28	WOS:000179361600032
J	Wright, JT; Bakris, G; Greene, T; Agodoa, LY; Appel, LJ; Charleston, J; Cheek, D; Douglas-Baltimore, JG; Gassman, J; Glassock, R; Hebert, L; Jamerson, K; Lewis, J; Phillips, RA; Toto, RD; Middleton, JP; Rostand, SG				Wright, JT; Bakris, G; Greene, T; Agodoa, LY; Appel, LJ; Charleston, J; Cheek, D; Douglas-Baltimore, JG; Gassman, J; Glassock, R; Hebert, L; Jamerson, K; Lewis, J; Phillips, RA; Toto, RD; Middleton, JP; Rostand, SG		African Amer Study Kidney Dis Hype	Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease - Results from the AASK trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	74th Annual Scientific Sessions of the American-Heart-Association	NOV 11-14, 2001	ANAHEIM, CA	Amer Heart Assoc			CONVERTING-ENZYME-INHIBITION; CALCIUM-CHANNEL BLOCKERS; STAGE RENAL-DISEASE; AFRICAN-AMERICAN; RISK-FACTOR; NEPHROSCLEROSIS; INSUFFICIENCY; NEPHROPATHY; PROTEINURIA; MORTALITY	Context Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD. Objective To compare the effects of 2 levels of blood pressure (BP) control and 3 antihypertensive drug classes on glomerular filtration rate (GFR) decline in hypertension. Design Randomized 3 x 2 factorial trial with enrollment from February 1995 to September 1998. Setting and Participants A total of 1094 African Americans aged 18 to 70 years with hypertensive renal disease (GFR, 20-65 mL/min per 1.73 m(2)) were recruited from 21 clinical centers throughout the United States and followed up for 3 to 6.4 years. Interventions Participants were randomly assigned to 1 of 2 mean arterial pressure goals, 102 to 107 mm Hg (usual; n=554) or 92 mm Hg or less (lower; n=540), and to initial treatment with either a beta-blocker (metoprolol 50-200 mg/d; n=441), an angiotensin-converting enzyme inhibitor (ramipril 2.5-10 mg/d; n=436) or a dihydropyridine calcium channel blocker, (amlodipine 5-10 mg/d; n=217). Open-label agents were added to achieve the assigned BP goals. Main Outcome Measures Rate of change in GFR (GFR slope); clinical composite outcome of reduction in GFR by 50% or more (or greater than or equal to25 mL/min per 1.73 m(2)) from baseline, ESRD, or death. Three primary treatment comparisons were specified: lower vs usual BP goal; ramipril vs metoprolol; and amlodipine vs metoprolol. Results Achieved BP averaged (SD) 128/78 (12/8) mm Hg in the lower BP group and 141/85 (12/7) mm Hg in the usual BP group. The mean (SE) GFR slope from baseline through 4 years did not differ significantly between the lower BP group (-2.21 [0.17] mL/min per 1.73 m(2) per year) and the usual BP group (-1.95 [0.17] mL/min per 1.73 ml per year; P=.24), and the lower BP goal did not significantly reduce the rate of the clinical composite outcome (risk reduction for lower BP group=2%; 95% confidence interval [CI], -22% to 21 %; P=.85). None of the drug group comparisons showed consistent significant differences in the GFR slope. However, compared with the metoprolol and amlodipine groups, the ramipril group manifested risk reductions in the clinical composite outcome of 22% (95% CI, 1%-38%; P=.04) and 38% (95% CI, 14%-56%; P=.004), respectively. There was no significant difference in the clinical composite outcome between the amlodipine and metoprolol groups. Conclusions No additional benefit of slowing progression of hypertensive nephrosclerosis was observed with the lower BP goal. Angiotensin-converting enzyme inhibitors appear to be more effective than beta-blockers or dihydropyridine calcium channel blockers in slowing GFR decline.	Case Western Reserve Univ, Univ Hosp Cleveland, Dept Med, Cleveland, OH 44106 USA; Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Dept Med, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Biostat, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; NIDDKD, Bethesda, MD 20892 USA; Johns Hopkins Univ, Dept Prevent Med, Baltimore, MD USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Ohio State Univ, Dept Med, Columbus, OH 43210 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; Vanderbilt Univ, Dept Med, Nashville, TN USA; Mt Sinai Sch Med, New York, NY USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Univ Alabama Birmingham, Birmingham, AL USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cleveland Clinic Foundation; Case Western Reserve University; Rush University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Johns Hopkins University; Medical University of South Carolina; University of California System; University of California Los Angeles; University System of Ohio; Ohio State University; University of Michigan System; University of Michigan; Vanderbilt University; Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Alabama System; University of Alabama Birmingham	Wright, JT (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Dept Med, 11000 Euclid Ave,Horwitz Tower,Suite 7311, Cleveland, OH 44106 USA.	jxw20@po.cwru.edu	Appel, Larry/GLT-2608-2022; Middleton, John/U-4471-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011104, M01RR000827, M01RR000052, M01RR000071, P20RR011145, M01RR000080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK048643, K24DK002818] Funding Source: NIH RePORTER; NCRR NIH HHS [2P20 RR11104, M01 RR00052, M01 RR00827, M01 RR000052, 5M01 RR-00071, M01 RR-00080, P20-RR11145] Funding Source: Medline; NIDDK NIH HHS [U01 DK048643, U01 DK045386, U01 DK045381, U01 DK048648, DK 2818-02] Funding Source: Medline; PHS HHS [M01 00032] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Bakris GL, 2000, ARCH INTERN MED, V160, P685, DOI 10.1001/archinte.160.5.685; Bakris GL, 1997, HYPERTENSION, V29, P744, DOI 10.1161/01.HYP.29.3.744; Bakris GL, 1996, KIDNEY INT, V50, P1641, DOI 10.1038/ki.1996.480; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; Carson P, 1999, J Card Fail, V5, P178, DOI 10.1016/S1071-9164(99)90001-5; DECESARIS R, 1993, J CARDIOVASC PHARM, V22, P208; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Estacio RO, 2000, DIABETES CARE, V23, pB54; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Fogo A, 1997, KIDNEY INT, V51, P244, DOI 10.1038/ki.1997.29; Guasch A, 1997, J AM SOC NEPHROL, V8, P793; Hall WD, 1997, AM J KIDNEY DIS, V29, P720, DOI 10.1016/S0272-6386(97)90125-6; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hebert Lee A., 1997, Hypertension (Dallas), V30, P428; Jafar TH, 2001, ANN INTERN MED, V135, P73, DOI 10.7326/0003-4819-135-2-200107170-00007; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Klag MJ, 1997, JAMA-J AM MED ASSOC, V277, P1293, DOI 10.1001/jama.277.16.1293; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Levey AS, 1996, J AM SOC NEPHROL, V7, P2097; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Lewis J, 2001, AM J KIDNEY DIS, V38, P744, DOI 10.1053/ajkd.2001.27691; LOCATELLI F, 1997, KIDNEY INT S, V63, P63; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P50; Porush JG, 1996, ARCH INTERN MED, V156, P1938; Psaty BM, 2001, ARCH INTERN MED, V161, P1183, DOI 10.1001/archinte.161.9.1183; Rahman M, 1997, ENDOCRIN METAB CLIN, V26, P125, DOI 10.1016/S0889-8529(05)70237-1; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1998, J AM SOC NEPHROL, V9, P2096; Ruggenenti P, 1999, LANCET, V354, P359, DOI 10.1016/S0140-6736(98)10363-X; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; STRIKER GE, 1992, AM J KIDNEY DIS, V20, P673, DOI 10.1016/S0272-6386(12)70239-1; TERWEE PM, 1994, ARCH INTERN MED, V154, P1185, DOI 10.1001/archinte.154.11.1185; TOTO RD, 1995, KIDNEY INT, V48, P851, DOI 10.1038/ki.1995.361; US Renal Data System, 1999, USRDS 1999 ANN DAT R; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; Whelton PK, 1996, J HUM HYPERTENS, V10, P683; WOODS JW, 1974, NEW ENGL J MED, V291, P10, DOI 10.1056/NEJM197407042910103; Wright JT, 1996, CONTROL CLIN TRIALS, V17, pS3, DOI 10.1016/S0197-2456(96)00081-5; Wright JT, 2002, ARCH INTERN MED, V162, P1636, DOI 10.1001/archinte.162.14.1636; 1997, ARCH INTERN MED, V157, P2413	50	1453	1489	1	74	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2002	288	19					2421	2431		10.1001/jama.288.19.2421	http://dx.doi.org/10.1001/jama.288.19.2421			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	616FB	12435255	Bronze			2022-12-28	WOS:000179292300025
J	Doye, A; Mettouchi, A; Bossis, G; Clement, R; Buisson-Touati, C; Flatau, G; Gagnoux, L; Piechaczyk, M; Boquet, P; Lemichez, E				Doye, A; Mettouchi, A; Bossis, G; Clement, R; Buisson-Touati, C; Flatau, G; Gagnoux, L; Piechaczyk, M; Boquet, P; Lemichez, E			CNF1 exploits the ubiquitin-proteasome machinery to restrict Rho GTPase activation for bacterial host cell invasion	CELL			English	Article							CYTOTOXIC NECROTIZING FACTOR-1; UROPATHOGENIC ESCHERICHIA-COLI; URINARY-TRACT INFECTIONS; ACTIN CYTOSKELETON; FACTOR TYPE-1; PROTEIN; TOXIN; DEAMIDATION; BINDING; DOMAIN	CNF1 toxin is a virulence factor produced by uropathogenic Escherichia coli. Upon cell binding and introduction into the cytosol, CNF1 deamidates glutamine 63 of RhoA (or 61 of Rac and Cdc42), rendering constitutively active these GTPases. Unexpectedly, we measured in bladder cells a transient CNF1-induced activation of Rho GTPases, maximal for Rac. Deactivation of Rac correlated with the increased susceptibility of its deamidated form to ubiquitin/proteasome-mediated degradation. Sensitivity to ubiquitylation could be generalized to other permanent-activated forms of Rac and to its sustained activation by Dbl. Degradation of the toxin-activated Rac allowed both host cell motility and efficient cell invasion by uropathogenic bacteria. CNF1 toxicity thus results from a restricted activation of Rho GTPases through hijacking the host cell proteasomal machinery.	Fac Med, INSERM, U452, IFR 50, F-06107 Nice, France; Fac Med, INSERM, U3825, IFR 50, F-06107 Nice, France; Ctr Antoine Lacassagne, CNRS, UMR 6543, IFR 72, F-06189 Nice, France; Inst Genet Mol, CNRS, UMR 5535, IFR 24, F-34293 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Lemichez, E (corresponding author), Fac Med, INSERM, U452, IFR 50, 28 Ave Valombrose, F-06107 Nice, France.		PIECHACZYK, Marc/E-7896-2013; Lemichez, Emmanuel/G-3559-2013; Bossis, Guillaume/C-7172-2012; Gagnoux, Laurent/O-9954-2016	PIECHACZYK, Marc/0000-0003-1367-2597; Lemichez, Emmanuel/0000-0001-9080-7761; METTOUCHI, Amel/0000-0003-1453-6482; bossis, guillaume/0000-0002-3349-8250				BLANCO J, 1992, RES MICROBIOL, V143, P869, DOI 10.1016/0923-2508(92)90074-X; BLUM G, 1995, FEMS MICROBIOL LETT, V126, P189, DOI 10.1016/0378-1097(95)00009-T; Bonacorsi SPP, 2000, INFECT IMMUN, V68, P2096, DOI 10.1128/IAI.68.4.2096-2101.2000; Boquet P, 1998, CURR OPIN MICROBIOL, V1, P66, DOI 10.1016/S1369-5274(98)80144-6; Boquet P, 2001, TOXICON, V39, P1673, DOI 10.1016/S0041-0101(01)00154-4; Buetow L, 2001, NAT STRUCT BIOL, V8, P584, DOI 10.1038/89610; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; FALKOW S, 1987, REV INFECT DIS, V9, P450; Flatau G, 2000, BIOCHEM BIOPH RES CO, V267, P588, DOI 10.1006/bbrc.1999.1904; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Horiguchi Y, 2001, TOXICON, V39, P1619, DOI 10.1016/S0041-0101(01)00149-0; Khan NA, 2002, J BIOL CHEM, V277, P15607, DOI 10.1074/jbc.M112224200; Landraud L, 2000, LETT APPL MICROBIOL, V30, P213, DOI 10.1046/j.1472-765x.2000.00698.x; Lemichez E, 1997, MOL MICROBIOL, V24, P1061, DOI 10.1046/j.1365-2958.1997.4151781.x; Lerm M, 2002, INFECT IMMUN, V70, P4053, DOI 10.1128/IAI.70.8.4053-4058.2002; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Lerm M, 1999, J BIOL CHEM, V274, P28999, DOI 10.1074/jbc.274.41.28999; Li XY, 2002, MOL CELL BIOL, V22, P1158, DOI 10.1128/MCB.22.4.1158-1171.2002; Lockman HA, 2002, INFECT IMMUN, V70, P2708, DOI 10.1128/IAI.70.5.2708-2714.2002; LOW D, 1984, INFECT IMMUN, V43, P353, DOI 10.1128/IAI.43.1.353-358.1984; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Pei S, 2001, MOL MICROBIOL, V41, P1237, DOI 10.1046/j.1365-2958.2001.02596.x; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, J CELL SCI, V114, P2713; SASAKAWA C, 1987, GENE, V56, P283; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Spoerner M, 2001, P NATL ACAD SCI USA, V98, P4944, DOI 10.1073/pnas.081441398; Stebbins CE, 2001, NATURE, V412, P701, DOI 10.1038/35089000	36	219	220	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 15	2002	111	4					553	564		10.1016/S0092-8674(02)01132-7	http://dx.doi.org/10.1016/S0092-8674(02)01132-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437928	Bronze			2022-12-28	WOS:000179346900008
J	Roderick, ML; Farquhar, GD				Roderick, ML; Farquhar, GD			The cause of decreased pan evaporation over the past 50 years	SCIENCE			English	Article							POTENTIAL EVAPOTRANSPIRATION; UNITED-STATES; DAILY MAXIMUM; TRENDS; TEMPERATURE; RADIATION; CLIMATE; CLOUDS; WATER; SOIL	Changes in the global water cycle can cause major environmental and socioeconomic impacts. As the average global temperature increases, it is generally expected that the air will become drier and that evaporation from terrestrial water bodies will increase. Paradoxically, terrestrial observations over the past 50 years show the reverse. Here, we show that the decrease in evaporation is consistent with what one would expect from the observed large and widespread decreases in sunlight resulting from increasing cloud coverage and aerosol concentration.	Australian Natl Univ, Inst Adv Studies, Res Sch Biol Sci, Cooperat Res Ctr Greenhouse Accounting, Canberra, ACT 0200, Australia	Australian National University	Farquhar, GD (corresponding author), Australian Natl Univ, Inst Adv Studies, Res Sch Biol Sci, Cooperat Res Ctr Greenhouse Accounting, Canberra, ACT 0200, Australia.	farquhar@rsbs.anu.edu.au	Roderick, Michael/C-9621-2009; FARQUHAR, GRAHAM D/A-3722-2008	Roderick, Michael/0000-0002-3630-7739; Farquhar, Graham/0000-0002-7065-1971				Abakumova GM, 1996, J CLIMATE, V9, P1319, DOI 10.1175/1520-0442(1996)009<1319:EOLTCI>2.0.CO;2; BRISTOW KL, 1984, AGR FOREST METEOROL, V31, P159, DOI 10.1016/0168-1923(84)90017-0; Brutsaert W, 1998, NATURE, V396, P30, DOI 10.1038/23845; Chattopadhyay N, 1997, AGR FOREST METEOROL, V87, P55, DOI 10.1016/S0168-1923(97)00006-3; Cohen S, 2002, AGR FOREST METEOROL, V111, P83, DOI 10.1016/S0168-1923(02)00016-3; Dai A, 1999, J CLIMATE, V12, P2451, DOI [10.1175/1520-0442(1999)012<2451:EOCSMP>2.0.CO;2, 10.1175/1520-0442(1999)012&lt;2451:EOCSMP&gt;2.0.CO;2]; Easterling DR, 1997, SCIENCE, V277, P364, DOI 10.1126/science.277.5324.364; Folland CK, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P99; Gaffen DJ, 1999, J CLIMATE, V12, P811, DOI 10.1175/1520-0442(1999)012<0811:CATOUS>2.0.CO;2; Gilgen H, 1998, J CLIMATE, V11, P2042, DOI 10.1175/1520-0442-11.8.2042; Golubev VS, 2001, GEOPHYS RES LETT, V28, P2665, DOI 10.1029/2000GL012851; Gu LH, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001242; KARL TR, 1993, B AM METEOROL SOC, V74, P1007, DOI 10.1175/1520-0477(1993)074<1007:ANPORG>2.0.CO;2; LINACRE ET, 1994, WATER INT, V19, P5, DOI 10.1080/02508069408686189; LINACRE ET, 1993, AGR FOREST METEOROL, V64, P237, DOI 10.1016/0168-1923(93)90031-C; PENMAN HL, 1948, PROC R SOC LON SER-A, V193, P120, DOI 10.1098/rspa.1948.0037; PETERSON TC, 1995, NATURE, V377, P687, DOI 10.1038/377687b0; PRIESTLEY CHB, 1972, MON WEATHER REV, V100, P81, DOI 10.1175/1520-0493(1972)100<0081:OTAOSH>2.3.CO;2; Ramanathan V, 2001, SCIENCE, V294, P2119, DOI 10.1126/science.1064034; Robinson PJ, 2000, INT J CLIMATOL, V20, P985, DOI 10.1002/1097-0088(200007)20:9<985::AID-JOC513>3.0.CO;2-W; Roderick ML, 2001, OECOLOGIA, V129, P21, DOI 10.1007/s004420100760; Stanhill G, 2001, AGR FOREST METEOROL, V107, P255, DOI 10.1016/S0168-1923(00)00241-0; Szilagyi J, 2001, J WATER RES PL-ASCE, V127, P354, DOI 10.1061/(ASCE)0733-9496(2001)127:6(354); Thomas A, 2000, INT J CLIMATOL, V20, P381, DOI 10.1002/(SICI)1097-0088(20000330)20:4&lt;381::AID-JOC477&gt;3.0.CO;2-K; Travis DJ, 2002, NATURE, V418, P601, DOI 10.1038/418601a	25	608	757	11	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1410	1411						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434057				2022-12-28	WOS:000179223100048
J	Buchman, TG				Buchman, TG			The community of the self	NATURE			English	Review							ORGAN DYSFUNCTION SYNDROME; LUTEINIZING-HORMONE; SYSTEMS; SHOCK; COMPLEXITY; CANNON,WALTER,B.; ORGANIZATION; REGULARITY; INCREASES; NETWORKS	Good health, which reflects the harmonious integration of molecules, cells, tissues and organs, is dynamically stable: when displaced by disease, compensation and correction are common, even without medical care. Physiology and computational biology now suggest that healthy dynamic stability arises through the combination of specific feedback mechanisms and spontaneous properties of interconnected networks. Today's physicians are already testing to 'see if the network is right'; tomorrow's physicians may well use therapies to 'make the network right'.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA	Washington University (WUSTL)	Buchman, TG (corresponding author), Washington Univ, Sch Med, Dept Surg, Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	buchman@msnotes.wustl.edu		Buchman, Timothy/0000-0001-7350-5921				Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Bernik TR, 2002, J EXP MED, V195, P781, DOI 10.1084/jem.20011714; Blalock JE, 2002, J EXP MED, V195, pF25, DOI 10.1084/jem.20020602; Chambers NK, 2000, SHOCK, V13, P497, DOI 10.1097/00024382-200006000-00013; Chambers NK, 2001, SHOCK, V16, P278, DOI 10.1097/00024382-200116040-00008; CHAUVET GA, 1993, PHILOS T R SOC B, V339, P425, DOI 10.1098/rstb.1993.0040; COLLINS JJ, 1995, PHYS REV E, V52, pR3321, DOI 10.1103/PhysRevE.52.R3321; DeMeester SL, 2001, FASEB J, V15, P270, DOI 10.1096/fj.00-0170hyp; Ellenby MS, 2001, SHOCK, V16, P274, DOI 10.1097/00024382-200116040-00007; Fink CC, 2000, BIOPHYS J, V79, P163, DOI 10.1016/S0006-3495(00)76281-3; Godin PJ, 1996, CRIT CARE MED, V24, P1117, DOI 10.1097/00003246-199607000-00009; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; Goldberger AL, 2002, P NATL ACAD SCI USA, V99, P2466, DOI 10.1073/pnas.012579499; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Gong YF, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.031904; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Kauffman S.A., 1993, ORIGINS ORDER; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kitano Hiroaki, 2001, P1; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; LIPSITZ LA, 1992, JAMA-J AM MED ASSOC, V267, P1806, DOI 10.1001/jama.267.13.1806; Marshall JC, 2001, CRIT CARE MED, V29, pS99, DOI 10.1097/00003246-200107001-00032; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Neiman A, 1999, PHYS REV E, V60, P284, DOI 10.1103/PhysRevE.60.284; Noble D, 2002, SCIENCE, V295, P1678, DOI 10.1126/science.1069881; Noble D, 2002, NAT REV MOL CELL BIO, V3, P460, DOI 10.1038/nrm810; PINCUS SM, 1994, MATH BIOSCI, V122, P161, DOI 10.1016/0025-5564(94)90056-6; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Pincus SM, 1996, P NATL ACAD SCI USA, V93, P14100, DOI 10.1073/pnas.93.24.14100; Schafer C, 1999, PHYS REV E, V60, P857, DOI 10.1103/PhysRevE.60.857; Schafer C, 1998, NATURE, V392, P239, DOI 10.1038/32567; Seely AJE, 2000, CRIT CARE MED, V28, P2193, DOI 10.1097/00003246-200007000-00003; Slutsky AS, 2002, J CLIN INVEST, V110, P737, DOI 10.1172/JCI200216551; Suki B, 1998, NATURE, V393, P127, DOI 10.1038/30130; Veldhuis JD, 1999, J CLIN ENDOCR METAB, V84, P3498, DOI 10.1210/jc.84.10.3498; Weiss YG, 2002, J CLIN INVEST, V110, P801, DOI 10.1172/JCI200215888; Wolkenhauer O, 2001, Brief Bioinform, V2, P258	39	155	163	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					246	251		10.1038/nature01260	http://dx.doi.org/10.1038/nature01260			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432410				2022-12-28	WOS:000179200900062
J	Carr, GL; Martin, MC; McKinney, WR; Jordan, K; Neil, GR; Williams, GP				Carr, GL; Martin, MC; McKinney, WR; Jordan, K; Neil, GR; Williams, GP			High-power terahertz radiation from relativistic electrons	NATURE			English	Article							COHERENT SYNCHROTRON-RADIATION; TRANSITION RADIATION; EMISSION; PULSES; LASER; MANIPULATION; GENERATION; BEAM	Terahertz (THz) radiation, which lies in the far-infrared region, is at the interface of electronics and photonics. Narrow-band THz radiation can be produced by free-electron lasers(1) and fast diodes(2,3). Broadband THz radiation can be produced by thermal sources and, more recently, by table-top laser-driven sources(4-6) and by short electron bunches in accelerators(7), but so far only with low power. Here we report calculations and measurements that confirm the production of high-power broadband THz radiation from subpicosecond electron bunches in an accelerator. The average power is nearly 20 watts, several orders of magnitude higher than any existing source, which could enable various new applications. In particular, many materials have distinct absorptive and dispersive properties in this spectral range, so that THz imaging could reveal interesting features. For example, it would be possible to image the distribution of specific proteins or water in tissue, or buried metal layers in semiconductors(8,9); the present source would allow full-field, real-time capture of such images. High peak and average power THz sources are also critical in driving new nonlinear phenomena and for pump-probe studies of dynamical properties of materials(10,11).	Jefferson Lab, Free Electron Laser Facil, Newport News, VA 23606 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source Div, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Jefferson National Accelerator; United States Department of Energy (DOE); Brookhaven National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Williams, GP (corresponding author), Jefferson Lab, Free Electron Laser Facil, 12000 Jefferson Ave, Newport News, VA 23606 USA.		McKinney, Wayne/F-2027-2014; Martin, Michael C./ABH-9841-2020; 1.4, ALS Beamline/I-1886-2014	McKinney, Wayne/0000-0003-2586-3139; Martin, Michael C./0000-0002-6611-070X; 				Andersson A, 2000, OPT ENG, V39, P3099, DOI 10.1117/1.1327498; Arp U, 2001, PHYS REV SPEC TOP-AC, V4, DOI 10.1103/PhysRevSTAB.4.054401; AUSTON DH, 1984, PHYS REV LETT, V53, P1555, DOI 10.1103/PhysRevLett.53.1555; Berryman KW, 1996, NUCL INSTRUM METH A, V375, P526, DOI 10.1016/0168-9002(96)00102-7; BONVALET A, 1995, APPL PHYS LETT, V67, P2907, DOI 10.1063/1.114838; Carr GL, 2001, NUCL INSTRUM METH A, V463, P387, DOI 10.1016/S0168-9002(01)00521-6; CHEN Q, 2001, ULTRAFAST LASERS TEC, P521; Cole BE, 2001, NATURE, V410, P60, DOI 10.1038/35065032; DORIA A, 1993, IEEE J QUANTUM ELECT, V29, P1428, DOI 10.1109/3.236158; Giovenale E, 1999, NUCL INSTRUM METH A, V437, P128, DOI 10.1016/S0168-9002(99)00486-6; HAPPEK U, 1991, PHYS REV LETT, V67, P2962, DOI 10.1103/PhysRevLett.67.2962; HIRSCHMUGL CJ, 1991, PHYS REV A, V44, P1316, DOI 10.1103/PhysRevA.44.1316; Huber R, 2001, NATURE, V414, P286, DOI 10.1038/35104522; HULBERT SL, 2001, HDB OPTICS CLASSICAL, V3; Jackson J., 1975, CLASSICAL ELECTRODYN; JAROSZYNSKI DA, 1993, PHYS REV LETT, V71, P3798, DOI 10.1103/PhysRevLett.71.3798; Lihn HC, 1996, PHYS REV LETT, V76, P4163, DOI 10.1103/PhysRevLett.76.4163; MOELLER KD, 1991, APPL OPTICS, V30, P4297; NAKAZATO T, 1989, PHYS REV LETT, V63, P1245, DOI 10.1103/PhysRevLett.63.1245; Neil GR, 2000, PHYS REV LETT, V84, P662, DOI 10.1103/PhysRevLett.84.662; NODVICK JS, 1954, PHYS REV, V96, P180, DOI 10.1103/PhysRev.96.180; Porterfield DW, 1999, IEEE T MICROW THEORY, V47, P419, DOI 10.1109/22.754875; RAMIAN G, 1992, NUCL INSTRUM METH A, V318, P225, DOI 10.1016/0168-9002(92)91056-F; Siegel PH, 2002, IEEE T MICROW THEORY, V50, P910, DOI 10.1109/22.989974; Tamada H, 1993, NUCL INSTRUM METH A, V331, P566; Wang DX, 1998, PHYS REV E, V57, P2283, DOI 10.1103/PhysRevE.57.2283; Winnerl S, 2000, APPL PHYS LETT, V77, P1259, DOI 10.1063/1.1290141; YOU D, 1993, OPT LETT, V18, P290, DOI 10.1364/OL.18.000290; YU LH, 1994, PHYS REV E, V49, P4480, DOI 10.1103/PhysRevE.49.4480; ZHANG ZC, 1995, COMPOUND OPTOELECTRO, P69	30	611	641	7	216	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					153	156		10.1038/nature01175	http://dx.doi.org/10.1038/nature01175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432385				2022-12-28	WOS:000179200900038
J	Rao, CV; Wolf, DM; Arkin, AP				Rao, CV; Wolf, DM; Arkin, AP			Control, exploitation and tolerance of intracellular noise	NATURE			English	Review							STOCHASTIC GENE-EXPRESSION; PHASE VARIATION; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; CHEMICAL LANGEVIN; NEGATIVE FEEDBACK; POSITIVE FEEDBACK; ROBUSTNESS; SIMULATION; NETWORKS	Noise has many roles in biological function, including generation of errors in DNA replication leading to mutation and evolution, noise-driven divergence of cell fates, noise-induced amplification of signals, and maintenance of the quantitative individuality of cells. Yet there is order to the behaviour and development of cells. They operate within strict parameters and in many cases this behaviour seems robust, implying that noise is largely filtered by the system. How can we explain the use, rejection and sensitivity to noise that is found in biological systems? An exploration of the sources and consequences of noise calls for the use of stochastic models.	Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Lawrence Berkeley Lab, Phys Biosci Div, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Rao, CV (corresponding author), Univ Calif Berkeley, Dept Bioengn, 1 Cyclotron Rd,MS 3-144, Berkeley, CA 94720 USA.	c_rao@lbl.gov; dmwolf@lbl.gov; aparkin@lbl.gov	Arkin, Adam/M-9941-2019; Arkin, Adam P/A-6751-2008	Arkin, Adam/0000-0002-4999-2931; Arkin, Adam P/0000-0002-4999-2931				ABRAHAM JM, 1985, P NATL ACAD SCI USA, V82, P5724, DOI 10.1073/pnas.82.17.5724; ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; Arkin A, 1998, GENETICS, V149, P1633; Arkin AP, 2001, CURR OPIN BIOTECH, V12, P638, DOI 10.1016/S0958-1669(01)00273-7; Arkin AP., 2000, SELF ORGANIZED BIOL, P112; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; BERG OG, 1978, J THEOR BIOL, V71, P587, DOI 10.1016/0022-5193(78)90326-0; Bren A, 2001, J MOL BIOL, V312, P699, DOI 10.1006/jmbi.2001.4992; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; Cook DL, 1998, P NATL ACAD SCI USA, V95, P15641, DOI 10.1073/pnas.95.26.15641; Detwiler PB, 2000, BIOPHYS J, V79, P2801, DOI 10.1016/S0006-3495(00)76519-2; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Fell D., 1997, UNDERSTANDING CONTRO; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Gammaitoni L, 1998, REV MOD PHYS, V70, P223, DOI 10.1103/RevModPhys.70.223; Gardiner C. W., 1990, HDB STOCHASTIC METHO; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Gibson MA, 2000, J PHYS CHEM A, V104, P1876, DOI 10.1021/jp993732q; Gillespie DT, 2002, J PHYS CHEM A, V106, P5063, DOI 10.1021/jp0128832; Gillespie DT, 2001, J CHEM PHYS, V115, P1716, DOI 10.1063/1.1378322; Gillespie DT, 2000, J CHEM PHYS, V113, P297, DOI 10.1063/1.481811; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Gonze D, 2002, P NATL ACAD SCI USA, V99, P673, DOI 10.1073/pnas.022628299; Hallet B, 2001, CURR OPIN MICROBIOL, V4, P570, DOI 10.1016/S1369-5274(00)00253-8; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Haseltine EL, 2002, J CHEM PHYS, V117, P6959, DOI 10.1063/1.1505860; Hasty J, 2000, P NATL ACAD SCI USA, V97, P2075, DOI 10.1073/pnas.040411297; Heinrich R., 1996, REGULATION CELLULAR; Houchmandzadeh B, 2002, NATURE, V415, P798, DOI 10.1038/415798a; KATSNER J, 2002, DEV BIOL, V246, P122; Kepler TB, 2001, BIOPHYS J, V81, P3116, DOI 10.1016/S0006-3495(01)75949-8; Kierzek AM, 2001, J BIOL CHEM, V276, P8165, DOI 10.1074/jbc.M006264200; Kloeden P.E., 1992, APPL MATH-CZECH, V23, DOI [10.1007/978-3-662-12616-5_4, 10.1007/978-3-662-12616-5]; KO MSH, 1991, J THEOR BIOL, V153, P181, DOI 10.1016/S0022-5193(05)80421-7; KO MSH, 1990, EMBO J, V9, P2835, DOI 10.1002/j.1460-2075.1990.tb07472.x; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; KURTZ T. G., 1981, APPROXIMATION POPULA, DOI 10.1137 1.9781611970333; Le Novere N, 2001, BIOINFORMATICS, V17, P575, DOI 10.1093/bioinformatics/17.6.575; Levin MD, 1998, BIOPHYS J, V74, P175, DOI 10.1016/S0006-3495(98)77777-X; Little JW, 1999, EMBO J, V18, P4299, DOI 10.1093/emboj/18.15.4299; MAYANI H, 1993, J CELL PHYSIOL, V157, P579, DOI 10.1002/jcp.1041570318; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Mehr IJ, 1998, MOL MICROBIOL, V30, P697, DOI 10.1046/j.1365-2958.1998.01089.x; Meir E, 2002, CURR BIOL, V12, P778, DOI 10.1016/S0960-9822(02)00839-4; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Morohashi M, 2002, J THEOR BIOL, V216, P19, DOI 10.1006/jtbi.2002.2537; Morton-Firth CJ, 1999, J MOL BIOL, V286, P1059, DOI 10.1006/jmbi.1999.2535; Morton-Firth CJ, 1998, J THEOR BIOL, V192, P117, DOI 10.1006/jtbi.1997.0651; Msadek T, 1999, TRENDS MICROBIOL, V7, P201, DOI 10.1016/S0966-842X(99)01479-1; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Paulsson J, 2000, P NATL ACAD SCI USA, V97, P7148, DOI 10.1073/pnas.110057697; Peak IRA, 1996, FEMS MICROBIOL LETT, V137, P109, DOI 10.1111/j.1574-6968.1996.tb08091.x; Ptashne M. A., 1998, GENETIC SWITCH PHAGE; RAO CV, IN PRESS J CHEM PHYS; Rodnina MV, 2001, TRENDS BIOCHEM SCI, V26, P124, DOI 10.1016/S0968-0004(00)01737-0; Russell DF, 1999, NATURE, V402, P291, DOI 10.1038/46279; SAMOILOV M, IN PRESS J PHYS CH A; Sauer FG, 2000, CURR OPIN MICROBIOL, V3, P65, DOI 10.1016/S1369-5274(99)00053-3; Shimizu Thomas Simon, 2001, P213; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; Slepchenko BM, 2002, ANNU REV BIOPH BIOM, V31, P423, DOI 10.1146/annurev.biophys.31.101101.140930; Smolen P, 2001, J NEUROSCI, V21, P6644, DOI 10.1523/JNEUROSCI.21-17-06644.2001; Smolen P, 2000, B MATH BIOL, V62, P247, DOI 10.1006/bulm.1999.0155; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Sternberg PW, 1997, CURR OPIN GENET DEV, V7, P543, DOI 10.1016/S0959-437X(97)80084-6; Thattai M, 2001, P NATL ACAD SCI USA, V98, P8614, DOI 10.1073/pnas.151588598; Thattai M, 2002, BIOPHYS J, V82, P2943, DOI 10.1016/S0006-3495(02)75635-X; van Oudenaarden A, 1999, NAT CELL BIOL, V1, P493, DOI 10.1038/70281; Vilar JMG, 2002, P NATL ACAD SCI USA, V99, P5988, DOI 10.1073/pnas.092133899; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; White JA, 2000, TRENDS NEUROSCI, V23, P131, DOI 10.1016/S0166-2236(99)01521-0; Wolf Denise M., 2002, OMICS A Journal of Integrative Biology, V6, P91, DOI 10.1089/15362310252780852; Wright AC, 2001, INFECT IMMUN, V69, P6893, DOI 10.1128/IAI.69.11.6893-6901.2001; Yi TM, 2000, P NATL ACAD SCI USA, V97, P4649, DOI 10.1073/pnas.97.9.4649; Ziebuhr W, 1999, MOL MICROBIOL, V32, P345, DOI 10.1046/j.1365-2958.1999.01353.x	86	754	764	2	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					231	237		10.1038/nature01258	http://dx.doi.org/10.1038/nature01258			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432408				2022-12-28	WOS:000179200900060
J	Zinner, D; Alberts, SC; Nunn, CL; Altmann, J				Zinner, D; Alberts, SC; Nunn, CL; Altmann, J			Evolutionary biology - Significance of primate sexual swellings	NATURE			English	Article							BABOONS		Deutsch Primatenzentrum GmbH, Abt Verhaltensforsch & Okol, D-37077 Gottingen, Germany; Duke Univ, Dept Biol, Durham, NC 27708 USA; Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA	Deutsches Primatenzentrum (DPZ); Duke University; University of California System; University of California Davis	Zinner, D (corresponding author), Deutsch Primatenzentrum GmbH, Abt Verhaltensforsch & Okol, D-37077 Gottingen, Germany.							ALBERTS SC, 1995, AM NAT, V145, P279, DOI 10.1086/285740; Altmann J, 2000, PRIMATE MALES, P236; CLUTTONBROCK TH, 1977, J ZOOL, V183, P1, DOI 10.1111/j.1469-7998.1977.tb04171.x; Domb LG, 2001, NATURE, V410, P204, DOI 10.1038/35065597; DOMB LG, 2000, SEXUAL SWELLINGS WIL; Fa JE, 1988, ECOLOGY BEHAV FOOD E; Hamilton W.J. III, 1984, P309; Nunn CL, 1999, ANIM BEHAV, V58, P229, DOI 10.1006/anbe.1999.1159; PACKER C, 1979, ANIM BEHAV, V27, P1, DOI 10.1016/0003-3472(79)90126-X; PAGEL M, 1994, ANIM BEHAV, V47, P1333, DOI 10.1006/anbe.1994.1181	10	45	47	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					142	143		10.1038/420142a	http://dx.doi.org/10.1038/420142a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432379				2022-12-28	WOS:000179200900032
J	Osrin, D; Tumbahangphe, KM; Shrestha, D; Mesko, N; Shtestha, BP; Manandhar, MK; Standing, H; Manandhar, DS; Costello, AMD				Osrin, D; Tumbahangphe, KM; Shrestha, D; Mesko, N; Shtestha, BP; Manandhar, MK; Standing, H; Manandhar, DS; Costello, AMD			Cross sectional, community based study of care of newborn infants in Nepal	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPOTHERMIA; DELIVERY; INDIA	Objective To determine home based newborn care practices in rural Nepal in order to inform strategies to improve neonatal outcome. Design Cross sectional, retrospective study using structured interviews. Setting Makwanpur district, Nepal. Participants 5411 married women aged 15 to 49 years who had given birth to a live baby in the past year. Main outcome measures Attendance at delivery, hygiene, thermal care, and early feeding practices. Results 4893 (90%) women gave birth at home. Attendance at delivery by skilled government health workers was low (334, 6%), as was attendance by traditional birth attendants (267, 5%). Only 461 (8%) women had used a clean home delivery kit, and about half of attendants had washed their,hands. Only 3482 (64%) newborn infants had been wrapped within half an hour of birth, and 4992 (92%) had been bathed within the first hour. 99% (5362) of babies were breast fed, 91% (4939) within six hours of birth. Practices with respect to colostrum and prelacteals were not a cause for anxiety. Conclusions Health promotion interventions most likely to improve newborn health in this setting include increasing attendance at delivery by skilled service providers, improving information for families about basic perinatal care, promotion of clean delivery practices, early cord cutting and wrapping of the baby, and avoidance of early bathing.	UCL, Inst Child Hlth, Int Perinatal Care Unit, London WC1N 1EH, England; Mother Infant Res Act, Kathmandu, Nepal; Nepal Adm Staff Coll, Ctr Local Governance, Kathmandu, Nepal; Univ Sussex, Inst Dev Studies, Hlth & Social Change Unit, Brighton BN1 9RH, E Sussex, England	University of London; University College London; University of Sussex	Costello, AMD (corresponding author), UCL, Inst Child Hlth, Int Perinatal Care Unit, London WC1N 1EH, England.	ipu@ich.ucl.ac.uk		Osrin, David/0000-0001-9691-9684				[Anonymous], 2002, WORLD DEV REP 2002; Bang A T, 2001, Indian Pediatr, V38, P952; BHAVE S A, 1989, Indian Pediatrics, V26, P1094; *CENTR BUR STAT, 2001, STAT YB NEP 2001; Claeson M, 2000, B WORLD HEALTH ORGAN, V78, P1192; *DEP HLTH SERV, 2001, 205657 DEP HLTH SERV; Ellis M, 1996, ARCH DIS CHILD-FETAL, V75, pF42, DOI 10.1136/fn.75.1.F42; *FAM HLTH DIV, 1998, CONTR TRAIN TBAS NEP; GOODBURN EA, 1995, STUD FAMILY PLANN, V26, P22, DOI 10.2307/2138048; IYENGAR SD, 1991, TROP GEOGR MED, V43, P293; JUSTICE J, 1983, SOC SCI MED, V17, P967, DOI 10.1016/0277-9536(83)90223-X; MANANDHAR M, 1999, BIRTHING PRACTICES S; *NAT PLANN COMM SE, 1998, FURTH AN REP AN DEL; *NAT PLANN COMM SE, 1998, FURTH AN REP ANT DEL; *NAT PLANN COMM SE, 1998, CAR PREGN DEL IMPL P; *NEP S AS CTR, 1998, NEP HUM DEV REP 1998; NICHTER M, 1983, HUM ORGAN, V42, P235, DOI 10.17730/humo.42.3.43081445235366lk; Pradhan A., 1997, NEPAL FAMILY HLTH SU; Pradhan A, 1997, NEP FAM HLTH SURV 19; Tamang S, 2001, CONTRIBUTIONS NEPALE, V28, P10; Thapa N, 2000, SOC SCI MED, V51, P1447, DOI 10.1016/S0277-9536(00)00045-9; TRAVERSO HP, 1989, LANCET, V1, P486; *UN CHILDR FUND, 1999, TRENDS CHILDH MORT D; *UN FUND POP ACT, 2000, STAT WORLDS POP 2000; *WHO, 1993, THERM CONTR NEWB PRA; World Bank, 2002, WORLD DEV REP; World Health Organization, 1996, ESS NEWB CAR REP TEC	27	84	84	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2002	325	7372					1063	1066		10.1136/bmj.325.7372.1063	http://dx.doi.org/10.1136/bmj.325.7372.1063			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424164	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000179415700017
J	Castellani, F; van Rossum, B; Diehl, A; Schubert, M; Rehbein, K; Oschkinat, H				Castellani, F; van Rossum, B; Diehl, A; Schubert, M; Rehbein, K; Oschkinat, H			Structure of a protein determined by solid-state magic-angle-spinning NMR spectroscopy	NATURE			English	Article							SPECTRIN SH3 DOMAIN; DISTANCE MEASUREMENTS; RHODOBACTER-SPHAEROIDES; MEMBRANE-PROTEINS; REACTION CENTERS; ROTATING SOLIDS; C-13; ASSIGNMENT; RESONANCE; ENVIRONMENT	The determination of a representative set of protein structures is a chief aim in structural genomics. Solid-state NMR may have a crucial role in structural investigations of those proteins that do not easily form crystals or are not accessible to solution NMR, such as amyloid systems 1 or membrane proteins(2-4). Here we present a protein structure determined by solid-state magic-angle-spinning (MAS) NMR. Almost complete C-13 and N-15 resonance assignments for a micro-crystalline preparation of the alpha-spectrin Src-homology 3 (SH3) domain(5) formed the basis for the extraction of a set of distance restraints. These restraints were derived from proton-driven spin diffusion (PDSD) spectra of biosynthetically site-directed, labelled samples obtained from bacteria grown using [1,3- C-13] glycerol or [2-C-13] glycerol as carbon sources. This allowed the observation of long-range distance correlations up to similar to7 Angstrom. The calculated global fold of the alpha-spectrin SH3 domain is based on 286 inter-residue C-13-C-13 and six N-15-N-15 restraints, all self-consistently obtained by solid-state MAS NMR. This MAS NMR procedure should be widely applicable to small membrane proteins that can be expressed in bacteria.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Free Univ Berlin, D-14195 Berlin, Germany	Free University of Berlin	Oschkinat, H (corresponding author), Forschungsinst Mol Pharmakol, Robert Rossle Str 10, D-13125 Berlin, Germany.		Schubert, Mario/B-3972-2008	Schubert, Mario/0000-0003-0278-4091; Diehl, Anne/0000-0001-7295-9972; Oschkinat, Hartmut/0000-0002-4384-9544				BENNETT AE, 1995, J CHEM PHYS, V103, P6951, DOI 10.1063/1.470372; Brown SP, 2001, CHEM REV, V101, P4125, DOI 10.1021/cr990132e; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Costa PR, 1997, J AM CHEM SOC, V119, P10821, DOI 10.1021/ja964313z; de Groot HJM, 2000, CURR OPIN STRUC BIOL, V10, P593, DOI 10.1016/S0959-440X(00)00136-6; EgorovaZachernyuk TA, 1997, BIOCHEMISTRY-US, V36, P7513, DOI 10.1021/bi962770m; Griffin RG, 1998, NAT STRUCT BIOL, V5, P508, DOI 10.1038/749; GRIFFITHS JM, 1994, J AM CHEM SOC, V116, P10178, DOI 10.1021/ja00101a042; Hodgkinson P, 1999, J MAGN RESON, V139, P46, DOI 10.1006/jmre.1999.1759; Hong M, 1999, J MAGN RESON, V139, P389, DOI 10.1006/jmre.1999.1805; Jaroniec CP, 2001, J AM CHEM SOC, V123, P3507, DOI 10.1021/ja003266e; Ketchem RR, 1996, J BIOMOL NMR, V8, P1; Kiihne S, 1998, J PHYS CHEM A, V102, P2274, DOI 10.1021/jp9721412; LeMaster DM, 1996, J AM CHEM SOC, V118, P9255, DOI 10.1021/ja960877r; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NIELSEN NC, 1994, J CHEM PHYS, V101, P1805, DOI 10.1063/1.467759; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; Pauli J, 2000, J MAGN RESON, V143, P411, DOI 10.1006/jmre.2000.2029; Pauli J, 2001, CHEMBIOCHEM, V2, P272, DOI 10.1002/1439-7633(20010401)2:4<272::AID-CBIC272>3.3.CO;2-U; Reif B, 2001, J MAGN RESON, V151, P320, DOI 10.1006/jmre.2001.2354; SHOCHAT S, 1995, SPECTROCHIM ACTA A, V51, P135, DOI 10.1016/0584-8539(94)00207-R; Straus SK, 1998, J BIOMOL NMR, V12, P39, DOI 10.1023/A:1008280716360; SZEVERENYI NM, 1982, J MAGN RESON, V47, P462, DOI 10.1016/0022-2364(82)90213-X; Tycko R, 2001, ANNU REV PHYS CHEM, V52, P575, DOI 10.1146/annurev.physchem.52.1.575; van Rossum BJ, 2001, CHEMBIOCHEM, V2, P906, DOI 10.1002/1439-7633(20011203)2:12<906::AID-CBIC906>3.0.CO;2-M; Verhoeven MA, 2001, BIOCHEMISTRY-US, V40, P3282, DOI 10.1021/bi0023798; Wuthrich K, 1986, NMR PROTEINS NUCL AC	28	748	759	4	246	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					98	102		10.1038/nature01070	http://dx.doi.org/10.1038/nature01070			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422222				2022-12-28	WOS:000179068100044
J	Youssef, S; Stuve, O; Patarroyo, JC; Ruiz, PJ; Radosevich, JL; Hur, EM; Bravo, M; Mitchell, DJ; Sobel, RA; Steinman, L; Zamvil, SS				Youssef, S; Stuve, O; Patarroyo, JC; Ruiz, PJ; Radosevich, JL; Hur, EM; Bravo, M; Mitchell, DJ; Sobel, RA; Steinman, L; Zamvil, SS			The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; II TRANSACTIVATOR GENE; T-CELLS; MULTIPLE-SCLEROSIS; EXPRESSION; STATINS; ASTROCYTES; CD4(+); LOVASTATIN; MICROGLIA	Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which are approved for cholesterol reduction, may also be beneficial in the treatment of inflammatory diseases(1-3). Atorvastatin (Lipitor) was tested in chronic and relapsing experimental autoimmune encephalomyelitis, a CD4+ Th1-mediated central nervous system (CNS) demyelinating disease model of multiple sclerosis(4,5). Here we show that oral atorvastatin prevented or reversed chronic and relapsing paralysis. Atorvastatin induced STAT6 phosphorylation and secretion of Th2 cytokines (interleukin (IL)-4, IL-5 and IL-10) and transforming growth factor (TGF)-beta. Conversely, STAT4 phosphorylation was inhibited and secretion of Th1 cytokines (IL-2, IL-12, interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha) was suppressed. Atorvastatin promoted differentiation of Th0 cells into Th2 cells. In adoptive transfer, these Th2 cells protected recipient mice from EAE induction. Atorvastatin reduced CNS infiltration and major histocompatibility complex (MHC) class II expression. Treatment of microglia inhibited IFN-gamma-inducible transcription at multiple MHC class II transactivator (CIITA) promoters and suppressed class II upregulation. Atorvastatin suppressed IFN-gamma-inducible expression of CD40, CD80 and CD86 co-stimulatory molecules. L-Mevalonate, the product of HMG-CoA reductase, reversed atorvastatin's effects on antigen-presenting cells (APC) and T cells. Atorvastatin treatment of either APC or T cells suppressed antigen-specific T-cell activation. Thus, atorvastatin has pleiotropic immunomodulatory effects involving both APC and T-cell compartments. Statins may be beneficial for multiple sclerosis and other Th1-mediated autoimmune diseases.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Stanford Univ, Beckman Ctr Mol Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol Neuropathol, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Stanford University; Stanford University	Zamvil, SS (corresponding author), Univ Calif San Francisco, Dept Neurol, 521 Parnassus Ave, San Francisco, CA 94143 USA.			Steinman, Lawrence/0000-0002-2437-2250; Sobel, Raymond/0000-0002-0477-9002				Aloisi F, 1999, EUR J IMMUNOL, V29, P2705, DOI 10.1002/(SICI)1521-4141(199909)29:09<2705::AID-IMMU2705>3.0.CO;2-1; Bernini F, 2001, CARDIOVASC DRUG THER, V15, P211, DOI 10.1023/A:1011908004965; BOTTAZZO GF, 1983, LANCET, V2, P1115; Cilla DD, 1996, CLIN PHARMACOL THER, V60, P687, DOI 10.1016/S0009-9236(96)90218-0; CUTHBERT JA, 1981, J IMMUNOL, V126, P2093; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dostal LA, 1996, FUND APPL TOXICOL, V32, P285, DOI 10.1006/faat.1996.0132; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARDARDOTTIR F, 1995, P NATL ACAD SCI USA, V92, P354, DOI 10.1073/pnas.92.2.354; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Maeda A, 1996, J NEUROPATH EXP NEUR, V55, P300, DOI 10.1097/00005072-199603000-00005; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Romano M, 2000, LAB INVEST, V80, P1095, DOI 10.1038/labinvest.3780115; Rudick RA, 2001, J NEURO-OPHTHALMOL, V21, P284, DOI 10.1097/00041327-200112000-00012; Slavin AJ, 2001, J CLIN INVEST, V108, P1133, DOI 10.1172/JCI200113360; Soos JM, 1998, J IMMUNOL, V161, P5959; Soos JM, 2001, GLIA, V36, P391, DOI 10.1002/glia.1125; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; Waldburger JM, 2001, J EXP MED, V194, P393, DOI 10.1084/jem.194.4.393; Walker WS, 1995, J NEUROIMMUNOL, V63, P163, DOI 10.1016/0165-5728(95)00146-8; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	30	905	952	1	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					78	84		10.1038/nature01158	http://dx.doi.org/10.1038/nature01158			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422218				2022-12-28	WOS:000179068100040
J	Dahl, JE; Liu, SG; Carlson, RMK				Dahl, JE; Liu, SG; Carlson, RMK			Isolation and structure of higher diamondoids, nanometer-sized diamond molecules	SCIENCE			English	Article							HYDROCARBONS; TETRAMANTANE	We exploited the exceptional thermal stability and diverse molecular shapes of higher diamondoids (C-22 and higher polymantanes) to isolate them from petroleum. Molecules containing 4 to 11 diamond-crystal cages were isolated and crystallized, and we obtained single-crystal x-ray structures for representatives from three families. Rigidity, strength, remarkable assortments of three-dimensional shapes, including resolvable chiral forms, and multiple, readily derivatizable attachment sites make them valuable nanometer-size molecular building blocks.	ChevronTexaco Technol Ventures, Mol Diamond Technol, Richmond, CA 94802 USA	Chevron	Carlson, RMK (corresponding author), ChevronTexaco Technol Ventures, Mol Diamond Technol, POB 1627, Richmond, CA 94802 USA.	Bobcarlson@ChevronTexaco.com						ANGUS JC, 1988, SCIENCE, V241, P913, DOI 10.1126/science.241.4868.913; BALABAN AT, 1978, TETRAHEDRON, V34, P3599, DOI 10.1016/0040-4020(78)88437-3; Brenner DW, 2002, CMES-COMP MODEL ENG, V3, P643; BURNS W, 1976, J CHEM SOC CHEM COMM, P893, DOI 10.1039/c39760000893; Cagin T, 1999, NANOTECHNOLOGY, V10, P278, DOI 10.1088/0957-4484/10/3/310; Dahl JE, 1999, NATURE, V399, P54, DOI 10.1038/19953; DAHL JE, UNPUB; Drexler K.E., 1992, NANOSYSTEMS MOL MACH; ELIEL EL, 1994, STEREOCHEMISTRY ORGA, P1166; Fort R. C., 1976, ADAMANTANE CHEM DIAM; GAVEZZOTTI A, 1989, J AM CHEM SOC, V111, P1835, DOI 10.1021/ja00187a044; HALA S, 1966, ANGEW CHEM INT EDIT, V5, P1045, DOI 10.1002/anie.196610451; Hirayama F, 2002, BIOORGAN MED CHEM, V10, P2597, DOI 10.1016/S0968-0896(02)00106-2; Lifshitz Y, 2002, SCIENCE, V297, P1531, DOI 10.1126/science.1074551; LIN R, 1995, FUEL, V74, P1512, DOI 10.1016/0016-2361(95)00116-M; Liu Shun-Wei, UNPUB; Marchand AP, 1995, ALDRICHIM ACTA, V28, P95; MCKERVEY MA, 1980, TETRAHEDRON, V36, P971, DOI 10.1016/0040-4020(80)80050-0; Meador MA, 1998, ANNU REV MATER SCI, V28, P599, DOI 10.1146/annurev.matsci.28.1.599; Moss GP, 1999, PURE APPL CHEM, V71, P513, DOI 10.1351/pac199971030513; Piekarczyk W, 1999, CRYST RES TECHNOL, V34, P553, DOI 10.1002/(SICI)1521-4079(199906)34:5/6<553::AID-CRAT553>3.0.CO;2-8; Ristein J., 2001, PROPERTIES GROWTH AP, P73; vonsR Schleyer P., 1990, CAGE HYDROCARBONS, P1; Whitesides GM, 2002, P NATL ACAD SCI USA, V99, P4769, DOI 10.1073/pnas.082065899; Zones SI, 1998, MICROPOR MESOPOR MAT, V21, P199, DOI 10.1016/S1387-1811(98)00011-0	25	470	501	2	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	2003	299	5603					96	99		10.1126/science.1078239	http://dx.doi.org/10.1126/science.1078239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	631JZ	12459548				2022-12-28	WOS:000180165800040
J	Simpson, EL; House, AO				Simpson, EL; House, AO			Involving users in the delivery and evaluation of mental health services: systematic review	BRITISH MEDICAL JOURNAL			English	Review							CONSUMER CASE-MANAGEMENT; RANDOMIZED TRIAL; OUTCOMES; SATISFACTION; PROVIDERS; ADVOCACY; PROGRAM; STAFF	Objectives To identify evidence from comparative studies on the effects of involving users in the delivery and evaluation of mental health services. Data sources English language articles published between January 1966 and October 2001 found by searching electronic databases. Study selection Systematic review of randomised controlled trials and other comparative studies of involving users in the delivery or evaluation of mental health services. Data extraction Patterns of delivery of services by employees who were cur-rent or former users of services and professional employees and the effects on trainees, research, or clients of mental health services. Results Five randomised controlled trials and seven other comparative studies were identified. Half of the studies considered involving users in managing cases. Involving users as employees of mental health services led to clients having greater satisfaction with personal circumstances and less hospitalisation. Providers of services who had been trained by users had more positive attitudes toward users. Clients reported being less satisfied with services when interviewed by users. Conclusions Users can be involved as employees, trainers, or researchers without detrimental effect. Involving users with severe mental disorders in the delivery and evaluation of services is feasible.	Univ Leeds, Acad Unit Psychiat & Behav Sci, Leeds LS2 9LT, W Yorkshire, England	University of Leeds	Simpson, EL (corresponding author), Univ Leeds, Acad Unit Psychiat & Behav Sci, Leeds LS2 9LT, W Yorkshire, England.			House, Allan/0000-0001-8721-8026				Carpenter J., 1997, CHOICE INFORM DIGNIT; Chinman MJ, 2001, COMMUNITY MENT HLT J, V37, P215, DOI 10.1023/A:1017577029956; Chinman MJ, 2000, J NERV MENT DIS, V188, P446, DOI 10.1097/00005053-200007000-00009; Clark CC, 1999, PSYCHIAT SERV, V50, P961, DOI 10.1176/ps.50.7.961; Clarke G N, 2000, Ment Health Serv Res, V2, P155, DOI 10.1023/A:1010141826867; COOK JA, 1995, COMMUNITY MENT HLT J, V31, P229, DOI 10.1007/BF02188749; Crawford MJ, 2002, BRIT MED J, V325, P1263, DOI 10.1136/bmj.325.7375.1263; Department of Health, 1999, NAT SERV FRAM MENT H; FELTON CJ, 1995, PSYCHIATR SERV, V46, P1037; Klein AR, 1998, RES SOCIAL WORK PRAC, V8, P529, DOI 10.1177/104973159800800503; Lyons JS, 1996, COMMUNITY MENT HLT J, V32, P33, DOI 10.1007/BF02249365; Marshall M, 2000, BRIT J PSYCHIAT, V176, P249, DOI 10.1192/bjp.176.3.249; Mental Health Task Force User Group, 1995, FORG OUR FUT LIGHT F; *NHS CTR REV DISS, 2001, UND SYST REV RES EFF; O'Donnell M, 1999, AUST NZ J PSYCHIAT, V33, P684, DOI 10.1046/j.1440-1614.1999.00629.x; O'Donnell M, 1998, AUST NZ J PSYCHIAT, V32, P873, DOI 10.3109/00048679809073878; Paulson R, 1999, COMMUNITY MENT HLT J, V35, P251, DOI 10.1023/A:1018745403590; POLOWCZYK D, 1993, HOSP COMMUNITY PSYCH, V44, P589; SIMPSON EL, 2002, GUIDE INVOLVING USER; SOLOMON P, 1995, EVAL PROGRAM PLANN, V18, P117, DOI 10.1016/0149-7189(95)00003-T; SOLOMON P, 1995, J MENT HEALTH ADMIN, V22, P135, DOI 10.1007/BF02518754; Solomon P, 1996, RES SOCIAL WORK PRAC, V6, P193, DOI 10.1177/104973159600600204; Wood J., 1999, NURSING TIMES RES, V4, P257, DOI [10.1177/136140969900400403, DOI 10.1177/136140969900400403]	23	179	180	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1265	1268		10.1136/bmj.325.7375.1265	http://dx.doi.org/10.1136/bmj.325.7375.1265			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	623HB	12458241	Green Published, Bronze			2022-12-28	WOS:000179696300014
J	Temple, R; Aldridge, V; Greenwood, R; Heyburn, P; Sampson, M; Stanley, K				Temple, R; Aldridge, V; Greenwood, R; Heyburn, P; Sampson, M; Stanley, K			Association between outcome of pregnancy and glycaemic control in early pregnancy in type 1 diabetes: population based study	BRITISH MEDICAL JOURNAL			English	Article							SPONTANEOUS-ABORTION; WOMEN		Norfolk & Norwich Hosp NHS Trust, Elsie Bertram Diabet Ctr, Norwich NR4 7UY, Norfolk, England; Norfolk & Norwich Hosp NHS Trust, E Anglia Ctr Fetal & Maternal Med, Norwich NR4 7UY, Norfolk, England		Temple, R (corresponding author), Norfolk & Norwich Hosp NHS Trust, Elsie Bertram Diabet Ctr, Norwich NR4 7UY, Norfolk, England.							Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275; HANSON U, 1990, DIABETOLOGIA, V33, P100, DOI 10.1007/BF00401047; Hawthorne G, 1997, BRIT MED J, V315, P279, DOI 10.1136/bmj.315.7103.279; Nielsen GL, 1997, ACTA DIABETOL, V34, P217, DOI 10.1007/s005920050077; ROSENN B, 1994, OBSTET GYNECOL, V84, P515	5	93	96	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1275	1276		10.1136/bmj.325.7375.1275	http://dx.doi.org/10.1136/bmj.325.7375.1275			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458245	Bronze, Green Published			2022-12-28	WOS:000179696300017
J	Carslaw, KS; Harrison, RG; Kirkby, J				Carslaw, KS; Harrison, RG; Kirkby, J			Cosmic rays, clouds, and climate	SCIENCE			English	Review							AEROSOL FORMATION; SOLAR-WIND; ATMOSPHERIC DYNAMICS; MISSING LINK; NUCLEATION; PARTICLES; FLUX; CONDENSATION; VARIABILITY; CONNECTION	It has been proposed that Earth's climate could be affected by changes in cloudiness caused by variations in the intensity of galactic cosmic rays in the atmosphere. This proposal stems from an observed correlation between cosmic ray intensity and Earth's average cloud cover over the course of one solar cycle. Some scientists question the reliability of the observations, whereas others, who accept them as reliable, suggest that the correlation may be caused by other physical phenomena with decadal periods or by a response to volcanic activity or El Nino. Nevertheless, the observation has raised the intriguing possibility that a cosmic ray-cloud interaction may help explain how a relatively small change in solar output can produce much larger changes in Earth's climate. Physical mechanisms have been proposed to explain how cosmic rays could affect clouds, but they need to be investigated further if the observation is to become more than just another correlation among geophysical variables.	Univ Leeds, Sch Environm, Inst Atmospher Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Reading, Dept Meteorol, Reading RG6 6BB, Berks, England; CERN, CH-1211 Geneva, Switzerland	University of Leeds; University of Reading; European Organization for Nuclear Research (CERN)	Carslaw, KS (corresponding author), Univ Leeds, Sch Environm, Inst Atmospher Sci, Leeds LS2 9JT, W Yorkshire, England.		Kirkby, Jasper/A-4973-2012; Harrison, R Giles/C-7635-2011; Carslaw, Ken S/C-8514-2009; Harrison, RG/GWQ-8421-2022	Kirkby, Jasper/0000-0003-2341-9069; Carslaw, Ken S/0000-0002-6800-154X; Harrison, RG/0000-0003-0693-347X				Beer J, 2000, SPACE SCI REV, V94, P53, DOI 10.1023/A:1026778013901; BEER J, 1990, NATURE, V347, P164, DOI 10.1038/347164a0; Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; Brenguier JL, 2000, J ATMOS SCI, V57, P803, DOI 10.1175/1520-0469(2000)057<0803:RPOBLC>2.0.CO;2; BRICARD J, 1968, J GEOPHYS RES, V73, P4487, DOI 10.1029/JB073i014p04487; DICKINSON RE, 1975, B AM METEOROL SOC, V56, P1240, DOI 10.1175/1520-0477(1975)056<1240:SVATLA>2.0.CO;2; Eichkorn S, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015044; Frohlich C, 1998, GEOPHYS RES LETT, V25, P4377, DOI 10.1029/1998GL900157; Frohlich C, 1998, IAU SYMP, P89; Haigh JD, 1996, SCIENCE, V272, P981, DOI 10.1126/science.272.5264.981; Harrison RG, 2001, J ATMOS SOL-TERR PHY, V63, P1811, DOI 10.1016/S1364-6826(01)00059-1; HARRISON RG, 2002, IN PRESS GEOPHYS RES; HERSCHEL W, 1801, PHILOS T R SOC LONDO, V265, P354; Hoyt D.V., 1997, ROLE SUN CLIMATE CHA; Jorgensen TS, 2000, J ATMOS SOL-TERR PHY, V62, P73, DOI 10.1016/S1364-6826(99)00106-6; Kernthaler SC, 1999, GEOPHYS RES LETT, V26, P863, DOI 10.1029/1999GL900121; KIRKBY J, 2001, P WORKSH ION AER CLO; Korhonen P, 1999, J GEOPHYS RES-ATMOS, V104, P26349, DOI 10.1029/1999JD900784; Kristjansson JE, 2000, J GEOPHYS RES-ATMOS, V105, P11851, DOI 10.1029/2000JD900029; Kulmala M, 2000, NATURE, V404, P66, DOI 10.1038/35003550; Lockwood M, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2002JA009431; Lockwood M, 1999, NATURE, V399, P437, DOI 10.1038/20867; Makela JM, 1997, GEOPHYS RES LETT, V24, P1219, DOI 10.1029/97GL00920; MARKSON R, 1981, NATURE, V291, P304, DOI 10.1038/291304a0; MARKSON R, 1980, SCIENCE, V208, P979, DOI 10.1126/science.208.4447.979; MARSH N, IN PRESS J GEOPHYS R, DOI DOI 10.1029/2002JD001264; Marsh ND, 2000, PHYS REV LETT, V85, P5004, DOI 10.1103/PhysRevLett.85.5004; NEY EP, 1959, NATURE, V183, P451, DOI 10.1038/183451a0; O'Dowd C, 1999, GEOPHYS RES LETT, V26, P1707, DOI 10.1029/1999GL900335; Penner JE, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P289; PUDOVKIN MI, 1995, J ATMOS TERR PHYS, V57, P1349, DOI 10.1016/0021-9169(94)00109-2; RAES F, 1986, J AEROSOL SCI, V17, P466, DOI 10.1016/0021-8502(86)90135-7; REITER R, 1992, PHENOMENA ATMOSPHERI; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; ROSSOW WB, 1991, B AM METEOROL SOC, V72, P2, DOI 10.1175/1520-0477(1991)072<0002:ICDP>2.0.CO;2; SUN B, 2002, J GEOPHYS RES, V107, pD14, DOI DOI 10.1029/2001JD000560; Svensmark H, 1997, J ATMOS SOL-TERR PHY, V59, P1225, DOI 10.1016/S1364-6826(97)00001-1; Tinsley BA, 2000, J ATMOS SCI, V57, P2118, DOI 10.1175/1520-0469(2000)057<2118:EOICOT>2.0.CO;2; TINSLEY BA, 1991, J GEOPHYS RES-ATMOS, V96, P22283, DOI 10.1029/91JD02473; TINSLEY BA, 1993, J GEOPHYS RES-ATMOS, V98, P10375, DOI 10.1029/93JD00627; Tinsley BA, 2000, SPACE SCI REV, V94, P231, DOI 10.1023/A:1026775408875; Tinsley BA, 1996, J GEOPHYS RES-ATMOS, V101, P29701, DOI 10.1029/96JD01990; Tripathi SN, 2002, ATMOS RES, V62, P57, DOI 10.1016/S0169-8095(02)00020-0; Turco RP, 2000, J AIR WASTE MANAGE, V50, P902, DOI 10.1080/10473289.2000.10464111; VOHRA KG, 1984, ATMOS ENVIRON, V18, P1653, DOI 10.1016/0004-6981(84)90387-1; WIGLEY TML, 1990, GEOPHYS RES LETT, V17, P2169, DOI 10.1029/GL017i012p02169; WILCOX JM, 1974, J ATMOS SCI, V31, P581, DOI 10.1175/1520-0469(1974)031<0581:IOSMSS>2.0.CO;2; Wilson Charles Thomson Rees, 1899, P R SOC LONDON, V64, P127; Wohlfrom KH, 2000, GEOPHYS RES LETT, V27, P3853, DOI 10.1029/2000GL011974; Yu FQ, 2000, GEOPHYS RES LETT, V27, P883, DOI 10.1029/1999GL011151; Yu FQ, 2001, J GEOPHYS RES-ATMOS, V106, P4797, DOI 10.1029/2000JD900539; Yu FQ, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2001JA000248	52	393	419	2	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1732	1737		10.1126/science.1076964	http://dx.doi.org/10.1126/science.1076964			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459578				2022-12-28	WOS:000179494800030
J	Rutter, J				Rutter, J			PAS domains and metabolic status signaling	SCIENCE			English	Editorial Material							CLOCK; NPAS2		Univ Texas, SW Med Ctr, Houston, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Rutter, J (corresponding author), Univ Texas, SW Med Ctr, Houston, TX 75390 USA.							Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; DIOUMET EM, 2002, SCIENCE         1121; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Rutter J, 2002, CELL, V111, P17, DOI 10.1016/S0092-8674(02)00974-1; Rutter J, 2001, P NATL ACAD SCI USA, V98, P8991, DOI 10.1073/pnas.161284798; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; RUTTER J, 2001, THESIS U TEXAS SW ME; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999	11	5	6	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1567	1568		10.1126/science.1080001	http://dx.doi.org/10.1126/science.1080001			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446897				2022-12-28	WOS:000179361600036
J	Kronenberg, F; Fugh-Berman, A				Kronenberg, F; Fugh-Berman, A			Complementary and alternative medicine for menopausal symptoms: A review of randomized, controlled trials	ANNALS OF INTERNAL MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; BREAST-CANCER SURVIVORS; QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; HOT FLASHES; VASOMOTOR SYMPTOMS; DOUBLE-BLIND; TRANSDERMAL PROGESTERONE; BEHAVIORAL TREATMENT; SOY PHYTOESTROGENS	Background: women commonly use soy products, herbs, and other complementary and alternative medicine (CAM) therapies for menopausal symptoms. Randomized, controlled trials have evaluated the efficacy and short-term safety of these therapies. Purpose: To review randomized, controlled trials of CAM therapies for menopausal symptoms in order to better inform practice and guide future research. Data Sources: Searches of MEDLINE for articles published from January 1966 through March 2002, of the Alternative and Complementary Database (AMED) of the British Library for articles published from January 1985 through December 2000, and of the authors' own extensive files. Search terms were hot flash/flush, menopause, and climacteric, combined with phytoestrogens, alternative medicine, herbal medicine, traditional medicine, Traditional Chinese Medicine (TCM), Ayuneda, naturopathy, chiropractic, osteopathy, massage, yoga, relaxation therapy, homeopathy, aromatherapy, and therapeutic touch. Study Selection: 29 randomized, controlled clinical trials of CAM therapies for hot flashes and other menopausal symptoms were identified; of these, 12 dealt with soy or soy extracts, 10 with herbs, and 7 with other CAM therapies. Data Extraction: Each author extracted information from half of the studies on the number of patients, study design, outcome measures, and results; the other author then checked these results. Data Synthesis: Soy seems to have modest benefit for hot flashes, but studies are not conclusive. Isoflavone preparations seem to be less effective than soy foods. Black cohosh may be effective for menopausal symptoms, especially hot flashes, but the lack of adequate long-term safety data (mainly on estrogenic stimulation of the breast or endometrium) precludes recommending long-term use. Single clinical trials have found that dong quai, evening primrose oil, a Chinese herb mixture, vitamin E, and acupuncture do not affect hot flashes; two trials have shown that red clover has no benefit for treating hot flashes. Conclusions: Black cohosh and foods that contain phytoestrogens show promise for the treatment of menopausal symptoms. Clinical trials do not support the use of other herbs or CAM therapies. Long-term safety data on individual isoflavones or isoflavone concentrates are not available.	George Washington Univ, Dept Hlth Care Sci, Sch Med, Washington, DC 20037 USA; Columbia Univ, New York, NY USA	George Washington University; Columbia University	Fugh-Berman, A (corresponding author), George Washington Univ, Dept Hlth Care Sci, Sch Med, 2300 K St NW, Washington, DC 20037 USA.	fk@columbia.edu			NCCIH NIH HHS [P50 AT00090] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P50AT000090] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ADLERCREUTZ H, 1992, LANCET, V339, P1233, DOI 10.1016/0140-6736(92)91174-7; Albertazzi P, 1998, OBSTET GYNECOL, V91, P6, DOI 10.1016/S0029-7844(97)00597-8; Amato P, 2002, MENOPAUSE, V9, P145, DOI 10.1097/00042192-200203000-00010; AVINA RL, 1978, WESTERN J MED, V128, P366; Baber R J, 1999, Climacteric, V2, P85, DOI 10.3109/13697139909025571; BAIRD DD, 1995, J CLIN ENDOCR METAB, V80, P1685, DOI 10.1210/jc.80.5.1685; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; Beal MW, 1998, J NURSE-MIDWIFERY, V43, P224, DOI 10.1016/S0091-2182(98)00009-3; BLATT MHG, 1953, ARCH INTERN MED, V91, P792, DOI 10.1001/archinte.1953.00240180101012; Brzezinski A, 1997, MENOPAUSE, V4, P89; CHENOY R, 1994, BRIT MED J, V308, P501, DOI 10.1136/bmj.308.6927.501; Cooper A, 1998, LANCET, V351, P1255, DOI 10.1016/S0140-6736(05)79323-5; CORNEY RH, 1991, J PSYCHOSOM RES, V35, P471, DOI 10.1016/0022-3999(91)90042-M; Dalais F S, 1998, Climacteric, V1, P124, DOI 10.3109/13697139809085527; Davis SR, 2001, MED J AUSTRALIA, V174, P68, DOI 10.5694/j.1326-5377.2001.tb143156.x; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1997, PAIN, V71, P123, DOI 10.1016/S0304-3959(97)03368-X; Foster S., 1999, TYLERS HONEST HERBAL; FREEDMAN RR, 1992, AM J OBSTET GYNECOL, V167, P436, DOI 10.1016/S0002-9378(11)91425-2; FREEDMAN RR, 1995, MENOPAUSE, V2, P211, DOI 10.1097/00042192-199502040-00005; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; GREENSPAN EM, 1983, JAMA-J AM MED ASSOC, V249, P2018, DOI 10.1001/jama.1983.03330390026012; Han KK, 2002, OBSTET GYNECOL, V99, P389, DOI 10.1016/S0029-7844(01)01744-6; HARE ML, 1993, MED ANTHROPOL Q, V7, P30, DOI 10.1525/maq.1993.7.1.02a00030; HIMMEL W, 1993, BRIT J GEN PRACT, V43, P232; Hirata JD, 1997, FERTIL STERIL, V68, P981, DOI 10.1016/S0015-0282(97)00397-X; HOPKINS MP, 1988, AM J OBSTET GYNECOL, V159, P1121, DOI 10.1016/0002-9378(88)90426-7; Irvin JH, 1996, J PSYCHOSOM OBST GYN, V17, P202, DOI 10.3109/01674829609025684; Jacobson JS, 2001, J CLIN ONCOL, V19, P2739, DOI 10.1200/JCO.2001.19.10.2739; JARRY H, 1985, PLANTA MED, V51, P316, DOI 10.1055/s-2007-969500; Kennelly EJ, 2002, PHYTOMEDICINE, V9, P461, DOI 10.1078/09447110260571733; Knight D C, 1999, Climacteric, V2, P79, DOI 10.3109/13697139909025570; Komesaroff P A, 2001, Climacteric, V4, P144; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; Kronenberg F, 1994, MENOPAUSE, V1, P171; Lee J., 1993, NATURAL PROGESTERONE; LEHMANNWILLENBROCK E, 1988, ZBL GYNAKOL, V110, P611; Leonetti HB, 1999, OBSTET GYNECOL, V94, P225, DOI 10.1016/S0029-7844(99)00266-5; Lewis JG, 2002, MATURITAS, V41, P1, DOI 10.1016/S0378-5122(01)00250-X; LOCK M, 1988, MATURITAS, V10, P317, DOI 10.1016/0378-5122(88)90067-9; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MCCOY J, 1996, P 212 AM CHEM SOC NA; MURKIES AL, 1995, MATURITAS, V21, P189, DOI 10.1016/0378-5122(95)00899-V; PUNNONEN R, 1980, BRIT MED J, V281, P1110, DOI 10.1136/bmj.281.6248.1110; Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068; Scambia G, 2000, MENOPAUSE, V7, P105, DOI 10.1097/00042192-200007020-00006; St Germain A, 2001, MENOPAUSE, V8, P17, DOI 10.1097/00042192-200101000-00005; Stoll W., 1987, THERAPEUTIKON, V1, P23; Struck D, 1997, PLANTA MED, V63, P289, DOI 10.1055/s-2006-957682; THOMPSON LU, 1991, NUTR CANCER, V16, P43, DOI 10.1080/01635589109514139; Upmalis DH, 2000, MENOPAUSE, V7, P236, DOI 10.1097/00042192-200007040-00005; Van Patten CL, 2002, J CLIN ONCOL, V20, P1449, DOI 10.1200/JCO.20.6.1449; WARNECKE G, 1985, MED WELT, V36, P871; Washburn S, 1999, MENOPAUSE, V6, P7; Wiklund IK, 1999, INT J CLIN PHARM RES, V19, P89; Wren BG, 1999, LANCET, V354, P1447, DOI 10.1016/S0140-6736(99)03430-3; WYON Y, 1995, MENOPAUSE, V2, P3; Zava DT, 1998, P SOC EXP BIOL MED, V217, P369	58	363	376	1	134	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					805	813		10.7326/0003-4819-137-10-200211190-00009	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616VE	12435217	Green Published			2022-12-28	WOS:000179323400004
J	Fagarasan, S; Muramatsu, M; Suzuki, K; Nagaoka, H; Hiai, H; Honjo, T				Fagarasan, S; Muramatsu, M; Suzuki, K; Nagaoka, H; Hiai, H; Honjo, T			Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora	SCIENCE			English	Article							IMMUNE-SYSTEM; AID; HYPERMUTATION; DEFICIENCY; EXPRESSION; CELLS; MICE	Activation-induced cytidine deaminase (AID) plays an essential role in class switch recombination (CSR) and somatic hypermutation (SHM) of immunoglobulin genes. We report here that deficiency in AID results in the development of hyperplasia of isolated lymphoid follicles (ILFs) associated with a 100-fold expansion of anaerobic. ora in the small intestine. Reduction of bacterial. ora by antibiotic treatment of AID(-/-) mice abolished ILF hyperplasia as well as the germinal center enlargement seen in secondary lymphoid tissues. Because an inability to switch to immunoglobulin A on its own does not lead to a similar phenotype, these results suggest that SHM of ILF B cells plays a critical role in regulating intestinal microflora.	Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Kanagawa 2300045, Japan	Kyoto University; Kyoto University; RIKEN	Honjo, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan.		Honjo, Tasuku/N-4470-2016; Fagarasan, Sidonia/A-5258-2016; Muramatsu, Masamichi/C-4339-2015	Fagarasan, Sidonia/0000-0003-2086-6402; Muramatsu, Masamichi/0000-0002-0153-3533				BASTLEIN C, 1988, ENDOSCOPY, V20, P272, DOI 10.1055/s-2007-1018192; Brandtzaeg P, 1999, IMMUNOL TODAY, V20, P141, DOI 10.1016/S0167-5699(98)01413-3; Burt JR RW, 1999, TXB GASTROENTEROLOGY, P1995; Cebra J. J., 1994, HDB MUCOSAL IMMUNOLO, P151; Cebra JJ, 1999, AM J CLIN NUTR, V69, p1046S, DOI 10.1093/ajcn/69.5.1046s; Fagarasan S, 2001, NATURE, V413, P639, DOI 10.1038/35098100; FAGARASAN S, UNPUB; Hamada H, 2002, J IMMUNOL, V168, P57, DOI 10.4049/jimmunol.168.1.57; Harriman GR, 1999, J IMMUNOL, V162, P2521; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; LeMaoult J, 1997, J IMMUNOL, V159, P3866; Levy Y, 1998, P NATL ACAD SCI USA, V95, P13135, DOI 10.1073/pnas.95.22.13135; METZGER D, COMMUNICATION; Moghaddami M, 1998, GASTROENTEROLOGY, V115, P1414, DOI 10.1016/S0016-5085(98)70020-4; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9	17	453	470	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1424	1427		10.1126/science.1077336	http://dx.doi.org/10.1126/science.1077336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434060				2022-12-28	WOS:000179223100053
J	Kohling, R				Kohling, R			GABA becomes exciting	SCIENCE			English	Editorial Material							POTENTIALS		Univ Munster, Inst Physiol, D-48149 Munster, Germany	University of Munster	Kohling, R (corresponding author), Univ Munster, Inst Physiol, D-48149 Munster, Germany.	kohling@uni-muenster.de	Köhling, Rüdiger/K-8647-2013	Köhling, Rüdiger/0000-0003-3330-4898				Avoli M, 1996, J NEUROSCI, V16, P3912; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; DICHTER MA, 1997, EPILEPSY COMPREHENSI, V1; HOUSER WA, 1997, EPILEPSY COMPREHENSI, V1; Kaila K, 1997, J NEUROSCI, V17, P7662; Kohling R, 1998, BRAIN, V121, P1073, DOI 10.1093/brain/121.6.1073; Kohling R, 2000, J NEUROSCI, V20, P6820, DOI 10.1523/JNEUROSCI.20-18-06820.2000; LIU Z, 1991, BRAIN RES, V545, P1, DOI 10.1016/0006-8993(91)91262-Y; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; RIVERA C, IN PRESS J CELL BIOL; SCHWARTZKROIN PA, 1986, EPILEPSIA, V27, P523, DOI 10.1111/j.1528-1157.1986.tb03578.x; Traub RD, 1996, EPILEPSIA, V37, P879, DOI 10.1111/j.1528-1157.1996.tb00042.x	13	36	37	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1350	1351						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434044				2022-12-28	WOS:000179223100032
J	Leape, LL				Leape, LL			Reporting of adverse events.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RISK MANAGEMENT; MEDICAL ERRORS; DRUG EVENTS; SURVEILLANCE; MALPRACTICE; INFECTIONS; QUALITY; DEATHS		Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Leape, LL (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.							[Anonymous], 2001, J COMM PERSPECT, V21, P1; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Billings CE., 1999, P ENHANCING PATIENT, P97; BOVBJERG RR, 1994, J HEALTH POLIT POLIC, V19, P207, DOI 10.1215/03616878-19-1-207; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; *CDCP, 2001, NNIS; COHEN M, 2000, ADVERSE EVENT ERROR; Cohen MR, 2000, BRIT MED J, V320, P728, DOI 10.1136/bmj.320.7237.728; CULLEN DJ, 1995, JOINT COMM J QUAL IM, V21, P541, DOI 10.1016/S1070-3241(16)30180-8; Flowers L, 2001, STATE BASED MANDATOR; FLOWERS L, 2000, STATES RESPONDING ME; Gaynes R, 2001, EMERG INFECT DIS, V7, P295, DOI 10.3201/eid0702.010230; Gostin L, 2000, JAMA-J AM MED ASSOC, V283, P1742, DOI 10.1001/jama.283.13.1742; HALEY RW, 1985, AM J EPIDEMIOL, V121, P182, DOI 10.1093/oxfordjournals.aje.a113990; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; *JOINT COMM ACCR H, 2000, RES JCAHO SENT EV RE; *KAIS FAM FDN, 2000, NAT SURV AM HLTH CAR; Kaufman Marc, 2000, WASH POST       0822, pA2; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, DOI 10.17226/9728; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; Malpass A, 1999, J Qual Clin Pract, V19, P27, DOI 10.1046/j.1440-1762.1999.00289.x; Mariner WK., 2001, MED ERROR REPORTING; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; MEARS D, 2002, J HEALTHC QUAL, V24, P15; MORATH J, 2002, PARTNERING FAMILIES; National Quality Forum, 2002, SER REP EV PAT SAF N; *NY STAT DEP HLTH, 2001, NY PAT OCC REP TRACK; PEAR R, 2000, NY TIMES        0223, pA12; Pronovost P, 2002, J CRIT CARE, V17, P78, DOI 10.1053/jcrc.2002.34363; RAYMOND B, 2001, DESIGN CONSIDERATION; ROSENTHAL J, 2001, CURRENT STATE PROGRA; ROSENTHAL J, 2001, COST IMPLICATIONS ST; Rozich J., 2001, J CLIN OUTCOMES MANA, V8, P27; Vincent C, 2000, BRIT MED J, V320, P777, DOI 10.1136/bmj.320.7237.777; Vincent C, 1998, BRIT MED J, V316, P1154, DOI 10.1136/bmj.316.7138.1154; *VT OXF NETW NEWSL, 2001, NETW MISS INCL PAT S; Wu AW, 2002, J CRIT CARE, V17, P86, DOI 10.1053/jcrc.2002.35100	39	486	501	3	29	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2002	347	20					1633	1638		10.1056/NEJMNEJMhpr011493	http://dx.doi.org/10.1056/NEJMNEJMhpr011493			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614KL	12432059				2022-12-28	WOS:000179187800033
J	Silva, TL				Silva, TL			Preventing child exploitation on the streets in the Philippines	LANCET			English	Editorial Material									Childhope Asia Philippines, Manila 1007, Philippines		Silva, TL (corresponding author), Childhope Asia Philippines, 1210 Penafrancia St, Manila 1007, Philippines.								0	6	6	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1507	1507		10.1016/S0140-6736(02)11480-2	http://dx.doi.org/10.1016/S0140-6736(02)11480-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433536				2022-12-28	WOS:000179186000033
J	van Dam, RM; Feskens, EJM				van Dam, RM; Feskens, EJM			Coffee consumption and risk of type 2 diabetes mellitus	LANCET			English	Article							GLUCOSE; INSULIN	Coffee is a major source of caffeine, which has been shown to acutely reduce sensitivity to insulin, but also has potentially beneficial effects. We prospectively investigated the association between coffee consumption and risk of clinical type 2 diabetes in a population-based cohort of 17 111 Dutch men and women aged 30-60 years. During 125 774 person years of follow-up, 306 new cases of type 2 diabetes were reported. After adjustment for potential confounders, individuals who drank at least seven cups of coffee a day were 0-50 (95% CI 0.35-0.72, p=0.0002) times as likely as those who drank two cups or fewer a day to develop type 2 diabetes. Coffee consumption was associated with a substantially lower risk of clinical type 2 diabetes.	Natl Inst Publ Hlth & Environm, Dept Chron Dis Epidemiol, NL-3720 BA Bilthoven, Netherlands	Netherlands National Institute for Public Health & the Environment	van Dam, RM (corresponding author), Natl Inst Publ Hlth & Environm, Dept Chron Dis Epidemiol, NL-3720 BA Bilthoven, Netherlands.		Feskens, Edith JM/A-3757-2012; Feskens, Edith/ABI-1446-2020; van Dam, Rob M/F-9674-2010	Feskens, Edith/0000-0001-5819-2488; van Dam, Rob M/0000-0002-7354-8734				Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874; Clifford MN, 2000, J SCI FOOD AGR, V80, P1033, DOI [10.1002/(SICI)1097-0010(20000515)80:7<1033::AID-JSFA595>3.0.CO;2-T, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1033::AID-JSFA595&gt;3.0.CO;2-T]; Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364; NAISMITH DJ, 1970, NUTR METAB, V12, P144; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472	5	328	341	1	42	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1477	1478		10.1016/S0140-6736(02)11436-X	http://dx.doi.org/10.1016/S0140-6736(02)11436-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433517				2022-12-28	WOS:000179186000014
J	Pizzorusso, T; Medini, P; Berardi, N; Chierzi, S; Fawcett, JW; Maffei, L				Pizzorusso, T; Medini, P; Berardi, N; Chierzi, S; Fawcett, JW; Maffei, L			Reactivation of ocular dominance plasticity in the adult visual cortex	SCIENCE			English	Article							CHONDROITIN-SULFATE PROTEOGLYCANS; EXPERIENCE-DEPENDENT PLASTICITY; EXTRACELLULAR-MATRIX; RAT-BRAIN; MONOCULAR DEPRIVATION; POSTNATAL-DEVELOPMENT; PERINEURONAL NETS; AXON GROWTH; IN-VIVO; REGENERATION	In young animals, monocular deprivation leads to an ocular dominance shift, whereas in adults after the critical period there is no such shift. Chondroitin sulphate proteoglycans ( CSPGs) are components of the extracellular matrix (ECM) inhibitory for axonal sprouting. We tested whether the developmental maturation of the ECM is inhibitory for experience-dependent plasticity in the visual cortex. The organization of CSPGs into perineuronal nets coincided with the end of the critical period and was delayed by dark rearing. After CSPG degradation with chondroitinase-ABC in adult rats, monocular deprivation caused an ocular dominance shift toward the nondeprived eye. The mature ECM is thus inhibitory for experience-dependent plasticity, and degradation of CSPGs reactivates cortical plasticity.	Scuola Normale Super Pisa, I-56100 Pisa, Italy; CNR, Ist Neurosci, I-56100 Pisa, Italy; Univ Cambridge, Ctr Brain Repair, Cambridge CB2 2PY, England; Univ Florence, Dipartimento Psicol, I-50123 Florence, Italy	Scuola Normale Superiore di Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); University of Cambridge; University of Florence	Pizzorusso, T (corresponding author), Scuola Normale Super Pisa, I-56100 Pisa, Italy.		Medini, Paolo/GWC-1936-2022; Medini, Paolo/R-7504-2018; Pizzorusso, Tommaso/D-1399-2013	Pizzorusso, Tommaso/0000-0001-5614-0668; Fawcett, James/0000-0002-7990-4568				Berardi N, 2000, CURR OPIN NEUROBIOL, V10, P138, DOI 10.1016/S0959-4388(99)00047-1; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bruckner G, 1998, EXP BRAIN RES, V121, P300, DOI 10.1007/s002210050463; Bruckner G, 2000, J COMP NEUROL, V428, P616, DOI 10.1002/1096-9861(20001225)428:4<616::AID-CNE3>3.0.CO;2-K; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Grumet M, 1996, PERSPECT DEV NEUROBI, V3, P319; HARAUZOV A, 2001, SOC NEUR ABSTR, V27, P10; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Kind PC, 2002, NATURE, V416, P430, DOI 10.1038/416430a; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; Koppe G, 1997, CELL TISSUE RES, V288, P33, DOI 10.1007/s004410050790; Lander C, 1997, J NEUROSCI, V17, P1928; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Matsui F, 1998, BRAIN RES, V790, P45, DOI 10.1016/S0006-8993(98)00009-2; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; RAMOA AS, 1988, EXP BRAIN RES, V73, P285; Rittenhouse CD, 1999, NATURE, V397, P347, DOI 10.1038/16922; SMITHTHOMAS LC, 1995, J CELL SCI, V108, P1307; Stern EA, 2001, NEURON, V31, P305, DOI 10.1016/S0896-6273(01)00360-9; Trachtenberg JT, 2001, J NEUROSCI, V21, P3476, DOI 10.1523/JNEUROSCI.21-10-03476.2001; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029	25	1163	1194	1	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1248	1251		10.1126/science.1072699	http://dx.doi.org/10.1126/science.1072699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424383				2022-12-28	WOS:000179080400055
J	Looker, AC; Cogswell, ME; Gunter, EW				Looker, AC; Cogswell, ME; Gunter, EW		CDC	Iron deficiency - United States, 1999-2000 (Reprinted from MMWR, vol 51, pg 897-899, 2002)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint									CDC, Div Hlth Examinat Stat, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA; CDC, Div Nutr & Phys Act, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA; CDC, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Looker, AC (corresponding author), CDC, Div Hlth Examinat Stat, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA.							Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P897	1	25	25	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2114	2116						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12425310				2022-12-28	WOS:000179048100012
J	Jartti, T; van den Hoogen, B; Garofalo, RP; Osterhaus, ADME; Ruuskanen, O				Jartti, T; van den Hoogen, B; Garofalo, RP; Osterhaus, ADME; Ruuskanen, O			Metapneumovirus and acute wheezing in children	LANCET			English	Article								A new respiratory virus, human metapneumovirus, was recently identified. We detected this virus by PCR in ten (8%) of 132 consecutive children admitted to Turku Hospital, Finland, for acute expiratory wheezing (median age 7 months, range 4-25). The mean duration of hospital stay was 2.5 days (SD 1-6) and mean duration of respiratory symptoms was 19 days (8). The white blood cell count, C-reactive protein, and regulated upon activation, normal T-cell-expressed and T-cell-secreted (RANTES) concentrations in nasal secretion remained low, whereas interleukin 8 concentrations in nasal secretion were high. Human metapneumovirus is a clinically important causative agent of acute wheezing in young children.	Turku Univ Hosp, Dept Paediat, Turku 20521, Finland; Univ Texas, Med Branch, Childrens Hosp, Galveston, TX 77550 USA; Erasmus Med Ctr, Dept Virol, Rotterdam, Netherlands	University of Turku; University of Texas System; University of Texas Medical Branch Galveston; Erasmus University Rotterdam; Erasmus MC	Jartti, T (corresponding author), Turku Univ Hosp, Dept Paediat, PL 52, Turku 20521, Finland.		Garofalo, Roberto P./AAF-7385-2022; Garofalo, Roberto P./ABL-2322-2022; van den Hoogen, Bernadette/J-5461-2013	Osterhaus, Albert/0000-0002-6074-1172	NIAID NIH HHS [AI 15939, P01 AI 46004] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015939, P01AI046004] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Makela MJ, 1998, J CLIN MICROBIOL, V36, P539; Peret TCT, 2002, J INFECT DIS, V185, P1660, DOI 10.1086/340518; Ruuskanen O, 1993, Curr Probl Pediatr, V23, P50, DOI 10.1016/0045-9380(93)90003-U; Saito T, 1997, J INFECT DIS, V175, P497, DOI 10.1093/infdis/175.3.497; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098	5	217	237	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1393	1394		10.1016/S0140-6736(02)11391-2	http://dx.doi.org/10.1016/S0140-6736(02)11391-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423987	Green Published, Bronze			2022-12-28	WOS:000179081600014
J	Mann, H				Mann, H			Clinical trial protocols: agreements between the FDA and industrial sponsors	LANCET			English	Editorial Material									Univ Hosp, Dept Radiol, Salt Lake City, UT 84132 USA		Mann, H (corresponding author), Univ Hosp, Dept Radiol, Salt Lake City, UT 84132 USA.	Howard.Mann@hsc.utah.edu						Djulbegovic B, 2001, Curr Oncol Rep, V3, P389, DOI 10.1007/s11912-001-0024-5; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman Benjamin, 1994, IRB, V16, P1, DOI 10.2307/3563572; Godlee F, 2001, BMC NEWS VIEWS, V2; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Sackett DL, 2001, CAN MED ASSOC J, V165, P1226; *US FDA, 1998, INF SHEETS GUID I RE; *US FDA CTR DRUG E, 2001, GUID IND E 10 CHOIC; *US FDA CTR DRUG E, 2002, GUID IND SPEC PROT A; 2001, US FED REG, V66, P4688	11	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 2	2002	360	9343					1345	1346		10.1016/S0140-6736(02)11415-2	http://dx.doi.org/10.1016/S0140-6736(02)11415-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423978	Bronze			2022-12-28	WOS:000179081600005
J	Boyle, E				Boyle, E			Oceanic salt switch	SCIENCE			English	Editorial Material							TEMPERATURE; WATERS		MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Boyle, E (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA.							ADKINS JF, 1908, SCIENCE, V298, P1769; BOYLE EA, 1987, NATURE, V330, P35, DOI 10.1038/330035a0; Broecker WS, 1998, J GEOPHYS RES-OCEANS, V103, P15833, DOI 10.1029/98JC00248; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; Duplessy JC, 1988, PALEOCEANOGRAPHY, V3, P343, DOI 10.1029/PA003i003p00343; FRIEDMAN I, 1988, J GEOPHYS RES-OCEANS, V93, P8249, DOI 10.1029/JC093iC07p08249; Harris RN, 1997, SCIENCE, V275, P1618, DOI 10.1126/science.275.5306.1618; LABEYRIE LD, 1987, NATURE, V327, P477, DOI 10.1038/327477a0; LAWRENCE JR, 1973, INITIAL REPORTS DEEP, V20, P891; Martin PA, 2002, EARTH PLANET SC LETT, V198, P193, DOI 10.1016/S0012-821X(02)00472-7; MCDUFF RE, 1985, INITIAL REP DEEP SEA, V86, P675; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; SHACKLETON NJ, 1987, QUATERNARY SCI REV, V6, P183, DOI 10.1016/0277-3791(87)90003-5; Warren BA., 1981, EVOLUTION PHYSICAL O, P6; Wunsch C, 2002, SCIENCE, V298, P1179, DOI 10.1126/science.1079329	15	11	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1724	1725		10.1126/science.1079238	http://dx.doi.org/10.1126/science.1079238			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459572				2022-12-28	WOS:000179494800025
J	Alam, MA; Smith, RK; Weir, BE; Silverman, PJ				Alam, MA; Smith, RK; Weir, BE; Silverman, PJ			Thindielectric films - Uncorrelated breakdown of integrated circuits	NATURE			English	Article									Agere Syst, Murray Hill, NJ 07076 USA	Broadcom; LSI Corporation	Alam, MA (corresponding author), Agere Syst, Murray Hill, NJ 07076 USA.	alam@agere.com						Alam MA, 2002, IEEE T ELECTRON DEV, V49, P239, DOI 10.1109/16.981213; CAPEHART TW, 1976, PHYS REV B, V13, P5021, DOI 10.1103/PhysRevB.13.5021; Degraeve R, 2001, INT RELIAB PHY SYM, P360, DOI 10.1109/RELPHY.2001.922928; HIPPEL ARV, 1937, J APPL PHYS, V8, P815; Kingon AI, 2000, NATURE, V406, P1032, DOI 10.1038/35023243; Moore G., 1965, ELECTRONICS, V38, P114, DOI [DOI 10.1109/N-SSC.2006.4785860, DOI 10.1109/JPROC.1998.658762]; OGAWA T, 1982, HDB ATMOSPHERICS, V1, P23; Packan PA, 1999, SCIENCE, V285, P2079, DOI 10.1126/science.285.5436.2079; Stathis JH, 1999, J APPL PHYS, V86, P5757, DOI 10.1063/1.371590; 1999, SEMICONDUCTOR IND AS	10	57	58	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	2002	420	6914					378	378		10.1038/420378a	http://dx.doi.org/10.1038/420378a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459774	Bronze			2022-12-28	WOS:000179494700028
J	Randolph, AG; Wypij, D; Venkataraman, ST; Hanson, JH; Gedeit, RG; Meert, KL; Luckett, PM; Forbes, P; Lilley, M; Thompson, J; Cheifetz, IM; Hibberd, P; Wetzel, R; Cox, PN; Arnold, JH				Randolph, AG; Wypij, D; Venkataraman, ST; Hanson, JH; Gedeit, RG; Meert, KL; Luckett, PM; Forbes, P; Lilley, M; Thompson, J; Cheifetz, IM; Hibberd, P; Wetzel, R; Cox, PN; Arnold, JH		PALISI Network	Effect of mechanical ventilator weaning protocols on respiratory outcomes in infants and children - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSPIRATORY PRESSURE; SUCCESSFUL EXTUBATION; PROLONGED SEDATION; SUPPORT; WITHDRAWAL; PREDICTORS; RISK	Context Ventilator management protocols shorten the time required to wean adult patients from mechanical ventilation. The efficacy of such weaning protocols among children has not been studied. Objective To evaluate whether weaning protocols are superior to standard care (no defined protocol) for infants and children with acute illnesses requiring mechanical ventilator support and whether a volume support weaning protocol using continuous automated adjustment of pressure support by the ventilator (ie, VSV) is superior to manual adjustment of pressure support by clinicians (ie, PSV). Design and Setting Randomized controlled trial conducted in,the pediatric intensive care units of 10 children's hospitals across North America from November 1999 through April 2001. Patients One hundred eighty-two spontaneously breathing children (<18 years old) who had been receiving ventilator support for more than 24 hours and who failed a test for extubation readiness on minimal pressure support. Interventions Patients were randomized to a PSV protocol (n=62), VSV protocol (n=60), or no protocol (n=60). Main Outcome Measures Duration of weaning time (from randomization to successful extubation); extubation failure (any invasive or noninvasive ventilator support within 48 hours of extubation). Results Extubation failure rates were not significantly different for PSV (15%), VSV (24%), and no protocol (17%) (P=.44). Among weaning successes, median duration of weaning was not significantly different for PSV (1.6 days), VSV (1.8 days), and no protocol (2.0 days) (P=.75). Male children more frequently failed extubation (odds ratio, 7.86; 95% confidence interval, 2.36-26.2; P<.001). Increased sedative use in the first 24 hours of weaning predicted extubation failure (P=.04) and, among extubation successes, duration of weaning (P<.001). Conclusions In contrast with adult patients, the majority of children are weaned from mechanical ventilator support in 2 days or less. Weaning protocols did not significantly shorten this brief duration of weaning.	Childrens Hosp, MICU, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Childrens Hosp Oakland, Oakland, CA USA; Childrens Hosp Milwaukee, Milwaukee, WI USA; Childrens Hosp Michigan, Detroit, MI 48201 USA; Childrens Med Ctr Dallas, Dallas, TX USA; Duke Childrens Hosp, Durham, NC USA; Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Children's Hospital of Michigan; Duke University; Children's Hospital Los Angeles; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Randolph, AG (corresponding author), Childrens Hosp, MICU, FA-108,300 Longwood Ave, Boston, MA 02115 USA.	adrienne.randolph@tch.harvard.edu	Cheifetz, Ira/I-8692-2019	Cheifetz, Ira/0000-0002-1174-1571; Gedeit, Rainer/0000-0003-2420-9493; Hibberd, Patricia/0000-0002-7455-8117; Wypij, David/0000-0001-8367-8711; Randolph, Adrienne/0000-0002-3084-3071	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004278] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR02172] Funding Source: Medline; NHLBI NIH HHS [K23 HL04278] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bock KR, 2000, CHEST, V118, P468, DOI 10.1378/chest.118.2.468; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1987, AM REV RESPIR DIS, V136, P411, DOI 10.1164/ajrccm/136.2.411; BROCHARD L, 1991, ANESTHESIOLOGY, V75, P739, DOI 10.1097/00000542-199111000-00004; ElKhatib MF, 1996, INTENS CARE MED, V22, P264, DOI 10.1007/BF01712248; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Hamill PV, 1977, VITAL HLTH STAT 11, V11, P1; HARRIS TR, 1996, ASSISTED VENTILATION, P29; Khan N, 1996, CRIT CARE MED, V24, P1568, DOI 10.1097/00003246-199609000-00023; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Lauterbach MD, 2001, NEUROPSYCHOLOGY, V15, P411, DOI 10.1037/0894-4105.15.3.411; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Martin Lynn D., 1995, Current Opinion in Pediatrics, V7, P250, DOI 10.1097/00008480-199506000-00003; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Randolph AG, 1999, NEW HORIZ-SCI PRACT, V7, P374; Schultz T R, 2001, Respir Care, V46, P772; Thiagarajan RR, 1999, AM J RESP CRIT CARE, V160, P1562, DOI 10.1164/ajrccm.160.5.9810036; TOBIAS JD, 1994, INTENS CARE MED, V20, P504, DOI 10.1007/BF01711905; Tobias JD, 1999, CRIT CARE MED, V27, P2262, DOI 10.1097/00003246-199910000-00033; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949; Woodruff D W, 1999, Nursing, V29, P34	25	241	254	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2002	288	20					2561	2568		10.1001/jama.288.20.2561	http://dx.doi.org/10.1001/jama.288.20.2561			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AL	12444863	Bronze			2022-12-28	WOS:000179394500023
J	Wald, DS; Law, M; Morris, JK				Wald, DS; Law, M; Morris, JK			Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							METHYLENETETRAHYDROFOLATE REDUCTASE GENE; CORONARY-HEART-DISEASE; METHYLENE-TETRAHYDROFOLATE REDUCTASE; PLASMA TOTAL HOMOCYSTEINE; SERUM TOTAL HOMOCYSTEINE; DEEP-VEIN THROMBOSIS; FACTOR-V-LEIDEN; FOLIC-ACID SUPPLEMENTATION; INTIMA-MEDIA THICKNESS; LOW FOLATE LEVELS	Objective To assess whether the association of serum homocysteine concentration with ischaemic heart disease, deep vein thrombosis and pulmonary embolism, and stroke is causal and, if so, to quantify the effect of homocysteine reduction in preventing them. Design Meta-analyses of the above three diseases using (a) 72 studies in which the prevalence of a mutation in the MTHFR gene (which increases homocysteine) was determined in cases (n= 16 849) and controls, and (b) 20 prospective studies (3820 participants) of serum homocysteine and disease risk. Main outcome measures Odds ratios of the three diseases for a 5 mumol/l increase in serum homocysteine concentration. Results There were significant associations between homocysteine and the three diseases. The odds ratios for a 5 mumol/l increase in serum homocysteine were, for ischaemic heart disease, 1.42 (95% confidence interval 1.11 to 1.84) in the genetic studies and 1.32 (1.19 to 1.45) in the prospective studies; for deep vein thrombosis with or without pulmonary embolism, 1.60 (1.15 to 2.22) in the genetic studies (there were no prospective studies); and, for stroke, 1.65 (0.66 to 4.13) in the genetic studies and 1.59 (1.29 to 1.96) in the prospective studies. Conclusions The genetic studies and the prospective studies do not share the same potential sources of error, but both yield similar highly significant results-strong evidence that the association between homocysteine and cardiovascular disease is causal. On this basis, lowering homocysteine concentrations by 3 mumol/l from current levels (achievable by increasing tolic acid intake) would reduce the risk of ischaemic heart disease by 16% (11% to 20%), deep vein thrombosis by 25% (8% to 38%), and stroke by 24% (15% to 33%).	Southampton Gen Hosp, Dept Cardiol, Southampton SO16 6YD, Hants, England; Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England	University of Southampton; University of London; Queen Mary University London	Wald, DS (corresponding author), Southampton Gen Hosp, Dept Cardiol, Southampton SO16 6YD, Hants, England.	davidwald@hotmail.com	Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X				Abbate R, 1998, THROMB HAEMOSTASIS, V79, P727; Adams M, 1996, QJM-MON J ASSOC PHYS, V89, P437; Akar N, 2000, THROMB RES, V97, P163, DOI 10.1016/S0049-3848(99)00157-7; Akar N, 1998, THROMB RES, V92, P79, DOI 10.1016/S0049-3848(98)00113-3; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; Alhenc-Gelas M, 1999, THROMB HAEMOSTASIS, V81, P506; Anderson JL, 1997, J AM COLL CARDIOL, V30, P1206, DOI 10.1016/S0735-1097(97)00310-0; Anderson JL, 2000, CIRCULATION, V102, P1227, DOI 10.1161/01.CIR.102.11.1227; Angchaisuksiri P, 2000, ACTA HAEMATOL-BASEL, V103, P191, DOI 10.1159/000041048; Arai K, 1997, DIABETES, V46, P2102, DOI 10.2337/diab.46.12.2102; Araujo F, 2000, THROMB HAEMOSTASIS, V83, P517; Ardissino D, 1999, BLOOD, V94, P46; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; Arruda VR, 1997, THROMB HAEMOSTASIS, V77, P818; Balta G, 1999, TURKISH J PEDIATR, V41, P197; Bostom AG, 1999, ANN INTERN MED, V131, P352, DOI 10.7326/0003-4819-131-5-199909070-00006; Bostom AG, 1999, ARCH INTERN MED, V159, P1077, DOI 10.1001/archinte.159.10.1077; Bots ML, 1999, ARCH INTERN MED, V159, P38, DOI 10.1001/archinte.159.1.38; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 2000, AM J CLIN NUTR, V72, P315; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; Brown K, 1998, BRIT J HAEMATOL, V103, P42, DOI 10.1046/j.1365-2141.1998.00935.x; Brugada R, 1997, ATHEROSCLEROSIS, V128, P107, DOI 10.1016/S0021-9150(96)05977-1; Brulhart MC, 1997, AM J HUM GENET, V60, P228; Cattaneo M, 1997, ARTERIOSCL THROM VAS, V17, P1662, DOI 10.1161/01.ATV.17.9.1662; Chambers JC, 2000, ARTERIOSCL THROM VAS, V20, P2448, DOI 10.1161/01.ATV.20.11.2448; Chango A, 2000, BRIT J NUTR, V84, P891, DOI 10.1017/s0007114500002518; Chango A, 2000, BRIT J NUTR, V83, P593, DOI 10.1017/S0007114500000751; Chao CL, 1999, ATHEROSCLEROSIS, V147, P379, DOI 10.1016/S0021-9150(99)00208-7; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; Christensen B, 1997, ARTERIOSCL THROM VAS, V17, P569, DOI 10.1161/01.ATV.17.3.569; Clarke R, 2001, J CARDIOVASC RISK, V8, P363, DOI 10.1097/00043798-200112000-00005; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Cleophas TJ, 2000, AM J CARDIOL, V86, P1005, DOI 10.1016/S0002-9149(00)01137-1; D'Angelo A, 2000, THROMB HAEMOSTASIS, V83, P563; Danesh J, 1998, J Cardiovasc Risk, V5, P229, DOI 10.1097/00043798-199808000-00004; Dekou V, 2001, ATHEROSCLEROSIS, V154, P659, DOI 10.1016/S0021-9150(00)00522-0; Deloughery TG, 1996, CIRCULATION, V94, P3074, DOI 10.1161/01.CIR.94.12.3074; Dilley A, 1998, AM J EPIDEMIOL, V147, P30; Dilley A, 2001, THROMB RES, V103, P109, DOI 10.1016/S0049-3848(01)00278-X; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; Eikelboom JW, 2000, STROKE, V31, P1069, DOI 10.1161/01.STR.31.5.1069; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Fallon UB, 2001, J EPIDEMIOL COMMUN H, V55, P91, DOI 10.1136/jech.55.2.91; Fallon UB, 2001, HEART, V85, P153, DOI 10.1136/heart.85.2.153; FALLON UB, 2001, HEART           0314; Fernandez-Arcas N, 1999, ATHEROSCLEROSIS, V145, P293, DOI 10.1016/S0021-9150(99)00080-5; Ferrer-Antunes C, 1998, THROMB HAEMOSTASIS, V80, P521; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; Fowkes FGR, 2000, ATHEROSCLEROSIS, V150, P179, DOI 10.1016/S0021-9150(99)00366-4; Franco RF, 1999, BRIT J HAEMATOL, V105, P556, DOI 10.1111/j.1365-2141.1999.01254.x; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Fujimura H, 2000, THROMB RES, V98, P1, DOI 10.1016/S0049-3848(99)00231-5; Gallagher PM, 1996, CIRCULATION, V94, P2154, DOI 10.1161/01.CIR.94.9.2154; Gardemann A, 1999, EUR HEART J, V20, P584, DOI 10.1053/euhj.1998.1340; Gemmati D, 1999, ARTERIOSCL THROM VAS, V19, P1761, DOI 10.1161/01.ATV.19.7.1761; Girelli D, 1998, BLOOD, V91, P4158, DOI 10.1182/blood.V91.11.4158.411k23_4158_4163; Gulec S, 2001, CLIN CARDIOL, V24, P281; Hsu LA, 2000, HUM HERED, V51, P41; Hsu TS, 2001, THROMB RES, V102, P387, DOI 10.1016/S0049-3848(01)00262-6; Isotalo PA, 2000, MOL DIAGN, V5, P59, DOI 10.1016/S1084-8592(00)00012-6; Izumi M, 1996, ATHEROSCLEROSIS, V121, P293, DOI 10.1016/0021-9150(95)05764-1; Jee SH, 2000, ATHEROSCLEROSIS, V153, P161, DOI 10.1016/S0021-9150(00)00389-0; Kark JD, 1999, ANN INTERN MED, V131, P321, DOI 10.7326/0003-4819-131-5-199909070-00002; Kawashiri M, 2000, AM J CARDIOL, V86, P840, DOI 10.1016/S0002-9149(00)01103-6; Kihara T, 1997, CIRCULATION, V96, P551; Kim CH, 2001, INT J CARDIOL, V78, P13, DOI 10.1016/S0167-5273(00)00431-9; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Kluijtmans LAJ, 1999, AM J HUM GENET, V65, P59, DOI 10.1086/302439; Kluijtmans LAJ, 1997, CIRCULATION, V96, P2573, DOI 10.1161/01.CIR.96.8.2573; Kluijtmans LAJ, 1998, THROMB HAEMOSTASIS, V79, P254, DOI 10.1055/s-0037-1614974; Kluijtmans LAJ, 1996, AM J HUM GENET, V58, P35; Knekt P, 2001, ARCH INTERN MED, V161, P1589, DOI 10.1001/archinte.161.13.1589; Knekt P, 2001, J INTERN MED, V249, P461, DOI 10.1046/j.1365-2796.2001.00830.x; Kosokabe T, 2001, CIRCULATION, V103, P2048; Kostulas K, 1998, EUR J CLIN INVEST, V28, P285; Lalouschek W, 1999, J LAB CLIN MED, V133, P575, DOI 10.1016/S0022-2143(99)90187-7; Law MR, 2002, BMJ-BRIT MED J, V324, P1570, DOI 10.1136/bmj.324.7353.1570; Legnani C, 1997, ARTERIOSCL THROM VAS, V17, P2924, DOI 10.1161/01.ATV.17.11.2924; Ma J, 1996, CIRCULATION, V94, P2410, DOI 10.1161/01.CIR.94.10.2410; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Mager A, 1999, CIRCULATION, V100, P2406, DOI 10.1161/01.CIR.100.24.2406; Malik NM, 1998, CLIN SCI, V95, P311, DOI 10.1042/CS19970193; Malinow MR, 1996, ATHEROSCLEROSIS, V126, P27, DOI 10.1016/0021-9150(96)05890-X; Malinow MR, 1997, ARTERIOSCL THROM VAS, V17, P1157, DOI 10.1161/01.ATV.17.6.1157; Margaglione M, 1998, THROMB HAEMOSTASIS, V79, P907; Markus H, 2001, STROKE, V32, P2465, DOI 10.1161/hs1101.098152; Mazza A, 2000, METABOLISM, V49, P718, DOI 10.1053/meta.2000.6254; Meisel C, 2001, ATHEROSCLEROSIS, V154, P651, DOI 10.1016/S0021-9150(00)00679-1; Morita H, 1998, ARTERIOSCL THROM VAS, V18, P1465, DOI 10.1161/01.ATV.18.9.1465; Morita H, 1997, CIRCULATION, V95, P2032, DOI 10.1161/01.CIR.95.8.2032; MUDD SH, 1985, AM J HUM GENET, V37, P1; Nakai K, 2000, CORONARY ARTERY DIS, V11, P47, DOI 10.1097/00019501-200002000-00009; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Ordonez AJG, 1999, HAEMATOLOGICA, V84, P190; Ou T, 1998, ATHEROSCLEROSIS, V137, P23, DOI 10.1016/S0021-9150(97)00244-X; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Petri M, 1996, LANCET, V348, P1120, DOI 10.1016/S0140-6736(96)03032-2; Philipp CS, 1998, THROMB HAEMOSTASIS, V80, P869; Pinto X, 2001, EUR J CLIN INVEST, V31, P24, DOI 10.1046/j.1365-2362.2001.00760.x; Press RD, 1999, DIAGN MOL PATHOL, V8, P54, DOI 10.1097/00019606-199903000-00009; Quere I, 1998, REV MED INTERNE, V19, P29, DOI 10.1016/S0248-8663(97)83696-X; Rassoul F, 2000, ANGIOLOGY, V51, P189, DOI 10.1177/000331970005100302; Reinhardt D, 1998, EUR J CLIN INVEST, V28, P20; Ridker PM, 1999, JAMA-J AM MED ASSOC, V281, P1817, DOI 10.1001/jama.281.19.1817; Rintelen C, 1999, BLOOD COAGUL FIBRIN, V10, P101, DOI 10.1097/00001721-199903000-00007; Salden A, 1997, BRIT J HAEMATOL, V99, P472; Salooja N, 1998, CLIN LAB HAEMATOL, V20, P357, DOI 10.1046/j.1365-2257.1998.00158.x; Saw SM, 2001, AM J CLIN NUTR, V73, P232; Schmitz C, 1996, CIRCULATION, V94, P1812, DOI 10.1161/01.CIR.94.8.1812; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; Schwartz SM, 1997, CIRCULATION, V96, P412; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Stehouwer CDA, 1999, KIDNEY INT, V55, P308, DOI 10.1046/j.1523-1755.1999.00256.x; Stehouwer CDA, 1998, ARTERIOSCL THROM VAS, V18, P1895, DOI 10.1161/01.ATV.18.12.1895; Szczeklik A, 2001, AM J MED GENET, V101, P36, DOI 10.1002/ajmg.1315; Thogersen AM, 2001, CORONARY ARTERY DIS, V12, P85, DOI 10.1097/00019501-200103000-00001; Todesco L, 1999, EUR J CLIN INVEST, V29, P1003; Tokgozoglu S, 1999, HEART, V81, P518, DOI 10.1136/hrt.81.5.518; Tosetto A, 1997, BRIT J HAEMATOL, V97, P804, DOI 10.1046/j.1365-2141.1997.1422957.x; Toydemir PB, 2000, J RHEUMATOL, V27, P2849; Tsai MY, 1999, ATHEROSCLEROSIS, V143, P163, DOI 10.1016/S0021-9150(98)00271-8; vanBockxmeer FM, 1997, CIRCULATION, V95, P21, DOI 10.1161/01.CIR.95.1.21; Varga M, 1998, BLOOD COAGUL FIBRIN, V9, P555, DOI 10.1097/00001721-199809000-00015; Verhoef P, 1998, J AM COLL CARDIOL, V32, P353, DOI 10.1016/S0735-1097(98)00244-7; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Verhoef P, 1997, ATHEROSCLEROSIS, V132, P105, DOI 10.1016/S0021-9150(97)00084-1; Vollset SE, 2001, AM J CLIN NUTR, V74, P130; Voutilainen S, 2000, J INTERN MED, V248, P217, DOI 10.1046/j.1365-2796.2000.00741.x; Vulapalli R, 2001, AM J CARDIOL, V87, P1289, DOI 10.1016/S0002-9149(01)01523-5; Wald DS, 2001, ARCH INTERN MED, V161, P695, DOI 10.1001/archinte.161.5.695; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; Whincup PH, 1999, HEART, V82, P448, DOI 10.1136/hrt.82.4.448; Wilcken DEL, 1997, J INHERIT METAB DIS, V20, P295, DOI 10.1023/A:1005373209964; Wilcken DEL, 1996, ARTERIOSCL THROM VAS, V16, P878, DOI 10.1161/01.ATV.16.7.878; Yoo JH, 2001, ANN NY ACAD SCI, V928, P344; Zheng YZ, 2000, BRIT J HAEMATOL, V109, P870, DOI 10.1046/j.1365-2141.2000.02112.x	139	1466	1573	2	115	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	2002	325	7374					1202	1206K		10.1136/bmj.325.7374.1202	http://dx.doi.org/10.1136/bmj.325.7374.1202			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446535	Bronze, Green Published			2022-12-28	WOS:000179506200018
J	Wilmshurst, P				Wilmshurst, P			Institutional corruption in medicine	BRITISH MEDICAL JOURNAL			English	Article									Royal Shrewsbury Hosp, Shrewsbury SY3 8XQ, Salop, England		Wilmshurst, P (corresponding author), Royal Shrewsbury Hosp, Shrewsbury SY3 8XQ, Salop, England.							BANERJEE AK, 1990, GUT, V31, pA593; BANERJEE AK, 1990, GUT, V31, P1358, DOI 10.1136/gut.31.12.1358; BJARNASON I, 1991, COMMUNICATION   0807; COE C, 2000, COMMUNICATION   1212; Farthing MJG, 2001, GUT, V48, P285, DOI 10.1136/gut.48.3.285; JOHNSON S, 1991, COMMUNICATION   0808; LAURANCE J, 2000, INDEPENDENT     1212; LUCAS A, 1997, COMMUNICATION   0407; Ramsay S, 2001, LANCET, V357, P780, DOI 10.1016/S0140-6736(05)71213-7; Wilmshurst P, 1997, LANCET, V349, P567, DOI 10.1016/S0140-6736(97)80121-3	10	20	22	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 23	2002	325	7374					1232	1235		10.1136/bmj.325.7374.1232	http://dx.doi.org/10.1136/bmj.325.7374.1232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446544				2022-12-28	WOS:000179506200029
J	Brown, P; Spalding, RE; ReVelle, DO; Tagliaferri, E; Worden, SP				Brown, P; Spalding, RE; ReVelle, DO; Tagliaferri, E; Worden, SP			The flux of small near-Earth objects colliding with the Earth	NATURE			English	Article							INFRASOUND; COLLISION; RADIATION; SATELLITE; IMPACTS; BOLIDES; ENTRY	Asteroids with diameters smaller than similar to50-100 m that collide with the Earth usually do not hit the ground as a single body; rather, they detonate in the atmosphere(1). These small objects can still cause considerable damage, such as occurred near Tunguska(2), Siberia, in 1908. The flux of small bodies is poorly constrained, however, in part because ground-based observational searches pursue strategies that lead them preferentially to find larger objects(3). ATunguska-class event - the energy of which we take to be equivalent to 10 megatons of TNT - was previously estimated to occur every 200 - 300 years, with the largest annual airburst calculated to be similar to20 kilotons (kton) TNT equivalent (ref. 4). Here we report satellite records of bolide detonations in the atmosphere over the past 8.5 years. We find that the flux of objects in the 1-10-m size range has the same power-law distribution as bodies with diameters > 50 m. From this we estimate that the Earth is hit on average annually by an object with similar to5 kton equivalent energy, and that Tunguska-like events occur about once every 1,000 years.	Univ Western Ontario, Dept Phys & Astron, London, ON N6A 3K7, Canada; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Sandia Natl Labs, Albuquerque, NM 87185 USA; ET Space Syst, Camarillo, CA 93012 USA; US Space Command, Directorate Operat, Peterson AFB, Colorado Springs, CO 80914 USA	Western University (University of Western Ontario); United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Sandia National Laboratories; National Aeronautics & Space Administration (NASA)	Brown, P (corresponding author), Univ Western Ontario, Dept Phys & Astron, London, ON N6A 3K7, Canada.	pbrown@uwo.ca		Brown, Peter/0000-0001-6130-7039				Borovicka J, 1996, ICARUS, V121, P484, DOI 10.1006/icar.1996.0104; BOROVICKA J, UNPUB METEORIT PLANE; Britt DT, 2000, ICARUS, V146, P213, DOI 10.1006/icar.2000.6374; Brown P, 1996, METORIT PLANET SCI, V31, P502, DOI 10.1111/j.1945-5100.1996.tb02092.x; BROWN P, 2002, GEOPHYS RES LETT, V29, P1; Brown PG, 2002, METEORIT PLANET SCI, V37, P661, DOI 10.1111/j.1945-5100.2002.tb00846.x; Ceplecha Z, 1998, SPACE SCI REV, V84, P327, DOI 10.1023/A:1005069928850; Ceplecha Z, 1996, P SOC PHOTO-OPT INS, V2813, P46, DOI 10.1117/12.256072; Halliday I, 1996, METORIT PLANET SCI, V31, P185, DOI 10.1111/j.1945-5100.1996.tb02014.x; Harris AW, 1999, ICARUS, V142, P464, DOI 10.1006/icar.1999.6248; HARRIS AW, 2002, IN PRESS P AST COM M; Hills JG, 1998, PLANET SPACE SCI, V46, P219, DOI 10.1016/S0032-0633(97)00051-2; Levison HF, 2002, SCIENCE, V296, P2212, DOI 10.1126/science.1070226; MCCORD TB, 1995, J GEOPHYS RES-PLANET, V100, P3245, DOI 10.1029/94JE02802; Morbidelli A, 2002, ICARUS, V158, P329, DOI 10.1006/icar.2002.6887; MORRISON D, 1994, HAZARDS DUE COMETS A, P59; Nemtchinov IV, 1997, ICARUS, V130, P259, DOI 10.1006/icar.1997.5821; Rabinowitz D, 2000, NATURE, V403, P165, DOI 10.1038/35003128; ReVelle DO, 1998, P SOC PHOTO-OPT INS, V3434, P66, DOI 10.1117/12.331223; REVELLE DO, 1980, J GEOPHYS RES, V85, P1803, DOI 10.1029/JB085iB04p01803; Revelle DO, 1997, ANN NY ACAD SCI, V822, P284, DOI 10.1111/j.1749-6632.1997.tb48347.x; REVELLE DO, 2001, ESA, P483; REVELLE DO, 2001, EUROPEAN SPACE AGENC, P507; REVELLE DO, 2001, EUROPEAN SPACE AGENC, P513; Sekanina Z, 1998, PLANET SPACE SCI, V46, P191, DOI 10.1016/S0032-0633(96)00154-7; SHOEMAKER EM, 1983, ANNU REV EARTH PL SC, V11, P461, DOI 10.1146/annurev.ea.11.050183.002333; Stuart JS, 2001, SCIENCE, V294, P1691, DOI 10.1126/science.1065318; Tagliaferri E., 1998, HAZARDS DUE COMETS A, P199; Werner SC, 2002, ICARUS, V156, P287, DOI 10.1006/icar.2001.6789	29	308	316	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	2002	420	6913					294	296		10.1038/nature01238	http://dx.doi.org/10.1038/nature01238			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447433				2022-12-28	WOS:000179340400035
J	Fisher, CM				Fisher, CM			Perspective: Transient ischemic attacks	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Fisher, CM (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.								0	30	30	1	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1642	1643		10.1056/NEJMp020129	http://dx.doi.org/10.1056/NEJMp020129			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444177				2022-12-28	WOS:000179339900001
J	Koutsky, LA; Ault, KA; Wheeler, CM; Brown, DR; Barr, E; Alvarez, FB; Chiacchierini, LM; Jansen, KU				Koutsky, LA; Ault, KA; Wheeler, CM; Brown, DR; Barr, E; Alvarez, FB; Chiacchierini, LM; Jansen, KU		Proof Priniciple Study Investigato	A controlled trial of a human papillomavirus type 16 vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-LIKE PARTICLES; ANTIBODY-RESPONSES; CERVICAL-CANCER; L1 PROTEIN; INFECTION; SERUM; NEUTRALIZATION; EXPRESSION; HPV-11; SAFETY	Background: Approximately 20 percent of adults become infected with human papillomavirus type 16 (HPV-16). Although most infections are benign, some progress to anogenital cancer. A vaccine that reduces the incidence of HPV-16 infection may provide important public health benefits. Methods: In this double-blind study, we randomly assigned 2392 young women (defined as females 16 to 23 years of age) to receive three doses of placebo or HPV-16 virus-like-particle vaccine (40 microg per dose), given at day 0, month 2, and month 6. Genital samples to test for HPV-16 DNA were obtained at enrollment, one month after the third vaccination, and every six months thereafter. Women were referred for colposcopy according to a protocol. Biopsy tissue was evaluated for cervical intraepithelial neoplasia and analyzed for HPV-16 DNA with use of the polymerase chain reaction. The primary end point was persistent HPV-16 infection, defined as the detection of HPV-16 DNA in samples obtained at two or more visits. The primary analysis was limited to women who were negative for HPV-16 DNA and HPV-16 antibodies at enrollment and HPV-16 DNA at month 7. Results: The women were followed for a median of 17.4 months after completing the vaccination regimen. The incidence of persistent HPV-16 infection was 3.8 per 100 woman-years at risk in the placebo group and 0 per 100 woman-years at risk in the vaccine group (100 percent efficacy; 95 percent confidence interval, 90 to 100; P<0.001). All nine cases of HPV-16-related cervical intraepithelial neoplasia occurred among the placebo recipients. Conclusions: Administration of this HPV-16 vaccine reduced the incidence of both HPV-16 infection and HPV-16-related cervical intraepithelial neoplasia. Immunizing HPV-16-negative women may eventually reduce the incidence of cervical cancer.	Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA; Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA; Merck Res Labs, Biol Clin Res, Blue Bell, PA USA; Merck Res Labs, Dept Biostat, Blue Bell, PA USA; Merck Res Labs, Dept Virus & Cell Biol, West Point, PA USA	University of Washington; University of Washington Seattle; University of Iowa; University of New Mexico; Indiana University System; Indiana University-Purdue University Indianapolis; Merck & Company; Merck & Company; Merck & Company	Koutsky, LA (corresponding author), HPV Res Grp, 1914 N 34th St,Suite 300, Seattle, WA 98103 USA.	kouts@u.washington.edu						BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Brown DR, 2001, J INFECT DIS, V184, P1183, DOI 10.1086/323645; Carter JJ, 2000, J INFECT DIS, V181, P1911, DOI 10.1086/315498; Cassidy WM, 2001, PEDIATRICS, V107, P626, DOI 10.1542/peds.107.4.626; Chan ISF, 1998, COMMUN STAT-THEOR M, V27, P1305, DOI 10.1080/03610929808832160; CHRISTENSEN ND, 1990, J VIROL, V64, P3151, DOI 10.1128/JVI.64.7.3151-3156.1990; HAGENSEE ME, 1993, J VIROL, V67, P315, DOI 10.1128/JVI.67.1.315-322.1993; Harro CD, 2001, JNCI-J NATL CANCER I, V93, P284, DOI 10.1093/jnci/93.4.284; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; *IARC, 1995, IARC MON EV CARC RIS, V64; JANSEN KU, 1995, VACCINE, V13, P1509, DOI 10.1016/0264-410X(95)00103-8; KIRNBAUER R, 1994, JNCI-J NATL CANCER I, V86, P494, DOI 10.1093/jnci/86.7.494; Koutsky LA, 2000, J NATL CANCER I, V92, P397, DOI 10.1093/jnci/92.5.397; KOUTSKY LA, 2001, 19 INT PAP C FLOR BR; Kulasingam SL, 2002, JAMA-J AM MED ASSOC, V288, P1749, DOI 10.1001/jama.288.14.1749; Kurman RJ, 1994, BETHESDA SYSTEM REPO; LIGLOF T, 2001, VACCINE, V20, P281; LIN YL, 1993, J VIROL, V67, P4154, DOI 10.1128/JVI.67.7.4154-4162.1993; Linglof T, 2001, VACCINE, V19, P3968, DOI 10.1016/S0264-410X(01)00134-7; Lowe RS, 1997, J INFECT DIS, V176, P1141, DOI 10.1086/514105; Moscicki AB, 2001, JAMA-J AM MED ASSOC, V285, P2995, DOI 10.1001/jama.285.23.2995; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; Palker TJ, 2001, VACCINE, V19, P3733, DOI 10.1016/S0264-410X(01)00093-7; POLAND GA, 2000, 18 INT PAP C BARC SP; STONE KM, 2000, 18 INT PAP C BARC SP; SUZICH JA, 1995, P NATL ACAD SCI USA, V92, P11553, DOI 10.1073/pnas.92.25.11553; Thomas KK, 2000, J INFECT DIS, V182, P1097, DOI 10.1086/315805; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201; Wideroff L, 1999, J INFECT DIS, V180, P1424, DOI 10.1086/315055; ZHOU J, 1991, VIROLOGY, V185, P251, DOI 10.1016/0042-6822(91)90772-4; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	33	1209	1314	12	147	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1645	1651		10.1056/NEJMoa020586	http://dx.doi.org/10.1056/NEJMoa020586			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444178	Bronze			2022-12-28	WOS:000179339900002
J	Ulmer, A; Fierlbeck, G				Ulmer, A; Fierlbeck, G			Oral manifestations of secondary syphilis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Tubingen Hosp, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Ulmer, A (corresponding author), Univ Tubingen Hosp, D-72076 Tubingen, Germany.								0	7	7	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1677	1677		10.1056/NEJMicm020403	http://dx.doi.org/10.1056/NEJMicm020403			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444182				2022-12-28	WOS:000179339900006
J	Wang, A; Kurdistani, SK; Grunstein, M				Wang, A; Kurdistani, SK; Grunstein, M			Requirement of Hos2 histone deacetylase for gene activity in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REPRESSION; IN-VIVO; RPD3; ACETYLTRANSFERASE; ACETYLATION; COMPLEX; GENOME; UME6	Histone deacetylases, typified by class I Rpd3 in the yeast Saccharomyces cerevisiae, have historically been associated with gene repression. We now demonstrate that Hos2, another member of the class I family, binds to the coding regions of genes primarily during gene activation, when it specifically deacetylates the lysines in H3 and H4 histone tails. Moreover, Hos2 is preferentially associated with genes of high activity genome-wide. We also show that Hos2 and an associated factor, Set3, are necessary for efficient transcription. Therefore, our data indicate that, in contrast to other class I histone deacetylases, Hos2 is directly required for gene activation.	Univ Calif Los Angeles, UCLA Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, UCLA Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Grunstein, M (corresponding author), Univ Calif Los Angeles, UCLA Sch Med, Dept Biol Chem, Boyer Hall, Los Angeles, CA 90095 USA.			Kurdistani, Siavash/0000-0003-3295-3511	NIGMS NIH HHS [GM23674] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023674, R37GM023674] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Hawkes NA, 2002, J BIOL CHEM, V277, P3047, DOI 10.1074/jbc.M110445200; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Pijnappel WWMP, 2001, GENE DEV, V15, P2991, DOI 10.1101/gad.207401; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; TURI TG, 1992, J BIOL CHEM, V267, P2046; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wang A. F., UNPUB; Winkler GS, 2002, P NATL ACAD SCI USA, V99, P3517, DOI 10.1073/pnas.022042899; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; YARGER JG, 1984, MOL CELL BIOCHEM, V61, P173	20	203	209	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1412	1414		10.1126/science.1077790	http://dx.doi.org/10.1126/science.1077790			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434058				2022-12-28	WOS:000179223100049
J	Kim, JH; Yoneya, M; Yokoyama, H				Kim, JH; Yoneya, M; Yokoyama, H			Tristable nematic liquid-crystal device using micropatterned surface alignment	NATURE			English	Article							BISTABILITY; ORIENTATION	It has long been appreciated that liquid-crystal (LC) devices in which the LC molecules adopt multiple stable orientations could drastically reduce the power consumption required for high-information-content displays. But for the commonly used nematic LCs, which are intrinsically uniaxial in symmetry, no industrially feasible multi-stable LC device has been realized(1-7). Recently we demonstrated how bistability can be robustly engineered into a nematic LC device, by patterning a substrate with an orientational chequerboard pattern that enforces orthogonal LC alignment in neighbouring square domains(8,9). As a result of the four-fold symmetry of the pattern, the two diagonal axes of the chequerboard become equally stable macroscopic orientations. Here we extend this symmetry approach to obtain a tristable surface-aligned nematic LC. A microscopic pattern exhibiting six-fold symmetry is inscribed on a polyimide surface using the stylus of an atomic force microscope. The hexagonal symmetry of the microscopic orientational domains in turn gives rise to three stable macroscopic LC orientations, which are mutually switchable by an in-plane electric field. The resulting switching mode is surface driven, and hence should be compatible with demanding flexible display applications.	Japan Sci & Technol Corp, ERATO, Yokoyama Nanostruct Liquid Crystal Project, Tsukuba, Ibaraki 3002635, Japan; Natl Inst Adv Ind Sci & Technol, Nanotechnol Res Inst, Tsukuba, Ibaraki 3058568, Japan	Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST)	Kim, JH (corresponding author), Japan Sci & Technol Corp, ERATO, Yokoyama Nanostruct Liquid Crystal Project, Tsukuba, Ibaraki 3002635, Japan.	kimjh@nanolc.jst.go.jp	Yoneya, Makoto/J-4182-2015	Yoneya, Makoto/0000-0002-4727-2498; Kim, Jong-Hyun/0000-0002-7503-5123				BARBERI R, 1989, APPL PHYS LETT, V55, P2506, DOI 10.1063/1.102012; BERREMAN DW, 1981, J APPL PHYS, V52, P3032, DOI 10.1063/1.329049; BLINOV LM, 1990, MOL CRYST LIQ CRYST, V179, P13; BOYD GD, 1980, APPL PHYS LETT, V36, P556, DOI 10.1063/1.91578; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; Kim JH, 2002, NANOTECHNOLOGY, V13, P133, DOI 10.1088/0957-4484/13/2/301; Kim JH, 2001, APPL PHYS LETT, V78, P3055, DOI 10.1063/1.1371246; Kim JY, 2001, MOL CRYST LIQ CRYST, V370, P151, DOI 10.1080/10587250108030059; ONG HL, 1984, J APPL PHYS, V55, P2809, DOI 10.1063/1.333319; Pidduck AJ, 1997, APPL PHYS LETT, V71, P2907, DOI 10.1063/1.120212; Rastegar A, 2001, J APPL PHYS, V89, P960, DOI 10.1063/1.1335649; RUESTSCHIM M, 1994, SCIENCE, V265, P512; SCHEFFER TJ, 1984, APPL PHYS LETT, V45, P1021, DOI 10.1063/1.95048; Schuddeboom PC, 1997, PHYS REV E, V56, P4294, DOI 10.1103/PhysRevE.56.4294; Schuddeboom PC, 1997, EUROPHYS LETT, V39, P515, DOI 10.1209/epl/i1997-00386-y; Yamaguchi R, 1996, JPN J APPL PHYS 2, V35, pL117, DOI 10.1143/JJAP.35.L117; YANG KH, 1983, JPN J APPL PHYS 1, V22, P389, DOI 10.1143/JJAP.22.389; YOKOYAMA H, 1997, HDB LIQUID CRYSTAL R, pCH6; Yoneya M, 2002, APPL PHYS LETT, V80, P374, DOI 10.1063/1.1435070	19	289	296	7	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					159	162		10.1038/nature01163	http://dx.doi.org/10.1038/nature01163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432387				2022-12-28	WOS:000179200900040
J	Cote, IM; Reynolds, JD				Cote, IM; Reynolds, JD			Predictive ecology to the rescue?	SCIENCE			English	Editorial Material									Univ E Anglia, Sch Biol Sci, Ctr Ecol Evolut & Conservat, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Cote, IM (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Ecol Evolut & Conservat, Norwich NR4 7TJ, Norfolk, England.	i.cote@uea.ac.uk	Cote, Isabelle/ABD-5898-2021; Reynolds, John D/L-6345-2015	Reynolds, John D/0000-0002-0459-0074				Hanski I., 1999, METAPOPULATION ECOLO; *IUCN, 2002 IUCN RED LIST T; Kolar CS, 2002, SCIENCE, V298, P1233, DOI 10.1126/science.1075753; Lens L, 1999, P ROY SOC B-BIOL SCI, V266, P1241, DOI 10.1098/rspb.1999.0769; Lens L, 2002, SCIENCE, V298, P1236, DOI 10.1126/science.1075664; Lens L, 2002, CONSERV BIOL, V16, P479, DOI 10.1046/j.1523-1739.2002.00516.x; Sakai AK, 2001, ANNU REV ECOL SYST, V32, P305, DOI 10.1146/annurev.ecolsys.32.081501.114037	7	21	23	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	2002	298	5596					1181	1182						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424357				2022-12-28	WOS:000179080400026
J	Kahn, H; Ballarini, R; Bellante, JJ; Heuer, AH				Kahn, H; Ballarini, R; Bellante, JJ; Heuer, AH			Fatigue failure in polysilicon not due to simple stress corrosion cracking	SCIENCE			English	Article							SINGLE-CRYSTAL SILICON; HIGH-CYCLE FATIGUE; THIN-FILMS; FRACTURE; GROWTH; MECHANICS	In the absence of a corrosive environment, brittle materials such as silicon should be immune to cyclic fatigue. However, fatigue effects are well known in micrometer-sized polycrystalline silicon ( polysilicon) samples tested in air. To investigate the origins of this phenomenon in polysilicon, we developed a fixed-grip fracture mechanics microspecimen but could find no evidence of static stress corrosion cracking. The environmental sensitivity of the fatigue resistance was also investigated under cyclic loading. For low-cycle fatigue, the behavior is independent of the ambient conditions, whether air or vacuum, but is strongly influenced by the ratio of compressive to tensile stresses experienced during each cycle. The fatigue damage most likely originates from contact stresses at processing-related surface asperities; subcritical crack growth then ensues during further cyclic loading. The lower far-field stresses involved in high-cycle fatigue induce reduced levels of fatigue damage. Under these conditions, a corrosive ambient such as laboratory air exacerbates the fatigue process. Without cyclic loading, polysilicon does not undergo stress corrosion cracking.	Case Western Reserve Univ, Cleveland, OH 44106 USA	Case Western Reserve University	Ballarini, R (corresponding author), Case Western Reserve Univ, 10900 Euclid Ave, Cleveland, OH 44106 USA.							Bagdahn J., 2001, Proceedings of the SPIE - The International Society for Optical Engineering, V4558, P159, DOI 10.1117/12.442998; Ballarini R, 2001, AM SOC TEST MATER, V1413, P37, DOI 10.1520/STP10979S; Chabal YJ, 2002, SURF SCI, V502, P41, DOI 10.1016/S0039-6028(01)01896-9; CHEN CP, 1982, J AM CERAM SOC, V65, pC49, DOI 10.1111/j.1151-2916.1982.tb10413.x; CONNALLY JA, 1992, SCIENCE, V256, P1537, DOI 10.1126/science.256.5063.1537; Fitzgerald AM, 2002, J MATER RES, V17, P683, DOI 10.1557/JMR.2002.0097; GHANDI SK, 1983, VLSI FABRICATION PRI, P373; JAMIESON JC, 1963, SCIENCE, V139, P762, DOI 10.1126/science.139.3556.762; Kahn H, 1999, P ROY SOC A-MATH PHY, V455, P3807, DOI 10.1098/rspa.1999.0478; MICHALSKE TA, 1983, J AM CERAM SOC, V66, P284, DOI 10.1111/j.1151-2916.1983.tb15715.x; Muhlstein CL, 2002, APPL PHYS LETT, V80, P1532, DOI 10.1063/1.1455142; Muhlstein CL, 2001, SENSOR ACTUAT A-PHYS, V94, P177, DOI 10.1016/S0924-4247(01)00709-9; Muhlstein CL, 2001, J MICROELECTROMECH S, V10, P593, DOI 10.1109/84.967383; RAJU IS, 1979, ENG FRACT MECH, V11, P817, DOI 10.1016/0013-7944(79)90139-5; SURESH S, 1990, INT J FRACTURE, V42, P41, DOI 10.1007/BF00018612; TSUCHIYA T, 1998, TECH DIG SENS S, V16, P277; Van Arsdell WW, 1999, J MICROELECTROMECH S, V8, P319, DOI 10.1109/84.788636; WIEDERHORN SM, 1974, J AM CERAM SOC, V57, P336, DOI 10.1111/j.1151-2916.1974.tb10917.x; Yang J, 2000, J MICROELECTROMECH S, V9, P485, DOI 10.1109/84.896770	19	127	134	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1215	1218						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12425330				2022-12-28	WOS:000179080400044
J	Kilger, C; Bartenbach, K				Kilger, C; Bartenbach, K			Patent law - New rules for German professors	SCIENCE			English	Editorial Material									ipal GmbH, D-10719 Berlin, Germany; CBH Attorneys, D-50672 Cologne, Germany		Kilger, C (corresponding author), ipal GmbH, Bundesalle 210, D-10719 Berlin, Germany.							BARTENBACH K, 2001, ARBEITNEHMERERFINDER, pR5; BARTENBACH K, 2002, MITT DT PATENTANW, V93, P165; BIBERFELD X, 1898, DTSCH VEREINIGUNG GE, P186; HERTEL B, COMMUNICATION; HOARTON L, COMMUNICATION; LOGEAIS E, COMMUNICATION; PICCARRETA V, COMMUNICATION; VOLZ FE, 1985, RECHT ARBEITNEHMERER, P9; 2002, EU WORKSH REL PAT VS	9	21	21	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1173	+		10.1126/science.1075269	http://dx.doi.org/10.1126/science.1075269			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424355				2022-12-28	WOS:000179080400021
J	Dubuquoy, L; Dharancy, S; Nutten, S; Pettersson, S; Auwerx, J; Desreumaux, P				Dubuquoy, L; Dharancy, S; Nutten, S; Pettersson, S; Auwerx, J; Desreumaux, P			Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases	LANCET			English	Review							MONOCYTE CHEMOTACTIC PROTEIN-1; HIGH-AFFINITY LIGAND; PPAR-GAMMA; GENE-EXPRESSION; TISSUE DISTRIBUTION; ADIPOSE-TISSUE; FATTY-ACIDS; ALZHEIMERS-DISEASE; NUCLEAR RECEPTOR; CELL-GROWTH	The peroxisome proliferator-activated receptor gamma (PPAR-gamma) and its partner the retinoid X receptor (RXR) are two nuclear receptors that are expressed mainly in adipose tissue and which have a role in lipid metabolism and insulin sensitisation. New sites of PPARgamma/RXR expression have been described, especially in the intestinal tract, pancreas, and liver. Concomitantly, new functions have been attributed to this heterodimer in regulation of inflammation, by its inhibition of nuclear factor (NF)-kappaB and via stress-kinase pathways. These new sites and functions of PPARgamma/RXR have led to novel ideas about pathophysiology of different inflammatory digestive diseases and to development of innovative treatment strategies with PPARgamma activators.	CHU Lille, Equipe Propre INSERM Physiopathol Malad Inflammat, F-59037 Lille, France; Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; Karolinska Inst, Microbiol & Tumour Biol Ctr, Div Mol Pathol, Lab Gastrobiol, Stockholm, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Karolinska Institutet	Desreumaux, P (corresponding author), CHU Lille, Hop Huriez, Serv Malad Appareil Digest & Nutr, F-59037 Lille, France.	pdesreumaux@chru-lille.fr	Desreumaux, Pierre F/R-6877-2018; Pettersson, Sven/F-9511-2015; Dubuquoy, laurent/J-4978-2015; Auwerx, Johan/ABE-9307-2021; Dubuquoy, Laurent/N-1623-2019	Desreumaux, Pierre F/0000-0002-6127-5281; Dubuquoy, laurent/0000-0003-3596-5497; Auwerx, Johan/0000-0002-5065-5393				Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; Auwerx J, 1999, CELL, V97, P161; Auwerx J, 2002, AM J PHYSIOL-GASTR L, V282, pG581, DOI 10.1152/ajpgi.00508.2001; Bedoucha M, 2001, J HEPATOL, V35, P17, DOI 10.1016/S0168-8278(01)00066-6; Bordji K, 2000, J BIOL CHEM, V275, P12243, DOI 10.1074/jbc.275.16.12243; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Caldwell SH, 2001, AM J GASTROENTEROL, V96, P519; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927; Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388; Clay CE, 2001, J BIOL CHEM, V276, P47131, DOI 10.1074/jbc.C100339200; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Cunard R, 2002, J IMMUNOL, V168, P2795, DOI 10.4049/jimmunol.168.6.2795; Day CP, 2002, GUT, V50, P585, DOI 10.1136/gut.50.5.585; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827; Desreumaux P, 1999, GASTROENTEROLOGY, V117, P73, DOI 10.1016/S0016-5085(99)70552-4; Dubois M, 2000, DIABETOLOGIA, V43, P1165, DOI 10.1007/s001250051508; Everett L, 2000, LIVER, V20, P191, DOI 10.1034/j.1600-0676.2000.020003191.x; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fajas L, 2001, J MOL ENDOCRINOL, V27, P1, DOI 10.1677/jme.0.0270001; FitzGerald GA, 2001, J CLIN INVEST, V107, P1335, DOI 10.1172/JCI13037; FLANIGAN A, 2001, GASTROENTEROLOGY S1, V120, pA753; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Fritsche J, 2000, BIOCHEM BIOPH RES CO, V270, P17, DOI 10.1006/bbrc.2000.2371; Fruchart JC, 2001, PHARMACOL RES, V44, P345, DOI 10.1006/phrs.2001.0871; Galli A, 2000, HEPATOLOGY, V31, P101, DOI 10.1002/hep.510310117; Galli A, 2001, J HEPATOL, V34, P92, DOI 10.1016/S0168-8278(01)81201-0; Greene M. E., 1995, Gene Expression, V4, P281; Hafraoui S, 1999, GASTROENTEROLOGY, V116, pA689; HAMAGUCHI M, 2001, GASTROENTEROLOGY S1, V120, pA162; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; Hsueh WA, 2001, ARTERIOSCL THROM VAS, V21, P1891, DOI 10.1161/hq1201.100261; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; Ji JD, 2001, J AUTOIMMUN, V17, P215, DOI 10.1006/jaut.2001.0542; Jia DM, 2001, GASTROENTEROLOGY, V120, pA207; JUNGLING E, 1988, ANAL BIOCHEM, V171, P150, DOI 10.1016/0003-2697(88)90136-4; KAMEI Y, 1993, BIOCHEM J, V293, P807, DOI 10.1042/bj2930807; KANE KF, 1995, GUT, V36, P255, DOI 10.1136/gut.36.2.255; Karlinger K, 2000, EUR J RADIOL, V35, P154, DOI 10.1016/S0720-048X(00)00238-2; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; Kitamura Y, 1999, BIOCHEM BIOPH RES CO, V254, P582, DOI 10.1006/bbrc.1998.9981; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Kohlroser J, 2000, AM J GASTROENTEROL, V95, P272; Landreth GE, 2001, NEUROBIOL AGING, V22, P937, DOI 10.1016/S0197-4580(01)00296-2; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Lewis JD, 2001, AM J GASTROENTEROL, V96, P3323; Long XL, 1999, J GERONTOL A-BIOL, V54, pB23, DOI 10.1093/gerona/54.1.B23; Lumpkin MM, 2000, PHARMACOL TOXICOL, V86, P20, DOI 10.1034/j.1600-0773.2000.d01-6.x; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Marra F, 1999, HEPATOLOGY, V29, P140, DOI 10.1002/hep.510290107; Marra F, 1998, AM J PATHOL, V152, P423; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; MASAMUNE A, 2001, GASTROENTEROLOGY S1, V120, pA511; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Nomura S, 2001, GASTROENTEROLOGY, V120, pA506, DOI 10.1016/S0016-5085(08)82513-9; Ohata M, 2000, EXP MOL PATHOL, V68, P13, DOI 10.1006/exmp.1999.2284; Pignatelli M, 2001, J CELL SCI, V114, P4117; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Schoonjans K, 2000, LANCET, V355, P1008, DOI 10.1016/S0140-6736(00)90002-3; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Shimizu K, 2000, PANCREAS, V21, P421, DOI 10.1097/00006676-200011000-00014; SHIMIZU K, 2001, GASTROENTEROLOGY S1, V120, pA123; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Subbarayan V, 2000, J CLIN INVEST, V105, P387, DOI 10.1172/JCI8150; TAKAGI T, 2001, GASTROENTEROLOGY S1, V120, pA609; Thacher SM, 2000, CURR PHARM DESIGN, V6, P25, DOI 10.2174/1381612003401415; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Toyoda M, 2002, GUT, V50, P563, DOI 10.1136/gut.50.4.563; Tsutsumi T, 2002, HEPATOLOGY, V35, P937, DOI 10.1053/jhep.2002.32470; Tugwood JD, 1996, ANN NY ACAD SCI, V804, P252, DOI 10.1111/j.1749-6632.1996.tb18620.x; Uchimura K, 2001, HEPATOLOGY, V33, P91, DOI 10.1053/jhep.2001.21145; Ulven SM, 1998, EUR J CELL BIOL, V77, P111, DOI 10.1016/S0171-9335(98)80078-2; Vanden Heuvel JP, 1999, TOXICOL SCI, V47, P1, DOI 10.1093/toxsci/47.1.1; VANDENHEUVEL JP, 1999, J NUTR, V129, P575; Walczak R, 2002, J LIPID RES, V43, P177; Wang JL, 1997, J NUTR, V127, P1297, DOI 10.1093/jn/127.7.1297; Wu GD, 2000, NEW ENGL J MED, V342, P651, DOI 10.1056/NEJM200003023420909; Wu KC, 2001, GASTROENTEROLOGY, V120, pA60; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966, DOI 10.1152/ajprenal.1999.277.6.F966; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	99	169	184	1	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 2	2002	360	9343					1410	1418		10.1016/S0140-6736(02)11395-X	http://dx.doi.org/10.1016/S0140-6736(02)11395-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12424006				2022-12-28	WOS:000179081600032
J	Lin, JM; Kilman, VL; Keegan, K; Paddock, B; Emery-Le, M; Rosbash, M; Allada, R				Lin, JM; Kilman, VL; Keegan, K; Paddock, B; Emery-Le, M; Rosbash, M; Allada, R			A role for casein kinase 2 alpha in the Drosophila circadian clock	NATURE			English	Article							NERVOUS-SYSTEM; DOUBLE-TIME; DNA-DAMAGE; PROTEIN; GENE; PERIOD; CK2; MELANOGASTER; RHYTHMS; NEUROPEPTIDE	Circadian clocks drive rhythmic behaviour in animals and are regulated by transcriptional feedback loops(1,2). For example, the Drosophila proteins Clock (Clk) and Cycle (Cyc) activate transcription of period (per) and timeless (tim). Per and Tim then associate, translocate to the nucleus, and repress the activity of Clk and Cyc. However, post-translational modifications are also critical to proper timing. Per and Timundergo rhythmic changes in phosphorylation(1), and evidence supports roles for two kinases in this process: Doubletime (Dbt) phosphorylates Per(3,4), whereas Shaggy (Sgg) phosphorylates Tim(5). Yet Sgg and Dbt often require a phosphoserine in their target site(6,7), and analysis of Per phosphorylation in dbt mutants(3,8) suggests a role for other kinases. Here we show that the catalytic subunit of Drosophila casein kinase 2 (CK2alpha) is expressed predominantly in the cytoplasm of key circadian pacemaker neurons. CK2alpha mutant flies show lengthened circadian period, decreased CK2 activity, and delayed nuclear entry of Per. These effects are probably direct, as CK2alpha specifically phosphorylates Per in vitro. We propose that CK2 is an evolutionary link between the divergent circadian systems of animals, plants and fungi.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Dept Pathol, Evanston, IL 60208 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA	Northwestern University; Northwestern University; Brandeis University; Howard Hughes Medical Institute	Allada, R (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, 2153 Sheridan Rd, Evanston, IL 60208 USA.							Allada R, 2001, ANNU REV NEUROSCI, V24, P1091, DOI 10.1146/annurev.neuro.24.1.1091; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Chen B, 1998, GENETICS, V149, P157; DAHMUS GK, 1984, J BIOL CHEM, V259, P9001; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; GOUELI BS, 1995, ANAL BIOCHEM, V225, P10, DOI 10.1006/abio.1995.1100; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; Harmer SL, 2001, ANNU REV CELL DEV BI, V17, P215, DOI 10.1146/annurev.cellbio.17.1.215; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; Kaneko M, 1997, J NEUROSCI, V17, P6745; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Park JH, 1998, J BIOL RHYTHM, V13, P219, DOI 10.1177/074873098129000066; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; RENN SC, 2000, CELL, V101, P113; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; Sugano S, 1999, P NATL ACAD SCI USA, V96, P12362, DOI 10.1073/pnas.96.22.12362; Sugano S, 1998, P NATL ACAD SCI USA, V95, P11020, DOI 10.1073/pnas.95.18.11020; Suri V, 2000, J NEUROSCI, V20, P7547; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Yang YH, 2002, GENE DEV, V16, P994, DOI 10.1101/gad.965102; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	29	293	300	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 26	2002	420	6917					816	820		10.1038/nature01235	http://dx.doi.org/10.1038/nature01235			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	626WR	12447397				2022-12-28	WOS:000179897300057
J	Walkden, G; Parker, J; Kelley, S				Walkden, G; Parker, J; Kelley, S			A late Triassic impact ejecta layer in southwestern Britain	SCIENCE			English	Article							TEKTITES; MICROTEKTITES; EXTINCTION; HAITI	Despite the 160 or so known terrestrial impact craters of Phanerozoic age, equivalent ejecta deposits within distal sedimentary successions are rare. We report a Triassic deposit in southwestern Britain that contains spherules and shocked quartz, characteristic of an impact ejecta layer. Inter- and intragranular potassium feldspar from the deposit yields an argon-argon age of 214 +/- 2.5 million years old. This is within the age range of several known Triassic impact craters, the two closest of which, both in age and location, are Manicouagan in northeastern Canada and Rochechouart in central France. The ejecta deposit provides an important sedimentary record of an extraterrestrial impact in the Mesozoic that will help to decipher the number and effect of impact events, the source and dynamics of the event that left this distinctive sedimentary marker, and the relation of this ejecta layer to the timing of extinctions in the fossil record.	Univ Aberdeen, Dept Geol & Petr Geol, Kings Coll, Aberdeen AB24 3UD, Scotland; Open Univ, Dept Earth Sci, Milton Keynes MK7 6AA, Bucks, England	University of Aberdeen; Open University - UK	Walkden, G (corresponding author), Univ Aberdeen, Dept Geol & Petr Geol, Kings Coll, Aberdeen AB24 3UD, Scotland.	spherules@abdn.ac.uk	Kelley, Simon/AAR-7075-2020	Kelley, Simon/0000-0002-1756-0480				Alvarez W., 1996, CRETACEOUS TERTIARY, P141; BENTON MJ, 1994, IN THE SHADOW OF THE DINOSAURS, P366; BICE DM, 1992, SCIENCE, V255, P443, DOI 10.1126/science.255.5043.443; BOHOR BF, 1995, METEORITICS, V30, P182, DOI 10.1111/j.1945-5100.1995.tb01113.x; BOHOR BF, 1990, LUNAR PLANET SCI, V23, P135; BOSTWICK JA, 1996, CRETACEOUS TERTIARY, P403; Engelhardt W. V., 1969, CONTRIB MINERAL PETR, V20, P203, DOI DOI 10.1007/BF00377477; Glass BP, 1997, METEORIT PLANET SCI, V32, P333, DOI 10.1111/j.1945-5100.1997.tb01276.x; GLASS BP, 1990, TECTONOPHYSICS, V171, P393, DOI 10.1016/0040-1951(90)90112-L; Grieve RAF, 1996, METEORIT PLANET SCI, V31, P6, DOI 10.1111/j.1945-5100.1996.tb02049.x; HODYCH JP, 1992, GEOLOGY, V20, P51, DOI 10.1130/0091-7613(1992)020<0051:DTMITE>2.3.CO;2; HOUNSLOW MW, INT GEOL CORR PROGR; IZETT GA, 1991, J GEOPHYS RES-PLANET, V96, P20879, DOI 10.1029/91JE02249; KELLEY SP, 1997, METEORITICS, V32, P171; Koeberl C., 1994, LARGE METEORITE IMPA, p133?152; KOEBERL C, 2001, LUNAR PLANET I CONTR, V1083; Lorenz RD, 2000, ICARUS, V144, P353, DOI 10.1006/icar.1999.6303; MCGETCHIN TR, 1973, EARTH PLANET SC LETT, V20, P226, DOI [10.1016/0012-821X(73)90162-3, 10.1016/0012-821X(74)90115-0]; Olsen PE, 2002, SCIENCE, V296, P1305, DOI 10.1126/science.1065522; OLSEN PE, 1999, INT WORKSH CLIM BIOT, V1; Palfy J, 2000, GEOLOGY, V28, P39, DOI 10.1130/0091-7613(2000)28<39:TTEMEF>2.0.CO;2; Spray JG, 1998, NATURE, V392, P171, DOI 10.1038/32397; STOFFLER D, 1975, J GEOPHYS RES, V80, P4062, DOI 10.1029/JB080i029p04062; WALKER TR, 1978, GEOL SOC AM BULL, V89, P353	24	62	64	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	2002	298	5601					2185	2188		10.1126/science.1076249	http://dx.doi.org/10.1126/science.1076249			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	624RA	12434010				2022-12-28	WOS:000179773700046
J	Sundar, S; Jha, TK; Thakur, CP; Engel, J; Sindermann, H; Fischer, C; Junge, K; Bryceson, A; Berman, J				Sundar, S; Jha, TK; Thakur, CP; Engel, J; Sindermann, H; Fischer, C; Junge, K; Bryceson, A; Berman, J			Oral miltefosine for Indian visceral leishmaniasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMPHOTERICIN-B; KALA-AZAR; TRIAL; DONOVANI	Background: There are 500,000 cases per year of visceral leishmaniasis, which occurs primarily in the Indian subcontinent. Almost all untreated patients die, and all the effective agents have been parenteral. Miltefosine is an oral agent that has been shown in small numbers of patients to have a favorable therapeutic index for Indian visceral leishmaniasis. We performed a clinical trial in India comparing miltefosine with the most effective standard treatment, amphotericin B. Methods: The study was a randomized, open-label comparison, in which 299 patients 12 years of age or older received orally administered miltefosine (50 or 100 mg [approximately 2.5 mg per kilogram of body weight] daily for 28 days) and 99 patients received intravenously administered amphotericin B (1 mg per kilogram every other day for a total of 15 injections). Results: The groups were well matched in terms of age, weight, proportion with previous failure of treatment for leishmaniasis, parasitologic grade of splenic aspirate, and splenomegaly. At the end of treatment, splenic aspirates were obtained from 293 patients in the miltefosine group and 98 patients in the amphotericin B group. No parasites were identified, for an initial cure rate of 100 percent. By six months after the completion of treatment, 282 of the 299 patients in the miltefosine group (94 percent [95 percent confidence interval, 91 to 97]) and 96 of the 99 patients in the amphotericin B group (97 percent) had not had a relapse; these patients were classified as cured. Vomiting and diarrhea, generally lasting one to two days, occurred in 38 percent and 20 percent of the patients in the miltefosine group, respectively. Conclusions: Oral miltefosine is an effective and safe treatment for Indian visceral leishmaniasis. Miltefosine may be particularly advantageous because it can be administered orally. It may also be helpful in regions where parasites are resistant to current agents.	Kala Azar Res Ctr, Brahmpura, Muzaffarpur, India; Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; Balaji Utthan Sanastan, Patna, Bihar, India; Zentaris Asta Med, Frankfurt, Germany; London Sch Hyg & Trop Med, London WC1, England; Walter Reed Army Inst Res, Silver Spring, MD USA	Banaras Hindu University (BHU); University of London; London School of Hygiene & Tropical Medicine; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Berman, J (corresponding author), Natl Ctr Complementary & Alternat Med, 6707 Democracy Blvd,Ste 401, Bethesda, MD 20892 USA.							Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; Bryceson A, 2001, TROP MED INT HEALTH, V6, P928, DOI 10.1046/j.1365-3156.2001.00795.x; *CANC THER EV PROG, 2002, COMM TOX CRIT; CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475; CROFT SL, 1987, BIOCHEM PHARMACOL, V36, P2633, DOI 10.1016/0006-2952(87)90543-0; *CTR DRUG EV RES, 1996, GUID IND E6 GOOD CLI; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Jha S N, 1991, J Assoc Physicians India, V39, P314; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; Jha TK, 1998, BRIT MED J, V316, P1200, DOI 10.1136/bmj.316.7139.1200; KUHLENCORD A, 1992, ANTIMICROB AGENTS CH, V36, P1630, DOI 10.1128/AAC.36.8.1630; Lux H, 2000, MOL BIOCHEM PARASIT, V111, P1, DOI 10.1016/S0166-6851(00)00278-4; Sundar S, 1999, ANN TROP MED PARASIT, V93, P589, DOI 10.1080/00034989958096; Sundar S, 1998, LANCET, V352, P1821, DOI 10.1016/S0140-6736(98)04367-0; Sundar S, 2000, CLIN INFECT DIS, V31, P1110, DOI 10.1086/318122; Sundar S, 2001, BRIT MED J, V323, P419, DOI 10.1136/bmj.323.7310.419; THAKUR CP, 1994, B WORLD HEALTH ORGAN, V72, P931; THAKUR CP, 1991, AM J TROP MED HYG, V45, P435, DOI 10.4269/ajtmh.1991.45.435	20	528	540	0	18	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1739	1746		10.1056/NEJMoa021556	http://dx.doi.org/10.1056/NEJMoa021556			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456849	Green Accepted			2022-12-28	WOS:000179468600003
J	Hartman, EE; Delbanco, T				Hartman, EE; Delbanco, T			A 44-year-old woman with difficulty walking, 2 years later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2002	288	20					2598	2598		10.1001/jama.288.20.2598	http://dx.doi.org/10.1001/jama.288.20.2598			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AL	12444867				2022-12-28	WOS:000179394500027
J	Paradise, JL				Paradise, JL			A 15-month-old child with recurrent otitis media	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MIDDLE-EAR EFFUSION; RESISTANT STREPTOCOCCUS-PNEUMONIAE; PNEUMOCOCCAL CONJUGATE VACCINE; RESPIRATORY SYNCYTIAL VIRUS; TYMPANOSTOMY-TUBE PLACEMENT; PENICILLIN-RESISTANT; RISK-FACTORS; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-TREATMENT; LANGUAGE-DEVELOPMENT		Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Paradise, JL (corresponding author), Childrens Hosp Pittsburgh, 3705 5th Ave, Pittsburgh, PA 15213 USA.	jpar@pitt.edu						ABRAMSON JS, 1994, PEDIATR INFECT DIS J, V13, P643, DOI 10.1097/00006454-199407000-00012; Ah-Tye C, 2001, PEDIATRICS, V107, P1251, DOI 10.1542/peds.107.6.1251; BARNETT ED, 1995, PEDIATR CLIN N AM, V42, P509; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; BERMAN S, 1992, J PEDIATR-US, V121, P249, DOI 10.1016/S0022-3476(05)81197-7; BERMAN S, 1992, PEDIATR INFECT DIS J, V11, P63, DOI 10.1097/00006454-199202000-00001; BESS FH, 1994, PEDIATRICS, V94, P959; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Block SL, 1998, PEDIATR INFECT DIS J, V17, P560, DOI 10.1097/00006454-199806000-00036; BLUESTONE CD, 1992, PEDIATR INFECT DIS J, V11, pS7, DOI 10.1097/00006454-199208001-00002; BLUESTONE CD, 1996, PEDIAT OTOLARYNGOLOG, V1, P388; BLUESTONE CD, 1977, CHOLESTEATOMA, P325; BLUESTONE CD, 1996, PEDIAT OTOLARYNGOLOG, V1, P495; BOKEN DJ, 1995, PEDIATR INFECT DIS J, V14, P879, DOI 10.1097/00006454-199510000-00012; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BROWNLEE RC, 1969, J PEDIATR, V75, P636, DOI 10.1016/S0022-3476(69)80460-9; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; Capra AM, 2000, PEDIATR INFECT DIS J, V19, P354, DOI 10.1097/00006454-200004000-00019; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; Casselbrant ML, 1999, JAMA-J AM MED ASSOC, V282, P2125, DOI 10.1001/jama.282.22.2125; Chonmaitree T, 2000, PEDIATR INFECT DIS J, V19, pS24, DOI 10.1097/00006454-200005001-00005; Ciftci E, 2001, PEDIATR INT, V43, P385, DOI 10.1046/j.1442-200X.2001.01422.x; CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009; COFFEY JD, 1966, PEDIATRICS, V38, P25; Cohen R, 2000, PEDIATR INFECT DIS J, V19, P458, DOI 10.1097/00006454-200005000-00013; CUNNINGHAM AS, 1994, CONT PEDIATR, V11, P17; CUNNINGHAMRUNDL.C, 1996, IMMUNOLOGIC DISORDER, P423; Damoiseaux RAMJ, 2000, BRIT MED J, V320, P350, DOI 10.1136/bmj.320.7231.350; Doern GV, 2001, ANTIMICROB AGENTS CH, V45, P1721, DOI 10.1128/AAC.45.6.1721-1729.2001; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P1, DOI 10.1097/00006454-199901000-00002; Dowell SF, 1998, PEDIATRICS, V101, P165; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; Faden H, 1998, PEDIATR INFECT DIS J, V17, P1105, DOI 10.1097/00006454-199812000-00002; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P208; Ghaffar FA, 2001, PEDIATR INFECT DIS J, V20, P376, DOI 10.1097/00006454-200104000-00003; Gok U, 2001, INT J PEDIATR OTORHI, V60, P49, DOI 10.1016/S0165-5876(01)00510-9; Hagan JF, 2001, PEDIATRICS, V108, P793; HEIKKINEN T, 1995, J PEDIATR-US, V126, P313, DOI 10.1016/S0022-3476(95)70569-4; Heikkinen T, 1999, NEW ENGL J MED, V340, P260, DOI 10.1056/NEJM199901283400402; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; Hoberman A, 1997, PEDIATR INFECT DIS J, V16, pS25, DOI 10.1097/00006454-199702001-00007; Hoberman A, 2000, PEDIATR ANN, V29, P609, DOI 10.3928/0090-4481-20001001-06; HOWIE VM, 1975, AM J DIS CHILD, V129, P679, DOI 10.1001/archpedi.1975.02120430016006; Joloba ML, 2001, CLIN INFECT DIS, V33, P1489, DOI 10.1086/323027; JORGENSEN F, 1990, PEDIATR INFECT DIS J, V9, P389; KALEIDA PH, 1991, PEDIATRICS, V87, P466; KAPLAN SL, 1995, PEDIATR RES, V37, pA179; Kay DJ, 2001, OTOLARYNG HEAD NECK, V124, P374, DOI 10.1067/mhn.2001.113941; Kilpi T, 2001, PEDIATR INFECT DIS J, V20, P654, DOI 10.1097/00006454-200107000-00004; Klein JO, 2000, PEDIATR INFECT DIS J, V19, P181, DOI 10.1097/00006454-200003000-00001; Kyaw MH, 2002, EPIDEMIOL INFECT, V128, P21, DOI 10.1017/S0950268801006331; Lahikainen E, 1953, ACTA OTO-LARYNGOL, V107, P1; Lanphear BP, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.3.e1; LEGGIADRO RJ, 1994, PEDIATRICS, V93, P500; Leibovitz E, 2000, PEDIATR INFECT DIS J, V19, P1040, DOI 10.1097/00006454-200011000-00003; LILDHOLDT T, 1983, ACTA OTO-LARYNGOL, P1; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MANDEL EM, 1992, PEDIATR INFECT DIS J, V11, P270, DOI 10.1097/00006454-199204000-00003; MANDEL EM, 1989, ARCH OTOLARYNGOL, V115, P1217; MARCHANT CD, 1984, J PEDIATR-US, V104, P826, DOI 10.1016/S0022-3476(84)80475-8; Marchisio P, 2002, CLIN INFECT DIS, V35, P168, DOI 10.1086/341028; Maw R, 1999, LANCET, V353, P960, DOI 10.1016/S0140-6736(98)05295-7; MORTIMER EA, 1956, PEDIATRICS, V17, P359; PANKUCH GA, 1995, ANTIMICROB AGENTS CH, V39, P1499, DOI 10.1128/AAC.39.7.1499; PAPARELLA MM, 1972, ANN OTO RHINOL LARYN, V81, P632, DOI 10.1177/000348947208100503; Paradise J L, 1992, Adv Pediatr, V39, P157; Paradise Jack L., 1993, Pediatric Research, V33, p121A; PARADISE JL, 1994, PEDIATRICS, V94, P853; PARADISE JL, 1987, J PEDIATR-US, V111, P948, DOI 10.1016/S0022-3476(87)80226-3; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; PARADISE JL, 1976, PEDIATRICS, V58, P198; PARADISE JL, 1969, PEDIATRICS, V44, P35; PARADISE JL, 1995, PEDIATRICS, V96, P712; PARADISE JL, 1980, PEDIATRICS, V65, P917; PARADISE JL, 1977, PEDIATRICS, V60, P86; Paradise JL, 2001, NEW ENGL J MED, V344, P1179, DOI 10.1056/NEJM200104193441601; PARADISE JL, 1982, NEW ENGL J MED, V307, P1074, DOI 10.1056/NEJM198210213071709; PARADISE JL, 1990, JAMA-J AM MED ASSOC, V263, P2066, DOI 10.1001/jama.263.15.2066; Paradise JL, 1997, JAMA-J AM MED ASSOC, V278, P1640, DOI 10.1001/jama.278.20.1640; PARADISE JL, 1994, ARCH PEDIAT ADOLESC, V148, pP31; Pichichero ME, 2001, OTOLARYNG HEAD NECK, V124, P381, DOI 10.1067/mhn.2001.114311; Pichichero ME, 2001, ARCH PEDIAT ADOL MED, V155, P1137, DOI 10.1001/archpedi.155.10.1137; Pitkaranta A, 1998, J PEDIATR-US, V133, P390, DOI 10.1016/S0022-3476(98)70276-8; Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; PRELLNER K, 1994, ACTA OTO-LARYNGOL, V114, P182, DOI 10.3109/00016489409126039; QVARNBERG Y, 1990, OTOLARYNG HEAD NECK, V102, P118, DOI 10.1177/019459989010200204; Rayner MG, 1998, JAMA-J AM MED ASSOC, V279, P296, DOI 10.1001/jama.279.4.296; Reinert RR, 2002, J ANTIMICROB CHEMOTH, V49, P61, DOI 10.1093/jac/49.1.61; RIDING KH, 1978, J PEDIATR-US, V93, P739, DOI 10.1016/S0022-3476(78)81069-5; ROSENFELD RM, 1992, OTOLARYNG HEAD NECK, V106, P378, DOI 10.1177/019459989210600411; Ross GH, 2001, ANTIMICROB AGENTS CH, V45, P2936, DOI 10.1128/AAC.45.10.2936-2938.2001; Rovers MM, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e42; SADE J, 1982, CHOLESTEATOMA MASTOI, P267; SCHWARTZ DM, 1978, ARCH OTOLARYNGOL, V104, P652; SEDERBERGOLSEN JF, 1989, ACTA OTO-LARYNGOL, V108, P448, DOI 10.3109/00016488909125552; SHURIN PA, 1979, NEW ENGL J MED, V300, P1121, DOI 10.1056/NEJM197905173002001; SHURIN PA, 1993, J PEDIATR-US, V123, P801, DOI 10.1016/S0022-3476(05)80865-0; SIMOES EA, 1996, J PEDIAT, V129, P193; SIPILA M, 1988, ACTA OTO-LARYNGOL, V106, P94, DOI 10.3109/00016488809107375; Steele RW, 2001, PEDIATR INFECT DIS J, V20, P1, DOI 10.1097/00006454-200101000-00001; STOOL SE, 1994, AHCPR PUBLICATION; Takata GS, 2001, PEDIATRICS, V108, P239, DOI 10.1542/peds.108.2.239; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; TOS M, 1976, ARCH OTOLARYNGOL, V102, P672, DOI 10.1001/archotol.1976.00780160068006; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; Vesa S, 2001, PEDIATR INFECT DIS J, V20, P574, DOI 10.1097/00006454-200106000-00006; Vogler RC, 2000, CLIN OTOLARYNGOL, V25, P392, DOI 10.1046/j.1365-2273.2000.00381.x; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344; Zola H, 1997, IMMUNOL CELL BIOL, V75, P587, DOI 10.1038/icb.1997.92	110	9	11	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2002	288	20					2589	2598		10.1001/jama.288.20.2589	http://dx.doi.org/10.1001/jama.288.20.2589			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AL	12444866				2022-12-28	WOS:000179394500026
J	Bass, RB; Strop, P; Barclay, M; Rees, DC				Bass, RB; Strop, P; Barclay, M; Rees, DC			Crystal structure of Escherichia coli MscS, a voltage-modulated and mechanosensitive channel	SCIENCE			English	Article							POTASSIUM CHANNEL; ION-CHANNEL; CYTOPLASMIC MEMBRANE; ACTIVATED CHANNELS; GATING MECHANISM; PATCH-CLAMP; PROTEIN; MOVEMENT; SENSOR; TRANSDUCTION	The mechanosensitive channel of small conductance (MscS) responds both to stretching of the cell membrane and to membrane depolarization. The crystal structure at 3.9 angstroms resolution demonstrates that Escherichia coli MscS folds as a membrane-spanning heptamer with a large cytoplasmic region. Each subunit contains three transmembrane helices (TM1, -2, and -3), with the TM3 helices lining the pore, while TM1 and TM2, with membrane-embedded arginines, are likely candidates for the tension and voltage sensors. The transmembrane pore, apparently captured in an open state, connects to a large chamber, formed within the cytoplasmic region, that connects to the cytoplasm through openings that may function as molecular filters. Although MscS is likely to be structurally distinct from other ion channels, similarities in gating mechanisms suggest common structural elements.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Rees, DC (corresponding author), CALTECH, Div Chem & Chem Engn, Mail Code 114-96, Pasadena, CA 91125 USA.	dcrees@caltech.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantor RS, 1997, J PHYS CHEM B, V101, P1723, DOI 10.1021/jp963911x; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; CUI C, 1995, J MEMBRANE BIOL, V144, P31; Cui C, 1996, J MEMBRANE BIOL, V150, P143, DOI 10.1007/s002329900039; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOWARD J, 1988, ANNU REV BIOPHYS BIO, V17, P99; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kloda Anna, 2002, Archaea, V1, P35, DOI 10.1155/2002/419261; Kong YF, 2002, P NATL ACAD SCI USA, V99, P5999, DOI 10.1073/pnas.092051099; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; McLaggan D, 2002, MOL MICROBIOL, V43, P521, DOI 10.1046/j.1365-2958.2002.02764.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Okada K, 2002, J BIOL CHEM, V277, P27682, DOI 10.1074/jbc.M202497200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Perozo E, 2001, J GEN PHYSIOL, V118, P193, DOI 10.1085/jgp.118.2.193; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Rees DC, 2000, J BIOL CHEM, V275, P713, DOI 10.1074/jbc.275.2.713; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; SHAPOVALOV G, UNPUB; Smart OS, 1997, BIOPHYS J, V72, P1109, DOI 10.1016/S0006-3495(97)78760-5; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Spencer RH, 2002, ANNU REV BIOPH BIOM, V31, P207, DOI 10.1146/annurev.biophys.31.082901.134329; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; STROP P, IN PRESS ADV PROT CH, V63; Sukharev S, 2002, BIOPHYS J, V83, P290, DOI 10.1016/S0006-3495(02)75169-2; Sukharev S, 2001, BIOPHYS J, V81, P917, DOI 10.1016/S0006-3495(01)75751-7; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	55	479	503	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1582	1587		10.1126/science.1077945	http://dx.doi.org/10.1126/science.1077945			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446901				2022-12-28	WOS:000179361600039
J	Johnston, SC				Johnston, SC			Transient ischemic attack	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE PROFESSIONALS; SHORT-TERM PROGNOSIS; AD-HOC-COMMITTEE; STROKE-COUNCIL; CAROTID-ENDARTERECTOMY; ATRIAL-FIBRILLATION; GUIDELINES; ASPIRIN; TRIAL; RISK		Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Johnston, SC (corresponding author), Univ Calif San Francisco, Dept Neurol, Box 0114,505 Parnassus Ave,M-798, San Francisco, CA 94143 USA.	clay.johnston@ucsfmedctr.org			NINDS NIH HHS [NS 02254] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers GW, 1999, STROKE, V30, P2502, DOI 10.1161/01.STR.30.11.2502; Albers GW, 2002, NEW ENGL J MED, V347, P1713, DOI 10.1056/NEJMsb020987; [Anonymous], 1998, JAMA, V279, P1265; Antithrombotic Trialists' Collaboration, 2002, BMJ-BRIT MED J, V324, P141, DOI DOI 10.1136/BMJ.324.7330.141; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bamford J, 2001, J NEUROL NEUROSUR PS, V70, pI3, DOI 10.1136/jnnp.70.suppl_1.i3; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Benavente O, 2001, NEW ENGL J MED, V345, P1084, DOI 10.1056/NEJMoa002994; Berge E, 2000, LANCET, V355, P1205, DOI 10.1016/S0140-6736(00)02085-7; Biller J, 1998, CIRCULATION, V97, P501; Bots ML, 1997, STROKE, V28, P768, DOI 10.1161/01.STR.28.4.768; BROTT TG, 2000, STROKE 1 HOURSE GUID; BRUST JCM, 1977, NEUROLOGY, V27, P701, DOI 10.1212/WNL.27.8.701; Byington RP, 2001, CIRCULATION, V103, P387; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; Culebras A, 1997, STROKE, V28, P1480, DOI 10.1161/01.STR.28.7.1480; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Ezekowitz MD, 1999, JAMA-J AM MED ASSOC, V281, P1830, DOI 10.1001/jama.281.19.1830; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FEINBERG WM, 1994, CIRCULATION, V89, P2950, DOI 10.1161/01.CIR.89.6.2950; FRATIGLIONI L, 1989, NEUROEPIDEMIOLOGY, V8, P87, DOI 10.1159/000110170; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Grotta JC, 2001, STROKE, V32, P661, DOI 10.1161/01.STR.32.3.661; GUBITZ G, 2000, COCHRANE DB SYST REV, V2; Gueyffier F, 1997, STROKE, V28, P2557, DOI 10.1161/01.STR.28.12.2557; Hankey G., 2000, COCHRANE DB SYST REV, V2, DOI [DOI 10.1002/14651858.CD001246, 10.1002/14651858.CD001246]; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Johnston SC, 1999, EUR NEUROL, V42, P105, DOI 10.1159/000069419; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; Kennedy J, 2002, STROKE, V33, P382; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; KOUDSTAAL PJ, 1989, STROKE, V20, P300, DOI 10.1161/01.STR.20.2.300; KRAAIJEVELD CL, 1984, STROKE, V15, P723, DOI 10.1161/01.STR.15.4.723; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mead GE, 1997, EUR J VASC ENDOVASC, V13, P112, DOI 10.1016/S1078-5884(97)80005-6; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; *NAT RES COUNC, 2000, TOX EFF METH, P55; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; PROGRESS Collaborative Grp, 2002, LANCET, V359, P2120; Rubins HB, 2001, CIRCULATION, V103, P2828; Sacco RL, 2001, NEW ENGL J MED, V345, P1113, DOI 10.1056/NEJMcp011227; Samsa GP, 1998, AM HEART J, V136, P703, DOI 10.1016/S0002-8703(98)70019-5; Saxena R, 2001, STROKE, V32, P2333, DOI 10.1161/hs1001.097093; STREIFLER JY, 1995, ARCH NEUROL-CHICAGO, V52, P246, DOI 10.1001/archneur.1995.00540270034016; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WAXMAN SG, 1983, STROKE, V14, P433, DOI 10.1161/01.STR.14.3.433; WHISNANT JP, 1973, MAYO CLIN PROC, V48, P194; Wolf PA, 1999, STROKE, V30, P1991, DOI 10.1161/01.STR.30.9.1991; Yusuf S, 2000, NEW ENGL J MED, V342, P145	55	126	138	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1687	1692		10.1056/NEJMcp020891	http://dx.doi.org/10.1056/NEJMcp020891			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444184				2022-12-28	WOS:000179339900008
J	Nikolaides, MG; Bausch, AR; Hsu, MF; Dinsmore, AD; Brenner, MP; Weitz, DA; Gay, C				Nikolaides, MG; Bausch, AR; Hsu, MF; Dinsmore, AD; Brenner, MP; Weitz, DA; Gay, C			Electric-field-induced capillary attraction between like-charged particles at liquid interfaces	NATURE			English	Article							COLLOIDAL SPHERES; FORCES; MENISCUS; FILMS; WATER	Nanometre- and micrometre-sized charged particles at aqueous interfaces are typically stabilized by a repulsive Coulomb interaction. If one of the phases forming the interface is a nonpolar substance ( such as air or oil) that cannot sustain a charge, the particles will exhibit long-ranged dipolar repulsion(1); if the interface area is confined, mutual repulsion between the particles can induce ordering(2) and even crystallization(3,4). However, particle ordering has also been observed in the absence of area confinement(5), suggesting that like-charged particles at interfaces can also experience attractive interactions(6). Interface deformations are known to cause capillary forces that attract neighbouring particles to each other, but a satisfying explanation for the origin of such distortions remains outstanding(7,8). Here we present quantitative measurements of attractive interactions between colloidal particles at an oil - water interface and show that the attraction can be explained by capillary forces that arise from a distortion of the interface shape that is due to electrostatic stresses caused by the particles' dipolar field. This explanation, which is consistent with all reports on interfacial particle ordering so far, also suggests that the attractive interactions might be controllable: by tuning the polarity of one of the interfacial fluids, it should be possible to adjust the electrostaticstresses of the system and hence the interparticle attractions.	Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; CNRS, Ctr Rech Paul Pascal, F-33600 Pessac, France; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University; Centre de Recherche Paul Pascal; Centre National de la Recherche Scientifique (CNRS); Harvard University	Weitz, DA (corresponding author), Tech Univ Munich, Lehrstuhl Biophys E22, D-8000 Munich, Germany.	weitz@deas.harvard.edu		Gay, Cyprien/0000-0002-2691-2601				Aveyard R, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.246102; BERGE B, 1993, CR ACAD SCI II, V317, P157; Bowden N, 1997, SCIENCE, V276, P233, DOI 10.1126/science.276.5310.233; CHAN DYC, 1981, J COLLOID INTERF SCI, V79, P410, DOI 10.1016/0021-9797(81)90092-8; Crocker JC, 1996, J COLLOID INTERF SCI, V179, P298, DOI 10.1006/jcis.1996.0217; DENKOV ND, 1993, NATURE, V361, P26, DOI 10.1038/361026a0; Golestanian R, 1996, PHYS REV E, V54, P6725, DOI 10.1103/PhysRevE.54.6725; GOULIAN M, 1993, EUROPHYS LETT, V22, P145, DOI 10.1209/0295-5075/22/2/012; HURD AJ, 1985, J PHYS A-MATH GEN, V18, P1055; KRALCHEVSKY PA, 1992, J COLLOID INTERF SCI, V151, P79, DOI 10.1016/0021-9797(92)90239-I; Kralchevsky PA, 2000, ADV COLLOID INTERFAC, V85, P145, DOI 10.1016/S0001-8686(99)00016-0; Kralchevsky PA, 2001, CURR OPIN COLLOID IN, V6, P383, DOI 10.1016/S1359-0294(01)00105-4; LANDAU LD, 1964, ELECTRODYNAMICS CONT; MORSE DC, 1993, EUROPHYS LETT, V22, P549, DOI 10.1209/0295-5075/22/7/012; ONADA GY, 1985, PHYS REV LETT, V55, P226; PIERANSKI P, 1980, PHYS REV LETT, V45, P569, DOI 10.1103/PhysRevLett.45.569; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; Quesada-Perez M, 2001, J CHEM PHYS, V115, P10897, DOI 10.1063/1.1421104; Ruiz-Garcia J, 1998, PHYS REV E, V58, P660, DOI 10.1103/PhysRevE.58.660; RUSSEL WB, 1989, COLLOIDAL DISPERSION; Stamou D, 2000, PHYS REV E, V62, P5263, DOI 10.1103/PhysRevE.62.5263; Wickman HH, 1998, NATURE, V393, P445, DOI 10.1038/30930	22	274	282	2	186	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					299	301		10.1038/nature01113	http://dx.doi.org/10.1038/nature01113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447435				2022-12-28	WOS:000179340400037
J	Bodenheimer, T; Lorig, K; Holman, H; Grumbach, K				Bodenheimer, T; Lorig, K; Holman, H; Grumbach, K			Patient self-management of chronic disease in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; HEALTH-STATUS; RHEUMATOID-ARTHRITIS; EDUCATION-PROGRAM; OLDER-ADULTS; OSTEOARTHRITIS; ADHERENCE; PEOPLE; PARTNERSHIP	Patients with chronic conditions make day-to-day, decisions about-self-manage-their illnesses. This reality introduces a new chronic disease paradigm: the patient-professional partnership, involving collaborative care and self-management education. Self-management education complements traditional patient education in supporting patients to live the best possible quality of life with their chronic condition. Whereas traditional patient education offers information and technical skills, self-management education teaches problem-solving skills. A central concept in self-management is self-efficacy-confidence to carry out a behavior necessary to reach a desired goal. Self-efficacy is enhanced when patients succeed in solving patient-identified problems. Evidence from controlled clinical trials suggests that (1) programs teaching self-management skills are more effective than information-only patient education in improving clinical outcomes; (2) in some circumstances, self-management education improves outcomes and can reduce costs for arthritis and probably for adult asthma patients; and (3) in initial studies, a self-management education program bringing together patients with a variety of chronic conditions may improve outcomes and reduce costs. Self-management education for chronic illness may soon become an integral part of high-quality primary care.	Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Stanford Univ, Dept Med, Palo Alto, CA 94304 USA	University of California System; University of California San Francisco; Stanford University	Bodenheimer, T (corresponding author), San Francisco Gen Hosp, Ward 83,1001 Potrero Ave, San Francisco, CA 94110 USA.	tbodie@earthlink.net	Young, Alexander/A-1523-2009; Grumbach, Kevin/L-9222-2016	Young, Alexander/0000-0002-9367-9213; 				Anderson RM, 2000, DIABETES EDUCATOR, V26, P597, DOI 10.1177/014572170002600405; ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943; ANDERSON RM, 1996, PRACTICAL PSYCHOL DI; ARNOLD MS, 1995, DIABETES EDUCATOR, V21, P308, DOI 10.1177/014572179502100408; Bailey WC, 1999, ARCH INTERN MED, V159, P2422, DOI 10.1001/archinte.159.20.2422; Bandura A., 1997, SELF EFFICACY EXERCI, P36, DOI 10.1007/SpringerReference_223312; Barlow JH, 1996, PATIENT EDUC COUNS, V27, P257, DOI 10.1016/0738-3991(95)00844-6; Barlow JH, 2000, HEALTH EDUC RES, V15, P665, DOI 10.1093/her/15.6.665; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Brus H, 1999, PATIENT EDUC COUNS, V36, P57, DOI 10.1016/S0738-3991(98)00087-1; CLEMENT S, 1995, DIABETES CARE, V18, P1204, DOI 10.2337/diacare.18.8.1204; Corbin J. M., 1988, UNENDING WORK CARE M; Cote J, 2000, Can Respir J, V7, P395; D'Zurilla T. J, 1986, PROBLEM SOLVING THER; *DEP HLTH, 2002, HLTH IN WEB SIT; Edworthy SM, 1999, J RHEUMATOL, V26, P1793; Elasy TA, 2001, PATIENT EDUC COUNS, V43, P121, DOI 10.1016/S0738-3991(00)00150-6; Fries JF, 1997, J RHEUMATOL, V24, P1378; Funnell M M, 1991, Diabetes Educ, V17, P37, DOI 10.1177/014572179101700108; Funnell MM, 2000, JAMA-J AM MED ASSOC, V284, P1709, DOI 10.1001/jama.284.13.1709; Gallefoss F, 1999, AM J RESP CRIT CARE, V159, P812, DOI 10.1164/ajrccm.159.3.9804047; GIBSON PG, 2001, LTD INFORMATION ONLY; GIBSON PG, 2001, SELF MANAGEMENT ED R; Glasgow RE, 1999, DIABETES CARE, V22, P2090, DOI 10.2337/diacare.22.12.2090; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Glasgow RE, 1997, PATIENT EDUC COUNS, V32, P175, DOI 10.1016/S0738-3991(97)00039-6; Glasgow RE, 1996, DIABETES EDUCATOR, V22, P573, DOI 10.1177/014572179602200605; Gotler RS, 2000, MED CARE, V38, P1200, DOI 10.1097/00005650-200012000-00007; Groessl EJ, 2000, AM J COMMUN PSYCHOL, V28, P455, DOI 10.1023/A:1005184414241; Hammond A, 2001, RHEUMATOLOGY, V40, P1044, DOI 10.1093/rheumatology/40.9.1044; Helliwell PS, 1999, RHEUMATOLOGY, V38, P303, DOI 10.1093/rheumatology/38.4.303; Holman H, 2000, BRIT MED J, V320, P526, DOI 10.1136/bmj.320.7234.526; Hopman-Rock M, 2000, J RHEUMATOL, V27, P1947; *I FUT, 2000, HLTH HLTH CAR 2010; Kauppinen R, 2001, RESP MED, V95, P56, DOI 10.1053/rmed.2000.0971; Keefe FJ, 1999, ARTHRIT CARE RES, V12, P101, DOI 10.1002/1529-0131(199904)12:2<101::AID-ART5>3.0.CO;2-9; Leveille SG, 1998, J AM GERIATR SOC, V46, P1191, DOI 10.1111/j.1532-5415.1998.tb04533.x; Levy ML, 2000, RESP MED, V94, P900, DOI 10.1053/rmed.2000.0861; Lindroth Y, 1997, ARTHRIT CARE RES, V10, P325, DOI 10.1002/art.1790100507; Lorig K., 1994, LIVING HLTH LIFE CHR; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Mazzuca SA, 1997, ARTHRITIS RHEUM-US, V40, P1466, DOI 10.1002/art.1780400815; *MICH DIAB TRAIN C, 2002, WEB SIT; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; Parker JC, 1995, ARTHRITIS RHEUM, V38, P1807, DOI 10.1002/art.1780381214; Riemsma RP, 1997, ARTHRIT CARE RES, V10, P238, DOI 10.1002/art.1790100405; Simeoni E, 1995, ARTHRIT CARE RES, V8, P102, DOI 10.1002/art.1790080208; *STANDF PAT ED RES, 2002, WEB SIT; *STANF PAT ED RES, 1997, CHRON DIS SELF MAN L; TAAL E, 1993, PATIENT EDUC COUNS, V20, P177, DOI 10.1016/0738-3991(93)90131-F; Van der Palen J, 1998, RESP MED, V92, P668, DOI 10.1016/S0954-6111(98)90516-9; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; 2001, DIABETES ED, V27, P899	55	2120	2169	8	320	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2002	288	19					2469	2475		10.1001/jama.288.19.2469	http://dx.doi.org/10.1001/jama.288.19.2469			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	616FB	12435261				2022-12-28	WOS:000179292300031
J	Randolph, WM; Goodwin, JS; Mahnken, JD; Freeman, JL				Randolph, WM; Goodwin, JS; Mahnken, JD; Freeman, JL			Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis	ANNALS OF INTERNAL MEDICINE			English	Article							SCREENING MAMMOGRAPHY; COMORBIDITY INDEX; ELDERLY-WOMEN; OLDER; HEALTH; MORTALITY; SURVIVAL; EFFICACY; COSTS	Background: There is little consensus about recommending mammography for women 75 years of age and older. These women have mammography less frequently and are more likely to receive a diagnosis of advanced breast cancer. Objective: To examine the relationship between use of screening mammography and size and stage of cancer at diagnosis in older women. Design: Retrospective cohort study. Setting: Tumor registries in the Surveillance, Epidemiology, and End Results (SEER) program. Patients: 12 038 women who were Medicare beneficiaries, were at least 69 years of age, resided in a SEER area, and received a new diagnosis of breast cancer in 1995 through 1996. Measurements: Screening mammograms obtained in the 2 years before breast cancer diagnosis (none, one, or at least two) and stage and size of tumor at diagnosis. Results: older women ( :75 years of age) had larger tumors at diagnosis and were less likely to have undergone screening mammography than younger women (69 to 74 years of age). The association between increased mammography use and smaller tumor size and stage was significantly greater in older women than in younger women (P = 0.010 for stage; P = 0.001 for size). The percentage of regular mammography users who received a diagnosis of high-stage disease (28% vs. 26%; P > 0.2) and the mean size of the tumors (15.0 mm vs. 15.1 mm; P > 0.2) did not significantly differ between younger and older women, respectively. These findings remained constant after controlling for factors that might contribute to biases. Conclusion: Mammography in older women is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis.	Univ Texas, Med Branch, Sealy Ctr Aging, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Freeman, JL (corresponding author), Univ Texas, Med Branch, Sealy Ctr Aging, 301 Univ Blvd, Galveston, TX 77555 USA.				NATIONAL CANCER INSTITUTE [R01CA072076] Funding Source: NIH RePORTER; NCI NIH HHS [CA72076] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AG HEALTHC RES QU, 2002, SCREEN BREAST CANC R; *AM GER SOC, 2002, BREAST CANC SCREEN O; American Cancer Society, 2002, CANC FACTS FIG 2002; Andersson I, 1997, J Natl Cancer Inst Monogr, P63; Blustein J, 1998, J AM GERIATR SOC, V46, P941, DOI 10.1111/j.1532-5415.1998.tb02746.x; BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; BREEN N, 1994, AM J PUBLIC HEALTH, V84, P62, DOI 10.2105/AJPH.84.1.62; Burns RB, 1996, J AM GERIATR SOC, V44, P922, DOI 10.1111/j.1532-5415.1996.tb01861.x; Caplan L S, 1996, Public Health Rev, V24, P193; CHAMBERLAIN J, 1988, LANCET, V2, P411; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen H H, 1995, J Med Screen, V2, P10; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Draper NR., 1998, WILEY SERIES PROBABI, V3rd ed.; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; GOODWIN JS, 1986, J AM GERIATR SOC, V34, P20, DOI 10.1111/j.1532-5415.1986.tb06335.x; HALABI S, 1993, CANCER DETECT PREV, V17, P359; Hedegaard HB, 1996, AM J PREV MED, V12, P51, DOI 10.1016/S0749-3797(18)30370-2; Hillner BE, 1996, BREAST CANCER RES TR, V40, P75, DOI 10.1007/BF01806004; *HLTH CAR FIN ADM, 2002, DAT US REF GUID; HOLMES FF, 1981, J AM GERIATR SOC, V29, P55, DOI 10.1111/j.1532-5415.1981.tb01227.x; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; MANDELBLATT JS, 1992, ANN INTERN MED, V116, P722, DOI 10.7326/0003-4819-116-9-722; May DS, 1998, ANN EPIDEMIOL, V8, P439, DOI 10.1016/S1047-2797(98)00010-6; McCarthy EP, 2000, J AM GERIATR SOC, V48, P1226, DOI 10.1111/j.1532-5415.2000.tb02595.x; Morrison AS, 1992, SCREENING CHRONIC DI; Parker J, 1998, AM J PREV MED, V15, P198, DOI 10.1016/S0749-3797(98)00045-2; POTOSKY AL, 1993, MED CARE, V31, P732; REIS L, 1999, SEER CANC STAT REV 1; REYNOLDS T, 1994, J NATL CANCER I, V86, P168, DOI 10.1093/jnci/86.3.168; Roux AVD, 2001, ANN EPIDEMIOL, V11, P395, DOI 10.1016/S1047-2797(01)00221-6; SAS Institute, 1999, SAS STAT US GUID VER; SATARIANO WA, 1994, ANN INTERN MED, V120, P104, DOI 10.7326/0003-4819-120-2-199401150-00002; Smith-Bindman R, 2000, AM J MED, V108, P112, DOI 10.1016/S0002-9343(99)00406-4; Tabar L, 2000, RADIOL CLIN N AM, V38, P625, DOI 10.1016/S0033-8389(05)70191-3; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1995, CANCER, V75, P2507, DOI 10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H; Tabar L, 1999, Swiss Surg, V5, P199, DOI 10.1024/1023-9332.5.5.199; *US DEP HHS, 2000, DHHS PUB; YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A; 1995, MMWR MORB MORTAL WKL, V44, P777	46	78	80	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					783	790		10.7326/0003-4819-137-10-200211190-00006	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	616VE	12435214				2022-12-28	WOS:000179323400001
J	Andersen, AMN; Vastrup, P; Wohlfahrt, J; Andersen, PK; Olsen, J; Melbye, M				Andersen, AMN; Vastrup, P; Wohlfahrt, J; Andersen, PK; Olsen, J; Melbye, M			Fever in pregnancy and risk of fetal death: a cohort study	LANCET			English	Article							NEURAL-TUBE DEFECTS; MATERNAL HYPERTHERMIA; SPONTANEOUS-ABORTION; TERATOGENIC AGENT; INFREQUENT CAUSE; ABNORMALITIES; POPULATION; EXPOSURE; EMBRYOS; UPDATE	Background Hyperthermia acts as a teratogen in some animals where it can induce resorption of the fetus and fetal death. Fever during pregnancy, especially in the period of embryogenesis, is also suspected as being a risk factor for fetal death in human beings. We did a large cohort study in Denmark to investigate this possibility. Methods We interviewed 24 040 women who were recruited in the first half of pregnancy to the Danish National Birth Cohort Study, and obtained information on the number of fever incidents during the first 16 weeks of pregnancy. For each fever episode, the highest measured body temperature, duration of incident, and gestational age were recorded. Outcomes of pregnancies were identified through linkage with the Civil Registration System and the National Discharge Registry. Cox's regression with time-dependent variables was used to estimate the relative risk of fetal death, taking delayed entry into account. Findings 1145 pregnancies resulted in a miscarriage or stillbirth (4.8%). During the first 16 pregnancy weeks 18.5% of the women experienced at least one episode of fever. However, we found no association between fever in pregnancy and fetal death before or after adjustment for known risk factors of fetal death (relative risk 0.95 [95% Cl 0.80-1.13]). This finding was consistent irrespective of measured maximum temperature, duration and number of fever incidents, or the gestational time of the fever incident, and was observed for fetal death in all three trimesters of pregnancy. Interpretation We found no evidence that fever in the first 16 weeks of pregnancy is associated with the risk of fetal death in clinically recognised pregnancies.	Statens Serum Inst, Danish Epidemiol Sci ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; Univ Aarhus, Danish Epidemiol Sci Ctr, Inst Epidemiol & Social Med, Aarhus, Denmark; Univ Copenhagen, Dept Biostat, Copenhagen, Denmark	Aarhus University; Statens Serum Institut; Aarhus University; University of Copenhagen	Andersen, AMN (corresponding author), Univ Copenhagen, Dept Social Med, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.		Nybo Andersen, Anne-Marie/AAA-1997-2022; Andersen, Anne-Marie Nybo/E-4993-2013	Nybo Andersen, Anne-Marie/0000-0002-4296-8488; Andersen, Anne-Marie Nybo/0000-0002-4296-8488; melbye, mads/0000-0001-8264-6785				ANDERSEN AK, 2000, THESIS U COPENHAGEN; BUXTON D, 1986, VET REC, V118, P510, DOI 10.1136/vr.118.18.510; Chambers CD, 1998, TERATOLOGY, V58, P251, DOI 10.1002/(SICI)1096-9926(199812)58:6<251::AID-TERA6>3.0.CO;2-L; CLARREN SK, 1979, J PEDIATR-US, V95, P81, DOI 10.1016/S0022-3476(79)80092-X; COCKROFT DL, 1978, TERATOLOGY, V17, P277, DOI 10.1002/tera.1420170306; EDWARDS MJ, 1995, REPROD TOXICOL, V9, P411, DOI 10.1016/0890-6238(95)00043-A; EDWARDS MJ, 1969, TERATOLOGY, V2, P313, DOI 10.1002/tera.1420020406; FAOAGALI JL, 1985, NEW ZEAL MED J, V98, P64; Farrow A, 1996, INT J EPIDEMIOL, V25, P797, DOI 10.1093/ije/25.4.797; GERMAIN MA, 1985, TERATOLOGY, V31, P265, DOI 10.1002/tera.1420310212; Graham JM, 1998, TERATOLOGY, V58, P209, DOI 10.1002/(SICI)1096-9926(199811)58:5<209::AID-TERA8>3.0.CO;2-Q; Hills, 1993, STAT MODELS EPIDEMIO; KLINE J, 1985, AM J EPIDEMIOL, V121, P832, DOI 10.1093/oxfordjournals.aje.a114054; LITTLE BB, 1991, AM J PERINAT, V8, P185, DOI 10.1055/s-2007-999373; LYNBERG MC, 1994, AM J EPIDEMIOL, V140, P244, DOI 10.1093/oxfordjournals.aje.a117243; MILLER P, 1978, LANCET, V1, P519; MILUNSKY A, 1992, JAMA-J AM MED ASSOC, V268, P882, DOI 10.1001/jama.268.7.882; NILSEN NO, 1984, TERATOLOGY, V30, P237, DOI 10.1002/tera.1420300211; Peterka M, 1996, REPROD TOXICOL, V10, P327, DOI 10.1016/0890-6238(96)00062-7; POSWILLO D, 1974, ANN ROY COLL SURG, V55, P171; *PUBL HLTH LAB SER, 1990, PROSPECTIVE STUDY HU, P1166; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P115; SASAKI J, 1995, TERATOLOGY, V51, P233, DOI 10.1002/tera.1420510407; Shaw GM, 1998, TERATOLOGY, V57, P1; SHIOTA K, 1982, AM J MED GENET, V12, P281, DOI 10.1002/ajmg.1320120306; Simpson JL, 1996, HUM REPROD, V11, P668, DOI 10.1093/HUMREP/11.3.668; Simpson JL, 1996, HUM REPROD, V11, P2058; TIKKANEN J, 1991, EUR J EPIDEMIOL, V7, P628; WARKANY J, 1986, TERATOLOGY, V33, P365, DOI 10.1002/tera.1420330316; 1996, SAS STAT SOFTWARE CH, P807	30	44	47	1	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1552	1556		10.1016/S0140-6736(02)11518-2	http://dx.doi.org/10.1016/S0140-6736(02)11518-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443593				2022-12-28	WOS:000179292400011
J	Chambers, CD; Jones, KL				Chambers, CD; Jones, KL			Risk for fetal death after fever in pregnancy	LANCET			English	Editorial Material							SPONTANEOUS-ABORTION; HYPERTHERMIA		Univ Calif San Diego, Dept Pediat, Div Dysmorphol Teratol, Sch Med, San Diego, CA 92103 USA	University of California System; University of California San Diego	Jones, KL (corresponding author), Univ Calif San Diego, Dept Pediat, Div Dysmorphol Teratol, Sch Med, San Diego, CA 92103 USA.							EDWARDS MJ, 1995, REPROD TOXICOL, V9, P411, DOI 10.1016/0890-6238(95)00043-A; HENDRICKX AG, 1979, TERATOLOGY, V19, P177, DOI 10.1002/tera.1420190208; KLINE J, 1985, AM J EPIDEMIOL, V121, P832, DOI 10.1093/oxfordjournals.aje.a114054; MILLER P, 1978, LANCET, V1, P519; Mills JL, 1999, NEW ENGL J MED, V340, P380, DOI 10.1056/NEJM199902043400509	5	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1526	1526		10.1016/S0140-6736(02)11575-3	http://dx.doi.org/10.1016/S0140-6736(02)11575-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443584				2022-12-28	WOS:000179292400002
J	Jenkins, GR; Hale, R; Papanastassiou, M; Crawford, MJ; Tyrer, P				Jenkins, GR; Hale, R; Papanastassiou, M; Crawford, MJ; Tyrer, P			Suicide rate 22 years after parasuicide: cohort study	BRITISH MEDICAL JOURNAL			English	Article							DELIBERATE SELF-HARM		E Ham Hosp, Dept Psychiat, London E7 8QR, England; Tavistock & Portman NHS Trust, Portman Clin, London NW3 5NA, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Publ Mental Hlth, London W2 1PD, England	Imperial College London	Jenkins, GR (corresponding author), Newnham Ctr Mental Hlth, Glen Rd, London E13 8SP, England.			Crawford, Mike/0000-0003-3137-5772				Crawford MJ, 1998, BRIT MED J, V317, P985, DOI 10.1136/bmj.317.7164.985; DeMoore GM, 1996, BRIT J PSYCHIAT, V169, P489, DOI 10.1192/bjp.169.4.489; GREER S, 1971, BRIT MED J, V1, P310, DOI 10.1136/bmj.1.5744.310; HAWTON K, 1988, BRIT J PSYCHIAT, V152, P59; *ROYAL COLL PSYCH, 1994, PSYCHIAT B, V7, P210	5	94	95	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2002	325	7373					1155	1155		10.1136/bmj.325.7373.1155	http://dx.doi.org/10.1136/bmj.325.7373.1155			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433767	Green Published, Bronze			2022-12-28	WOS:000179443100023
J	Post, E; Forchhammer, MC				Post, E; Forchhammer, MC			Synchronization of animal population dynamics by large-scale climate	NATURE			English	Article							NORTH-ATLANTIC OSCILLATION; DENSITY; FLUCTUATIONS; PHENOLOGY; ECOLOGY; TRENDS; CANADA; SHEEP	The hypothesis that animal population dynamics may be synchronized by climate(1) is highly relevant in the context of climate change because it suggests that several populations might respond simultaneously to climatic trends if their dynamics are entrained by environmental correlation. The dynamics of many species throughout the Northern Hemisphere are influenced by a single large-scale climate system, the North Atlantic Oscillation (NAO)(2,3), which exerts highly correlated regional effects on local weather(4). But efforts to attribute synchronous fluctuations of contiguous populations to large-scale climate are confounded by the synchronizing influences of dispersal or trophic interactions(5). Here we report that the dynamics of caribou and musk oxen on opposite coasts of Greenland show spatial synchrony among populations of both species that correlates with the NAO index. Our analysis shows that the NAO has an influence in the high degree of cross-species synchrony between pairs of caribou and musk oxen populations separated by a minimum of 1,000 km of inland ice. The vast distances, and complete physical and ecological separation of these species, rule out spatial coupling by dispersal or interaction. These results indicate that animal populations of different species may respond synchronously to global climate change over large regions.	Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; Univ Copenhagen, Inst Zool, Dept Populat Ecol, DK-2100 Copenhagen, Denmark	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Copenhagen	Post, E (corresponding author), Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA.		Forchhammer, Mads/I-7474-2013					Blasius B, 2000, NATURE, V406, P846, DOI 10.1038/35022646; Born ErikW., 2001, ECOLOGY GREENLAND; FORCHHAMMER M, 1993, ECOGRAPHY, V16, P299, DOI 10.1111/j.1600-0587.1993.tb00219.x; Forchhammer MC, 1998, NATURE, V391, P29, DOI 10.1038/34070; Forchhammer MC, 2001, J ANIM ECOL, V70, P721, DOI 10.1046/j.0021-8790.2001.00532.x; Forchhammer MC, 2002, POPUL ECOL, V44, P113, DOI 10.1007/s101440200013; Forchhammer MC, 1998, P ROY SOC B-BIOL SCI, V265, P341, DOI 10.1098/rspb.1998.0301; Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291; Haydon DT, 2001, P NATL ACAD SCI USA, V98, P13149, DOI 10.1073/pnas.221275198; Hedges LV, 1999, ECOLOGY, V80, P1150, DOI 10.1890/0012-9658(1999)080[1150:TMAORR]2.0.CO;2; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Klein David R., 1999, Ecological Bulletins, V47, P96; Koenig WD, 1999, TRENDS ECOL EVOL, V14, P22, DOI 10.1016/S0169-5347(98)01533-X; Lodwick G. D., 1970, Australian Computer Journal, V2, P104; Marshall J, 2001, INT J CLIMATOL, V21, P1863, DOI 10.1002/joc.693; Meldgaard M., 1986, Meddelelser om Gronland Bioscience, V20, P1; Milner JM, 1999, J ANIM ECOL, V68, P1235, DOI 10.1046/j.1365-2656.1999.00366.x; MORAN PAP, 1953, AUST J ZOOL, V1, P291, DOI 10.1071/ZO9530291; Ottersen G, 2001, OECOLOGIA, V128, P1, DOI 10.1007/s004420100655; Post E, 1999, ECOLOGY, V80, P1322, DOI 10.1890/0012-9658(1999)080[1322:CVPPAN]2.0.CO;2; Post E, 2001, EVOLUTION, V55, P830, DOI 10.1554/0014-3820(2001)055[0830:RAIWED]2.0.CO;2; Post E, 1999, J WILDLIFE MANAGE, V63, P335, DOI 10.2307/3802517; POST E, IN PRESS ECOLOGY; Ranta E, 1999, P ROY SOC B-BIOL SCI, V266, P1851, DOI 10.1098/rspb.1999.0856; Ranta E, 1997, OIKOS, V78, P136, DOI 10.2307/3545809; Ranta E, 1997, SCIENCE, V278, P1621, DOI 10.1126/science.278.5343.1621; Schwartz MK, 2002, NATURE, V415, P520, DOI 10.1038/415520a; Skogland T, 1989, COMP SOCIAL ORG WILD; *SPSS INC, 1998, SYSTAT WIND VERS 8 0; Stenseth NC, 1999, SCIENCE, V285, P1071, DOI 10.1126/science.285.5430.1071; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a	31	233	241	4	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					168	171		10.1038/nature01064	http://dx.doi.org/10.1038/nature01064			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432390				2022-12-28	WOS:000179200900043
J	Blackman, MB; Sorkin, JD; Munzer, T; Bellantoni, MF; Busby-Whitehead, J; Stevens, TE; Jayme, J; O'Connor, KG; Christmas, C; Tobin, JD; Stewart, KJ; Cottrell, E; St Clair, C; Pabst, KM; Harman, SM				Blackman, MB; Sorkin, JD; Munzer, T; Bellantoni, MF; Busby-Whitehead, J; Stevens, TE; Jayme, J; O'Connor, KG; Christmas, C; Tobin, JD; Stewart, KJ; Cottrell, E; St Clair, C; Pabst, KM; Harman, SM			Growth hormone and sex steroid administration in healthy aged women and men - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; MUSCLE STRENGTH; FACTOR-I; TESTOSTERONE REPLACEMENT; BODY-COMPOSITION; HYPOGONADAL MEN; OLDER MEN; ESTROGEN REPLACEMENT; RESISTANCE EXERCISE	Context Hormone administration to elderly individuals can increase lean body mass (LBM) and decrease fat, but interactive effects of growth hormone (GH) and sex steroids and their influence on strength and endurance are unknown. Objective To evaluate the effects of recombinant human GH and/or sex steroids on body composition, strength, endurance, and adverse outcomes in aged persons. Design, Setting, and Participants A 26-week randomized, double-blind, placebo-controlled parallel-group trial in healthy, ambulatory, community-dwelling US women (n=57) and men (n=74) aged 65 to 88 years recruited between June 1992 and July 1998. Interventions Participants were randomized to receive GH (starting dose, 30 mug/kg reduced to 20 mug/kg, subcutaneously 3 times/wk) + sex steroids (women: transdermal estradiol,100 mug/d, plus oral medroxyprogesterone acetate, 10 mg/d, during the last 10 days of each 28-day cycle [HRT]; men: testosterone enanthate, biweekly intramuscular injections of 100 mg) (n=35); GH + placebo sex steroid (n=30); sex steroid + placebo GH (n=35); or placebo GH + placebo sex steroid (n=31) in a 2 x 2 factorial design. Main Outcome Measures Lean body mass, fat mass, muscle strength, maximum oxygen uptake ((V) over doto(2)max) during treadmill test, and adverse effects. Results In women, LBM increased by 0.4 kg with placebo, 1.2 kg with HRT (P=.09), 1.0 kg with GH (P=.001), and 2.1 kg with GH+HRT (P<.001). Fat mass decreased significantly in the GH and GH+HRT groups. In men, LBM increased by 0.1 kg with placebo, 1.4 kg with testosterone (P=.06), 3.1 kg with GH (P<.001), and 4.3 kg with GH+testosterone (P<.001). Fat mass decreased significantly with GH and GH+testosterone. Women's strength decreased in the placebo group and increased's strength nonsignificantly with HRT (P=.09), GH (P=.29), and GH+HRT (P=.14). Men also did not increase significantly except for a marginally significant increase of 13.5 kg with GH+testosterone (P=.05). Women's (V) over dot o(2)max declined by 0.4 mL/min/kg in the placebo and HRT groups but increased with GH (P=.07) and GH+HRT (P=.06). 3 Men's (V) over dot o(2)max declined by 1.2 mL/min/kg with placebo and by 0.4 mL/min/kg with testosterone (P=.49) but increased with GH (P=.11) and with GH+testosterone (P<.001). Changes in strength (r=0.355; P<.001) and in (V) over dot o(2)max (r=0.320; P=.002) were directly related to changes in LBM. Edema was significantly more common in women taking GH (39% vs 0%) and GH+HRT (38% vs 0%). Carpal tunnel symptoms were more common in men taking GH+testosterone (32% vs 0%) and arthralgias were more common in men taking GH (41% vs 0%). Diabetes or glucose intolerance occurred in 18 GH-treated men vs 7 not receiving GH (P=.006). Conclusions In this study, GH with or without sex steroids in healthy, aged women and men increased LBM and decreased fat mass. Sex steroid + GH increased muscle strength marginally and (V) over dot o(2)max in men, but women had no significant change in strength or cardiovascular endurance. Because adverse effects were frequent (importantly, diabetes and glucose intolerance), GH interventions; in the elderly should be confined to controlled studies.	Natl Ctr Complementary & Alternat Med, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA; NIA, Endocrine Sect, NIH, Lab Clin Invest,Intramural Res Program, Bethesda, MD 20892 USA; NIA, Metab Sect, NIH, Lab Clin Invest,Intramural Res Program, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Burgerspital, St Gallen, Switzerland; Univ N Carolina, Sch Med, Div Geriatr Med, Chapel Hill, NC USA; Univ S Alabama, Sch Med, Div Geriatr Med, Mobile, AL USA; Louth Hosp, Louth, Ireland; Kronos Res Inst, Phoenix, AZ USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Baltimore; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of South Alabama	Blackman, MB (corresponding author), Natl Ctr Complementary & Alternat Med, NIH, 8 West Dr,Bldg 15 B-1, Bethesda, MD 20892 USA.			Bellantoni, Michele/0000-0001-8525-2247	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NCRR NIH HHS [M0-1-RR-02719] Funding Source: Medline; NIA NIH HHS [R0-1 AG11005] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abs R, 1999, CLIN ENDOCRINOL, V50, P703, DOI 10.1046/j.1365-2265.1999.00695.x; Barbulescu K, 2001, MOL ENDOCRINOL, V15, P1803, DOI 10.1210/me.15.10.1803; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BELLANTONI MF, 1991, J CLIN ENDOCR METAB, V72, P172, DOI 10.1210/jcem-72-1-172; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P407, DOI 10.1210/jc.82.2.407; BLACKMAN MR, 1999, SEX STEROID INTERACT, P44; BLACKMAN MR, 1995, ENDOCRINOLOGY, P2702; BRUCE RA, 1966, AM HEART J, V71, P455, DOI 10.1016/0002-8703(66)90210-9; Burman P, 1997, J CLIN ENDOCR METAB, V82, P550, DOI 10.1210/jc.82.2.550; Cappola AR, 2001, J CLIN ENDOCR METAB, V86, P4139, DOI 10.1210/jc.86.9.4139; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; Cefalu WT, 1998, METABOLISM, V47, P401, DOI 10.1016/S0026-0495(98)90050-6; Christmas C, 2002, J GERONTOL A-BIOL, V57, pM12, DOI 10.1093/gerona/57.1.M12; COHN L, 1993, CLIN ENDOCRINOL, V39, P417, DOI 10.1111/j.1365-2265.1993.tb02388.x; CUNEO RC, 1991, J APPL PHYSIOL, V70, P688, DOI 10.1152/jappl.1991.70.2.688; Cuttica CM, 1997, AGING CLIN EXP RES, V9, P193, DOI 10.1007/BF03340149; DAWSONHUGHES B, 1986, J CLIN ENDOCR METAB, V63, P424, DOI 10.1210/jcem-63-2-424; Dobs AS, 2002, J CLIN ENDOCR METAB, V87, P1509, DOI 10.1210/jc.87.4.1509; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Ferrando AA, 2002, AM J PHYSIOL-ENDOC M, V282, pE601, DOI 10.1152/ajpendo.00362.2001; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; Friend KE, 1996, J CLIN ENDOCR METAB, V81, P2250, DOI 10.1210/jc.81.6.2250; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gentili A, 2002, J CLIN ENDOCR METAB, V87, P825, DOI 10.1210/jc.87.2.825; HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W; Hajjar RR, 1997, J CLIN ENDOCR METAB, V82, P3793, DOI 10.1210/jc.82.11.3793; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Hayes VY, 2001, J CLIN ENDOCR METAB, V86, P2211, DOI 10.1210/jc.86.5.2211; Ho Ken K. Y., 1996, Endocrine Journal, V43, pS57; HULKA BS, 1980, JAMA-J AM MED ASSOC, V244, P2419; Johnston D. G., 1999, Journal of Endocrinological Investigation, V22, P37; KLATZ R, 1997, GROW YOUNG HGH AMAZI; KRITZSILVERSTEIN D, 1994, J BONE MINER RES, V9, P45, DOI 10.1002/jbmr.5650090107; Lasco A, 2000, DIABETES CARE, V23, P422, DOI 10.2337/diacare.23.3.422; Lindle RS, 1997, J APPL PHYSIOL, V83, P1581, DOI 10.1152/jappl.1997.83.5.1581; MALOZOWSKI S, 1993, NEW ENGL J MED, V329, P665, DOI 10.1056/NEJM199308263290917; MARDH G, 1994, ENDOCRINOLOGY MET SA, V1, P43; Marin P, 1992, Eur J Med, V1, P329; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; Miller MM, 1999, EXP GERONTOL, V34, P587, DOI 10.1016/S0531-5565(99)00032-7; Munzer T, 2001, J CLIN ENDOCR METAB, V86, P3604, DOI 10.1210/jc.86.8.3604; O'Connor KG, 1998, J GERONTOL A-BIOL, V53, pM176, DOI 10.1093/gerona/53A.3.M176; O'Sullivan AJ, 1998, J CLIN INVEST, V102, P1035, DOI 10.1172/JCI2773; Papadakis MA, 1996, ANN INTERN MED, V124, P708, DOI 10.7326/0003-4819-124-8-199604150-00002; Rosenfalck AM, 1999, GROWTH HORM IGF RES, V9, P96, DOI 10.1054/ghir.1999.0091; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Roy TA, 2002, AM J PHYSIOL-ENDOC M, V283, pE284, DOI 10.1152/ajpendo.00334.2001; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; Savine R, 2000, HORM RES, V53, P37, DOI 10.1159/000023531; SHIMOKATA H, 1989, INT J OBESITY, V13, P455; Sih R, 1997, J CLIN ENDOCR METAB, V82, P1661, DOI 10.1210/jc.82.6.1661; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647; Snyder PJ, 2000, J CLIN ENDOCR METAB, V85, P2670, DOI 10.1210/jc.85.8.2670; Sorensen MB, 2001, OBES RES, V9, P622, DOI 10.1038/oby.2001.81; Swerdlow AJ, 2002, LANCET, V360, P273, DOI 10.1016/S0140-6736(02)09519-3; Taaffe DR, 1999, J AM GERIATR SOC, V47, P1208, DOI 10.1111/j.1532-5415.1999.tb05201.x; TAAFFE DR, 1994, J CLIN ENDOCR METAB, V79, P1361, DOI 10.1210/jc.79.5.1361; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; Vitiello MV, 1997, J GERONTOL A-BIOL, V52, pM149, DOI 10.1093/gerona/52A.3.M149; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4	62	325	351	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2282	2292		10.1001/jama.288.18.2282	http://dx.doi.org/10.1001/jama.288.18.2282			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425705	Bronze			2022-12-28	WOS:000179186400027
J	Amadi, B; Mwiya, M; Musuku, J; Watuka, A; Sianongo, S; Ayoub, A; Kelly, P				Amadi, B; Mwiya, M; Musuku, J; Watuka, A; Sianongo, S; Ayoub, A; Kelly, P			Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial	LANCET			English	Article							DOUBLE-BLIND; PERSISTENT DIARRHEA; GUINEA-BISSAU; PLACEBO; PARVUM; PAROMOMYCIN; TIZOXANIDE; MANAGEMENT; INFECTION; COMMUNITY	Background Cryptosporidiosis in children in developing countries causes persistent diarrhoea and malnutrition and is associated with increased mortality, but there is no effective treatment. We aimed to assess the effect of nitazoxanide-a new broad-spectrum antiparasitic drug-on morbidity and mortality in Zambian children with diarrhoea due to Cryptosporidium parvum. Methods Children with cryptosporidial diarrhoea who were admitted to the University Teaching Hospital, Lusaka, Zambia, between November, 2000, and July, 2001, and whose parents consented to their having an HIV test were randomly assigned nitazoxanide (100 mg twice daily orally for 3 days) or placebo. The primary endpoint was clinical response on day 7 after the start of treatment. Secondary endpoints included parasitological response by day 10 and mortality at day 8. Analysis was by intention to treat, with exclusion of patients subsequently found to be negative for C parvum or co-infected at baseline. The trial was stratified by HIV serology. Findings 50 HIV-seropositive and 50 HIV-seronegative children were recruited for the study, four of whom were subsequently excluded. In HIV-seronegative children, diarrhoea resolved in 14 (56%) of 25 receiving nitazoxanide and 5 (23%) of 22 receiving placebo (difference 33%, 95% CI 7-59; p=0.037). C parvum was eradicated from stool in 13 (52%) of 25 receiving nitazoxanide and three (14%) of 22 receiving placebo (38%, 95% CI 14-63; p=0.007). Four children (18%) of 22 in the placebo group had died by day 8, compared with none of 25 in the nitazoxanide group (-18%, 34 to 2; p=0-041). HIV-seropositive children did not benefit from nitazoxanide. Nitazoxanide was not significantly associated with adverse events in either stratum. Interpretation A 3-day course of nitazoxanide significantly improved the resolution of diarrhoea, parasitological eradication,. and mortality in HIV-seronegative, but not HIV-seropositive, children.	St Bartholomews & Royal London Sch Med & Dent, Dept Adult & Paediat Gastroenterol, London E1 2AD, England; Univ Zambia, Sch Med, Dept Paediat, Lusaka, Zambia; Univ Zambia, Sch Med, Dept Pathol, Lusaka, Zambia; Univ Zambia, Sch Med, Dept Med, Lusaka, Zambia; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England	University of London; Queen Mary University London; University of Zambia; University of Zambia; University of Zambia; University of London; London School of Hygiene & Tropical Medicine	Kelly, P (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Adult & Paediat Gastroenterol, London E1 2AD, England.	m.p.kelly@qmul.ac.uk		Kelly, Paul/0000-0003-0844-6448				Amadi B, 2001, J PEDIATR GASTR NUTR, V32, P550, DOI 10.1097/00005176-200105000-00011; [Anonymous], 1970, LANCET, V2, P302; BLANSHARD C, 1992, Q J MED, V85, P813; Brewster DR, 1997, EUR J CLIN NUTR, V51, P139, DOI 10.1038/sj.ejcn.1600367; COOPERSTOCK M, 1992, CLIN INFECT DIS, V15, pS244, DOI 10.1093/clind/15.Supplement_1.S244; Dubreuil L, 1996, ANTIMICROB AGENTS CH, V40, P2266, DOI 10.1128/AAC.40.10.2266; Gargala G, 2000, J ANTIMICROB CHEMOTH, V46, P57, DOI 10.1093/jac/46.1.57; Gilles HM, 2002, TRENDS PARASITOL, V18, P95, DOI 10.1016/S1471-4922(01)02205-X; Griffiths J K, 1998, Adv Parasitol, V40, P37, DOI 10.1016/S0065-308X(08)60117-7; Guerrant DI, 1999, AM J TROP MED HYG, V61, P707, DOI 10.4269/ajtmh.1999.61.707; Guerrant RL, 2001, CLIN INFECT DIS, V32, P331, DOI 10.1086/318514; Guerrant RL, 1997, EMERG INFECT DIS, V3, P51, DOI 10.3201/eid0301.970106; Hewitt RG, 2000, CLIN INFECT DIS, V31, P1084, DOI 10.1086/318155; Lima AAM, 2000, J INFECT DIS, V181, P1643, DOI 10.1086/315423; MOLBAK K, 1993, BRIT MED J, V307, P417, DOI 10.1136/bmj.307.6901.417; Molbak K, 1997, AM J CLIN NUTR, V65, P149, DOI 10.1093/ajcn/65.1.149; Ortiz JJ, 2001, ALIMENT PHARM THER, V15, P1409, DOI 10.1046/j.1365-2036.2001.01066.x; ORTIZ JJ, IN PRESS T R SOC TRO; PHILLIPS AD, 1992, GUT, V33, P1057, DOI 10.1136/gut.33.8.1057; Rossignol JF, 1998, T ROY SOC TROP MED H, V92, P663, DOI 10.1016/S0035-9203(98)90804-5; Rossignol JF, 2001, J INFECT DIS, V184, P381, DOI 10.1086/322038; Rossignol JFA, 2001, J INFECT DIS, V184, P103, DOI 10.1086/321008; SOAVE R, 2002, IN PRESS CLIN PHARM; SOLOMON SM, 1990, JPEN-PARENTER ENTER, V14, P90, DOI 10.1177/014860719001400190; Theodos CM, 1998, ANTIMICROB AGENTS CH, V42, P1959, DOI 10.1128/AAC.42.8.1959; Waterlow JC, 1992, PROTEIN ENERGY MALNU; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419; World Medical Association, 2000, 52 WMA GEN ASS ED UK	28	233	257	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 2	2002	360	9343					1375	1380		10.1016/S0140-6736(02)11401-2	http://dx.doi.org/10.1016/S0140-6736(02)11401-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423984				2022-12-28	WOS:000179081600011
J	O'Hara, KM; Hemmer, SL; Gehm, ME; Granade, SR; Thomas, JE				O'Hara, KM; Hemmer, SL; Gehm, ME; Granade, SR; Thomas, JE			Observation of a strongly interacting degenerate Fermi gas of atoms	SCIENCE			English	Article							LI-6; COLLISIONS	We report on the observation of a highly degenerate, strongly interacting Fermi gas of atoms. Fermionic lithium-6 atoms in an optical trap are evaporatively cooled to degeneracy using a magnetic field to induce strong, resonant interactions. Upon abruptly releasing the cloud from the trap, the gas is observed to expand rapidly in the transverse direction while remaining nearly stationary in the axial direction. We interpret the expansion dynamics in terms of collisionless superfluid and collisional hydrodynamics. For the data taken at the longest evaporation times, we find that collisional hydrodynamics does not provide a satisfactory explanation, whereas superfluidity is plausible.	Duke Univ, Dept Phys, Durham, NC 27708 USA	Duke University	Thomas, JE (corresponding author), Duke Univ, Dept Phys, Durham, NC 27708 USA.	jet@phy.duke.edu	Thomas, John/Q-9759-2018	Thomas, John/0000-0002-0018-2831; Gehm, Michael/0000-0003-4163-749X				Butts DA, 1997, PHYS REV A, V55, P4346, DOI 10.1103/PhysRevA.55.4346; Combescot R, 1999, PHYS REV LETT, V83, P3766, DOI 10.1103/PhysRevLett.83.3766; DeMarco B, 2001, PHYS REV LETT, V86, P5409, DOI 10.1103/PhysRevLett.86.5409; DeMarco B, 1999, SCIENCE, V285, P1703, DOI 10.1126/science.285.5434.1703; Dieckmann K, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.203201; Granade SR, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.120405; Gupta S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.140401; Heiselberg H, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.043606; Holland M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.120406; Houbiers M, 1997, PHYS REV A, V56, P4864, DOI 10.1103/PhysRevA.56.4864; Houbiers M, 1998, PHYS REV A, V57, pR1497, DOI 10.1103/PhysRevA.57.R1497; JOCHIM S, IN PRESS PHYS REV LE; Kagan Y, 1997, PHYS REV A, V55, pR18, DOI 10.1103/PhysRevA.55.R18; Kokkelmans SJJMF, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.053617; LIU WV, CONDMAT0208052; Loftus T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.173201; Luiten OJ, 1996, PHYS REV A, V53, P381, DOI 10.1103/PhysRevA.53.381; MENOTTI C, ARXIVORGABSCONDMAT02; Modugno G, 2002, SCIENCE, V297, P2240, DOI 10.1126/science.1077386; O'Hara KM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.041401; O'Hara KM, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.051403; Randeria M., 1995, BOSE EINSTEIN CONDEN, P355; Roati G, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.150403; Schreck F, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.080403; Stoof HTC, 1996, PHYS REV LETT, V76, P10, DOI 10.1103/PhysRevLett.76.10; Timmermans E, 2001, PHYS LETT A, V285, P228, DOI 10.1016/S0375-9601(01)00346-2; Truscott AG, 2001, SCIENCE, V291, P2570, DOI 10.1126/science.1059318	27	784	788	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	2002	298	5601					2179	2182		10.1126/science.1079107	http://dx.doi.org/10.1126/science.1079107			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	624RA	12424386	Green Submitted			2022-12-28	WOS:000179773700044
J	Bosanac, I; Alattia, JR; Mal, TK; Chan, J; Talarico, S; Tong, FK; Tong, KI; Yoshikawa, F; Furuichi, T; Iwai, M; Michikawa, T; Mikoshiba, K; Ikura, M				Bosanac, I; Alattia, JR; Mal, TK; Chan, J; Talarico, S; Tong, FK; Tong, KI; Yoshikawa, F; Furuichi, T; Iwai, M; Michikawa, T; Mikoshiba, K; Ikura, M			Structure of the inositol 1,4,5-trisphosphate receptor binding core in complex with its ligand	NATURE			English	Article							DOMAIN; SITE; RECOGNITION; EFFICIENT	In a variety of cells, the Ca2+ signalling process is mediated by the endoplasmic-reticulum-membrane-associated Ca2+ release channel, inositol 1,4,5-trisphosphate (InsP(3)) receptor (InsP(3)R)(1). Being ubiquitous and present in organisms ranging from humans to Caenorhabditis elegans, InsP(3)R has a vital role in the control of cellular and physiological processes as diverse as cell division, cell proliferation, apoptosis, fertilization, development, (b)ehaviour, memory and learning(2). Mouse type I InsP(3)R (InsP(3)R1), found in high abundance in cerebellar Purkinje cells, is a polypeptide with three major functionally distinct regions: the amino-terminal InsP(3)-binding region, the central modulatory region and the carboxy-terminal channel region (2). Here we present a 2.2-Angstrom crystal structure of the InsP(3)-binding core of mouse InsP(3)R1 in complex with InsP(3). The asymmetric, boomerang-like structure consists of an N-terminal beta-trefoil domain and a C-terminal alpha-helical domain containing an 'armadillo repeat'-like fold. The cleft formed by the two domains exposes a cluster of arginine and lysine residues that coordinate the three phosphoryl groups of InsP(3). Putative Ca2+-binding sites are identified in two separate locations within the InsP(3)-binding core.	Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Tokyo 1088639, Japan; Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; RIKEN, Inst Brain Res, Lab Dev Neurobiol & Mol Neurogenesis, Wako, Saitama 3510198, Japan; JST, ICORP, Calcium Oscillat Project, Tokyo 1080071, Japan	University of Tokyo; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; RIKEN; Japan Science & Technology Agency (JST)	Ikura, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Tokyo 1088639, Japan.		Mal, Tapas K/A-9453-2011; Furuichi, Teiichi/B-5086-2014; Mikoshiba, Katsuhiko/N-7943-2015	Mal, Tapas K/0000-0002-0625-2095; Furuichi, Teiichi/0000-0002-9676-1888; 				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hamada K, 2002, J BIOL CHEM, V277, P21115, DOI 10.1074/jbc.C200244200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hotoda H, 1999, BIOCHEMISTRY-US, V38, P9234, DOI 10.1021/bi990114r; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Jiang QX, 2002, EMBO J, V21, P3575, DOI 10.1093/emboj/cdf380; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOZIKOWSKI AP, 1993, J AM CHEM SOC, V115, P4429, DOI 10.1021/ja00064a002; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Marchant JS, 1997, CURR BIOL, V7, P510, DOI 10.1016/S0960-9822(06)00222-3; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; OVERDUIN M, 2001, MOL INTERVENTIONS, V1, P151; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wilcox RA, 1998, TRENDS PHARMACOL SCI, V19, P467, DOI 10.1016/S0165-6147(98)01260-7; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498	30	261	267	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 12	2002	420	6916					696	700		10.1038/nature01268	http://dx.doi.org/10.1038/nature01268			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	624GK	12442173				2022-12-28	WOS:000179751800052
J	Halder, GJ; Kepert, CJ; Moubaraki, B; Murray, KS; Cashion, JD				Halder, GJ; Kepert, CJ; Moubaraki, B; Murray, KS; Cashion, JD			Guest-dependent spin crossover in a nanoporous molecular framework material	SCIENCE			English	Article							X-RAY; COORDINATION POLYMER; TRANSITION; TEMPERATURE; PRESSURE; BEHAVIOR; NETWORKS; COMPLEX; CRYSTAL; LIGAND	The nanoporous metal-organic framework Fe-2(azpy)(4)(NCS)(4).(guest) (azpy is trans-4,4'-azopyridine) displays reversible uptake and release of guest molecules and contains electronic switching centers that are sensitive to the nature of the sorbed guests. The switching of this material arises from the presence of iron(II) spin crossover centers within the framework lattice, the sorbed phases undergoing "half-spin" crossovers, and the desorbed phase showing no switching property. The interpenetrated framework structure displays a considerable flexibility with guest uptake and release, causing substantial changes in the local geometry of the iron(II) centers. The generation of a host lattice that interacts with exchangeable guest species in a switchable fashion has implications for the generation of previously undeveloped advanced materials with applications in areas such as molecular sensing.	Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia; Monash Univ, Sch Chem, Melbourne, Vic 3800, Australia; Monash Univ, Sch Phys & Mat Engn, Melbourne, Vic 3800, Australia	University of Sydney; Monash University; Monash University	Kepert, CJ (corresponding author), Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia.		Halder, Gregory J/C-5357-2013; Cashion, John/AAE-7048-2019; Kepert, Cameron J/C-3079-2019	Kepert, Cameron J/0000-0002-6105-9706				Abrahams BF, 1998, ANGEW CHEM INT EDIT, V37, P2656, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2656::AID-ANIE2656>3.0.CO;2-M; ATWOOD JL, 1996, COMPREHENSIVE SUPRAM, V6; Biradha K, 2000, ANGEW CHEM INT EDIT, V39, P3843, DOI 10.1002/1521-3773(20001103)39:21<3843::AID-ANIE3843>3.0.CO;2-#; Breuning E, 2000, ANGEW CHEM INT EDIT, V39, P2504, DOI 10.1002/1521-3773(20000717)39:14<2504::AID-ANIE2504>3.0.CO;2-B; Brooker S, 1999, ANGEW CHEM INT EDIT, V38, P408, DOI 10.1002/(SICI)1521-3773(19990201)38:3<408::AID-ANIE408>3.0.CO;2-P; CORBIN DR, 1990, J AM CHEM SOC, V112, P4821, DOI 10.1021/ja00168a029; DECURTINS S, 1984, CHEM PHYS LETT, V105, P1, DOI 10.1016/0009-2614(84)80403-0; Eddaoudi M, 2002, SCIENCE, V295, P469, DOI 10.1126/science.1067208; Garcia Y, 1998, CHEM MATER, V10, P2426, DOI 10.1021/cm980107+; Garcia Y, 1999, INORG CHEM, V38, P4663, DOI 10.1021/ic990511q; Gutlich P, 2000, CHEM SOC REV, V29, P419, DOI 10.1039/b003504l; Hollingsworth MD, 2002, SCIENCE, V295, P2410; HOSKINS BF, 1990, J AM CHEM SOC, V112, P1546, DOI 10.1021/ja00160a038; Kahn O, 1999, CHEM-EUR J, V5, P3443, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3443::AID-CHEM3443>3.0.CO;2-#; Kahn O, 1998, SCIENCE, V279, P44, DOI 10.1126/science.279.5347.44; Kepert CJ, 1998, ANGEW CHEM INT EDIT, V37, P3158, DOI 10.1002/(SICI)1521-3773(19981204)37:22<3158::AID-ANIE3158>3.0.CO;2-8; Kepert CJ, 1999, CHEM COMMUN, P375, DOI 10.1039/a809746a; Kepert CJ, 2000, J AM CHEM SOC, V122, P5158, DOI 10.1021/ja993814s; Kitazawa T, 1996, J MATER CHEM, V6, P119, DOI 10.1039/jm9960600119; Kondo M, 2000, CHEM MATER, V12, P1288, DOI 10.1021/cm990612m; Lehn JM, 2002, SCIENCE, V295, P2400, DOI 10.1126/science.1071063; Li H, 1999, NATURE, V402, P276, DOI 10.1038/46248; Moliner N, 2000, INORG CHEM, V39, P5390, DOI 10.1021/ic0005588; Niel V, 2001, INORG CHEM, V40, P3838, DOI 10.1021/ic010259y; Nossov AV, 2001, J AM CHEM SOC, V123, P3563, DOI 10.1021/ja002767x; OZAROWSKI A, 1991, INORG CHEM, V30, P3167, DOI 10.1021/ic00016a013; REAL JA, 1995, SCIENCE, V268, P265, DOI 10.1126/science.268.5208.265; Roubeau O, 2002, CHEM MATER, V14, P2559, DOI 10.1021/cm0116626; Seo JS, 2000, NATURE, V404, P982, DOI 10.1038/35010088; Zaworotko MJ, 1999, NATURE, V402, P242, DOI 10.1038/46182	30	1329	1341	9	427	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1762	1765		10.1126/science.1075948	http://dx.doi.org/10.1126/science.1075948			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459583				2022-12-28	WOS:000179494800037
J	Zammit, S; Allebeck, P; Andreasson, S; Lundberg, I; Lewis, G				Zammit, S; Allebeck, P; Andreasson, S; Lundberg, I; Lewis, G			Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							DOPAMINE	Objectives An association between use of cannabis in adolescence and subsequent risk of schizophrenia was previously reported in a follow up of Swedish conscripts. Arguments were raised that this association may be due to use of drugs other than cannabis and that personality traits may have confounded results. We performed a further analysis of this cohort to address these uncertainties while extending the follow up period to identify additional cases. Design Historical cohort study. Setting 1969-70 survey of Swedish conscripts (> 97% of the country's male population aged 18-20). Participants 50 087 subjects: data were available on self reported use of cannabis and other drugs, and on several social and psychological characteristics. Main outcome measures Admissions to hospital for ICD-8/9 schizophrenia and other psychoses, as determined by record linkage. Results Cannabis was associated with an increased risk of developing schizophrenia in a dose dependent fashion both for subjects who had ever used cannabis (adjusted odds ratio for linear trend of increasing frequency 1.2, 95% confidence interval 1.1 to 1.4, P < 0.001), mid for subjects who had used only cannabis and no other drugs (adjusted odds ratio for linear trend 1.3, 1.1 to 1.5, P < 0.015). The adjusted odds ratio for using cannabis > 50 times was 6.7 (2.1 to 21.7) in the cannabis only group. Similar results were obtained when analysis was restricted to subjects developing schizophrenia after five years after conscription, to exclude prodromal cases. Conclusions Cannabis use is associated with an increased risk of developing schizophrenia, consistent with a causal relation. This association is not explained by use of other psychoactive drugs or personality traits relating to social integration.	Univ Wales Coll Med, Dept Psychol Med, Cardiff CF14 4XN, S Glam, Wales; Univ Gothenburg, Dept Social Med, Gothenburg, Sweden; Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; Univ Bristol, Div Psychiat, Bristol, Avon, England	Cardiff University; University of Gothenburg; Karolinska Institutet; University of Bristol	Zammit, S (corresponding author), Univ Wales Coll Med, Dept Psychol Med, Cardiff CF14 4XN, S Glam, Wales.		Young, Alexander/A-1523-2009; Lewis, Glyn/E-9944-2012	Young, Alexander/0000-0002-9367-9213; Lewis, Glyn/0000-0001-5205-8245; Zammit, Stanley/0000-0002-2647-9211				ANDREASSON S, 1987, LANCET, V2, P1483, DOI 10.1016/s0140-6736(87)92620-1; ANDREASSON S, 1989, ACTA PSYCHIAT SCAND, V79, P505, DOI 10.1111/j.1600-0447.1989.tb10296.x; Andreasson S, 1990, MISUSE ALCOHOL CANNA; CHEN K, 1995, AM J PUBLIC HEALTH, V85, P41, DOI 10.2105/AJPH.85.1.41; David AS, 1997, PSYCHOL MED, V27, P1311, DOI 10.1017/S0033291797005680; DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474; GEDDES JR, 1995, PSYCHOL MED, V25, P859, DOI 10.1017/S003329170003511X; Greenland S, 1998, MODERN EPIDEMIOLOGY, P231; Hall W, 2000, AUST NZ J PSYCHIAT, V34, P26, DOI 10.1046/j.1440-1614.2000.00685.x; Hall W., 1994, HLTH PSYCHOL CONSEQU; JABLENSKY A, 1986, SCHIZOPHRENIA BULL, V12, P52, DOI 10.1093/schbul/12.1.52; Johns A, 2001, BRIT J PSYCHIAT, V178, P116, DOI 10.1192/bjp.178.2.116; JOHNSON BA, 1988, LANCET, V1, P592; Johnstone EC, 1998, COMPANION PSYCHIAT S, P369; Kristjansson E, 1987, NORD PSYKIATR TIDSSK, V41, P229, DOI DOI 10.3109/08039488709103182; Lewis G, 2000, BRIT J PSYCHIAT, V177, P416, DOI 10.1192/bjp.177.5.416; LEWIS G, 1992, LANCET, V340, P137, DOI 10.1016/0140-6736(92)93213-7; Malmberg A, 1998, BRIT J PSYCHIAT, V172, P308, DOI 10.1192/bjp.172.4.308; NEGRETE JC, 1989, BRIT J ADDICT, V84, P349; Otto U, 1980, Acta Psychiatr Scand Suppl, V282, P1; SINGLETON N, 2001, PSYCHIAT MORBIDITY A; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; THOMAS HUW, 1993, BRIT J PSYCHIAT, V163, P141, DOI 10.1192/bjp.163.2.141; World Health Organization, 1974, GLOSS MENT DIS GUID; ZAMMIT S, IN PRESS INVESTIGATI; ZAMMIT S, IN PRESS PATERNAL AG	26	544	559	4	70	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 23	2002	325	7374					1199	1201		10.1136/bmj.325.7374.1199	http://dx.doi.org/10.1136/bmj.325.7374.1199			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	619YU	12446534	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000179506200017
J	Lip, GYH; Kamath, S; Hart, RG				Lip, GYH; Kamath, S; Hart, RG			ABC of antithrombotic therapy - Antithrombotic therapy for cerebrovascular disorders	BRITISH MEDICAL JOURNAL			English	Article									City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	University of Birmingham; University of Texas System; University of Texas Health San Antonio	Lip, GYH (corresponding author), City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England.							Adams HP, 2002, STROKE, V33, P856, DOI 10.1161/hs0302.104628; Albers CW, 2001, CHEST, V119, p300S, DOI 10.1378/chest.119.1_suppl.300S; Atkinson RP, 2000, THROMB RES, V98, pV97; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Sandercock P, 1997, LANCET, V349, P1569	8	8	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2002	325	7373					1161	1163		10.1136/bmj.325.7373.1161	http://dx.doi.org/10.1136/bmj.325.7373.1161			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433770	Green Published			2022-12-28	WOS:000179443100027
J	McCabe, R; Heath, C; Burns, T; Priebe, S				McCabe, R; Heath, C; Burns, T; Priebe, S			Engagement of patients with psychosis in the consultation: conversation analytic study	BRITISH MEDICAL JOURNAL			English	Article							SATISFACTION; INTERVIEW; OUTCOMES	Objective To investigate how doctors engage with patients with psychotic illness in routine consultations. Design Conversation analysis of 32 consultations between psychiatrists and patients with schizophrenia or schizoaffective disorder. Setting Two psychiatric outpatient clinics in east London and south west London. Participants 7 psychiatrists and 32 patients with schizophrenia or schizoaffective disorder. Main outcome measure Mutual engagement in communication during the consultation. Results Patients actively attempted to talk about the content of their psychotic symptoms in consultations by asking direct questions, repeating their questions and utterances, and producing these utterances in the concluding part of the consultation. In response, doctors hesitated, responded with a question rather than with an answer, and smiled or laughed (when informal carers were present), indicating that they were reluctant to engage with patients' concerns about their psychotic symptoms. Conclusions Patients repeatedly attempted to talk about the content of their psychotic symptoms, which was a source of noticeable interactional tension and difficulty. Addressing patients' concerns about their illness may lead to a more satisfactory outcome of the consultation and improve engagement of such patients in the health services.	Barts & London Sch Med, Newham Ctr Mental Hlth, Unit Social & Community Psychiat, London E13 8SP, England; Univ London Kings Coll, Ctr Management, London SE1 8WA, England; St George Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England	University of London; Queen Mary University London; University of London; King's College London; St Georges University London	McCabe, R (corresponding author), Barts & London Sch Med, Newham Ctr Mental Hlth, Unit Social & Community Psychiat, London E13 8SP, England.		McCabe, Rose/A-9802-2013	Heath, Christian/0000-0003-3196-0197; McCabe, Rose/0000-0003-2041-7383; Priebe, Stefan/0000-0001-9864-3394				BERGMANN JR, 1992, TALK WORK; BERTAKIS KD, 1991, J FAM PRACTICE, V32, P175; Department of Health, 2000, NHS PLAN PLAN INV PL; Department of Health, 1999, MOD STAND SERV MOD; Drew P, 2001, Health Expect, V4, P58, DOI 10.1046/j.1369-6513.2001.00125.x; FRANKEL RM, 1990, INTERACTION COMPETEN; Haakana M., 2002, J SOCIOLING, V6, P207, DOI [10.1111/1467-9481.00185, DOI 10.1111/1467-9481.00185]; Haakana M., 2001, TEXT, V21, P187, DOI [https://doi.org/10.1515/text.1.21.1-2.187, DOI 10.1515/TEXT.1.21.1-2.187]; Heritage J, 1984, STRUCTURES SOCIAL AC; JEFFERSON G, 1992, TALK WORK; Jefferson G., 1984, STRUCTURES SOCIAL AC, pix; Killaspy H, 2000, BRIT J PSYCHIAT, V176, P160, DOI 10.1192/bjp.176.2.160; Levinson S. C., 1983, PRAGMATICS; Little P, 2001, BRIT MED J, V323, P908, DOI 10.1136/bmj.323.7318.908; Palmer D, 2000, SOCIOL HEALTH ILL, V22, P661, DOI 10.1111/1467-9566.00225; Perakyla A., 1997, QUALITATIVE ANAL ISS, P201; perakyla anssi, 1995, AIDS COUNSELLING I I; Pomerantz Anita., 1984, STRUCTURES SOCIAL AC, P57; ROTER DL, 1987, MED CARE, V25, P437, DOI 10.1097/00005650-198705000-00007; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; SACKS H, 1974, LANGUAGE, V50, P696, DOI 10.2307/412243; STEWART MA, 1984, SOC SCI MED, V19, P167, DOI 10.1016/0277-9536(84)90284-3; TENHAVE P, 1999, DOING CONVERSATION A	23	149	151	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2002	325	7373					1148	1151		10.1136/bmj.325.7373.1148	http://dx.doi.org/10.1136/bmj.325.7373.1148			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433765	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000179443100020
J	Labarrere, CA; Lee, JB; Nelson, DR; Al-Hassani, M; Miller, SJ; Pitts, DE				Labarrere, CA; Lee, JB; Nelson, DR; Al-Hassani, M; Miller, SJ; Pitts, DE			C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study	LANCET			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; APPARENTLY HEALTHY-MEN; UNSTABLE ANGINA; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PLASMA-CONCENTRATION; ELEVATED LEVELS; HEART-DISEASE; GRAFT FAILURE; RISK-FACTORS	Background Arterial endothelial expression and raised serum concentrations of the soluble form of intercellular adhesion molecule-1 (ICAM-1) are implicated in development of transplant coronary artery disease. We investigated whether C-reactive protein, known to stimulate ICAM-1, was associated with increased ICAM-1 concentration and subsequent development of coronary artery disease. Methods With sandwich ELISAs, we measured C-reactive protein and soluble ICAM-1 in serial serum samples obtained during the first 3 months after transplantation in 109 heart-transplant patients. Matching endomyocardial biopsy samples were screened immunohistochemically for arterial endothelial ICAM-1. Serial coronary angiograms were assessed for development, severity, and progression of coronary artery disease. Findings We showed a significant correlation (p=0.001) between raised concentrations of C-reactive protein and arterial endothelial ICAM-1 expression in endomyocardial biopsy samples. We also noted a significant relation between C-reactive protein and soluble CAM-1 concentrations soon after transplantation (p=0.003). Early raised C-reactive protein concentrations were associated with development (p=0.004), increased severity (p=0.02), and enhanced rate of progression (p=0.01) of coronary artery disease, and with heightened frequency of ischaemic events (p=0.049) and graft failure (p=0.04). Interpretation C-reactive protein concentration can be used to identify heart-transplant patients at increased risk of coronary artery disease and graft failure. Treatments directed at reduction of C-reactive protein concentration could improve patients' outcome.	Methodist Indiana Univ, Riley Hosp, Clarian Hlth Partners, Methodist Res Inst, Indianapolis, IN USA; Methodist Indiana Univ, Riley Hosp, Clarian Hlth Partners, Dept Transplantat, Indianapolis, IN USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA	Indiana University System; James Whitcomb Riley Hospital Children; Indiana University System; James Whitcomb Riley Hospital Children; Cleveland Clinic Foundation	Labarrere, CA (corresponding author), Methodist Res Inst Clarian Hlth, 1701 N Senate Blvd, Indianapolis, IN 46202 USA.	clabarrere@clarian.org		Nelson, David/0000-0002-3240-0725				Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Blankenberg S, 2001, CIRCULATION, V104, P1336, DOI 10.1161/hc3701.095949; Costanzo MR, 1998, J HEART LUNG TRANSPL, V17, P744; Eisenberg MS, 2000, CIRCULATION, V102, P2100, DOI 10.1161/01.CIR.102.17.2100; Gag SZ, 1996, J AM COLL CARDIOL, V28, P673, DOI 10.1016/0735-1097(96)00201-X; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Hwang SJ, 1997, CIRCULATION, V96, P4219; JACKSON E, 2001, HEMOSTASIS THROMBOSI, P1179; JOHNSON DE, 1989, J HEART TRANSPLANT, V8, P349; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Labarrere CA, 2000, CIRCULATION, V102, P1549, DOI 10.1161/01.CIR.102.13.1549; Labarrere CA, 2000, JAMA-J AM MED ASSOC, V284, P457, DOI 10.1001/jama.284.4.457; LABARRERE CA, 1995, NEW ENGL J MED, V333, P1111, DOI 10.1056/NEJM199510263331704; Labarrere CA, 1997, JAMA-J AM MED ASSOC, V278, P1169, DOI 10.1001/jama.278.14.1169; Lagrand WK, 1999, CIRCULATION, V100, P96, DOI 10.1161/01.CIR.100.1.96; Liuzzo G, 1996, CIRCULATION, V94, P2373, DOI 10.1161/01.CIR.94.10.2373; Mueck AO, 2001, EXP CLIN ENDOCR DIAB, V109, P181, DOI 10.1055/s-2001-14843; Pasceri V, 2000, CIRCULATION, V102, P2165; Rebuzzi AG, 1998, AM J CARDIOL, V82, P715, DOI 10.1016/S0002-9149(98)00458-5; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Shah PK, 2000, CIRCULATION, V101, P1758, DOI 10.1161/01.CIR.101.15.1758; Zhu JH, 1999, J AM COLL CARDIOL, V34, P1738, DOI 10.1016/S0735-1097(99)00410-6	30	94	96	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	2002	360	9344					1462	1467		10.1016/S0140-6736(02)11473-5	http://dx.doi.org/10.1016/S0140-6736(02)11473-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433514				2022-12-28	WOS:000179186000011
J	Lens, L; Van Dongen, S; Norris, K; Githiru, M; Matthysen, E				Lens, L; Van Dongen, S; Norris, K; Githiru, M; Matthysen, E			Avian persistence in fragmented rainforest	SCIENCE			English	Article							FLUCTUATING ASYMMETRY; CONSERVATION; FITNESS	What factors determine the persistence of species in fragmented habitats? To address this question, we studied the relative impacts of forest deterioration and fragmentation on bird species in 12 rainforest fragments in Kenya, combining 6 years of individual capture-recapture data with measurements of current captures and museum specimens. Species mobility, as estimated from species-specific dispersal rates, and tolerance to habitat deterioration, as estimated from change in fluctuating asymmetry with increasing habitat disturbance, explained 88% of the variation in patch occupancy among eight forest bird species. Occupancy increased with mobility and with tolerance to deterioration, where both variables contributed equally to this relationship. We conclude that individual-level study, such as of dispersal behavior and phenotypic development, can predict patterns of persistence at the species level. More generally, for conservation tactics to stand a high chance of success, they should include action both within sites, to minimize habitat deterioration, and across landscapes, to maximize dispersal.	Univ Antwerp, Dept Biol, B-2610 Antwerp, Belgium; Natl Museums Kenya, Dept Ornithol, Nairobi, Kenya; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Antwerp; University of Reading; University of Oxford	Lens, L (corresponding author), Univ Ghent, Dept Biol, Lab Terr Ecol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	luc.lens@rug.ac.be	Rodewald, Amanda D/I-6308-2016	Rodewald, Amanda D/0000-0002-6719-6306; Lens, Luc/0000-0002-0241-2215				Carbone C, 2002, SCIENCE, V295, P2273, DOI 10.1126/science.1067994; CLARKE GM, 1995, CONSERV BIOL, V9, P18, DOI 10.1046/j.1523-1739.1995.09010018.x; Congdon P., 2001, BAYESIAN STAT MODELL; Dias PC, 1996, TRENDS ECOL EVOL, V11, P326, DOI 10.1016/0169-5347(96)10037-9; Etienne RS, 2001, AM NAT, V158, P389, DOI 10.1086/321986; GILKS WR, 1994, STATISTICIAN, V43, P169, DOI 10.2307/2348941; Hale ML, 2001, SCIENCE, V293, P2246, DOI 10.1126/science.1062574; Lens L, 1999, P ROY SOC B-BIOL SCI, V266, P1241, DOI 10.1098/rspb.1999.0769; Lens L, 2002, BIOL REV, V77, P27, DOI 10.1017/S1464793101005796; Lens L, 2002, CONSERV BIOL, V16, P479, DOI 10.1046/j.1523-1739.2002.00516.x; Lima SL, 1996, TRENDS ECOL EVOL, V11, P131, DOI 10.1016/0169-5347(96)81094-9; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; ROBINSON GR, 1992, SCIENCE, V257, P524, DOI 10.1126/science.257.5069.524; van Dongen S, 1999, J EVOLUTION BIOL, V12, P94, DOI 10.1046/j.1420-9101.1999.00012.x; VANVALEN L, 1962, EVOLUTION, V16, P125; White GC, 1999, BIRD STUDY, V46, P120, DOI 10.1080/00063659909477239	16	142	153	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	2002	298	5596					1236	1238		10.1126/science.1075664	http://dx.doi.org/10.1126/science.1075664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424379				2022-12-28	WOS:000179080400051
J	Miller, GT; Pitnick, S				Miller, GT; Pitnick, S			Sperm-female coevolution in Drosophila	SCIENCE			English	Article							RAPID EVOLUTION; REPRODUCTIVE PROTEINS; BODY-SIZE; COMPETITION; COST	Rapid evolution of reproductive traits has been attributed to sexual selection arising from interaction between the sexes. However, little is known about the nature of selection driving the evolution of interacting sex-specific phenotypes. Using populations of Drosophila melanogaster selected for divergent sperm length or female sperm-storage organ length, we experimentally show that male fertilization success is determined by an interaction between sperm and female morphology. In addition, sperm length evolution occurred as a correlated response to selection on the female reproductive tract. Giant sperm tails are the cellular equivalent of the peacock's tail, having evolved because females evolved reproductive tracts that selectively bias paternity in favor of males with longer sperm.	Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA	Syracuse University	Pitnick, S (corresponding author), Syracuse Univ, Dept Biol, 108 Coll Pl, Syracuse, NY 13244 USA.	sspitnic@syr.edu						Andersson Malte, 1994; Arnqvist G, 2002, EVOLUTION, V56, P936; BAKKER TCM, 1995, J EVOLUTION BIOL, V8, P129, DOI 10.1046/j.1420-9101.1995.8020129.x; Birkhead TR, 2000, EVOLUTION, V54, P1057; Briskie JV, 1997, EVOLUTION, V51, P937, DOI 10.1111/j.1558-5646.1997.tb03674.x; Clark AG, 1999, SCIENCE, V283, P217, DOI 10.1126/science.283.5399.217; Eady PE, 2001, J ZOOL, V253, P47, DOI 10.1017/S095283690100005X; GAGE MJG, 1994, P ROY SOC B-BIOL SCI, V258, P247, DOI 10.1098/rspb.1994.0169; Gage MJG, 1998, P ROY SOC B-BIOL SCI, V265, P97, DOI 10.1098/rspb.1998.0269; Gavrilets S, 2000, NATURE, V403, P886, DOI 10.1038/35002564; Jamieson B.G., 1987, ULTRASTRUCTURE PHYLO; Karr TL, 1996, NATURE, V379, P405, DOI 10.1038/379405a0; LaMunyon CW, 2002, P ROY SOC B-BIOL SCI, V269, P1125, DOI 10.1098/rspb.2002.1996; Miller GT, 2001, HEREDITY, V87, P25, DOI 10.1046/j.1365-2540.2001.00903.x; MILLER GT, IN PRESS J EVOL BIOL; Morrow EH, 2001, P ROY SOC B-BIOL SCI, V268, P2281, DOI 10.1098/rspb.2001.1807; Parker GA, 1998, PHILOS T R SOC B, V353, P261, DOI 10.1098/rstb.1998.0208; Pitnick S, 1996, AM NAT, V148, P57, DOI 10.1086/285911; Pitnick S, 2001, P ROY SOC B-BIOL SCI, V268, P1071, DOI 10.1098/rspb.2001.1621; PITNICK S, 1995, P NATL ACAD SCI USA, V92, P10614, DOI 10.1073/pnas.92.23.10614; Pitnick S, 1999, EVOLUTION, V53, P1804, DOI [10.2307/2640442, 10.1111/j.1558-5646.1999.tb04564.x]; Pitnick S, 2002, P ROY SOC B-BIOL SCI, V269, P1821, DOI 10.1098/rspb.2002.2090; PITNICK S, UNPUB; Rakitin A, 1999, CAN J FISH AQUAT SCI, V56, P2315, DOI 10.1139/cjfas-56-12-2315; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Simmons LW, 2002, EVOLUTION, V56, P1622, DOI 10.1111/j.0014-3820.2002.tb01474.x; SIMMONS LW, 2001, SPERM CONPETITION IT; Sutton KA, 1997, J MOL EVOL, V45, P579, DOI 10.1007/PL00006262; Swanson WJ, 2002, NAT REV GENET, V3, P137, DOI 10.1038/nrg733; Swanson WJ, 2001, P NATL ACAD SCI USA, V98, P2509, DOI 10.1073/pnas.051605998; Swanson WJ, 2001, P NATL ACAD SCI USA, V98, P7375, DOI 10.1073/pnas.131568198; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070	33	349	351	0	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	2002	298	5596					1230	1233		10.1126/science.1076968	http://dx.doi.org/10.1126/science.1076968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424377				2022-12-28	WOS:000179080400049
J	Dedi, R; Turney, JH				Dedi, R; Turney, JH			Clinical picture - Obstructive nephropathy and iliac aneurysm	LANCET			English	Editorial Material									Leeds Gen Infirm, Dept Nephrol, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; University of Leeds	Dedi, R (corresponding author), Leeds Gen Infirm, Dept Nephrol, Wellcome Wing, Leeds LS1 3EX, W Yorkshire, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1374	1374		10.1016/S0140-6736(02)11400-0	http://dx.doi.org/10.1016/S0140-6736(02)11400-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423983	Bronze			2022-12-28	WOS:000179081600010
J	MacKie, RM; Bray, CA; Hole, DJ				MacKie, RM; Bray, CA; Hole, DJ			Observational study of type of surgical training and outcome of definitive surgery for primary malignant melanoma	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; MARGINS		Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow	MacKie, RM (corresponding author), Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland.		Kelly, Caroline/AAZ-4146-2021	Kelly, Caroline/0000-0002-5330-7888				BALCH CM, 1993, ANN SURG, V218, P262, DOI 10.1097/00000658-199309000-00005; COX DR, 1972, J R STAT SOC B, V34, P187; MacKie RM, 1997, BRIT MED J, V315, P1117, DOI 10.1136/bmj.315.7116.1117; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; VERONESI U, 1988, NEW ENGL J MED, V318, P1159, DOI 10.1056/NEJM198805053181804	5	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1276	1277		10.1136/bmj.325.7375.1276	http://dx.doi.org/10.1136/bmj.325.7375.1276			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458246	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000179696300018
J	Bezerra, JA; Tiao, G; Ryckman, FC; Alonso, M; Sabla, GE; Shneider, B; Sokol, RJ; Aronow, BJ				Bezerra, JA; Tiao, G; Ryckman, FC; Alonso, M; Sabla, GE; Shneider, B; Sokol, RJ; Aronow, BJ			Genetic induction of proinflammatory immunity in children with billary atresia	LANCET			English	Article							EXTRAHEPATIC BILIARY ATRESIA; BILE-DUCTS; T-CELLS; EXPRESSION; LIVER; INTERLEUKIN-8; OSTEOPONTIN; DISEASE; GAMMA	Background Biliary atresia is the commonest cause of pathological jaundice in infants and the leading indication for liver transplantation in children worldwide. The cause and pathogenesis remain largely unknown. Because of clinical heterogeneity and experimental difficulties in addressing molecular mechanisms underlying multifactorial disorders in human beings, we searched for genomic signatures of biliary atresia in affected infants. Methods We generated pools of biotinylated cRNA from livers of 14 infants with biliary atresia and six with neonatal intrahepatic cholestasis (diseased controls) and hybridised the cRNA against oligonucleotide-based gene chips. Immunohistochemistry and reverse transcriptase (RT)-PCR were used to assess the specificity of the findings and functional commitment of lymphocytes in affected livers. Findings Data filtering, to identify genes that are differentially expressed, and cluster analysis revealed a predominant and coordinated activation of immunity/inflammation genes within the livers of infants with biliary atresia. Most of the genes showed differential lymphocyte function, with activation of osteopontin, a regulator of cell-mediated (T-helper 1 [Th-1]) immunity in T-helper lymphocytes, and suppression of immunoglobulin genes in early stages of disease. These findings were associated with production of interferon gamma in 65% of infants with biliary atresia and no diseased control. However, histologically similar inflammatory infiltrates were present in livers of both groups, implying differential activation states of similar cell types. Interpretation Livers of infants with biliary atresia have a coordinated activation of genes involved in lymphocyte differentiation. Among these genes, the overexpression of osteopontin and interferon gamma points to a potential role of Th-1-like cytokines in disease pathogenesis.	Childrens Hosp, Med Ctr, Div Pediat Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Surg, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Cincinnati, OH USA; Mt Sinai Sch Med, Div Pediat Gastroenterol & Hepatol, New York, NY USA; Univ Colorado, Hlth Sci Ctr, Pediat Liver Ctr, Sect Pediat Gastroenterol Hepatol & Nutr, Denver, CO USA; Childrens Hosp, Denver, CO 80218 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Icahn School of Medicine at Mount Sinai; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	Bezerra, JA (corresponding author), Childrens Hosp, Med Ctr, Div Pediat Gastroenterol Hepatol & Nutr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Aronow, Bruce J/F-8438-2012					Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; Ahmed AFKU, 2001, J PATHOL, V193, P383; Balistreri WF, 1996, HEPATOLOGY, V23, P1682, DOI 10.1002/hep.510230652; Bezerra JA, 1999, P NATL ACAD SCI USA, V96, P15143, DOI 10.1073/pnas.96.26.15143; Broome U, 1997, J HEPATOL, V26, P857, DOI 10.1016/S0168-8278(97)80253-X; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Davenport M, 2001, J PEDIATR SURG, V36, P1017, DOI 10.1053/jpsu.2001.24730; Delhanty PJD, 2001, AM J PHYSIOL-ENDOC M, V280, pE287, DOI 10.1152/ajpendo.2001.280.2.E287; Eystathioy T, 2000, J AUTOIMMUN, V14, P179, DOI 10.1006/jaut.1999.0359; Fukushi M, 1999, FEBS LETT, V442, P83, DOI 10.1016/S0014-5793(98)01631-7; Hu HM, 1998, J IMMUNOL, V160, P2334; Kameda H, 1998, ANN RHEUM DIS, V57, P366, DOI 10.1136/ard.57.6.366; Kelley-Loughnane N, 2002, HEPATOLOGY, V35, P525, DOI 10.1053/jhep.2002.31351; Lamireau T, 1999, J HEPATOL, V31, P248, DOI 10.1016/S0168-8278(99)80221-9; Marchant A, 1999, J IMMUNOL, V163, P2249; Mazziotti MV, 1999, HEPATOLOGY, V30, P372, DOI 10.1002/hep.510300223; Mukaida N, 1998, CYTOKINE GROWTH F R, V9, P9, DOI 10.1016/S1359-6101(97)00022-1; O'Regan AW, 2000, J LEUKOCYTE BIOL, V68, P495; OHYA T, 1995, J PEDIATR SURG, V30, P515, DOI 10.1016/0022-3468(95)90120-5; Oxelius VA, 1999, SCAND J IMMUNOL, V50, P440, DOI 10.1046/j.1365-3083.1999.00618.x; Oxelius VA, 1998, INT ARCH ALLERGY IMM, V115, P215, DOI 10.1159/000023903; Petersen C, 1997, J PEDIATR SURG, V32, P1190, DOI 10.1016/S0022-3468(97)90680-1; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75, DOI 10.1159/000237512; Ramm GA, 1998, AM J PATHOL, V153, P527, DOI 10.1016/S0002-9440(10)65595-2; RIEPENHOFFTALTY M, 1993, PEDIATR RES, V33, P394; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Urushihara N, 2000, J PEDIATR SURG, V35, P446, DOI 10.1016/S0022-3468(00)90211-2; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; Zeilhofer HU, 2000, CURR OPIN HEMATOL, V7, P178, DOI 10.1097/00062752-200005000-00009	30	144	155	1	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 23	2002	360	9346					1653	1659		10.1016/S0140-6736(02)11603-5	http://dx.doi.org/10.1016/S0140-6736(02)11603-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457789				2022-12-28	WOS:000179393900011
J	Hayman, G; Bansal, A				Hayman, G; Bansal, A			Drug points - Antibody deficiency associated with carbamazepine	BMJ-BRITISH MEDICAL JOURNAL			English	Letter							HYPOGAMMAGLOBULINEMIA		Epsom & St Helier NHS Trust, Carshalton SM5 1AA, Surrey, England		Hayman, G (corresponding author), Epsom & St Helier NHS Trust, Carshalton SM5 1AA, Surrey, England.	Grant.Hayman@epsom-sthelier.nhs.uk						Hammarstrom L, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P250; RODRIGUEZ MCG, 1983, J CLIN LAB IMMUNOL, V11, P55; Spickett GP, 1996, J NEUROL NEUROSUR PS, V60, P459, DOI 10.1136/jnnp.60.4.459; van Ginneken EEM, 1999, NETH J MED, V54, P158, DOI 10.1016/S0300-2977(98)00140-5	4	12	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	2002	325	7374					1213	1213		10.1136/bmj.325.7374.1213	http://dx.doi.org/10.1136/bmj.325.7374.1213			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446538	Green Published, Bronze			2022-12-28	WOS:000179506200021
J	Power, C				Power, C			Childhood adversity still matters for adult health outcomes	LANCET			English	Editorial Material									Inst Child Hlth, London WC1N 1EH, England	University of London; University College London	Power, C (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	c.power@ich.ucl.ac.uk						Ben Shlomo, 1997, LIFECOURSE APPROACH; DREVER F, 1997, SERIES DS, V15; Gregg P., 1999, FISCAL STUDIES, V20, P163; Gunnell DJ, 1998, J EPIDEMIOL COMMUN H, V52, P142, DOI 10.1136/jech.52.3.142; Keating DP, 1999, DEV HLTH WEALTH NATI; Parsons TJ, 1999, INT J OBESITY, V23, pS1; Power C, 1999, AM J PUBLIC HEALTH, V89, P1059, DOI 10.2105/AJPH.89.7.1059; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; STRACHAN DP, 1997, LIFECOURSE APPROACH	9	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2002	360	9346					1619	1620		10.1016/S0140-6736(02)11651-5	http://dx.doi.org/10.1016/S0140-6736(02)11651-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457781				2022-12-28	WOS:000179393900003
J	Stanberry, LR; Spruance, SL; Cunningham, AL; Bernstein, DI; Mindel, A; Sacks, S; Tyring, S; Aoki, FY; Slaoui, M; Denis, M; Vandepapeliere, P; Dubin, G				Stanberry, LR; Spruance, SL; Cunningham, AL; Bernstein, DI; Mindel, A; Sacks, S; Tyring, S; Aoki, FY; Slaoui, M; Denis, M; Vandepapeliere, P; Dubin, G		GlaxoSmithKline Herpes Vaccine Eff	Glycoprotein-D-adjuvant vaccine to prevent genital herpes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS TYPE-2; INFECTION; CHABAUDI; DISEASE; SYSTEM; IMPACT; HSV-2; CELLS	Background: An effective prophylactic vaccine would help control the spread of genital herpes. Methods: We conducted two double-blind, randomized trials of a herpes simplex virus type 2 (HSV-2) glycoprotein-D-subunit vaccine with alum and 3-O-deacylated-monophosphoryl lipid A in subjects whose regular sexual partners had a history of genital herpes. In Study 1, subjects were seronegative for herpes simplex virus type 1 (HSV-1) and HSV-2; in Study 2, subjects were of any HSV serologic status. At months 0, 1, and 6, subjects received either vaccine or a control injection and were evaluated for 19 months. The primary end point was the occurrence of genital herpes disease in all subjects in Study 1 and in HSV-2-seronegative female subjects in Study 2. Results: A total of 847 subjects who were seronegative for both HSV-1 and HSV-2 (268 of them women, in Study 1) and 1867 subjects who were seronegative for HSV-2 (710 of them women, in Study 2) underwent randomization and received injections. Vaccination was well tolerated and elicited humoral and cellular responses. Overall, the efficacy of the vaccine was 38 percent in Study 1 (95 percent confidence interval, -18 to 68 percent; 15 cases occurred in the vaccine group and 24 in the control group), and efficacy in female subjects was 42 percent in Study 2 (95 percent confidence interval, -31 to 74 percent; 9 cases occurred in the vaccine group and 16 in the control group). In both studies, further analysis showed that the vaccine was efficacious in women who were seronegative for both HSV-1 and HSV-2: efficacy in Study 1 was 73 percent (95 percent confidence interval, 19 to 91 percent; P=0.01), and efficacy in Study 2 was 74 percent (95 percent confidence interval, 9 to 93 percent; P=0.02). It was not efficacious in women who were seropositive for HSV-1 and seronegative for HSV-2 at base line or in men. Conclusions: These studies suggest that the glycoprotein D vaccine has efficacy against genital herpes in women who are seronegative for both HSV-1 and HSV-2 at base line but not in those who are seropositive for HSV-1 and seronegative for HSV-2. It had no efficacy in men, regardless of their HSV serologic status.	Univ Texas, Med Branch, Galveston, TX 77550 USA; Univ Utah, Salt Lake City, UT USA; Westmead Hosp, Westmead Millennium Inst, Westmead, NSW 2145, Australia; Westmead Hosp, Sexually Transmitted Infect Res Ctr, Westmead, NSW 2145, Australia; Univ Sydney, Westmead, NSW 2145, Australia; Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; Viridae Clin Sci, Vancouver, BC, Canada; Univ Manitoba, Winnipeg, MB, Canada; GlaxoSmithKline Biol, Rixensart, Belgium	University of Texas System; University of Texas Medical Branch Galveston; Utah System of Higher Education; University of Utah; University of Sydney; Westmead Institute for Medical Research; University of Sydney; University of Sydney; Cincinnati Children's Hospital Medical Center; University of Manitoba; GlaxoSmithKline	Stanberry, LR (corresponding author), Univ Texas, Med Branch, Childrens Hosp 3 300, Dept Pediat, 301 Univ Blvd, Galveston, TX 77555 USA.			Cunningham, Anthony/0000-0002-6744-5667; Mindel, Adrian/0000-0002-8780-9982				Af Geijersstam V, 1998, INT J CANCER, V76, P341, DOI 10.1002/(SICI)1097-0215(19980504)76:3&lt;341::AID-IJC10&gt;3.0.CO;2-E; Ashley RL, 1999, CLIN MICROBIOL REV, V12, P1; Barna M, 1996, J NEUROIMMUNOL, V67, P31, DOI 10.1016/0165-5728(96)00022-7; BASTIN C, 1994, 34 INT C ANT AG CHEM, P26; CARNEY O, 1994, GENITOURIN MED, V70, P40; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331; Cunningham A L, 2001, Herpes, V8 Suppl 1, p6A; CUNNINGHAM AL, 2000, SEXUALLY TRANSMITTED, P3; Deshpande SP, 2000, MICROBES INFECT, V2, P973, DOI 10.1016/S1286-4579(00)00339-7; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; FRANCOTTE M, 1993, 18 INT HERP WORKSH P, pC38; Han X, 2001, J VIROL, V75, P7789; HERMAND P, 1992, 17 INT HERP WORKSH E, P388; HERMAND P, 1992, 17 INT HERP WORKSH E, P376; Kim SH, 1999, J IMMUNOL, V162, P5561; KIMURA H, 1990, MED MICROBIOL IMMUN, V179, P177, DOI 10.1007/BF00195248; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; Langenberg A, 1989, ANN INTERN MED, V110, P822; Langenberg AGM, 1999, NEW ENGL J MED, V341, P1432, DOI 10.1056/NEJM199911043411904; LEROUXROELS G, 1994, 34 INT C ANT AG CHEM, P205; Mindel A, 1996, SCAND J INFECT DIS, P27; Moore A, 1999, VACCINE, V17, P2517, DOI 10.1016/S0264-410X(99)00062-6; Patel R, 1999, SEX TRANSM INFECT, V75, P398, DOI 10.1136/sti.75.6.398; REEVES WC, 1981, NEW ENGL J MED, V305, P315, DOI 10.1056/NEJM198108063050604; SIMMONS A, 1984, J VIROL, V52, P816, DOI 10.1128/JVI.52.3.816-821.1984; Singh M, 1998, VACCINE, V16, P1822, DOI 10.1016/S0264-410X(98)00179-0; SKOLDENBERG B, 1975, SCAND J INFECT DIS, V7, P227, DOI 10.3109/inf.1975.7.issue-4.01; Stanberry LR, 2000, CLIN INFECT DIS, V30, P549, DOI 10.1086/313687; Su Z, 2000, INFECT IMMUN, V68, P4399, DOI 10.1128/IAI.68.8.4399-4406.2000; Thoelen S, 2001, VACCINE, V19, P2400, DOI 10.1016/S0264-410X(00)00462-X; Whitacre CC, 1999, SCIENCE, V283, P1277, DOI 10.1126/science.283.5406.1277; Wilcoxen SC, 2000, J IMMUNOL, V164, P6237, DOI 10.4049/jimmunol.164.12.6237; WUNDERLICH F, 1993, VACCINE, V11, P1097, DOI 10.1016/0264-410X(93)90068-9	34	589	645	0	25	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1652	1661		10.1056/NEJMoa011915	http://dx.doi.org/10.1056/NEJMoa011915			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444179				2022-12-28	WOS:000179339900003
J	Fagan, PJ; Wise, TN; Schmidt, CW; Berlin, FS				Fagan, PJ; Wise, TN; Schmidt, CW; Berlin, FS			Pedophilia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILD SEXUAL ABUSE; ADOLESCENT PROBLEM BEHAVIORS; OFFENDER RECIDIVISM; MEDROXYPROGESTERONE ACETATE; PSYCHOPATHOLOGY; METAANALYSIS; ORIENTATION; COMORBIDITY; PARAPHILIA; HISTORY	This article addresses the risk factors associated with the psychiatric disorder pedophilia, its treatment, and treatment outcomes. it addresses physician responsibilities associated with case identification of victims and possible roles in the medical management of pedophilia. The essential feature of pedophilia is that an individual is sexually attracted exclusively or in part to prepubescent children. While pedophilia may be limited to fantasies and impulses, pedophilic behaviors are the primary concern of both the mental health and criminal justice systems. Remote risk factors for development of pedophilia often include the individual having been sexually abused as a child. Proximate risk factors for its behavioral expression are prevalence of comorbid psychiatric disorders and substance abuse disorders. Current treatment goals focus on stopping the behavior and achieving long-term behavioral control,in the community. Common treatment methods are cognitive-behavioral, group therapy, and, when appropriate, medications such as androgen-lowering agents that can act as sexual appetite suppressants. Meta-analyses have established that treatment is more effective than nontreatment in preventing recidivism of sexual offenders in general, a finding that has a high probability of application to individuals with pedophilia. Pedophilia is a chronic psychiatric disorder, but it is treatable in terms of developing strategies for preventing behavioral expression. Ultimately, reducing the prevalence of pedophilic behavior requires further collaboration between the criminal justice system and the health care communities.	Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Lutherville Timonium, MD USA	Johns Hopkins University	Fagan, PJ (corresponding author), Sexual Behav Consultat Unit, 10751 Falls Rd,Greenspring Stn,Suite 300, Lutherville Timonium, MD 21093 USA.	pfagan@jhmi.edu						ABEL GG, 1995, PSYCHIAT CLIN N AM, V18, P139, DOI 10.1016/S0193-953X(18)30076-5; ABEL GG, 1989, PERSPECTIVES BEHAVIO, P223; Alexander M A, 1999, Sex Abuse, V11, P101; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barbaree Howard E., 1997, P175; Bensley LS, 1999, J ADOLESCENT HEALTH, V24, P163; Bensley LS, 1999, J ADOLESCENT HEALTH, V24, P173; Berlin F. S., 1991, AM J FORENSIC PSYCH, V12, P5; BERLIN FS, 1991, AM J PSYCHIAT, V148, P449; BERLIN FS, 1991, AM J PSYCHIAT, V148, P1572; Berlin FS, 2000, AM J PSYCHIAT, V157, P838, DOI 10.1176/appi.ajp.157.5.838; BERLIN FS, 1988, ANN NY ACAD SCI, V528, P183, DOI 10.1111/j.1749-6632.1988.tb50861.x; Berlin FS, 2002, ARCH SEX BEHAV, V31, P479; BERLIN FS, 1981, AM J PSYCHIAT, V138, P601; BERLIN FS, 1995, TREATMENT PSYCHIAT D; BERLIN FS, 1983, SEXUAL AGGRESSOR CUR, P82; BERLIN FS, 2002, NEW ENGL J MED, V336, P1030; BERLIN FS, 1986, AM J FORENSIC PSYCH, V7, P13; Blanchard R, 1999, ARCH SEX BEHAV, V28, P111, DOI 10.1023/A:1018754004962; Bradford JMW, 2000, J SEX RES, V37, P248, DOI 10.1080/00224490009552045; BRADFORD JMW, 1985, BEHAVIORAL SCI LAW, V3, P355; Bremer J, 1959, ASEXUALIZATION FOLLO; Christian CW, 2000, PEDIATRICS, V106, P100, DOI 10.1542/peds.106.1.100; CONTE JR, 1989, CHILD ABUSE NEGLECT, V13, P293, DOI 10.1016/0145-2134(89)90016-1; COOPER AJ, 1986, CAN J PSYCHIAT, V31, P73, DOI 10.1177/070674378603100116; COOPER AJ, 1992, CAN J PSYCHIAT, V37, P687, DOI 10.1177/070674379203701003; Dhawan S., 1996, SEX ABUSE-J RES TR, V8, P7, DOI DOI 10.1177/107906329600800102; FAIRWEATHER DS, 1947, J MENT SCI, V93, P201, DOI 10.1192/bjp.93.391.201; FINKELHOR D, 1994, CHILD ABUSE NEGLECT, V18, P409, DOI 10.1016/0145-2134(94)90026-4; Finkelhor D., 1980, CHILD ABUSE NEGLECT, V4, P265, DOI [DOI 10.1016/0145-2134(80)90045-9, 10.1016/0145-2134(80)90045-9]; Frasier LD, 1997, PEDIATR ANN, V26, P306, DOI 10.3928/0090-4481-19970501-09; FREEMANLONGO RE, 2002, REVISITING MEGANS LA; FREUD S, 1985, 3 ESSAYS THEORY SEXU, P259; FREUND K, 1983, ARCH SEX BEHAV, V12, P369, DOI 10.1007/BF01542881; Freund K, 1980, Acta Psychiatr Scand Suppl, V287, P5; FREUND K, 1994, ARCH SEX BEHAV, V23, P553, DOI 10.1007/BF01541497; Friedrich WN, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.4.e9; FULLER AK, 1989, JAMA-J AM MED ASSOC, V261, P602, DOI 10.1001/jama.261.4.602; FURBY L, 1989, PSYCHOL BULL, V105, P3, DOI 10.1037/0033-2909.105.1.3; GAFFNEY GR, 1984, BRIT J PSYCHIAT, V145, P657, DOI 10.1192/bjp.145.6.657; GALBREATH NW, 2002, SEX INTERNET GUIDEBO; Gallagher C. A., 1999, CORRECTIONS MANAGEME, V3, P19; GREEN AH, 1993, J AM ACAD CHILD PSY, V32, P890, DOI 10.1097/00004583-199309000-00002; Greenberg DM, 1997, SEX ABUSE-J RES TR, V9, P349; Grossman LS, 1999, PSYCHIATR SERV, V50, P349, DOI 10.1176/ps.50.3.349; GROTH AN, 1978, J AM CRIMINAL JUSTIC, V41, P17; HALL GCN, 1995, J CONSULT CLIN PSYCH, V63, P802, DOI 10.1037/0022-006X.63.5.802; Hanson R. K., 1988, ANN SEX RES, V1, P485, DOI DOI 10.1007/BF00854712; Hanson R Karl, 2002, Sex Abuse, V14, P169, DOI 10.1023/A:1014624315814; Hanson RK, 1998, J CONSULT CLIN PSYCH, V66, P348, DOI 10.1037/0022-006X.66.2.348; HESS EH, 1966, BIOL BASIS BEHAV, P107; Hucker S., 1988, ANN SEX RES, V1, P227, DOI DOI 10.1007/BF00852799; Kairys SW, 1999, PEDIATRICS, V103, P186; KELLY RJ, 1982, CLIN PSYCHOL REV, V2, P387, DOI 10.1016/0272-7358(82)90020-4; Krafft-Ebing R., 1886, PSYCHOPATHIA SEXUALI; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; Maes M, 2001, NEUROPSYCHOPHARMACOL, V24, P37, DOI 10.1016/S0893-133X(00)00177-9; Maes M, 2001, PSYCHIAT RES, V103, P43, DOI 10.1016/S0165-1781(01)00268-2; MARKS IM, 1981, AM J PSYCHIAT, V138, P750; Marshall W. L., 1997, P152; Marshall WL, 2000, CLIN PSYCHOL REV, V20, P807, DOI 10.1016/S0272-7358(99)00013-6; MCCANN J, 1990, PEDIATRICS, V86, P428; MCCONAGHY N, 1989, ARCH SEX BEHAV, V18, P357, DOI 10.1007/BF01541954; McConaghy N, 1998, AUST NZ J PSYCHIAT, V32, P252, DOI 10.3109/00048679809062736; McCreary BD, 1999, CAN J PSYCHIAT, V44, P350, DOI 10.1177/070674379904400404; Mendez MF, 2000, J NEUROPSYCH CLIN N, V12, P71, DOI 10.1176/jnp.12.1.71; MENTEER T, 2002, HOUSE BUILT SAND WIL; Molnar BE, 2001, AM J PUBLIC HEALTH, V91, P753, DOI 10.2105/AJPH.91.5.753; Molnar BE, 2001, PSYCHOL MED, V31, P965, DOI 10.1017/S0033291701004329; Money J., 1980, LOVE LOVE SICKNESS; Murray JB, 2000, J PSYCHOL, V134, P211, DOI 10.1080/00223980009600863; Nabokov Vladimir, 1993, LOLITA; Petrunik MG, 2002, INT J OFFENDER THER, V46, P483, DOI 10.1177/0306624X02464009; PINTA ER, 1978, BIOL PSYCHIAT, V13, P369; Raymond NC, 1999, AM J PSYCHIAT, V156, P786; Robins LN, 2002, DIAGNOSTIC INTERVIEW; Rosler A, 1998, NEW ENGL J MED, V338, P416, DOI 10.1056/nejm199802123380702; SEDLAK AJ, 1996, EXECUTIVE SUMMARY 3R; Snyder H. N., 2000, NCJ182990 US DEP JUS; Sturup G. K., 1968, TREATING UNTREATABLE; STURUP GK, 1960, LAW CONTEMP PROBL, V25, P361, DOI 10.2307/1190382; Swanston HY, 1997, PEDIATRICS, V100, P600, DOI 10.1542/peds.100.4.600; THIBAUT F, 1993, ACTA PSYCHIAT SCAND, V87, P445, DOI 10.1111/j.1600-0447.1993.tb03402.x; WISSOW LS, 1995, NEW ENGL J MED, V332, P1425, DOI 10.1056/NEJM199505253322107	84	54	55	3	89	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2002	288	19					2458	2465		10.1001/jama.288.19.2458	http://dx.doi.org/10.1001/jama.288.19.2458			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	616FB	12435259				2022-12-28	WOS:000179292300029
J	Snow, V; Weiss, K; Wall, EM; Mottur-Pilson, C				Snow, V; Weiss, K; Wall, EM; Mottur-Pilson, C		Amer Acad Family Physicians; Amer Coll Physicians	Pharmacologic management of acute attacks of migraine and prevention of migraine headache	ANNALS OF INTERNAL MEDICINE			English	Review							DIHYDROERGOTAMINE NASAL SPRAY; DOUBLE-BLIND CROSSOVER; PROPHYLACTIC TREATMENT; NAPROXEN SODIUM; TOLFENAMIC ACID; SUBCUTANEOUS SUMATRIPTAN; AMERICAN MIGRAINE; DIVALPROEX SODIUM; ORAL SUMATRIPTAN; 25 MG		Amer Coll Physicians, Amer Soc Int Med, Philadelphia, PA 19106 USA	American College of Physicians	Snow, V (corresponding author), Amer Coll Physicians, Amer Soc Int Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	vincenza@mail.acponline.org						Adam E I, 1978, J R Coll Gen Pract, V28, P587; ADLY C, 1992, HEADACHE, V32, P101, DOI 10.1111/j.1526-4610.1992.hed3202101.x; ALDEEB SM, 1992, HEADACHE, V32, P461; ANDERSSON PG, 1983, CEPHALALGIA, V3, P207, DOI 10.1046/j.1468-2982.1983.0304207.x; ARTHUR G P, 1971, New Zealand Medical Journal, V73, P5; AUTRET A, 1987, CEPHALALGIA S6, V7, P451; BELLAVANCE AJ, 1990, HEADACHE, V30, P710, DOI 10.1111/j.1526-4610.1990.hed3011710.x; BORGESEN SE, 1974, ACTA NEUROL SCAND, V50, P651; BOUREAU F, 1994, CEPHALALGIA, V14, P156, DOI 10.1046/j.1468-2982.1994.1402156.x; BOUSSER MG, 1988, CEPHALALGIA, V8, P187, DOI 10.1046/j.1468-2982.1988.0803187.x; BRIGGS RS, 1979, HEADACHE, V19, P379, DOI 10.1111/j.1526-4610.1979.hed1907379.x; CADY RK, 1991, JAMA-J AM MED ASSOC, V265, P2831, DOI 10.1001/jama.265.21.2831; CALLAHAM M, 1986, HEADACHE, V26, P168, DOI 10.1111/j.1526-4610.1986.hed2604168.x; Carroll J D, 1975, Curr Med Res Opin, V3, P68, DOI 10.1185/03007997509113649; COPPOLA M, 1995, ANN EMERG MED, V26, P541, DOI 10.1016/S0196-0644(95)70001-3; Couch J R, 1976, Trans Am Neurol Assoc, V101, P234; COUCH JR, 1979, ARCH NEUROL-CHICAGO, V36, P695, DOI 10.1001/archneur.1979.00500470065013; CUTLER N, 1995, NEUROLOGY, V45, pS5; Cutler NR, 1996, CEPHALALGIA, V16, P113, DOI 10.1046/j.1468-2982.1996.1602113.x; DAS SM, 1979, ACTA NEUROL SCAND, V60, P214; DAWSON R, 1991, EUR NEUROL, V31, P332; DIAMOND S, 1993, HEADACHE Q-CURR TREA, V4, P169; DIAMOND S, 1975, HEADACHE, V15, P211, DOI 10.1111/j.1526-4610.1975.hed1503211.x; DIAMOND S, 1976, HEADACHE, V15, P282, DOI 10.1111/j.1526-4610.1976.hed1504282.x; EDWARDS C, 1991, EUR NEUROL, V31, P300; Elkind AH, 1989, CEPHALALGIA S10, V9, P369; ELLIS GL, 1993, ANN EMERG MED, V22, P191, DOI 10.1016/S0196-0644(05)80201-X; FERRARI MD, 1991, NEW ENGL J MED, V325, P316; FORSSMAN B, 1976, HEADACHE, V16, P238, DOI 10.1111/j.1526-4610.1976.hed1605238.x; FORSSMAN B, 1983, HEADACHE, V23, P188, DOI 10.1111/j.1526-4610.1983.hed2304188.x; FREITAG FG, 1984, J AM OSTEOPATH ASSOC, V84, P343; FRENKEN CWGM, 1984, CLIN NEUROL NEUROSUR, V86, P17, DOI 10.1016/0303-8467(84)90273-7; Gallagher RM, 1996, ARCH NEUROL-CHICAGO, V53, P1285, DOI 10.1001/archneur.1996.00550120097022; Gijsman H, 1997, CEPHALALGIA, V17, P647, DOI 10.1046/j.1468-2982.1997.1706647.x; Goldstein J, 1998, HEADACHE, V38, P516, DOI 10.1046/j.1526-4610.1998.3807516.x; GOMERSALL JD, 1973, J NEUROL NEUROSUR PS, V36, P684, DOI 10.1136/jnnp.36.4.684; HAKKARAINEN H, 1979, LANCET, V2, P326; HAVANKAKANNIAINEN H, 1989, HEADACHE, V29, P507, DOI 10.1111/j.1526-4610.1989.hed2908507.x; HERING R, 1992, CEPHALALGIA, V12, P81, DOI 10.1046/j.1468-2982.1992.1202081.x; HERRMANN WM, 1978, J INT MED RES, V6, P476, DOI 10.1177/030006057800600611; HOFFERT M, 1995, HEADACHE, V35, P177; HOFFERT MJ, 1995, HEADACHE, V35, P65, DOI 10.1111/j.1526-4610.1995.hed3502065.x; JENSEN R, 1994, NEUROLOGY, V44, P647, DOI 10.1212/WNL.44.4.647; JOHANNSSON V, 1987, HEADACHE, V27, P372, DOI 10.1111/j.1526-4610.1987.hed2707372.x; JOHNSON ES, 1985, CEPHALALGIA, V5, P5, DOI 10.1046/j.1468-2982.1985.0501005.x; JOHNSON RH, 1986, ACTA NEUROL SCAND, V73, P490, DOI 10.1111/j.1600-0404.1986.tb04591.x; KANGASNIEMI P, 1987, CEPHALALGIA, V7, P231, DOI 10.1046/j.1468-2982.1987.0704231.x; Klapper J, 1997, CEPHALALGIA, V17, P103, DOI 10.1046/j.1468-2982.1997.1702103.x; KLAPPER J, 1991, CEPHALALGIA, V11, P159, DOI 10.1177/0333102491011S1186; KLAPPER JA, 1994, HEADACHE Q-CURR TREA, V5, P50; Klassen A, 1997, HEADACHE, V37, P640, DOI 10.1046/j.1526-4610.1997.3710640.x; KLOSTER R, 1992, CEPHALALGIA, V12, P169, DOI 10.1046/j.1468-2982.1992.1203169.x; KRAKOWSKI AJ, 1973, PSYCHOSOMATICS, V14, P302; LANCE JW, 1963, MED J AUST       JUN, P814; LAWRENCE ER, 1977, HEADACHE, V17, P109, DOI 10.1111/j.1526-4610.1977.hed1703109.x; LINDEGAARD KF, 1980, HEADACHE, V20, P96, DOI 10.1111/j.1526-4610.1980.hed2002096.x; Lipton RB, 2001, HEADACHE, V41, P638, DOI 10.1046/j.1526-4610.2001.041007638.x; Lipton RB, 1998, ARCH NEUROL-CHICAGO, V55, P210, DOI 10.1001/archneur.55.2.210; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; LOUIS P, 1981, HEADACHE, V21, P235, DOI 10.1111/j.1526-4610.1981.hed2106235.x; MARTUCCI N, 1983, CEPHALALGIA, V3, P151, DOI 10.1177/03331024830030S124; Matchar DB, 2000, JAMA-J AM MED ASSOC, V284, P2640, DOI 10.1001/jama.284.20.2640; Matchar DB., 2000, NEUROLOGY, V54, P58, DOI [10.1212/WNL.54.1.58, DOI 10.1212/WNL.54.1.58]; MATHEW N, 1998, 17 ANN M AM PAIN SOC; Mathew NT, 1997, NEUROLOGY, V49, P1485, DOI 10.1212/WNL.49.6.1485; MATHEW NT, 1981, HEADACHE, V21, P105, DOI 10.1111/j.1526-4610.1981.hed2103105.x; MATHEW NT, 1995, ARCH NEUROL-CHICAGO, V52, P281, DOI 10.1001/archneur.1995.00540270077022; MATHEW NT, 1992, ARCH NEUROL-CHICAGO, V49, P1271, DOI 10.1001/archneur.1992.00530360073020; McCrory DC, 2000, EVIDENCE BASED GUIDE; MELLOR C, 1991, EUR NEUROL, V31, P306; MIKKELSEN B, 1986, ACTA NEUROL SCAND, V73, P423, DOI 10.1111/j.1600-0404.1986.tb03299.x; MONDRUP K, 1977, ACTA NEUROL SCAND, V56, P405; Myllyla VV, 1998, HEADACHE, V38, P201, DOI 10.1046/j.1526-4610.1998.3803201.x; NAPPI G, 1994, J NEUROL, V241, P138; NEUMAN M, 1986, INT J CLIN PHARM RES, V6, P11; *NTIS, 1999, DRUG TREATM PREV MIG; OSTERMAN PO, 1977, ACTA NEUROL SCAND, V56, P17; PEDERSEN E, 1966, CLIN PHARMACOL THER, V7, P520; Pfaffenrath V, 1998, HEADACHE, V38, P184, DOI 10.1046/j.1526-4610.1998.3803184.x; PINI LA, 1995, J INT MED RES, V23, P96, DOI 10.1177/030006059502300202; PRADALIER A, 1989, CEPHALALGIA, V9, P247, DOI 10.1046/j.1468-2982.1989.0904247.x; Ramadan N. M., 2000, EVIDENCE BASED GUIDE; Rapoport AM, 1997, NEUROLOGY, V49, P1210, DOI 10.1212/WNL.49.5.1210; ROHR J, 1985, CEPHALALGIA S3, V5, P142; RUSSELL MB, 1994, CEPHALALGIA, V14, P291, DOI 10.1046/j.1468-2982.1994.1404291.x; Ryan R, 1997, NEUROLOGY, V49, P1225, DOI 10.1212/WNL.49.5.1225; Ryan R E, 1968, Headache, V8, P118, DOI 10.1111/j.1526-4610.1968.hed0803118.x; RYAN RE, 1975, HEADACHE, V15, P202, DOI 10.1111/j.1526-4610.1975.hed1503202.x; RYAN RE, 1974, HEADACHE, V14, P33, DOI 10.1111/j.1526-4610.1974.hed1401033.x; RYAN RE, 1983, HEADACHE, V23, P26; RYAN RE, 1971, HEADACHE, V11, P6, DOI 10.1111/j.1526-4610.1971.hed110106.x; SALONEN R, 1994, J NEUROL, V241, P463, DOI 10.1007/BF00919706; SANCES G, 1990, HEADACHE, V30, P705, DOI 10.1111/j.1526-4610.1990.hed3011705.x; SANCES G, 1989, CEPHALALGIA S10, V9, P444; SARGENT J, 1995, NEUROLOGY, V45, pS10; SARGENT J, 1985, HEADACHE, V25, P320; SARGENT JD, 1988, HEADACHE, V28, P263, DOI 10.1111/j.1526-4610.1988.hed2804263.x; SHAFAR J, 1972, LANCET, V1, P403; SHEKELLE RB, 1964, CLIN PHARMACOL THER, V5, P201; SILBERSTEIN SD, 1998, HEADACHE CLIN PRACTI, P11; Solomon GD, 1997, NEUROLOGY, V49, P1219, DOI 10.1212/WNL.49.5.1219; SOMERVILLE BW, 1978, HEADACHE, V18, P75, DOI 10.1111/j.1526-4610.1978.hed1802075.x; SORENSEN PS, 1986, CEPHALALGIA, V6, P7, DOI 10.1046/j.1468-2982.1986.0601007.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Steiner TJ, 1998, CEPHALALGIA, V18, P283, DOI 10.1046/j.1468-2982.1998.1805283.x; STEINER TJ, 1988, HEADACHE, V28, P15, DOI 10.1111/j.1365-2524.1988.hed2801015.x; STELLAR S, 1984, JAMA-J AM MED ASSOC, V252, P2576; SUDILOVSKY A, 1986, HEADACHE, V26, P325; Szekely B, 1989, CEPHALALGIA, V9, P452; Teall J, 1998, HEADACHE, V38, P281, DOI 10.1046/j.1526-4610.1998.3804281.x; TEK DS, 1990, ANN EMERG MED, V19, P1083, DOI 10.1016/S0196-0644(05)81508-2; TFELTHANSEN P, 1984, CEPHALALGIA, V4, P107, DOI 10.1046/j.1468-2982.1984.0402107.x; TFELTHANSEN P, 1984, ACTA NEUROL SCAND, V69, P1, DOI 10.1111/j.1600-0404.1984.tb07772.x; TOKOLA RA, 1984, CEPHALALGIA, V4, P253, DOI 10.1046/j.1468-2982.1984.0404253.x; TULUNAY FC, 1987, CEPHALALGIA, V7, P131, DOI 10.1046/j.1468-2982.1987.0702131.x; Visser WH, 1996, ARCH NEUROL-CHICAGO, V53, P1132, DOI 10.1001/archneur.1996.00550110072014; Visser WH, 1996, NEUROLOGY, V46, P522, DOI 10.1212/WNL.46.2.522; WELCH KMA, 1985, NEUROLOGY, V35, P1304, DOI 10.1212/WNL.35.9.1304; ZIEGLER D, 1994, NEUROLOGY, V44, P447, DOI 10.1212/WNL.44.3_Part_1.447; ZIEGLER DK, 1985, ARCH NEUROL-CHICAGO, V42, P582, DOI 10.1001/archneur.1985.04060060084014; ZUDDAS A, 1985, CEPHALALGIA S3, V5, P514	121	153	162	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					840	849		10.7326/0003-4819-137-10-200211190-00014	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00014			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616VE	12435222				2022-12-28	WOS:000179323400008
J	Gera, T; Sachdev, HPS				Gera, T; Sachdev, HPS			Effect of iron supplementation on incidence of infectious illness in children: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PLACEBO-CONTROLLED TRIAL; DEFICIENCY ANEMIA; HEMOGLOBIN LEVELS; FORTIFIED MILK; YOUNG-CHILDREN; ORAL IRON; INFANTS; MALARIA; MORBIDITY; THERAPY	Objective To evaluate the effect of iron supplementation on the incidence of infections in children. Design Systematic review of randomised controlled trials. Data sources 28 randomised controlled trials (six unpublished and 22 published) on 7892 children. Interventions Oral or parenteral iron supplementation or fortified formula milk or cereals. Outcomes Incidence of all recorded infectious illnesses, and individual illnesses, including respiratory tract infection, diarrhoea, malaria, other infections, and prevalence of positive smear results for malaria. Results The pooled estimate (random effects model) of the incidence rate ratio (iron v placebo) was 1.02 (95% confidence interval 0.96 to 1.08, P=0.54; P < 0.0001 for heterogeneity). The incidence rate difference (iron minus placebo) for all recorded illnesses was 0.06 episodes/child year (-0.06 to 0.18, P=0.34; P < 0.0001 for heterogeneity). However, there was an increase in the risk of developing diarrhoea (incidence rate ratio 1.11, 1.01 to 1.23, P=0.04), but this would not have an overall important on public health (incidence rate difference 0.05 episodes/child year, -0.03 to 0.13; P=0.21). The occurrence of other illnesses and positive results on malaria smears (adjusted for positive smears at baseline) were not significantly affected by iron administration. On meta-regression, the statistical heterogeneity could not be explained by the variables studied. Conclusion Iron supplementation has no apparent harmful effect on the overall incidence of infectious illnesses in children, though it slightly increases the risk of developing diarrhoea.	Maulana Azad Med Coll, Dept Paediat, Div Clin Epidemiol, New Delhi 110002, India	Maulana Azad Medical College	Sachdev, HPS (corresponding author), E-6-12,Vasant Vihar, New Delhi 110057, India.	hpssachdev@hotmail.com		Sachdev, Harshpal Singh/0000-0002-4956-9391				ADAM Z, 1996, THESIS U LONDON LOND; ANDELMAN MB, 1966, AM J DIS CHILD, V111, P45, DOI 10.1001/archpedi.1966.02090040081007; ANGELES IT, 1993, AM J CLIN NUTR, V58, P339, DOI 10.1093/ajcn/58.3.339; AngelesAgdeppa I, 1997, AM J CLIN NUTR, V66, P177, DOI 10.1093/ajcn/66.1.177; BATES CJ, 1987, T ROY SOC TROP MED H, V81, P286, DOI 10.1016/0035-9203(87)90244-6; BECK HP, 1999, T R SOC TROP MED HYG, V93; Berger J, 2000, EUR J CLIN NUTR, V54, P29, DOI 10.1038/sj.ejcn.1600888; BHASKARAM C, 1975, BMJ-BRIT MED J, V3, P522, DOI 10.1136/bmj.3.5982.522; BRUNSER O, 1993, EUR J CLIN NUTR, V47, P317; BURMAN D, 1972, ARCH DIS CHILD, V47, P261, DOI 10.1136/adc.47.252.261; CANTWELL RJ, 1972, CLIN PEDIATR, V11, P443, DOI 10.1177/000992287201100807; CHANDRA RK, 1973, ARCH DIS CHILD, V48, P864, DOI 10.1136/adc.48.11.864; CHIPPAUX JP, 1991, B SOC PATHOL EXOT, V84, P54; CHWANG LC, 1988, AM J CLIN NUTR, V47, P496, DOI 10.1093/ajcn/47.3.496; Clarke M, 2001, COCHRANE REV HDB; DAMODARAN M, 1979, INDIAN J MED RES, V69, P448; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; FUERTH JH, 1974, J PEDIAT, V80, P974; Gebreselassie H., 1996, THESIS MCGILL U QUEB; HALLBERG L, 1966, ACTA MED SCAND, VS, P3; HARVEY PWJ, 1989, AM J TROP MED HYG, V40, P12, DOI 10.4269/ajtmh.1989.40.12; HEMMINKI E, 1995, NUTR RES, V15, P491, DOI 10.1016/0271-5317(95)00016-X; HERESI G, 1987, NUTR RES, V7, P915, DOI 10.1016/S0271-5317(87)80160-4; HERESI G, 1995, SCAND J INFECT DIS, V27, P385, DOI 10.3109/00365549509032736; HEYWOOD A, 1989, AM J CLIN NUTR, V50, P630, DOI 10.1093/ajcn/50.3.630; Hurrell RF, 1997, NUTR REV, V55, P210, DOI 10.1111/j.1753-4887.1997.tb01608.x; IDJRADINATA P, 1994, LANCET, V343, P1252, DOI 10.1016/S0140-6736(94)92151-2; IRIGOYEN M, 1991, PEDIATRICS, V88, P320; JAMES JA, 1960, PEDIATRICS, V26, P368; JAVAID N, 1991, ACTA PAEDIATR SCAND, P141; Juni P, 2001, SYSTEMATIC REV HLTH, P87; KADIISKA MB, 1995, J CLIN INVEST, V96, P1653, DOI 10.1172/JCI118205; Kochan I, 1973, Curr Top Microbiol Immunol, V60, P1; LAWLESS JW, 1994, J NUTR, V124, P645, DOI 10.1093/jn/124.5.645; MAUER AM, 1985, PEDIATRICS, V75, P976; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; Mitra AK, 1997, J NUTR, V127, P1451, DOI 10.1093/jn/127.8.1451; MURRAY MJ, 1978, BRIT MED J, V2, P1113, DOI 10.1136/bmj.2.6145.1113; OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P603, DOI 10.1016/0035-9203(86)90154-9; Oppenheimer SJ, 2001, J NUTR, V131, p616S, DOI 10.1093/jn/131.2.616S; OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P596, DOI 10.1016/0035-9203(86)90153-7; Palupi L, 1997, AM J CLIN NUTR, V65, P1057, DOI 10.1093/ajcn/65.4.1057; Picaud JC, 1999, PRENAT NEONAT MED, V4, P472; POLLITT E, 1993, ANNU REV NUTR, V13, P521, DOI 10.1146/annurev.nu.13.070193.002513; POWER HM, 1991, ANN TROP PAEDIATR, V11, P57, DOI 10.1080/02724936.1991.11747479; Rosado JL, 1997, AM J CLIN NUTR, V65, P13, DOI 10.1093/ajcn/65.1.13; Singhal A, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.3.e38; SMITH AW, 1989, ANN TROP PAEDIATR, V9, P17, DOI 10.1080/02724936.1989.11748589; Srigiridhar K, 1998, FREE RADICAL BIO MED, V25, P660, DOI 10.1016/S0891-5849(98)00086-0; Sterne J. A. C., 2008, SYSTEMATIC REV HLTH, V323, P189, DOI [10.1002/9780470693926.ch11, DOI 10.1002/9780470693926.CH11]; Tatli MM, 2000, PEDIATR INT, V42, P289, DOI 10.1046/j.1442-200x.2000.01217.x; *UN ADM COMM COORD, 2000, 4 REP WORLD NUTR SIT; van Stuijvenberg ME, 1999, AM J CLIN NUTR, V69, P497; vandenHombergh J, 1996, J TROP PEDIATRICS, V42, P220, DOI 10.1093/tropej/42.4.220; vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7	55	199	203	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	2002	325	7373					1142	1144B		10.1136/bmj.325.7373.1142	http://dx.doi.org/10.1136/bmj.325.7373.1142			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433763	Bronze, Green Published			2022-12-28	WOS:000179443100018
J	Delaunay, A; Pflieger, D; Barrault, MB; Vinh, J; Toledano, MB				Delaunay, A; Pflieger, D; Barrault, MB; Vinh, J; Toledano, MB			A thiol peroxidase is an H2O2 receptor and redox-transducer in gene activation	CELL			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS-RESPONSE; TRANSCRIPTION FACTOR; NUCLEAR EXPORT; SACCHAROMYCES-CEREVISIAE; THIOREDOXIN; YAP1; REDUCTASE; CATALYSIS; PROTEINS	The Yap1 transcription factor regulates hydroperoxide homeostasis in S. cerevisiae. Yap1 is activated by oxidation when hydroperoxide levels increase. We show that Yap1 is not directly oxidized by hydroperoxide. We identified the glutathione peroxidase (GPX)-like enzyme Gpx3 as a second component of the pathway, serving the role of sensor and transducer of the hydroperoxide signal to Yap1. When oxidized by H2O2, Gpx3 Cys36 bridges Yap1 Cys598 by a disulfide bond. This intermolecular disulfide bond is then resolved into a Yap1 intramolecular disulfide bond, the activated form of the regulator. Thioredoxin turns off the pathway by reducing both sensor and regulator. These data reveal a redox-signaling function for a GPx-like enzyme and elucidate a eukaryotic hydroperoxide-sensing mechanism. Gpx3 is thus a hydroperoxide receptor and redox-transducer.	CEA Saclay, Lab Stress Oxydants & Canc, SBGM, DBJC, F-91191 Gif Sur Yvette, France; Ecole Super Phys & Chim Ind Ville Paris, CNRS, UMR 7637, Lab Neurobiol & Divers Cellulaire, F-75231 Paris, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Toledano, MB (corresponding author), CEA Saclay, Lab Stress Oxydants & Canc, SBGM, DBJC, F-91191 Gif Sur Yvette, France.	toledano@jonas.saclay.cea.fr	Delaunay-moisan, Agnes/GRX-7749-2022; Vinh, Joelle/K-1347-2015	Delaunay-moisan, Agnes/0000-0003-3105-221X; Vinh, Joelle/0000-0001-7184-2668				Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Carmel-Harel O, 2001, MOL MICROBIOL, V39, P595, DOI 10.1046/j.1365-2958.2001.02255.x; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Godeas C, 1997, BIOL REPROD, V57, P1502, DOI 10.1095/biolreprod57.6.1502; Gonzalez-Flecha B, 2000, ANN NY ACAD SCI, V899, P69; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Maiorino M, 1999, BIOFACTORS, V10, P251, DOI 10.1002/biof.5520100224; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIKORSKI RS, 1989, GENETICS, V122, P19; Spector D, 2001, J BIOL CHEM, V276, P7011, DOI 10.1074/jbc.M009814200; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Ursini F, 1997, BIOMED ENVIRON SCI, V10, P327; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200; WU AL, 1993, J BIOL CHEM, V268, P18850; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	31	666	695	2	67	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	2002	111	4					471	481		10.1016/S0092-8674(02)01048-6	http://dx.doi.org/10.1016/S0092-8674(02)01048-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437921	Bronze			2022-12-28	WOS:000179346900001
J	O'Kelly, I; Butler, MH; Zilberberg, N; Goldstein, SAN				O'Kelly, I; Butler, MH; Zilberberg, N; Goldstein, SAN			Forward transport: 14-3-3 binding overcomes retention in endoplasmic reticulum by dibasic signals	CELL			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; 2 PORE DOMAINS; POTASSIUM LEAK CHANNELS; INVARIANT CHAIN; PROTEIN-KINASE; K+ CHANNEL; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEINS; 14-3-3-PROTEINS; TRAFFICKING	Proteins with dibasic retention motifs are subject to retrograde transport to endoplasmic reticulum (ER) by COPI-coated vesicles. As forward transport requires escape from ER retention, general release mechanisms have been expected. Here, KCNK3 potassium channels are shown to bear two cytoplasmic trafficking motifs: an N-terminal dibasic site that binds P-COP to hold channels in ER and a C-terminal "release" site that binds the ubiquitous intracellular regulator 14-3-3beta on a nonclassical motif in a phosphorylation-dependent fashion to suppress P-COP binding and allow forward transport. The strategy appears to be common. The major histocompatibility antigen class II-associated invariant chain lip35 exhibits dibasic retention, carries a release motif, and shows mutually exclusive binding of P-COP and 14-3-3beta on adjacent N-terminal sites. Other retained proteins are demonstrated to carry functional 14-3-3beta release motifs.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, New Haven, CT 06536 USA	Yale University; Yale University; Yale University	Goldstein, SAN (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St, New Haven, CT 06536 USA.		Zilberberg, Noam/F-2005-2012; Goldstein, Steven A./E-9817-2015	Zilberberg, Noam/0000-0002-7848-2391; Goldstein, Steven A./0000-0001-5207-5061				Anderson HA, 1999, J IMMUNOL, V163, P5435; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; Campbell JK, 1997, BIOCHEMISTRY-US, V36, P15363, DOI 10.1021/bi9708085; Craparo A, 1997, J BIOL CHEM, V272, P11663; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Czirjak G, 2000, MOL ENDOCRINOL, V14, P863, DOI 10.1210/me.14.6.863; Drisdel RC, 2000, J NEUROSCI, V20, P133, DOI 10.1523/JNEUROSCI.20-01-00133.2000; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Gopalakrishnan M, 1997, MOL PHARMACOL, V52, P524, DOI 10.1124/mol.52.3.524; Ilan N, 2001, BIOPHYS J, V80, P241, DOI 10.1016/S0006-3495(01)76010-9; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; Keller SH, 2001, J BIOL CHEM, V276, P18384, DOI 10.1074/jbc.M100691200; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Kim YM, 1999, HEALTH COMMUN, V11, P1, DOI 10.1207/s15327027hc1101_1; Kindler CH, 1999, ANESTHESIOLOGY, V90, P1092, DOI 10.1097/00000542-199904000-00024; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; Kuwana T, 1998, P NATL ACAD SCI USA, V95, P1056, DOI 10.1073/pnas.95.3.1056; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; Lopes CMB, 2001, J BIOL CHEM, V276, P24449, DOI 10.1074/jbc.C100184200; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; McGehee DS, 1999, ANN NY ACAD SCI, V868, P565, DOI 10.1111/j.1749-6632.1999.tb11330.x; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Schroder-Kohne S, 1998, J CELL SCI, V111, P3459; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zarei MM, 2001, J BIOL CHEM, V276, P16232, DOI 10.1074/jbc.M008852200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198; Zhou Y, 1999, NEURON, V22, P809, DOI 10.1016/S0896-6273(00)80739-4; Zilberberg N, 2001, NEURON, V32, P635, DOI 10.1016/S0896-6273(01)00503-7	56	237	241	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 15	2002	111	4					577	588		10.1016/S0092-8674(02)01040-1	http://dx.doi.org/10.1016/S0092-8674(02)01040-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437930	Bronze			2022-12-28	WOS:000179346900010
J	Minetti, AE; Ardigo, LP				Minetti, AE; Ardigo, LP			Biomechanics: Halteres used in ancient Olympic long jump	NATURE			English	Article									Manchester Metropolitan Univ, Dept Exercise & Sport Sci, Ctr Biophys & Clin Res Human Movement, Alsager ST7 2HL, England	Manchester Metropolitan University	Minetti, AE (corresponding author), Manchester Metropolitan Univ, Dept Exercise & Sport Sci, Ctr Biophys & Clin Res Human Movement, Alsager ST7 2HL, England.		Minetti, Alberto Enrico/P-2320-2017; Ardigò, Luca Paolo/H-8955-2019	Minetti, Alberto Enrico/0000-0002-0120-4406; Ardigò, Luca Paolo/0000-0001-7677-5070				ARISTOTLE, PROBLEMATA, V3, pA705; EBERT J, 1963, ABHANDLUNGEN SACHSIS, V66; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; JUTHNER J, 1896, ANTIKE TURNGERATHE; MINETTI AE, 1993, J PHYSIOL-LONDON, V472, P725, DOI 10.1113/jphysiol.1993.sp019969; Perrin D., 1993, ISOKINETIC EXERCISE; WASSMANNSDORFF K, 1885, MONATSSCHRIFT TURNWE, P4; WESTING SH, 1988, EUR J APPL PHYSIOL O, V58, P100, DOI 10.1007/BF00636611	8	29	30	9	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					141	142		10.1038/420141a	http://dx.doi.org/10.1038/420141a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432378				2022-12-28	WOS:000179200900031
J	Scharmer, GRB; Gudiksen, BV; Kiselman, D; Lofdahl, MG; van der Voort, LHMR				Scharmer, GRB; Gudiksen, BV; Kiselman, D; Lofdahl, MG; van der Voort, LHMR			Dark cores in sunspot penumbral filaments	NATURE			English	Article							FINE-STRUCTURE; FLUX TUBE; FLOW; SUN	Sunspot umbrae-the dark central regions of the spots-are surrounded by brighter filamentary penumbrae, the existence of which remains largely inexplicable(1). The penumbral filaments contain magnetic fields with varying inclinations(2) and are associated with flowing gas(3-5), but discriminating between theoretical models(6-8) has been difficult because the structure of the filaments has not hitherto been resolved. Here we report observations of penumbral filaments that reveal dark cores inside them. We cannot determine the nature of these dark cores, but their very existence provides a crucial test for any model of penumbrae. Our images also reveal other very small structures, in line with the view that many of the fundamental physical processes in the solar photosphere occur on scales smaller than 100 km.	Royal Swedish Acad Sci, AlbaNova Univ Ctr, Inst Solar Phys, SE-10691 Stockholm, Sweden	Royal Swedish Academy of Sciences	Kiselman, D (corresponding author), Royal Swedish Acad Sci, AlbaNova Univ Ctr, Inst Solar Phys, SE-10691 Stockholm, Sweden.	dan@astro.su.se	Löfdahl, Mats/AAD-9481-2022	Löfdahl, Mats/0000-0002-2472-5677				DANIELSON RE, 1961, ASTROPHYS J, V134, P289, DOI 10.1086/147159; Evershed J., 1909, MNRAS, V69, P454, DOI [10.1093/mnras/69.5.454, DOI 10.1093/MNRAS/69.5.454]; Galsgaard K, 1997, J GEOPHYS RES-SPACE, V102, P219, DOI 10.1029/96JA01462; LIVINGSTON W, 1991, NATURE, V350, P45, DOI 10.1038/350045a0; Lofdahl MG, 2001, ASTRON ASTROPHYS, V377, P1128, DOI 10.1051/0004-6361:20011118; LOFDAHL MG, P SPIE, V4792; Montesinos B, 1997, NATURE, V390, P485, DOI 10.1038/37307; MULLER R, 1973, SOL PHYS, V29, P55, DOI 10.1007/BF00153440; PARKER EN, 1992, NATO ADV SCI I C-MAT, V375, P413; PARKER EN, 1972, ASTROPHYS J, V174, P499, DOI 10.1086/151512; SCHARMER GB, P SPIE, V4853; Schlichenmaier R, 1998, ASTRON ASTROPHYS, V337, P897; Schlichenmaier R, 1999, ASTRON ASTROPHYS, V349, P961; Sobotka M, 1999, ASTRON ASTROPHYS, V348, P621; SPRUIT HC, 1987, ROLE FINE SCALE MAGN, P199; Thomas JH, 1998, NATURE, V396, P114, DOI 10.1038/24044; TITLE AM, 1993, ASTROPHYS J, V403, P780, DOI 10.1086/172249	17	194	196	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					151	153		10.1038/nature01173	http://dx.doi.org/10.1038/nature01173			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432384				2022-12-28	WOS:000179200900037
J	Rose, JS				Rose, JS			All our children: human rights and children of the street	LANCET			English	Editorial Material							YOUTH		Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Publ Hlth, Baltimore, MD 21218 USA	Johns Hopkins University	Rose, JS (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Publ Hlth, Baltimore, MD 21218 USA.							BARKER G, 1991, EXPLOITED INTREPRENE; *EUR NETW STREET C, 1996, STREET CHILDR N S CO; KIPKE MD, 1995, ARCH PEDIAT ADOL MED, V149, P513, DOI 10.1001/archpedi.1995.02170180043006; Kipke MD, 1997, ADOLESCENCE, V32, P655; Summerfield D, 1998, LANCET, V351, P1955, DOI 10.1016/S0140-6736(98)06056-5	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1506	1506		10.1016/S0140-6736(02)11479-6	http://dx.doi.org/10.1016/S0140-6736(02)11479-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	614JV	12433535				2022-12-28	WOS:000179186000032
J	Summerfield, D				Summerfield, D			Effects of war: moral knowledge, revenge, reconciliation, and medicalised concepts of "recovery"	BRITISH MEDICAL JOURNAL			English	Article							SOUTH-AFRICA; COMMISSION; TRUTH		Inst Psychiat, London SE5 8AF, England	University of London; King's College London	Summerfield, D (corresponding author), Inst Psychiat, London SE5 8AF, England.							Bracken Patrick., 2002, TRAUMA CULTURE MEANI; Centers for Disease Control and Prevention, 1999, MENT HLTH ASS KOS; Hayner PriscillaB., 2001, UNSPEAKABLE TRUTHS C; HONWANA A, 2001, NONWESTERN CONCEPTS; INGLEBY D, 1989, INT J MENT HEALTH, V17, P16, DOI 10.1080/00207411.1988.11449111; JONES L, 1995, BRIT MED J, V310, P1052, DOI 10.1136/bmj.310.6986.1052; Kaminer D, 2001, BRIT J PSYCHIAT, V178, P373, DOI 10.1192/bjp.178.4.373; Last M, 2000, Med Confl Surviv, V16, P370, DOI 10.1080/13623690008409537; LOUGHREY G, 1997, PSYCHOL TRAUMA DEV A; MCAFEE B, 1998, INSTEAD MED REPORT B; Pupavac V, 2001, DISASTERS, V25, P358, DOI 10.1111/1467-7717.00184; Summerfield D, 1999, SOC SCI MED, V48, P1449, DOI 10.1016/S0277-9536(98)00450-X; Summerfield D, 1997, BRIT MED J, V315, P1393, DOI 10.1136/bmj.315.7120.1393; TAUSSIG M, 1980, SOC SCI MED, V148, P3; United Nations Children's Fund, 1996, STAT WORLDS CHILDR; Woodside D, 1999, Med Confl Surviv, V15, P355, DOI 10.1080/13623699908409477; 2001, GUARDIAN        0810, P2	17	89	92	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2002	325	7372					1105	1107		10.1136/bmj.325.7372.1105	http://dx.doi.org/10.1136/bmj.325.7372.1105			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	618JV	12424176	Green Published			2022-12-28	WOS:000179415700029
J	van Mook, WNKA; Huslewe-Evers, RPMG				van Mook, WNKA; Huslewe-Evers, RPMG			Abdominal compartment syndrome	LANCET			English	Editorial Material									Univ Hosp Maastricht, Dept Intens Care, NL-6202 Maastricht, Netherlands	Maastricht University	van Mook, WNKA (corresponding author), Univ Hosp Maastricht, Dept Intens Care, NL-6202 Maastricht, Netherlands.								0	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1502	1502		10.1016/S0140-6736(02)11482-6	http://dx.doi.org/10.1016/S0140-6736(02)11482-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433533				2022-12-28	WOS:000179186000030
J	Greenspan, SL; Emkey, RD; Bone, HG; Weiss, SR; Bell, NH; Downs, RW; McKeever, C; Miller, SS; Davidson, M; Bolognese, MA; Mulloy, AL; Heyden, N; Wu, M; Kaur, A; Lombardi, A				Greenspan, SL; Emkey, RD; Bone, HG; Weiss, SR; Bell, NH; Downs, RW; McKeever, C; Miller, SS; Davidson, M; Bolognese, MA; Mulloy, AL; Heyden, N; Wu, M; Kaur, A; Lombardi, A			Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; HIP FRACTURE; WOMEN; TURNOVER; RISK; MARKERS; DENSITY	Background: Combination therapy with alendronate and estrogen for 2 years increases bone mineral density at the spine and hip more than does therapy with either agent alone. Changes in bone mineral density after discontinuation of therapy have not been compared directly. Objective: To determine the rate of bone loss when therapy with alendronate, estrogen, or both agents is discontinued. Design: Double-blind, placebo-controlled discontinuation trial. Setting: 18 U.S. centers. Patients: 244 postmenopausal, hysterectomized women 44 to 77 years of age. Intervention: 2 years of therapy with alendronate, 10 mg/d (n = 92); conjugated estrogen, 0.625 mg/d (n = 143); alendronate and conjugated estrogen (n = 140); or placebo (n = 50). At year 3, women were allocated into five groups: Twenty-eight women continued to take placebo and 44 women continued to take combination therapy, but 50 women taking alendronate, 81 taking conjugated estrogen, and 41 taking combination therapy were switched to placebo. Measurements: Bone mineral density and biochemical markers of bone turnover. Results: Women taking alendronate or combination therapy who were switched to placebo for year 3 of the study maintained bone mass. Bone mineral density in these women was 4.1 % (Cl, 2.6% to 5.7%) and 6.6% (Cl, 5.0% to 8.2%) higher, respectively, at the spine (P < 0.001 for both treatment comparisons) and 3.5% (Cl, 2.3% to 4.6%) and 3.0% (Cl, 1.8% to 4.2%) higher, respectively, at the trochanter (P < 0.001 for both treatment comparisons) than that in women previously taking estrogen who were switched to placebo. in contrast, women who were taking estrogen and were switched to placebo during year 3 experienced a 4.5% decrease at the spine (95% Cl, -5.0% to -4.0%) and a 2.4% decrease at the trochanter (Cl, -2.7% to -2.1 %) (P < 0.001 for both changes). Compared with women who took placebo for 3 years, women who took estrogen for 2 years and were then switched to placebo had a bone mineral density that was 2.9% higher (Cl, 1.2% to 4.6%) at the spine (P < 0.05) and 2.9% higher (Cl, 1.6% to 4.2%) at the trochanter (P < 0.001). Changes in biochemical markers during year 3 did not differ among the groups that discontinued active treatment. Conclusions: Accelerated bone loss is seen after withdrawal of estrogen therapy but not after withdrawal of alendronate or combination therapy. The differential effects after withdrawal of therapy should be considered in the management of postmenopausal osteoporosis.	Univ Pittsburgh, Osteoporosis Prevent & Treatment Ctr, Pittsburgh, PA 15213 USA; Radiant Res Reading, Wyomissing, PA USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Michigan Bone & Mineral Clin, Detroit, MI USA; San Diego Endocrinol & Med Clin, San Diego, CA USA; Med Univ S Carolina, Charleston, SC 29425 USA; Virginia Commonwealth Univ, Richmond, VA 23298 USA; Res Hlth, Houston, TX USA; SAM Clin Res Ctr, San Antonio, TX USA; Chicago Ctr Clin Res, Chicago, IL USA; Bethesda Hlth Res, Bethesda, MD USA; Med Coll Georgia, Augusta, GA 30912 USA; Merck & Co Inc, Rahway, NJ 07065 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Beth Israel Deaconess Medical Center; Medical University of South Carolina; Virginia Commonwealth University; University System of Georgia; Augusta University; Merck & Company	Greenspan, SL (corresponding author), Univ Pittsburgh, Osteoporosis Prevent & Treatment Ctr, Kaufmann Med Bldg,Suite 1110,3471 5th Ave, Pittsburgh, PA 15213 USA.	GriffithsD@msx.dept-med.pitt.edu						Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1981, LANCET, V1, P459; Eastell R, 2000, J BONE MINER RES, V15, P594, DOI 10.1359/jbmr.2000.15.3.594; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; Garnero P, 1996, J BONE MINER RES, V11, P1531; Greenspan SL, 1997, CALCIFIED TISSUE INT, V60, P419, DOI 10.1007/s002239900256; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Hochberg MC, 1999, ARTHRITIS RHEUM-US, V42, P1246, DOI 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LINDSAY R, 1980, LANCET, V2, P1151; Lindsay R, 1999, J CLIN ENDOCR METAB, V84, P3076, DOI 10.1210/jc.84.9.3076; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; Miller PD, 1999, J CLIN DENSITOM, V2, P323, DOI 10.1385/JCD:2:3:323; Neter J, 1990, APPL LINEAR STAT MOD; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; Stock JL, 1997, AM J MED, V103, P291, DOI 10.1016/S0002-9343(97)00130-7; Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231	21	152	158	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					875	883		10.7326/0003-4819-137-11-200212030-00008	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622GY	12458987				2022-12-28	WOS:000179639700003
J	Castells, X; Rodoreda, I; Pedros, C; Cereza, G; Laporte, JR				Castells, X; Rodoreda, I; Pedros, C; Cereza, G; Laporte, JR			Drug points - Dysgeusia and burning mouth syndrome by eprosartan	BRITISH MEDICAL JOURNAL			English	Letter							LOSARTAN		Univ Vall Hebron, Fdn Inst Catala Farmacol, Serv Farmacol Clin, Barcelona 08035, Spain; Area Basica Salut Pla Urgell, Mollerusa, Lleida, Spain		Laporte, JR (corresponding author), Univ Vall Hebron, Fdn Inst Catala Farmacol, Serv Farmacol Clin, Barcelona 08035, Spain.		Laporte, Joan-Ramon/A-1302-2011; Pedrós, Consuelo/M-3684-2019; Pedros, Consuelo/N-7183-2013	Pedrós, Consuelo/0000-0001-8198-7166; 				Heeringa M, 1998, ANN INTERN MED, V129, P72, DOI 10.7326/0003-4819-129-1-199807010-00023; MALNICK SD, 1999, MED GEN MED, V4, pE33; Mazzolai L, 1999, DRUG SAFETY, V21, P23, DOI 10.2165/00002018-199921010-00003; Schlienger RG, 1996, LANCET, V347, P471, DOI 10.1016/S0140-6736(96)90047-1; STRODTER D, 1994, NIEREN HOCHDRUCK, V23, P217	6	11	11	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1277	1277		10.1136/bmj.325.7375.1277	http://dx.doi.org/10.1136/bmj.325.7375.1277			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458247	Bronze, Green Published			2022-12-28	WOS:000179696300019
J	Collins, R; Armitage, J				Collins, R; Armitage, J			High-risk elderly patients PROSPER from cholesterol-lowering therapy	LANCET			English	Editorial Material							CORONARY-HEART-DISEASE; PRAVASTATIN; EVENTS; PREVENTION; MEN		Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Collins, R (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Harkness Bldg, Oxford OX2 6HE, England.	secretary@ctsu.ox.ac.uk						Campeau L, 1997, NEW ENGL J MED, V336, P153; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DOWNS JR, 1995, AM J CARDIOL, V75, P1130; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Hunt D, 2001, ANN INTERN MED, V134, P931, DOI 10.7326/0003-4819-134-10-200105150-00007; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sacks FM, 2000, CIRCULATION, V102, P1893, DOI 10.1161/01.CIR.102.16.1893; Serruys PWJC, 2002, JAMA-J AM MED ASSOC, V287, P3215, DOI 10.1001/jama.287.24.3215; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shepherd J, 1999, AM J CARDIOL, V84, P1192, DOI 10.1016/S0002-9149(99)00533-0; SIMES J, 2002, ANN INTERN MED, V136; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	15	25	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2002	360	9346					1618	1619		10.1016/S0140-6736(02)11650-3	http://dx.doi.org/10.1016/S0140-6736(02)11650-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457780				2022-12-28	WOS:000179393900002
J	Hillis, JM; Ernst, MO; Banks, MS; Landy, MS				Hillis, JM; Ernst, MO; Banks, MS; Landy, MS			Combining sensory information: Mandatory fusion within, but not between, senses	SCIENCE			English	Article							CUE COMBINATION; TEXTURE; SLANT; SHAPE	Humans use multiple sources of sensory information to estimate environmental properties. For example, the eyes and hands both provide relevant information about an object's shape. The eyes estimate shape using binocular disparity, perspective projection, etc. The hands supply haptic shape information by means of tactile and proprioceptive cues. Combining information across cues can improve estimation of object properties but may come at a cost: loss of single-cue information. We report that single-cue information is indeed lost when cues from within the same sensory modality (disparity and texture gradients in vision) are combined, but not when different modalities (vision and haptics) are combined.	Univ Calif Berkeley, Sch Optometry, Vis Sci Program, Berkeley, CA 94720 USA; Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany; Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA; NYU, Dept Psychol, New York, NY 10003 USA; NYU, Ctr Neural Sci, New York, NY 10003 USA	University of California System; University of California Berkeley; Max Planck Society; University of California System; University of California Berkeley; New York University; New York University	Hillis, JM (corresponding author), Univ Penn, Dept Psychol, 3815 Walnut St, Philadelphia, PA 19104 USA.	jmhillis@CATTELL.psych.upenn.edu		Landy, Michael/0000-0002-2079-4552; Ernst, Marc/0000-0003-4197-8569	NATIONAL EYE INSTITUTE [R01EY012851, R01EY008266] Funding Source: NIH RePORTER; NEI NIH HHS [EY08266, EY12851] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Backus BT, 1999, VISION RES, V39, P1143, DOI 10.1016/S0042-6989(98)00139-4; BACKUS BT, 2002, ADV NEURAL INFORMA 7, V14, pCH1; Brenner E, 1999, VISION RES, V39, P975, DOI 10.1016/S0042-6989(98)00162-X; Clark J.J., 1990, DATA FUSION SENSORY; DEBERG M, 2002, COMPUTATIONAL GEOMET; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; JOHNSTON EB, 1994, VISION RES, V34, P2259, DOI 10.1016/0042-6989(94)90106-6; Jordan M. I, 1997, SELF ORG COMPUTATION, P117, DOI DOI 10.1016/S0166-4115(97)80006-4; Knill DC, 1998, VISION RES, V38, P1683, DOI 10.1016/S0042-6989(97)00325-8; LANDY MS, 1995, VISION RES, V35, P389, DOI 10.1016/0042-6989(94)00176-M; Landy MS, 2001, J OPT SOC AM A, V18, P2307, DOI 10.1364/JOSAA.18.002307; RICHARDS W, 1979, SENS PROCESS, V3, P207	12	310	315	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1627	1630		10.1126/science.1075396	http://dx.doi.org/10.1126/science.1075396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446912				2022-12-28	WOS:000179361600051
J	Malka, V; Fritzler, S; Lefebvre, E; Aleonard, MM; Burgy, F; Chambaret, JP; Chemin, JF; Krushelnick, K; Malka, G; Mangles, SPD; Najmudin, Z; Pittman, M; Rousseau, JP; Scheurer, JN; Walton, B; Dangor, AE				Malka, V; Fritzler, S; Lefebvre, E; Aleonard, MM; Burgy, F; Chambaret, JP; Chemin, JF; Krushelnick, K; Malka, G; Mangles, SPD; Najmudin, Z; Pittman, M; Rousseau, JP; Scheurer, JN; Walton, B; Dangor, AE			Electron acceleration by a wake field forced by an intense ultrashort laser pulse	SCIENCE			English	Article							WAKEFIELDS; GENERATION; EXCITATION; EVOLUTION; BEAM	Plasmas are an attractive medium for the next generation of particle accelerators because they can support electric fields greater than several hundred gigavolts per meter. These accelerating fields are generated by relativistic plasma waves-space-charge oscillations-that can be excited when a high-intensity laser propagates through a plasma. Large currents of background electrons can then be trapped and subsequently accelerated by these relativistic waves. In the forced laser wake field regime, where the laser pulse length is of the order of the plasma wavelength, we show that a gain in maximum electron energy of up to 200 megaelectronvolts can be achieved, along with an improvement in the quality of the ultrashort electron beam.	Ecole Polytech, CNRS,UMR 7639, Ecole Natl Super Tech Avancees, Lab Opt Appl, F-91761 Palaiseau, France; CEA, DAM Ile de France, Dept Phys Theor & Appl, F-91680 Bruyeres Le Chatel, France; Univ Bordeaux 1, IN2P3, Ctr Etud Nucl Bordeaux Gradignan, F-33175 Gradignan, France; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2BZ, England	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Institut Polytechnique de Paris; CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Universite de Bordeaux; Imperial College London	Malka, V (corresponding author), Ecole Polytech, CNRS,UMR 7639, Ecole Natl Super Tech Avancees, Lab Opt Appl, F-91761 Palaiseau, France.	victor.malka@ensta.fr	Krushelnick, Karl/AAZ-3028-2020; Mangles, Stuart/Q-5829-2019; Najmudin, Zulfikar/ABH-5942-2020; Lefebvre, Erik/B-9835-2009; Mangles, Stuart PD/F-9070-2014; Malka, Victor/F-5260-2010; Malka, Victor/AAU-2963-2020	Mangles, Stuart/0000-0003-2443-4201; Najmudin, Zulfikar/0000-0001-6323-4005; Mangles, Stuart PD/0000-0003-2443-4201; Malka, Victor/0000-0002-0488-2587; Malka, Victor/0000-0002-0488-2587				AKHIEZER AI, 1956, ZH EKSP TEOR FIZ, V3, P696; ANDREEV NE, 1992, JETP LETT+, V55, P571; ANTONSEN TM, 1992, PHYS REV LETT, V69, P2204, DOI 10.1103/PhysRevLett.69.2204; BULANOV SV, 1989, JETP LETT+, V50, P198; Clayton CE, 1998, PHYS REV LETT, V81, P100, DOI 10.1103/PhysRevLett.81.100; Decker CD, 1996, PHYS PLASMAS, V3, P2047, DOI 10.1063/1.872001; Decker CD, 1996, PHYS PLASMAS, V3, P414, DOI 10.1063/1.871868; Edwards RD, 2002, APPL PHYS LETT, V80, P2129, DOI 10.1063/1.1464221; ESAREY E, 1994, PHYS REV LETT, V72, P2887, DOI 10.1103/PhysRevLett.72.2887; Esarey E, 1996, IEEE T PLASMA SCI, V24, P252, DOI 10.1109/27.509991; FRITZLER S, UNPUB; LeBlanc SP, 1996, PHYS REV LETT, V77, P5381, DOI 10.1103/PhysRevLett.77.5381; Leemans WP, 1996, IEEE T PLASMA SCI, V24, P331, DOI 10.1109/27.509997; Malka V, 2000, REV SCI INSTRUM, V71, P2329, DOI 10.1063/1.1150619; MODENA A, 1995, NATURE, V377, P606, DOI 10.1038/377606a0; Moore CI, 1997, PHYS REV LETT, V79, P3909, DOI 10.1103/PhysRevLett.79.3909; Najmudin Z, 2000, IEEE T PLASMA SCI, V28, P1057, DOI 10.1109/27.893290; Pittman M, 2002, APPL PHYS B-LASERS O, V74, P529, DOI 10.1007/s003400200838; Pukhov A, 1999, PHYS PLASMAS, V6, P2847, DOI 10.1063/1.873242; Pukhov A, 2002, APPL PHYS B-LASERS O, V74, P355, DOI 10.1007/s003400200795; Santala MIK, 2001, PHYS REV LETT, V86, P1227, DOI 10.1103/PhysRevLett.86.1227; SPRANGLE P, 1992, PHYS REV LETT, V69, P2200, DOI 10.1103/PhysRevLett.69.2200; STRICKLAND D, 1985, OPT COMMUN, V56, P219, DOI 10.1016/0030-4018(85)90120-8; TAJIMA T, 1979, PHYS REV LETT, V43, P267, DOI 10.1103/PhysRevLett.43.267; Ting A, 1996, PHYS REV LETT, V77, P5377, DOI 10.1103/PhysRevLett.77.5377; YAMAZAKI Y, 1992, NUCL INSTRUM METH A, V322, P139, DOI 10.1016/0168-9002(92)90021-U	26	547	567	3	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1596	1600		10.1126/science.1076782	http://dx.doi.org/10.1126/science.1076782			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446903				2022-12-28	WOS:000179361600042
J	Garlanda, C; Hirsch, E; Bozza, S; Salustri, A; De Acetis, M; Nota, R; Maccagno, A; Riva, F; Bottazzi, B; Peri, G; Doni, A; Vago, L; Botto, M; De Santis, R; Carminati, P; Siracusa, G; Altruda, F; Vecchi, A; Romani, L; Mantovani, A				Garlanda, C; Hirsch, E; Bozza, S; Salustri, A; De Acetis, M; Nota, R; Maccagno, A; Riva, F; Bottazzi, B; Peri, G; Doni, A; Vago, L; Botto, M; De Santis, R; Carminati, P; Siracusa, G; Altruda, F; Vecchi, A; Romani, L; Mantovani, A			Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response	NATURE			English	Article							AMYLOID-P COMPONENT; C-REACTIVE PROTEIN; ACUTE-PHASE PROTEINS; INVASIVE ASPERGILLOSIS; A-PROTEIN; FAMILY; INFECTION; MEMBER; MONONUCLEAR; EXPRESSION	Pentraxins are a superfamily of conserved proteins that are characterized by a cyclic multimeric structure(1). The classical short pentraxins, C-reactive protein (CRP) and serum amyloid P component (SAP), are acute-phase proteins produced in the liver in response to inflammatory mediators(2-4). Short pentraxins regulate innate resistance to microbes and the scavenging of cellular debris and extracellular matrix components(2-5). In contrast, long pentraxins have an unrelated, long amino-terminal domain coupled to the carboxy-terminal pentraxin domain, and differ, with respect to short pentraxins, in their gene organization, chromosomal localization, cellular source, and in their stimuli-inducing and ligand-recognition ability(6). To investigate the in vivo function of the long pentraxin PTX3, we generated mice deficient in Ptx3 by homologous recombination. Ptx3-null mice were susceptible to invasive pulmonary aspergillosis. Ptx3 binds selected microbial agents, including conidia of Aspergillus fumigatus, and we found that susceptibility of Ptx3-null mice was associated with defective recognition of conidia by alveolar macrophages and dendritic cells, as well as inappropriate induction of an adaptive type 2 response. Thus, the long pentraxin Ptx3 is a secreted pattern-recognition receptor that has a non-redundant role in resistance to selected microbial agents, in particular to the opportunistic fungal pathogen Aspergillus fumigatus.	Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, I-20157 Milan, Italy; Univ Turin, Dept Genet Biol & Biochem, Turin, Italy; Univ Perugia, Dept Expt Med & Biochem Sci, Microbiol Sect, I-06100 Perugia, Italy; Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, Rome, Italy; Univ Milan, Osped Luigi Sacco, Inst Pathol, Milan, Italy; Imperial Coll Sch Med, Hammersmith Hosp, Div Med, Rheumatol Sect, London, England; SigmaTau SpA, Rome, Italy; Univ Milan, Inst Gen Pathol, Ctr IDET, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Turin; University of Perugia; University of Rome Tor Vergata; University of Milan; Luigi Sacco Hospital; Imperial College London; University of Milan	Mantovani, A (corresponding author), Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, Via Eritrea 62, I-20157 Milan, Italy.		bottazzi, barbara/ABH-9274-2020; Garlanda, Cecilia/K-4601-2016; Riva, Federica/B-9287-2013; Mantovani, Alberto/HCI-7449-2022; Hirsch, Emilio/F-4848-2013; Romani, Luigina/O-9987-2018	bottazzi, barbara/0000-0002-1930-9257; Garlanda, Cecilia/0000-0002-1510-7703; Riva, Federica/0000-0002-1270-1627; Mantovani, Alberto/0000-0001-5578-236X; Hirsch, Emilio/0000-0002-9073-6024; Romani, Luigina/0000-0002-1356-525X; SALUSTRI, ANTONIETTA/0000-0002-8731-1041; DE SANTIS, Rita/0000-0002-5037-0611; Doni, Andrea/0000-0001-9203-5814				ALLES VV, 1994, BLOOD, V84, P3483; Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Bozza S, 2002, J IMMUNOL, V168, P1362, DOI 10.4049/jimmunol.168.3.1362; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; Cenci E, 1997, INFECT IMMUN, V65, P564, DOI 10.1128/IAI.65.2.564-570.1997; Denning DW, 1998, CLIN INFECT DIS, V26, P781, DOI 10.1086/513943; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; Introna M, 1996, BLOOD, V87, P1862; LEE GW, 1994, J IMMUNOL, V153, P3700; LEE GW, 1993, J IMMUNOL, V150, P1804; Mantovani A., 2002, CYTOKINE REFERENCE; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mencacci A., 2000, Current Pharmaceutical Biotechnology, V1, P235, DOI 10.2174/1389201003378924; Mencacci A, 2001, BLOOD, V97, P1483, DOI 10.1182/blood.V97.5.1483; Muller B, 2001, CRIT CARE MED, V29, P1404, DOI 10.1097/00003246-200107000-00017; Noursadeghi M, 2000, P NATL ACAD SCI USA, V97, P14584, DOI 10.1073/pnas.97.26.14584; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; Peri G, 2000, CIRCULATION, V102, P636, DOI 10.1161/01.CIR.102.6.636; Romani L, 1997, CURR OPIN IMMUNOL, V9, P484, DOI 10.1016/S0952-7915(97)80099-4; Rovere P, 2000, BLOOD, V96, P4300; SCHAFFNER A, 1982, J CLIN INVEST, V69, P617, DOI 10.1172/JCI110489; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; Szalai AJ, 1997, IMMUNOL RES, V16, P127, DOI 10.1007/BF02786357; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; VILLA P, 1995, CLIN DIAGN LAB IMMUN, V2, P549, DOI 10.1128/CDLI.2.5.549-553.1995; WATANABE Y, 1986, INFECT IMMUN, V52, P730, DOI 10.1128/IAI.52.3.730-735.1986	27	531	553	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					182	186		10.1038/nature01195	http://dx.doi.org/10.1038/nature01195			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432394				2022-12-28	WOS:000179200900047
J	Keyomarsi, K; Tucker, SL; Buchholz, TA; Callister, M; Ding, Y; Hortobagyi, GN; Bedrosian, I; Knickerbocker, C; Toyofuku, W; Lowe, M; Herliczek, TW; Bacus, SS				Keyomarsi, K; Tucker, SL; Buchholz, TA; Callister, M; Ding, Y; Hortobagyi, GN; Bedrosian, I; Knickerbocker, C; Toyofuku, W; Lowe, M; Herliczek, TW; Bacus, SS			Cyclin E and survival in patients with breast cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							E OVEREXPRESSION; IMAGE-ANALYSIS; ESTROGEN-RECEPTOR; PROGNOSTIC MARKER; REDUNDANT CYCLIN; PHASE-TRANSITION; EXPRESSION; CELLS; CARCINOMA; AMPLIFICATION	Background: Cyclin E, a regulator of the cell cycle, affects the behavior of breast-cancer cells. We investigated whether levels of cyclin E in the tumor correlated with survival among patients with breast cancer. Methods: Tumor tissue from 395 patients with breast cancer was assayed for cyclin E, cyclin D1, cyclin D3, and the HER-2/neu oncogene with the use of Western blot analysis. Full-length, low-molecular-weight, and total cyclin E were measured. Immunohistochemical assessments of cyclin E were also made of 256 tumors. We sought correlations between levels of these molecular markers and disease-specific and overall survival. Results: The median follow-up was 6.4 years. A high level of the low-molecular-weight isoforms of cyclin E, as detected by Western blotting, correlated strongly with disease-specific survival whether axillary lymph nodes were negative or positive for metastases (P<0.001). Among 114 patients with stage I breast cancer, none of the 102 patients with low levels of cyclin E in the tumor had died of breast cancer by five years after diagnosis, whereas all 12 patients with a high level of low-molecular-weight cyclin E had died of breast cancer within that period. In multivariate analysis, a high total cyclin E level or high levels of the low-molecular-weight forms of cyclin E were significantly correlated with poor outcome. The hazard ratio for death from breast cancer for patients with high total cyclin E levels as compared with those with low total cyclin E levels was 13.3 -- about eight times as high as the hazard ratios associated with other independent clinical and pathological risk factors. Conclusions: Levels of total cyclin E and low-molecular-weight cyclin E in tumor tissue, as measured by Western blot assay, correlate strongly with survival in patients with breast cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Div Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Wadsworth Ctr, Div Mol Med, Albany, NY USA; Quantitat Diagnost Labs, Elmhurst, NY USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Wadsworth Center	Keyomarsi, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849	NCI NIH HHS [R29-CA666062, R01-CA87548, T32CA77050, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087548, T32CA077050, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 1998, LANCET, V352, P930; BACUS S, 1988, AM J CLIN PATHOL, V90, P233, DOI 10.1093/ajcp/90.3.233; BACUS SS, 1989, AM J PATHOL, V135, P783; BACUS SS, 1993, PATHOL ANNU, V28, P179; BERCHUCK A, 1992, GYNECOL ONCOL, V44, P61, DOI 10.1016/0090-8258(92)90013-9; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Clarke M, 1998, LANCET, V351, P1451; COX DR, 1972, J R STAT SOC B, V34, P187; Donnellan R, 2001, HUM PATHOL, V32, P89, DOI 10.1053/hupa.2001.21141; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; DOU QP, 1993, CANCER RES, V53, P1493; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; Harwell RM, 2000, CANCER RES, V60, P481; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Scuderi R, 1996, BLOOD, V87, P3360, DOI 10.1182/blood.V87.8.3360.bloodjournal8783360; SCUDERI R, 1996, BLOOD, V88, P1083; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; TAYLOR SR, 1989, CYTOMETRY, V10, P382, DOI 10.1002/cyto.990100404; Voogd AC, 2001, J CLIN ONCOL, V19, P1688, DOI 10.1200/JCO.2001.19.6.1688; Wang A, 1996, J CANCER RES CLIN, V122, P122, DOI 10.1007/BF01226270; YAMASHITA JI, 1994, BRIT J CANCER, V69, P72, DOI 10.1038/bjc.1994.11	35	456	484	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2002	347	20					1566	1575		10.1056/NEJMoa021153	http://dx.doi.org/10.1056/NEJMoa021153			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614KL	12432043	Bronze			2022-12-28	WOS:000179187800004
J	Searls, DB				Searls, DB			The language of genes	NATURE			English	Review							CONTEXT-FREE GRAMMARS; STRUCTURE PREDICTION; PROTEIN FUNCTIONS; GENOME; RNA; DNA; FAMILY; PHYLOGENY; SEQUENCES; TEXTS	Linguistic metaphors have been woven into the fabric of molecular biology since its inception. The determination of the human genome sequence has brought these metaphors to the forefront of the popular imagination, with the natural extension of the notion of DNA as language to that of the genome as the 'book of life'. But do these analogies go deeper and, if so, can the methods developed for analysing languages be applied to molecular biology? In fact, many techniques used in bioinformatics, even if developed independently, may be seen to be grounded in linguistics. Further interweaving of these fields will be instrumental in extending our understanding of the language of life.	GlaxoSmithKline, Genet Res, Bioinformat Div, King Of Prussia, PA 19406 USA	GlaxoSmithKline	Searls, DB (corresponding author), GlaxoSmithKline, Genet Res, Bioinformat Div, 709 Swedeland Rd,POB 1539, King Of Prussia, PA 19406 USA.	david_b_searls@gsk.com		Searls, David/0000-0001-7840-8274				Abe H, 2001, ARTIF CELL BLOOD SUB, V29, P275, DOI 10.1081/BIO-100104230; Aitchison J., 1999, LINGUISTICS; Altman RB, 2001, CURR OPIN STRUC BIOL, V11, P340, DOI 10.1016/S0959-440X(00)00212-8; BALDI P, 2001, BIOINFORMATICS MACHI; Barbrook AC, 1998, NATURE, V394, P839, DOI 10.1038/29667; Barnbrook G., 1996, LANGUAGE COMPUTERS; Binongo J. N. G., 1999, Literary & Linguistic Computing, V14, P445, DOI 10.1093/llc/14.4.445; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P2561, DOI 10.1093/nar/12.5.2561; Brown M, 1996, Pac Symp Biocomput, P109; Brown M P, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P57; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Campbell Lyle., 1999, HIST LINGUISTICS INT; Cavalli-Sforza LL., 2000, GENES PEOPLES LANGUA; Chomsky N., 2002, JANUA LINGUARUM; COLLADOVIDES J, 1989, J THEOR BIOL, V136, P403, DOI 10.1016/S0022-5193(89)80156-0; Darwin Charles, 1871, DESCENT MAN; Dawkins Richard, 1976, SELFISH GENE; DONG S, 1994, GENOMICS, V23, P540, DOI 10.1006/geno.1994.1541; Durbin R., 1998, BIOL SEQUENCE ANAL P; FERRARI JR, 1995, J SOC BEHAV PERS, V10, P143; Garcia-Vallve S, 2000, GENOME RES, V10, P1719, DOI 10.1101/gr.130000; Harrison PM, 2002, J MOL BIOL, V318, P1155, DOI 10.1016/S0022-2836(02)00109-2; HEAD T, 1987, B MATH BIOL, V49, P737, DOI 10.1016/S0092-8240(87)90018-8; Holmes D. I., 1995, LIT LINGUIST COMPUT, V10, P111, DOI DOI 10.1093/LLC/10.2.111; Holmes I, 2002, Pac Symp Biocomput, P163; Hoorn J. F., 1999, Literary & Linguistic Computing, V14, P311, DOI 10.1093/llc/14.3.311; Hoover D. L., 2001, Literary & Linguistic Computing, V16, P421, DOI 10.1093/llc/16.4.421; Hopcroft J.E., 1979, INTRO AUTOMATA THEOR; Hoyle DC, 2002, BIOINFORMATICS, V18, P576, DOI 10.1093/bioinformatics/18.4.576; Huynen MA, 1998, MOL BIOL EVOL, V15, P583, DOI 10.1093/oxfordjournals.molbev.a025959; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Joshi A.K., 1985, NATURAL LANGUAGE PRO, P206, DOI [10.1017/CBO9780511597855.007, DOI 10.1017/CBO9780511597855]; Jung J, 2001, PROTEIN SCI, V10, P1881, DOI 10.1110/ps.05801; Jurafsky Daniel, 2000, SPEECH LANGUAGE PROC, V1st; Knudsen B, 1999, BIOINFORMATICS, V15, P446, DOI 10.1093/bioinformatics/15.6.446; KRUSKAL JB, 1973, LEXICOSTATISTICS GEN, P30; Leopold E, 2002, MACH LEARN, V46, P423, DOI 10.1023/A:1012491419635; Leung SW, 2001, BIOINFORMATICS, V17, P226, DOI 10.1093/bioinformatics/17.3.226; Lin J, 2000, GENOME RES, V10, P808, DOI 10.1101/gr.10.6.808; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Lupas AN, 2001, J STRUCT BIOL, V134, P191, DOI 10.1006/jsbi.2001.4393; Lyngso RB, 2000, J COMPUT BIOL, V7, P409, DOI 10.1089/106652700750050862; Mandelbrot B, 1983, FRACTAL GEOMETRY NAT; MANTEGNA RN, 1994, PHYS REV LETT, V73, P3169, DOI 10.1103/PhysRevLett.73.3169; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; McKeown K.R., 2000, HDB NATURAL LANGUAGE, P507; MCWHORTER JH, 2001, POWER BABEL NATURAL, P128; Mushegian A, 1999, CURR OPIN GENET DEV, V9, P709, DOI 10.1016/S0959-437X(99)00023-4; Nowak MA, 2002, NATURE, V417, P611, DOI 10.1038/nature00771; Park J, 2001, J MOL BIOL, V307, P929, DOI 10.1006/jmbi.2001.4526; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Pennock RT, 1999, TOWER BABEL EVIDENCE; PLATNICK NI, 1977, SYST ZOOL, V26, P380, DOI 10.2307/2412794; Popov O, 1996, BIOSYSTEMS, V38, P65, DOI 10.1016/0303-2647(95)01568-X; Przytycka T, 2002, PROTEIN SCI, V11, P409, DOI 10.1110/ps.24701; Qian J, 2001, J MOL BIOL, V313, P673, DOI 10.1006/jmbi.2001.5079; Reese MG, 2000, GENOME RES, V10, P529, DOI 10.1101/gr.10.4.529; Rivas E, 2000, BIOINFORMATICS, V16, P334, DOI 10.1093/bioinformatics/16.4.334; Rivas E, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-8; Rosenblueth DA, 1996, COMPUT APPL BIOSCI, V12, P415; Rudman J, 1997, COMPUT HUMANITIES, V31, P351, DOI 10.1023/A:1001018624850; Rzhetsky A, 2001, BIOINFORMATICS, V17, P988, DOI 10.1093/bioinformatics/17.10.988; SAKAKIBARA Y, 1994, NUCLEIC ACIDS RES, V22, P5112, DOI 10.1093/nar/22.23.5112; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SCHUSTER P, 1994, P ROY SOC B-BIOL SCI, V255, P279, DOI 10.1098/rspb.1994.0040; Searls D B, 2001, Pharmacogenomics J, V1, P88; Searls D. B, 1999, MATH SUPPORT MOL BIO, P117; Searls D. B., 1993, ARTIF INTELL, P47; Searls DB, 1997, COMPUT APPL BIOSCI, V13, P333; SEARLS DB, 1992, AM SCI, V80, P579; SEARLS DB, 1989, LOGIC PROGRAMM, P189; Searls DB, 2001, J COMPUT BIOL, V8, P339, DOI 10.1089/10665270152530881; Searls DB, 2001, BIOINFORMATICS, V17, P579, DOI 10.1093/bioinformatics/17.7.579; SEARLS DB, 1995, J LOGIC PROGRAM, V24, P73, DOI 10.1016/0743-1066(95)00034-H; SEARLS DB, 1988, P 7 NAT C ART INT, P386; SHIEBER SM, 1985, LINGUIST PHILOS, V8, P333, DOI 10.1007/BF00630917; Smadja F., 1993, Computational Linguistics, V19, P143; Snel B, 1999, NAT GENET, V21, P108, DOI 10.1038/5052; Spencer M., 2001, Literary & Linguistic Computing, V16, P467, DOI 10.1093/llc/16.4.467; Swadesh M., 1952, P AM PHILOS SOC, V96, P452, DOI DOI 10.2307/3143802; Tanselle G. Thomas, 1998, LIT ARTIFACTS; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Tekaia F, 1999, GENOME RES, V9, P550; Trifonov EN, 1996, COMPUT APPL BIOSCI, V12, P423; Uemura Y, 1999, THEOR COMPUT SCI, V210, P277, DOI 10.1016/S0304-3975(98)00090-5; Warnow T, 1997, P NATL ACAD SCI USA, V94, P6585, DOI 10.1073/pnas.94.13.6585; Westhead DR, 1999, PROTEIN SCI, V8, P897; WHITE O, 1993, NUCLEIC ACIDS RES, V21, P3829, DOI 10.1093/nar/21.16.3829; Yandell MD, 2002, NAT REV GENET, V3, P601, DOI 10.1038/nrg861; Zipf G. K., 1949, HUMAN BEHAV PRINCIPL	90	192	201	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					211	217		10.1038/nature01255	http://dx.doi.org/10.1038/nature01255			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432405				2022-12-28	WOS:000179200900057
J	Suarez, RK; Jones, DR				Suarez, RK; Jones, DR			Peter W. Hochachka (1937-2002) - Obituary	NATURE			English	Biographical-Item									Univ Calif Santa Barbara, Dept Ecol Evolut & Marine Biol, Santa Barbara, CA 93106 USA; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada	University of California System; University of California Santa Barbara; University of British Columbia	Suarez, RK (corresponding author), Univ Calif Santa Barbara, Dept Ecol Evolut & Marine Biol, Santa Barbara, CA 93106 USA.								0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					140	140		10.1038/420140a	http://dx.doi.org/10.1038/420140a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432377	Bronze			2022-12-28	WOS:000179200900030
J	Eriksson, B; Bergqvist, D; Kalebo, P; Dahl, OE; Lindbratt, S; Bylock, A; Frison, L; Eriksson, UG; Welin, L; Gustafsson, D				Eriksson, B; Bergqvist, D; Kalebo, P; Dahl, OE; Lindbratt, S; Bylock, A; Frison, L; Eriksson, UG; Welin, L; Gustafsson, D			Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial	LANCET			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; RECOMBINANT HIRUDIN; PULMONARY-EMBOLISM; SURGERY; PROPHYLAXIS; WARFARIN	Background Heparins substantially reduce the risk of thromboembolic complications after total hip or knee replacement. However, they can be given only by injection and have several other drawbacks. We did a multicentre, randomised, double-blind study to examine the dose-response relation of subcutaneous melagatran, a direct thrombin inhibitor, followed by oral ximelagatran as thromboprophylaxis after total hip or knee replacement. We aimed to compare the efficacy and safety with that of dalteparin. Methods Of 1900 patients, 1495 were assigned to four dose categories of subcutaneous melagatran from just before surgery (1.00 mg, 1.50 mg, 2.25 mg, or 3.00 mg twice daily) followed from the day after surgery by oral ximelagatran (8 mg, 12 mg, 18 mg, or 24 mg twice daily). 381 patients were assigned subcutaneous dalteparin 5000 IU once daily, from the evening before surgery. Bilateral venography was done at 7-10 days, and clinically suspected venous thromboembolism (VTE) was confirmed radiologically. The primary endpoint was the rate of deep-vein thrombosis and pulmonary embolism (PE). Analyses were by intention to treat. Findings 1876 patients underwent total replacement of hip (n=1270) or knee (n=606); evaluable venograms were obtained in 1473 (79%). Four patients without evaluable venograms had PE. Overall, a significant dose-dependent decrease in VTE was seen with melagatran/ximelagatran (lowest to highest group: 111 [37.8%], 70 [24.1%], 71 [23.7%], and 43 [15.1%]; p=00001); there were also significant relations for both total hip and total knee replacement individually. The frequency of VTE was significantly lower with the highest dose of melagatran/ximelagatran than with dalteparin (15.1% vs 28.2%, p<0.0001). There were no reoperations due to bleeding and no critical organ bleeding. Excessive surgical bleeding was uncommon but more frequent in the highest dose group. Interpretation This sequential therapy was effective and safe in patients undergoing major joint replacement surgery. The findings should be confirmed in a large phase III trial.	Sahlgrenska Univ Hosp Ostra, Dept Orthopaed Surg, SE-41685 Gothenburg, Sweden; Sahlgrenska Univ Hosp Ostra, Dept Radiol, SE-41685 Gothenburg, Sweden; Acad Hosp, Dept Vasc Surg, Uppsala, Sweden; Ullevaal Univ Hosp, Res Forum, Dept Orthopaed, Oslo, Norway; Scandinavian Clin Res Inst, Gothenburg, Sweden; AstraZeneca R&D, Molndal, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; University of Oslo; AstraZeneca	Eriksson, B (corresponding author), Sahlgrenska Univ Hosp Ostra, Dept Orthopaed Surg, SE-41685 Gothenburg, Sweden.			Eriksson, Bengt/0000-0001-6894-7434				BIELLO DR, 1979, AM J ROENTGENOL, V133, P1033, DOI 10.2214/ajr.133.6.1033; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Dahl OE, 1995, BLOOD COAGUL FIBRIN, V6, P709, DOI 10.1097/00001721-199512000-00003; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; Eriksson BI, 1997, NEW ENGL J MED, V337, P1329, DOI 10.1056/NEJM199711063371901; Eriksson BI, 2002, THROMB HAEMOSTASIS, V87, P231; Eriksson BI, 1996, LANCET, V347, P635, DOI 10.1016/S0140-6736(96)91200-3; Eriksson U. G., 2000, Haemostasis, V30, P164; Eriksson UG, 1999, BLOOD, V94, p26A; Francis CW, 1997, J BONE JOINT SURG AM, V79A, P1365, DOI 10.2106/00004623-199709000-00011; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; GINSBERG JS, 1994, CIRCULATION, V90, P2385, DOI 10.1161/01.CIR.90.5.2385; Gustafsson D, 2001, THROMB RES, V101, P171, DOI 10.1016/S0049-3848(00)00399-6; Havig O, 1977, Acta Chir Scand Suppl, V478, P1; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; Hull RD, 2000, ARCH INTERN MED, V160, P2199, DOI 10.1001/archinte.160.14.2199; Johansson L, 2000, BLOOD, V96, p57A; Kalebo P, 1996, THROMB HAEMOSTASIS, V76, P893; LINDBRATT S, 1995, THROMB HAEMOSTASIS, V73, P1452; MOHR DN, 1993, ARCH INTERN MED, V153, P2221, DOI 10.1001/archinte.153.19.2221; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134	22	241	248	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1441	1447		10.1016/S0140-6736(02)11469-3	http://dx.doi.org/10.1016/S0140-6736(02)11469-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433510				2022-12-28	WOS:000179186000007
J	Hennessy, S; Bilker, WB; Knauss, JS; Margolis, DJ; Kimmel, SE; Reynolds, RF; Glasser, DB; Morrison, MF; Strom, BL				Hennessy, S; Bilker, WB; Knauss, JS; Margolis, DJ; Kimmel, SE; Reynolds, RF; Glasser, DB; Morrison, MF; Strom, BL			Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data	BRITISH MEDICAL JOURNAL			English	Article							DEATH; RISK; PROLONGATION; EXPERIENCE; PSORIASIS	Objective To examine the rates of cardiac arrest and ventricular arrhythmia in patients with treated schizophrenia and in non-schizophrenic controls. Design Cohort study of outpatients using administrative data. Setting 3 US Medicaid programmes. Participants Patients with schizophrenia treated with clozapine, haloperidol, risperidone, or thioridazine; a control group of patients with glaucoma; and a control group of patients with psoriasis. Main outcome measure Diagnosis of cardiac arrest or ventricular arrhythmia. Results Patients with treated schizophrenia had higher rates of cardiac arrest and ventricular arrhythmia than controls, with rate ratios ranging from 1.7 to 3.2. Overall, thioridazine was not associated with an increased risk compared with haloperidol (rate ratio 0.9, 95% confidence interval 0.7 to 1.2). However, thioridazine showed an increased risk of events at doses greater than or equal to600 mg (2.6, 1.0 to 6.6; P=0.049) and a linear dose-response relation (P=0.038). Conclusions The increased risk of cardiac arrest and ventricular arrhythmia in patients with treated schizophrenia could be due to the disease or its treatment. Overall, the risk with thioridazine was no worse than that with haloperidol. Thioridazine may, however, have a higher risk at high doses, although this finding could be due to chance. To reduce cardiac risk, thioridazine should be prescribed at the lowest dose needed to obtain an optimal therapeutic effect.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Pfizer, Epidemiol, New York, NY 10017 USA; Pfizer, Sexual Hlth, New York, NY 10017 USA; Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Pfizer; Pfizer; University of Pennsylvania	Hennessy, S (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.		Bilker, Warren/AAS-3515-2021		NIA NIH HHS [1K23AG000987, K23 AG000987] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K23AG000987] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bhana N, 2000, DRUG AGING, V16, P451, DOI 10.2165/00002512-200016060-00005; *BRIT MED ASS, 2001, BRIT NATL FORM, V172; *BRIT MED ASS, 2001, BRIT NAT FORM, V172; BUCKLEY NA, 1995, J TOXICOL-CLIN TOXIC, V33, P199, DOI 10.3109/15563659509017984; Cavero I, 2000, Expert Opin Pharmacother, V1, P947, DOI 10.1517/14656566.1.5.947; *COMM PROPR MED PR, 1997, 12171997 COMM PROPR; De Ponti F, 2000, EUR J CLIN PHARMACOL, V56, P1, DOI 10.1007/s002280050714; De Ponti F, 2001, EUR J CLIN PHARMACOL, V57, P185, DOI 10.1007/s002280100290; DEMAILLY P, 1984, OPHTHALMOLOGICA, V188, P65, DOI 10.1159/000309344; *FED DRUGS ADM, 2000, BRIEF DOC ZELD CAPS; *FED DRUGS ADM PSY, 2000, BRIEF DOC ZELD CAPS; Leuraud K, 2001, STAT MED, V20, P3335, DOI 10.1002/sim.959; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Margolis D, 2001, ARCH DERMATOL, V137, P778; National Center for Health Statistics, AMB CAR DRUG DAT SYS; Ray WA, 2001, ARCH GEN PSYCHIAT, V58, P1161, DOI 10.1001/archpsyc.58.12.1161; Reilly JG, 2000, LANCET, V355, P1048, DOI 10.1016/S0140-6736(00)02035-3; Sesso HD, 2000, AM J EPIDEMIOL, V152, P107, DOI 10.1093/aje/152.2.107; Staffa JA, 1995, CLIN THER, V17, P1062, DOI 10.1016/0149-2918(95)80085-9; STERN RS, 1988, J INVEST DERMATOL, V91, P197, DOI 10.1111/1523-1747.ep12464847; Zarate CA, 2001, ARCH GEN PSYCHIAT, V58, P1168, DOI 10.1001/archpsyc.58.12.1168	21	191	194	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2002	325	7372					1070	1072A		10.1136/bmj.325.7372.1070	http://dx.doi.org/10.1136/bmj.325.7372.1070			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424166	Green Published, Bronze			2022-12-28	WOS:000179415700019
J	Lip, GYH; Chin, BSP; Prasad, N				Lip, GYH; Chin, BSP; Prasad, N			ABC of antithrombotic therapy - Antithrombotic therapy in myocardial infarction and stable angina	BMJ-BRITISH MEDICAL JOURNAL			English	Review							THROMBOLYSIS		City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Univ Dept Med, Birmingham, W Midlands, England	University of Birmingham	Lip, GYH (corresponding author), City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Univ Dept Med, Birmingham, W Midlands, England.							[Anonymous], 1988, LANCET, V2, P349; Cairns JA, 2001, CHEST, V119, p228S, DOI 10.1378/chest.119.1_suppl.228S; Collins R, 1996, BMJ-BRIT MED J, V313, P652; MOUNSEY JP, 1995, BRIT HEART J, V74, P348; *NAT I CLIN EXC, 2002, TECHN APPR GUID 52 G; Ohman EM, 2001, CHEST, V119, p253S, DOI 10.1378/chest.119.1_suppl.253S; Oldroyd KG, 2000, HEART, V84, P113, DOI 10.1136/heart.84.2.113; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	8	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	2002	325	7375					1287	1289		10.1136/bmj.325.7375.1287	http://dx.doi.org/10.1136/bmj.325.7375.1287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458252	Green Published			2022-12-28	WOS:000179696300022
J	Gallo, RC				Gallo, RC			Historical essay - The early years of HIV/AIDS	SCIENCE			English	Editorial Material							HUMAN RETROVIRUSES; GROWTH; CELLS; INVITRO		Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Gallo, RC (corresponding author), Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA.							Chermann JC, 2001, J HUMAN VIROL, V4, P289, DOI 10.1097/01.QHV.0000021382.12087.D5; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; Gallo RC, 2002, IMMUNOL REV, V185, P236, DOI 10.1034/j.1600-065X.2002.18520.x; GALLO RC, 1995, NAT MED, V1, P753, DOI 10.1038/nm0895-753; Gallo RC, 2000, J HUMAN VIROL, V3, P1; Gallo RC., 1991, VIRUS HUNTING AIDS C; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KULSTAD Ruth, 1986, AIDS PAPERS SCI 1982; MIER JW, 1980, P NATL ACAD SCI-BIOL, V77, P6134, DOI 10.1073/pnas.77.10.6134; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; RUSCETTI FW, 1977, J IMMUNOL, V119, P131; SAFAI B, 1984, LANCET, V1, P1438, DOI 10.1016/S0140-6736(84)91933-0; SALAHUDDIN SZ, 1981, BLOOD, V58, P931; SARNGADHARAN MG, 1972, NATURE-NEW BIOL, V240, P67, DOI 10.1038/newbio240067a0; SARNGADHARAN MG, 1978, BIOCHIM BIOPHYS ACTA, V516, P419, DOI 10.1016/0304-419X(78)90019-7; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	18	42	51	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1728	1730		10.1126/science.1078050	http://dx.doi.org/10.1126/science.1078050			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459576				2022-12-28	WOS:000179494800028
J	de Jonge, N; Lamy, Y; Schoots, K; Oosterkamp, TH				de Jonge, N; Lamy, Y; Schoots, K; Oosterkamp, TH			High brightness electron beam from a multi-walled carbon nanotube	NATURE			English	Article							IN-FIELD EMISSION; MICROSCOPY	Carbon nanotubes can act as electron sources(1) with very rigid structures(2), making them particularly interesting for use as point electron sources in high-resolution electron-beam instruments. Promising results have been reported with respect to some important requirements for such applications: a stable emitted current(3,4,5) and a long lifetime(6),(7). Two parameters of an electron source affect the resolution of these instruments: the energy spread of the emitted electrons and a parameter called the reduced brightness, which depends on the angular current density and the virtual source size. Several authors have measured a low energy spread associated with electron emission(3,7,8,9). Here we measure the reduced brightness, and find a value that is more than a factor of ten larger than provided by state-of-the-art electron sources in electron microscopes. In addition, we show that an individual multi-walled carbon nanotube emits most current into a single narrow beam. On the basis of these results, we expect that carbon nanotube electron sources will lead to a significant improvement in the performance of high-resolution electron-beam instruments.	Philips Res Labs, NL-5656 AA Eindhoven, Netherlands; Ecole Super Phys & Chim Ind Ville Paris, F-75005 Paris, France; Leiden Inst Phys, NL-2333 CA Leiden, Netherlands	Philips; Philips Research; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Leiden University	de Jonge, N (corresponding author), Philips Res Labs, Prof Holstlaan 4, NL-5656 AA Eindhoven, Netherlands.		de Jonge, Niels/B-5677-2008	de Jonge, Niels/0000-0002-3969-6821				Bonard JM, 1999, APPL PHYS A-MATER, V69, P245, DOI 10.1007/s003390050998; COLBERT DT, 1994, SCIENCE, V266, P1218, DOI 10.1126/science.266.5188.1218; Dean KA, 1999, J VAC SCI TECHNOL B, V17, P1959, DOI 10.1116/1.590856; Dean KA, 1999, APPL PHYS LETT, V75, P3017, DOI 10.1063/1.125219; Dean KA, 1999, J APPL PHYS, V85, P3832, DOI 10.1063/1.369753; DEJONGE N, IN PRESS ULTRAMICROS; Fransen MJ, 1999, APPL SURF SCI, V146, P312, DOI 10.1016/S0169-4332(99)00056-2; FRANSEN MJ, 1995, APPL SUR SCI, V94, P107; Groning O, 2000, J VAC SCI TECHNOL B, V18, P665, DOI 10.1116/1.591258; Hawkes P.W., 1996, PRINCIPLES ELECT OPT, V3; Hawkes PW., 1996, PRINCIPLES ELECT OPT, V2; ORLOFF J, 1989, ULTRAMICROSCOPY, V28, P88, DOI 10.1016/0304-3991(89)90278-7; Purcell ST, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.105502; Saito R., 1998, PHYS PROPERTIES CARB; Saito Y, 2000, CARBON, V38, P169, DOI 10.1016/S0008-6223(99)00139-6; Saito Y, 1997, NATURE, V389, P554, DOI 10.1038/39221; Schmid H, 1997, APPL PHYS LETT, V70, P2679, DOI 10.1063/1.118978; SPENCE JCH, 1994, J VAC SCI TECHNOL A, V12, P542, DOI 10.1116/1.579166; van Veen AHV, 2001, J VAC SCI TECHNOL B, V19, P2038, DOI 10.1116/1.1409390	19	455	477	1	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					393	395		10.1038/nature01233	http://dx.doi.org/10.1038/nature01233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459778				2022-12-28	WOS:000179494700032
J	Di Bisceglie, AM				Di Bisceglie, AM			An error rationalised is still a mistake	LANCET			English	Editorial Material									St Louis Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, St Louis, MO 63110 USA	Saint Louis University	Di Bisceglie, AM (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, 3635 Vista Ave, St Louis, MO 63110 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 23	2002	360	9346					1688	1688		10.1016/S0140-6736(02)11609-6	http://dx.doi.org/10.1016/S0140-6736(02)11609-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457806				2022-12-28	WOS:000179393900028
J	Shepherd, J; Blauw, GJ; Murphy, MB; Bollen, ELEM; Buckley, BM; Cobbe, SM; Ford, I; Gaw, A; Hyland, M; Jukema, JW; Kamper, AM; Macfarlane, PW; Meinders, AE; Norrie, J; Packard, CJ; Perry, IJ; Stott, DJ; Sweeney, BJ; Twomey, C; Westendorp, RGJ				Shepherd, J; Blauw, GJ; Murphy, MB; Bollen, ELEM; Buckley, BM; Cobbe, SM; Ford, I; Gaw, A; Hyland, M; Jukema, JW; Kamper, AM; Macfarlane, PW; Meinders, AE; Norrie, J; Packard, CJ; Perry, IJ; Stott, DJ; Sweeney, BJ; Twomey, C; Westendorp, RGJ		PROPSER Study Grp	Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial	LANCET			English	Article							CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; COGNITIVE FUNCTION; CHOLESTEROL; EVENTS; PREVENTION; MORTALITY; PREVALENCE; STATINS; PEOPLE	Background Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged individuals, their efficacy and safety in elderly people is not fully established. Our aim was to test the benefits of pravastatin treatment in an elderly cohort of men and women with, or at high risk of developing, cardiovascular disease and stroke. Methods We did a randomised controlled trial in which we assigned 5804 men (n=2804) and women (n=3000) aged 70-82 years with a history of, or risk factors for, vascular disease to pravastatin (40 mg per day; n=2891) or placebo (n=2913). Baseline cholesterol concentrations ranged from 4.0 mmol/L to 9.0 mmol/L. Follow-up was 3.2 years on average and our primary endpoint was a composite of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke. Analysis was by intention-to-treat. Findings Pravastatin lowered LDL cholesterol concentrations by 34% and reduced the incidence of the primary endpoint to 408 events compared with 473 on placebo (hazard ratio 0.85, 95% CI 0.74-0.97, p=0.014). Coronary heart disease death and non-fatal myocardial infarction risk was also reduced (0.81, 0.69-0.94, p=0.006). Stroke risk was unaffected (1.03, 0.81-1.31, p=0.8), but the hazard ratio for transient ischaemic attack was 0.75 (0.55-1.00, p=0.051). New cancer diagnoses were more frequent on pravastatin than on placebo (1.25, 1.04-1.51, p=0.020). However, incorporation of this finding in a meta-analysis of all pravastatin and all statin trials showed no overall increase in risk. Mortality from coronary disease fell by 24% (p=0.043) in the pravastatin group. Pravastatin had no significant effect on cognitive function or disability. Interpretation Pravastatin given for 3 years reduced the risk of coronary disease in elderly individuals. PROSPER therefore extends to elderly individuals the treatment strategy currently used in middle aged people.	Univ Glasgow, Royal Infirm, Dept Pathol Biochem, Glasgow G4 0SF, Lanark, Scotland; N Glasgow Univ NHS Trust, Glasgow, Lanark, Scotland; Robertson Ctr Biostat, Glasgow, Lanark, Scotland; Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; Univ Coll Cork, Dept Pharmacol & Therapeut, Cork, Ireland; Univ Coll Cork, Dept Epidemiol & Publ Hlth, Cork, Ireland; Cork Univ Hosp, Dept Geriatr Med, Cork, Ireland; Cork Univ Hosp, Dept Neurol, Cork, Ireland; Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Internal Med, Leiden, Netherlands	Royal Infirmary of Edinburgh; University of Glasgow; University of Glasgow; University of Glasgow; University College Cork; University College Cork; University College Cork; University College Cork; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Shepherd, J (corresponding author), Univ Glasgow, Royal Infirm, Dept Pathol Biochem, Glasgow G4 0SF, Lanark, Scotland.	jshepherd@gri-biochem.org.uk	Blauw, Gerard/AAW-7904-2021; Murphy, Michael B/A-1310-2011; Sweeney, Brian/O-7767-2019; Jukema, J. Wouter/ABD-6503-2021; Sweeney, Brian J/D-2569-2013; Blauw, Gerard/GWD-1079-2022; Ford, Ian/ABE-6145-2020	Jukema, J. Wouter/0000-0002-3246-8359; Murphy, Michael/0000-0001-6722-7080; Perry, Ivan/0000-0002-4965-9792				Bjerre LM, 2001, AM J MED, V110, P716, DOI 10.1016/S0002-9343(01)00705-7; BRETELER MMB, 1994, NEUROLOGY, V44, P1246, DOI 10.1212/WNL.44.7.1246; Byington RP, 2001, CIRCULATION, V103, P387; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Esiri MM, 2001, LANCET, V357, P169; Ford I, 2002, CURR CONTR TRIALS C, V3, DOI 10.1186/1468-6708-3-8; FURBERG C, 1995, AM J CARDIOL, V76, P899; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Houx PJ, 2002, J NEUROL NEUROSUR PS, V73, P385, DOI 10.1136/jnnp.73.4.385; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; KEECH A, 1992, POSTGRAD MED J, V68, P870; Macfarlane PW, 1996, J ELECTROCARDIOL, V29, P29, DOI 10.1016/S0022-0736(96)80016-1; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 1998, AM J CARDIOL, V81, P333, DOI 10.1016/S0002-9149(97)00904-1; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Qizilbash N, 1995, LANCET, V346, P1647; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sacks FM, 2000, CIRCULATION, V102, P1893, DOI 10.1161/01.CIR.102.16.1893; Schatz IJ, 2001, LANCET, V358, P351, DOI 10.1016/S0140-6736(01)05553-2; Serruys PWJC, 2002, JAMA-J AM MED ASSOC, V287, P3215, DOI 10.1001/jama.287.24.3215; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shepherd J, 1999, AM J CARDIOL, V84, P1192, DOI 10.1016/S0002-9149(99)00533-0; SHIPLEY MJ, 1991, BRIT MED J, V303, P89, DOI 10.1136/bmj.303.6794.89; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	29	2444	2571	0	129	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2002	360	9346					1623	1630		10.1016/S0140-6736(02)11600-X	http://dx.doi.org/10.1016/S0140-6736(02)11600-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457784				2022-12-28	WOS:000179393900006
J	Bezanilla, F; Perozo, E				Bezanilla, F; Perozo, E			Force and voltage sensors in one structure	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; MECHANOSENSITIVE CHANNELS; ION-CHANNEL; MSCL; MEMBRANE		Univ Calif Los Angeles, Dept Physiol & Anesthesiol, Los Angeles, CA 90095 USA; Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of California System; University of California Los Angeles; University of Virginia	Bezanilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol & Anesthesiol, Los Angeles, CA 90095 USA.							Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Blount P, 1999, Methods Enzymol, V294, P458; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; CUI C, 1995, J MEMBRANE BIOL, V144, P31; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999	15	16	19	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1562	1563		10.1126/science.1079369	http://dx.doi.org/10.1126/science.1079369			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446894				2022-12-28	WOS:000179361600033
J	Harvey, CF; Swartz, CH; Badruzzaman, ABM; Keon-Blute, N; Yu, W; Ali, MA; Jay, J; Beckie, R; Niedan, V; Brabander, D; Oates, PM; Ashfaque, KN; Islam, S; Hemond, HF; Ahmed, MF				Harvey, CF; Swartz, CH; Badruzzaman, ABM; Keon-Blute, N; Yu, W; Ali, MA; Jay, J; Beckie, R; Niedan, V; Brabander, D; Oates, PM; Ashfaque, KN; Islam, S; Hemond, HF; Ahmed, MF			Arsenic mobility and groundwater extraction in Bangladesh	SCIENCE			English	Article							CARBON	High levels of arsenic in well water are causing widespread poisoning in Bangladesh. In a typical aquifer in southern Bangladesh, chemical data imply that arsenic mobilization is associated with recent inflow of carbon. High concentrations of radiocarbon-young methane indicate that young carbon has driven recent biogeochemical processes, and irrigation pumping is sufficient to have drawn water to the depth where dissolved arsenic is at a maximum. The results of field injection of molasses, nitrate, and low-arsenic water show that organic carbon or its degradation products may quickly mobilize arsenic, oxidants may lower arsenic concentrations, and sorption of arsenic is limited by saturation of aquifer materials.	MIT, Dept Civil & Environm Engn, Ralph M Parsons Lab, Cambridge, MA 01239 USA; Bangladesh Univ Engn & Technol, Dhaka 1000, Bangladesh; Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z1, Canada; Univ Cincinnati, Dept Civil & Environm Engn, Cincinnati, OH 45221 USA	Massachusetts Institute of Technology (MIT); Bangladesh University of Engineering & Technology (BUET); University of British Columbia; University System of Ohio; University of Cincinnati	Harvey, CF (corresponding author), MIT, Dept Civil & Environm Engn, Ralph M Parsons Lab, Cambridge, MA 01239 USA.		harvey, charles F/A-8601-2012	harvey, charles F/0000-0002-7759-4447; Beckie, Roger/0000-0001-6152-4420; Brabander, Daniel/0000-0002-2967-3087	NIEHS NIH HHS [P30ES02109] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Appelo CAJ, 2002, ENVIRON SCI TECHNOL, V36, P3096, DOI 10.1021/es010130n; Chowdhury TR, 1999, NATURE, V401, P545, DOI 10.1038/44056; Das D., 1995, P INT C ARS GROUNDW; Goodbred SL, 1999, GEOLOGY, V27, P559, DOI 10.1130/0091-7613(1999)027<0559:HAMSBF>2.3.CO;2; Harvey CF, 2002, SCIENCE, V296; HARVEY CF, 2001, ENV SCI, V8, P491; Keon NE, 2001, ENVIRON SCI TECHNOL, V35, P2778, DOI 10.1021/es001511o; Khan FH, 1991, GEOLOGY BANGLADESH; Kinniburgh D., 2001, ARSENIC CONTAMINATIO; McArthur JM, 2001, WATER RESOUR RES, V37, P109, DOI 10.1029/2000WR900270; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; Nordstrom DK, 2000, MINOR ELEMENTS 2000: PROCESSING AND ENVIRONMENTAL ASPECTS OF AS, SB, SE, TE, AND BI, P21; Senn DB, 2002, SCIENCE, V296, P2373, DOI 10.1126/science.1072402; Smedley PL, 2002, APPL GEOCHEM, V17, P517, DOI 10.1016/S0883-2927(02)00018-5; Smith AH, 2000, B WORLD HEALTH ORGAN, V78, P1093; Whiticar MJ, 1999, CHEM GEOL, V161, P291, DOI 10.1016/S0009-2541(99)00092-3; YAPP CJ, 1986, GEOCHIM COSMOCHIM AC, V50, P1213, DOI 10.1016/0016-7037(86)90404-7; YU WH, IN PRESS WATER RESOU	18	933	968	20	455	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1602	1606		10.1126/science.1076978	http://dx.doi.org/10.1126/science.1076978			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446905				2022-12-28	WOS:000179361600044
J	Devereaux, PJ; Schunemann, HJ; Ravindran, N; Bhandari, M; Garg, AX; Choi, PTL; Grant, BJB; Haines, T; Lacchetti, C; Weaver, B; Lavis, JN; Cook, DJ; Haslam, DRS; Sullivan, T; Guyatt, GH				Devereaux, PJ; Schunemann, HJ; Ravindran, N; Bhandari, M; Garg, AX; Choi, PTL; Grant, BJB; Haines, T; Lacchetti, C; Weaver, B; Lavis, JN; Cook, DJ; Haslam, DRS; Sullivan, T; Guyatt, GH			Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers - A systematic review and meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							STAGE RENAL-DISEASE; DIALYSIS FACILITIES; PATIENTS SURVIVAL; REUSE PRACTICES; OWNERSHIP; TRANSPLANTATION; METAANALYSIS; OUTCOMES; PRICE; UNIT	Context Private for-profit and private not-for-profit dialysis facilities provide the majority of hemodialysis care in the United States. There has been extensive debate about whether the profit status of these facilities influences patient mortality. Objective To determine whether a difference in adjusted mortality rates exists between hemodialysis patients receiving care in private for-profit vs private not-for-profit dialysis centers. Data Sources We searched 11 bibliographic databases, reviewed our own files, and contacted experts in June 2001-January 2002. In June 2002, we also searched PubMed using the "related articles" feature, SciSearch, and the reference lists of all studies that fulfilled our eligibility criteria. Study Selection We included published and unpublished observational studies that directly compared the mortality rates of hemodialysis patients in private for-profit and private not-for-profit dialysis centers and provided adjusted mortality rates. We masked the study results prior to determining study eligibility, and teams of 2 reviewers independently evaluated the eligibility of all studies. Eight observational studies that included more than 500000 patient-years of data fulfilled our eligibility criteria. Data Extraction Teams of 2 reviewers independently abstracted data on study characteristics, sampling method, data sources, and factors controlled for in the analyses. Reviewers resolved disagreements by consensus. Data Synthesis The studies reported data from January 1, 1973, through December 31,1997, and included a median of 1342 facilities per study. Six of the 8 studies showed a statistically significant increase in adjusted mortality in for-profit facilities, 1 showed a nonsignificant trend toward increased mortality in for-profit facilities, and 1 showed a nonsignificant trend toward decreased mortality in for-profit facilities. The pooled estimate, using a random-effects model, demonstrated that private for-profit dialysis centers were associated with an increased risk of death (relative risk, 1.08; 95% confidence interval, 1.04-1.13; P<.001). This relative risk suggests that there are annually 2500 (with a plausible range of 1200-4000) excessive premature deaths in US for-profit dialysis centers. Conclusions Hemodialysis care in private not-for-profit centers is associated with a lower risk of mortality compared with care in private for-profit centers.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada; McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; Univ Buffalo, Dept Med, Buffalo, NY USA; Univ Buffalo, Dept Physiol & Biophys, Buffalo, NY USA; Univ Buffalo, Dept Social & Prevent Med, Buffalo, NY USA; Vet Affairs Med Ctr, Buffalo, NY USA; Univ Toronto, Fac Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Canadian Inst Adv Res, Inst Work & Hlth, Toronto, ON, Canada; Canadian Inst Adv Res, Populat Hlth Program, Toronto, ON, Canada; Univ Western Ontario, Div Nephrol, London, ON, Canada	McMaster University; McMaster University; McMaster University; McMaster University; McMaster University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Toronto; University of Toronto; Canadian Institute for Advanced Research (CIFAR); Institute for Work & Health; Canadian Institute for Advanced Research (CIFAR); Western University (University of Western Ontario)	Devereaux, PJ (corresponding author), McMaster Univ, Fac Hlth Sci Clin Epidemiol & Biostat, Room 2C12,1200 Main St, W Hamilton, ON L8N 3Z5, Canada.	philipj@mcmaster.ca	Garg, Amit X/G-3295-2011; Devereaux, PJ/AAY-1757-2021; Bhandari, Mohit/AAQ-1675-2021; Devereaux, PJ/AAF-2862-2019; Lavis, John N/I-7555-2013	Lavis, John N/0000-0001-7917-3657; Schunemann, Holger/0000-0003-3211-8479; Devereaux, PJ/0000-0003-2935-637X				BANDER SJ, 2000, NEPHROL NEWS ISS FEB, P13; Collins AJ, 1998, J AM SOC NEPHROL, V9, P2108; Copas JB, 2001, STAT METHODS MED RES, V10, P251, DOI 10.1191/096228001678227776; DELISSOVOY G, 1994, MED CARE, V32, P130, DOI 10.1097/00005650-199402000-00004; Devereaux PJ, 2002, CAN MED ASSOC J, V166, P1399; Ebben JP, 2000, AM J KIDNEY DIS, V35, P244, DOI 10.1016/S0272-6386(00)70333-7; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; FARLEY DO, 1993, THESIS SANTA MONICA; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Friedman B S, 1990, Adv Health Econ Health Serv Res, V11, P131; Garg PP, 2001, SEMIN DIALYSIS, V14, P153, DOI 10.1046/j.1525-139X.2001.00042.x; Garg PP, 1999, NEW ENGL J MED, V341, P1653, DOI 10.1056/NEJM199911253412205; Hasan MM, 1996, NEW ENGL J MED, V334, P1055, DOI 10.1056/NEJM199604183341610; HELD PJ, 1990, AM J KIDNEY DIS, V15, P441, DOI 10.1016/S0272-6386(12)70362-1; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HELD PJ, 1994, AM J KIDNEY DIS, V23, P692, DOI 10.1016/S0272-6386(12)70280-9; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; Hirth RA, 2000, INQUIRY-J HEALTH CAR, V37, P282; Irvin RA, 2000, ASAIO J, V46, P775, DOI 10.1097/00002480-200011000-00023; IRVIN RA, 1988, QUALITY CARE ASYMMET, P55; McClellan WM, 1998, J AM SOC NEPHROL, V9, P1940; MCCULLOUGH KP, 2001, ASAIO J, V47, P158; Meyer KB, 2002, AM J MED, V112, P232, DOI 10.1016/S0002-9343(01)01100-7; Nissenson AR, 2000, NEW ENGL J MED, V342, P1054; Nudelman PM, 1996, NEW ENGL J MED, V334, P1057, DOI 10.1056/NEJM199604183341611; OXMAN A, 2002, USERS GUIDES MED LIT, P155; PLOUGH AL, 1984, NEW ENGL J MED, V310, P1432, DOI 10.1056/NEJM198405313102205; Port FK, 2000, NEW ENGL J MED, V342, P1053; Port FK, 2001, AM J KIDNEY DIS, V37, P276, DOI 10.1053/ajkd.2001.21290; RELMAN AS, 1980, NEW ENGL J MED, V303, P996, DOI 10.1056/NEJM198010233031708; SCHLESINGER M, 1989, MED CARE, V27, P244, DOI 10.1097/00005650-198903000-00003; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; *US REN DATA SYST, 2001, USRDS 2001 ANN DAT R; US Renal Data System, 1997, USRDS 1997 ANN DAT R; US Renal Data System, 1999, USRDS 1999 ANN DAT R; US Renal Data System, 1996, USRDS 1996 ANN DAT R; Woolhandler S, 1999, NEW ENGL J MED, V341, P444, DOI 10.1056/NEJM199908053410611; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	39	135	139	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2002	288	19					2449	2457		10.1001/jama.288.19.2449	http://dx.doi.org/10.1001/jama.288.19.2449			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FB	12435258				2022-12-28	WOS:000179292300028
J	Mabuchi, H; Doherty, AC				Mabuchi, H; Doherty, AC			Cavity quantum electrodynamics: Coherence in context	SCIENCE			English	Article							PHOTON NUMBER STATES; SINGLE ATOMS; ENTANGLEMENT; BISTABILITY; GENERATION; REDUCTION; DYNAMICS; MOTION; FIELD	Modern cavity quantum electrodynamics (cavity QED) illuminates the most fundamental aspects of coherence and decoherence in quantum mechanics. Experiments on atoms in cavities can be described by elementary models but reveal intriguing subtleties of the interplay of coherent dynamics with external couplings. Recent activity in this area has pioneered powerful new approaches to the study of quantum coherence and has fueled the growth of quantum information science. In years to come, the purview of cavity QED will continue to grow as researchers build on a rich infrastructure to attack some of the most pressing open questions in micro- and mesoscopic physics.	CALTECH, Dept Phys, Pasadena, CA 91125 USA	California Institute of Technology	Mabuchi, H (corresponding author), CALTECH, Dept Phys, Mail Code 12-33, Pasadena, CA 91125 USA.	hmabuchi@caltech.edu	Doherty, Andrew/D-1816-2010	Doherty, Andrew/0000-0002-8069-7754; Mabuchi, Hideo/0000-0002-5156-7678				AN K, 1994, PHYS REV LETT, V73, P3375, DOI 10.1103/PhysRevLett.73.3375; Belavkin VP, 1999, REP MATH PHYS, V43, P405, DOI 10.1016/S0034-4877(00)86386-7; Berman P., 1994, CAVITY QUANTUM ELECT; Bertet P, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.143601; Brattke S, 2001, PHYS REV LETT, V86, P3534, DOI 10.1103/PhysRevLett.86.3534; Brune M, 1996, PHYS REV LETT, V77, P4887, DOI 10.1103/PhysRevLett.77.4887; CARMICHAEL HJ, 1989, PHYS REV A, V39, P1200, DOI 10.1103/PhysRevA.39.1200; CHAPMAN MS, COMMUNICATION; Cirac JI, 1997, PHYS REV LETT, V78, P3221, DOI 10.1103/PhysRevLett.78.3221; Denisov A, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.243601; Doherty AC, 1999, PHYS REV A, V60, P2700, DOI 10.1103/PhysRevA.60.2700; Doherty AC, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.013401; Doherty AC, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.012105; Doherty AC, 1998, PHYS REV A, V57, P4804, DOI 10.1103/PhysRevA.57.4804; Folman R, 2000, PHYS REV LETT, V84, P4749, DOI 10.1103/PhysRevLett.84.4749; Foster GT, 2000, PHYS REV LETT, V85, P3149, DOI 10.1103/PhysRevLett.85.3149; Greiner C, 2000, PHYS REV LETT, V85, P3793, DOI 10.1103/PhysRevLett.85.3793; Guthohrlein GR, 2001, NATURE, V414, P49, DOI 10.1038/35102129; Hagley E, 1997, PHYS REV LETT, V79, P1, DOI 10.1103/PhysRevLett.79.1; Hennrich M, 2000, PHYS REV LETT, V85, P4872, DOI 10.1103/PhysRevLett.85.4872; HINDS EA, 1990, ADV ATOM MOL OPT PHY, V28, P237, DOI 10.1016/S1049-250X(08)60201-3; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; Hood CJ, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.033804; Kimble HJ, 1998, PHYS SCRIPTA, VT76, P127, DOI 10.1238/Physica.Topical.076a00127; KIMBLE HJ, IN PRESS REV MOD PHY; Kiraz A, 2001, APPL PHYS LETT, V78, P3932, DOI 10.1063/1.1379987; Kuhn A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067901; Kuhr S, 2001, SCIENCE, V293, P278, DOI 10.1126/science.1062725; LUGIATO LA, 1984, PROG OPTICS, V21, P69, DOI 10.1016/S0079-6638(08)70122-7; Mabuchi H, 1999, APPL PHYS B-LASERS O, V68, P1095, DOI 10.1007/s003400050751; Mabuchi H, 1999, PHYS REV LETT, V82, P1798, DOI 10.1103/PhysRevLett.82.1798; Mabuchi H, 1996, OPT LETT, V21, P1393, DOI 10.1364/OL.21.001393; Maitre X, 1997, PHYS REV LETT, V79, P769, DOI 10.1103/PhysRevLett.79.769; Mundt AB, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.103001; Nogues G, 1999, NATURE, V400, P239, DOI 10.1038/22275; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; PARKINS AS, 1995, PHYS REV A, V51, P1578, DOI 10.1103/PhysRevA.51.1578; Parkins AS, 1999, J OPT B-QUANTUM S O, V1, P496, DOI 10.1088/1464-4266/1/4/323; Pinkse PWH, 2000, NATURE, V404, P365, DOI 10.1038/35006006; QUADT R, 1995, PHYS REV LETT, V74, P351, DOI 10.1103/PhysRevLett.74.351; Raimond JM, 2001, REV MOD PHYS, V73, P565, DOI 10.1103/RevModPhys.73.565; Rauschenbeutel A, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.050301; Rauschenbeutel A, 2000, SCIENCE, V288, P2024, DOI 10.1126/science.288.5473.2024; Rauschenbeutel A, 1999, PHYS REV LETT, V83, P5166, DOI 10.1103/PhysRevLett.83.5166; REMPE G, 1995, APPL PHYS B-LASERS O, V60, P233, DOI 10.1007/BF01135867; Schlosser N, 2001, NATURE, V411, P1024, DOI 10.1038/35082512; Smith WP, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.133601; Thomsen LK, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.061801; Treussart F, 1998, EUR PHYS J D, V1, P235, DOI 10.1007/s100530050087; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; TURCHETTE QA, 1995, APPL PHYS B-LASERS O, V60, pS1; Varcoe BTH, 2000, NATURE, V403, P743, DOI 10.1038/35001526; Vernooy DW, 1998, PHYS REV A, V57, pR2293, DOI 10.1103/PhysRevA.57.R2293; Vuckovic J, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.016608; Walther H, 2002, ADV CHEM PHYS, V122, P167; Weidinger M, 1999, PHYS REV LETT, V82, P3795, DOI 10.1103/PhysRevLett.82.3795; WISEMAN HM, 1993, PHYS REV A, V47, P642, DOI 10.1103/PhysRevA.47.642; Ye J, 1999, PHYS REV LETT, V83, P4987, DOI 10.1103/PhysRevLett.83.4987	59	523	531	1	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1372	1377		10.1126/science.1078446	http://dx.doi.org/10.1126/science.1078446			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434052				2022-12-28	WOS:000179223100040
J	Yang, MY; Bowmaker, M; Reyes, A; Vergani, L; Angeli, P; Gringeri, E; Jacobs, HT; Holt, IJ				Yang, MY; Bowmaker, M; Reyes, A; Vergani, L; Angeli, P; Gringeri, E; Jacobs, HT; Holt, IJ			Biased incorporation of ribonucleotides on the mitochondrial L-strand accounts for apparent strand-asymmetric DNA replication	CELL			English	Article							SEQUENCE; ORGANIZATION; INITIATION; GENOME	Recently, we presented evidence for conventional, strand-coupled replication of mammalian mitochondrial DNA (Holt et al., 2000). Partially single-stranded replication intermediates detected in the same DNA preparations were assumed to derive from the previously described, strand-asymmetric mode of mitochondrial DNA replication. Here, we show that bona fide replication intermediates from highly purified mitochondria are essentially duplex throughout their length, but contain widespread regions of RNA:DNA hybrid, as a result of the incorporation of ribonucleotides on the light strand which are subsequently converted to DNA. Ribonucleotide-rich regions can be degraded to generate partially single-stranded molecules by RNase H treatment in vitro or during DNA extraction from crude mitochondria. Mammalian mitochondrial DNA replication thus proceeds mainly, or exclusively, by a strand-coupled mechanism.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Padua, Dept Neurol Sci & Psychiat, I-35128 Padua, Italy; Univ Padua, Dept Clin & Expt Med, I-35128 Padua, Italy; Univ Padua, Dept Surg & Gastroenterol Sci, I-35128 Padua, Italy; Univ Tampere, Tampere Univ Hosp, FIN-33014 Tampere, Finland; Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Padua; University of Padua; University of Padua; Tampere University; Tampere University Hospital; Tampere University; University of Glasgow	Holt, IJ (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Jacobs, Howard T/G-2434-2011; GRINGERI, ENRICO/AAB-9315-2019; Yang, Mingyao/AAX-9927-2020; Angeli, Paolo/A-9759-2015; Gringeri, Enrico/K-4199-2018	GRINGERI, ENRICO/0000-0002-3459-7306; Yang, Mingyao/0000-0001-6508-2738; holt, ian/0000-0001-5468-0193; Jacobs, Howard/0000-0003-1895-6003	MRC [MC_U105663140] Funding Source: UKRI; Medical Research Council [MC_U105663140] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BLAIR DG, 1972, P NATL ACAD SCI USA, V69, P2518, DOI 10.1073/pnas.69.9.2518; BOGENHAGEN D, 1977, CELL, V12, P471; BRENNICKE A, 1981, PLASMID, V6, P332; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; DEFRANCESCO L, 1981, NUCLEIC ACIDS RES, V9, P6017, DOI 10.1093/nar/9.22.6017; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GILLUM AM, 1978, P NATL ACAD SCI USA, V75, P735; GROSSMAN LI, 1973, P NATL ACAD SCI USA, V70, P3339, DOI 10.1073/pnas.70.12.3339; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; INSELBURG J, 1974, P NATL ACAD SCI USA, V71, P2256, DOI 10.1073/pnas.71.6.2256; Kornberg A., 1992, DNA REPLICATION; LOCKSHON D, 1995, CELL, V81, P947, DOI 10.1016/0092-8674(95)90014-4; Sambrook J., 2002, MOL CLONING LAB MANU; SPADARI S, 1974, J BIOL CHEM, V249, P5809; ten Asbroek ALMA, 2002, EUR J BIOCHEM, V269, P583, DOI 10.1046/j.0014-2956.2001.02686.x	19	203	209	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 15	2002	111	4					495	505		10.1016/S0092-8674(02)01075-9	http://dx.doi.org/10.1016/S0092-8674(02)01075-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437923	Bronze			2022-12-28	WOS:000179346900003
J	Murphy, C; Schubert, CR; Cruickshanks, KJ; Klein, BEK; Klein, R; Nondahl, DM				Murphy, C; Schubert, CR; Cruickshanks, KJ; Klein, BEK; Klein, R; Nondahl, DM			Prevalence of olfactory impairment in older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EVENT-RELATED POTENTIALS; CHEMOSENSORY PERCEPTION; SMELL IDENTIFICATION; MITRAL CELLS; BEAVER-DAM; TASTE; AGE; DISEASE; BULB; DYSFUNCTION	Context Older adults represent the fastest-growing segment of the US population, and prevalences of vision and hearing impairment have been extensively evaluated. However, despite the importance of sense of smell for nutrition and safety, the prevalence of olfactory impairment in older US adults has not been studied. Objective To determine the prevalence of olfactory impairment in older adults. Design, Setting, and Participants A total of 2491 Beaver Dam, Wis, residents aged 53 to 97 years participating in the 5-year follow-up examination (1998-2000) for the Epidemiology of Hearing Loss Study, a population-based, cross-sectional study. Main Outcome Measures Olfactory impairment, assessed by the San Diego Odor Identification Test and self-report.. Results The mean (SD) prevalence of impaired olfaction was 24.5% (1.7%). The prevalence increased with age; 62.5% (95% confidence interval [CI], 57.4%-67.7%) of 80- to 97-year-olds had olfactory impairment. Olfactory impairment was more prevalent among men (adjusted prevalence ratio, 1.92; 95% CI, 1.65-2.19). Current smoking, stroke, epilepsy, and nasal congestion or upper respiratory tract infection were also associated with increased prevalence of olfactory impairment. Self-reported olfactory impairment was low (9.5%) and this measure became less accurate with age. In the oldest group, aged 80 to 97 years, sensitivity of self-report was 12% for women and 18% for men. Conclusions This study demonstrates that prevalence of olfactory impairment among older adults is high and increases with age. Self-report significantly underestimated prevalence rates obtained by olfaction testing. Physicians and caregivers should be particularly alert to the potential for olfactory impairment in the elderly population.	San Diego State Univ, Sch Med, Joint Doctoral Program, San Diego, CA 92120 USA; Univ Calif San Diego, Sch Med, San Diego, CA USA; Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA; Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA	California State University System; San Diego State University; University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Murphy, C (corresponding author), San Diego State Univ, Sch Med, Joint Doctoral Program, 6363 Alvarado Ct,Suite 101, San Diego, CA 92120 USA.	cmurphy@sciences.sdsu.edu		Klein, Ronald/0000-0002-4428-6237	NEI NIH HHS [EY06594] Funding Source: Medline; NIA NIH HHS [AG04085, R01 AG004085, AG11099] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011099, R01AG004085, R37AG004085, R37AG011099] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BHATNAGAR KP, 1987, ANAT REC, V218, P73, DOI 10.1002/ar.1092180112; CAIN WS, 1988, LARYNGOSCOPE, V98, P83; CHALKE HD, 1957, BRIT MED J, V2, P915, DOI 10.1136/bmj.2.5050.915; DAVIDSON TM, 1995, POSTGRAD MED, V98, P107, DOI 10.1080/00325481.1995.11946020; DAVIDSON TM, 1987, WESTERN J MED, V146, P434; DAVIES L, 1992, NESTLE NUTR WORKS SE, V29, P203; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; DOTY RL, 1984, SCIENCE, V226, P1441, DOI 10.1126/science.6505700; Doty RL., 1991, SMELL TASTE HLTH DIS, P449; Drewnowski A, 2001, J GERONTOL A-BIOL, V56, P89, DOI 10.1093/gerona/56.suppl_2.89; EKMAN G, 1967, SCAND J PSYCHOL, V8, P177, DOI 10.1111/j.1467-9450.1967.tb01392.x; ESKENAZI B, 1986, NEUROPSYCHOLOGIA, V24, P553, DOI 10.1016/0028-3932(86)90099-0; FELDMAN JI, 1986, AM J OTOLARYNG, V7, P431, DOI 10.1016/S0196-0709(86)80019-9; HALL JR, 1997, PATTERNS FIRE CASUAL, V2, P14; Hoffman HJ, 1998, ANN NY ACAD SCI, V855, P716, DOI 10.1111/j.1749-6632.1998.tb10650.x; Jernigan TL, 2001, NEUROBIOL AGING, V22, P581, DOI 10.1016/S0197-4580(01)00217-2; Jones N, 1998, J LARYNGOL OTOL, V112, P11, DOI 10.1017/S0022215100139829; KENDALL M, 1979, ADV THEORY STAT, V2, P580; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310; Kunihara KSN, 1994, OLFACTION TASTE, P609; MANTEL N, 1959, J NATL CANCER I, V22, P719; Meisami E, 1998, ANN NY ACAD SCI, V855, P708, DOI 10.1111/j.1749-6632.1998.tb10649.x; Morgan CD, 1997, EVOKED POTENTIAL, V104, P351, DOI 10.1016/S0168-5597(97)00020-8; MORGAN CD, 1995, J CLIN EXP NEUROPSYC, V17, P793, DOI 10.1080/01688639508405168; MURPHY C, 1993, CRIT REV FOOD SCI, V33, P3, DOI 10.1080/10408399309527607; Murphy C, 2000, INT J PSYCHOPHYSIOL, V36, P133, DOI 10.1016/S0167-8760(99)00107-5; MURPHY C, 1992, NESTLE NUTR WORKS SE, V29, P79; MURPHY C, 1989, ANN NY ACAD SCI, V561, P251; MURPHY C, 1994, CHEM SENSES, V19, P47, DOI 10.1093/chemse/19.1.47; MURPHY C, 2002, HDB OLFACTION GUSTAT, P461; NAKASHIMA T, 1984, ARCH OTOLARYNGOL, V110, P641; NAKASHIMA T, 1985, LARYNGOSCOPE, V95, P391; *NIH, NIH PUBL; NORDIN S, 1995, J GERONTOL B-PSYCHOL, V50, pP187, DOI 10.1093/geronb/50B.4.P187; SAS Institute Inc, 1999, SAS STAT US GUID VER; Schiffman S., 1991, SMELL TASTE HLTH DIS, P845; SCHIFFMAN SS, 1993, CRIT REV FOOD SCI, V33, P17, DOI 10.1080/10408399309527608; Schiffman SS, 1999, PHYSIOL BEHAV, V66, P183, DOI 10.1016/S0031-9384(98)00263-7; Schiffman SS, 1999, NUTRITION, V15, P767, DOI 10.1016/S0899-9007(99)00152-5; SCHIFFMAN SS, 1993, PHYSIOL BEHAV, V53, P395, DOI 10.1016/0031-9384(93)90224-4; Schiffman SS, 1997, JAMA-J AM MED ASSOC, V278, P1357, DOI 10.1001/jama.278.16.1357; SCHIFFMAN SS, 1983, NEW ENGL J MED, V308, P1275; SCHIFFMAN SS, 1983, NEW ENGL J MED, V308, P1337; SCHIFFMAN SS, 1986, CLIN MEASUREMENT TAS, P326; Schiffman SS., 1992, SCIENCE OLFACTION, P500, DOI 10.1007/978-1-4612-2836-3_18; Settle R., 1991, SMELL TASTE HLTH DIS, P829; SHIP JA, 1993, J GERONTOL, V48, pM26, DOI 10.1093/geronj/48.1.M26; Ship JA, 1996, J GERONTOL A-BIOL, V51, pM86, DOI 10.1093/gerona/51A.2.M86; Smith CG, 1941, ARCHIV OTOLARYNGOL, V34, P533; Stevens MH, 2001, LARYNGOSCOPE, V111, P200, DOI 10.1097/00005537-200102000-00002; *US BUR CENS, CENS 2000 SUMM FIL 1; VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625; VELLAS B, 1992, NESTLE NUTR WORKS SE, V29, P75; Wakimoto P, 2001, J GERONTOL A-BIOL, V56, P65, DOI 10.1093/gerona/56.suppl_2.65; WYSOCKI CJ, 1989, ANN NY ACAD SCI, V561, P12, DOI 10.1111/j.1749-6632.1989.tb20966.x; Yousem DM, 1999, AM J NEURORADIOL, V20, P600; Zervakis J, 2000, PHYSIOL BEHAV, V68, P405, DOI 10.1016/S0031-9384(99)00208-5; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; [No title captured]	59	702	723	3	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2307	2312		10.1001/jama.288.18.2307	http://dx.doi.org/10.1001/jama.288.18.2307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425708	Bronze			2022-12-28	WOS:000179186400030
J	Cosgaya, JM; Chan, JR; Shooter, EM				Cosgaya, JM; Chan, JR; Shooter, EM			The neurotrophin receptor p75(NTR) as a positive modulator of myelination	SCIENCE			English	Article							NERVE GROWTH-FACTOR; SCIATIC-NERVE; MESSENGER-RNA; SCHWANN-CELLS; PERIPHERAL-NERVE; SYSTEM; NGF; EXPRESSION; ROLES	Schwann cells in developing and regenerating peripheral nerves express elevated levels of the neurotrophin receptor p75(NTR). Neurotrophins are key mediators of peripheral nervous system myelination. Our results show that myelin formation is inhibited in the absence of functional p75(NTR) and enhanced by blocking TrkC activity. Moreover, the enhancement of myelin formation by endogenous brain-derived neurotrophic factor is mediated by the p75(NTR) receptor, whereas TrkC receptors are responsible for neurotrophin-3 inhibition. Thus p75(NTR) and TrkC receptors have opposite effects on myelination.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Shooter, EM (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, 299 Campus Dr,Fairchild Bldg, Stanford, CA 94305 USA.	eshooter@cmgm.stanford.edu	Cosgaya, Jose M/B-4936-2008	Cosgaya, Jose Miguel/0000-0002-6005-2916	NINDS NIH HHS [NS04270] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chan JR, 2001, P NATL ACAD SCI USA, V98, P14661, DOI 10.1073/pnas.251543398; FUNAKOSHI H, 1993, J CELL BIOL, V123, P455, DOI 10.1083/jcb.123.2.455; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Meier C, 1999, J NEUROSCI, V19, P3847; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Parmantier E, 1999, NEURON, V23, P713, DOI 10.1016/S0896-6273(01)80030-1; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; SEBERT ME, 1993, J NEUROSCI RES, V36, P357, DOI 10.1002/jnr.490360402; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; Stevens B, 2000, SCIENCE, V287, P2267, DOI 10.1126/science.287.5461.2267; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Yang B, 2002, NAT NEUROSCI, V5, P539, DOI 10.1038/nn853; Zanazzi G, 2001, J CELL BIOL, V152, P1289, DOI 10.1083/jcb.152.6.1289	21	261	283	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	2002	298	5596					1245	1248		10.1126/science.1076595	http://dx.doi.org/10.1126/science.1076595			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424382				2022-12-28	WOS:000179080400054
J	Schiermeier, Q				Schiermeier, Q			Maths adds up for Berlin centre	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					348	348		10.1038/420348b	http://dx.doi.org/10.1038/420348b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459745	Bronze			2022-12-28	WOS:000179494700005
J	Patton, GC; Coffey, C; Carlin, JB; Degenhardt, L; Lynskey, M; Hall, W				Patton, GC; Coffey, C; Carlin, JB; Degenhardt, L; Lynskey, M; Hall, W			Cannabis use and mental health in young people: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DRUG-USE; COMMUNITY; ABUSE	Objective To determine whether cannabis use in adolescence predisposes to higher rates of depression and anxiety in young adulthood. Design Seven wave cohort study over six years. Setting 44 schools in the Australian state of Victoria. Participants A statewide secondary school sample of 1601 students aged 14-15 followed for seven years. Main outcome measure Interview measure of depression and anxiety (revised clinical interview schedule) at wave 7. Results Some 60% of participants had used cannabis by the age of 20; 7% were daily users at that point. Daily use in young women was associated with an over fivefold increase in the odds of reporting a state of depression and anxiety after adjustment for intercurrent use of other substances (odds ratio 5.6, 95% confidence interval 2.6 to 12). Weekly or more frequent cannabis use in teenagers predicted an approximately twofold increase in risk for later depression and anxiety (1.9, 1.1 to 3.3) after adjustment for potential baseline confounders. In contrast, depression and anxiety in teenagers predicted neither later weekly nor daily cannabis use. Conclusions Frequent cannabis use in teenage girls predicts later depression and anxiety, with daily users carrying the highest risk. Given recent increasing levels of cannabis use, measures to reduce frequent and heavy recreational use seem warranted.	Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Parkville, Vic 3052, Australia; Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Parkville, Vic, Australia; Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Univ Queensland, Inst Mol Biosci, Off Publ Policy & Eth, Brisbane, Qld 4072, Australia	Murdoch Children's Research Institute; Murdoch Children's Research Institute; University of New South Wales Sydney; Washington University (WUSTL); University of Queensland	Patton, GC (corresponding author), Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Parkville, Vic 3052, Australia.	gpatton@cryptic.rch.unimelb.edu.au	Degenhardt, Louisa J/D-4515-2012; Ribeiro, Ana Cristina/HHN-7466-2022; Carlin, John/AAG-4332-2020; Hall, Wayne D/A-3283-2008; Lynskey, michael T/B-9179-2016; Lynskey, Michael T/A-3181-2008; Carlin, John B/B-3492-2012; Patton, George C/B-5246-2013	Degenhardt, Louisa J/0000-0002-8513-2218; Ribeiro, Ana Cristina/0000-0002-0493-8376; Carlin, John/0000-0002-2694-9463; Hall, Wayne D/0000-0003-1984-0096; Carlin, John B/0000-0002-2694-9463; Patton, George C/0000-0001-5039-8326				Ameri A, 1999, PROG NEUROBIOL, V58, P315, DOI 10.1016/S0301-0082(98)00087-2; Bebbington PE, 1998, PSYCHOL MED, V28, P9, DOI 10.1017/S0033291797006077; Bovasso GB, 2001, AM J PSYCHIAT, V158, P2033, DOI 10.1176/appi.ajp.158.12.2033; Degenhardt L, 2001, ADDICTION, V96, P1603, DOI 10.1046/j.1360-0443.2001.961116037.x; Fergusson DM, 1997, ADDICTION, V92, P279; Green BE, 2000, J HEALTH SOC BEHAV, V41, P40, DOI 10.2307/2676359; Hall W, 1998, DRUG ALCOHOL REV, V17, P433, DOI 10.1080/09595239800187271; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; Lewis G., 1992, MANUAL CIS R; LINSZEN DH, 1994, ARCH GEN PSYCHIAT, V51, P273; McGee R, 2000, ADDICTION, V95, P491, DOI 10.1046/j.1360-0443.2000.9544912.x; MOFFITT TE, 1988, AUST NZ J CRIMINOL, V21, P227, DOI 10.1177/000486588802100405; PAPERNY DM, 1990, J PEDIATR-US, V116, P456, DOI 10.1016/S0022-3476(05)82844-6; PATON S, 1977, J GENET PSYCHOL, V131, P267, DOI 10.1080/00221325.1977.10533299; RAMSAY M, 1977, DRUG USED DECLARED 1; Reilly D, 1998, ADDICTION, V93, P837, DOI 10.1046/j.1360-0443.1998.9368375.x; Rey JM, 2002, BRIT J PSYCHIAT, V180, P216, DOI 10.1192/bjp.180.3.216; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; Schafer JL, 2002, J COMPUT GRAPH STAT, V11, P437, DOI 10.1198/106186002760180608; Smart RG, 2000, ADDICT BEHAV, V25, P455, DOI 10.1016/S0306-4603(99)00013-1; Strang J, 2000, BMJ-BRIT MED J, V320, P108, DOI 10.1136/bmj.320.7227.108; Thomas H, 1996, DRUG ALCOHOL DEPEN, V42, P201, DOI 10.1016/S0376-8716(96)01277-X; Troisi A, 1998, ADDICTION, V93, P487, DOI 10.1046/j.1360-0443.1998.9344874.x	23	598	616	3	104	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	2002	325	7374					1195	1198		10.1136/bmj.325.7374.1195	http://dx.doi.org/10.1136/bmj.325.7374.1195			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	619YU	12446533	Green Published, Bronze			2022-12-28	WOS:000179506200016
J	Ayanian, JZ; Landrum, MB; Guadagnoli, E; Gaccione, P				Ayanian, JZ; Landrum, MB; Guadagnoli, E; Gaccione, P			Specialty of ambulatory care physicians and mortality among elderly patients after myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; RIGHT HEART CATHETERIZATION; MEDICARE PATIENTS; PROPENSITY SCORE; CARDIOLOGISTS; GENERALIST; QUALITY; OUTCOMES; ASSOCIATION; MANAGEMENT	Background: The outcome after myocardial infarction may be influenced by the type of physician providing ambulatory care. Methods: We studied 35,520 patients 65 years of age or older who were hospitalized for myocardial infarction in seven states during 1994 and 1995 and who survived for at least three months after discharge. From Medicare claims, we identified ambulatory visits to cardiologists, internists, and family practitioners. Using propensity scores to adjust for demographic, clinical, and hospital characteristics, we analyzed treatment and mortality at two years among patients matched according to their estimated propensity to receive care from a cardiologist within three months after discharge. Results: As compared with patients who saw only an internist or a family practitioner in the three months after discharge, patients who saw a cardiologist were younger, were more likely to be white, were more likely to be male, had fewer coexisting conditions, and were more likely to have undergone invasive cardiac procedures while hospitalized (P<0.01 for all comparisons). Patients who saw a cardiologist were more likely to undergo cardiac procedures and rehabilitation after discharge. Patients who saw a cardiologist had a lower two-year mortality rate than matched patients who saw only an internist or a family practitioner (14.6 percent vs. 18.3 percent, P<0.001). Patients who saw both a cardiologist and an internist or a family practitioner had a lower mortality rate than matched patients who saw only a cardiologist (11.1 percent vs. 12.1 percent, P=0.02). Conclusions: Ambulatory visits to cardiologists were associated with greater use of cardiac procedures and decreased mortality after myocardial infarction. Concurrent care by an internist or a family practitioner was associated with a further reduction in mortality.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.				AHRQ HHS [R01 HS09718, R01 HS08071] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009718, R01HS008071] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM MED ASS, 1997, PHYS CURR PROC TERM; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; Ayanian JZ, 2000, AM J MED, V108, P259, DOI 10.1016/S0002-9343(99)00455-6; Ayanian JZ, 2002, ARCH INTERN MED, V162, P1013, DOI 10.1001/archinte.162.9.1013; Baldwin LM, 2002, MED CARE, V40, P82; Casale PN, 1998, J AM COLL CARDIOL, V32, P885, DOI 10.1016/S0735-1097(98)00325-8; Chen J, 2000, AM J MED, V108, P460, DOI 10.1016/S0002-9343(00)00331-4; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Donohoe MT, 1998, ARCH INTERN MED, V158, P1596, DOI 10.1001/archinte.158.15.1596; Frances CD, 1999, ARCH INTERN MED, V159, P1429, DOI 10.1001/archinte.159.13.1429; Frances CD, 2000, HEALTH SERV RES, V35, P1093; Go AS, 2000, AM J MED, V108, P216, DOI 10.1016/S0002-9343(99)00430-1; Hardarson T, 2001, J INTERN MED, V249, P495, DOI 10.1046/j.1365-2796.2001.00834.x; Harrold LR, 1999, J GEN INTERN MED, V14, P499, DOI 10.1046/j.1525-1497.1999.08168.x; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; LANDRUM MB, 2001, HLTH SERV OUTCOMES R, V2, P221, DOI DOI 10.1023/A:1020367111374; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; Majumdar SR, 2001, J GEN INTERN MED, V16, P351, DOI 10.1046/j.1525-1497.2001.016006351.x; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Nash IS, 1999, AM J CARDIOL, V83, P650, DOI 10.1016/S0002-9149(98)00961-8; Nash IS, 1997, J AM COLL CARDIOL, V29, P475, DOI 10.1016/S0735-1097(96)00528-1; O'Connor GT, 1999, JAMA-J AM MED ASSOC, V281, P627, DOI 10.1001/jama.281.7.627; Petersen LA, 2000, NEW ENGL J MED, V343, P1934, DOI 10.1056/NEJM200012283432606; Polanczyk CA, 2001, JAMA-J AM MED ASSOC, V286, P309, DOI 10.1001/jama.286.3.309; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Seddon ME, 2001, AM J MED, V111, P24, DOI 10.1016/S0002-9343(01)00741-0; Sundararajan V, 2002, ANN INTERN MED, V136, P349, DOI 10.7326/0003-4819-136-5-200203050-00007; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Willison DJ, 1998, ARCH INTERN MED, V158, P1778, DOI 10.1001/archinte.158.16.1778	34	163	164	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1678	1686		10.1056/NEJMsa020080	http://dx.doi.org/10.1056/NEJMsa020080			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444183	Bronze			2022-12-28	WOS:000179339900007
J	Eckardt, LH; Naumann, K; Pankau, WM; Rein, M; Schweitzer, M; Windhab, N; von Kiedrowski, G				Eckardt, LH; Naumann, K; Pankau, WM; Rein, M; Schweitzer, M; Windhab, N; von Kiedrowski, G			DNA nanotechnology: Chemical copying of connectivity	NATURE			English	Editorial Material							LIGATION		Ruhr Univ Bochum, Lehrstuhl Bioorgan Chem, D-44780 Bochum, Germany	Ruhr University Bochum	Eckardt, LH (corresponding author), Ruhr Univ Bochum, Lehrstuhl Bioorgan Chem, D-44780 Bochum, Germany.	kiedro@ernie.orch.ruhr-uni-bochum.de		Naumann, Kai/0000-0003-2151-1048				CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; Cochran JR, 2000, CHEM BIOL, V7, P683, DOI 10.1016/S1074-5521(00)00019-3; Dawson PE, 1997, J AM CHEM SOC, V119, P4325, DOI 10.1021/ja962656r; DORENBECK A, IN PRESS ANGEW CHEM; Li ZY, 2002, J AM CHEM SOC, V124, P746, DOI 10.1021/ja017319j; Luther A, 1998, NATURE, V396, P245, DOI 10.1038/24343; Raddatz S, 2002, NUCLEIC ACIDS RES, V30, P4793, DOI 10.1093/nar/gkf594; Scheffler M, 1999, ANGEW CHEM INT EDIT, V38, P3312; Stetsenko DA, 2000, J ORG CHEM, V65, P4900, DOI 10.1021/jo000214z; van Aalten DMF, 1999, P NATL ACAD SCI USA, V96, P11809, DOI 10.1073/pnas.96.21.11809	10	132	136	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	2002	420	6913					286	286		10.1038/420286a	http://dx.doi.org/10.1038/420286a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447432	Bronze			2022-12-28	WOS:000179340400033
J	Yamamoto, M; Sato, S; Hemmi, H; Sanjo, H; Uematsu, S; Kaisho, T; Hoshino, K; Takeuchi, O; Kobayashi, M; Fujita, T; Takeda, K; Akira, S				Yamamoto, M; Sato, S; Hemmi, H; Sanjo, H; Uematsu, S; Kaisho, T; Hoshino, K; Takeuchi, O; Kobayashi, M; Fujita, T; Takeda, K; Akira, S			Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4	NATURE			English	Article							DOUBLE-STRANDED-RNA; NF-KAPPA-B; SIGNALING PATHWAY; TOLL; RECOGNITION; ENDOTOXIN; CELLS	Signal transduction through Toll-like receptors ( TLRs) originates from their intracellular Toll/interleukin-1 receptor (TIR) domain, which binds to MyD88, a common adaptor protein containing a TIR domain(1-4). Although cytokine production is completely abolished in MyD88-deficient mice, some responses to lipopolysaccharide (LPS), including the induction of interferon-inducible genes and the maturation of dendritic cells, are still observed(5-7). Another adaptor, TIRAP ( also known as Mal), has been cloned as a molecule that specifically associates with TLR4 and thus may be responsible for the MyD88-independent response(8,9). Here we report that LPS-induced splenocyte proliferation and cytokine production are abolished in mice lacking TIRAP. As in MyD88-deficient mice, LPS activation of the nuclear factor NF-kappaB and mitogen-activated protein kinases is induced with delayed kinetics in TIRAP-deficient mice(5). Expression of interferon-inducible genes and the maturation of dendritic cells is observed in these mice; they also show defective response to TLR2 ligands, but not to stimuli that activate TLR3, TLR7 or TLR9. In contrast to previous suggestions, our results show that TIRAP is not specific to TLR4 signalling and does not participate in the MyD88-independent pathway. Instead, TIRAP has a crucial role in the MyD88-dependent signalling pathway shared by TLR2 and TLR4.	Osaka Univ, Res Inst Microbial Dis, Dept Host Def, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Suita, Osaka 5650871, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Kanagawa 2300045, Japan; Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan	Osaka University; Japan Science & Technology Agency (JST); RIKEN; Tokyo Metropolitan Institute of Medical Science	Akira, S (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Host Def, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Hoshino, Katsuaki/AAE-2830-2022; Akira, Shizuo/C-3134-2009; Takeuchi, Osamu/D-6007-2011; Kaisho, Tsuneyasu/B-4130-2012; Takeuchi, Osamu/AAG-9359-2019; Takeda, Kiyoshi/C-9331-2009; Hoshino, Katsuaki/L-9162-2014	Hoshino, Katsuaki/0000-0003-0493-4815; Takeuchi, Osamu/0000-0002-1260-6232; Hoshino, Katsuaki/0000-0003-0493-4815; Sato, Shintaro/0000-0001-5156-3354				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; IMER JL, 2001, TRENDS CELL BIOL, V11, P304; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; O'Neill LAJ, 2002, TRENDS IMMUNOL, V23, P296, DOI 10.1016/S1471-4906(02)02222-6; Sato S, 2002, INT IMMUNOL, V14, P783, DOI 10.1093/intimm/dxf046; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774	19	755	829	2	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					324	329		10.1038/nature01182	http://dx.doi.org/10.1038/nature01182			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447441				2022-12-28	WOS:000179340400044
J	Crowther, C; Henderson-Smart, D				Crowther, C; Henderson-Smart, D			Prenatal phenobarbital before very-preterm birth and neurodevelopmental outcome	LANCET			English	Editorial Material							HEMORRHAGE; NEWBORN; INFANTS		Univ Adelaide, Dept Obstet & Gynaecol, Maternal Perinatal Clin Trials Unit, Adelaide, SA 5001, Australia; Univ Sydney, Neonatal Med Royal Prince Alfred Hosp, NSW Ctr Perinatal Serv Res, Sydney, NSW 2006, Australia	University of Adelaide; University of Sydney	Crowther, C (corresponding author), Univ Adelaide, Dept Obstet & Gynaecol, Maternal Perinatal Clin Trials Unit, Adelaide, SA 5001, Australia.							CROWLEY P, 2002, COCHRANE LIB; Doyle L, 1996, LANCET, V348, P975, DOI 10.1016/S0140-6736(05)64922-7; Early Supported Discharge Trialists, 2002, COCHRANE LIB; GODDARDFINEGOLD J, 1987, PEDIATRICS, V79, P901; Shankaran S, 1997, NEW ENGL J MED, V337, P466, DOI 10.1056/NEJM199708143370705; Shankaran S, 2002, AM J OBSTET GYNECOL, V187, P171, DOI 10.1067/mob.2002.122445; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; WIMBERLEY PD, 1982, ACTA PAEDIATR SCAND, V71, P537, DOI 10.1111/j.1651-2227.1982.tb09471.x; 2002, COCHRANE LIB, V3	9	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1529	1530		10.1016/S0140-6736(02)11578-9	http://dx.doi.org/10.1016/S0140-6736(02)11578-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443587				2022-12-28	WOS:000179292400005
J	Reik, W; Dean, W				Reik, W; Dean, W			Back to the beginning	NATURE			English	Editorial Material									Babraham Inst, Dev Genet Programme, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Reik, W (corresponding author), Babraham Inst, Dev Genet Programme, Cambridge CB2 4AT, England.		Reik, Wolf/I-6794-2012	Dean, Wendy/0000-0001-9441-5044; Reik, Wolf/0000-0003-0216-9881				Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; GURDON JB, 1966, NATURE, V210, P1240, DOI 10.1038/2101240a0; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Solter D, 2000, NAT REV GENET, V1, P199, DOI 10.1038/35042066; Waddington C. H, 1940, ORG AND GENES	5	15	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					127	127		10.1038/420127a	http://dx.doi.org/10.1038/420127a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432368	Bronze			2022-12-28	WOS:000179200900022
J	Dieckgraefe, BK; Korzenik, JR				Dieckgraefe, BK; Korzenik, JR			Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor	LANCET			English	Article								Treatment for Crohn's disease is aimed at immunosuppression. Yet inherited disorders associated with defective innate immunity often lead to development of a Crohn's-like disease. We performed an open-label dose-escalation trial (4-8 mug/kg per day) to investigate the safety and possible benefit of granulocyte-macrophage colony-stimulating factor (GM-CSF) in the treatment of 15 patients with moderate to severe Crohn's disease. No patients had worsening of their disease. Adverse events were negligible and included minor injection site reactions and bone pain. Patients had a significant decrease in mean Crohn's disease activity index (CDAI) score during treatment (p<0.0001). After 8 weeks of treatment, mean CDAI had fallen by 190 points. Overall, 12 patients had a decrease in CDAI of more than 100 points, and eight achieved clinical remission. Retreatment was effective, and treatment was associated with increased quality-of-life measures. GM-CSF may offer an alternative to traditional immunosuppression in treatment of Crohn's disease.	Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol, St Louis, MO 63110 USA	Washington University (WUSTL)	Dieckgraefe, BK (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol, 660 S Euclid Ave,Box 8124, St Louis, MO 63110 USA.				NCRR NIH HHS [M01RR00036] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEST WR, 1976, GASTROENTEROLOGY, V70, P439; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; Korzenik JR, 2000, DIGEST DIS SCI, V45, P1121, DOI 10.1023/A:1005541700805; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114	4	145	152	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1478	1480		10.1016/S0140-6736(02)11437-1	http://dx.doi.org/10.1016/S0140-6736(02)11437-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433518				2022-12-28	WOS:000179186000015
J	Patz, JA; Kovats, RS				Patz, JA; Kovats, RS			Hotspots in climate change and human health	BMJ-BRITISH MEDICAL JOURNAL			English	Review							UNITED-STATES; EL-NINO; LEPTOSPIROSIS; TEMPERATURE; VARIABILITY; WATERBORNE; MORTALITY; EPIDEMIC; DISEASES; IMPACTS		Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of London; London School of Hygiene & Tropical Medicine	Patz, JA (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe, Baltimore, MD 21205 USA.	jpatz@jhsph.edu		Kovats, Sari/0000-0002-4823-8099				Bouma MJ, 1997, TROP MED INT HEALTH, V2, P1122, DOI 10.1046/j.1365-3156.1997.d01-210.x; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P841; Checkley W, 2000, LANCET, V355, P442, DOI 10.1016/S0140-6736(00)82010-3; Cox J, 1999, MAPPING MALARIA RISK; Curriero FC, 2002, AM J EPIDEMIOL, V155, P80, DOI 10.1093/aje/155.1.80; Curriero FC, 2001, AM J PUBLIC HEALTH, V91, P1194, DOI 10.2105/AJPH.91.8.1194; Gubler DJ, 2001, ENVIRON HEALTH PERSP, V109, P223, DOI 10.2307/3435012; Kalkstein LS, 1997, ENVIRON HEALTH PERSP, V105, P84, DOI 10.2307/3433067; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; Kilboume E.M., 1997, PUBLIC HLTH CONSEQUE, P51; Ko AI, 1999, LANCET, V354, P820, DOI 10.1016/S0140-6736(99)80012-9; Koren HS, 1997, ENVIRON HEALTH PERSP, V105, P534, DOI 10.2307/3433583; KOREN HS, 1995, INT ARCH ALLERGY IMM, V107, P236, DOI 10.1159/000236989; KOVATS RS, 2000, CLIMATE VECTORBORNE; MALILAY J, 1997, PUBLIC HLTH CONSEQUE; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; MCMICHAEL A, 2001, CLIMATE CHANGE 2001; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; MYERS N, 1995, ENV EXODUS ENNERGENT; National Research Council, 2001, WEATH CLIM EC INF DI; NICHOLLS R, 1995, CLIMATE CHANGES INT, P92; Patz JA, 1999, CURR OPIN MICROBIOL, V2, P445, DOI 10.1016/S1369-5274(99)80078-2; Patz JA, 2001, HUM ECOL RISK ASSESS, V7, P1317, DOI 10.1080/20018091095023; Patz JA, 2000, ENVIRON HEALTH PERSP, V108, P367, DOI 10.2307/3454357; Patz JA, 2000, ANNU REV PUBL HEALTH, V21, P271, DOI 10.1146/annurev.publhealth.21.1.271; Rose JB, 2001, ENVIRON HEALTH PERSP, V109, P211, DOI 10.2307/3435011; SIDDIQUE AK, 1991, J DIARRHOEAL DIS RES, V9, P310; Task Force on Climate and Health, 1999, EL NIN HLTH; Trevejo RT, 1998, J INFECT DIS, V178, P1457, DOI 10.1086/314424; *UN FOOD AGR ORG, 1999, STAT FOOD INS WORLD; Watson R, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, pIX; Watson RT, 2001, CLIMATE CHANGE 2001: IMPACTS, ADAPTATION, AND VULNERABILITY, pIX; Whitman S, 1997, AM J PUBLIC HEALTH, V87, P1515, DOI 10.2105/AJPH.87.9.1515; Woodward A, 2000, B WORLD HEALTH ORGAN, V78, P1148	34	86	93	0	33	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2002	325	7372					1094	1098		10.1136/bmj.325.7372.1094	http://dx.doi.org/10.1136/bmj.325.7372.1094			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424173	Green Accepted, Green Published			2022-12-28	WOS:000179415700026
J	Spronk, PE; Ince, C; Gardien, MJ; Mathura, KR; Oudemans-van Straaten, HM; Zandstra, DF				Spronk, PE; Ince, C; Gardien, MJ; Mathura, KR; Oudemans-van Straaten, HM; Zandstra, DF			Nitroglycerin in septic shock after intravascular volume resuscitation	LANCET			English	Article							MICROCIRCULATION; SEPSIS	In patients with septic shock, oxygen consumption is increased, but oxygen delivery and extraction is impaired, partly because of microcirculatory shutdown and shunting. Orthogonal polarisation spectral (OPS) imaging allows visualisation of the microcirculation. We used this technique to assess microcirculatory flow in septic-shock patients who had a mean arterial blood pressure of more than 60 mm Hg and central venous pressure greater than 12 mm Hg. The infusion of 0.5 mg of nitroglycerin intravenously then resulted in a marked increase in microvascular flow on OPS imaging. Improved recruitment of the microcirculation could be a new resuscitation endpoint in septic shock.	Onze Lieve Vrouw Hosp, Dept Intens Care Med, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Anesthesiol, NL-1105 AZ Amsterdam, Netherlands	Onze Lieve Vrouwe Gasthuis Hospital; University of Amsterdam; Academic Medical Center Amsterdam	Spronk, PE (corresponding author), Gelre Ziekenhuizen, Dept Intens Care Med, Locatie Lukas,Albert Schweitzerlaan 31, NL-7334 DZ Apeldoorn, Netherlands.							Ince C, 1999, CRIT CARE MED, V27, P1369, DOI 10.1097/00003246-199907000-00031; Lehr HA, 2000, J PATHOL, V190, P373, DOI 10.1002/(SICI)1096-9896(200002)190:3&lt;373::AID-PATH593&gt;3.0.CO;2-3; Mathura KR, 2001, J APPL PHYSIOL, V91, P74, DOI 10.1152/jappl.2001.91.1.74; Mathura KR, 2001, LANCET, V358, P1698, DOI 10.1016/S0140-6736(01)06722-8; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307	5	383	406	1	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1395	1396		10.1016/S0140-6736(02)11393-6	http://dx.doi.org/10.1016/S0140-6736(02)11393-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423989				2022-12-28	WOS:000179081600016
J	Wentworth, P; McDunn, JE; Wentworth, AD; Takeuchi, C; Nieva, J; Jones, T; Bautista, C; Ruedi, JM; Gutierrez, A; Janda, KD; Babior, BM; Eschenmoser, A; Lerner, RA				Wentworth, P; McDunn, JE; Wentworth, AD; Takeuchi, C; Nieva, J; Jones, T; Bautista, C; Ruedi, JM; Gutierrez, A; Janda, KD; Babior, BM; Eschenmoser, A; Lerner, RA			Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation	SCIENCE			English	Article							MOLECULAR-OXYGEN; SINGLET OXYGEN; NEUTROPHILS; INDIGO-5,5'-DISULFONATE; PARTICLES	Recently, we showed that antibodies catalyze the generation of hydrogen peroxide (H2O2) from singlet molecular oxygen (O-1(2)*) and water. Here, we show that this process can lead to efficient killing of bacteria, regardless of the antigen specificity of the antibody. H2O2 production by antibodies alone was found to be not sufficient for bacterial killing. Our studies suggested that the antibody-catalyzed water-oxidation pathway produced an additional molecular species with a chemical signature similar to that of ozone. This species is also generated during the oxidative burst of activated human neutrophils and during inflammation. These observations suggest that alternative pathways may exist for biological killing of bacteria that are mediated by potent oxidants previously unknown to biology.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; ETH Honggerberg, Organ Chem Lab, CH-8093 Zurich, Switzerland	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Swiss Federal Institutes of Technology Domain; ETH Zurich	Wentworth, P (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		McDunn, Jonathan/A-6816-2009	McDunn, Jonathan/0000-0001-8792-828X	NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043858, R29GM043858] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA27489] Funding Source: Medline; NIAID NIH HHS [5T32AI07606] Funding Source: Medline; NIGMS NIH HHS [GM43858] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER EL, 1978, J IMMUNOL METHODS, V22, P263, DOI 10.1016/0022-1759(78)90034-0; BERTHIAUME F, 1994, BIO-TECHNOL, V12, P703, DOI 10.1038/nbt0794-703; Cho HY, 2001, AM J PHYSIOL-LUNG C, V280, pL537, DOI 10.1152/ajplung.2001.280.3.L537; GLAZE WH, 1987, OZONE-SCI ENG, V9, P335; GORMAN AA, 1981, CHEM SOC REV, V10, P205, DOI 10.1039/cs9811000205; Hofman P, 2000, INFECT IMMUN, V68, P449, DOI 10.1128/IAI.68.2.449-455.2000; Joos GF, 2000, ALLERGY, V55, P321, DOI 10.1034/j.1398-9995.2000.00112.x; Klebanoff SJ, 1998, ENCY IMMUNOLOGY, P1713, DOI [10.1006/rwei.1999.0435, DOI 10.1006/RWEI.1999.0435]; Kohl J, 1999, MOL IMMUNOL, V36, P893, DOI 10.1016/S0161-5890(99)00111-X; Kuo CH, 1999, CAN J CHEM ENG, V77, P473, DOI 10.1002/cjce.5450770306; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; SIM RB, 1991, IMMUNOL TODAY, V12, P307, DOI 10.1016/0167-5699(91)90004-D; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; STEINBECK MJ, 1993, J BIOL CHEM, V268, P15649; TAKEUCHI K, 1990, ANAL CHIM ACTA, V230, P183, DOI 10.1016/S0003-2670(00)82779-8; TAKEUCHI K, 1989, ANAL CHEM, V61, P619, DOI 10.1021/ac00181a025; Wentworth AD, 2000, P NATL ACAD SCI USA, V97, P10930, DOI 10.1073/pnas.97.20.10930; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Wentworth P, 2002, SCIENCE, V296, P2247, DOI 10.1126/science.296.5576.2247; WILKINSON F, 1993, J PHYS CHEM REF DATA, V22, P113, DOI 10.1063/1.555934; Xu X, 2002, P NATL ACAD SCI USA, V99, P3376, DOI 10.1073/pnas.052710099	21	283	310	3	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 13	2002	298	5601					2195	2199		10.1126/science.1077642	http://dx.doi.org/10.1126/science.1077642			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	624RA	12434011				2022-12-28	WOS:000179773700049
J	Harris, R; Lohr, KN				Harris, R; Lohr, KN			Screening for prostate cancer: An update of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							QUALITY-OF-LIFE; DIGITAL RECTAL EXAMINATION; LONG-TERM SURVIVAL; ANDROGEN DEPRIVATION THERAPY; BEAM RADIATION-THERAPY; WANING SEXUAL FUNCTION; RADICAL PROSTATECTOMY; SURVEILLANCE SERIES; INTERPRETING TRENDS; ANTIGEN LEVELS	Background: In U.S. men, prostate cancer is the most common noncutaneous cancer and the second leading cause of cancer death. Screening for prostate cancer is controversial. Purpose: To examine for the U.S. Preventive Services Task Force the evidence of benefits and harms of screening and earlier treatment. Data Sources: MEDLINE and the Cochrane Library, experts, and bibliographies of reviews. Study Selection: Researchers developed eight questions representing a logical chain between screening and reduced mortality, along with eligibility criteria for admissible evidence for each question. Admissible evidence was obtained by searching the data sources. Data Extraction: Two reviewers abstracted relevant information using standardized abstraction forms and graded article quality according to Task Force criteria. Data Synthesis: No conclusive direct evidence shows that screening reduces prostate cancer mortality. Some screening tests can detect prostate cancer at an earlier stage than clinical detection. One study provides good evidence that radical prostatectomy reduces disease-specific mortality for men with localized prostate cancer detected clinically. No study has examined the additional benefit of earlier treatment after detection by screening. Men with a life expectancy of fewer than 10 years are unlikely to benefit from screening even under favorable assumptions. Each treatment is associated with several well-documented potential harms. Conclusions: Although potential harms of screening for prostate cancer can be established, the presence or magnitude of potential benefits cannot. Therefore, the net benefit of screening cannot be determined.						Lohr, Kathleen/0000-0002-3825-0713	PHS HHS [290-97-0011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adolfsson J, 1998, EUR UROL, V33, P11, DOI 10.1159/000019528; Albertsen PC, 1998, JAMA-J AM MED ASSOC, V280, P975, DOI 10.1001/jama.280.11.975; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; [Anonymous], 1997, Br J Urol, V79, P235; ARONSON N, 1999, AHCPR PUBLICATION; Babaian RJ, 2000, UROLOGY, V56, P1000, DOI 10.1016/S0090-4295(00)00830-X; Babaian RJ, 2001, J UROLOGY, V165, P757, DOI 10.1016/S0022-5347(05)66519-6; BANGMA CH, 1995, UROLOGY, V46, P779, DOI 10.1016/S0090-4295(99)80343-4; BANGMA CH, 1995, SCAND J CLIN LAB INV, V55, P35, DOI 10.3109/00365519509090562; BARRY MJ, 1995, UROLOGY, V46, P445, DOI 10.1016/S0090-4295(99)80255-6; Bartsch G, 2001, UROLOGY, V58, P417, DOI 10.1016/S0090-4295(01)01264-X; Bartsch Georg, 2000, Journal of Urology, V163, P88; Beard CJ, 1997, J CLIN ONCOL, V15, P223, DOI 10.1200/JCO.1997.15.1.223; Begg CB, 2002, NEW ENGL J MED, V346, P1138, DOI 10.1056/NEJMsa011788; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; Brandeis JM, 2000, J UROLOGY, V163, P851, DOI 10.1016/S0022-5347(05)67818-4; Brawer MK, 1996, EUR UROL, V29, P19; Brawley OW, 1997, CANCER-AM CANCER SOC, V80, P1857, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3; Carter HB, 1997, JAMA-J AM MED ASSOC, V277, P1456, DOI 10.1001/jama.277.18.1456; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; Catalona WJ, 2000, UROLOGY, V56, P255, DOI 10.1016/S0090-4295(00)00637-3; CATALONA WJ, 1994, J UROLOGY, V152, P2037, DOI 10.1016/S0022-5347(17)32300-5; Catalona WJ, 1998, JAMA-J AM MED ASSOC, V279, P1542, DOI 10.1001/jama.279.19.1542; Catalona WJ, 1997, JAMA-J AM MED ASSOC, V277, P1452, DOI 10.1001/jama.277.18.1452; CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; Chen CT, 2001, INT J RADIAT ONCOL, V50, P591, DOI 10.1016/S0360-3016(01)01504-8; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Coley CM, 1997, ANN INTERN MED, V126, P468, DOI 10.7326/0003-4819-126-6-199703150-00010; Collins MM, 1997, JAMA-J AM MED ASSOC, V278, P1516, DOI 10.1001/jama.278.18.1516; Concato J, 1997, J GEN INTERN MED, V12, P607, DOI 10.1046/j.1525-1497.1997.07120.x; Concato J, 2001, J CLIN EPIDEMIOL, V54, P558, DOI 10.1016/S0895-4356(00)00355-3; Corn BW, 1999, UROLOGY, V54, P495, DOI 10.1016/S0090-4295(99)00186-7; Crocetti E, 2001, JNCI-J NATL CANCER I, V93, P876, DOI 10.1093/jnci/93.11.876-a; Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022-5347(05)68000-7; Djavan B, 2000, J UROLOGY, V163, P1144, DOI 10.1016/S0022-5347(05)67711-7; Etzioni R, 1999, J NATL CANCER I, V91, P1033, DOI 10.1093/jnci/91.12.1033; Feuer EJ, 1999, JNCI-J NATL CANCER I, V91, P1025, DOI 10.1093/jnci/91.12.1025; Finne P, 2000, J UROLOGY, V164, P1956, DOI 10.1016/S0022-5347(05)66927-3; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; Fossa SD, 1997, EUR UROL, V31, P3; Fowler FJ, 2002, CANCER-AM CANCER SOC, V95, P287, DOI 10.1002/cncr.10656; Fowler FJ, 1996, J CLIN ONCOL, V14, P2258, DOI 10.1200/JCO.1996.14.8.2258; Fransson P, 1996, CANCER, V78, P1066, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1066::AID-CNCR17>3.0.CO;2-0; Fransson P, 2001, CANCER-AM CANCER SOC, V92, P3111, DOI 10.1002/1097-0142(20011215)92:12<3111::AID-CNCR10160>3.0.CO;2-E; FRIEDMAN GD, 1991, LANCET, V337, P1526, DOI 10.1016/0140-6736(91)93207-P; Fulmer BR, 2001, CANCER-AM CANCER SOC, V91, P2046, DOI 10.1002/1097-0142(20010601)91:11<2046::AID-CNCR1231>3.0.CO;2-W; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Gelblum DY, 1999, INT J RADIAT ONCOL, V45, P59, DOI 10.1016/S0360-3016(99)00176-5; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; Granfors T, 1998, J UROLOGY, V159, P2030, DOI 10.1016/S0022-5347(01)63235-X; Hamilton AS, 2001, J CLIN ONCOL, V19, P2517, DOI 10.1200/JCO.2001.19.9.2517; Hankey BF, 1999, JNCI-J NATL CANCER I, V91, P1017, DOI 10.1093/jnci/91.12.1017; HARRIS R, 2002, SCREENING PROSTATE C; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Helgason A, 1996, BRIT J CANCER, V73, P1417, DOI 10.1038/bjc.1996.268; Helgason AR, 1997, J UROLOGY, V158, P155, DOI 10.1097/00005392-199707000-00050; HOCHSTETLER JA, 1995, PROSTATE, V26, P316, DOI 10.1002/pros.2990260607; Hoedemaeker RF, 2001, J NATL CANCER I, V93, P1153, DOI 10.1093/jnci/93.15.1153; Hoffman RM, 2000, J GEN INTERN MED, V15, P739, DOI 10.1046/j.1525-1497.2000.90907.x; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Hoogendam A, 1999, FAM PRACT, V16, P621, DOI 10.1093/fampra/16.6.621; Horninger W, 2000, EUR J CANCER, V36, P1322, DOI 10.1016/S0959-8049(00)00113-1; Hu K, 1998, INT J RADIAT ONCOL, V41, P263, DOI 10.1016/S0360-3016(98)00080-7; Jacobsen SJ, 1998, UROLOGY, V52, P173, DOI 10.1016/S0090-4295(98)00171-X; Jacobsen SJ, 1996, ARCH INTERN MED, V156, P2462, DOI 10.1001/archinte.156.21.2462; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Kattan MW, 1997, J GEN INTERN MED, V12, P299, DOI 10.1046/j.1525-1497.1997.012005299.x; KEETCH DW, 1994, J UROLOGY, V151, P1571, DOI 10.1016/S0022-5347(17)35304-1; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; Krupski T, 2000, UROLOGY, V55, P736, DOI 10.1016/S0090-4295(99)00597-X; LABRIE F, 1993, CLIN INVEST MED, V16, P425; Labrie F, 1996, UROLOGY, V47, P212, DOI 10.1016/S0090-4295(99)80419-1; Labrie F, 1999, PROSTATE, V38, P83, DOI 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; Legler JM, 1998, CANCER CAUSE CONTROL, V9, P519, DOI 10.1023/A:1008805718310; Lein M, 2001, EUR UROL, V39, P57, DOI 10.1159/000052413; Levine MA, 1998, J UROLOGY, V159, P471, DOI 10.1016/S0022-5347(01)63951-X; LITTRUP PJ, 1994, CANCER-AM CANCER SOC, V74, P3146, DOI 10.1002/1097-0142(19941215)74:12<3146::AID-CNCR2820741214>3.0.CO;2-Z; Litwin MS, 2000, J UROLOGY, V164, P1973, DOI 10.1016/S0022-5347(05)66931-5; Litwin MS, 1999, UROLOGY, V54, P503, DOI 10.1016/S0090-4295(99)00172-7; Litwin MS, 2000, J UROLOGY, V163, P1806; Litwin MS, 2001, J UROLOGY, V166, P587, DOI 10.1016/S0022-5347(05)65989-7; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; LITWIN MS, 1995, CANCER, V75, P2000, DOI 10.1002/1097-0142(19950401)75:7+<2000::AID-CNCR2820751641>3.0.CO;2-4; Lodding P, 1998, J UROLOGY, V159, P899, DOI 10.1016/S0022-5347(01)63766-2; Lu-Yao G, 2002, BMJ-BRIT MED J, V325, P740, DOI 10.1136/bmj.325.7367.740; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LuYao GL, 1997, LANCET, V349, P906, DOI 10.1016/S0140-6736(96)09380-4; Maattanen L, 1999, BRIT J CANCER, V79, P1210, DOI 10.1038/sj.bjc.6690194; Madalinska JB, 2001, J CLIN ONCOL, V19, P1619, DOI 10.1200/JCO.2001.19.6.1619; Martin E, 1999, EUR UROL, V35, P26, DOI 10.1159/000019815; Meigs JB, 1996, J GEN INTERN MED, V11, P505, DOI 10.1007/BF02599596; Messing EM, 1999, NEW ENGL J MED, V341, P1781, DOI 10.1056/NEJM199912093412401; Mettlin C, 1999, PROSTATE, V39, P153, DOI 10.1002/(SICI)1097-0045(19990515)39:3<153::AID-PROS2>3.0.CO;2-V; Mettlin C, 1996, CANCER, V77, P150, DOI 10.1002/(SICI)1097-0142(19960101)77:1<150::AID-CNCR25>3.0.CO;2-3; METTLIN C, 1994, CANCER, V74, P1615, DOI 10.1002/1097-0142(19940901)74:5<1615::AID-CNCR2820740520>3.0.CO;2-6; Meyer F, 1999, J UROLOGY, V161, P1189, DOI 10.1016/S0022-5347(01)61628-8; Mitchell IDC, 2001, J UROLOGY, V165, P1549, DOI 10.1016/S0022-5347(05)66346-X; Moon T D, 1995, J Natl Cancer Inst Monogr, P69; Morote J, 1999, EUR UROL, V36, P111, DOI 10.1159/000067981; Nguyen LN, 1998, UROLOGY, V51, P991, DOI 10.1016/S0090-4295(98)00028-4; Norlen B J, 1994, Can J Oncol, V4 Suppl 1, P38; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; Okegawa T, 2000, EUR UROL, V38, P380, DOI 10.1159/000020312; Oliver S, 2000, LANCET, V355, P1788, DOI 10.1016/S0140-6736(00)02269-8; Oliver SE, 2001, INT J CANCER, V92, P893, DOI 10.1002/ijc.1260; Olsson LE, 2001, UROLOGY, V58, P570, DOI 10.1016/S0090-4295(01)01261-4; OPTENBERG SA, 1995, J UROLOGY, V153, P1870, DOI 10.1016/S0022-5347(01)67334-8; PAULSON DF, 1994, J UROLOGY, V152, P1826, DOI 10.1016/S0022-5347(17)32395-9; PILEPICH MV, 1995, INT J RADIAT ONCOL, V32, P175, DOI 10.1016/0360-3016(95)00536-8; Pilepich MV, 1997, J CLIN ONCOL, V15, P1013, DOI 10.1200/JCO.1997.15.3.1013; Pilepich MV, 2001, INT J RADIAT ONCOL, V50, P1243, DOI 10.1016/S0360-3016(01)01579-6; Potosky AL, 2000, JNCI-J NATL CANCER I, V92, P1582, DOI 10.1093/jnci/92.19.1582; Potosky AL, 2002, J NATL CANCER I, V94, P430, DOI 10.1093/jnci/94.6.430; Potosky AL, 2001, J CLIN ONCOL, V19, P3750, DOI 10.1200/JCO.2001.19.17.3750; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Rabbani F, 1998, J UROLOGY, V159, P1247, DOI 10.1016/S0022-5347(01)63574-2; Reissigl A, 1996, UROLOGY, V48, P62, DOI 10.1016/S0090-4295(96)00612-7; Richert-Boe KE, 1998, J MED SCREEN, V5, P99, DOI 10.1136/jms.5.2.99; RICHIE JP, 1993, UROLOGY, V42, P365, DOI 10.1016/0090-4295(93)90359-I; Ries LAG, 2002, SEER CANC STAT REV; Roach M, 2000, INT J RADIAT ONCOL, V47, P609, DOI 10.1016/S0360-3016(00)00578-2; Roach M, 1996, INT J RADIAT ONCOL, V35, P869, DOI 10.1016/0360-3016(96)00206-4; Roberts RO, 1999, J UROLOGY, V161, P529, DOI 10.1016/S0022-5347(01)61941-4; Robinson JW, 1997, CANCER, V79, P538, DOI 10.1002/(SICI)1097-0142(19970201)79:3<538::AID-CNCR16>3.0.CO;2-4; Ross KS, 2000, JAMA-J AM MED ASSOC, V284, P1399, DOI 10.1001/jama.284.11.1399; ROSS RK, 1996, CANC EPIDEMIOLOGY PR, P1180; Sandblom G, 2000, UROLOGY, V56, P442, DOI 10.1016/S0090-4295(00)00696-8; Schellhammer PF, 2000, UROLOGY, V56, P436, DOI 10.1016/S0090-4295(00)00711-1; Schmidt JD, 1996, PROSTATE, V28, P51; Schroder F, 1994, Scand J Urol Nephrol Suppl, V162, P51; Schroder FH, 1998, JNCI-J NATL CANCER I, V90, P1817, DOI 10.1093/jnci/90.23.1817; Schroder FH, 2000, J UROLOGY, V163, P806, DOI 10.1016/S0022-5347(05)67809-3; Schwartz K, 2002, CANCER, V95, P82, DOI 10.1002/cncr.10650; Seidenfeld J, 2000, ANN INTERN MED, V132, P566, DOI 10.7326/0003-4819-132-7-200004040-00009; ShraderBogen CL, 1997, CANCER, V79, P1977, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1977::AID-CNCR20>3.0.CO;2-R; Siegel T, 2001, J UROLOGY, V165, P430, DOI 10.1097/00005392-200102000-00019; SMITH DS, 1995, UROLOGY, V45, P70, DOI 10.1016/S0090-4295(95)96812-1; Smith DS, 1996, JAMA-J AM MED ASSOC, V276, P1309, DOI 10.1001/jama.276.16.1309; SMITH DS, 1994, J UROLOGY, V152, P1163, DOI 10.1016/S0022-5347(17)32528-4; SMITH DS, 1994, J UROLOGY, V152, P1732, DOI 10.1016/S0022-5347(17)32372-8; Stanford JL, 2000, JAMA-J AM MED ASSOC, V283, P354, DOI 10.1001/jama.283.3.354; STANFORD JL, 1999, NIH PUBLICATION; Steineck G, 2002, NEW ENGL J MED, V347, P790, DOI 10.1056/NEJMoa021483; STENMAN UH, 1991, CANCER RES, V51, P222; STENMAN UH, 1994, LANCET, V344, P1594, DOI 10.1016/S0140-6736(94)90405-7; Stewart CS, 2001, J UROLOGY, V166, P86, DOI 10.1016/S0022-5347(05)66083-1; Stock RG, 2001, J UROLOGY, V165, P436, DOI 10.1097/00005392-200102000-00020; Strum SB, 1997, BRIT J UROL, V79, P933, DOI 10.1046/j.1464-410X.1997.00234.x; Talcott JA, 1997, J NATL CANCER I, V89, P1117, DOI 10.1093/jnci/89.15.1117; Tarone RE, 2000, EPIDEMIOLOGY, V11, P167, DOI 10.1097/00001648-200003000-00014; Terris MK, 1999, UROLOGY, V54, P486, DOI 10.1016/S0090-4295(99)00148-X; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P119; WALSH PC, 1994, J UROLOGY, V152, P1831, DOI 10.1016/S0022-5347(17)32396-0; Walsh PC, 2000, UROLOGY, V55, P58, DOI 10.1016/S0090-4295(99)00397-0; WIDMARK A, 1994, CANCER, V74, P2520, DOI 10.1002/1097-0142(19941101)74:9<2520::AID-CNCR2820740921>3.0.CO;2-Q; Wilt TJ, 1999, MED CARE, V37, P1046, DOI 10.1097/00005650-199910000-00008; Woolf SH, 1996, JAMA-J AM MED ASSOC, V276, P28; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6; ZINCKE H, 1994, J CLIN ONCOL, V12, P2254, DOI 10.1200/JCO.1994.12.11.2254	163	264	273	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					917	929		10.7326/0003-4819-137-11-200212030-00014	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00014			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622GY	12458993				2022-12-28	WOS:000179639700008
J	Marshall, MN; Hiscock, J; Sibbald, B				Marshall, MN; Hiscock, J; Sibbald, B			Attitudes to the public release of comparative information on the quality of general practice care: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							PERFORMANCE DATA; CARDIAC-SURGERY; CONSUMERS	Objectives To examine the attitudes of service users, general practitioners, and clinical governance leads based in primary care trusts to the public dissemination of comparative reports on quality of care in general practice, to guide the policy and practice of public disclosure of information in primary care. Design Qualitative focus group study using mock quality report cards as prompts for discussion. Setting 12 focus groups held in an urban area in north west England and a semirural area in the south of England.. Participants 35 service users, 24 general practitioners, and 18 clinical governance leads. Results There was general support for the principle of publishing comparative information, but all three stakeholder groups expressed concerns about the practical implications. Attitudes were strongly influenced by experience of comparative reports from other sectors-for example, school league tables. Service users distrusted what they saw as the political motivation driving the initiative, expressed a desire to "protect" their practices from political and managerial interference, and were uneasy about practices being encouraged to compete against each other. General practitioners focused on the unfairness of drawing comparisons from current data and the risks of "gaming" the results. Clinical governance leads thought that public disclosure would damage their developmental approach to implementing clinical governance. The initial negative response to the quality reports seemed to diminish on reflection. Conclusions Despite support for the principle of greater openness, the planned publication of information about quality of care in general practice is likely to face considerable opposition, not only from professional groups but also from the public. A greater understanding of the practical implications of public reporting is required before the potential benefits can be realised.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Natl Ctr Social Res, London WC1V 0AX, England	University of Manchester	Marshall, MN (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.							Department of Health, 2000, NHS PLAN PLAN INV PL; DRANOVE D, 2002, IS MORE INFORMATION; EdgmanLevitan S, 1996, HEALTH AFFAIR, V15, P42, DOI 10.1377/hlthaff.15.4.42; Epstein AM, 2000, JAMA-J AM MED ASSOC, V283, P1884, DOI 10.1001/jama.283.14.1884; FOSTER, 2002, FOSTER GOOD HOSP GUI; Hibbard JH, 1997, HEALTH AFFAIR, V16, P218, DOI 10.1377/hlthaff.16.3.218; Lansky D, 1998, HEALTH AFFAIR, V17, P40, DOI 10.1377/hlthaff.17.4.40; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; MANNION R, 2000, 1 U YORK CTR HLTH EC; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Marshall MN, 2001, QUAL HEALTH CARE, V10, P67, DOI 10.1136/qhc.10.2.67; Marshall MN, 2000, DYING KNOW PUBLIC RE; McKee M, 1997, J ROY SOC MED, V90, P187, DOI 10.1177/014107689709000403; MORGAN DL, 1988, FOCUS GROUPS QUALITA; Mukamel DB, 1998, MED CARE, V36, P945, DOI 10.1097/00005650-199807000-00002; *NHS EX, 1999, QUAL PERF NHS PERF I; RITCHIE J, IN PRESS QUALITATIVE; Robinson S, 1997, JOINT COMM J QUAL IM, V23, P239, DOI 10.1016/S1070-3241(16)30313-3; ROGERS A, 1999, DEMANDING PATIENTS A; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; Schneider EC, 2001, QUAL HEALTH CARE, V10, P96, DOI 10.1136/qhc.10.2.96; Smith P., 1995, INT J PUBLIC ADMIN, V18, P277, DOI DOI 10.1080/01900699508525011; VLADECK BC, 1988, HEALTH AFFAIR, V7, P122, DOI 10.1377/hlthaff.7.1.122	23	41	43	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1278	1281		10.1136/bmj.325.7375.1278	http://dx.doi.org/10.1136/bmj.325.7375.1278			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	623HB	12458248	Green Published, hybrid			2022-12-28	WOS:000179696300020
J	Yamey, G				Yamey, G			Who in 2002 - Why does the world still need WHO?	BRITISH MEDICAL JOURNAL			English	Article							HEALTH		BLJ Unified, Best Treatments, London WC1H 9JR, England		Yamey, G (corresponding author), BLJ Unified, Best Treatments, London WC1H 9JR, England.							[Anonymous], 1983, INT HLTH REG; Buse K, 1998, LANCET, V351, P665, DOI 10.1016/S0140-6736(97)11453-2; Buse K, 1997, SOC SCI MED, V45, P449, DOI 10.1016/S0277-9536(96)00365-6; *COMM EXP TOB IND, 2000, TOB CO STRAT UND TOB; DANIELS D, 2002, ACHIEVING IMPACT ROL; Frenk J, 2002, BRIT MED J, V325, P95, DOI 10.1136/bmj.325.7355.95; Gilmore AB, 2002, BMJ-BRIT MED J, V325, P846, DOI 10.1136/bmj.325.7369.846; *GLOB FUND FIGHT A, PLEDG GLOB FUND FIGH; *GLOB FUND FIGHT A, 2001, TECHN REV ADV; Godlee F, 2000, BRIT MED J, V321, P314, DOI 10.1136/bmj.321.7257.314; Kapp C, 2002, LANCET, V360, P1225, DOI 10.1016/S0140-6736(02)11294-3; MISSONI E, GLOBAL FUND GLOBAL B; The World Bank Group, MILL DEV GOALS; *UN WIR, 1999, VACC GAT DON 6 BILL; *WHO, 2000, GEN PROGR WORK 2002; *WHO, 1998, REP ADV BOD REL ISS; *WHO, 2001, PROP PROGR BUDG 2002; *WHO, 2002, IMPR WHO PERF COUNTR; Woodman R, 1999, BRIT MED J, V318, P893, DOI 10.1136/bmj.318.7188.893b; *WORLD BANK GROUP, MULT HIV AIDS PROGR; World Health Organization, 1981, INT COD MARK BREAST	21	16	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1294	1298		10.1136/bmj.325.7375.1294	http://dx.doi.org/10.1136/bmj.325.7375.1294			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458254	Green Published			2022-12-28	WOS:000179696300024
J	Mehta, RL; Pascual, MT; Soroko, S; Chertow, GM				Mehta, RL; Pascual, MT; Soroko, S; Chertow, GM		PICARD Study Grp	Diuretics, mortality, and nonrecovery of renal function in acute renal	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE TUBULAR-NECROSIS; RANDOMIZED TRIAL; CARDIAC-SURGERY; FAILURE; FUROSEMIDE; DIALYSIS; MANNITOL; DYSFUNCTION; MANAGEMENT; DOPAMINE	Context Acute renal failure is associated with high mortality and morbidity. Diuretic agents continue to be used in this setting despite a lack of evidence supporting their benefit. Objective To determine whether the use of diuretics is associated with adverse or favorable outcomes in critically ill patients with acute renal failure. Design Cohort study conducted from October 1989 to September 1995. Patients and Setting A total of 552 patients with acute renal failure in intensive care units at 4 academic medical centers affiliated with the University of California. Patients were categorized by the use of diuretics on the day of nephrology consultation and, in companion analyses, by diuretic use at any time during the first week following consultation. Main Outcome Measures All-cause hospital mortality, nonrecovery of renal function, and the combined outcome of death or nonrecovery. Results Diuretics were used in 326 patients (59%) at the time of nephrology consultation. Patients treated with diuretics on or before the day of consultation were older and more likely to have a history of congestive heart failure, nephrotoxic (rather than ischemic or multifactorial) origin of acute renal failure, acute respiratory failure, and lower serum urea nitrogen concentrations. With adjustment for relevant covariates and propensity scores, diuretic use Was associated with a significant increase in the risk of death or nonrecovery of renal function (odds ratio, 1.77; 95% confidence interval, 1.14-2.76). The risk was magnified (odds ratio, 3.12; 95% confidence interval, 1.73-5.62) when patients who died within the first week following consultation were excluded. The increased risk was borne largely by patients who were relatively unresponsive, to diuretics. Conclusions The use of diuretics in critically ill patients with acute renal failure was associated with an increased risk of death and nonrecovery of renal function. Although observational data prohibit causal inference, it is unlikely that diuretics afford any material benefit in this clinical setting. In the absence of compelling contradictory data from a randomized, blinded clinical trial, the widespread use of diuretics in critically ill patients with acute renal failure should be discouraged.	Univ Calif San Diego, Med Ctr, Div Nephrol, San Diego, CA 92103 USA; Univ Calif San Francisco, Mt Zion Med Ctr, Div Nephrol, San Francisco, CA 94120 USA; Moffitt Long Hosp, Div Nephrol, San Francisco, CA USA	University of California System; University of California San Diego; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	Chertow, GM (corresponding author), Univ Calif San Francisco, Dept Med Res, UCSF Laurel Hts,Suite 430,3333 Calif St, San Francisco, CA 94118 USA.		Mehta, Ravindra/ACD-4769-2022	Mehta, Ravindra/0000-0002-0908-2968; Chertow, Glenn/0000-0002-7599-0534; NOIRI, Eisei/0000-0002-9515-7582	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053412] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK53412-0] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RJ, 1977, NEW ENGL J MED, V296, P1134, DOI 10.1056/NEJM197705192962002; Bates DW, 2001, CLIN INFECT DIS, V32, P686, DOI 10.1086/319211; Bellomo R, 2000, LANCET, V356, P2139; Bellomo R, 1998, KIDNEY INT, V53, pS106; BROWN CB, 1981, CLIN NEPHROL, V15, P90; BROWN RS, 1979, CRIT CARE MED, V7, P63, DOI 10.1097/00003246-197902000-00007; BULLOCK ML, 1985, AM J KIDNEY DIS, V5, P97, DOI 10.1016/S0272-6386(85)80003-2; Cantarovich F, 1996, RENAL FAILURE, V18, P585, DOI 10.3109/08860229609047681; CHANG RWS, 1988, CRIT CARE MED, V16, P34, DOI 10.1097/00003246-198801000-00007; Chertow GM, 1998, AM J MED, V104, P343, DOI 10.1016/S0002-9343(98)00058-8; Chertow GM, 1998, J AM SOC NEPHROL, V9, P692; DAVIDMAN M, 1991, ARCH INTERN MED, V151, P1809, DOI 10.1001/archinte.151.9.1809; DIAMOND JR, 1982, ARCH INTERN MED, V142, P1882, DOI 10.1001/archinte.142.10.1882; Gerlach AT, 2000, PHARMACOTHERAPY, V20, P540, DOI 10.1592/phco.20.6.540.35154; GUBERN JM, 1988, SURGERY, V103, P39; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kellum, 1997, Crit Care, V1, P53, DOI 10.1186/cc103; Kellum JA, 1997, BLOOD PURIFICAT, V15, P319, DOI 10.1159/000170350; Klahr S, 1998, NEW ENGL J MED, V338, P671, DOI 10.1056/NEJM199803053381007; KLEINKNECHT D, 1976, NEPHRON, V17, P51, DOI 10.1159/000180710; Lassnigg A, 2000, J AM SOC NEPHROL, V11, P97, DOI 10.1681/ASN.V11197; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; Lewis J, 2000, AM J KIDNEY DIS, V36, P767, DOI 10.1053/ajkd.2000.17659; Liano F, 1998, SEMIN NEPHROL, V18, P541; LIANO F, 1993, NEPHRON, V63, P21, DOI 10.1159/000187139; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; Mehta RL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000014692.19351.52; Mehta RL, 2001, KIDNEY INT, V60, P1154, DOI 10.1046/j.1523-1755.2001.0600031154.x; MEHTA RL, IN PRESS AM J MED; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Shilliday IR, 1997, NEPHROL DIAL TRANSPL, V12, P2592, DOI 10.1093/ndt/12.12.2592; Sladen R N, 2000, Anesthesiol Clin North Am, V18, P739, DOI 10.1016/S0889-8537(05)70192-9; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Venkataram R, 2001, CONTRIB NEPHROL, V132, P158; Visweswaran P, 1997, J AM SOC NEPHROL, V8, P1028; WEINSTEIN JM, 1992, NEPHRON, V62, P413, DOI 10.1159/000187090; Wilson W C, 2001, Anesthesiol Clin North Am, V19, P841	39	387	404	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2002	288	20					2547	2553		10.1001/jama.288.20.2547	http://dx.doi.org/10.1001/jama.288.20.2547			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AL	12444861	Bronze			2022-12-28	WOS:000179394500021
J	Raymond, J; Zhaxybayeva, O; Gogarten, JP; Gerdes, SY; Blankenship, RE				Raymond, J; Zhaxybayeva, O; Gogarten, JP; Gerdes, SY; Blankenship, RE			Whole-genome analysis of photosynthetic prokaryotes	SCIENCE			English	Article							HORIZONTAL GENE-TRANSFER; EARLY EVOLUTION; SEQUENCE; DATABASE	The process of photosynthesis has had profound global-scale effects on Earth; however, its origin and evolution remain enigmatic. Here we report a whole-genome comparison of representatives from all. five groups of photosynthetic prokaryotes and show that horizontal gene transfer has been pivotal in their evolution. Excluding a small number of orthologs that show congruent phylogenies, the genomes of these organisms represent mosaics of genes with very different evolutionary histories. We have also analyzed a subset of "photosynthesisspecific" genes that were elucidated through a differential genome comparison. Our results explain incoherencies in previous data-limited phylogenetic analyses of phototrophic bacteria and indicate that the core components of photosynthesis have been subject to lateral transfer.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA; Integrated Genom, Chicago, IL 60612 USA	Arizona State University; Arizona State University-Tempe; University of Connecticut	Blankenship, RE (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.		Zhaxybayeva, Olga/A-9665-2009	Gogarten, Johann Peter/0000-0001-6459-6518; Zhaxybayeva, Olga/0000-0002-1809-3909				[Anonymous], 2002, PHOTOSYNTHETICA; Aravind L, 1998, TRENDS GENET, V14, P442, DOI 10.1016/S0168-9525(98)01553-4; Baymann D, 2001, BBA-BIOENERGETICS, V1507, P291, DOI 10.1016/S0005-2728(01)00209-2; Brocks JJ, 1999, SCIENCE, V285, P1033, DOI 10.1126/science.285.5430.1033; BURKE DH, 1993, P NATL ACAD SCI USA, V90, P7134, DOI 10.1073/pnas.90.15.7134; Gogarten JP, 1999, CURR OPIN GENET DEV, V9, P630, DOI 10.1016/S0959-437X(99)00029-5; Gupta RS, 1999, MOL MICROBIOL, V32, P893, DOI 10.1046/j.1365-2958.1999.01417.x; Hedges SB, 2001, BMC EVOL BIOL, V1, DOI 10.1186/1471-2148-1-4; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; Koonin EV, 2001, ANNU REV MICROBIOL, V55, P709, DOI 10.1146/annurev.micro.55.1.709; Maidak BL, 2001, NUCLEIC ACIDS RES, V29, P173, DOI 10.1093/nar/29.1.173; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; OYAIZU H, 1987, SYST APPL MICROBIOL, V9, P47, DOI 10.1016/S0723-2020(87)80055-3; RAYMOND J, UNPUB; Rye R, 1998, AM J SCI, V298, P621, DOI 10.2475/ajs.298.8.621; Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; VERMAAS WFJ, 1994, PHOTOSYNTH RES, V41, P285, DOI 10.1007/BF02184169; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Xiong J, 2000, SCIENCE, V289, P1724, DOI 10.1126/science.289.5485.1724; Xiong J, 2002, ANNU REV PLANT BIOL, V53, P503, DOI 10.1146/annurev.arplant.53.100301.135212; Zhaxybayeva O, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-4	24	195	215	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1616	1620		10.1126/science.1075558	http://dx.doi.org/10.1126/science.1075558			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446909				2022-12-28	WOS:000179361600048
J	Zhou, ZH; Clarke, JA; Zhang, FC				Zhou, ZH; Clarke, JA; Zhang, FC			Archaeoraptor's better half	NATURE			English	Editorial Material									Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; Amer Museum Nat Hist, Sect Vertebrate Paleontol, New York, NY 10024 USA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; American Museum of Natural History (AMNH)	Zhou, ZH (corresponding author), Inst Vertebrate Paleontol & Paleoanthropol, POB 643, Beijing 100044, Peoples R China.		/B-4978-2011	/0000-0003-2218-2637				Dalton R, 2000, NATURE, V403, P689, DOI 10.1038/35001723; Rowe T, 2001, NATURE, V410, P539, DOI 10.1038/35069145; Sloan C.P., 1999, NATL GEOGR, V196, P98; Xu X, 2000, NATURE, V408, P705, DOI 10.1038/35047056; Zhang M.M., 2001, JEHOL BIOTA; ZHOU Z, 2001, CHINESE SCI BULL, V46, P371; Zhou ZH, 2002, NATURE, V418, P405, DOI 10.1038/nature00930	7	31	35	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					285	285		10.1038/420285a	http://dx.doi.org/10.1038/420285a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447431				2022-12-28	WOS:000179340400032
J	Kuh, D; Hardy, R; Langenberg, C; Richards, M; Wadsworth, MEJ				Kuh, D; Hardy, R; Langenberg, C; Richards, M; Wadsworth, MEJ			Mortality in adults aged 26-54 years related to socioeconomic conditions in childhood and adulthood: post war birth cohort study	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; SOCIAL-CLASS; POSITION; HEALTH; WOMEN; RISK; LIFE; MEN	Objective To examine premature mortality in adults in relation to socioeconomic conditions in childhood and adulthood. Design Nationally representative birth cohort study with prospective information on socioeconomic conditions. Setting England, Scotland, and Wales. Study members 2132 women and 2322 men born in March 1946 and followed until age 55 years. Main outcome measures Deaths between 26 and 54 years of age notified by the NHS central register. Results Study members whose father's occupation was manual at age 4, or who lived in the worst housing, or who received the poorest care in childhood had double the death rate during adulthood of those living in the best socioeconomic conditions. All indicators of socioeconomic disadvantage at age 26 years, particularly lack of home ownership, were associated with a higher death rate. Manual origins and poor care in childhood remained associated with mortality even after adjusting for social class in adulthood or home ownership. The hazard ratio was 2.6 (95% confidence interval 1.5 to 4.4) for those living in manual households as children and as adults compared with those living in non-manual households at both life stages. The hazard ratio for those from manual origins who did not own their own home at age 26 years was 4.9 (2.3 to 10.5) compared with those from non-manual origins who were home owners. Conclusions Socioeconomic conditions in childhood as well as early adulthood have strongly influenced the survival of British people born in the immediate post war era.	Royal Free & UCL, Dept Epidemiol & Publ Hlth, MRC, Natl Survey Hlth & Dev, London WC1E 6BT, England	University of London; University College London	Kuh, D (corresponding author), Royal Free & UCL, Dept Epidemiol & Publ Hlth, MRC, Natl Survey Hlth & Dev, London WC1E 6BT, England.	d.kuh@ucl.ac.uk	Kuh, Diana/L-6019-2014; Langenberg, Claudia/ABG-9067-2021; Hardy, Rebecca/AFR-1989-2022	Kuh, Diana/0000-0001-7386-2857; Langenberg, Claudia/0000-0002-5017-7344; Hardy, Rebecca/0000-0001-9949-0799; Richards, Marcus/0000-0001-9191-2192				Barker DJP, 1998, MOTHERS BABIES HLTH; CASELLI G, 1989, POP STUD-J DEMOG, V43, P133, DOI 10.1080/0032472031000143886; CLAUSSEN B, IN PRESS J EPIDEMIOL; ELO IT, 1992, POPUL INDEX, V58, P186, DOI 10.2307/3644718; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Frankel S, 1999, AM J EPIDEMIOL, V150, P1081, DOI 10.1093/oxfordjournals.aje.a009932; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; Gunnell DJ, 1998, J EPIDEMIOL COMMUN H, V52, P142, DOI 10.1136/jech.52.3.142; HALSEY HH, 2000, 20 CENTURY BRIT SOCI; HARDING S, 1999, HLTH STAT Q, V3, P30; Heslop P, 2001, SOC SCI MED, V53, P477, DOI 10.1016/S0277-9536(00)00350-6; Kuh D, 2002, LIFE COURSE APPROACH; Leon DA, 2000, BRIT MED J, V320, P1705, DOI 10.1136/bmj.320.7251.1705; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; PECK MN, 1994, SOC SCI MED, V39, P553; Pensola TH, 2002, EUR J PUBLIC HEALTH, V12, P29, DOI 10.1093/eurpub/12.1.29; PLESS IB, 1989, DEV MED CHILD NEUROL, V31, P746; Preston SH, 1998, SOC SCI MED, V47, P1231, DOI 10.1016/S0277-9536(98)00180-4; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Smith GD, 2001, J EPIDEMIOL COMMUN H, V55, P340, DOI 10.1136/jech.55.5.340; VAGERO D, 1994, LANCET, V343, P1224, DOI 10.1016/S0140-6736(94)92432-5; Wadsworth MEJ, 1997, PAEDIATR PERINAT EP, V11, P2, DOI 10.1046/j.1365-3016.1997.d01-7.x; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8	24	178	179	1	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2002	325	7372					1076	1080		10.1136/bmj.325.7372.1076	http://dx.doi.org/10.1136/bmj.325.7372.1076			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	618JV	12424168	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000179415700021
J	Makin, AJ; Silverman, SH; Lip, GYH				Makin, AJ; Silverman, SH; Lip, GYH			ABC of antithrombotic therapy - Antithrombotic therapy in peripheral vascular disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review									City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England	University of Birmingham	Makin, AJ (corresponding author), City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Jackson MR, 2001, CHEST, V119, p283S, DOI 10.1378/chest.119.1_suppl.283S	5	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2002	325	7372					1101	1104		10.1136/bmj.325.7372.1101	http://dx.doi.org/10.1136/bmj.325.7372.1101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424175	Green Published			2022-12-28	WOS:000179415700028
J	Gamezo, VN; Khokhlov, AM; Oran, ES; Chtchelkanova, AY; Rosenberg, RO				Gamezo, VN; Khokhlov, AM; Oran, ES; Chtchelkanova, AY; Rosenberg, RO			Thermonuclear supernovae: Simulations of the deflagration stage and their implications	SCIENCE			English	Article							DELAYED-DETONATION MODEL; IA SUPERNOVAE; LIGHT CURVES; ACCELERATING UNIVERSE; EXPLOSION MODELS; HUBBLE CONSTANT; WHITE-DWARFS; FLAMES; DECELERATION; PROPAGATION	Large-scale, three-dimensional numerical simulations of the deflagration stage of a thermonuclear supernova explosion show the formation and evolution of a highly convoluted turbulent. flame in the gravitational field of an expanding carbon-oxygen white dwarf. The flame dynamics are dominated by the gravity-induced Rayleigh-Taylor instability that controls the burning rate. The thermonuclear deflagration releases enough energy to produce a healthy explosion. The turbulent. flame, however, leaves large amounts of unburned and partially burned material near the star center, whereas observations that imply these materials are present only in outer layers. This disagreement could be resolved if the deflagration triggers a detonation.	USN, Res Lab, Computat Phys & Fluid Dynam Lab, Washington, DC 20375 USA; USN, Res Lab, Ctr Computat Sci, Washington, DC 20375 USA; Strateg Anal Inc, Arlington, VA 22201 USA	United States Department of Defense; United States Navy; Naval Research Laboratory; United States Department of Defense; United States Navy; Naval Research Laboratory	Gamezo, VN (corresponding author), USN, Res Lab, Computat Phys & Fluid Dynam Lab, Washington, DC 20375 USA.		Gamezo, Vadim/AFN-1933-2022					ARNETT D, 1994, ASTROPHYS J, V427, P330, DOI 10.1086/174143; ARNETT D, 1994, ASTROPHYS J, V427, P315, DOI 10.1086/174142; ARNETT WD, 1969, ASTROPHYS SPACE SCI, V5, P180, DOI 10.1007/BF00650291; Branch D, 1998, ANNU REV ASTRON ASTR, V36, P17, DOI 10.1146/annurev.astro.36.1.17; BRANCH D, 1995, PHYS REP, V256, P53, DOI 10.1016/0370-1573(94)00101-8; Burrows A, 2000, NATURE, V403, P727, DOI 10.1038/35001501; Filippenko AV, 1997, ANNU REV ASTRON ASTR, V35, P309, DOI 10.1146/annurev.astro.35.1.309; Fisher A, 1997, ASTROPHYS J, V481, pL89, DOI 10.1086/310660; Gamezo VN, 1999, ASTROPHYS J, V512, P827, DOI 10.1086/306784; HAMUY M, 1995, ASTRON J, V109, P1, DOI 10.1086/117251; HANSEN CJ, 1969, ASTROPHYS SPACE SCI, V3, P464, DOI 10.1007/BF00653366; Hillebrandt W, 2000, ANNU REV ASTRON ASTR, V38, P191, DOI 10.1146/annurev.astro.38.1.191; Hoflich P, 1996, ASTROPHYS J, V472, pL81, DOI 10.1086/310363; Hoflich P, 2002, ASTROPHYS J, V568, P779, DOI 10.1086/338981; HOFLICH P, 1995, ASTROPHYS J, V443, P89, DOI 10.1086/175505; HOFLICH P, 1995, ASTROPHYS J, V444, P831, DOI 10.1086/175656; Hoflich P, 1996, ASTROPHYS J, V457, P500, DOI 10.1086/176748; Howell DA, 2001, ASTROPHYS J, V556, P302, DOI 10.1086/321584; HOYLE F, 1960, ASTROPHYS J, V132, P565, DOI 10.1086/146963; JEFFERY DJ, 1992, ASTROPHYS J, V397, P304, DOI 10.1086/171787; KHOKHLOV A, 1993, ASTRON ASTROPHYS, V270, P223; KHOKHLOV A, 1994, ASTROPHYS J, V424, pL115, DOI 10.1086/187288; KHOKHLOV AM, 1991, ASTRON ASTROPHYS, V245, P114; Khokhlov AM, 1998, J COMPUT PHYS, V143, P519, DOI 10.1006/jcph.1998.9998; Khokhlov AM, 1996, COMBUST FLAME, V105, P28, DOI 10.1016/0010-2180(95)00157-3; KHOKHLOV AM, 1989, MON NOT R ASTRON SOC, V239, P785, DOI 10.1093/mnras/239.3.785; KHOKHLOV AM, 1995, ASTROPHYS J, V449, P695, DOI 10.1086/176091; Khokhlov AM, 1997, ASTROPHYS J, V478, P678, DOI 10.1086/303815; Khokhlov AM, 1999, COMBUST FLAME, V119, P400, DOI 10.1016/S0010-2180(99)00058-9; KIRSHNER RP, 1993, ASTROPHYS J, V415, P589, DOI 10.1086/173188; LIVNE E, 1993, ASTROPHYS J, V406, pL17, DOI 10.1086/186776; Mazzali PA, 2001, MON NOT R ASTRON SOC, V321, P341, DOI 10.1046/j.1365-8711.2001.04018.x; NOMOTO K, 1976, ASTROPHYS SPACE SCI, V39, pL37, DOI 10.1007/BF00648354; NOMOTO K, 1984, ASTROPHYS J, V286, P644, DOI 10.1086/162639; Nomoto K, 1997, SCIENCE, V276, P1378, DOI 10.1126/science.276.5317.1378; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; Phillips M.M., 1993, ASTROPHYS J LETT, V413, P105; Reinecke M, 2002, ASTRON ASTROPHYS, V391, P1167, DOI 10.1051/0004-6361:20020885; Reinecke M, 2002, ASTRON ASTROPHYS, V386, P936, DOI 10.1051/0004-6361:20020323; Riess AG, 2001, ASTROPHYS J, V560, P49, DOI 10.1086/322348; RIESS AG, 1995, ASTROPHYS J, V438, pL17, DOI 10.1086/187704; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Thomas RC, 2002, ASTROPHYS J, V567, P1037, DOI 10.1086/338679; TIMMES FX, 1992, ASTROPHYS J, V396, P649, DOI 10.1086/171746; Wang LF, 1997, ASTROPHYS J, V476, pL27, DOI 10.1086/310495; WHEELER JC, 1990, REP PROG PHYS, V53, P1467, DOI 10.1088/0034-4885/53/12/001; WHEELER JC, 1995, PHYS REP, V256, P211, DOI 10.1016/0370-1573(94)00109-G; WHEELER JC, IN PRESS AM J PHYS; WOOSLEY SE, 1986, ANNU REV ASTRON ASTR, V24, P205, DOI 10.1146/annurev.aa.24.090186.001225; YAMAOKA H, 1992, APJ, V393, P55	52	284	288	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 3	2003	299	5603					77	81		10.1126/science.1078129	http://dx.doi.org/10.1126/science.1078129			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	631JZ	12446871	Green Submitted			2022-12-28	WOS:000180165800035
J	Mayer, L; Quinn, T; Wadsley, J; Stadel, J				Mayer, L; Quinn, T; Wadsley, J; Stadel, J			Formation of giant planets by fragmentation of protoplanetary disks	SCIENCE			English	Article							SMOOTHED PARTICLE HYDRODYNAMICS; PROTOSTELLAR DISKS; INSTABILITIES; RESOLUTION; MIGRATION; ACCRETION; LIFETIMES; EVOLUTION; OBJECTS; GROWTH	The evolution of gravitationally unstable protoplanetary gaseous disks has been studied with the use of three-dimensional smoothed particle hydrodynamics simulations with unprecedented resolution. We have considered disks with initial masses and temperature profiles consistent with those inferred for the protosolar nebula and for other protoplanetary disks. We show that long-lasting, self-gravitating protoplanets arise after a few disk orbital periods if cooling is efficient enough to maintain the temperature close to 50 K. The resulting bodies have masses and orbital eccentricities similar to those of detected extrasolar planets.	Univ Washington, Dept Astron, Seattle, WA 98195 USA; McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada; Univ Victoria, Dept Phys & Astron, Victoria, BC V8W 3PG, Canada	University of Washington; University of Washington Seattle; McMaster University; University of Victoria	Mayer, L (corresponding author), Univ Zurich, Inst Theoret Phys, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	lucio@physik.nizh.ch; trq@astro.washington.edu		Quinn, Thomas/0000-0001-5510-2803; Stadel, Joachim Gerhard/0000-0001-7565-8622				Bally J, 1998, ASTRON J, V116, P854, DOI 10.1086/300469; BALSARA DS, 1995, J COMPUT PHYS, V121, P357, DOI 10.1016/S0021-9991(95)90221-X; Bate MR, 1997, MON NOT R ASTRON SOC, V288, P1060, DOI 10.1093/mnras/288.4.1060; Boss AP, 1997, SCIENCE, V276, P1836, DOI 10.1126/science.276.5320.1836; Boss AP, 2002, ICARUS, V156, P291, DOI 10.1006/icar.2002.6816; Boss AP, 1998, ANNU REV EARTH PL SC, V26, P53, DOI 10.1146/annurev.earth.26.1.53; Boss AP, 1998, ASTROPHYS J, V503, P923, DOI 10.1086/306036; Boss AP, 2001, ASTROPHYS J, V563, P367, DOI 10.1086/323694; D'Alessio P, 2001, ASTROPHYS J, V553, P321, DOI 10.1086/320655; GINGOLD RA, 1977, MON NOT R ASTRON SOC, V181, P375, DOI 10.1093/mnras/181.3.375; Guillot T, 1999, SCIENCE, V286, P72, DOI 10.1126/science.286.5437.72; Haisch KE, 2001, ASTROPHYS J, V553, pL153, DOI 10.1086/320685; Lissauer JJ, 2001, NATURE, V409, P23, DOI 10.1038/35051182; Luhman KL, 2002, ASTROPHYS J, V566, P1132, DOI 10.1086/338338; Marcy GW, 1998, ANNU REV ASTRON ASTR, V36, P57, DOI 10.1146/annurev.astro.36.1.57; Marcy GW, 2000, PUBL ASTRON SOC PAC, V112, P137, DOI 10.1086/316516; Nelson AF, 1998, ASTROPHYS J, V502, P342, DOI 10.1086/305869; Nelson AF, 2000, ASTROPHYS J, V529, P357, DOI 10.1086/308238; Nelson RP, 2000, MON NOT R ASTRON SOC, V318, P18, DOI 10.1046/j.1365-8711.2000.03605.x; Pickett BK, 2000, ASTROPHYS J, V529, P1034, DOI 10.1086/308301; Pickett BK, 2000, ASTROPHYS J, V540, pL95, DOI 10.1086/312884; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; Stadel J, 2002, SPRINGER INT SER ENG, V657, P501; Tanaka H, 2002, ASTROPHYS J, V565, P1257, DOI 10.1086/324713; Terquem C, 2002, MON NOT R ASTRON SOC, V332, pL39, DOI 10.1046/j.1365-8711.2002.05493.x; Thommes EW, 2002, ASTRON J, V123, P2862, DOI 10.1086/339975; Throop HB, 2001, SCIENCE, V292, P1686, DOI 10.1126/science.1059093; WEIDENSCHILLING SJ, 1977, ASTROPHYS SPACE SCI, V51, P153, DOI 10.1007/BF00642464	32	229	230	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1756	1759		10.1126/science.1077635	http://dx.doi.org/10.1126/science.1077635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459581	Green Submitted			2022-12-28	WOS:000179494800035
J	de la Torre, J; Bishop, J				de la Torre, J; Bishop, J			Something fishy going on in the heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	de la Torre, J (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1769	1769		10.1056/NEJMicm020274	http://dx.doi.org/10.1056/NEJMicm020274			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456853				2022-12-28	WOS:000179468600007
J	Das, G; Talukdar, P; Matile, S				Das, G; Talukdar, P; Matile, S			Fluorometric detection of enzyme activity with synthetic supramolecular pores	SCIENCE			English	Article							CHANNELS; SENSORS	The reversible blockage of synthetic pores formed by rigid-rod beta barrels, either by substrates or products, was used to sense a variety of enzymatic reactions in high-throughput format with "naked-eye" fluorescent detection. Improvement of sensor sensitivity beyond three orders of magnitude by straightforward internal mutations underscores the functional plasticity of rigid-rod beta barrels. Such detectors of enzyme activity with the aforementioned characteristics are needed in areas as diverse as proteomics and environmentally benign organic synthesis.	Univ Geneva, Dept Organ Chem, CH-1211 Geneva, Switzerland	University of Geneva	Matile, S (corresponding author), Univ Geneva, Dept Organ Chem, CH-1211 Geneva, Switzerland.		Talukdar, Pinaki/B-5966-2011; Matile, Stefan/AFL-7826-2022; Das, Gopal/AAW-4611-2020	Talukdar, Pinaki/0000-0003-3951-4335; Matile, Stefan/0000-0002-8537-8349; Das, Gopal/0000-0003-0043-1372				Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038; Cheley S, 2002, CHEM BIOL, V9, P829, DOI 10.1016/S1074-5521(02)00172-2; CZARNIK AW, 1994, ACCOUNTS CHEM RES, V27, P302, DOI 10.1021/ar00046a003; Das G, 2002, CHEMBIOCHEM, V3, P1089, DOI 10.1002/1439-7633(20021104)3:11<1089::AID-CBIC1089>3.0.CO;2-V; Das G, 2002, P NATL ACAD SCI USA, V99, P5183, DOI 10.1073/pnas.022547899; Gokel GW, 2001, CHEM SOC REV, V30, P274, DOI 10.1039/b008667n; Kirkovits GJ, 2000, ADV SUPR CH, V7, P1; Komoszynski M, 1996, BBA-MOL CELL RES, V1310, P233, DOI 10.1016/0167-4889(95)00135-2; Machajewski TD, 2000, ANGEW CHEM INT EDIT, V39, P1352, DOI 10.1002/(SICI)1521-3773(20000417)39:8<1352::AID-ANIE1352>3.0.CO;2-J; Matile S, 2001, CHEM SOC REV, V30, P158, DOI 10.1039/b008101i; PALCIC MM, 1994, METHOD ENZYMOL, V230, P300; Scrimin P, 1999, CURR OPIN CHEM BIOL, V3, P730, DOI 10.1016/S1367-5931(99)90031-5; Snowden TS, 1999, CURR OPIN CHEM BIOL, V3, P740, DOI 10.1016/S1367-5931(99)00034-4; Wahler D, 2001, CURR OPIN CHEM BIOL, V5, P152, DOI 10.1016/S1367-5931(00)00184-8; WHITESIDES GM, 1995, ACCOUNTS CHEM RES, V28, P37, DOI 10.1021/ar00049a006; Wymer N, 2000, CURR OPIN CHEM BIOL, V4, P110, DOI 10.1016/S1367-5931(99)00061-7	16	162	163	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1600	1602		10.1126/science.1077353	http://dx.doi.org/10.1126/science.1077353			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446904				2022-12-28	WOS:000179361600043
J	Hare, B; Brown, M; Williamson, C; Tomasello, M				Hare, B; Brown, M; Williamson, C; Tomasello, M			The domestication of social cognition in dogs	SCIENCE			English	Article							EXPERIMENTER-GIVEN CUES; OBJECT-CHOICE TASKS; CANIS-FAMILIARIS; CHIMPANZEES KNOW; PAN-TROGLODYTES; YOUNG-CHILDREN; GAZE; COMPREHENSION; CONSPECIFICS; FOLLOW	Dogs are more skillful than great apes at a number of tasks in which they must read human communicative signals indicating the location of hidden food. In this study, we found that wolves who were raised by humans do not show these same skills, whereas domestic dog puppies only a few weeks old, even those that have had little human contact, do show these skills. These findings suggest that during the process of domestication, dogs have been selected for a set of social-cognitive abilities that enable them to communicate with humans in unique ways.	Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA; Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; Wolf Hollow Wolf Sanctuary, Ipswich, MA 01938 USA	Harvard University; Max Planck Society	Hare, B (corresponding author), Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA.	bhare@fas.harvard.edu	Brown, Michelle/A-5173-2010	Brown, Michelle/0000-0002-2995-1745				Agnetta B., 2000, ANIMAL COGNITION, V3, P107, DOI [10.1007/s100710000070, DOI 10.1007/S100710000070, DOI 10.1177/0963721416667718]; ANDERSON JR, 1995, ANIM BEHAV, V49, P201, DOI 10.1016/0003-3472(95)80168-5; BELYAEV DK, 1979, J HERED, V70, P301, DOI 10.1093/oxfordjournals.jhered.a109263; BYRNE R, 1998, MACHIAVELLIAN INTELL; Call J, 1998, Anim Cogn, V1, P89, DOI 10.1007/s100710050013; FRANK H, 1989, B PSYCHONOMIC SOC, V27, P455; FRANK H, 1982, ANIM BEHAV, V30, P95, DOI 10.1016/S0003-3472(82)80241-8; Hare B, 2000, ANIM BEHAV, V59, P771, DOI 10.1006/anbe.1999.1377; Hare B, 1999, J COMP PSYCHOL, V113, P173, DOI 10.1037/0735-7036.113.2.173; Hare B, 2001, ANIM BEHAV, V61, P139, DOI 10.1006/anbe.2000.1518; Hare B., 1998, EVOL COMMUN, V2, P137; Humphrey NK., 1976, GROWING POINTS ETHOL, P303; Itakura S, 1998, J COMP PSYCHOL, V112, P119, DOI 10.1037/0735-7036.112.2.119; Neiworth JJ, 2002, J COMP PSYCHOL, V116, P3, DOI 10.1037//0735-7036.116.1.3; Peignot P, 1999, J COMP PSYCHOL, V113, P253, DOI 10.1037/0735-7036.113.3.253; Povinelli DJ, 1999, BRIT J DEV PSYCHOL, V17, P37, DOI 10.1348/026151099165140; Povinelli DJ, 1997, COGNITIVE DEV, V12, P327, DOI 10.1016/S0885-2014(97)90017-4; Santos Laurie R., 1999, Animal Cognition, V2, P131, DOI 10.1007/s100710050033; Soproni K, 2002, J COMP PSYCHOL, V116, P27, DOI 10.1037//0735-7036.116.1.27; Soproni K, 2001, J COMP PSYCHOL, V115, P122, DOI 10.1037//0735-7036.115.2.122; Tomasello M, 1999, ANIM BEHAV, V58, P769, DOI 10.1006/anbe.1999.1192; Tomasello M, 1997, CHILD DEV, V68, P1067, DOI 10.2307/1132292; Tomasello M, 1998, ANIM BEHAV, V55, P1063, DOI 10.1006/anbe.1997.0636; Tomasello M, 1997, PRIMATE COGNITION; Vick SJ, 2000, J COMP PSYCHOL, V114, P200, DOI 10.1037//0735-7036.114.2.200; Vila C, 1997, SCIENCE, V276, P1687, DOI 10.1126/science.276.5319.1687	26	668	691	9	410	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1634	1636		10.1126/science.1072702	http://dx.doi.org/10.1126/science.1072702			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	617KV	12446914	Green Submitted			2022-12-28	WOS:000179361600053
J	Sargis, EJ				Sargis, EJ			Primate origins nailed	SCIENCE			English	Editorial Material							GLIDING BEHAVIOR; PAROMOMYIDS; MAMMALIA; TREE		Yale Univ, Dept Anthropol, New Haven, CT 06520 USA	Yale University	Sargis, EJ (corresponding author), Yale Univ, Dept Anthropol, POB 208277, New Haven, CT 06520 USA.							BEARD KC, 1993, MAMMAL PHYLOGENY : PLACENTALS, P129; BEARD KC, 1990, NATURE, V345, P340, DOI 10.1038/345340a0; Bloch J, 2001, U MICHIGAN PAPERS PA, V33, P185; Bloch JI, 2002, SCIENCE, V298, P1606, DOI 10.1126/science.1078249; Cartmill Matt, 1992, Evolutionary Anthropology, V1, P105, DOI 10.1002/evan.1360010308; Hamrick MW, 1999, AM J PHYS ANTHROPOL, V109, P397; KRAUSE DW, 1991, J HUM EVOL, V21, P177, DOI 10.1016/0047-2484(91)90060-9; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; RASMUSSEN DT, 1990, AM J PRIMATOL, V22, P263, DOI 10.1002/ajp.1350220406; RUNESTAD JA, 1995, AM J PHYS ANTHROPOL, V98, P101, DOI 10.1002/ajpa.1330980202; Sargis EJ, 2002, J MORPHOL, V254, P149, DOI 10.1002/jmor.10025; Sargis EJ, 2001, J ZOOL, V253, P485, DOI 10.1017/S0952836901000449; SILCOX MT, 2001, THESIS JOHN HOPKINS; SUSSMAN RW, 1991, AM J PRIMATOL, V23, P209, DOI 10.1002/ajp.1350230402; Szalay F.S., 1980, P133; SZALAY FS, 1988, J HUM EVOL, V17, P1, DOI 10.1016/0047-2484(88)90047-4	17	26	30	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1564	1565		10.1126/science.1079034	http://dx.doi.org/10.1126/science.1079034			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	617KV	12446895				2022-12-28	WOS:000179361600034
J	Abraham, J				Abraham, J			Making regulation responsive to commercial interests: streamlining drug industry watchdogs	BRITISH MEDICAL JOURNAL			English	Article									Univ Sussex, Sch Social Sci, Brighton BN1 9SN, E Sussex, England	University of Sussex	Abraham, J (corresponding author), Univ Sussex, Sch Social Sci, Brighton BN1 9SN, E Sussex, England.							Abraham J, 1996, SCI POLITICS PHARM I; Abraham J., 2000, REGULATING MED EUROP; ANDERSSON F, 1999, INT J HLTH SERV, V22, P62; Anon, 1989, SCRIP, V1374, P4; Anon, 1994, SCRIP, V1978, P5; *ASS BRIT PHARM IN, 1971, ABPI ANN REP 1970 71, P10; BERGER A, 1993, BRIT MED J, V319, P1292; *BGA, 1993, SCRIP, V1864, P5; *BGA, 1989, SCRIP, V1446, P3; *BGA, 1989, SCRIP, V1395, P8; *BGA, 1989, SCRIP, V1432, P4; Kessler DA, 1996, JAMA-J AM MED ASSOC, V276, P1826, DOI 10.1001/jama.276.22.1826; *MIN HLTH, 1962, PHARM J, V189, P451; ZAHN M, 1994, REGULATORY AFFAI AUG, P669; 1989, SCRIP, V1415, P3; 1988, SCRIP, V1279, P3; 1988, SCRIP, V1369, P8; 1991, SCRIP, V1632, P2; 1994, SCRIP, P24; 1988, SCRIP, V1285, P6; 1987, SCRIP, V1213, P1	21	17	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2002	325	7373					1164	1167		10.1136/bmj.325.7373.1164	http://dx.doi.org/10.1136/bmj.325.7373.1164			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433771	Green Published, Green Accepted			2022-12-28	WOS:000179443100028
J	Kasevich, MA				Kasevich, MA			Coherence with atoms	SCIENCE			English	Article							QUANTUM PHASE; BOSE; INTERFEROMETER; SPECTROSCOPY; INTERFERENCE; SOLITONS; PHOTON	The past decade has seen dramatic progress in our ability to manipulate and coherently control the motion of atoms. This progress has both fundamental and applied importance. On the one hand, recent experiments are providing new perspectives for the study of quantum phase transitions and highly entangled quantum states. On the other hand, this exquisite control offers the prospect of a new generation of force sensors of unprecedented sensitivity and accuracy.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA	Stanford University	Kasevich, MA (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.							ACHDEV S, 1999, QUANTUM PHASE TRANSI; ANDERSON B, 1999, P INT SCH PHYS ENR F; Anderson BP, 1998, SCIENCE, V282, P1686, DOI 10.1126/science.282.5394.1686; Andrews MR, 1997, SCIENCE, V275, P637, DOI 10.1126/science.275.5300.637; BARONE A, 1982, PHYSICS APPL JOSEPHS; Berman P., 1997, ATOM INTERFEROMETRY; Bouyer P, 1997, PHYS REV A, V56, pR1083, DOI 10.1103/PhysRevA.56.R1083; Burger S, 1999, PHYS REV LETT, V83, P5198, DOI 10.1103/PhysRevLett.83.5198; Burt EA, 1997, PHYS REV LETT, V79, P337, DOI 10.1103/PhysRevLett.79.337; Castin Y, 1997, PHYS REV A, V55, P4330, DOI 10.1103/PhysRevA.55.4330; Cataliotti FS, 2001, SCIENCE, V293, P843, DOI 10.1126/science.1062612; CHAPMAN MS, 1995, PHYS REV LETT, V75, P3783, DOI 10.1103/PhysRevLett.75.3783; Chikkatur AP, 2002, SCIENCE, V296, P2193, DOI 10.1126/science.296.5576.2193; COHENTANNOUDJI CN, 1990, PHYS TODAY, V43, P33, DOI 10.1063/1.881239; Cornell EA, 1998, SCI AM, V278, P40, DOI 10.1038/scientificamerican0398-40; Deng L, 1999, NATURE, V398, P218, DOI 10.1038/18395; Denschlag J, 2000, SCIENCE, V287, P97, DOI 10.1126/science.287.5450.97; Greiner M, 2002, NATURE, V419, P51, DOI 10.1038/nature00968; Gustavson TL, 2000, CLASSICAL QUANT GRAV, V17, P2385, DOI 10.1088/0264-9381/17/12/311; Hansel W, 2001, NATURE, V413, P498, DOI 10.1038/35097032; HOLLAND MJ, 1993, PHYS REV LETT, V71, P1355, DOI 10.1103/PhysRevLett.71.1355; Javanainen J, 1996, PHYS REV LETT, V76, P161, DOI 10.1103/PhysRevLett.76.161; KASEVICH M, 1991, PHYS REV LETT, V67, P181, DOI 10.1103/PhysRevLett.67.181; Kerman AJ, 2000, PHYS REV LETT, V84, P439, DOI 10.1103/PhysRevLett.84.439; Ketterle W, 1997, PHYS REV A, V56, P3291, DOI 10.1103/PhysRevA.56.3291; Ketterle W, 1996, ADV ATOM MOL OPT PHY, V37, P181; KITAGAWA M, 1993, PHYS REV A, V47, P5138, DOI 10.1103/PhysRevA.47.5138; Kokorowski DA, 2001, PHYS REV LETT, V86, P2191, DOI 10.1103/PhysRevLett.86.2191; Kuzmich A, 2000, PHYS REV LETT, V85, P1594, DOI 10.1103/PhysRevLett.85.1594; Leanhardt AE, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.040401; LEEUWEN E, 2000, LEADING EDGE, V19, P1296; Mabuchi H, 2002, SCIENCE, V298, P1372, DOI 10.1126/science.1078446; Mabuchi H, 1996, OPT LETT, V21, P1393, DOI 10.1364/OL.21.001393; McGuirk JM, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.033608; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Orzel C, 2001, SCIENCE, V291, P2386, DOI 10.1126/science.1058149; OTT H, 2001, PHYS REV LETT, V87; Peters A, 1999, NATURE, V400, P849, DOI 10.1038/23655; Sorensen A, 2001, NATURE, V409, P63, DOI 10.1038/35051038; Treutlein P, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.051401; Vogels JM, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.020401; Yasuda M, 1996, PHYS REV LETT, V77, P3090, DOI 10.1103/PhysRevLett.77.3090; Zorn AH, 2002, 2002 IEEE POSITION LOCATION AND NAVIGATION SYMPOSIUM, P66, DOI 10.1109/PLANS.2002.998890	49	94	97	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1363	1368		10.1126/science.1079430	http://dx.doi.org/10.1126/science.1079430			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434050				2022-12-28	WOS:000179223100038
J	Pfeifer, M; Boncristiano, S; Bondolfi, L; Stalder, A; Deller, T; Staufenbiel, M; Mathews, PM; Jucker, M				Pfeifer, M; Boncristiano, S; Bondolfi, L; Stalder, A; Deller, T; Staufenbiel, M; Mathews, PM; Jucker, M			Cerebral hemorrhage after passive anti-A beta immunotherapy	SCIENCE			English	Article							AMYLOID ANGIOPATHY; DISEASE		Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; Univ Frankfurt, Inst Clin Neuroanat, D-60590 Frankfurt, Germany; Novartis Pharma, CH-4002 Basel, Switzerland; NYU, Sch Med, Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA	University of Basel; Goethe University Frankfurt; Novartis; Nathan Kline Institute for Psychiatric Research; New York University	Jucker, M (corresponding author), Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland.		Pfeifer, Matthias/GRJ-4579-2022	Mathews, Paul/0000-0003-1742-7687				Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Greenberg SM, 1998, NEUROLOGY, V51, P690, DOI 10.1212/WNL.51.3.690; Jellinger KA, 2002, J NEURAL TRANSM, V109, P813, DOI 10.1007/s007020200068; MAEDA A, 1993, STROKE, V24, P1857, DOI 10.1161/01.STR.24.12.1857; Paris D, 2000, NEUROBIOL AGING, V21, P183, DOI 10.1016/S0197-4580(99)00111-6; Poduslo JF, 2001, NEUROREPORT, V12, P3197, DOI 10.1097/00001756-200110290-00011; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Winkler DT, 2001, J NEUROSCI, V21, P1619, DOI 10.1523/JNEUROSCI.21-05-01619.2001	9	418	480	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1379	1379		10.1126/science.1078259	http://dx.doi.org/10.1126/science.1078259			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434053				2022-12-28	WOS:000179223100041
J	Kmita, M; Fraudeau, N; Herault, Y; Duboule, D				Kmita, M; Fraudeau, N; Herault, Y; Duboule, D			Serial deletions and duplications suggest a mechanism for the collinearity of Hoxd genes in limbs	NATURE			English	Article							REGULATORY CONTROLS; BETA-GLOBIN; COMPLEX; EXPRESSION; COLINEARITY; MICE; MOUSE; MORPHOGENESIS; TRANSCRIPTION; HIERARCHY	Hox genes, located at one end of the HoxD cluster, are essential for the development of the extremities of our limbs; that is, the digits. This 'collinear' correspondence is accompanied by a gradual decrease in the transcriptional efficiency of the genes. To decipher the underlying regulatory mechanisms, and thus to understand better how digits develop, we engineered a series of deletions and duplications in vivo. We find that HoxD genes compete for a remote enhancer that recognizes the locus in a polar fashion, with a preference for the 5' extremity. Modifications in either the number or topography of Hoxd loci induced regulatory reallocations affecting both the number and morphology of digits. These results demonstrate why genes located at the extremity of the cluster are expressed at the distal end of the limbs, following a gradual reduction in transcriptional efficiency, and thus highlight the mechanistic nature of collinearity in limbs.	Univ Geneva, Dept Zool & Anim Biol, NCCR Frontiers Genet, CH-1211 Geneva 4, Switzerland	University of Geneva	Duboule, D (corresponding author), Univ Geneva, Dept Zool & Anim Biol, NCCR Frontiers Genet, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.		kmita, marie/AAU-9620-2020; Herault, Yann/B-5500-2012	Herault, Yann/0000-0001-7049-6900; duboule, denis/0000-0001-9961-2960; Kmita, Marie/0000-0003-4021-0478				Davis AP, 1996, DEVELOPMENT, V122, P1175; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1994, SCIENCE, V266, P575, DOI 10.1126/science.7939709; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; DUBOULE D, 1995, CURR OPIN GENET DEV, V5, P525, DOI 10.1016/0959-437X(95)90058-O; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FromentalRamain C, 1996, DEVELOPMENT, V122, P461; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; Goff DJ, 1997, DEVELOPMENT, V124, P627; Herault Y, 1997, DEVELOPMENT, V124, P3493; Herault Y, 1998, NAT GENET, V20, P381, DOI 10.1038/3861; Herault Y, 1999, DEV BIOL, V208, P157, DOI 10.1006/dbio.1998.9179; Herault Y, 1996, EMBO J, V15, P6727, DOI 10.1002/j.1460-2075.1996.tb01062.x; Herault Y, 1998, DEVELOPMENT, V125, P1669; INOUYE M, 1976, Congenital Anomalies, V16, P171; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; Kmita M, 2000, NAT GENET, V26, P451, DOI 10.1038/82593; Kmita M, 2000, GENE DEV, V14, P198; KMITA M, 1976, DEVELOPMENT, V129, P5521; Kondo T, 1998, MOL CELL, V1, P289, DOI 10.1016/S1097-2765(00)80029-5; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Peichel CL, 1997, DEVELOPMENT, V124, P3481; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; Spitz F, 2001, GENE DEV, V15, P2209, DOI 10.1101/gad.205701; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; Vidal F, 1998, MOL REPROD DEV, V51, P274, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;274::AID-MRD6&gt;3.0.CO;2-M; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Zakany J, 1997, P NATL ACAD SCI USA, V94, P13695, DOI 10.1073/pnas.94.25.13695	35	177	179	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					145	150		10.1038/nature01189	http://dx.doi.org/10.1038/nature01189			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432383				2022-12-28	WOS:000179200900036
J	Baqui, AH; Black, RE; El Arifeen, S; Yunus, M; Chakraborty, Y; Ahmed, S; Vaughan, JP				Baqui, AH; Black, RE; El Arifeen, S; Yunus, M; Chakraborty, Y; Ahmed, S; Vaughan, JP			Effect of zinc supplementation started during diarrhoea on morbidity and mortality in Bangladeshi children: community randomised trial	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-INFECTIONS; DOUBLE-BLIND; DEFICIENCY; INFANTS	Objective To evaluate the effect on morbidity and mortality of providing daily zinc for 14 days to children with diarrhoea. Design Cluster randomised comparison. Setting Matlab field site of International Center for Diarrhoeal Disease Research, Bangladesh. Participants 8070 children aged 3-59 months contributed 11 881 child years of observation during a two year period. Intervention Children with diarrhoea in the intervention clusters were treated with zinc (20 mg per day for 14 days); all children with diarrhoea were treated with oral rehydration therapy. Main outcome measures Duration of episode of diarrhoea, incidence of diarrhoea and acute lower respiratory infections, admission to hospital for diarrhoea or acute lower respiratory infections, and child mortality. Results About 40% (399/1007) of diarrhoeal episodes were treated with zinc in the first four months of the trial; the rate rose to 67% (350/526) in month 5 and to >80% (364/434) in month 7 and was sustained at that level. Children in the intervention cluster received. zinc for about seven days on average during each episode of diarrhoea. They had a shorter duration (hazard ratio 0.76, 95% confidence interval 0.65 to 0.90) and lower incidence of diarrhoea (rate ratio 0.85, 0.76 to 0.96) than children in the comparison group. Incidence of acute lower respiratory infection was reduced in the-intervention group but hot in the comparison group. Admission to hospital of children with diarrhoea was lower in the intervention group than in the comparison group (0.76, 0.59 to 0.98). Admission for acute lower respiratory infection was lower in the intervention group, but this was not statistically significant (0.81, 0.53 to 1.23). The rate of non-injury deaths in the intervention clusters was considerably lower (0.49, 0.25 to 0.94). Conclusions The lower rates of child morbidity and mortality with zinc treatment represent substantial benefits from a simple and inexpensive intervention that can be incorporated in existing efforts to control diarrhoeal disease.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat & Family Hlth, Baltimore, MD 21205 USA; Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Child Hlth Program, Dhaka 1000, Bangladesh; Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Matlab Hlth Res Program, Dhaka 1000, Bangladesh; London Sch Hyg & Trop Med, London WC1A 7HT, England	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); University of London; London School of Hygiene & Tropical Medicine	Baqui, AH (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.			Arifeen, Shams/0000-0002-5372-5932; Black, Robert/0000-0001-9926-7984				Baqui AH, 1998, B WORLD HEALTH ORGAN, V76, P161; BETTGER WJ, 1981, LIFE SCI, V28, P1425, DOI 10.1016/0024-3205(81)90374-X; Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7; Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516; CASTILLODURAN C, 1988, J PEDIATR-US, V113, P452, DOI 10.1016/S0022-3476(88)80627-9; FENWICK PK, 1990, AM J CLIN NUTR, V52, P166, DOI 10.1093/ajcn/52.1.166; GEBHARD RL, 1983, J NUTR, V113, P855, DOI 10.1093/jn/113.4.855; GOLDEN BE, 1985, TRACE ELEMENTS MAN A, V5, P228; *HLTH DEM SURV SYS, 2000, 87 ICDDR HLTH DEM SU; Rosado JL, 1997, AM J CLIN NUTR, V65, P13, DOI 10.1093/ajcn/65.1.13; Roy SK, 1997, ARCH DIS CHILD, V77, P196, DOI 10.1136/adc.77.3.196; Ruel MT, 1997, PEDIATRICS, V99, P808, DOI 10.1542/peds.99.6.808; Sazawal S, 1998, PEDIATRICS, V102, P1, DOI 10.1542/peds.102.1.1; Sazawal S, 1997, AM J CLIN NUTR, V66, P413, DOI 10.1093/ajcn/66.2.413; SAZAWAL S, 1995, NEW ENGL J MED, V333, P839, DOI 10.1056/NEJM199509283331304; Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S	17	212	219	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2002	325	7372					1059	1062		10.1136/bmj.325.7372.1059	http://dx.doi.org/10.1136/bmj.325.7372.1059			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424162	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000179415700015
J	Benson, T				Benson, T			Why general practitioners use computers and hospital doctors do not - Part 1: incentives	BRITISH MEDICAL JOURNAL			English	Article									Abies Ltd, London NW3 1RX, England		Benson, T (corresponding author), Abies Ltd, 24 Carlingford Rd, London NW3 1RX, England.			Benson, Tim/0000-0002-2101-1353				BAKKER AR, 1978, CONCLUDING REPORT NO; BENSON T, 1991, MED INFORMATICS REPO; BRADSHAWSMITH JH, 1976, BRIT MED J, V1, P1395, DOI 10.1136/bmj.1.6022.1395; COLLINS T, 1997, CRASH 10 EASY WAYS A; DELOITTE, 2000, EMERGING EUROPEAN HL; *DEP HLTH, 2001, EL TRANSM PRESCR ETP; Department of Health, 2002, DEL 21 CENT IT SUPP; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; FOGARTY L, 1997, J INFORMATICS PRIMAR, P2; HERBERT SI, 1982, TIME DECISION COMPUT, P5; *HIMSS LEAD SURV, 2002, 13 ANN HIMSS LEAD SU; HODGE MH, 1990, HIST MED INFORM, P328; *I MED, 1997, COMP BAS PAT REC ESS; Institute of Medicine, 2001, CROSSING QUALITY CHA; KAZIMIRSKI M, COMPUTER LITERACY EL; Lindberg DonaldA.B., 1990, HIST MED INFORM, P4; MALCOLM A, 1982, COMPUTERS GEN PRACTI; *NHS INF AUTH, 2002, NHS CONN PROGR; Preece J, 2000, USE COMPUTERS GEN PR; Preece J F, 1970, Int J Biomed Comput, V1, P329, DOI 10.1016/0020-7101(70)90006-1; *ROYAL COLL GEN PR, 2000, RCGP INF SHEET OCT 2; VANBEMMEL JH, 1997, COMPUTER BASED PATIE, P21; Wanless, 2002, SECURING OUR FUTURE	23	66	66	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2002	325	7372					1086	1089		10.1136/bmj.325.7372.1086	http://dx.doi.org/10.1136/bmj.325.7372.1086			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424171	Green Published, Bronze			2022-12-28	WOS:000179415700024
J	Rothschild, B; Helbling, M; Miles, C				Rothschild, B; Helbling, M; Miles, C			Spondyloarthropathy in the Jurassic	LANCET			English	Editorial Material									Arthrit Ctr NE Ohio, Youngstown, OH 44512 USA; Natl Museum Ancient Life, Lehi, UT 84043 USA		Rothschild, B (corresponding author), Arthrit Ctr NE Ohio, Youngstown, OH 44512 USA.								0	19	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1454	1454		10.1016/S0140-6736(02)11471-1	http://dx.doi.org/10.1016/S0140-6736(02)11471-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433512				2022-12-28	WOS:000179186000009
J	Zamvar, V; Williams, D; Hall, J; Payne, N; Cann, C; Young, K; Karthikeyan, S; Dunne, J				Zamvar, V; Williams, D; Hall, J; Payne, N; Cann, C; Young, K; Karthikeyan, S; Dunne, J			Assessment of neurocognitive impairment after off-pump and on-pump techniques for coronary artery bypass graft surgery: prospective randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY BYPASS; CARDIAC-SURGERY; MICROEMBOLI; DYSFUNCTION; OPERATIONS; OUTCOMES	Objective To assess neurocognitive impairment after the off-pump and on-pump techniques for coronary artery bypass graft surgery in patients with triple vessel disease. Design Randomised controlled trial. Setting University Hospital of Wales, Cardiff. Participants 60 patients undergoing coronary artery bypass graft surgery for triple vessel disease prospectively randomised to the off-pump or on-pump technique. Main outcome measures Change in scores in nine standard neuropsychometric tests administered preoperatively and at 1 and 10 weeks postoperatively. Results The on-pump group showed a significantly greater deterioration in scores for two and three tests at 1 week and 10 weeks postoperatively, respectively, than the off-pump group. The on-pump group also showed a significantly higher incidence of major deterioration in one of the tests both I week and 10 weeks postoperatively. The incidence of neurocognitive impairment at 1 week postoperatively was 27% (8 out of 30) in the off-pump group and 63% (19 out of 30) in the on-pump group (P=0.004); and at 10 weeks postoperatively was 10% (3 out of 30) in the off-pump group and 40% (12 out of 30) in the on-pump group (P=0.017). Conclusion Off-pump coronary artery bypass graft surgery results in less neurocognitive impairment than the on-pump technique.	Univ Wales Hosp, Dept Cardiac Surg, Cardiff CF14 4XW, S Glam, Wales; Univ Wales Hosp, Dept Anaesthesiol, Cardiff CF14 4XW, S Glam, Wales; Providence Hlth Syst, Med Data Res Ctr, Portland, OR 97225 USA; UK Natl External Qual Assurance Scheme, Dept Immunol, Sheffield S5 7YT, S Yorkshire, England	Cardiff University; Cardiff University	Zamvar, V (corresponding author), Royal Infirm Edinburgh NHS Trust, Dept Cardiac Surg, Edinburgh EH3 9YW, Midlothian, Scotland.		Zamvar, Vipin/J-3430-2013	Zamvar, Vipin/0000-0003-2447-828X				Angelini GD, 2002, LANCET, V359, P1194, DOI 10.1016/S0140-6736(02)08216-8; BLAUTH CI, 1988, J THORAC CARDIOV SUR, V95, P668; Borger MA, 2001, J THORAC CARDIOV SUR, V121, P743, DOI 10.1067/mtc.2001.112526; Diegeler A, 2000, ANN THORAC SURG, V69, P1162, DOI 10.1016/S0003-4975(99)01574-X; GILLINOV AM, 1991, J THORAC CARDIOVASC, V104, P1110; HARRIS DN, 1993, LANCET, V342, P586, DOI 10.1016/0140-6736(93)91412-F; KEOGH BE, NATL ADULT CARDIAC S, P133; Lloyd CT, 2000, J THORAC CARDIOV SUR, V119, P148, DOI 10.1016/S0022-5223(00)70230-3; Mahanna EP, 1996, ANN THORAC SURG, V61, P1342, DOI 10.1016/0003-4975(95)01095-5; McKhann GM, 1997, ANN THORAC SURG, V63, P510; MURKIN JM, 1995, ANN THORAC SURG, V59, P1289, DOI 10.1016/0003-4975(95)00106-U; Nelson H., 1978, NATL ADULT READING T; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; PUGSLEY W, 1994, STROKE, V25, P1393, DOI 10.1161/01.STR.25.7.1393; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; SHAW PJ, 1989, Q J MED, V72, P633; SONTANIEMI KA, 1986, STROKE, V17, P410; Taggart DP, 1999, J THORAC CARDIOV SUR, V118, P414, DOI 10.1016/S0022-5223(99)70177-7; TAYLOR KM, 1993, CARDIAC SURG BRAIN, P1; Van Dijk D, 2002, JAMA-J AM MED ASSOC, V287, P1405, DOI 10.1001/jama.287.11.1405; Vingerhoets G, 1997, EUR J CARDIO-THORAC, V11, P424, DOI 10.1016/S1010-7940(96)01031-7; Westaby S, 2000, J THORAC CARDIOV SUR, V119, P132, DOI 10.1016/S0022-5223(00)70228-5; Zamvar VY, 2002, HEART SURG FORUM, V5, P109	23	158	160	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1268	1271		10.1136/bmj.325.7375.1268	http://dx.doi.org/10.1136/bmj.325.7375.1268			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458242	Green Published, Bronze			2022-12-28	WOS:000179696300015
J	Hauser, MD; Chomsky, N; Fitch, WT				Hauser, MD; Chomsky, N; Fitch, WT			The faculty of language: What is it, who has it, and how did it evolve?	SCIENCE			English	Review							MACACA-MULATTA; RHESUS-MONKEY; ALARM CALLS; PANGLOSSIAN PARADIGM; CHIMPANZEES KNOW; HUMAN INFANTS; SPEECH; EVOLUTION; DISCRIMINATION; PERCEPTION	We argue that an understanding of the faculty of language requires substantial interdisciplinary cooperation. We suggest how current developments in linguistics can be profitably wedded to work in evolutionary biology, anthropology, psychology, and neuroscience. We submit that a distinction should be made between the faculty of language in the broad sense (FLB) and in the narrow sense (FLN). FLB includes a sensory-motor system, a conceptual-intentional system, and the computational mechanisms for recursion, providing the capacity to generate an infinite range of expressions from a finite set of elements. We hypothesize that FLN only includes recursion and is the only uniquely human component of the faculty of language. We further argue that FLN may have evolved for reasons other than language, hence comparative studies might look for evidence of such computations outside of the domain of communication (for example, number, navigation, and social relations).	Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; MIT, Dept Linguist & Philosophy, Cambridge, MA 02138 USA	Harvard University; Massachusetts Institute of Technology (MIT)	Hauser, MD (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.	mdhauser@wjh.harvard.edu	Galantucci, Bruno/E-5770-2010; silitonga, andi/AAP-3083-2021	silitonga, andi/0000-0002-7878-6985				Barrett L., 2002, HUMAN EVOLUTIONARY P; Batali J., 1998, APPROACHES EVOLUTION; BICKERTON D, 1990, SPECIES LANGUAGE; Bloom P, 1998, TRENDS COGN SCI, V2, P67, DOI 10.1016/S1364-6613(98)01121-8; BOYSEN ST, 1989, J COMP PSYCHOL, V103, P23, DOI 10.1037/0735-7036.103.1.23; Brannon EM, 1998, SCIENCE, V282, P746, DOI 10.1126/science.282.5389.746; Brown S, 2000, ORIGINS OF MUSIC, P3; Buss David M., 1999, EVOLUTIONARY PSYCHOL; Carey S, 2001, MIND LANG, V16, P37, DOI 10.1111/1468-0017.00155; CHENEY DL, 1990, MONKEYS SEE WORLD MI; CHOMSKY N, 1956, IRE T INFORM THEOR, V2, P113; Chomsky N, 1980, RULES REPRESENTATION; Chomsky N., 1958, INF CONTROL, V1, P91, DOI [DOI 10.1016/S0019-9958(58)90082-2, 10.1016/S0019-9958(58)90082-2]; Chomsky N., 1975, REFLECTIONS LANGUAGE; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; Chomsky Noam, 1975, LOGICAL STRUCTURE LI; CHOMSKY Noam, 1986, KNOWLEDGE LANGUAGE I; Clayton NS, 1998, NATURE, V395, P272, DOI 10.1038/26216; Collins, 1997, LOCAL ECON; Darwin C., 1877, ORIGIN SPECIES; Darwin C., 1871, P475; Dawkins R., 1986, BLIND WATCHMAKER; Dehaene S., 1997, NUMBER SENSE; DENNETT DC, 1983, BEHAV BRAIN SCI, V6, P343, DOI 10.1017/S0140525X00016393; DITTUS WPJ, 1984, ANIM BEHAV, V32, P470, DOI 10.1016/S0003-3472(84)80283-3; DOOLING RJ, 1995, J ACOUST SOC AM, V97, P1839, DOI 10.1121/1.412058; Doupe AJ, 1999, ANNU REV NEUROSCI, V22, P567, DOI 10.1146/annurev.neuro.22.1.567; Dunbar R., 1996, GROOMING GOSSIP EVOL; Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025; Epstein Samuel David, 1999, WORKING MINIMALISM; Fischer J, 1998, ANIM BEHAV, V55, P799, DOI 10.1006/anbe.1997.0663; Fitch WT, 2000, ETHOLOGY, V106, P559, DOI 10.1046/j.1439-0310.2000.00572.x; Fitch WT, 1997, J ACOUST SOC AM, V102, P1213, DOI 10.1121/1.421048; Fitch WT, 2000, TRENDS COGN SCI, V4, P258, DOI 10.1016/S1364-6613(00)01494-7; Fitch WT, 2001, P ROY SOC B-BIOL SCI, V268, P1669, DOI 10.1098/rspb.2001.1704; FITCH WT, UNPUB; Gallistel CR, 1996, J EXP BIOL, V199, P211; Gallistel CR, 2000, TRENDS COGN SCI, V4, P59, DOI 10.1016/S1364-6613(99)01424-2; Gehring WJ., 1998, MASTER CONTROL GENES; Gergely G, 2002, NATURE, V415, P755, DOI 10.1038/415755a; GOLD EM, 1967, INFORM CONTROL, V10, P447, DOI 10.1016/S0019-9958(67)91165-5; GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086; GOULD SJ, 1976, EVOLUTION BRAIN BEHA, P175; GOUZOULES S, 1984, ANIM BEHAV, V32, P182, DOI 10.1016/S0003-3472(84)80336-X; Haegeman L., 1991, INTRO GOVT BINDING T; Hare B, 2000, ANIM BEHAV, V59, P771, DOI 10.1006/anbe.1999.1377; Hare B, 2001, ANIM BEHAV, V61, P139, DOI 10.1006/anbe.2000.1518; Harris ZS, 1955, LANGUAGE, V31, P190, DOI 10.2307/411036; Hauser, 1996, EVOL COMMUN; Hauser M.D., 2001, LANGUAGE BRAIN COGNI, P417; HAUSER MD, 1993, ANIM BEHAV, V45, P423, DOI 10.1006/anbe.1993.1054; Hauser MD, 1998, ANIM BEHAV, V55, P1647, DOI 10.1006/anbe.1997.0712; Hauser MD, 2002, COGNITION, V86, pB15, DOI 10.1016/S0010-0277(02)00139-7; Hauser MD, 2001, COGNITION, V78, pB53, DOI 10.1016/S0010-0277(00)00132-3; HERMAN LM, 1984, COGNITION, V16, P129, DOI 10.1016/0010-0277(84)90003-9; Heyes CM, 1998, BEHAV BRAIN SCI, V21, P101, DOI 10.1017/S0140525X98000703; Iacoboni M, 1999, SCIENCE, V286, P2526, DOI 10.1126/science.286.5449.2526; Jackendoff R, 1999, TRENDS COGN SCI, V3, P272, DOI 10.1016/S1364-6613(99)01333-9; JACKENDORFF R, 2002, FDN LANGUAGE; Janik VM, 2000, ANIM BEHAV, V60, P1, DOI 10.1006/anbe.2000.1410; Jenkins L., 2000, BIOLINGUISTICS; Kawai N, 2000, NATURE, V403, P39, DOI 10.1038/47405; Kimura D., 1993, NEUROMOTOR MECH HUMA; Kluender KR, 1998, J ACOUST SOC AM, V104, P3568, DOI 10.1121/1.423939; KLUENDER KR, 1987, SCIENCE, V237, P1195, DOI 10.1126/science.3629235; KLUENDER KR, IN PRESS LISTENING S; KUHL PK, 1982, PERCEPT PSYCHOPHYS, V32, P542, DOI 10.3758/BF03204208; KUHL PK, 1991, PERCEPT PSYCHOPHYS, V50, P93, DOI 10.3758/BF03212211; KUHL PK, 1975, SCIENCE, V190, P69, DOI 10.1126/science.1166301; Lenneberg, 1967, BIOL FDN LANGUAGE, DOI 10.1080/21548331.1967.11707799; Liberman AM, 2000, TRENDS COGN SCI, V4, P187, DOI 10.1016/S1364-6613(00)01471-6; LIBERMAN AM, 1957, J EXP PSYCHOL, V54, P358, DOI 10.1037/h0044417; LIBERMAN AM, 1967, PSYCHOL REV, V74, P431, DOI 10.1037/h0020279; LIBERMAN AM, 1996, SPEECH SPECIAL CODE; LIEBERMAN P, 1991, UNIQUELY HUMAN; Lieberman P., 1984, BIOL EVOLUTION LANGU; MacNeilage PF, 1998, BEHAV BRAIN SCI, V21, P499, DOI 10.1017/S0140525X98001265; Marcus GF, 1999, SCIENCE, V283, P77, DOI 10.1126/science.283.5398.77; MARLER P, 1970, AM SCI, V58, P669; Marler P, 1997, J NEUROBIOL, V33, P501; MARLER P, 1991, COGNITIVE ETHOLOGY M, P135; MATSUZAWA T, 1985, NATURE, V315, P57, DOI 10.1038/315057a0; MCGURK H, 1976, NATURE, V264, P746, DOI 10.1038/264746a0; MELTZOFF AN, 1994, INFANT BEHAV DEV, V17, P83, DOI 10.1016/0163-6383(94)90024-8; Nottebohm F, 1999, DESIGN OF ANIMAL COMMUNICATION, P63; Nowak MA, 2000, NATURE, V404, P495, DOI 10.1038/35006635; Nowak MA, 2001, TRENDS COGN SCI, V5, P288, DOI 10.1016/S1364-6613(00)01683-1; Nowak MA, 2001, SCIENCE, V291, P114, DOI 10.1126/science.291.5501.114; OWREN MJ, 1990, J COMP PSYCHOL, V104, P20; OWREN MJ, 1988, J ACOUST SOC AM, V83, P1927, DOI 10.1121/1.396477; PETITTO LA, 1991, SCIENCE, V251, P1493, DOI 10.1126/science.2006424; PINKER S, 1990, BEHAV BRAIN SCI, V13, P707, DOI 10.1017/S0140525X00081061; Ramus F, 2000, SCIENCE, V288, P349, DOI 10.1126/science.288.5464.349; Rendall D, 1998, J ACOUST SOC AM, V103, P602, DOI 10.1121/1.421104; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; Saffran JR, 1999, COGNITION, V70, P27, DOI 10.1016/S0010-0277(98)00075-4; Santos LR, 2002, COGNITION, V83, P241, DOI 10.1016/S0010-0277(02)00006-9; SAVAGERUMBAUGH ES, 1993, MONOGR SOC RES CHILD, V58, pR5; SEYFARTH RM, 1980, SCIENCE, V210, P801, DOI 10.1126/science.7433999; Seyfarth RM, 1999, DESIGN OF ANIMAL COMMUNICATION, P391; Sinnott JM, 1997, J ACOUST SOC AM, V102, P588, DOI 10.1121/1.419732; SLOBODCHIKOFF CN, 1991, ANIM BEHAV, V42, P713, DOI 10.1016/S0003-3472(05)80117-4; SOMMERS MS, 1992, J ACOUST SOC AM, V91, P3499, DOI 10.1121/1.402839; Studdert-Kennedy M, 1983, Hum Neurobiol, V2, P191; Studdert-Kennedy M., 1998, APPROACHES EVOLUTION, P202; Szathmary E, 1995, MAJOR TRANSITIONS EV; TERRACE HS, IN PRESS PSYCHOL SCI; Whiten Andrew, 1996, P291, DOI 10.1016/B978-012273965-1/50015-7; Williams G. C., 1966, P307; Wray A., 2002, TRANSITION LANGUAGE; WYNN K, 1992, COGNITIVE PSYCHOL, V24, P220, DOI 10.1016/0010-0285(92)90008-P; ZATORRE R, 2000, BIOL FDN MUSIC; Zuberbuhler K, 1999, J COMP PSYCHOL, V113, P33, DOI 10.1037/0735-7036.113.1.33; [No title captured]	114	2470	2547	26	933	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1569	1579		10.1126/science.298.5598.1569	http://dx.doi.org/10.1126/science.298.5598.1569			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446899	Green Submitted			2022-12-28	WOS:000179361600037
J	Leonard, JA; Wayne, RK; Wheeler, J; Valadez, R; Guillen, S; Vila, C				Leonard, JA; Wayne, RK; Wheeler, J; Valadez, R; Guillen, S; Vila, C			Ancient DNA evidence for Old World origin of New World dogs	SCIENCE			English	Article							WOLF; EVOLUTION	Mitochondrial DNA sequences isolated from ancient dog remains from Latin America and Alaska showed that native American dogs originated from multiple Old World lineages of dogs that accompanied late Pleistocene humans across the Bering Strait. One clade of dog sequences was unique to the New World, which is consistent with a period of geographic isolation. This unique clade was absent from a large sample of modern dogs, which implies that European colonists systematically discouraged the breeding of native American dogs.	Univ Calif Los Angeles, Dept Organism Biol Ecol & Evolut, Los Angeles, CA 90095 USA; CONOPA, Coordinadora Invest & Desarrollo Camelidos, Lima 19, Peru; Univ Nacl Autonoma Mexico, Inst Invest Antropol, Lab Paleozool, Mexico City 04510, DF, Mexico; Bioanthropol Fdn Peru, Ctr Mallqui, Lima 11, Peru; Uppsala Univ, Dept Evolutionary Biol, S-75236 Uppsala, Sweden	University of California System; University of California Los Angeles; Universidad Nacional Autonoma de Mexico; Uppsala University	Leonard, JA (corresponding author), Smithsonian Inst, Natl Museum Nat Hist, Dept Systemat Biol, Genet Program, 3001 Connecticut Ave NW, Washington, DC 20008 USA.	Leonard.Jennifer@NMNH.SI.edu	Vila, Carles/H-4893-2013; Leonard, Jennifer/A-7894-2010	Vila, Carles/0000-0002-4206-5246; wheeler, jane/0000-0001-9020-0660; Leonard, Jennifer/0000-0003-0291-7819				Avise J.C., 2000, PHYLOGEOGRAPHY HIST; Barnes I, 2002, SCIENCE, V295, P2267, DOI 10.1126/science.1067814; Clutton-Brock J., 1999, NATURAL HIST DOMESTI; CLUTTONBROCK J, 1994, J ZOOL, V233, P19, DOI 10.1111/j.1469-7998.1994.tb05259.x; DAYAN T, 1994, J ARCHAEOL SCI, V21, P633, DOI 10.1006/jasc.1994.1062; Derevanko A.P., 1998, PALAEOLITHIC SIBERIA, P5; Fiedel SJ, 2000, J ARCHAEOL RES, V8, P39, DOI 10.1023/A:1009400309773; Gamble C., 1999, PALAEOLITHIC SOC EUR; Goebel T, 1999, EVOL ANTHROPOL, V8, P208; GRAYSON DK, 1988, ANTR PAP AM MUS NAT, V66; Koop B.F., 2000, DOGS TIME ARCHAEOLOG, P271; MOREY DF, 1994, AM SCI, V82, P336; NOBIS G, 1979, UMSCHAU, V79, P610; Olsen S.J., 1985, ORIGINS DOMESTIC DOG; Randi E, 2002, CONSERV GENET, V3, P31; Schwartz Marion, 1997, HIST DOGS EARLY AM; Scott J.P., 1965, DOG BEHAV GENETIC BA; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; VALADEZ AZOA R., 2000, BAR INT SERIES, V889, P193; VALADEZ R, 2002, ASOC MEXI MED VET ES, V13, P6; VALADEZ R., 1999, HIST XOLOITZCUINTLE; Vila C, 1999, MOL ECOL, V8, P2089, DOI 10.1046/j.1365-294x.1999.00825.x; Vila C, 1999, J HERED, V90, P71, DOI 10.1093/jhered/90.1.71; Vila C, 1999, CONSERV BIOL, V13, P195, DOI 10.1046/j.1523-1739.1999.97425.x; Vila C, 1997, SCIENCE, V276, P1687, DOI 10.1126/science.276.5319.1687; WAYNE RK, 1987, SYST ZOOL, V36, P339, DOI 10.2307/2413399; Zarr J., 1999, BIOSTATISTICAL ANAL	27	297	321	2	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1613	1616		10.1126/science.1076980	http://dx.doi.org/10.1126/science.1076980			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446908	Green Published			2022-12-28	WOS:000179361600047
J	Redman, RS; Sheehan, KB; Stout, RG; Rodriguez, RJ; Henson, JM				Redman, RS; Sheehan, KB; Stout, RG; Rodriguez, RJ; Henson, JM			Thermotolerance generated by plant/fungal symbiosis	SCIENCE			English	Article									US Geol Survey, WFRC, Seattle, WA 98115 USA; Univ Washington, Dept Bot, Seattle, WA 98195 USA; Montana State Univ, Dept Plant Sci, Bozeman, MT 59717 USA; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA; Montana State Univ, Thermal Biol Inst, Bozeman, MT 59717 USA	United States Department of the Interior; United States Geological Survey; University of Washington; University of Washington Seattle; Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman	Rodriguez, RJ (corresponding author), US Geol Survey, WFRC, 6505 NE 65th St, Seattle, WA 98115 USA.							Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Lewis D.H., 1985, P29; Petrini O., 1986, MICROBIOLOGY PHYLLOS, P175; Redman RS, 1999, PLANT PHYSIOL, V119, P795, DOI 10.1104/pp.119.2.795; Redman RS, 2001, NEW PHYTOL, V151, P705, DOI 10.1046/j.0028-646x.2001.00210.x; Redman RS, 1999, APPL ENVIRON MICROB, V65, P5193; SIVANESAN A, 1987, MYCOL PAP, V158, P104; Smallwood MF, 1999, PLANT RESPONSES ENV; White T.J., 1990, PCR PROTOCOLS GUIDE, P315	9	450	524	5	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1581	1581		10.1126/science.1072191	http://dx.doi.org/10.1126/science.1072191			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446900	Green Submitted			2022-12-28	WOS:000179361600038
J	Friedman, ND; Kaye, KS; Stout, JE; McGarry, SA; Trivette, SL; Briggs, JP; Lamm, W; Clark, C; MacFarquhar, J; Walton, AL; Reller, LB; Sexton, DJ				Friedman, ND; Kaye, KS; Stout, JE; McGarry, SA; Trivette, SL; Briggs, JP; Lamm, W; Clark, C; MacFarquhar, J; Walton, AL; Reller, LB; Sexton, DJ			Health care-associated bloodstream infections in adults: A reason to change the accepted definition of community-acquired infections	ANNALS OF INTERNAL MEDICINE			English	Article							STAPHYLOCOCCUS-AUREUS BACTEREMIA; RESISTANT ENTEROCOCCUS-FAECIUM; METHICILLIN RESISTANCE; NOSOCOMIAL INFECTIONS; CLINICAL-SIGNIFICANCE; RISK-FACTORS; COLONIZATION; IMPACT; SURVEILLANCE; FACILITIES	Background: Bloodstream infections occurring in persons residing in the community, regardless of whether those persons have been receiving health care in an outpatient facility, have traditionally been categorized as community-acquired infections. Objective: To develop a new classification scheme for bloodstream infections that distinguishes among community-acquired, health care-associated, and nosocomial infections. Design: Prospective observational study. Setting: one academic medical center and two community hospitals. Patients: All adult patients admitted to the hospital with bloodstream infection. Measurements: Demographic characteristics, living arrangements before hospitalization, comorbid medical conditions, factors predisposing to bloodstream infection, date of hospitalization, dates and number of positive blood cultures, results of microbiological susceptibility testing, dates of hospital discharge or death, and mortality rates at 3 to 6 months of follow-up. Results: 504 patients with bloodstream infections were enrolled; 143 (28%) had community-acquired bloodstream infections, 186 (37%) had health care-associated bloodstream infections, and 175 (35%) had nosocomial bloodstream infections. Of the 186 patients with health care-associated bloodstream infection, 29 resided in a nursing home, 64 were receiving home health care, 78 were receiving intravenous or intravascular therapy at home or in a clinic, and 117 had been hospitalized in the 90 days before their bloodstream infection. Cancer was more common in patients with health care-associated or nosocomial bloodstream infection than in patients with community-acquired bloodstream infection. Intravascular devices were the most common source of health care-associated and nosocomial infections, and Staphylococcus aureus was the most frequent pathogen in these types of infections. Methicillin-resistant S. aureus occurred with similar frequency in the groups with health care-associated infection (52%) and nosocomial infection (61%) but was uncommon in the group with community-acquired bloodstream infection (14%) (P = 0.001). Mortality rate at follow-up was greater in patients with health care-associated infection (29% versus 16%; P = 0.019) or nosocomial infection (37% versus 16%; P < 0.001) than in patients with community-acquired infection. Conclusions: Health care-associated bloodstream infections are similar to nosocomial infections in terms of frequency of various comorbid conditions, source of infection, pathogens and their susceptibility patterns, and mortality rate at follow-up. A separate category for health care-associated bloodstream infections is justified, and this new category will have obvious implications for choices about empirical therapy and infection-control surveillance.	Duke Univ, Med Ctr, Div Infect Dis, Durham, NC 27710 USA; Durham Reg Hosp, Durham, NC USA; Nash Gen Hosp, Rocky Mount, NC USA	Duke University	Sexton, DJ (corresponding author), Duke Univ, Med Ctr, Div Infect Dis, Box 3605, Durham, NC 27710 USA.		Kaye, Keith/AAF-1048-2019	Stout, Jason/0000-0002-6698-8176; Sexton, Daniel J/0000-0001-9604-5948				Baden LR, 2001, CLIN INFECT DIS, V33, P1654, DOI 10.1086/323762; Beltrami EL, 2000, AM J INFECT CONTROL, V28, P282, DOI 10.1067/mic.2000.106276; BROWN RB, 1994, AM J INFECT CONTROL, V22, P149, DOI 10.1016/0196-6553(94)90003-5; Darouiche RO, 1996, CLIN INFECT DIS, V23, P260, DOI 10.1093/clinids/23.2.260; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GRAHAM DR, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90351-W; GRAHAM DR, 2000, 4 DEC INT C NOS HEAL; Henning KJ, 1996, PEDIATR INFECT DIS J, V15, P848, DOI 10.1097/00006454-199610000-00004; Horan TC, 1997, AM J INFECT CONTROL, V25, P112, DOI 10.1016/S0196-6553(97)90037-7; Jarvis WR, 1996, INFECT CONT HOSP EP, V17, P552; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; MCGOWAN JE, 1989, ANTIMICROB AGENTS CH, V33, P1855, DOI 10.1128/AAC.33.11.1855; Morin CA, 2001, J INFECT DIS, V184, P1029, DOI 10.1086/323459; *NAT COM CLIN LAB, 2001, M100S11 NCCLS; Padiglione AA, 2001, INFECT CONT HOSP EP, V22, P576, DOI 10.1086/501955; Richard P, 2001, CLIN INFECT DIS, V32, P162, DOI 10.1086/317551; Scanvic A, 2001, CLIN INFECT DIS, V32, P1393, DOI 10.1086/320151; Senthilkumar A, 2001, CLIN INFECT DIS, V33, P1412, DOI 10.1086/322656; Smith PW, 2000, AM J INFECT CONTROL, V28, P8, DOI 10.1016/S0196-6553(00)90005-1; Steinberg JP, 1996, CLIN INFECT DIS, V23, P255, DOI 10.1093/clinids/23.2.255; Stevenson KB, 2000, INFECT CONT HOSP EP, V21, P200, DOI 10.1086/501744; Warren DK, 2001, CLIN INFECT DIS, V33, P1329, DOI 10.1086/322483; Warshawsky B, 2000, INFECT CONT HOSP EP, V21, P724, DOI 10.1086/501718; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P35, DOI 10.1093/clinids/5.1.35; Weinstein RA, 2001, NEW ENGL J MED, V344, P1544, DOI 10.1056/NEJM200105173442009; 2001, SOCIAL SECURITY DEAT	27	1201	1230	0	34	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					791	797		10.7326/0003-4819-137-10-200211190-00007	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616VE	12435215				2022-12-28	WOS:000179323400002
J	Henry, D; Lexchin, J				Henry, D; Lexchin, J			The pharmaceutical industry as a medicines provider	LANCET			English	Article							CONFLICT-OF-INTEREST; DRUG DONATIONS	Rising prices of medicines are putting them beyond the reach of many people, even in rich countries. In less-developed countries, millions of individuals do not have access to essential drugs. Drug development is failing to address the major health needs of these countries. The prices of patented medicines usually far exceed the marginal costs of their production; the industry maintains that high prices and patent protection are necessary to compensate for high development costs of innovative products. There is controversy over these claims. Concerns about the harmful effects of the international system of intellectual property rights have led the World Trade Organization to relax the demands placed on least developed countries, and to advocate differential pricing of essential drugs. How these actions will help countries that lack domestic production capacity is unclear. Better access to essential drugs may be achieved through voluntary licensing arrangements between international pharmaceutical companies and manufacturers in developing countries.	Univ Newcastle, Fac Hlth, Sch Med Practice & Populat Hlth, Newcastle, NSW 2308, Australia; Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada; York Univ, Sch Hlth Policy & Management, Toronto, ON M3J 2R7, Canada	University of Newcastle; University of Toronto; York University - Canada	Henry, D (corresponding author), Newcastle Mater Hosp, Level 5,Clin Sci Bldg, Waratah, NSW 2298, Australia.	mddah@mail.newcastle.edu.au	Henry, David/AAU-4650-2020; Henry, David/AAJ-4332-2020	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242				Angell M, 2000, NEW ENGL J MED, V342, P1902, DOI 10.1056/NEJM200006223422509; [Anonymous], 2001, LANCET, V358, P1563; [Anonymous], 2001, SCRIP, V2673, P18; ARNO P, 2001, TULANE LAW REV   JAN; Arnst C, 2002, BUSINESS WEEK   0506, P30; BANTA DH, 2001, JAMA-J AM MED ASSOC, V25, P2844; BARRETT A, 2001, BUSINESS WEEK   0712; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; BOSELEY S, 2001, GUARDIAN        1010; Boulet P., 2000, PHARM WTO TRIPS AGRE; Braae R, 1999, PHARMACOECONOMICS, V16, P649, DOI 10.2165/00019053-199916060-00004; Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; COCKBURN I, 1997, PUBLIC PRIVATE INTER; *CONS PROJ TECHN, BACKGR INF 14 FDA AP; Cookson R, 2001, BRIT MED J, V323, P743, DOI 10.1136/bmj.323.7315.743; Correa C, 2002, IMPLICATIONS DOHA DE; DIMASI JA, 1995, CLIN PHARMACOL THER, V58, P1, DOI 10.1016/0009-9236(95)90066-7; DIMASI JA, 1991, J HEALTH ECON, V10, P107, DOI 10.1016/0167-6296(91)90001-4; Doha WTO Ministerial, 2001, DECL TRIPS AGR PUBL; *DRUGS NEGL DIS WO, 2001, FAT IMB CRIS RES DEV; FERIA C, 2002, SCRIP, V109, P12; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; GELLMAN B, 2000, WASHINGTON POST 1228; GELLMAN B, 2000, WASHINGTON POST 1227; GILLIS CM, 2001, PHARM CHEM HORIZONS; Grootendorst PV, 2001, CAN MED ASSOC J, V165, P1011; GUILLOUX A, HIDDEN PRICED TAGSD; Henry DA, 2001, MED J AUSTRALIA, V174, P209, DOI 10.5694/j.1326-5377.2001.tb143234.x; IMS Health, 2000, MERG DRIV DOM; *IMS HLTH, 2001, IMS HLTH DRUG MON; LAMY S, 1999, ORPHAN DRUGS FINAL R; MARTIN Y, 1999, SCRIPS COMPLETE GUID, V1; *MED SANS FRONT, MATT LIF DEATH ROL P; *MIN STAFF SPEC IN, 1999, PRESCR DRUG PRIC US; Mokhiber Russell, TOP 100 CORPORATE CR; *OFF TECHN ASS, 1993, PHARM R D COSTS RISK; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; *PHARM RES MAN AM, 2001, PHARM IND PROF 2001; *PHARM RES MAN AM, 2001, PHARM IND PRIM 2001; POLLARD S, 2001, WALL STREET J   1217; *PROD COMM, 2002, INT PHARM PRIC DIFF; Reich MR, 1999, B WORLD HEALTH ORGAN, V77, P675; Richards F, 2000, LANCET, V355, P1663, DOI 10.1016/S0140-6736(00)02235-2; Robine, LABOUR MARKET SOCIAL; SCHOUTEN E, 1995, BRIT MED J, V311, P684, DOI 10.1136/bmj.311.7006.684; SHEEHAN P, 2001, SYDNEY MORNING  0331; Sidley P, 2000, BRIT MED J, V320, P1095; Sidley P, 2001, BRIT MED J, V322, P635, DOI 10.1136/bmj.322.7287.635; Snell B, 2001, LANCET, V358, P578, DOI 10.1016/S0140-6736(01)05712-9; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; *US DEP JUST, 4 FOR EX LEAD EUR VI; *WHO, WHO MED STRAT 2000 2; *WHO, ESS DRUGS MED POL RA; *WHO, 2001, WORKSH DIDD PRIC FIN; WHO, 2002, ESS MED WHO MOD LIST; *WHO, 1999, ESS DRUGS MED POL GU	57	90	94	1	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2002	360	9345					1590	1595		10.1016/S0140-6736(02)11527-3	http://dx.doi.org/10.1016/S0140-6736(02)11527-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443614				2022-12-28	WOS:000179292400032
J	Chatterjee, M; Osborne, J; Bestetti, G; Chang, Y; Moore, PS				Chatterjee, M; Osborne, J; Bestetti, G; Chang, Y; Moore, PS			Viral IL-6-induced cell proliferation and immune evasion of interferon activity	SCIENCE			English	Article							HUMAN-HERPESVIRUS-8 ENCODES; CYTOKINE; EXPRESSION; GP130; IL-6; INTERLEUKIN-6; GROWTH; ALPHA; TRANSCRIPTION; HOMOLOGS	Lymphoma cells infected with Kaposi's sarcoma-associated herpesvirus are autocrine dependent on virus-derived interleukin-6 (IL-6), but not on cellular IL-6. During viral infection, host cells induce the antiviral factor interferon (IFN) to up-regulate p21, initiate cell cycle arrest, and inhibit virus replication. Viral IL-6, however, blocks IFN signaling. A viral transcriptional program exists in which only the viral IL-6 gene is directly activated by IFN-alpha, allowing the virus to modify its cellular environment by sensing and responding to levels of intracellular IFN signaling. The human cytokine cannot mimic this effect because IFN-alpha down-regulates the IL-6 receptor, gp80. Viral IL-6 bypasses the gp80 regulatory checkpoint by binding directly to the gp130 transducer molecule, resulting in tumor cell autocrine dependence on the viral cytokine for proliferation and survival.	Univ Pittsburgh, Inst Canc, Mol Virol Program, Hillman Canc Ctr 1 8, Pittsburgh, PA 15213 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Columbia University	Chang, Y (corresponding author), Univ Pittsburgh, Inst Canc, Mol Virol Program, Hillman Canc Ctr 1 8, 5117 Ctr Ave, Pittsburgh, PA 15213 USA.	yc70@pitt.edu; psm9@pitt.edu	Moore, Patrick/GVR-8294-2022; Moore, Patrick S./F-3960-2011; Chang, Yuan/F-4146-2011	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041	NCI NIH HHS [CA76586, CA87661] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076586, P01CA087661] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Chang J, 2000, VIROLOGY, V266, P17, DOI 10.1006/viro.1999.0077; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hideshima T, 2000, CLIN CANCER RES, V6, P1180; Jones KD, 1999, BLOOD, V94, P2871; MEURS E, 1988, EMBO J, V7, P1689, DOI 10.1002/j.1460-2075.1988.tb02997.x; Molden J, 1997, J BIOL CHEM, V272, P19625, DOI 10.1074/jbc.272.31.19625; Moore PS, 1998, TRENDS GENET, V14, P144, DOI 10.1016/S0168-9525(98)01408-5; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; Mullberg J, 2000, J IMMUNOL, V164, P4672, DOI 10.4049/jimmunol.164.9.4672; Neipel F, 1997, J VIROL, V71, P839, DOI 10.1128/JVI.71.1.839-842.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Osborne J, 1999, HUM IMMUNOL, V60, P921, DOI 10.1016/S0198-8859(99)00083-X; Parravicini C, 1997, AM J PATHOL, V151, P1517; PELSCZAR MJ, 1972, MICROBIOLOGY, P5; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SCHWABE M, 1994, J CLIN INVEST, V94, P2317, DOI 10.1172/JCI117596; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Teruya-Feldstein J, 1998, LAB INVEST, V78, P1637	27	168	181	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1432	1435		10.1126/science.1074883	http://dx.doi.org/10.1126/science.1074883			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434062				2022-12-28	WOS:000179223100055
J	Cohen, I; Navarro, V; Clemenceau, S; Baulac, M; Miles, R				Cohen, I; Navarro, V; Clemenceau, S; Baulac, M; Miles, R			On the origin of interictal activity in human temporal lobe epilepsy in vitro	SCIENCE			English	Article							BURST DISCHARGE; DENTATE GYRUS; HIPPOCAMPUS; NEURONS; SLICES; REGION; RATS	The origin and mechanisms of human interictal epileptic discharges remain unclear. Here, we describe a spontaneous, rhythmic activity initiated in the subiculum of slices from patients with temporal lobe epilepsy. Synchronous events were similar to interictal discharges of patient electroencephalograms. They were suppressed by antagonists of either glutamatergic or gamma-aminobutyric acid (GABA)-ergic signaling. The network of neurons discharging during population events comprises both subicular interneurons and a subgroup of pyramidal cells. In these pyramidal cells, GABAergic synaptic events reversed at depolarized potentials. Depolarizing GABAergic responses in neurons downstream to the sclerotic CA1 region contribute to human interictal activity.	Univ Paris 06, CHU Pitie Salpetriere, EMI 0224, F-75013 Paris, France; Hop La Pitie Salpetriere APHP, CNRS, UPR 640, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Miles, R (corresponding author), Univ Paris 06, CHU Pitie Salpetriere, EMI 0224, F-75013 Paris, France.	rmiles@biomedicale.univ-paris5.fr	Navarro, Vincent/G-1534-2013	Navarro, Vincent/0000-0003-0077-8114; Miles, Richard/0000-0001-7303-0233; Cohen, Ivan/0000-0001-6046-5289	NIMH NIH HHS [MH54671] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Cohen I, 2000, J PHYSIOL-LONDON, V524, P485, DOI 10.1111/j.1469-7793.2000.00485.x; COHEN I, UNPUB; Colder BW, 1996, J NEUROPHYSIOL, V75, P2496, DOI 10.1152/jn.1996.75.6.2496; DASILVA FHL, 1990, PHYSIOL REV, V70, P453, DOI 10.1152/physrev.1990.70.2.453; DICHTER M, 1969, J NEUROPHYSIOL, V32, P649, DOI 10.1152/jn.1969.32.5.649; ENGEL J, 1994, CURR OPIN NEUROL, V7, P140, DOI 10.1097/00019052-199404000-00010; FISHER RS, 1989, BRAIN RES REV, V14, P245, DOI 10.1016/0165-0173(89)90003-9; Greene JRT, 1997, J COMP NEUROL, V380, P395, DOI 10.1002/(SICI)1096-9861(19970414)380:3<395::AID-CNE8>3.0.CO;2-Y; Kohling R, 1998, BRAIN, V121, P1073, DOI 10.1093/brain/121.6.1073; Lehericy S, 1997, NEURORADIOLOGY, V39, P788, DOI 10.1007/s002340050507; Lewis D V, 1999, Curr Opin Neurol, V12, P197, DOI 10.1097/00019052-199904000-00011; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Parra P, 1998, NEURON, V20, P983, DOI 10.1016/S0896-6273(00)80479-1; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418, DOI 10.1152/jn.1998.79.1.418; PRINCE DA, 1967, ARCH NEUROL-CHICAGO, V16, P194, DOI 10.1001/archneur.1967.00470200082007; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Salin P, 1995, J NEUROSCI, V15, P8234; SCHWARTZKROIN PA, 1983, ANN NEUROL, V13, P249, DOI 10.1002/ana.410130305; SCHWARTZKROIN PA, 1986, EPILEPSIA, V27, P523, DOI 10.1111/j.1528-1157.1986.tb03578.x; STEWART M, 1993, J NEUROPHYSIOL, V70, P232, DOI 10.1152/jn.1993.70.1.232; Sutula T, 1998, J COMP NEUROL, V390, P578, DOI 10.1002/(SICI)1096-9861(19980126)390:4<578::AID-CNE9>3.0.CO;2-Y; Vale C, 2000, J NEUROSCI, V20, P1912; WONG RKS, 1983, J NEUROPHYSIOL, V49, P442, DOI 10.1152/jn.1983.49.2.442	24	683	698	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1418	1421		10.1126/science.1076510	http://dx.doi.org/10.1126/science.1076510			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434059				2022-12-28	WOS:000179223100051
J	Ohashi, PS				Ohashi, PS			Exposing thy self	SCIENCE			English	Editorial Material							REGULATORY T-CELLS; TOLERANCE; INDUCTION; PREVENTION; GENE		Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Dept Immunol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Ohashi, PS (corresponding author), Ontario Canc Inst, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Ohashi, Pamela S./0000-0003-2915-9317				Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Bjorses P, 1998, HUM MOL GENET, V7, P1547, DOI 10.1093/hmg/7.10.1547; Heino M, 1999, BIOCHEM BIOPH RES CO, V257, P821, DOI 10.1006/bbrc.1999.0308; HEROLD KC, 1992, J EXP MED, V176, P1107, DOI 10.1084/jem.176.4.1107; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; KYEWSKI B, TRENDS IMMUNOL, V23, P364; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; POSSELT AM, 1992, SCIENCE, V256, P1321, DOI 10.1126/science.1598576; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Sakaguchi S, 2001, NAT IMMUNOL, V2, P283, DOI 10.1038/86283; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Tung KSK, 1997, CURR OPIN IMMUNOL, V9, P839, DOI 10.1016/S0952-7915(97)80187-2	15	4	4	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1348	1349		10.1126/science.1079323	http://dx.doi.org/10.1126/science.1079323			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434042				2022-12-28	WOS:000179223100030
J	Goldbeter, A				Goldbeter, A			Computational approaches to cellular rhythms	NATURE			English	Review							CIRCADIAN-RHYTHMS; SIGNAL-TRANSDUCTION; NUMERICAL-ANALYSIS; NEGATIVE FEEDBACK; WAVE-PROPAGATION; MODEL; OSCILLATIONS; FREQUENCY; COMPLEX; CHAOS	Oscillations arise in genetic and metabolic networks as a result of various modes of cellular regulation. In view of the large number of variables involved and of the complexity of feedback processes that generate oscillations, mathematical models and numerical simulations are needed to fully grasp the molecular mechanisms and functions of biological rhythms. Models are also necessary to comprehend the transition from simple to complex oscillatory behaviour and to delineate the conditions under which they arise. Examples ranging from calcium oscillations to pulsatile intercellular communication and circadian rhythms illustrate how computational biology contributes to clarify the molecular and dynamical bases of cellular rhythms.	Free Univ Brussels, Fac Sci, Unite Chronobiol Theor, B-1050 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Goldbeter, A (corresponding author), Free Univ Brussels, Fac Sci, Unite Chronobiol Theor, Campus Plaine,CP231, B-1050 Brussels, Belgium.							Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; BELCHETZ PE, 1978, SCIENCE, V202, P631, DOI 10.1126/science.100883; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BOITEUX A, 1975, P NATL ACAD SCI USA, V72, P3829, DOI 10.1073/pnas.72.10.3829; BRETSCHNEIDER T, 1995, P NATL ACAD SCI USA, V92, P4387, DOI 10.1073/pnas.92.10.4387; CHADWICK DJ, 2000, NOV FDN S, V227; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; Doedel EJ., 1981, CONG NUMER, V30, P265; Dormann D, 2001, J CELL SCI, V114, P2513; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; DUPONT G, 1994, BIOPHYS J, V67, P2191, DOI 10.1016/S0006-3495(94)80705-2; Dupont G, 2000, FASEB J, V14, P279, DOI 10.1096/fasebj.14.2.279; Ebisawa T, 2001, EMBO REP, V2, P342, DOI 10.1093/embo-reports/kve070; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Fessard A., 1936, PROPRIETES RYTHMIQUE; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Glass L, 1988, CLOCKS CHAOS RHYTHMS; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GOLDBETER A, 1991, P NATL ACAD SCI USA, V88, P9107, DOI 10.1073/pnas.88.20.9107; Goldbeter A, 2000, Novartis Found Symp, V227, P19; GOLDBETER A, 1995, P ROY SOC B-BIOL SCI, V261, P319, DOI 10.1098/rspb.1995.0153; Goldbeter A, 2001, CHAOS, V11, P247, DOI 10.1063/1.1345727; GOLDBETER A, 1976, ANNU REV BIOPHYS BIO, V5, P449, DOI 10.1146/annurev.bb.05.060176.002313; Goldbeter A., 1996, BIOCH OSCILLATIONS C; Gonze D, 2002, P NATL ACAD SCI USA, V99, P673, DOI 10.1073/pnas.022628299; Gonze D, 2002, J THEOR BIOL, V214, P577, DOI 10.1006/jtbi.2001.2476; GOODWIN BRIAN C., 1965, ADVANCE ENZYME REGULAT, V3, P425, DOI 10.1016/0065-2571(65)90067-1; Gorbunova YV, 2002, NATURE, V418, P93, DOI 10.1038/nature00835; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HESS B, 1971, ANNU REV BIOCHEM, V40, P237, DOI 10.1146/annurev.bi.40.070171.001321; HINDMARSH PC, 1990, HORM RES, V33, P83, DOI 10.1159/000181590; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Hynne R, 2001, BIOPHYS CHEM, V94, P121; JACQUET M, UNPUB NATURE; Keener J., 1998, MATH PHYSL; KNOBIL E, 1981, NEW ENGL J MED, V305, P1582, DOI 10.1056/NEJM198112243052611; Koch C., 1998, METHODS NEURONAL MOD, DOI 10.1016/s0898-1221(98)91179-8; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; Kronauer RE, 1999, J BIOL RHYTHM, V14, P500, DOI 10.1177/074873099129001073; Kummer U, 2000, BIOPHYS J, V79, P1188, DOI 10.1016/S0006-3495(00)76373-9; Lauzeral J, 1997, P NATL ACAD SCI USA, V94, P9153, DOI 10.1073/pnas.94.17.9153; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; Leloup JC, 2001, AM J PHYSIOL-REG I, V280, pR1206, DOI 10.1152/ajpregu.2001.280.4.R1206; LELOUP JC, UNPUB P NATL ACAD SC; LI YX, 1989, BIOPHYS J, V55, P125, DOI 10.1016/S0006-3495(89)82785-7; MAKI LW, 1995, B MATH BIOL, V57, P569, DOI 10.1007/BF02460784; Maroto M, 2001, CURR TOP DEV BIOL, V51, P221, DOI 10.1016/S0070-2153(01)51007-8; MARTIEL JL, 1987, BIOPHYS J, V52, P807, DOI 10.1016/S0006-3495(87)83275-7; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; NICOLIS G, 1977, ORG NONEQUILIBRIUM S; Nielsen K, 1997, J THEOR BIOL, V186, P303, DOI 10.1006/jtbi.1996.0366; Noble D, 2002, SCIENCE, V295, P1678, DOI 10.1126/science.1069881; NOVAK B, 1993, J CELL SCI, V106, P1153; OLSEN LF, 1985, Q REV BIOPHYS, V18, P165, DOI 10.1017/S0033583500005175; Palsson E, 1996, P NATL ACAD SCI USA, V93, P1151, DOI 10.1073/pnas.93.3.1151; Petty HR, 2001, IMMUNOL RES, V23, P85, DOI 10.1385/IR:23:1:85; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reijenga KA, 2002, BIOPHYS J, V82, P99, DOI 10.1016/S0006-3495(02)75377-0; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Richardson GS, 1996, J CLIN NEUROPHYSIOL, V13, P17, DOI 10.1097/00004691-199601000-00003; Rinzel J., 1987, Lecture Notes in Biomathematics, V71, P267; Ruoff P, 2001, J THEOR BIOL, V209, P29, DOI 10.1006/jtbi.2000.2239; Schuster S, 2002, EUR J BIOCHEM, V269, P1333, DOI 10.1046/j.0014-2956.2001.02720.x; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; SHEN P, 1995, CELL CALCIUM, V17, P225, DOI 10.1016/0143-4160(95)90037-3; Smolen P, 2001, J NEUROSCI, V21, P6644, DOI 10.1523/JNEUROSCI.21-17-06644.2001; SNEYD J, 1994, AM J PHYSIOL, V266, pC293, DOI 10.1152/ajpcell.1994.266.1.C293; Spitzer NC, 2000, BIOESSAYS, V22, P811; Swillens S, 1999, P NATL ACAD SCI USA, V96, P13750, DOI 10.1073/pnas.96.24.13750; TANG YH, 1995, PHILOS T ROY SOC B, V349, P179, DOI 10.1098/rstb.1995.0102; TERMONIA Y, 1981, P NATL ACAD SCI-BIOL, V78, P2952, DOI 10.1073/pnas.78.5.2952; Thomas R., 1990, BIOL FEEDBACK; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; Tyson JJ, 2001, J THEOR BIOL, V210, P249, DOI 10.1006/jtbi.2001.2293; Tyson JJ, 2001, NAT REV MOL CELL BIO, V2, P908, DOI 10.1038/35103078; Tyson JJ, 1999, BIOPHYS J, V77, P2411, DOI 10.1016/S0006-3495(99)77078-5; Ueda HR, 2001, J THEOR BIOL, V210, P401, DOI 10.1006/jtbi.2000.2226; Vilar JMG, 2002, P NATL ACAD SCI USA, V99, P5988, DOI 10.1073/pnas.092133899; Volterra V, 1926, NATURE, V118, P558, DOI 10.1038/118558a0; Wagner C, 1998, AM J PHYSIOL-ENDOC M, V275, pE1046, DOI 10.1152/ajpendo.1998.275.6.E1046; Winfree AT., 1980, GEOMETRY BIOL TIME; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	89	437	450	2	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					238	245		10.1038/nature01259	http://dx.doi.org/10.1038/nature01259			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432409				2022-12-28	WOS:000179200900061
J	Grima, B; Lamouroux, A; Chelot, E; Papin, C; Limbourg-Bouchon, B; Rouyer, F				Grima, B; Lamouroux, A; Chelot, E; Papin, C; Limbourg-Bouchon, B; Rouyer, F			The F-box protein Slimb controls the levels of clock proteins Period and Timeless	NATURE			English	Article							DROSOPHILA CIRCADIAN CLOCK; UBIQUITIN-LIGASE COMPLEX; KINASE-I-EPSILON; KAPPA-B-ALPHA; BETA-TRCP; GENE; LIGHT; WINGLESS; RHYTHMS; PHOSPHORYLATION	The Drosophila circadian clock is driven by daily fluctuations of the proteins Period and Timeless, which associate in a complex and negatively regulate the transcription of their own genes(1,2). Protein phosphorylation has a central role in this feedback loop, by controlling Per stability in both cytoplasmic and nuclear compartments(3-6) as well as Per/Tim nuclear transfer(7,8). However, the pathways regulating degradation of phosphorylated Per and Tim are unknown. Here we show that the product of the slimb (slmb) gene(9)-a member of the F-box/WD40 protein family of the ubiquitin ligase SCF complex that targets phosphorylated proteins for degradation(10-13)-is an essential component of the Drosophila circadian clock. slmb mutants are behaviourally arrhythmic, and can be rescued by targeted expression of Slmb in the clock neurons. In constant darkness, highly phosphorylated forms of the Per and Tim proteins are constitutively present in the mutants, indicating that the control of their cyclic degradation is impaired. Because levels of Per and Tim oscillate in slmb mutants maintained in light: dark conditions, light- and clock-controlled degradation of Per and Tim do not rely on the same mechanisms.	CNRS, Inst Neurobiol Alfred Fessard, NGI, UPR 2216, F-91198 Gif Sur Yvette, France; CNRS, Ctr Genet Mol, UPR 2167, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Rouyer, F (corresponding author), CNRS, Inst Neurobiol Alfred Fessard, NGI, UPR 2216, Av Terrasse, F-91198 Gif Sur Yvette, France.		Rouyer, François/L-9043-2018	Rouyer, François/0000-0001-5641-397X				Allada R, 2001, ANNU REV NEUROSCI, V24, P1091, DOI 10.1146/annurev.neuro.24.1.1091; Blanchardon E, 2001, EUR J NEUROSCI, V13, P871, DOI 10.1046/j.0953-816x.2000.01450.x; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kaneko M, 2000, J NEUROBIOL, V43, P207, DOI 10.1002/(SICI)1097-4695(20000605)43:3<207::AID-NEU1>3.0.CO;2-0; Kloss B, 2001, NEURON, V30, P699, DOI 10.1016/S0896-6273(01)00320-8; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Miletich I, 2000, MECH DEVELOP, V93, P15, DOI 10.1016/S0925-4773(00)00256-2; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Pai LM, 1997, DEVELOPMENT, V124, P2255; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Stanewsky R, 1997, J NEUROSCI, V17, P676; Suri V, 2000, J NEUROSCI, V20, P7547; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yang ZH, 2001, NEURON, V29, P453, DOI 10.1016/S0896-6273(01)00218-5; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	30	219	223	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					178	182		10.1038/nature01122	http://dx.doi.org/10.1038/nature01122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432393				2022-12-28	WOS:000179200900046
J	Burgio, KL; Goode, PS; Locher, JL; Umlauf, MG; Roth, DL; Richter, HE; Varner, RE; Lloyd, LK				Burgio, KL; Goode, PS; Locher, JL; Umlauf, MG; Roth, DL; Richter, HE; Varner, RE; Lloyd, LK			Behavioral training with and without biofeedback in the treatment of urge incontinence in older women - A Randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-INCONTINENCE; BLADDER; EFFICACY	Context Previous research on urge urinary incontinence has demonstrated that multicomponent behavioral training with biofeedback is safe and effective, yet it has not been established whether biofeedback is an essential component that heightens therapeutic efficacy. Objective To examine the role of biofeedback in a multicomponent behavioral training program for urge incontinence in community-dwelling older women. Design Prospective, randomized controlled trial conducted from April 1, 1995, to March 30, 2001. Setting University-based outpatient continence clinic in the United States. Patients A volunteer sample of 222 ambulatory, nondemented, community-dwelling women aged 55 to 92 years with urge incontinence or mixed incontinence with urge as the predominant pattern. Patients were stratified by race, type of incontinence (urge only vs mixed), and severity (frequency of accidents). Interventions Patients were randomly assigned to receive 8 weeks (4 visits) of bio-feedback-assisted behavioral training (n=73), 8 weeks (4 visits) of behavioral training fee without biofeedback (verbal feedback based on vaginal palpation; n=74), or 8 weeks, of self-administered behavioral treatment using a self-help booklet (control condition; n=75). Main Outcome Measures Reduction in the number of incontinence episodes as documented in bladder diaries, patients' perceptions and satisfaction, and changes in quality of life. Results Intention-to-treat analysis showed that behavioral training with biofeedback yielded a mean 63.1% reduction (SD, 42.7%) in incontinence, verbal feedback a mean 69.4% reduction (SD; 32.7%), and the self-help booklet a mean 58.6% reduction (SD, 38.8%). The 3 groups were not significantly different from each other (P=.23). The groups differed significantly regarding patient satisfaction: 75.0% of the biofeedback group, 85.5% of the verbal feedback group, and 55.7% of the self-help booklet group reported being completely satisfied with treatment (P=.001). Significant improvements were seen across all 3 groups on 3 quality-of-life instruments, with no significant between-group differences. Conclusions Biofeedback to teach pelvic floor muscle control, verbal feedback based on vaginal palpation, and a self-help booklet in a first-line behavioral training program all;achieved comparable improvements in urge incontinence in community-dwelling older women. Patients' perceptions of treatment were significantly better for the 2 behavioral training interventions.	Dept Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA; Univ Alabama, Sch Med, Birmingham, AL USA; Univ Alabama, Ctr Aging, Birmingham, AL USA; Univ Alabama, Sch Nursing, Birmingham, AL USA; Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA	Geriatric Research Education & Clinical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Burgio, KL (corresponding author), Birmingham Vet Affairs Med Ctr, GRECC-11G,700 19th St S, Birmingham, AL 35233 USA.		Umlauf, Mary Grace/A-5021-2015	Locher, Julie/0000-0002-2639-6459; Richter, Holly E/0000-0001-7741-5771	NATIONAL INSTITUTE ON AGING [R01AG008010] Funding Source: NIH RePORTER; NIA NIH HHS [AG R0108010] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAIGISSMITH J, 1989, GERONTOLOGIST, V29, P229, DOI 10.1093/geront/29.2.229; Berghmans LCM, 1996, NEUROUROL URODYNAM, V15, P37, DOI 10.1002/(SICI)1520-6777(1996)15:1<37::AID-NAU4>3.0.CO;2-G; BUMP RC, 1993, OBSTET GYNECOL, V81, P421; BURGIO KL, 1985, ANN INTERN MED, V103, P507, DOI 10.7326/0003-4819-103-4-507; BURGIO KL, 1986, AM J OBSTET GYNECOL, V154, P58; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; BURGIO KL, 1989, J UROLOGY, V141, P303, DOI 10.1016/S0022-5347(17)40747-6; Burgio KL, 1989, STAYING DRY PRACTICA; BURTON JR, 1988, J AM GERIATR SOC, V36, P693, DOI 10.1111/j.1532-5415.1988.tb07170.x; CARDOZO LD, 1978, BRIT J UROL, V50, P521, DOI 10.1111/j.1464-410X.1978.tb06204.x; Derogatis L.R, 1983, SCL 90 R ADM SCORING, VII; DIOKNO AC, 1986, J UROLOGY, V136, P1022; Elser DM, 1999, NEUROUROL URODYNAM, V18, P427, DOI 10.1002/(SICI)1520-6777(1999)18:5<427::AID-NAU3>3.0.CO;2-0; ENGEL BT, 1974, NEW ENGL J MED, V290, P646, DOI 10.1056/NEJM197403212901202; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Howard D, 2000, OBSTET GYNECOL, V96, P622, DOI 10.1016/S0029-7844(00)00956-X; Hunskaar S, 2000, INT UROGYNECOL J, V11, P301, DOI 10.1007/s001920070021; Locher JL, 2001, J GERONTOL A-BIOL, V56, pM32, DOI 10.1093/gerona/56.1.M32; Shepherd A M, 1983, Physiotherapy, V69, P113; SHUMAKER SA, 1994, QUAL LIFE RES, V3, P291, DOI 10.1007/BF00451721; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wein AJ, 1998, UROLOGY, V51, P43, DOI 10.1016/S0090-4295(98)90009-7; [No title captured]	24	190	191	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2293	2299		10.1001/jama.288.18.2293	http://dx.doi.org/10.1001/jama.288.18.2293			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425706	Bronze			2022-12-28	WOS:000179186400028
J	Muntoni, F; Brockington, M; Blake, DJ; Torelli, S; Brown, SC				Muntoni, F; Brockington, M; Blake, DJ; Torelli, S; Brown, SC			Defective glycosylation in muscular dystrophy	LANCET			English	Review							ALPHA-DYSTROGLYCAN; BASAL LAMINA; DEFICIENCY; MUTATIONS; GENE; GLYCOSYLTRANSFERASE; OLIGOSACCHARIDES; DISORDER	Context Over the past 15 years the causative genes of several inherited muscular dystrophies have been identified. These genes encode sarcolemmal, extracellular matrix, sarcomeric, and nuclear envelope proteins. Although the post-translational processing of muscle proteins has a significant role in their correct assembly and function, these processes have not been shown to be primarily involved in the pathogenesis of muscular dystrophies until recently. In the past 18 months, four different forms of inherited muscular dystrophy in human beings have been associated with mutation in genes encoding for putative glycosyltransferases. Aberrant glycosylation of alpha-dystroglycan, an external membrane protein expressed in muscle, brain, and other tissues, is a common feature in these disorders, alpha-dystroglycan is highly glycosylated, its sugar component varying in different tissues and controlling its interaction with extracellular matrix partners. Disrupted glycosylation of alpha-dystroglycan results in a loss of these interaction giving rise to both progressive muscle degeneration and abnormal neuronal migration in the brain. Starting point Kevin Campbell and colleagues have recently demonstrated that patients with muscle-eye-brain disease (MEB) and Fukuyama congenital muscular dystrophy (FCMD), as well as the myodystrophy (myd) mouse, have an abnormally glycosyated form of alpha-dystroglycan (Nature 2002; 418: 417-22 and 422-25). The abnormally glycosylated protein did not bind to three of its extracellular matrix ligands, laminin alpha2 chain, agrin, and neurexin. The investigators also showed that a neuronal migration disorder occurs in both the myd mouse and in a brain-restricted alpha-dystrolyglycan knock-out mouse that is similar to that seen patients with MEB and FCMD. These results identify alpha-dystroglycan as having an essential role in both muscle and brain development and function. Where next Emphasis is moving away from identifying the protein components of the muscle fibre that are involved in muscular dystrophies towards the post-translational processing of proteins and the enzymes involved in these modifications. This opens up new avenues of research. Abnormal glycosylation of alpha-dystroglycan may underlie other as yet uncharacterised forms of muscular dystrophy and neuronal migration disorders .	Univ London Imperial Coll Sci Technol & Med, Dept Paediat, Dubowitz Neuromuscular Ctr, London W12 0NN, England; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	Imperial College London; University of London; University College London; University of Oxford	Muntoni, F (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Paediat & Neonatal Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	f.muntoni@ic.ac.uk		Brown, Sue/0000-0001-8112-933X				Brockington M, 2001, HUM MOL GENET, V10, P2851, DOI 10.1093/hmg/10.25.2851; Brockington M, 2001, AM J HUM GENET, V69, P1198, DOI 10.1086/324412; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chiba A, 1997, J BIOL CHEM, V272, P2156; Currier S, 2002, AM J HUM GENET, V71, P258; Endo T, 1999, BBA-GEN SUBJECTS, V1473, P237, DOI 10.1016/S0304-4165(99)00182-8; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Haltia M, 1997, ANN NEUROL, V41, P173, DOI 10.1002/ana.410410208; Hansske B, 2002, J CLIN INVEST, V109, P725, DOI 10.1172/JCI200214010; Hayashi YK, 2001, NEUROLOGY, V57, P115, DOI 10.1212/WNL.57.1.115; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Ishii H, 1997, NEUROMUSCULAR DISORD, V7, P191, DOI 10.1016/S0960-8966(97)00462-8; Jaeken J, 2001, ANNU REV GENOM HUM G, V2, P129, DOI 10.1146/annurev.genom.2.1.129; JAEKEN J, 1980, PEDIATR RES, V14, P179, DOI 10.1203/00006450-198002000-00117; Kano H, 2002, BIOCHEM BIOPH RES CO, V291, P1283, DOI 10.1006/bbrc.2002.6608; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Minetti C, 1996, NEUROLOGY, V46, P1354, DOI 10.1212/WNL.46.5.1354; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wibawa T, 2002, TROP MED INT HEALTH, V7, P631, DOI 10.1046/j.1365-3156.2002.00908.x; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3	27	116	119	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 2	2002	360	9343					1419	1421		10.1016/S0140-6736(02)11397-3	http://dx.doi.org/10.1016/S0140-6736(02)11397-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12424008				2022-12-28	WOS:000179081600034
J	Floyd, JS; Tolstoy, M; Mutter, JC; Scholz, CH				Floyd, JS; Tolstoy, M; Mutter, JC; Scholz, CH			Seismotectonics of mid-ocean ridge propagation in Hess Deep	SCIENCE			English	Article							GALAPAGOS TRIPLE JUNCTION; MIDOCEAN RIDGES; PACIFIC-OCEAN; EAST PACIFIC; FAULT GROWTH; TECTONICS; SHEAR	Hydroacoustic data from the eastern equatorial Pacific reveal low-magnitude seismicity concentrated at the propagating tip of the Galapagos Rise in Hess Deep. The patterns of seismicity and faulting are similar to those observed in the process zone of laboratory-scale propagating tensile cracks. Because the fracture energy required for propagation scales with crack length and process zone size, it follows that ridges can propagate stably in the brittle crust without exceptional resisting forces as proposed by previous models based on linear elastic fracture mechanics.	Columbia Univ, Dept Earth & Environm Sci, Palisades, NY 10964 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Columbia Univ, Earth Inst, Palisades, NY 10964 USA	Columbia University; Columbia University; Columbia University	Floyd, JS (corresponding author), Columbia Univ, Dept Earth & Environm Sci, 61 Route 9W, Palisades, NY 10964 USA.	jsfloyd@ldeo.columbia.edu						Allan J., 1993, P ODP INIT REPTS, P5, DOI [10.2973/odp.proc.ir.147.101.1993, DOI 10.2973/ODP.PROC.IR.147.101.1993]; Bohnenstiehl DR, 2002, TECTONOPHYSICS, V354, P49, DOI 10.1016/S0040-1951(02)00289-5; BUCK WR, 1988, TECTONICS, V7, P213, DOI 10.1029/TC007i002p00213; COWIE PA, 1992, J STRUCT GEOL, V14, P1133, DOI 10.1016/0191-8141(92)90065-5; Crouch SL, 1983, BOUNDARY ELEMENT MET, DOI DOI 10.1115/1.3167130; DAWERS NH, 1993, GEOLOGY, V21, P1107, DOI 10.1130/0091-7613(1993)021<1107:GONFDL>2.3.CO;2; Delaney JR, 1998, SCIENCE, V281, P222, DOI 10.1126/science.281.5374.222; DZIEWONSKI AM, 1990, PHYS EARTH PLANET IN, V62, P185, DOI 10.1016/0031-9201(90)90165-T; Floyd JS, 2001, NATURE, V411, P779, DOI 10.1038/35081040; Fox CG, 2001, J GEOPHYS RES-SOL EA, V106, P4183, DOI 10.1029/2000JB900404; FRANCHETEAU J, 1990, EARTH PLANET SC LETT, V101, P281, DOI 10.1016/0012-821X(90)90160-Y; Griffith A.A., 1921, PHILOS T R SOC LOND, V221, P163, DOI [10.1098/rsta.1921.0006, DOI 10.1098/RSTA.1921.0006]; HEY RN, 1972, NATURE, V237, P20, DOI 10.1038/237020a0; HEY RN, 1980, J GEOPHYS RES, V85, P2647; HOLDEN JC, 1972, NATURE, V235, P266, DOI 10.1038/235266a0; KARSON JA, 2002, G CUBED, V3; KING GCP, 1994, B SEISMOL SOC AM, V84, P935; LOCKNER DA, 1991, NATURE, V350, P39, DOI 10.1038/350039a0; LONSDALE P, 1988, J GEOPHYS RES, V93, P13511; MACDONALD KC, 1991, SCIENCE, V253, P986, DOI 10.1126/science.253.5023.986; MORGAN JP, 1985, J GEOPHYS RES-SOLID, V90, P8603, DOI 10.1029/JB090iB10p08603; OKADA Y, 1992, B SEISMOL SOC AM, V82, P1018; PARMENTIER EM, 1989, GEOPHYS RES LETT, V16, P183, DOI 10.1029/GL016i002p00183; RECHES Z, 1994, J GEOPHYS RES-SOL EA, V99, P18159, DOI 10.1029/94JB00115; SCHMITZ W, 1982, MAR GEOL, V46, pM17, DOI 10.1016/0025-3227(82)90149-9; Scholz C.H., 2002, MECH EARTHQUAKES FAU, DOI 10.1017/CBO9780511818516; SEARLE RC, 1986, MAR GEOPHYS RES, V8, P95; Smith WHF, 1997, SCIENCE, V277, P1956, DOI 10.1126/science.277.5334.1956; Toda S, 2000, GEOPHYS RES LETT, V27, P2301, DOI 10.1029/1999GL011129; Tolstoy I, 1950, B SEISMOL SOC AM, V40, P25; Vermilye JM, 1998, J GEOPHYS RES-SOL EA, V103, P12223, DOI 10.1029/98JB00957; ZONENSHAIN LP, 1980, MAR GEOL, V37, P209, DOI 10.1016/0025-3227(80)90102-4	32	9	10	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1765	1768		10.1126/science.1077950	http://dx.doi.org/10.1126/science.1077950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459584				2022-12-28	WOS:000179494800038
J	Head, JN; Melosh, HJ; Ivanov, BA				Head, JN; Melosh, HJ; Ivanov, BA			Martian meteorite launch: High-speed ejecta from small craters	SCIENCE			English	Article							IMPACT EJECTA; SHERGOTTITE; CHASSIGNY; ORIGIN; TIMES; MARS	We performed high-resolution computer simulations of impacts into homogeneous and layered martian terrain analogs to try to account for the ages and characteristics of the martian meteorite collection found on Earth. We found that craters as small as similar to3 kilometers can eject similar to10(7) decimeter-sized fragments from Mars, which is enough to expect those fragments to appear in the terrestrial collection. This minimum crater diameter is at least four times smaller than previous estimates and depends on the physical composition of the target material. Terrain covered by a weak layer such as an impact-generated regolith requires larger, therefore rarer, impacts to eject meteorites. Because older terrain is more likely to be mantled with such material, we estimate that the martian meteorites will be biased toward younger ages, which is consistent with the meteorite collection.	Univ Arizona, Dept Planetary Sci, Tucson, AZ 85721 USA; Raytheon Missile Syst, Tucson, AZ 85734 USA; Russian Acad Sci, Inst Dynam Geospheres, Moscow 117939, Russia	University of Arizona; Russian Academy of Sciences; Sadovsky Institute of Geosphere Dynamics of the Russian Academy of Sciences	Head, JN (corresponding author), Univ Arizona, Dept Planetary Sci, 1629 E Univ Blvd, Tucson, AZ 85721 USA.		Ivanov, Boris A/E-1413-2016	Ivanov, Boris A/0000-0002-9938-9428				Amsden A.A., 1980, LA8095 LOS AL NAT LA; Bottke W.F., 1994, HAZARDS DUE COMETS A, P337; Eugster O, 1997, GEOCHIM COSMOCHIM AC, V61, P2749, DOI 10.1016/S0016-7037(97)00115-4; Folco L, 1999, METEORIT PLANET SCI, V34, pA36; Gladman B, 1997, ICARUS, V130, P228, DOI 10.1006/icar.1997.5828; Gladman BJ, 1996, SCIENCE, V271, P1387, DOI 10.1126/science.271.5254.1387; Grossman JN, 1999, METEORIT PLANET SCI, V34, pA169, DOI 10.1111/j.1945-5100.1999.tb01762.x; Hartmann WK, 1999, METEORIT PLANET SCI, V34, P167, DOI 10.1111/j.1945-5100.1999.tb01743.x; HEAD J, 1995, EAS, V76, pF336; Head J.W., 2000, 31 LUN PLAN SCI C; HEAD JN, 2001, 32 LUN PLAN SCI C; IVANOV BA, 2001, CHRONOLOGY EVOLUTION, P87, DOI DOI 10.1007/978-94-017-1035-0_4; JAGOUTZ E, 1999, LUNAR PLANET SCI, V30, P1808; Kojima H., 1997, ANTARCT METEORITE RE, V10, P3; Langenhorst F, 1999, METEORIT PLANET SCI, V34, P43, DOI 10.1111/j.1945-5100.1999.tb01730.x; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; Melosh H.J., 1989, OXFORD MONOGRAPHS GE; MELOSH HJ, 1984, ICARUS, V59, P234, DOI 10.1016/0019-1035(84)90026-5; MELOSH HJ, 1992, J GEOPHYS RES-PLANET, V97, P14735, DOI 10.1029/92JE01632; MELOSH HJ, 1991, ADV SPACE RES-SERIES, V11, P87, DOI 10.1016/0273-1177(91)90235-C; NAGAO K, 1997, ANTARCT METEORITE RE, V10, P125; NISHIIZUMI K, 1999, 30 LUN PLAN SCI C; Nyquist LE, 1998, J GEOPHYS RES-PLANET, V103, P31445, DOI 10.1029/98JE01965; SATTERWHITE C, 1991, ANTARCT METEORITE NE, V14; Schmidt R.M., 1987, INT J IMPACT ENG, V5, P543, DOI [DOI 10.1016/0734-743X(87)90069-8, 10.1016/0734-743X(87)90069-8]; SCORE R, 1995, ANTARCT METEORITE NE, V18; SCORE R, 1990, ANTARCT METEORITE NE, V13; Tanaka K. L., 1992, MARS, P345; Terribilini D, 1998, METEORIT PLANET SCI, V33, P677, DOI 10.1111/j.1945-5100.1998.tb01673.x; Treiman AH, 1998, METEORIT PLANET SCI, V33, P753, DOI 10.1111/j.1945-5100.1998.tb01681.x; TREIMAN AH, 1995, J GEOPHYS RES-PLANET, V100, P5329, DOI 10.1029/94JE02184; VICKERY AM, 1987, SCIENCE, V237, P738, DOI 10.1126/science.237.4816.738; VONNEUMANN J, 1950, J APPL PHYS, V21, P232, DOI 10.1063/1.1699639; WARREN PH, 1994, ICARUS, V111, P338, DOI 10.1006/icar.1994.1149; WETHERILL GW, 1984, METEORITICS, V19, P1; Wood C.A., 1981, P LUNAR PLANET SCI C, V12B, P1359	36	141	142	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1752	1756		10.1126/science.1077483	http://dx.doi.org/10.1126/science.1077483			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12424385				2022-12-28	WOS:000179494800034
J	Percy, KE; Awmack, CS; Lindroth, RL; Kubiske, ME; Kopper, BJ; Isebrands, JG; Pregitzer, KS; Hendrey, GR; Dickson, RE; Zak, DR; Oksanen, E; Sober, J; Harrington, R; Karnosky, DF				Percy, KE; Awmack, CS; Lindroth, RL; Kubiske, ME; Kopper, BJ; Isebrands, JG; Pregitzer, KS; Hendrey, GR; Dickson, RE; Zak, DR; Oksanen, E; Sober, J; Harrington, R; Karnosky, DF			Altered performance of forest pests under atmospheres enriched by CO2 and O-3	NATURE			English	Article							CARBON-DIOXIDE; ASPEN; MANAGEMENT; RESPONSES; SYSTEMS; GROWTH	Human activity causes increasing background concentrations of the greenhouse gases CO2 and O-3(1). Increased levels of CO2 can be found in all terrestrial ecosystems(2). Damaging O-3 concentrations currently occur over 29% of the world's temperate and subpolar forests but are predicted to affect fully 60% by 2100 (ref. 3). Although individual effects of CO2 and O-3 on vegetation have been widely investigated, very little is known about their interaction, and long-term studies on mature trees and higher trophic levels are extremely rare(4). Here we present evidence from the most widely distributed North American tree species(5), Populus tremuloides, showing that CO2 and O-3, singly and in combination, affected productivity, physical and chemical leaf defences and, because of changes in plant quality, insect and disease populations. Our data show that feedbacks to plant growth from changes induced by CO2 and O-3 in plant quality and pest performance are likely. Assessments of global change effects on forest ecosystems must therefore consider the interacting effects of CO2 and O-3 on plant performance, as well as the implications of increased pest activity.	Canadian Forest Serv, Atlantic Forestry Ctr, Nat Resources Canada, Fredericton, NB E3B 5P7, Canada; Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA; US Forest Serv, N Cent Res Stn, Rhinelander, WI 54501 USA; Michigan Technol Univ, Sch Forest Resources & Environm Sci, Houghton, MI 49931 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA; Univ Kuopio, Dept Ecol & Environm Sci, FIN-70211 Kuopio, Finland; Rothamsted Res, Plant & Invertebrate Ecol Div, Harpenden AL5 2JQ, Herts, England	Natural Resources Canada; Canadian Forest Service; University of Wisconsin System; University of Wisconsin Madison; United States Department of Agriculture (USDA); United States Forest Service; Michigan Technological University; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Michigan System; University of Michigan; University of Eastern Finland; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Percy, KE (corresponding author), Canadian Forest Serv, Atlantic Forestry Ctr, Nat Resources Canada, Fredericton, NB E3B 5P7, Canada.		Lindroth, Richard L/A-8538-2009; Zak, Donald R/C-6004-2012	Lindroth, Richard L/0000-0003-4587-7255; Oksanen, Elina/0000-0002-1866-736X; Zak, Donald/0000-0002-9730-7337				Awmack CS, 2002, ANNU REV ENTOMOL, V47, P817, DOI 10.1146/annurev.ento.47.091201.145300; BARNOLA JM, 1995, TELLUS B, V47, P264, DOI 10.1034/j.1600-0889.47.issue1.22.x; Ciais P, 2000, ECOL APPL, V10, P1574, DOI 10.1890/1051-0761(2000)010[1574:RBCFAI]2.0.CO;2; David AJ, 2001, FOREST CHRON, V77, P525, DOI 10.5558/tfc77525-3; Davis C., 1997, FIELD GUIDE TREE DIS; Dickson RE, 1998, CAN J FOREST RES, V28, P1706, DOI 10.1139/cjfr-28-11-1706; DICKSON RE, 2000, NC214 USDA FOR SERV; Eigenbrode S.D., 1996, PLANT CUTICLES AN IN, P201; Finlayson-Pitts B.J., 1999, CHEM UPPER LOWER ATM; FITZGERALD TD, 1995, TENT CATERPILLARS; Fowler D, 1999, WATER AIR SOIL POLL, V116, P5, DOI 10.1023/A:1005249231882; Hendrey GR, 1999, GLOBAL CHANGE BIOL, V5, P293, DOI 10.1046/j.1365-2486.1999.00228.x; HOLLOWAY PJ, 1969, J SCI FOOD AGR, V20, P124, DOI 10.1002/jsfa.2740200214; IPCC, 2001, 3 ASSESSMENT REPORT; *IPCC SECR INT PAN, 2001, IPCC CLIM CHANG 2001; Isebrands JG, 2001, ENVIRON POLLUT, V115, P359, DOI 10.1016/S0269-7491(01)00227-5; Jeffree C. E, 1996, PLANT CUTICLES INTEG, P33; Karnosky DF, 2002, GLOBAL CHANGE BIOL, V8, P329, DOI 10.1046/j.1354-1013.2002.00479.x; Karnosky DF, 1999, WATER AIR SOIL POLL, V116, P311, DOI 10.1023/A:1005276824459; Lindroth RL, 1996, RECENT ADV PHYTOCHEM, V30, P25; LINDROTH RL, 1993, ECOLOGY, V74, P763, DOI 10.2307/1940804; Martineau R., 1984, INSECTS HARMFUL FORE; McLaughlin S, 1999, WATER AIR SOIL POLL, V116, P151, DOI 10.1023/A:1005215112743; MENDGEN K, 1996, PLANT CUTICLES, P175; Parry D, 2001, ECOL ENTOMOL, V26, P281, DOI 10.1046/j.1365-2311.2001.00319.x; Perala D.A., 1990, SILVICS N AM HARDWOO, P555; Percy KE, 1994, AIR POLLUTANTS LEAF, V36, P67; Tuskan GA, 2001, FOREST CHRON, V77, P259, DOI 10.5558/tfc77259-2; *USDA FOR SERV, 2001, APH; ZILLER WG, 1974, CANADIAN FORESTRY SE, V1329	30	219	245	1	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					403	407		10.1038/nature01028	http://dx.doi.org/10.1038/nature01028			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459738	Green Published			2022-12-28	WOS:000179494700036
J	Hergott, LJ				Hergott, LJ			Playing the Moonlight Sonata from memory - Celebrating the wonders of our difficult life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Campbell Joseph, 1988, POWER MYTH; Hergott LJ, 2001, JAMA-J AM MED ASSOC, V285, P1938, DOI 10.1001/jama.285.15.1938; Hergott LJ, 1998, ANN INTERN MED, V128, P149, DOI 10.7326/0003-4819-128-2-199801150-00013	3	4	4	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2002	288	20					2516	2517		10.1001/jama.288.20.2516	http://dx.doi.org/10.1001/jama.288.20.2516			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AL	12444844				2022-12-28	WOS:000179394500001
J	Whitty, CJM; Rowland, M; Sanderson, F; Mutabingwa, TK				Whitty, CJM; Rowland, M; Sanderson, F; Mutabingwa, TK			Science, medicine, and the future - Malaria	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IMPREGNATED BEDNETS; FALCIPARUM-MALARIA; ANOPHELES-GAMBIAE; GENOME SEQUENCE; PLASMODIUM; RESISTANT; INSECTICIDES; DAPSONE		London Sch Hyg & Trop Med, Gates Malaria Partnership, London WC1B 3DP, England; John Radcliffe Hosp, Nuffield Dept Med, Oxford OX2 9DU, England; Natl Inst Med Res, Dar Es Salaam, Tanzania	University of London; London School of Hygiene & Tropical Medicine; University of Oxford; National Institute of Medical Research	Whitty, CJM (corresponding author), London Sch Hyg & Trop Med, Gates Malaria Partnership, London WC1B 3DP, England.		Whitty, Christopher/C-7740-2012	Whitty, Christopher/0000-0002-6076-5027				Chandre F, 1999, B WORLD HEALTH ORGAN, V77, P230; Curtis CF, 1998, PHILOS T ROY SOC B, V353, P1769, DOI 10.1098/rstb.1998.0329; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Good MF, 2001, NAT REV IMMUNOL, V1, P117, DOI 10.1038/35100540; Hargreaves K, 2000, MED VET ENTOMOL, V14, P181, DOI 10.1046/j.1365-2915.2000.00234.x; Hay SI, 2002, NATURE, V415, P905, DOI 10.1038/415905a; HEWITT S, 1995, MED VET ENTOMOL, V9, P344, DOI 10.1111/j.1365-2915.1995.tb00002.x; Hoffman SL, 2002, NATURE, V415, P702, DOI 10.1038/415702a; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Kolaczinski JH, 2000, B ENTOMOL RES, V90, P125; LENGELER C, 2002, COCHRANE LIB; Lycett GJ, 2002, NATURE, V417, P387, DOI 10.1038/417387a; Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9; Mutabingwa TK, 2001, T ROY SOC TROP MED H, V95, P433, DOI 10.1016/S0035-9203(01)90207-X; N'Guessan R, 2001, MED VET ENTOMOL, V15, P97, DOI 10.1046/j.1365-2915.2001.00284.x; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; Rogers DJ, 2002, NATURE, V415, P710, DOI 10.1038/415710a; Rowland M, 1999, T ROY SOC TROP MED H, V93, P465, DOI 10.1016/S0035-9203(99)90341-3; Rowland M, 2001, LANCET, V357, P1837, DOI 10.1016/S0140-6736(00)04955-2; Rowland M, 2001, ANN TROP MED PARASIT, V95, P741, DOI 10.1080/00034980120103405; Schellenberg JRMA, 2001, LANCET, V357, P1241, DOI 10.1016/S0140-6736(00)04404-4; van Vugt M, 2000, T ROY SOC TROP MED H, V94, P545, DOI 10.1016/S0035-9203(00)90082-8; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; Zaim M, 2002, TRENDS PARASITOL, V18, P161, DOI 10.1016/S1471-4922(01)02220-6	25	24	24	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	2002	325	7374					1221	1224		10.1136/bmj.325.7374.1221	http://dx.doi.org/10.1136/bmj.325.7374.1221			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446541	Green Accepted, Green Published			2022-12-28	WOS:000179506200024
J	Park, Y; Kelley, RL; Oh, H; Kuroda, MI; Meller, VH				Park, Y; Kelley, RL; Oh, H; Kuroda, MI; Meller, VH			Extent of chromatin spreading determined by roX RNA recruitment of MSL proteins	SCIENCE			English	Article							DOSAGE COMPENSATION COMPLEX; X-CHROMOSOME; HISTONE H3; ENTRY SITE; LYSINE 9; DROSOPHILA; GENES	The untranslated roX1 and roX2 RNAs are components of the Drosophila male-specific lethal (MSL) complex, which modifies histones to up-regulate transcription of the male X chromosome. roX genes are normally located on the X chromosome, and roX transgenes can misdirect the dosage compensation machinery to spread locally on other chromosomes. Here we de. ne MSL protein abundance as a determinant of whether the MSL complex will spread in cis from an autosomal roX transgene. The number of expressed roX genes in a nucleus was inversely correlated with spreading from roX transgenes. We suggest a model in which MSL proteins assemble into active complexes by binding nascent roX transcripts. When MSL protein/roX RNA ratios are high, assembly will be efficient, and complexes may be completed while still tethered to the DNA template. We propose that this local production of MSL complexes determines the extent of spreading into flanking chromatin.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; Tufts Univ, Dept Biol, Medford, MA 02155 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Tufts University	Kuroda, MI (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045744, R01GM058427, R01GM045744] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58427, GM45744] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; Bhadra U, 1999, GENETICS, V152, P249; Chang KA, 1998, GENETICS, V150, P699; Choi KW, 1996, P NATL ACAD SCI USA, V93, P5737, DOI 10.1073/pnas.93.12.5737; Franke A, 1999, MOL CELL, V4, P117, DOI 10.1016/S1097-2765(00)80193-8; Henry RA, 2001, J BIOL CHEM, V276, P31953, DOI 10.1074/jbc.M103008200; Ho YG, 2002, MOL CELL, V9, P291, DOI 10.1016/S1097-2765(02)00447-1; Kageyama Y, 2001, EMBO J, V20, P2236, DOI 10.1093/emboj/20.9.2236; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lucchesi JC, 1998, CURR OPIN GENET DEV, V8, P179, DOI 10.1016/S0959-437X(98)80139-1; Meller VH, 2000, CURR BIOL, V10, P136, DOI 10.1016/S0960-9822(00)00311-0; Meller VH, 2002, EMBO J, V21, P1084, DOI 10.1093/emboj/21.5.1084; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Netter S, 1998, GENETICS, V149, P257; Park Y, 2001, SCIENCE, V293, P1083, DOI 10.1126/science.1063073; Park Y. I., UNPUB; Wang YM, 2001, CELL, V105, P433, DOI 10.1016/S0092-8674(01)00325-7	21	103	103	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1620	1623		10.1126/science.1076686	http://dx.doi.org/10.1126/science.1076686			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446910				2022-12-28	WOS:000179361600049
J	Stelling, J; Klamt, S; Bettenbrock, K; Schuster, S; Gilles, ED				Stelling, J; Klamt, S; Bettenbrock, K; Schuster, S; Gilles, ED			Metabolic network structure determines key aspects of functionality and regulation	NATURE			English	Article							ESCHERICHIA-COLI; BIOCHEMICAL NETWORKS; COMPLEX NETWORKS; PATHWAY; DEFINITION; TRANSCRIPTOME; CAPABILITIES; ORGANIZATION	The relationship between structure, function and regulation in complex cellular networks is a still largely open question(1-3). Systems biology aims to explain this relationship by combining experimental and theoretical approaches(4). Current theories have various strengths and shortcomings in providing an integrated, predictive description of cellular networks. Specifically, dynamic mathematical modelling of large-scale networks meets difficulties because the necessary mechanistic detail and kinetic parameters are rarely available. In contrast, structure-oriented analyses only require network topology, which is well known in many cases. Previous approaches of this type focus on network robustness(5) or metabolic phenotype(2,6), but do not give predictions on cellular regulation. Here, we devise a theoretical method for simultaneously predicting key aspects of network functionality, robustness and gene regulation from network structure alone. This is achieved by determining and analysing the non-decomposable pathways able to operate coherently at steady state (elementary flux modes). We use the example of Escherichia coli central metabolism to illustrate the method.	Max Planck Inst Dynam Complex Tech Syst, D-39106 Magdeburg, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Stelling, J (corresponding author), Max Planck Inst Dynam Complex Tech Syst, D-39106 Magdeburg, Germany.		Stelling, Joerg/F-7499-2010; Bettenbrock, Katja/AAN-5812-2020	Stelling, Joerg/0000-0002-1145-891X; Klamt, Steffen/0000-0003-2563-7561				Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Bilke S, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.036106; Canonaco F, 2001, FEMS MICROBIOL LETT, V204, P247, DOI 10.1111/j.1574-6968.2001.tb10892.x; Cleveland WS., 1993, VISUALIZING DATA; Cornish-Bowden A, 2001, TRENDS BIOCHEM SCI, V26, P463, DOI 10.1016/S0968-0004(01)01920-X; Covert MW, 2002, J BIOL CHEM, V277, P28058, DOI 10.1074/jbc.M201691200; Dandekar T, 1999, BIOCHEM J, V343, P115, DOI 10.1042/0264-6021:3430115; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Ge H, 2001, NAT GENET, V29, P482, DOI 10.1038/ng776; Heinrich R., 1996, REGULATION CELLULAR; Holter NS, 2000, P NATL ACAD SCI USA, V97, P8409, DOI 10.1073/pnas.150242097; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; KLAMT S, IN PRESS BIOINFORMAT; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Oh MK, 2000, BIOTECHNOL PROGR, V16, P278, DOI 10.1021/bp000002n; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Schilling CH, 2000, J THEOR BIOL, V203, P229, DOI 10.1006/jtbi.2000.1073; Schuster S, 2000, NAT BIOTECHNOL, V18, P326, DOI 10.1038/73786; Schuster S, 1999, TRENDS BIOTECHNOL, V17, P53, DOI 10.1016/S0167-7799(98)01290-6; Stelling J., 2001, P 2 INT C SYST BIOL, P181; Stelling Jorg, 2001, P189; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; ter Kuile BH, 2001, FEBS LETT, V500, P169, DOI 10.1016/S0014-5793(01)02613-8; Van Dien SJ, 2002, BIOTECHNOL BIOENG, V78, P296, DOI 10.1002/bit.10200; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085	29	552	583	5	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					190	193		10.1038/nature01166	http://dx.doi.org/10.1038/nature01166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432396				2022-12-28	WOS:000179200900049
J	Petticrew, M; Bell, R; Hunter, D				Petticrew, M; Bell, R; Hunter, D			Influence of psychological coping on survival and recurrence in people with cancer: systematic review	BRITISH MEDICAL JOURNAL			English	Review							BONE-MARROW TRANSPLANTATION; METASTATIC BREAST-CANCER; PSYCHOSOCIAL PREDICTORS; GASTROINTESTINAL CANCER; LUNG-CANCER; TIME; STRATEGIES; MELANOMA; DISEASE; PROGNOSIS	Objective To summarise the evidence On the effect of psychological coping styles (including fighting spirit, helplessness/hopelessness, denial, and avoidance) on survival and recurrence in patients with cancer. Design Systematic review of published and unpublished prospective observational studies. Main outcome measures Survival from or recurrence of cancer. Results 26 studies investigated the association between psychological coping styles and survival from cancer, and 11 studies investigated recurrence. Most of the studies that investigated fighting spirit (10 studies) or helplessness/hopelessness (12 studies) found no significant associations with survival or recurrence. The evidence that other coping styles play an important part was also weak. Positive findings tended to be confined to small or methodologically flawed studies; lack of adjustment for potential confounding variables was common. Positive conclusions seemed to be more commonly reported by smaller studies, indicating potential publication bias. Conclusion There is little consistent evidence that psychological coping styles play an important part in survival from or recurrence of cancer. People with cancer should not feel pressured into adopting particular coping styles to improve survival or reduce the risk of recurrence.	MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ Newcastle Upon Tyne, Sch Med, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Queens Univ, Kingston, ON K7L 3N6, Canada	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; Newcastle University - UK; Queens University - Canada	Petticrew, M (corresponding author), MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.		Petticrew, Mark/AAY-6274-2021					ACHTE K, 1979, PSYCHIAT FENN, P19; ANDRYKOWSKI MA, 1994, PSYCHOSOM MED, V56, P432, DOI 10.1097/00006842-199409000-00008; Brown JE, 2000, BRIT J CANCER, V83, P1448, DOI 10.1054/bjoc.2000.1471; Buddeberg C, 1996, J PSYCHOSOM RES, V40, P255, DOI 10.1016/0022-3999(95)00518-8; BUDDEBERG C, 1991, PSYCHOTHER PSYCHOSOM, V55, P151, DOI 10.1159/000288423; Buddeberg C, 1990, Schweiz Arch Neurol Psychiatr (1985), V141, P429; Buddeberg C, 1997, J PSYCHOSOM RES, V43, P625; Butow PN, 1999, J CLIN ONCOL, V17, P2256, DOI 10.1200/JCO.1999.17.7.2256; Butow PN, 2000, ANN ONCOL, V11, P469, DOI 10.1023/A:1008396330433; CASSILETH BR, 1988, J CLIN ONCOL, V6, P1753, DOI 10.1200/JCO.1988.6.11.1753; CASSILETH BR, 1985, NEW ENGL J MED, V312, P1551, DOI 10.1056/NEJM198506133122406; CODY M, 1994, PSYCHO-ONCOLOGY, V3, P141; De Boer MF, 1998, CANCER-AM CANCER SOC, V83, P2567; DEAN C, 1989, J PSYCHOSOM RES, V33, P561, DOI 10.1016/0022-3999(89)90063-9; DEROGATIS LR, 1979, JAMA-J AM MED ASSOC, V242, P1504, DOI 10.1001/jama.242.14.1504; Edelman S, 2000, J PSYCHOSOM RES, V49, P149, DOI 10.1016/S0022-3999(00)00153-7; EPPINGJORDAN JE, 1994, HEALTH PSYCHOL, V13, P539, DOI 10.1037/0278-6133.13.6.539; Faller H, 1997, PSYCHOTHER PSYCH MED, V47, P206; Faller H, 1999, ARCH GEN PSYCHIAT, V56, P756, DOI 10.1001/archpsyc.56.8.756; Giraldi T, 1997, PSYCHOTHER PSYCHOSOM, V66, P229, DOI 10.1159/000289140; GREER S, 1990, LANCET, V335, P49, DOI 10.1016/0140-6736(90)90173-3; GREER S, 1979, LANCET, V2, P785, DOI 10.1016/S0140-6736(79)92127-5; HISLOP TG, 1987, J CHRON DIS, V40, P729; JENSEN MR, 1987, J PERS, V55, P317, DOI 10.1111/j.1467-6494.1987.tb00439.x; Kahn HA, 1989, STAT METHODS EPIDEMI; Molassiotis A, 1997, J PSYCHOSOM RES, V42, P275, DOI 10.1016/S0022-3999(96)00298-X; Morris T, 1992, PSYCHO-ONCOLOGY, V1, P105; Murphy KC, 1996, BONE MARROW TRANSPL, V18, P199; Nordin K, 1997, ACTA ONCOL, V36, P803, DOI 10.3109/02841869709001361; Nordin K, 1998, PSYCHO-ONCOLOGY, V7, P413, DOI 10.1002/(SICI)1099-1611(1998090)7:5<413::AID-PON318>3.3.CO;2-H; PETTINGALE KW, 1984, J PSYCHOSOM RES, V28, P363, DOI 10.1016/0022-3999(84)90066-7; PETTINGALE KW, 1985, LANCET, V1, P750; Reynolds P, 2000, AM J EPIDEMIOL, V152, P940, DOI 10.1093/aje/152.10.940; RICHARDSON JL, 1990, J PSYCHOSOM RES, V34, P189, DOI 10.1016/0022-3999(90)90053-7; Ringdal GI, 1995, J PSYCHOSOC ONCOL, V13, P47, DOI 10.1300/J077V13N03_03; Ringdal GI, 1996, BRIT J CANCER, V73, P1594, DOI 10.1038/bjc.1996.300; ROGENTINE GN, 1979, PSYCHOSOM MED, V41, P647; Sainsbury JRC, 2000, BRIT MED J, V321, P745, DOI 10.1136/bmj.321.7263.745; Schulz R, 1996, PSYCHOL AGING, V11, P304, DOI 10.1037/0882-7974.11.2.304; SILBERFARB PM, 1991, J CLIN ONCOL, V9, P2219, DOI 10.1200/JCO.1991.9.12.2219; Tschuschke V, 2001, J PSYCHOSOM RES, V50, P277, DOI 10.1016/S0022-3999(01)00202-1; Watson M, 1999, LANCET, V354, P1331, DOI 10.1016/S0140-6736(98)11392-2	42	174	178	2	28	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2002	325	7372					1066	1069		10.1136/bmj.325.7372.1066	http://dx.doi.org/10.1136/bmj.325.7372.1066			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	618JV	12424165	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000179415700018
J	Fox, K; Caterson, B				Fox, K; Caterson, B			Freeing the brain from the perineuronal net	SCIENCE			English	Editorial Material							CHONDROITIN-SULFATE PROTEOGLYCANS; PLASTICITY; CORTEX		Cardiff Univ, Neurosci Res Grp, Cardiff CF10 3US, S Glam, Wales; Cardiff Univ, Cardiff Sch Biosci, Connect Tissue Biol Labs, Cardiff CF10 3US, S Glam, Wales	Cardiff University; Cardiff University	Fox, K (corresponding author), Cardiff Univ, Neurosci Res Grp, Cardiff CF10 3US, S Glam, Wales.		Caterson, Bruce/A-8085-2010; Fox, Kevin/E-8836-2010	Fox, Kevin/0000-0002-2563-112X; Caterson, Bruce/0000-0001-6016-0661				Bruckner G, 1998, EXP BRAIN RES, V121, P300, DOI 10.1007/s002210050463; DAW NW, 1995, VISUAL DEV, pCH9; HOCKFIELD S, 1990, COLD SPRING HARB SYM, V55, P505; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Maleski M, 1997, GLIA, V20, P193, DOI 10.1002/(SICI)1098-1136(199707)20:3<193::AID-GLIA3>3.0.CO;2-9; MULLER CM, 1989, NATURE, V342, P427, DOI 10.1038/342427a0; Nutt CL, 2001, NEUROSCIENTIST, V7, P113, DOI 10.1177/107385840100700206; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003	11	46	47	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1187	1189		10.1126/science.1079224	http://dx.doi.org/10.1126/science.1079224			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424361				2022-12-28	WOS:000179080400030
J	Venkitaraman, AR				Venkitaraman, AR			Connecting Fanconi's anaemia to breast cancer predisposition	LANCET			English	Editorial Material							BRCA1		Univ Cambridge, CR UK Dept Oncol, Cambridge CB2 2XZ, England; Hutchison MRC Res Ctr, MRC, Canc Cell Unit, Cambridge CB2 2XZ, England	University of Cambridge	Venkitaraman, AR (corresponding author), Univ Cambridge, CR UK Dept Oncol, Cambridge CB2 2XZ, England.	arv22@cam.ac.uk						de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	11	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 2	2002	360	9343					1344	1345		10.1016/S0140-6736(02)11414-0	http://dx.doi.org/10.1016/S0140-6736(02)11414-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423977				2022-12-28	WOS:000179081600004
J	Meltzer, D; Manning, WG; Morrison, J; Shah, MN; Jin, L; Guth, T; Levinson, W				Meltzer, D; Manning, WG; Morrison, J; Shah, MN; Jin, L; Guth, T; Levinson, W			Effects of physician experience on costs and outcomes on an academic general medicine service: Results of a trial of hospitalists	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL COMORBIDITY INDEX; HEALTH-CARE-SYSTEM; EFFICIENCY; MORTALITY; FACULTY; VOLUME; IMPACT	Background: Hospitalists may decrease costs and improve outcomes in hospitalized patients, but existing evidence is limited and has not identified mechanisms for such effects. Objective: To study the costs and outcomes for patients on an academic general medicine service assigned to teams led by hospitalists and non hospitalists. Design: Cohort study. Setting: Academic general medicine service. Patients: 6511 patients admitted to the hospital from July 1997 through June 1999. Intervention: All patients admitted every fourth day were assigned to 1 of 2 hospitalists caring for inpatients 6 months each year or 1 of 58 nonhospitalists caring for inpatients 1 to 2 months each year. Measurements: Length of stay; inpatient costs; and 30-, 60, and 365-day mortality. Results: Patients assigned to hospitalists (24.8%) and nonhospitalists (75.2%) did not differ in age, race, sex, diagnosis mix, or Charlson index score. In year 1, average adjusted length of stay was 0.29 day shorter for patients cared for by hospitalists than by nonhospitalists (95% Cl, -0.66 to 0.06 day; P = 0.06); in year 2, average adjusted length of stay was 0.49 day shorter for patients cared for by hospitalists (Cl, -0.79 to -0.15 day; P = 0.01). Average adjusted costs were not significantly reduced for hospitalists compared with nonhospitalists in year 1 but were reduced by $782 in year 2 (Cl, -$1313 to -$187; P = 0.01). When years 1 and 2 were combined or when year 1 was analyzed alone, 30-day mortality was not significantly different for hospitalists and non hospitalists; however, 30-day mortality was 4.2% for hospitalists compared with 6.0% for nonhospitalists in year 2 (Cl for difference, 1.8 percentage points [-3.6 to -0.1 percentage points]; P = 0.04) and the adjusted relative risk was 0.65 (Cl, 0.44 to 0.96; P = 0.03). In multivariate analyses, resource use decreased with the physician's cumulative experience in caring for a patient's primary diagnosis. Mortality showed a similar pattern. Conclusions: Hospitalist care was associated with lower costs and short-term mortality in the second but not the first year of hospitalists' experience. Disease-specific physician experience may reduce resource use and improve patient outcomes; in addition, it may be an important determinant of the effectiveness of hospitalists.	Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA	University of Chicago	Meltzer, D (corresponding author), Univ Chicago, Gen Internal Med Sect, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.	dmeltzer@medicine.bsd.uchicago.edu	Meltzer, David/C-2926-2009	Meltzer, David/0000-0003-2790-7393; Shah, Manish/0000-0001-6331-1074				ALVEY W, 1979, SOC SECUR BULL, V42, P15; Auerbach AD, 2002, ANN INTERN MED, V137, P859, DOI 10.7326/0003-4819-137-11-200212030-00006; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Diamond HS, 1998, ANN INTERN MED, V129, P197, DOI 10.7326/0003-4819-129-3-199808010-00006; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; GERTIS M, 1993, PATIENTS EYES; GRUMBACH K, 1993, NEW ENGL J MED, V328, P940, DOI 10.1056/NEJM199304013281308; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; IKEGAMI N, 1995, NEW ENGL J MED, V333, P1295, DOI 10.1056/NEJM199511093331922; Kearns PJ, 2001, ARCH INTERN MED, V161, P235, DOI 10.1001/archinte.161.2.235; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LUFT HS, 1990, HLTH ADM PR PERSPECT; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; MCCULLAGH F, 1989, GEN LINEAR MODELS; Michota F, 1998, CLEV CLIN J MED, V65, P297, DOI 10.3949/ccjm.65.6.297; Norton EC, 1998, HEALTH SERV RES, V33, P1191; Peabody JW, 1996, JAMA-J AM MED ASSOC, V276, P1944, DOI 10.1001/jama.276.24.1944; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WARE JE, 1995, SCORE SF12 PHYSICAL; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; 2002, SOCIAL SECURITY DEAT	26	264	264	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					866	874		10.7326/0003-4819-137-11-200212030-00007	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	622GY	12458986				2022-12-28	WOS:000179639700002
J	Ferraro, PJ; Kiss, A				Ferraro, PJ; Kiss, A			Ecology - Direct payments to conserve biodiversity	SCIENCE			English	Editorial Material							INTEGRATED CONSERVATION		Georgia State Univ, Andrew Young Sch Policy Studies, Dept Econ, Atlanta, GA 30303 USA; World Bank, Environm & Social Dev Unit, Washington, DC 20433 USA	University System of Georgia; Georgia State University; The World Bank	Ferraro, PJ (corresponding author), Georgia State Univ, Andrew Young Sch Policy Studies, Dept Econ, Atlanta, GA 30303 USA.	pferraro@gsu.edu; akiss@worldbank.org	Ferraro, Paul J/B-4435-2014	Ferraro, Paul J/0000-0002-4777-5108				Achard F, 2002, SCIENCE, V297, P999, DOI 10.1126/science.1070656; [Anonymous], 2002, CONSERVATION PRACTIC; Balmford A, 2002, SCIENCE, V297, P950, DOI 10.1126/science.1073947; Barrett CB, 1998, LAND ECON, V74, P449, DOI 10.2307/3146878; CONRAD JC, 2001, ENV POLICY WORKING P; Ferraro P. J., 2001, Resources (Washington), P17; Ferraro PJ, 2002, LAND ECON, V78, P339, DOI 10.2307/3146894; Ferraro PJ, 2001, CONSERV BIOL, V15, P990, DOI 10.1046/j.1523-1739.2001.015004990.x; GICHOHI H, 2002, 16 ANN M SOC CONS BI; Gullison RE, 2000, NATURE, V404, P923, DOI 10.1038/35010151; HARDNER J, 2002, SCI AM           MAY, P89; James A, 2001, BIOSCIENCE, V51, P43, DOI 10.1641/0006-3568(2001)051[0043:CWATCB]2.0.CO;2; KISS A, IN PRESS GETTING BIO; Myers N, 2001, PERVERSE SUBSIDIES; *NAT CONS WASH, 2002, 2001 ANN REP; *ORG EC COOP DEV, 1997, ENV EFF AGR LAND DIV; ORTIZ E, 2002, 16 ANN M SOC CONS BI; ORTIZ E, COMMUNICATION; Peters J, 1998, J AGR ENVIRON ETHIC, V11, P17, DOI 10.1023/A:1007796628731; Pimm SL, 2001, SCIENCE, V293, P2207, DOI 10.1126/science.1061626; Rice It, 2002, 16 ANN M SOC CONS BI; ROE D, 2001, SERIES INT I ENV DEV, V8; Salafsky N, 1999, EVALUATING LINKAGES; *SOC CONS BIOL, 2002, 16 ANN M SOC CONS BI; TEWARI DD, 1996, UNASYLVA, V187, P26; *USDA, 2001, FY 2001 BUDG SUMM; [No title captured]	27	562	583	4	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1718	1719		10.1126/science.1078104	http://dx.doi.org/10.1126/science.1078104			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459569				2022-12-28	WOS:000179494800020
J	Moore, GWK; Holdsworth, G; Alverson, K				Moore, GWK; Holdsworth, G; Alverson, K			Climate change in the North Pacific region over the past three centuries	NATURE			English	Article							ICE-CORE; GEOPOTENTIAL HEIGHT; TIME-SERIES; TEMPERATURE; HEMISPHERE; VARIABILITY; REANALYSIS; IMPACTS; TRENDS; ENSO	The relatively short length of most instrumental climate records restricts the study of climate variability(1,2), and it is therefore essential to extend the record into the past with the help of proxy data. Only since the late 1940s have atmospheric data been available(3) that are sufficient in quality and spatial resolution to identify the dominant patterns of climate variability, such as the Pacific North America pattern(4,5) and the Pacific Decadal Oscillation(6). Here we present a 301-year snow accumulation record from an ice core at a height of 5,340 m above sea level-from Mount Logan, in northwestern North America. This record shows features that are closely linked with the Pacific North America pattern for the period of instrumental data availability. Our record extends back in time to cover the period from the closing stages of the Little Ice Age to the warmest decade in the past millennium(7). We find a positive, accelerating trend in snow accumulation after the middle of the nineteenth century. This trend is paralleled by a warming over northwestern North America which has been associated with secular changes in both the Pacific North America pattern and the Pacific Decadal Oscillation.	Univ Toronto, Dept Phys, Toronto, ON M5S 1A7, Canada; Univ Calgary, Arctic Inst N Amer, Calgary, AB T2N 1N4, Canada; PAGES Int Project Off, CH-3011 Bern, Switzerland	University of Toronto; University of Calgary	Moore, GWK (corresponding author), Univ Toronto, Dept Phys, 60 St George St, Toronto, ON M5S 1A7, Canada.		Moore, Kent/D-8518-2011	Moore, Kent/0000-0002-3986-5605				Alverson K, 2001, SCIENCE, V293, P47; BARNSTON AG, 1987, MON WEATHER REV, V115, P1083, DOI 10.1175/1520-0493(1987)115<1083:CSAPOL>2.0.CO;2; Biondi F, 2001, J CLIMATE, V14, P5, DOI 10.1175/1520-0442(2001)014<0005:NPDCVS>2.0.CO;2; BLACKMON ML, 1976, J ATMOS SCI, V33, P1607, DOI 10.1175/1520-0469(1976)033<1607:ACSSOT>2.0.CO;2; Esper J, 2002, SCIENCE, V295, P2250, DOI 10.1126/science.1066208; Finney BP, 2000, SCIENCE, V290, P795, DOI 10.1126/science.290.5492.795; HOLDSWORTH G, 1992, CLIMATE AD 1500; Houghton J. T., 2001, 3 IPCC; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Kistler R, 2001, B AM METEOROL SOC, V82, P247, DOI 10.1175/1520-0477(2001)082<0247:TNNYRM>2.3.CO;2; Mann ME, 1996, CLIMATIC CHANGE, V33, P409, DOI 10.1007/BF00142586; Mann ME, 2002, SCIENCE, V297, P1481, DOI 10.1126/science.1074318; Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2; MAYEWSKI PA, 1993, ATMOS ENVIRON A-GEN, V27, P2915, DOI 10.1016/0960-1686(93)90323-Q; Moore GWK, 2001, GEOPHYS RES LETT, V28, P3457, DOI 10.1029/2000GL012397; MOORE GWK, 2002, IN PRESS ANN GLACIOL; Peixoto J. P., 1992, PHYS CLIMATE, DOI DOI 10.1063/1.2809772; Santer BD, 2000, J GEOPHYS RES-ATMOS, V105, P7337, DOI 10.1029/1999JD901105; Smirnov VV, 1999, J CLIMATE, V12, P681, DOI 10.1175/1520-0442(1999)012<0681:SATSOA>2.0.CO;2; TRENBERTH KE, 1990, B AM METEOROL SOC, V71, P988, DOI 10.1175/1520-0477(1990)071<0988:ROICCI>2.0.CO;2; WALLACE JM, 1981, MON WEATHER REV, V109, P784, DOI 10.1175/1520-0493(1981)109<0784:TITGHF>2.0.CO;2; WALLACE JM, 1995, SCIENCE, V270, P780, DOI 10.1126/science.270.5237.780; WHITLOW S, 1994, TELLUS B, V46, P234, DOI 10.1034/j.1600-0889.1994.t01-2-00006.x; Wunsch C, 1999, B AM METEOROL SOC, V80, P245, DOI 10.1175/1520-0477(1999)080<0245:TIOSCR>2.0.CO;2; Zhang Y, 1997, J CLIMATE, V10, P1004, DOI 10.1175/1520-0442(1997)010<1004:ELIV>2.0.CO;2	26	84	88	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					401	403		10.1038/nature01229	http://dx.doi.org/10.1038/nature01229			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459737				2022-12-28	WOS:000179494700035
J	Yoshizawa, K; Rimm, EB; Morris, JS; Spate, VL; Hsieh, CC; Spiegelman, D; Stampfer, MJ; Willett, WC				Yoshizawa, K; Rimm, EB; Morris, JS; Spate, VL; Hsieh, CC; Spiegelman, D; Stampfer, MJ; Willett, WC			Mercury and the risk of coronary heart disease in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; DIETARY-INTAKE; FATTY-ACIDS; METHYLMERCURY; SELENIUM; TOXICITY; FISH; REPRODUCIBILITY; VALIDITY; CADMIUM	Background: A high dietary intake of mercury from consumption of fish has been hypothesized to increase the risk of coronary heart disease. Methods: Using a nested case-control design, we investigated the association between mercury levels in toenails and the risk of coronary heart disease among male health professionals with no previous history of cardiovascular disease or cancer who were 40 to 75 years of age in 1986. Toenail clippings were collected in 1987 from 33,737 cohort members, and during five years of follow-up, we documented 470 cases of coronary heart disease (coronary-artery surgery, nonfatal myocardial infarction, and fatal coronary heart disease). Each patient was matched according to age and smoking status with a randomly selected control subject. Results: The mercury level was significantly correlated with fish consumption (Spearman r = 0.42, P<0.001), and the mean mercury level was higher in dentists than in nondentists (mean, 0.91 and 0.45 microg per gram, respectively; P<0.001). After age, smoking, and other risk factors for coronary heart disease had been controlled for, the mercury level was not significantly associated with the risk of coronary heart disease. When the highest and lowest quintiles of mercury level were compared, the relative risk of coronary heart disease was 0.97 in the highest level (95 percent confidence interval, 0.63 to 1.50; P value for trend = 0.78). Adjustment for intake of n-3 fatty acids from fish did not appreciably change these results. Conclusions: Our findings do not support an association between total mercury exposure and the risk of coronary heart disease, but a weak relation cannot be ruled out.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Missouri, Res Reactor Ctr, Columbia, MO USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Missouri System; University of Missouri Columbia	Yoshizawa, K (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.		Yoshizawa, Kazuko/AAP-3316-2020	Yoshizawa, Kazuko/0000-0003-0393-6130	NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; CHENG TP, 1994, NUCL INSTRUM METH A, V353, P457, DOI 10.1016/0168-9002(94)91698-5; CHMIELNICKA J, 1983, ENVIRON RES, V31, P266, DOI 10.1016/0013-9351(83)90003-8; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GANTHER HE, 1972, SCIENCE, V175, P1122, DOI 10.1126/science.175.4026.1122; GANTHER HE, 1974, J FOOD SCI, V39, P1, DOI 10.1111/j.1365-2621.1974.tb00974.x; GARLAND M, 1993, CANCER EPIDEM BIOMAR, V2, P493; GARLAND M, 1994, CANCER EPIDEM BIOMAR, V3, P523; Guallar E, 2002, NEW ENGL J MED, V347, P1747, DOI 10.1056/NEJMoa020157; HUNTER DJ, 1990, AM J EPIDEMIOL, V132, P114, DOI 10.1093/oxfordjournals.aje.a115623; KOMSTASZUMSKA E, 1983, TOXICOL LETT, V17, P349, DOI 10.1016/0378-4274(83)90249-7; KRISTENSEN TS, 1989, SCAND J WORK ENV HEA, V15, P245, DOI 10.5271/sjweh.1854; LINDER MC, 1991, NUTR BIOCH METABOLIS, P268; LUND BO, 1993, BIOCHEM PHARMACOL, V45, P2017, DOI 10.1016/0006-2952(93)90012-L; MacIntosh DL, 1997, CANCER EPIDEM BIOMAR, V6, P1043; Magos L, 1997, MET IONS BIOL SYST, V34, P321; PARIZEK J, 1967, EXPERIENTIA, V23, P142, DOI 10.1007/BF02135970; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; Rissanen T, 2000, CIRCULATION, V102, P2677, DOI 10.1161/01.CIR.102.22.2677; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645; SCHROEDER HA, 1973, TRACE ELEMENTS MAN S; SINGHAL RK, 1987, FASEB J, V1, P220, DOI 10.1096/fasebj.1.3.2887478; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; STEINBERG D, 1991, CIRCULATION, V84, P1420, DOI 10.1161/01.CIR.84.3.1420; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STOEWSAND GS, 1974, B ENVIRON CONTAM TOX, V11, P152, DOI 10.1007/BF01684595; SUMINO K, 1977, NATURE, V268, P73, DOI 10.1038/268073a0	30	209	212	0	18	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1755	1760		10.1056/NEJMoa021437	http://dx.doi.org/10.1056/NEJMoa021437			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456851				2022-12-28	WOS:000179468600005
J	Fallowfield, L; Jenkins, V				Fallowfield, L; Jenkins, V			Acronymic trials: the good, the bad, and the coercive	LANCET			English	Editorial Material									Canc Res UK, Sussex Psychosocial Oncol Grp, Brighton, E Sussex, England; Univ Sussex, Sussex Med Sch, Brighton BN1 9QG, E Sussex, England	Cancer Research UK; University of Sussex; University of Brighton; University of Sussex	Fallowfield, L (corresponding author), Canc Res UK, Sussex Psychosocial Oncol Grp, Brighton, E Sussex, England.			Fallowfield, Lesley/0000-0003-0577-4518				JUNG CG, 1969, ANA PSYCHOL ITS THEO; Lader EW, 2002, LANCET, V360, P576, DOI 10.1016/S0140-6736(02)09737-4; Orlowski JP, 2002, CHEST, V121, P2023, DOI 10.1378/chest.121.6.2023; Tyler LK, 1997, COGN NEUROPSYCHOL, V14, P293, DOI 10.1080/026432997381583	4	6	6	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 23	2002	360	9346					1622	1622		10.1016/S0140-6736(02)11653-9	http://dx.doi.org/10.1016/S0140-6736(02)11653-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	618AE	12457783				2022-12-28	WOS:000179393900005
J	Bloch, JI; Boyer, DM				Bloch, JI; Boyer, DM			Grasping primate origins	SCIENCE			English	Article							FUNCTIONAL-MORPHOLOGY; TUPAIIDS MAMMALIA; SUBSTRATE USE; CARPOLESTIDAE; PLESIADAPIFORMES; ADAPTATIONS; SCANDENTIA; MARSUPIALS; DIAGNOSIS; EVOLUTION	The evolutionary history that led to Eocene-and-later primates of modern aspect (Euprimates) has been uncertain. We describe a skeleton of Paleocene plesiadapiform Carpolestes simpsoni that includes most of the skull and many postcranial bones. Phylogenetic analyses indicate that Carpolestidae are closely related to Euprimates. C. simpsoni had long fingers and an opposable hallux with a nail. It lacked orbital convergence and an ankle specialized for leaping. We infer that the ancestor of Euprimates was primitively an arboreal grasper adapted for terminal branch feeding rather than a specialized leaper or visually directed predator.	Univ Michigan, Museum Paleontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Bloch, JI (corresponding author), Univ Michigan, Museum Paleontol, 1109 Geddes Rd, Ann Arbor, MI 48109 USA.	carpo@umich.edu	Self, Casey J/B-6871-2011	Boyer, Douglas/0000-0002-8697-2999; Bloch, Jonathan/0000-0003-1484-6931				BEARD KC, 1993, MAMMAL PHYLOGENY : PLACENTALS, P129; BEARD KC, 1995, ANN CARNEGIE MUS, V64, P1; BEARD KC, 1991, ORIGINES BIPEDIE CHE, P63; BIKNEVICIUS AR, 1986, AM J PHYS ANTHROPOL, V71, P157, DOI 10.1002/ajpa.1330710204; Bloch J, 2001, U MICHIGAN PAPERS PA, V33, P185; Bloch JI, 2001, T GEOBIOL, V18, P95; Bloch JI, 2002, J VERTEBR PALEONTOL, V22, P366, DOI 10.1671/0272-4634(2002)022[0366:NPPFTC]2.0.CO;2; Bloch JI, 2001, AM J PHYS ANTHROPOL, V116, P184, DOI 10.1002/ajpa.1114; Bloch JI, 2001, J VERTEBR PALEONTOL, V21, P119, DOI 10.1671/0272-4634(2001)021[0119:SAOPCM]2.0.CO;2; Bloch Jonathan I., 1998, Contributions from the Museum of Paleontology University of Michigan, V30, P131; Bowen GJ, 2002, SCIENCE, V295, P2062, DOI 10.1126/science.1068700; Bowen GJ, 2002, J SEDIMENT RES, V72, P46, DOI 10.1306/061901720046; CARTMILL M, 1974, SCIENCE, V184, P436, DOI 10.1126/science.184.4135.436; CARTMILL M, 1992, EVOL ANTHROPOL, V6, P111; DAGOSTO M, 1988, J HUM EVOL, V17, P35, DOI 10.1016/0047-2484(88)90048-6; DASHZEVEG D, 1977, Acta Palaeontologica Polonica, V22, P119; Fox Richard C., 1993, Journal of Vertebrate Paleontology, V13, P516; Gingerich P.D., 1989, U MICHIGAN PAPERS PA, V28, P1; GINGERICH PD, 1975, NATURE, V253, P111, DOI 10.1038/253111a0; GINGERICH PD, 1987, CONTRIB MUS PALEONTO, V27, P265; GINGERICH PD, 2000, EARLY PALEOGENE WARM, P57; Gunnell GF., 1989, U MICH PAP PALEONT, V27, P1; Hamrick MW, 2001, J HUM EVOL, V40, P339, DOI 10.1006/jhev.2001.0467; HOFFSTETTER R, 1977, B MEM SOC ANTHRO PAR, V4, P327, DOI 10.3406/bmsap.1977.1886; KAY RF, 1992, AM J PHYS ANTHROPOL, V89, P477, DOI 10.1002/ajpa.1330890409; KRAUSE DW, 1991, J HUM EVOL, V21, P177, DOI 10.1016/0047-2484(91)90060-9; Lemelin P, 1999, J ZOOL, V247, P165, DOI 10.1017/S0952836999002046; MAAS MC, 1988, PALEOBIOLOGY, V14, P410, DOI 10.1017/S0094837300012148; MCKENNA MC, 1966, FOLIA PRIMATOL, V4, P1, DOI 10.1159/000155041; McKenna MC, 1997, CLASSIFICATION MAMMA; RASMUSSEN DT, 1990, AM J PRIMATOL, V22, P263, DOI 10.1002/ajp.1350220406; ROSE K D, 1975, Bulletin of the Museum of Comparative Zoology, V147, P1; RUNESTAD JA, 1995, AM J PHYS ANTHROPOL, V98, P101, DOI 10.1002/ajpa.1330980202; RUSSELL DONALD E., 1964, MEM MUS NAT HIST NATUR NOW SER SER C SCI TERRE, V13, P1; Sargis EJ, 2002, J MORPHOL, V254, P149, DOI 10.1002/jmor.10025; Sargis EJ, 2001, J ZOOL, V253, P473, DOI 10.1017/S0952836901000437; Sargis EJ, 2001, J ZOOL, V253, P485, DOI 10.1017/S0952836901000449; Silcox M.T., 2001, THESIS J HOPKINS U; Silcox MT, 2001, J VERTEBR PALEONTOL, V21, P132, DOI 10.1671/0272-4634(2001)021[0132:NSOERM]2.0.CO;2; Stafford BJ, 1998, J MORPHOL, V235, P135, DOI 10.1002/(SICI)1097-4687(199802)235:2<135::AID-JMOR4>3.0.CO;2-8; SUSSMAN RW, 1978, SCIENCE, V200, P731, DOI 10.1126/science.200.4343.731; SUSSMAN RW, 1991, AM J PRIMATOL, V23, P209, DOI 10.1002/ajp.1350230402; Szalay F. S., 1969, Bulletin of the American Museum of Natural History, V140, P195; Szalay F.S., 1980, P133; Szalay Frederick S., 1993, P187; SZALAY FS, 1980, FOLIA PRIMATOL, V34, P1, DOI 10.1159/000155946; SZALAY FS, 1987, YEARB PHYS ANTHROPOL, V30, P75; SZALAY FS, 1975, FOLIA PRIMATOL, V23, P158, DOI 10.1159/000155669; SZALAY FS, 1968, EVOLUTION, V22, P19, DOI 10.1111/j.1558-5646.1968.tb03445.x; SZALAY FS, 1988, J HUM EVOL, V17, P1, DOI 10.1016/0047-2484(88)90047-4; SZALAY FS, 1975, APPROACHES PRIMATE P, P136; Wible John R., 1993, P111; WIBLE JR, 1987, J HUM EVOL, V16, P1, DOI 10.1016/0047-2484(87)90058-3	53	171	183	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1606	1610		10.1126/science.1078249	http://dx.doi.org/10.1126/science.1078249			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446906				2022-12-28	WOS:000179361600045
J	Albers, GW; Caplan, LR; Easton, JD; Fayad, PB; Mohr, JP; Saver, JL; Sherman, DG				Albers, GW; Caplan, LR; Easton, JD; Fayad, PB; Mohr, JP; Saver, JL; Sherman, DG		TIA Working Grp	Transient ischemic attack - Proposal for a new definition.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COMPUTED-TOMOGRAPHY; CEREBRAL INFARCTION; STROKE; PROGNOSIS; TIA		Stanford Univ, Sch Med, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brown Univ, Sch Med, Providence, RI 02903 USA; Univ Nebraska, Med Ctr, Omaha, NE 68198 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA	Stanford University; Harvard University; Harvard Medical School; Brown University; University of Nebraska System; University of Nebraska Medical Center; Columbia University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System; University of Texas Health San Antonio	Albers, GW (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.		Mohr, J/AAO-9694-2020	Saver, Jeffrey/0000-0001-9141-2251; Albers, Gregory/0000-0003-0263-4632				ACHESON J, 1964, LANCET, V2, P871; [Anonymous], 1975, Stroke, V6, P564; Ay H, 1999, STROKE, V30, P235; CAPLAN LR, 1988, NEUROLOGY, V38, P791, DOI 10.1212/WNL.38.5.791; CONNEALLY PM, 1978, JAMA-J AM MED ASSOC, V240, P742, DOI 10.1001/jama.240.8.742; Culebras A, 1997, STROKE, V28, P1480, DOI 10.1161/01.STR.28.7.1480; DAVALOS A, 1988, J NEUROL, V235, P155, DOI 10.1007/BF00314306; DENNIS M, 1990, J NEUROL, V237, P257, DOI 10.1007/BF00314630; Engelter ST, 1999, STROKE, V30, P2762, DOI 10.1161/01.STR.30.12.2759-c; EVANS GW, 1991, STROKE, V22, P431, DOI 10.1161/01.STR.22.4.431; Fisher CM, 1958, CEREBRAL VASCULAR DI, P81; Garcia JH, 1996, STROKE, V27, P761, DOI 10.1161/01.STR.27.4.761; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; LEVY DE, 1988, NEUROLOGY, V38, P674, DOI 10.1212/WNL.38.5.674; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; MARSHALL J, 1964, Q J MED, V33, P309; *NAT I NEUR DIS BL, 1958, NEUROLOGY, V8, P395; PESSIN MS, 1977, NEW ENGL J MED, V296, P358, DOI 10.1056/NEJM197702172960703; SIEKERT RG, 1965, CEREBRAL VASCULAR DI; TOOLE JF, 1991, STROKE, V22, P99, DOI 10.1161/01.STR.22.1.99; WAXMAN SG, 1983, STROKE, V14, P433, DOI 10.1161/01.STR.14.3.433; WEISBERG LA, 1991, NEUROLOGY, V41, P1410, DOI 10.1212/WNL.41.9.1410; WHISNANT JP, 1974, STROKE, V5, P68, DOI 10.1161/01.STR.5.1.68; WILTERDINK JL, 1992, ARCH NEUROL-CHICAGO, V49, P857, DOI 10.1001/archneur.1992.00530320089016	26	543	592	1	36	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1713	1716		10.1056/NEJMsb020987	http://dx.doi.org/10.1056/NEJMsb020987			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444191				2022-12-28	WOS:000179339900015
J	Sasaki, T; Matsumoto, T; Yamamoto, K; Sakata, K; Baba, T; Katayose, Y; Wu, JZ; Niimura, Y; Cheng, ZK; Nagamura, Y; Antonio, BA; Kanamori, H; Hosokawa, S; Masukawa, M; Arikawa, K; Chiden, Y; Hayashi, M; Okamoto, M; Ando, T; Aoki, H; Arita, K; Hamada, M; Harada, C; Hijishita, S; Honda, M; Ichikawa, Y; Idonuma, A; Iijima, M; Ikeno, M; Ito, S; Ito, T; Ito, Y; Ito, Y; Iwabuchi, A; Kamiya, K; Karasawa, W; Katagiri, S; Kikuta, A; Kobayashi, N; Kono, I; Machita, K; Maehara, T; Mizuno, H; Mizubayashi, T; Mukai, Y; Nagasaki, H; Nakashima, M; Nakama, Y; Nakamichi, Y; Nakamura, M; Namiki, N; Negishi, M; Ohta, I; Ono, N; Saji, S; Sakai, K; Shibata, M; Shimokawa, T; Shomura, A; Song, JY; Takazaki, Y; Terasawa, K; Tsuji, K; Waki, K; Yamagata, H; Yamane, H; Yoshiki, S; Yoshihara, R; Yukawa, K; Zhong, HS; Iwama, H; Endo, T; Ito, H; Hahn, JH; Kim, HI; Eun, MY; Yano, M; Jiang, JM; Gojohori, T				Sasaki, T; Matsumoto, T; Yamamoto, K; Sakata, K; Baba, T; Katayose, Y; Wu, JZ; Niimura, Y; Cheng, ZK; Nagamura, Y; Antonio, BA; Kanamori, H; Hosokawa, S; Masukawa, M; Arikawa, K; Chiden, Y; Hayashi, M; Okamoto, M; Ando, T; Aoki, H; Arita, K; Hamada, M; Harada, C; Hijishita, S; Honda, M; Ichikawa, Y; Idonuma, A; Iijima, M; Ikeno, M; Ito, S; Ito, T; Ito, Y; Ito, Y; Iwabuchi, A; Kamiya, K; Karasawa, W; Katagiri, S; Kikuta, A; Kobayashi, N; Kono, I; Machita, K; Maehara, T; Mizuno, H; Mizubayashi, T; Mukai, Y; Nagasaki, H; Nakashima, M; Nakama, Y; Nakamichi, Y; Nakamura, M; Namiki, N; Negishi, M; Ohta, I; Ono, N; Saji, S; Sakai, K; Shibata, M; Shimokawa, T; Shomura, A; Song, JY; Takazaki, Y; Terasawa, K; Tsuji, K; Waki, K; Yamagata, H; Yamane, H; Yoshiki, S; Yoshihara, R; Yukawa, K; Zhong, HS; Iwama, H; Endo, T; Ito, H; Hahn, JH; Kim, HI; Eun, MY; Yano, M; Jiang, JM; Gojohori, T			The genome sequence and structure of rice chromosome 1	NATURE			English	Article							TRANSFER-RNA GENES; ARABIDOPSIS-THALIANA; DRAFT SEQUENCE; DNA; EVOLUTION; MAP	The rice species Oryza sativa is considered to be a model plant because of its small genome size, extensive genetic map, relative ease of transformation and synteny with other cereal crops(1-4). Here we report the essentially complete sequence of chromosome 1, the longest chromosome in the rice genome. We summarize characteristics of the chromosome structure and the biological insight gained from the sequence. The analysis of 43.3 megabases (Mb) of non-overlapping sequence reveals 6,756 protein coding genes, of which 3,161 show homology to proteins of Arabidopsis thaliana, another model plant. About 30% ( 2,073) of the genes have been functionally categorized. Rice chromosome 1 is (G + C)-rich, especially in its coding regions, and is characterized by several gene families that are dispersed or arranged in tandem repeats. Comparison with a draft sequence(5) indicates the importance of a high-quality finished sequence.	Natl Inst Agrobiol Sci, Rice Genome Res Program, Tsukuba, Ibaraki 3058602, Japan; Inst Soc Technoinnovat Agr Forestry & Fisheries, Tsukuba, Ibaraki 3058602, Japan; Natl Inst Genet, Ctr Informat Biol, Mishima, Shizuoka 4118540, Japan; Natl Inst Genet, DNA Data Bank Japan, Mishima, Shizuoka 4118540, Japan; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA; Tokyo Med & Dent Univ, Dept Bioinformat, Bunkyo Ku, Tokyo 1138510, Japan; Natl Inst Agr Sci & Technol, Rice Genome Sequencing Project, RDA, Suwon 441707, South Korea	National Institute of Agrobiological Sciences - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; University of Wisconsin System; University of Wisconsin Madison; Tokyo Medical & Dental University (TMDU); Rural Development Administration (RDA)	Sasaki, T (corresponding author), Natl Inst Agrobiol Sci, Rice Genome Res Program, 1-2 Kannondai 2 Chome, Tsukuba, Ibaraki 3058602, Japan.	tsasaki@nias.affrc.go.jp	Arikawa, Koji/M-4771-2018; Jiang, Jiming/V-6060-2019; Ito, Hidetaka/Y-2865-2018; Jiang, Jiming/A-9614-2009; Yano, Masahiro/AAC-5441-2019; Waki, Kazunori/T-6444-2019	Arikawa, Koji/0000-0002-9508-2429; Jiang, Jiming/0000-0002-6435-6140; Jiang, Jiming/0000-0002-6435-6140; Yano, Masahiro/0000-0003-1510-4622; Waki, Kazunori/0000-0001-7311-7208; Tsugane, Mika/0000-0002-7991-5224; Mizuno, Hiroshi/0000-0002-4110-4717				Baba T., 2000, Bulletin of the National Institute of Agrobiological Resources, P41; Barakat A, 1997, P NATL ACAD SCI USA, V94, P6857, DOI 10.1073/pnas.94.13.6857; Barry GF, 2001, PLANT PHYSIOL, V125, P1164, DOI 10.1104/pp.125.3.1164; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cheng ZK, 2001, GENOME RES, V11, P2133, DOI 10.1101/gr.194601; Cheng ZK, 2002, PLANT CELL, V14, P1691, DOI 10.1105/tpc.003079; Dong FG, 1998, P NATL ACAD SCI USA, V95, P8135, DOI 10.1073/pnas.95.14.8135; Feng Q, 2002, NATURE, V420, P316, DOI 10.1038/nature01183; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Harushima Y, 1998, GENETICS, V148, P479; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Sakata K, 2002, NUCLEIC ACIDS RES, V30, P98, DOI 10.1093/nar/30.1.98; Sasaki A, 2002, NATURE, V416, P701, DOI 10.1038/416701a; Sasaki T, 2000, CURR OPIN PLANT BIOL, V3, P138, DOI 10.1016/S1369-5266(99)00047-3; WESSLER SR, 1995, CURR OPIN GENET DEV, V5, P814, DOI 10.1016/0959-437X(95)80016-X; Wu JZ, 2002, PLANT CELL, V14, P525, DOI 10.1105/tpc.010274; Yamamoto K, 1997, PLANT MOL BIOL, V35, P135, DOI 10.1023/A:1005735322577; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037	21	423	1068	3	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					312	316		10.1038/nature01184	http://dx.doi.org/10.1038/nature01184			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447438	hybrid			2022-12-28	WOS:000179340400041
J	van Walraven, C; Hart, RG; Singer, DE; Laupacis, A; Connolly, S; Petersen, P; Koudstaal, PJ; Chang, YC; Hellemons, B				van Walraven, C; Hart, RG; Singer, DE; Laupacis, A; Connolly, S; Petersen, P; Koudstaal, PJ; Chang, YC; Hellemons, B			Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation - An individual patient meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIXED MINIDOSE WARFARIN; STROKE PREVENTION; ANTITHROMBOTIC THERAPY; SECONDARY PREVENTION; TRIAL; THROMBOEMBOLISM	Context Patients with nonvalvular atrial fibrillation (AF) have an increased risk of stroke and other vascular events. Objective To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K-inhibiting oral anticoagulants or acetylsalicylic acid (aspirin). Design Pooled analysis of patient-level data from 6 published, randomized clinical trials. Patients A total of 4052 patients with AF randomly assigned to receive therapeutic doses of oral anticoagulant or aspirin with or without low-dose oral anticoagulants. Main Outcome Measures Ischemic and hemorrhagic stroke, other cardiovascular events, all-cause death, and major bleeding events. Person-year incidence rates were calculated to provide crude comparisons. Relative efficacy was assessed using proportional hazards modeling stratified by study. The variation of the oral anticoagulant's relative effect by pertinent patient factors was explored with interaction terms. All analyses were conducted using the intention-to-treat principle. Results Patients receiving oral anticoagulant and aspirin were balanced for important prognostic factors. There was no significant heterogeneity between trials in the relative efficacy of oral anticoagulant vs aspirin for any outcome. Patients receiving oral anticoagulant were significantly less likely to experience any stroke (2.4 vs 4.5 events per 100 patient-years; hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.43-0.71), ischemic stroke (HR, 0.48; 95% CI, 0.37-0.63), or cardiovascular events (HR, 0.71; 95% CI, 0.59-0.85) but were more likely to experience major bleeding (2.2 vs 1.3 events per 100 patient-years; HR, 1.71; 95% CI, 1.21-2.41). The reduction in ischemic stroke risk was similar in patients with paroxysmal AF (1.5 vs 4.7 events per 100 patient-years; HR, 0.32; 95% CI, 0.16-0.61; P<.001). Treating 1000 patients with AF for 1 year with oral anticoagulant rather than aspirin would prevent 23 ischemic strokes while causing 9 additional major bleeds. Overall all-cause survival did not differ but appeared to improve for oral anticoagulant patients 3 years after therapy was started. Conclusions Compared with aspirin, oral anticoagulant significantly decreases the risk of all strokes, ischemic strokes, and cardiovascular events for patients with nonvalvular chronic or paroxysmal AF but modestly increases the absolute risk of major bleeding. The balance of benefits and risks varies by patient subgroup.	Ottawa Hlth Res Inst, Clin Epidemiol Unit, Ottawa, ON, Canada; Inst Clin Evaluat Sci, Ottawa, ON, Canada; Canadian Inst Hlth Res, Ottawa, ON, Canada; Univ Texas, Dept Med, San Antonio, TX 78285 USA; Massachusetts Gen Hosp, Div Gen Med, Clin Epidemiol Unit, Boston, MA 02114 USA; McMaster Univ, Hamilton, ON, Canada; Hvidovre Univ Hosp, Copenhagen, Denmark; Erasmus MC, Dept Neurol, Rotterdam, Netherlands; Univ Maastricht, Maastricht, Netherlands	University of Ottawa; Ottawa Hospital Research Institute; Institute for Work & Health; University of Texas System; Harvard University; Massachusetts General Hospital; McMaster University; University of Copenhagen; Erasmus University Rotterdam; Erasmus MC; Maastricht University	van Walraven, C (corresponding author), Ottawa Civic Hosp, Ottawa Hlth Res Inst, Clin Epidemiol Unit, F-6,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	carlv@ohri.ca						ALBERS GW, 1994, ARCH INTERN MED, V154, P1443, DOI 10.1001/archinte.154.13.1443; ALBERS GW, 1991, ANN INTERN MED, V115, P727, DOI 10.7326/0003-4819-115-9-727; Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; ALBERS GW, 1991, ANN NEUROL, V30, P511, DOI 10.1002/ana.410300402; Albers GW, 1998, ARCH INTERN MED, V158, P1487, DOI 10.1001/archinte.158.14.1487; Allison P, 2000, SURVIVAL ANAL USING, P111; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; [Anonymous], 1997, ARCH INTERN MED, V157, P1237; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BENAVENTE O, COCHRANE DATABASE SY; Blackshear JL, 1996, LANCET, V348, P633; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Devereaux PJ, 2001, BMJ-BRIT MED J, V323, P1218, DOI 10.1136/bmj.323.7323.1218; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; Ebrahim S, 2001, ACP J Club, V135, pA17; Evans A, 2001, ARCH INTERN MED, V161, P1443, DOI 10.1001/archinte.161.11.1443; Ezekowitz M, 1998, ARCH INTERN MED, V158, P1316; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Ezekowitz MD, 1999, JAMA-J AM MED ASSOC, V281, P1830, DOI 10.1001/jama.281.19.1830; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Gage BF, 2001, ANN INTERN MED, V134, P465, DOI 10.7326/0003-4819-134-6-200103200-00011; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; Green CJ, 1997, CAN J CARDIOL, V13, P811; Greenberg MK, 1998, NEUROLOGY, V51, P671; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Harrell Jr FE, 2001, REGRESSION MODELING, P465; Hart RG, 1998, NEUROLOGY, V51, P674, DOI 10.1212/WNL.51.3.674; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hart RG, 2001, STROKE, V32, P803, DOI 10.1161/01.STR.32.3.803; Hellemons BSP, 1999, BMJ-BRIT MED J, V319, P958, DOI 10.1136/bmj.319.7215.958; Howard PA, 1997, ANN PHARMACOTHER, V31, P1187, DOI 10.1177/106002809703101012; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KITCHENS JM, 1986, J GEN INTERN MED, V1, P126, DOI 10.1007/BF02599816; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Koudstaal PJ, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000185.pub2, DOI 10.1002/14651858.CD000185.PUB2]; Koudstaal PJ, 2000, COCHRANE DB SYST REV; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; Morocutti C, 1997, STROKE, V28, P1015, DOI 10.1161/01.STR.28.5.1015; Pengo V, 1998, AM J CARDIOL, V82, P433, DOI 10.1016/S0002-9149(98)00357-9; PETERSEN P, 1989, LANCET, V1, P175; Posada IS, 1999, AM HEART J, V138, P137, DOI 10.1016/S0002-8703(99)70259-0; Rothman K., 1998, MODERN EPIDEMIOLOGY, P253; Segal JB, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001938.PUB2]; Singer D E, 1993, Ann Epidemiol, V3, P563; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; Stroke Prevention in Atrial Fibrillation Investigators, 1995, J Stroke Cerebrovasc Dis, V5, P147, DOI 10.1016/S1052-3057(10)80166-1; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; Takkouche B, 1999, AM J EPIDEMIOL, V150, P206; Taylor FC, 1996, BRIT MED J, V312, P286; Taylor FC, 2001, BMJ-BRIT MED J, V322, P321, DOI 10.1136/bmj.322.7282.321; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	58	528	537	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2002	288	19					2441	2448		10.1001/jama.288.19.2441	http://dx.doi.org/10.1001/jama.288.19.2441			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FB	12435257	Bronze			2022-12-28	WOS:000179292300027
J	Flansbaum, BE; Huddleston, JM				Flansbaum, BE; Huddleston, JM			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; THERAPY; RISK		New York Presbyterian Hosp, New York, NY USA; Mayo Clin, Rochester, MN USA	NewYork-Presbyterian Hospital; Mayo Clinic	Flansbaum, BE (corresponding author), Columbia Univ, Dept Med, Sect Hosp Med, 177 Ft Washington Ave, New York, NY 10032 USA.	bef7@columbia.edu		Huddleston, Jeanne/0000-0001-9101-4122				Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Overhage JM, 1996, ARCH INTERN MED, V156, P1551, DOI 10.1001/archinte.156.14.1551; Pitt B, 1999, NEW ENGL J MED, V341, P70, DOI 10.1056/NEJM199907083410202; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Stenestrand U, 2001, JAMA-J AM MED ASSOC, V285, P430, DOI 10.1001/jama.285.4.430; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Walsh TJ, 1999, NEW ENGL J MED, V340, P764, DOI 10.1056/NEJM199903113401004	9	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					814	822		10.7326/0003-4819-137-10-200211190-00010	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616VE	12435218				2022-12-28	WOS:000179323400005
J	Forrester, JS				Forrester, JS			Prevention of plaque rupture: A new paradigm of therapy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; APOLIPOPROTEIN-A-I; ANGIOTENSIN-CONVERTING-ENZYME; REVERSE CHOLESTEROL TRANSPORT; RANDOMIZED CONTROLLED-TRIAL; INCREASES COLLAGEN CONTENT; TUMOR-NECROSIS-FACTOR; SECONDARY PREVENTION	Acute coronary syndromes-unstable angina, myocardial infarction, and sudden cardiac death-are caused by acute disruption of an unstable coronary atheroma. Unstable plaques have three histologic characteristics: a large lipid core, many inflammatory cells, and a thin fibrous cap. Because the unstable plaque is not necessarily obstructive, it may cause no symptoms before rupture. The cellular processes that lead to the characteristic histologic features of unstable plaque have recently been identified. This new understanding of the cell biology of plaque instability suggests new therapeutic strategies: passivation of the endothelium, reduction of low-density lipoprotein (LDL) in the vessel wall by decreasing serum LDL levels or accelerating reverse cholesterol transport, inhibition of LDL oxidation, inhibition of inflammatory cytokine expression, and inhibition of thrombus formation. Although the morbidity and mortality resulting from acute coronary disease have been reduced by more than :50% over the past 30 years, it is reasonable to anticipate further reductions of similar magnitude in the decade ahead.	Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Forrester, JS (corresponding author), Cedars Sinai Med Ctr, Div Cardiol, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.							Aikawa M, 1998, CIRCULATION, V97, P2433, DOI 10.1161/01.CIR.97.24.2433; Anderson JL, 1999, CIRCULATION, V99, P1540, DOI 10.1161/01.CIR.99.12.1540; AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BARATH P, 1990, AM J CARDIOL, V65, P297, DOI 10.1016/0002-9149(90)90291-8; BARATH P, 1988, J AM COLL CARDIOL, V9, P52; Barter PJ, 1997, CLIN EXP PHARMACOL P, V24, P286, DOI 10.1111/j.1440-1681.1997.tb01821.x; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; Bocan TMA, 1998, ATHEROSCLEROSIS, V139, P21, DOI 10.1016/S0021-9150(98)00046-X; Bonnefont-Rousselot D, 1999, CLIN CHEM LAB MED, V37, P939, DOI 10.1515/CCLM.1999.139; Bostom AG, 2000, LANCET, V355, P511, DOI 10.1016/S0140-6736(99)00437-7; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; BURR ML, 1989, LANCET, V2, P757; Campeau L, 1997, NEW ENGL J MED, V336, P153; Casscells W, 1996, LANCET, V347, P1447, DOI 10.1016/S0140-6736(96)91684-0; Chen YH, 1997, CIRCULATION, V95, P1169; Crisby M, 2001, CIRCULATION, V103, P926, DOI 10.1161/01.cir.103.7.926; Danesh J, 1999, JAMA-J AM MED ASSOC, V282, P2169, DOI 10.1001/jama.282.22.2169; Davies MJ, 1997, NEW ENGL J MED, V336, P1312, DOI 10.1056/NEJM199705013361809; De Caterina R, 2001, LIPIDS, V36, pS69, DOI 10.1007/s11745-001-0685-9; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DELALLERAMOYA M, 1994, ARTERIOSCLER THROMB, V14, P1056, DOI 10.1161/01.ATV.14.7.1056; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; Dong ZM, 1998, J CLIN INVEST, V102, P145, DOI 10.1172/JCI3001; Dunne M, 1999, AM HEART J, V138, pS542, DOI 10.1016/S0002-8703(99)70297-8; Eriksson M, 1999, CIRCULATION, V100, P594, DOI 10.1161/01.CIR.100.6.594; FALK E, 1992, CIRCULATION, V86, P30; Felton CV, 1997, ARTERIOSCL THROM VAS, V17, P1337, DOI 10.1161/01.ATV.17.7.1337; FORRESTER JS, 1987, CIRCULATION, V75, P505, DOI 10.1161/01.CIR.75.3.505; Forrester JS, 1996, J AM COLL CARDIOL, V27, P991, DOI 10.1016/0735-1097(96)87732-1; Forrester JS, 1997, CIRCULATION, V96, P1360, DOI 10.1161/01.CIR.96.4.1360; Forrester JS, 2000, J AM COLL CARDIOL, V36, P1419, DOI 10.1016/S0735-1097(00)00829-9; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; Grayston JT, 1999, AM HEART J, V138, pS545, DOI 10.1016/S0002-8703(99)70298-X; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1999, EUR HEART J, V20, P121, DOI 10.1053/euhj.1998.1283; Hasegawa A, 1999, Nihon Rinsho, V57, P2754; Henderson EL, 1999, CIRCULATION, V99, P96, DOI 10.1161/01.CIR.99.1.96; HernandezPresa M, 1997, CIRCULATION, V95, P1532; Ikonomidis I, 1999, CIRCULATION, V100, P793, DOI 10.1161/01.CIR.100.8.793; Kaartinen M, 1996, CIRCULATION, V94, P2787, DOI 10.1161/01.CIR.94.11.2787; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; LaFleur DW, 1997, J BIOL CHEM, V272, P32798, DOI 10.1074/jbc.272.52.32798; Leaf A, 1998, WORLD REV NUTR DIET, V83, P24; LENDON CL, 1991, ATHEROSCLEROSIS, V87, P87, DOI 10.1016/0021-9150(91)90235-U; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Lijnen HR, 1999, CIRC RES, V85, P1186; Mellwig KP, 1998, ATHEROSCLEROSIS, V139, P173, DOI 10.1016/S0021-9150(98)00055-0; MIYAZAKI A, 1995, ARTERIOSCL THROM VAS, V15, P1882, DOI 10.1161/01.ATV.15.11.1882; Miyazaki M, 1999, BRIT J PHARMACOL, V128, P523, DOI 10.1038/sj.bjp.0702833; Muhlestein JB, 2000, CIRCULATION, V102, P1755; Navalkar S, 2001, J AM COLL CARDIOL, V37, P440, DOI 10.1016/S0735-1097(00)01138-4; Nicolosi RJ, 1998, ATHEROSCLEROSIS, V137, P77, DOI 10.1016/S0021-9150(97)00279-7; Pasceri V, 1999, CIRCULATION, V100, P2124, DOI 10.1161/01.CIR.100.21.2124; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Rajavashisth TB, 1999, CIRCULATION, V99, P3103, DOI 10.1161/01.CIR.99.24.3103; Rittershaus CW, 2000, ARTERIOSCL THROM VAS, V20, P2106, DOI 10.1161/01.ATV.20.9.2106; Rohde LE, 1998, ARTERIOSCL THROM VAS, V18, P1765, DOI 10.1161/01.ATV.18.11.1765; Ross R, 1999, AM HEART J, V138, pS419, DOI 10.1016/S0002-8703(99)70266-8; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Saren P, 1996, J IMMUNOL, V157, P4159; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Shah PK, 1998, CIRCULATION, V97, P780, DOI 10.1161/01.CIR.97.8.780; SHAH PK, 1995, CIRCULATION, V92, P1565; Shechter Michael, 1999, Journal of the American College of Cardiology, V33, p271A; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shovman O, 2002, IMMUNOL RES, V25, P271, DOI 10.1385/IR:25:3:271; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; Song K, 1998, ATHEROSCLEROSIS, V138, P171, DOI 10.1016/S0021-9150(98)00021-5; Spady DK, 1999, CIRCULATION, V100, P576, DOI 10.1161/01.CIR.100.6.576; Stefanadis C, 1999, CIRCULATION, V99, P1965, DOI 10.1161/01.CIR.99.15.1965; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Szczeklik A, 1999, J AM COLL CARDIOL, V33, P1286, DOI 10.1016/S0735-1097(99)00023-6; Tangirala RK, 1999, CIRCULATION, V100, P1816, DOI 10.1161/01.CIR.100.17.1816; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; Tribble DL, 1999, CIRCULATION, V99, P591, DOI 10.1161/01.CIR.99.4.591; Tummala PE, 1999, CIRCULATION, V100, P1223, DOI 10.1161/01.CIR.100.11.1223; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; VANDERWAL AC, 1992, AM J PATHOL, V141, P1427; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; Vermeulen EGJ, 2000, LANCET, V355, P517, DOI 10.1016/S0140-6736(99)07391-2; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; Vogel RA, 1999, AM J MED, V107, P479, DOI 10.1016/S0002-9343(99)00261-2; Vollset SE, 2001, AM J CLIN NUTR, V74, P130; Wallner K, 1999, CIRCULATION, V99, P1284, DOI 10.1161/01.CIR.99.10.1284; Warnholtz A, 1999, CIRCULATION, V99, P2027, DOI 10.1161/01.CIR.99.15.2027; Woollett LA, 1997, J LIPID RES, V38, P2289; Xu XP, 1999, CIRCULATION, V99, P993, DOI 10.1161/01.CIR.99.8.993; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2000, NEW ENGL J MED, V342, P145	103	39	43	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					823	833		10.7326/0003-4819-137-10-200211190-00012	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00012			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616VE	12435220				2022-12-28	WOS:000179323400006
J	Roberts, KA; Dixon-Woods, M; Fitzpatrick, R; Abrams, KR; Jones, DR				Roberts, KA; Dixon-Woods, M; Fitzpatrick, R; Abrams, KR; Jones, DR			Factors affecting uptake of childhood immunisation: a Bayesian synthesis of qualitative and quantitative evidence	LANCET			English	Article							SYSTEMATIC REVIEWS; INTERVENTIONS; MMR	Falls in levels of measles, mumps, and rubella (MMR) immunisation in the UK and the continuing debate on how to respond to this situation emphasise the importance of identifying and understanding the factors that affect the uptake of recommended childhood immunisations. Both qualitative and quantitative evidence could be useful in this process. We aimed to explore the feasibility and value of an approach to formal synthesis of qualitative and quantitative evidence in the context of factors affecting the uptake of childhood immunisation in developed countries. We used a Bayesian approach to meta-analysis. Evidence from 11 qualitative and 32 quantitative studies of factors affecting uptake of childhood immunisation was combined and assessed. We conclude that use of either qualitative or quantitative research alone might not identify all relevant factors, or might result in inappropriate judgments about their importance, and could thus lead to inappropriate formulation of evidence-based policy. Further development of our methods might enable rigorous synthesis of qualitative and quantitative evidence in this and other contexts.	Univ Leicester, Leicester LE1 6TP, Leics, England; Univ Oxford, Nuffield Coll, Oxford, England	University of Leicester; University of Oxford	Jones, DR (corresponding author), Univ Leicester, Leicester LE1 6TP, Leics, England.	drj@le.ac.uk	Abrams, Keith/AAA-2557-2020	Dixon-Woods, Mary/0000-0002-5915-0041; Abrams, Keith/0000-0002-7557-1567; fitzpatrick, Ray/0000-0003-0607-0563				Alcock Sharon, 2002, BMJ-BRIT MED J, V324, P492; Ashraf H, 2001, LANCET, V357, P1341, DOI 10.1016/S0140-6736(00)04531-1; Barbour R S, 1999, J Health Serv Res Policy, V4, P39; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; Buck D, 1997, SEIZURE, V6, P87, DOI 10.1016/S1059-1311(97)80060-X; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; CAMPBELL R, IN PRESS SOC SCI MED; Dixon-Woods M, 2001, BRIT MED J, V323, P765, DOI 10.1136/bmj.323.7316.765; Dixon-Woods M, 2001, J EVAL CLIN PRACT, V7, P125, DOI 10.1046/j.1365-2753.2001.00257.x; Genest C., 1986, STAT SCI, V1, P114, DOI [10.1214/ss/1177013825, DOI 10.1214/SS]; GRANT M, 2002, DEV OPTIMAL SEARCH S; JONES DR, METAANALYSIS QUALITA; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Malterud K, 2001, LANCET, V358, P397, DOI 10.1016/S0140-6736(01)05548-9; NEW SJ, 1991, SOC SCI MED, V33, P509, DOI 10.1016/0277-9536(91)90333-8; *NHS CTR REV DISS, 2001, UND SYST REV RES EFF; Noblit GW, 1998, METAETHNOGRAPHY SYNT; O'Hagan A, 1998, J ROY STAT SOC D-STA, V47, P21, DOI 10.1111/1467-9884.00114; Popay J, 1998, J ROY SOC MED, V91, P32, DOI 10.1177/014107689809135S08; Ramsay S, 2002, LANCET, V359, P590, DOI 10.1016/S0140-6736(02)07771-1; Sowden A, 2000, COCHRANE DB SYST REV, V2; Spiegelhalter D J, 2000, Health Technol Assess, V4, P1; Sutton AJ, 2001, STAT METHODS MED RES, V10, P277, DOI 10.1191/096228001678227794; Sutton AJAK, 2000, METHODS METAANALYSIS; Taylor B, 2002, BRIT MED J, V324, P393, DOI 10.1136/bmj.324.7334.393; Udovic SL, 1998, PEDIATR ANN, V27, P355, DOI 10.3928/0090-4481-19980601-10	26	91	92	3	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2002	360	9345					1596	1599		10.1016/S0140-6736(02)11560-1	http://dx.doi.org/10.1016/S0140-6736(02)11560-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443615				2022-12-28	WOS:000179292400033
J	Sankar, P; Cho, MK				Sankar, P; Cho, MK			Toward a new vocabulary of human genetic variation	SCIENCE			English	Editorial Material							RACE; PHARMACOGENOMICS; POPULATIONS; DIVERSITY; GENOMICS		Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Stanford Ctr Biomed Eth, Palo Alto, CA 94304 USA	University of Pennsylvania; Pennsylvania Medicine; Stanford University	Sankar, P (corresponding author), Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA.	sankarp@mail.med.upenn.edu; micho@stanford.edu			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002189] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG002189-01, R01 HGO 2189-02, R01 HG002189-02] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Anand S S, 1999, Ethn Health, V4, P241, DOI 10.1080/13557859998029; Angier Natalie, 2000, NY TIMES        1107, pF1; [Anonymous], 1996, BRIT MED J, V312, P1094; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Collins FS, 2001, CANCER, V91, P221, DOI 10.1002/1097-0142(20010101)91:1+<221::AID-CNCR8>3.3.CO;2-0; Crawford DC, 2000, AM J HUM GENET, V66, P480, DOI 10.1086/302762; Cyranoski D, 2002, NATURE, V416, P115, DOI 10.1038/416115a; Foster MW, 2002, GENOME RES, V12, P844, DOI 10.1101/gr.99202; Freeman HP, 1998, CANCER, V82, P219, DOI 10.1002/(SICI)1097-0142(19980101)82:1<219::AID-CNCR27>3.0.CO;2-4; Fritsche E, 2000, MUTAT RES-GENOMICS, V432, P1, DOI 10.1016/S1383-5726(99)00009-6; Gilbert W., 1992, CODE CODES SCI SOCIA, P84; Haynes MA, 1999, UNEQUAL BURDEN CANC, DOI 10.17226/6377; Jorde LB, 1997, P NATL ACAD SCI USA, V94, P3100, DOI 10.1073/pnas.94.7.3100; Kalow W, 2001, CLIN PHARMACOL THER, V70, P1, DOI 10.1067/mcp.2001.116714; Krings M, 1999, AM J HUM GENET, V64, P1166, DOI 10.1086/302314; Marks J., 2002, WHAT IT MEANS BE PRI; Montague A., 1942, MANS MOST DANGEROUS; Nebert DW, 2001, TRENDS BIOTECHNOL, V19, P519, DOI 10.1016/S0167-7799(01)01805-4; Oppenheimer GM, 2001, AM J PUBLIC HEALTH, V91, P1049, DOI 10.2105/AJPH.91.7.1049; Owens K, 1999, SCIENCE, V286, P451, DOI 10.1126/science.286.5439.451; Risch N., 2002, GENOME BIOL, V3; Rivara FP, 2001, ARCH PEDIAT ADOL MED, V155, P119, DOI 10.1001/archpedi.155.2.119; Romualdi C, 2002, GENOME RES, V12, P602, DOI 10.1101/gr.214902; Schwartz RS, 2001, NEW ENGL J MED, V344, P1392, DOI 10.1056/NEJM200105033441810; Shriver MD, 1997, AM J HUM GENET, V60, P957; Stolberg S G, 2001, N Y Times Web, pA16; Witzig R, 1996, ANN INTERN MED, V125, P675, DOI 10.7326/0003-4819-125-8-199610150-00008; 2001, NATURE GENET, V29, P239; 2000, NATURE GENET, V24, P97	29	104	107	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1337	1338		10.1126/science.1074447	http://dx.doi.org/10.1126/science.1074447			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434037	Green Accepted			2022-12-28	WOS:000179223100022
J	Service, RF				Service, RF			Battle to become the next-generation x-ray source	SCIENCE			English	News Item								For the first time in decades, researchers are looking past synchrotron storage rings for their x-ray future.											0	50	50	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1356	1358		10.1126/science.298.5597.1356	http://dx.doi.org/10.1126/science.298.5597.1356			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434047				2022-12-28	WOS:000179223100035
J	Biondi, B; Palmieri, EA; Lombardi, G; Fazio, S				Biondi, B; Palmieri, EA; Lombardi, G; Fazio, S			Effects of subclinical thyroid dysfunction on the heart	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY-ARTERY-DISEASE; THYROTROPIN-SUPPRESSIVE THERAPY; QUALITY-OF-LIFE; VENTRICULAR DIASTOLIC DYSFUNCTION; IODINE-INDUCED HYPERTHYROIDISM; L-THYROXINE THERAPY; 20-YEAR FOLLOW-UP; RISK-FACTOR; DOUBLE-BLIND; AUTOIMMUNE-THYROIDITIS	Background: mounting evidence indicates that subclinical thyroid dysfunction has important clinical effects and prognostic implications, supporting the view that it is not a compensated biochemical change sensu strictu. Purpose: To review clinical information on the effects of subclinical thyroid dysfunction on the heart. Data Sources: English-language articles identified from files and a MEDLINE search (1970-September 2001), references of relevant articles, textbooks, and meeting abstracts. impaired left ventricular diastolic function at rest, systolic dysfunction on effort, and enhanced risk for atherosclerosis and myocardial infarction. Subclinical hyperthyroidism is associated with increased heart rate, atrial arrhythmias, increased left ventricular mass with marginal concentric remodeling, impaired ventricular relaxation, reduced exercise performance, and increased risk for cardiovascular death. All abnormalities were reversed by restoration of euthyroidism (suclinical hypothyroidism) or were blunted by beta-blockade and tailoring of the L-thyroxine dose (subclinical hyperthyroidism). Study Selection: Reports on the effects of subclinical hypothyroidism and subclinical hyperthyroidism on the cardiovascular system in humans. Data Extraction: Data on cardiac structure and performance, arrhythmias, and risk for coronary artery disease were independently assessed by all authors and summarized. Data Synthesis: Subclinical hypothyroidism is associated with impaired left ventricular diastolic function at rest, systolic dysfunction on effort, and enhanced risk for atherosclerosis and myocardial infarction. Subclinical hyperthyroidism is associated with increased heart rate, atrial arrhythmias, increased left ventricular mass with marginal concentric remodeling, impaired ventricular relaxation, reduced exercise performance, and increased risk for cardiovascular death. All abnormalities were reversed by restoration of euthyroidism (subclinical hypothyroidism) or were blunted by beta-blockade and tailoring of the L-thyroxine dose (subclinical hyperthyroidism). Conclusion: The heart responds to the minimal but persistent changes in circulating thyroid hormone levels typical of subclinical thyroid dysfunction. Thus, the condition is not a compensated biochemical change sensu strictu, and timely treatment should be considered in an attempt to avoid adverse cardiovascular effects.	Univ Naples Federico II, Sch Med, Dept Clin & Mol Endocrinol & Oncol, I-80131 Naples, Italy	University of Naples Federico II	Biondi, B (corresponding author), Univ Naples Federico II, Sch Med, Dept Clin & Mol Endocrinol & Oncol, Via S Pansini 5, I-80131 Naples, Italy.	bebiondi@libero.it	Biondi, Bernadette/AAH-7664-2020	Biondi, Bernadette/0000-0001-8360-4464				Adlin V, 1998, AM FAM PHYSICIAN, V57, P776; Aghini-Lombardi F, 1999, J CLIN ENDOCR METAB, V84, P561, DOI 10.1210/jc.84.2.561; ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; AMIDI M, 1968, CIRCULATION, V38, P229, DOI 10.1161/01.CIR.38.2.229; Arem R, 1996, THYROID, V6, P397, DOI 10.1089/thy.1996.6.397; Ayala AR, 2000, ENDOCRIN METAB CLIN, V29, P399, DOI 10.1016/S0889-8529(05)70139-0; BALL MJ, 1991, J ROY SOC MED, V84, P527, DOI 10.1177/014107689108400908; BANOVAC K, 1989, ARCH INTERN MED, V149, P809, DOI 10.1001/archinte.149.4.809; BASTENIE PA, 1977, LANCET, V2, P155; Bauer DC, 1998, AM J MED, V104, P546, DOI 10.1016/S0002-9343(98)00116-8; BELFIORE A, 1983, J CLIN ENDOCR METAB, V56, P283, DOI 10.1210/jcem-56-2-283; BELL GM, 1985, CLIN ENDOCRINOL, V22, P83, DOI 10.1111/j.1365-2265.1985.tb01068.x; BELL GM, 1983, CLIN ENDOCRINOL, V18, P511, DOI 10.1111/j.1365-2265.1983.tb02881.x; Biondi B, 1996, J CLIN ENDOCR METAB, V81, P4224, DOI 10.1210/jc.81.12.4224; Biondi B, 1999, J CLIN ENDOCR METAB, V84, P2064, DOI 10.1210/jc.84.6.2064; BIONDI B, 1994, J CLIN ENDOCR METAB, V78, P1028, DOI 10.1210/jc.78.5.1028; BIONDI B, 1993, J CLIN ENDOCR METAB, V77, P334, DOI 10.1210/jc.77.2.334; Biondi B, 2000, J CLIN ENDOCR METAB, V85, P4701, DOI 10.1210/jc.85.12.4701; Biondi B, 1999, Cardiologia, V44, P443; BONOW RO, 1992, ANN INTERN MED, V117, P502, DOI 10.7326/0003-4819-117-6-502; BOUGH EW, 1978, ARCH INTERN MED, V138, P1476, DOI 10.1001/archinte.138.10.1476; Bourdoux PP, 1996, LANCET, V347, P552, DOI 10.1016/S0140-6736(96)91188-5; BOUTIN JM, 1986, CLIN ENDOCRINOL, V25, P579, DOI 10.1111/j.1365-2265.1986.tb03612.x; Brenta G., 2000, Endocrine Journal, V47, P221; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Caraccio N., 2000, Endocrine Journal, V47, P225; Ching GW, 1996, HEART, V75, P363, DOI 10.1136/hrt.75.4.363; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; Cooper DS, 1998, THYROID, V8, P737, DOI 10.1089/thy.1998.8.737; Cooper DS, 1998, ANN INTERN MED, V129, P135, DOI 10.7326/0003-4819-129-2-199807150-00016; Cooper DS, 2001, NEW ENGL J MED, V345, P260, DOI 10.1056/NEJM200107263450406; CUOCOLO A, 1990, CIRCULATION, V81, P978, DOI 10.1161/01.CIR.81.3.978; Danese ND, 2000, J CLIN ENDOCR METAB, V85, P2993, DOI 10.1210/jcem.85.9.6841; DAVIES PH, 1992, J CLIN ENDOCR METAB, V74, P1189, DOI 10.1210/jc.74.5.1189; DEAN JW, 1985, BRIT MED J, V290, P1555, DOI 10.1136/bmj.290.6481.1555; Di Bello V, 2000, J AM SOC ECHOCARDIOG, V13, P832, DOI 10.1067/mje.2000.106397; Diekmann T, 1998, J CLIN ENDOCR METAB, V83, P1752, DOI 10.1210/jc.83.5.1752; Dunn JT, 1998, THYROID, V8, P101, DOI 10.1089/thy.1998.8.101; ELTE JWF, 1990, POSTGRAD MED J, V66, P186, DOI 10.1136/pgmj.66.773.186; Fadel BM, 2000, CLIN CARDIOL, V23, P402, DOI 10.1002/clc.4960230605; Fatourechi V, 2001, LANCET, V358, P856, DOI 10.1016/S0140-6736(01)06036-6; FAZIO S, 1995, J CLIN ENDOCR METAB, V80, P2222, DOI 10.1210/jc.80.7.2222; FOLDES J, 1987, ACTA MED HUNG, V44, P337; FORFAR JC, 1985, Q J MED, V57, P857; GEUL KW, 1993, CLIN ENDOCRINOL, V39, P275, DOI 10.1111/j.1365-2265.1993.tb02366.x; Greenland P, 1999, AM J EPIDEMIOL, V149, P853; GRUND FM, 1989, ARCH INTERN MED, V149, P921, DOI 10.1001/archinte.149.4.921; Haider AW, 1998, J AM COLL CARDIOL, V32, P1454, DOI 10.1016/S0735-1097(98)00407-0; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; HAMBURGER JI, 1980, J CLIN ENDOCR METAB, V50, P1089, DOI 10.1210/jcem-50-6-1089; HAWKINS BR, 1980, LANCET, V2, P1057; HEINONEN OP, 1972, LANCET, V1, P785; Helfand M, 1998, ANN INTERN MED, V129, P144, DOI 10.7326/0003-4819-129-2-199807150-00020; HENNESSEY JV, 1986, ANN INTERN MED, V105, P11, DOI 10.7326/0003-4819-105-1-11; Hussein WI, 1999, ANN INTERN MED, V131, P348, DOI 10.7326/0003-4819-131-5-199909070-00005; JENNINGS PE, 1984, BRIT MED J, V289, P1645, DOI 10.1136/bmj.289.6459.1645; Kahaly GJ, 2000, THYROID, V10, P665, DOI 10.1089/10507250050137743; KLEIN I, 1994, J CLIN ENDOCR METAB, V78, P1026, DOI 10.1210/jc.78.5.1026; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; Klein IL, 2000, WERNER INGBARS THYRO, P777; KUNG AWC, 1995, CLIN ENDOCRINOL, V43, P445, DOI 10.1111/j.1365-2265.1995.tb02616.x; LADENSON PW, 1993, J CLIN ENDOCR METAB, V77, P332, DOI 10.1210/jc.77.2.332; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; Lekakis J, 1997, THYROID, V7, P411, DOI 10.1089/thy.1997.7.411; LEVEY GS, 1990, AM J MED, V88, P642, DOI 10.1016/0002-9343(90)90533-J; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; Marqusee E, 1998, ENDOCRIN METAB CLIN, V27, P37, DOI 10.1016/S0889-8529(05)70296-6; Mercuro G, 2000, J CLIN ENDOCR METAB, V85, P159, DOI 10.1210/jc.85.1.159; MINTZ G, 1991, J CLIN ENDOCR METAB, V73, P146, DOI 10.1210/jcem-73-1-146; Miura S, 1996, ENDOCR J, V43, P657, DOI 10.1507/endocrj.43.657; Monzani F, 2001, J CLIN ENDOCR METAB, V86, P1110, DOI 10.1210/jc.86.3.1110; Morris MS, 2001, ATHEROSCLEROSIS, V155, P195, DOI 10.1016/S0021-9150(00)00537-2; MULLER B, 1995, NEW ENGL J MED, V333, P964, DOI 10.1056/NEJM199510123331503; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; OETTGEN P, 1994, AM J CARDIOL, V73, P955, DOI 10.1016/0002-9149(94)90138-4; Padayatty S, 1998, J CLIN ENDOCR METAB, V83, P2607, DOI 10.1210/jc.83.7.2607; Parle JV, 2001, LANCET, V358, P861, DOI 10.1016/S0140-6736(01)06067-6; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PARLE JV, 1992, CLIN ENDOCRINOL, V37, P411, DOI 10.1111/j.1365-2265.1992.tb02351.x; Parry CH., 1825, COLLECTIONS UNPUBLIS, P111; Perk M, 1997, CAN J CARDIOL, V13, P273; Peters A, 2000, ARCH INTERN MED, V160, P1993, DOI 10.1001/archinte.160.13.1993; Pirich C, 2000, J CLIN EPIDEMIOL, V53, P623, DOI 10.1016/S0895-4356(99)00187-0; POLIKAR R, 1993, CIRCULATION, V87, P1435, DOI 10.1161/01.CIR.87.5.1435; RIDGWAY EC, 1981, J CLIN ENDOCR METAB, V53, P1238, DOI 10.1210/jcem-53-6-1238; ROHRER D, 1988, J BIOL CHEM, V263, P6941; Ross Douglas S., 1996, P1010; Ross Douglas S., 1996, P1016; ROSS DS, 1990, J CLIN ENDOCR METAB, V71, P764, DOI 10.1210/jcem-71-3-764; Samuels MH, 1998, THYROID, V8, P803, DOI 10.1089/thy.1998.8.803; SANDROCK D, 1993, ACTA ENDOCRINOL-COP, V128, P51, DOI 10.1530/acta.0.1280051; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; SAWIN CT, 1991, ARCH INTERN MED, V151, P165, DOI 10.1001/archinte.151.1.165; SERIES JJ, 1988, CLIN CHIM ACTA, V172, P217, DOI 10.1016/0009-8981(88)90326-9; Sgarbi J. A., 2000, Endocrine Journal, V47, P179; Shapiro LE, 1997, J CLIN ENDOCR METAB, V82, P2592, DOI 10.1210/jc.82.8.2592; Stanbury JB, 1998, THYROID, V8, P83, DOI 10.1089/thy.1998.8.83; STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7; STEINBERG AD, 1968, ANN INTERN MED, V68, P338, DOI 10.7326/0003-4819-68-2-338; STOTT DJ, 1991, Q J MED, V78, P77; SUNDBECK G, 1991, ARCH INTERN MED, V151, P549, DOI 10.1001/archinte.151.3.549; Surks MI, 1996, AM J MED, V100, P217, DOI 10.1016/S0002-9343(97)89462-4; TENERZ A, 1990, J INTERN MED, V228, P229; TIECHE M, 1981, BRIT HEART J, V46, P202, DOI 10.1136/hrt.46.2.202; TOFT AD, 1994, NEW ENGL J MED, V331, P174; Toft AD, 2001, NEW ENGL J MED, V345, P512, DOI 10.1056/NEJMcp010145; TSENG KH, 1989, J CLIN ENDOCR METAB, V69, P633, DOI 10.1210/jcem-69-3-633; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P495, DOI 10.1111/j.1365-2265.1977.tb01341.x; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; Tzotzas T, 2000, THYROID, V10, P803, DOI 10.1089/thy.2000.10.803; Vanderpump Mark P. J., 1996, P474; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Vanderpump MPJ, 1996, THYROID, V6, P155; VANHAELST L, 1967, LANCET, V2, P800, DOI 10.1016/S0140-6736(67)92235-0; Wang C, 1997, ENDOCRIN METAB CLIN, V26, P189, DOI 10.1016/S0889-8529(05)70240-1	117	294	317	2	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					904	914		10.7326/0003-4819-137-11-200212030-00011	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00011			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622GY	12458990				2022-12-28	WOS:000179639700006
J	Gallo, RC; Montagnier, L				Gallo, RC; Montagnier, L			Historical essay - Enhanced Prospects for the future	SCIENCE			English	Editorial Material							HIV-1; INHIBITION		Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; World Fdn AIDS Res & Prevent, F-75015 Paris, France	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Gallo, RC (corresponding author), Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA.							Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Davis C, 2001, J HUMAN VIROL, V4, P113; Fouts T, 2002, P NATL ACAD SCI USA, V99, P11842, DOI 10.1073/pnas.182412199; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Heredia A, 2000, J ACQ IMMUN DEF SYND, V25, P246, DOI 10.1097/00126334-200011010-00006; Khanna KV, 2002, J CLIN INVEST, V109, P205; LaBranche CC, 2001, ANTIVIR RES, V50, P95, DOI 10.1016/S0166-3542(01)00130-9; Moore JP, 1999, NAT MED, V5, P142, DOI 10.1038/5502; Palani A, 2002, J MED CHEM, V45, P3143, DOI 10.1021/jm0200815	9	14	19	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1730	1731		10.1126/science.1079864	http://dx.doi.org/10.1126/science.1079864			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459577				2022-12-28	WOS:000179494800029
J	Montagnier, L				Montagnier, L			Historical essay - A history of HIV discovery	SCIENCE			English	Editorial Material							HUMAN RETROVIRUS; AIDS; LAV; RECEPTOR; VIRUS		World Fdn Aids Res & Prevent, F-75015 Paris, France		Montagnier, L (corresponding author), World Fdn Aids Res & Prevent, 1 Rue Miollis, F-75015 Paris, France.							ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; BARRESINOUSSI F, 1979, ANN INST PASTEUR MIC, VB130, P349; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; CREPIN M, 1984, BIOCHEM BIOPH RES CO, V118, P324, DOI 10.1016/0006-291X(84)91104-5; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KULSTAD Ruth, 1986, AIDS PAPERS SCI 1982; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; MONTAGNIER Luc, 1984, HUMAN T CELL LEUKEMI, P363; VIGIER P, 1975, INT J CANCER, V15, P67, DOI 10.1002/ijc.2910150109; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026	13	55	62	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1727	1728		10.1126/science.1079027	http://dx.doi.org/10.1126/science.1079027			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459575				2022-12-28	WOS:000179494800027
J	Olson, JW; Maier, RJ				Olson, JW; Maier, RJ			Molecular hydrogen as an energy source for Helicobacter pylori	SCIENCE			English	Article							TRANSIT-TIME; EXPRESSION; GENE; HINDGUT	The gastric pathogen Helicobacter pylori is known to be able to use molecular hydrogen as a respiratory substrate when grown in the laboratory. We found that hydrogen is available in the gastric mucosa of mice and that its use greatly increased the stomach colonization by H. pylori. Hydrogenase activity in H. pylori is constitutive but increased fivefold upon incubation with hydrogen. Hydrogen concentrations measured in the stomachs of live mice were found to be 10 to 50 times as high as the H. pylori affinity for hydrogen. A hydrogenase mutant strain is much less efficient in its colonization of mice. Therefore, hydrogen present in animals as a consequence of normal colonic. ora is an energy-yielding substrate that can facilitate the maintenance of a pathogenic bacterium.	Univ Georgia, Dept Microbiol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Maier, RJ (corresponding author), Univ Georgia, Dept Microbiol, Athens, GA 30602 USA.							BLACK LK, 1994, J BACTERIOL, V176, P7102, DOI 10.1128/JB.176.22.7102-7106.1994; Blaser MJ, 1998, BRIT MED J, V316, P1507, DOI 10.1136/bmj.316.7143.1507; BOND JH, 1975, J LAB CLIN MED, V85, P546; BROWN NJ, 1987, GUT, V28, P849, DOI 10.1136/gut.28.7.849; COLBEAU A, 1992, J BACTERIOL, V174, P4258, DOI 10.1128/JB.174.13.4258-4264.1992; Doig P, 1999, MICROBIOL MOL BIOL R, V63, P675, DOI 10.1128/MMBR.63.3.675-707.1999; Ebert A, 1997, APPL ENVIRON MICROB, V63, P4039, DOI 10.1128/AEM.63.10.4039-4046.1997; KUENEN G, 1999, BIOL PROKARYOTES, pCH10; Lemke T, 2001, APPL ENVIRON MICROB, V67, P4657, DOI 10.1128/AEM.67.10.4657-4661.2001; Lenz O, 1997, J BACTERIOL, V179, P1655, DOI 10.1128/jb.179.5.1655-1663.1997; LEVITT MD, 1969, NEW ENGL J MED, V281, P122, DOI 10.1056/NEJM196907172810303; Maier RJ, 1996, FEMS MICROBIOL LETT, V141, P71; MCCRAE RE, 1978, BIOCHEM BIOPH RES CO, V80, P384, DOI 10.1016/0006-291X(78)90688-5; REYNOLDS DJ, 1994, MICROBIOL-UK, V140, P2649, DOI 10.1099/00221287-140-10-2649; Salyers A, 2002, BACTERIAL PATHOGENES; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WOLIN MJ, 1994, ACETOGENESIS, pCH13; ZUKOWSKI MM, 1983, P NATL ACAD SCI-BIOL, V80, P1101, DOI 10.1073/pnas.80.4.1101; [No title captured]	19	229	247	4	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1788	1790		10.1126/science.1077123	http://dx.doi.org/10.1126/science.1077123			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459589				2022-12-28	WOS:000179494800045
J	Adam, D				Adam, D			Manchester merger set to proceed as southerners go solo	NATURE			English	News Item																		2002, NATURE, V416, P114; 2002, NATURE, V419, P658	2	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					350	350		10.1038/420350a	http://dx.doi.org/10.1038/420350a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459749	Bronze			2022-12-28	WOS:000179494700008
J	Takano, J; Noguchi, K; Yasumori, M; Kobayashi, M; Gajdos, Z; Miwa, K; Hayashi, H; Yoneyama, T; Fujiwara, T				Takano, J; Noguchi, K; Yasumori, M; Kobayashi, M; Gajdos, Z; Miwa, K; Hayashi, H; Yoneyama, T; Fujiwara, T			Arabidopsis boron transporter for xylem loading	NATURE			English	Article							MEDIATED GENE-TRANSFER; SACCHAROMYCES-CEREVISIAE; BORIC-ACID; THALIANA MUTANT; PLANTS; TRANSLOCATION; PERMEABILITY; EXPRESSION; SUNFLOWER; MEMBRANE	Boron deficiency hampers the productivity of 132 crops in more than 80 countries(1). Boron is essential in higher plants primarily for maintaining the integrity of cell walls(2-4) and is also beneficial and might be essential in animals(5) and in yeast(6). Understanding the molecular mechanism(s) of boron transport is crucial for alleviating boron deficiency. Here we describe the molecular identification of boron transporters in biological systems. The Arabidopsis thaliana mutant bor1-1 is sensitive to boron deficiency(7,8). Uptake studies indicated that xylem loading is the key step for boron accumulation in shoots with a low external boron supply and that the bor1-1 mutant is defective in this process. Positional cloning identified BOR1 as a membrane protein with homology to bicarbonate transporters in animals. Moreover, a fusion protein of BOR1 and green fluorescent protein (GFP) localized to the plasma membrane in transformed cells. The promoter of BOR1 drove GFP expression in root pericycle cells. When expressed in yeast, BOR1 decreased boron concentrations in cells. We show here that BOR1 is an efflux-type boron transporter for xylem loading and is essential for protecting shoots from boron deficiency.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Fujiwara, T (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan.	atorufu@mail.ecc.u-tokyo.ac.jp	MIWA, Kyoko/D-4220-2009; Khan, Raza/D-2130-2011; Noguchi, Kyotaro/B-4137-2013; FUJIWARA, Toru/A-4119-2011; Takano, Junpei/A-5255-2012	Khan, Raza/0000-0003-4622-8177; Takano, Junpei/0000-0002-7474-3101; Miwa, Kyoko/0000-0001-7328-3628				Alper SL, 2002, J NEPHROL, V15, pS41; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Bennett A, 1999, J NUTR, V129, P2236, DOI 10.1093/jn/129.12.2236; Brown PH, 2002, PLANT BIOLOGY, V4, P205, DOI 10.1055/s-2002-25740; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Dannel F, 1998, J PLANT PHYSIOL, V153, P615, DOI 10.1016/S0176-1617(98)80212-5; Dannel F, 2000, AUST J PLANT PHYSIOL, V27, P397; Dannel F, 2002, PLANT BIOLOGY, V4, P193, DOI 10.1055/s-2002-25730; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; Dordas C, 2000, PLANT PHYSIOL, V124, P1349, DOI 10.1104/pp.124.3.1349; Dordas C, 2001, BIOL TRACE ELEM RES, V81, P127, DOI 10.1385/BTER:81:2:127; FUJIWARA T, 1992, PLANT PHYSIOL, V99, P263, DOI 10.1104/pp.99.1.263; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; JEFFERSON RA, 1987, EMBO J, V6, P3901; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Nielsen FH, 2000, NUTRITION, V16, P512, DOI 10.1016/S0899-9007(00)00324-5; Noguchi K, 2000, J PLANT PHYSIOL, V156, P751, DOI 10.1016/S0176-1617(00)80242-4; Noguchi K, 1997, PLANT PHYSIOL, V115, P901, DOI 10.1104/pp.115.3.901; O'Neill MA, 2001, SCIENCE, V294, P846, DOI 10.1126/science.1062319; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POIRIER Y, 1991, PLANT PHYSIOL, V97, P1087, DOI 10.1104/pp.97.3.1087; RAVEN JA, 1980, NEW PHYTOL, V84, P231, DOI 10.1111/j.1469-8137.1980.tb04424.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shorrocks VM, 1997, PLANT SOIL, V193, P121, DOI 10.1023/A:1004216126069; Soleimani M, 2002, J NEPHROL, V15, pS32; Stangoulis JCR, 2001, PLANTA, V213, P142, DOI 10.1007/s004250000484; Takano J, 2001, SOIL SCI PLANT NUTR, V47, P345, DOI 10.1080/00380768.2001.10408398; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yasumori M., 1999, Plant nutrition - molecular biology and genetics. Proceedings of the Sixth International Symposium on Genetics and Molecular Biology of Plant Nutrition, Elsinore, Denmark, 17-21 August 1998., P269; Zhao RM, 2001, AM J PHYSIOL-CELL PH, V281, pC33, DOI 10.1152/ajpcell.2001.281.1.C33	30	451	479	7	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	2002	420	6913					337	340		10.1038/nature01139	http://dx.doi.org/10.1038/nature01139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447444				2022-12-28	WOS:000179340400047
J	Meade, T; Zuhrie, R; Cook, C; Cooper, J				Meade, T; Zuhrie, R; Cook, C; Cooper, J		MRC Gen Practice Res Framework	Bezafibrate in men with lower extremity arterial disease: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; FIBRINOGEN; GEMFIBROZIL; PREVENTION	Objective To assess the effect of bezafibrate on the risk of coronary heart disease and stroke in men with lower extremity arterial disease. Design Double blind placebo controlled randomised trial. Setting 85 general practices and nine hospital vascular clinics. Participants 1568 men, mean age 68.2 years (range 35 to 92) at recruitment. Interventions Bezafibrate 400 mg daily (783 men) or placebo (785 men). Main outcome measures Combination of coronary heart disease and of stroke. All coronary events, fatal and non-fatal coronary events separately, and strokes alone (secondary end points). Results Bezafibrate did not reduce the incidence of coronary heart disease and stroke. There were 150 and 160 events in the active and placebo groups respectively (relative risk 0.96, 95% confidence interval 0.76 to 1.21). There were 90 and 111 major coronary events in the active and placebo groups respectively (0.81, 0.60 to 1.08), of which 64 and 65 were fatal (0.95, 0.66 to 1.37) and 26 and 46 non-fatal (0.60, 0.36 to 0.99). Beneficial effects on non-fatal events were greatest in men aged < 65 years at entry, in whom benefit was also seen for all coronary events (0.38, 0.20 to 0.72). There were no significant effects in older men. There were 60 strokes in those on active treatment and 49 in those on placebo (1.34, 0.80 to 2.01). There were 204 and 195 deaths from all causes in the two groups respectively (1.03, 0.83 to 1.26). Bezafibrate reduced the severity of intermittent claudication for up to three years. Conclusions Bezafibrate has no effect on the incidence of coronary heart disease and of stroke combined but may reduce the incidence of non-fatal coronary events, particularly in those aged < 65 years at entry, in whom all coronary events may also be reduced.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England; Wolfson Inst Prevent Med, MRC, Epidemiol & Med Care Unit, London EC1M 6BQ, England	University of London; London School of Hygiene & Tropical Medicine; University of London; Queen Mary University London	Meade, T (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.							BANERJEE AK, 1992, THROMB HAEMOSTASIS, V68, P261; *COMM PRINC INV, 1978, HEART J, P1069; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; DOWNS JR, 1995, AM J CARDIOL, V75, P1130; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDBOURT U, 1993, AM J CARDIOL, V71, P909, DOI 10.1016/0002-9149(93)90905-R; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Jonkers IJAM, 1999, LANCET, V354, P1208, DOI 10.1016/S0140-6736(05)75415-5; KOSTER T, 1994, THROMB HAEMOSTASIS, V71, P719; LENG GC, 1991, EPIDEMIOLOGY PERIPHE, P167; Meade TW, 2001, CURR CONTR TRIALS C, V2, P195, DOI 10.1186/CVM-2-4-195; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Meade TW., 1994, HAEMOSTASIS THROMBOS, V3rd ed, P1199; MONTALESCOT G, 1995, CIRCULATION, V92, P31, DOI 10.1161/01.CIR.92.1.31; *MRC GEN PRACT RES, 1998, LANCET, V321, P129; RESCH KL, 1992, ANN INTERN MED, V117, P371, DOI 10.7326/0003-4819-117-5-371; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Schlesinger Z, 2000, CIRCULATION, V102, P21, DOI 10.1161/01.CIR.102.1.21; Steiner G, 2001, LANCET, V357, P905	21	164	165	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2002	325	7373					1139	1141		10.1136/bmj.325.7373.1139	http://dx.doi.org/10.1136/bmj.325.7373.1139			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433762	Green Published, Bronze			2022-12-28	WOS:000179443100017
J	Moore, S; Corner, J; Haviland, J; Wells, M; Salmon, E; Normand, C; Brada, M; O'Brien, M; Smith, I				Moore, S; Corner, J; Haviland, J; Wells, M; Salmon, E; Normand, C; Brada, M; O'Brien, M; Smith, I			Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE; INSTRUMENT; DEATH	Objective To assess the effectiveness of nurse led follow up in the management of patients with lung cancer. Design Randomised controlled trial. Setting Specialist cancer hospital and three cancer units in southeastern England. Participants 203 patients with lung cancer who had completed their initial treatment and were expected to survive for at least 3 months. Intervention Nurse led follow up of outpatients compared with conventional medical follow up. Outcome measures Quality of life, patients' satisfaction, general practitioners' satisfaction, survival, symptom-free survival, progression-free survival, use of resources, and comparison of costs. Results Patient acceptability of nurse led follow up was high: 75% (203/271) of eligible patients consented to participate. Patients who received the intervention had less severe dyspnoea at 3 months (P=0.03) and had better scores for emotional functioning (P=0.03) and less peripheral neuropathy (P=0.05) at 12 months. Intervention group patients scored significantly better in most satisfaction subscales at 3, 6, and 12 months (P < 0.01 for all subscales at 3 months). No significant differences in general practitioners' overall satisfaction were seen between the two groups. No differences were seen in survival or rates of objective progression, although nurses recorded progression of symptoms sooner than doctors (P=0.01). Intervention patients were more likely to die at home rather than in a hospital or hospice (P=0.04), attended fewer consultations with a hospital doctor during the first 3 months (P=0.004), had fewer radiographs during the first 6 months (P=0.04), and had more radiotherapy within the first 3 months (P=0.01). No other differences were seen between the two groups in terms of the use of resources. Conclusion Nurse led follow up was acceptable to lung cancer patients and general practitioners and led to positive outcomes.	Univ Southampton, Sch Nursing & Midwifery, Southampton SO17 1BJ, Hants, England; Royal Marsden Hosp, Inst Canc Res, Ctr Canc & Palliat Care Studies, London SW3 6JJ, England; Inst Canc Res, Clin Trials & Stat Unit, Epidemiol Sect, Sutton SM2 5NG, Surrey, England; London Sch Hyg & Trop Med, Dept Epidemiol & Publ Hlth, London WC1A 7HT, England; Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England	University of Southampton; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine; Royal Marsden NHS Foundation Trust	Corner, J (corresponding author), Univ Southampton, Sch Nursing & Midwifery, Southampton SO17 1BJ, Hants, England.	j.l.corner@soton.ac.uk		Haviland, Joanne/0000-0001-5728-3636; Wells, Mary/0000-0001-5789-2773; Corner, Jessica/0000-0002-2240-8133; Normand, Charles/0000-0002-0885-5754				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Avis M, 1995, J Nurs Manag, V3, P59, DOI 10.1111/j.1365-2834.1995.tb00082.x; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; *DEP HLTH, 2000, NEW NHS 2000 REF COS; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; Faithfull S, 2001, BRIT J CANCER, V85, P1853, DOI 10.1054/bjoc.2001.2173; FAYERS P, 1995, EORTC QLQ 30 SCORING; GHEZZI P, 1994, JAMA-J AM MED ASSOC, V271, P1587, DOI 10.1001/jama.1994.03510440047031; Grande GE, 1999, BRIT MED J, V319, P1472, DOI 10.1136/bmj.319.7223.1472; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Grunfeld E, 1996, BMJ-BRIT MED J, V313, P665; Hinton John, 1994, Palliative Medicine, V8, P183, DOI 10.1177/026921639400800302; Hopwood P, 2000, J CLIN ONCOL, V18, P893, DOI 10.1200/JCO.2000.18.4.893; KIEVIT J, 1995, EUR J CANCER, V31A, P1222, DOI 10.1016/0959-8049(95)00155-C; MAGUIRE P, 1985, BRIT J HOSP MED, V34, P100; MCWHINNEY IR, 1994, BRIT MED J, V309, P1340, DOI 10.1136/bmj.309.6965.1340; Moore S, 1999, NURSING TIMES RES, V4, P432; *NAT CANC ALL, 1996, PAT CTR SERV WHAT PA; Netten A.P., 2000, UNIT COSTS HLTH SOCI; *OFF NAT STAT, 1997, MORT STAT GEN REV RE; Radford JA, 1997, BRIT MED J, V314, P343, DOI 10.1136/bmj.314.7077.343a; STEVENS W, 2000, CASTING HLTH CARE IN; Thomas LH, 1996, QUAL HEALTH CARE, V5, P67, DOI 10.1136/qshc.5.2.67; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; Wolf M H, 1978, J Behav Med, V1, P391, DOI 10.1007/BF00846695	25	188	189	1	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	2002	325	7373					1145	1147		10.1136/bmj.325.7373.1145	http://dx.doi.org/10.1136/bmj.325.7373.1145			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433764	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000179443100019
J	Geissler, A; Chacinska, A; Truscott, KN; Wiedemann, N; Brandner, K; Sickmann, A; Meyer, HE; Meisinger, C; Pfanner, N; Rehling, P				Geissler, A; Chacinska, A; Truscott, KN; Wiedemann, N; Brandner, K; Sickmann, A; Meyer, HE; Meisinger, C; Pfanner, N; Rehling, P			The mitochondrial presequence translocase: An essential role of Tim50 in directing preproteins to the import channel	CELL			English	Article							PROTEIN IMPORT; INNER-MEMBRANE; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; SORTING SIGNAL; MATRIX HSP70; RECEPTORS; INTERACTS; COMPLEX; TIM23	Mitochondrial proteins with N-terminal targeting signals are transported across the inner membrane via the presequence translocase, which consists of membrane-integrated channel proteins and the matrix Hsp70 import motor. It has not been known how pre-proteins are directed to the import channel. We have identified the essential protein Tim50, which exposes its major domain to the intermembrane space. Tim50 interacts with preproteins in transit and directs them to the channel protein Tim23. Inactivation of Tim50 strongly inhibits the import of preproteins with a classical matrix-targeting signal, while preproteins carrying an additional inner membrane-sorting signal do not strictly depend on Tim50. Thus, Tim50 is crucial for guiding the precursors of matrix proteins to their insertion site in the inner membrane.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Fak Biol, D-79104 Freiburg, Germany; Ruhr Univ Bochum, Med Proteom Ctr, D-44780 Bochum, Germany	University of Freiburg; Ruhr University Bochum	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	nikolaus.pfanner@biochemie.uni-freiburg.de	Sickmann, Albert/A-1010-2011; Truscott, Kaye/D-3362-2012; Pfanner, Nikolaus/AAV-7878-2021; Meisinger, Chris/J-1110-2014	Sickmann, Albert/0000-0002-2388-5265; Meisinger, Chris/0000-0002-8326-3548; Truscott, Kaye/0000-0002-5352-9835; Chacinska, Agnieszka/0000-0002-2832-2568; Wiedemann, Nils/0000-0001-8305-6728				Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOM J, 1995, EUR J BIOCHEM, V232, P309, DOI 10.1111/j.1432-1033.1995.tb20813.x; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; GARTNER F, 1995, EMBO J, V14, P6043, DOI 10.1002/j.1460-2075.1995.tb00293.x; GARTNER F, 1995, J BIOL CHEM, V270, P3788; Geissler A, 2000, MOL BIOL CELL, V11, P3977, DOI 10.1091/mbc.11.11.3977; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Kanamori T, 1997, P NATL ACAD SCI USA, V94, P485, DOI 10.1073/pnas.94.2.485; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Ryan KR, 1998, MOL CELL BIOL, V18, P178, DOI 10.1128/MCB.18.1.178; RYAN KR, 1993, J BIOL CHEM, V268, P23743; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; Sickman A, 2002, J CHROMATOGR B, V771, P167, DOI 10.1016/S1570-0232(01)00626-2; Siniossoglou S, 2000, J BIOL CHEM, V275, P19352, DOI 10.1074/jbc.M001314200; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119	30	202	208	0	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	2002	111	4					507	518		10.1016/S0092-8674(02)01073-5	http://dx.doi.org/10.1016/S0092-8674(02)01073-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437924	Bronze			2022-12-28	WOS:000179346900004
J	Linhardt, RJ; Toida, T				Linhardt, RJ; Toida, T			Ultra-high resolution separation comes of age	SCIENCE			English	Article							CAPILLARY-ELECTROPHORESIS; ELECTROKINETIC CHROMATOGRAPHY		Univ Iowa, Dept Chem, Div Med & Nat Prod Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem & Biochem Engn, Iowa City, IA 52242 USA; Chiba Univ, Grad Sch Pharmaceut Sci, Dept Bioanalyt Chem, Chiba 2638522, Japan	University of Iowa; University of Iowa; Chiba University	Linhardt, RJ (corresponding author), Univ Iowa, Dept Chem, Div Med & Nat Prod Chem, Iowa City, IA 52242 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622, R01HL062244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62244, HL52622] Funding Source: Medline; NIGMS NIH HHS [GM38060] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albargheuthi MN, 2000, ELECTROPHORESIS, V21, P4096, DOI 10.1002/1522-2683(200012)21:18<4096::AID-ELPS4096>3.0.CO;2-W; Amini A, 2001, ELECTROPHORESIS, V22, P3107, DOI 10.1002/1522-2683(200109)22:15<3107::AID-ELPS3107>3.0.CO;2-Z; Baldwin RP, 2000, ELECTROPHORESIS, V21, P4017, DOI 10.1002/1522-2683(200012)21:18<4017::AID-ELPS4017>3.3.CO;2-X; Chiu DT, 1998, SCIENCE, V279, P1190, DOI 10.1126/science.279.5354.1190; Dolnik V, 2001, ELECTROPHORESIS, V22, P4163, DOI 10.1002/1522-2683(200111)22:19<4163::AID-ELPS4163>3.0.CO;2-9; Dovichi N J, 2001, Methods Mol Biol, V167, P225; GORDON MJ, 1988, SCIENCE, V242, P224, DOI 10.1126/science.242.4876.224; Hjerten S, 1967, Chromatogr Rev, V9, P122, DOI 10.1016/0009-5907(67)80003-6; Horvath J, 2001, ELECTROPHORESIS, V22, P644, DOI 10.1002/1522-2683(200102)22:4<644::AID-ELPS644>3.0.CO;2-3; JORGENSON JW, 1981, ANAL CHEM, V53, P1298, DOI 10.1021/ac00231a037; Lacher NA, 2001, ELECTROPHORESIS, V22, P2526, DOI 10.1002/1522-2683(200107)22:12<2526::AID-ELPS2526>3.0.CO;2-K; Larsen LA, 2000, COMB CHEM HIGH T SCR, V3, P393; Liu CY, 2001, ELECTROPHORESIS, V22, P612, DOI 10.1002/1522-2683(200102)22:4<612::AID-ELPS612>3.0.CO;2-N; Manetto G, 2000, THER DRUG MONIT, V22, P84, DOI 10.1097/00007691-200002000-00018; Patrick JS, 2001, ELECTROPHORESIS, V22, P4179, DOI 10.1002/1522-2683(200111)22:19<4179::AID-ELPS4179>3.0.CO;2-8; Pesek JJ, 2000, J CHROMATOGR A, V887, P31, DOI 10.1016/S0021-9673(00)00180-1; Pyell U, 2001, FRESEN J ANAL CHEM, V371, P691, DOI 10.1007/s002160100981; Sutherland JC, 2001, ELECTROPHORESIS, V22, P843, DOI 10.1002/1522-2683()22:5<843::AID-ELPS843>3.0.CO;2-9; Swinney K, 2000, ELECTROPHORESIS, V21, P1239, DOI 10.1002/(SICI)1522-2683(20000401)21:7<1239::AID-ELPS1239>3.0.CO;2-6; THANAWIROON C, 2002, AFFINITY CAPILLARY E, P265; Valaskovic GA, 1996, SCIENCE, V273, P1199, DOI 10.1126/science.273.5279.1199; Waterval JCM, 2000, ELECTROPHORESIS, V21, P4029, DOI 10.1002/1522-2683(200012)21:18<4029::AID-ELPS4029>3.0.CO;2-S; Yeung ES, 1999, J CHROMATOGR A, V830, P243, DOI 10.1016/S0021-9673(98)00920-0	23	40	41	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1441	1442		10.1126/science.298.5597.1441	http://dx.doi.org/10.1126/science.298.5597.1441			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434063				2022-12-28	WOS:000179223100057
J	Patterson, RL; van Rossum, DB; Ford, DL; Hurt, KJ; Bae, SS; Suh, PG; Kurosaki, T; Snyder, SH; Gill, DL				Patterson, RL; van Rossum, DB; Ford, DL; Hurt, KJ; Bae, SS; Suh, PG; Kurosaki, T; Snyder, SH; Gill, DL			Phospholipase C-gamma is required for agonist-induced Ca2+ entry	CELL			English	Article							NECROTIC CELL-DEATH; TYROSINE PHOSPHORYLATION; STORE DEPLETION; TRPC3 CHANNELS; CALCIUM-ENTRY; RECEPTOR; PROTEIN; ACTIVATION; C-GAMMA-1; MECHANISM	We report here that PLC-gamma isoforms are required for agonist-induced Ca2+ entry (ACE). Overexpressed wild-type PLC-gamma1 or a lipase-inactive mutant PLC-gamma1 each augmented ACE in PC12 cells, while a deletion mutant lacking the region containing the SH3 domain of PLC-gamma1 was ineffective. RNA interference to deplete either PLC-gamma1 or PLC-gamma2 in PC12 and A7r5 cells inhibited ACE. In DT40 B lymphocytes expressing only PLC-gamma2, overexpressed muscarinic M5 receptors (M5R) activated ACE. Using DT40 PLC-gamma2 knockout cells, M5R stimulation of ER Ca2+ store release was unaffected, but ACE was abolished. Normal ACE was restored by transient expression of PLC-gamma2 or a lipase-inactive PLC-gamma2 mutant. The results indicate a lipase-independent role of PLC-gamma in the physiological agonist-induced activation of Ca2+ entry.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk 790784, South Korea; Kansai Med Univ, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Pohang University of Science & Technology (POSTECH); Kansai Medical University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	ssnyder@jhmi.edu	Hurt, K. Joseph/J-8266-2019; Suh, Pann-Ghill/F-3610-2010; Kurosaki, Tomohiro/D-1306-2009	Hurt, K. Joseph/0000-0001-6906-350X; Kurosaki, Tomohiro/0000-0002-6352-304X; van Rossum, Damian/0000-0003-1011-2586	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55426] Funding Source: Medline; NIDA NIH HHS [DA-00074] Funding Source: Medline; NIH HHS [NH65090] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arrieumerlou C, 2000, J IMMUNOL, V165, P3182, DOI 10.4049/jimmunol.165.6.3182; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P976, DOI 10.1016/0006-291X(89)92204-3; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Fernando KC, 1997, BIOCHEM J, V328, P463; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Heuss C, 1999, NAT NEUROSCI, V2, P1070, DOI 10.1038/15996; Heuss C, 2000, TRENDS NEUROSCI, V23, P469, DOI 10.1016/S0166-2236(00)01643-X; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; Kim MJ, 2000, BIOCHEMISTRY-US, V39, P8674, DOI 10.1021/bi992558t; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kurosaki T, 2000, IMMUNOL REV, V176, P19; LIAO CF, 1989, J BIOL CHEM, V264, P7328; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; MONTELL C, 2001, PHYSL PHYLOGENY FUNC; NIKODIJEVIC B, 1994, CELL MOL NEUROBIOL, V14, P27, DOI 10.1007/BF02088587; Onofri F, 2000, J BIOL CHEM, V275, P29857, DOI 10.1074/jbc.M006018200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Puceat M, 1996, BIOCHEM J, V318, P723, DOI 10.1042/bj3180723; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Quitterer U, 1999, P NATL ACAD SCI USA, V96, P10626, DOI 10.1073/pnas.96.19.10626; Raghu P, 2000, MOL CELL NEUROSCI, V15, P429, DOI 10.1006/mcne.2000.0846; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; UFRETVINCENTY CA, 1995, J BIOL CHEM, V270, P26790, DOI 10.1074/jbc.270.45.26790; van de Water B, 1999, CHEM RES TOXICOL, V12, P943, DOI 10.1021/tx990054q; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; Venema VJ, 1998, BIOCHEM BIOPH RES CO, V246, P70, DOI 10.1006/bbrc.1998.8574; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Xu KL, 2001, NEURON, V31, P957, DOI 10.1016/S0896-6273(01)00432-9; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	59	158	168	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	2002	111	4					529	541		10.1016/S0092-8674(02)01045-0	http://dx.doi.org/10.1016/S0092-8674(02)01045-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437926	Bronze			2022-12-28	WOS:000179346900006
J	Deecke, VB; Slater, PJB; Ford, JKB				Deecke, VB; Slater, PJB; Ford, JKB			Selective habituation shapes acoustic predator recognition in harbour seals	NATURE			English	Article							WHALES ORCINUS-ORCA; RESIDENT KILLER WHALES; GENETIC DIFFERENTIATION; POPULATIONS; EVOLUTION; BEHAVIOR	Predation is a major force in shaping the behaviour of animals(1-3), so that precise identification of predators will confer substantial selective advantages on animals that serve as food to others. Because experience with a predator can be lethal, early researchers studying birds suggested that predator recognition does not require learning(4,5). However, a predator image that can be modified by learning and experience will be advantageous in situations where cues associated with the predator are highly variable or change over time. In this study, we investigated the response of harbour seals (Phoca vitulina) to the underwater calls of different populations of killer whales (Orcinus orca). We found that the seals responded strongly to the calls of mammal-eating killer whales and unfamiliar fish-eating killer whales but not to the familiar calls of the local fish-eating population. This demonstrates that wild harbour seals are capable of complex acoustic discrimination and that they modify their predator image by selectively habituating to the calls of harmless killer whales. Fear in these animals is therefore focused on local threats by learning and experience.	Univ St Andrews, Sch Biol, St Andrews KY16 9TS, Fife, Scotland; Vancouver Aquarium Marine Sci Ctr, Vancouver, BC V6B 3X8, Canada; Fisheries & Oceans Canada, Pacific Biol Stn, Nanaimo, BC V9T 6N7, Canada	University of St Andrews; Fisheries & Oceans Canada	Deecke, VB (corresponding author), Univ St Andrews, Sch Biol, St Andrews KY16 9TS, Fife, Scotland.	vd2@st-andrews.ac.uk		Deecke, Volker/0000-0003-2781-5915				BarrettLennard LG, 1996, ANIM BEHAV, V51, P553, DOI 10.1006/anbe.1996.0059; BARRETTLENNARD LG, 2000, THESIS U BRIT COLUMB; Bigg M.A., 1990, REP INT WHALING COMM, V12, P384; Bradbury Jack W., 1998, pi; CURIO E, 1993, ADV STUD BEHAV, V22, P135, DOI 10.1016/S0065-3454(08)60407-6; Deecke VB, 2000, ANIM BEHAV, V60, P629, DOI 10.1006/anbe.2000.1454; Ford JKB, 1998, CAN J ZOOL, V76, P1456, DOI 10.1139/cjz-76-8-1456; FORD JKB, 1991, CAN J ZOOL, V69, P1454, DOI 10.1139/z91-206; FORD JKB, 1989, CAN J ZOOL, V67, P727, DOI 10.1139/z89-105; GLIWICZ MZ, 1986, NATURE, V320, P746, DOI 10.1038/320746a0; HOELZEL AR, 1991, HEREDITY, V66, P191, DOI 10.1038/hdy.1991.24; Hoelzel AR, 1998, J HERED, V89, P121, DOI 10.1093/jhered/89.2.121; KROODSMA DE, 1989, ANIM BEHAV, V37, P600, DOI 10.1016/0003-3472(89)90039-0; Lorenz K., 1939, VERH DTSCH ZOOL GES, P69; MILLER P.J.O., 2000, THESIS MIT; MOHL B, 1968, Journal of Auditory Research, V8, P27; Nichol LM, 1996, CAN J ZOOL, V74, P983, DOI 10.1139/z96-111; Rattenborg NC, 1999, NATURE, V397, P397, DOI 10.1038/17037; Saulitis E, 2000, MAR MAMMAL SCI, V16, P94, DOI 10.1111/j.1748-7692.2000.tb00906.x; SCHLEIDT WM, 1961, NATURWISSENSCHAFTEN, V48, P141, DOI 10.1007/BF00631948; Tinbergen N., 1948, Wilson Bulletin, V60, P6; TUTTLE MD, 1981, SCIENCE, V214, P677, DOI 10.1126/science.214.4521.677; Wiley R. Haven, 1994, P157; Yurk H, 2002, ANIM BEHAV, V63, P1103, DOI 10.1006/anbe.2002.3012; Zar J. H., 1996, BIOSTATISTICAL ANAL	25	144	152	0	93	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					171	173		10.1038/nature01030	http://dx.doi.org/10.1038/nature01030			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432391				2022-12-28	WOS:000179200900044
J	Hurley, AC; Volicer, L				Hurley, AC; Volicer, L			Alzheimer disease - "It's okay, mama, if you want to go, it's okay"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NURSING-HOME PLACEMENT; RANDOMIZED CONTROLLED TRIAL; TERMINALLY ILL PATIENTS; END-STAGE DEMENTIA; LONG-TERM-CARE; COGNITIVE IMPAIRMENT; FEVER-MANAGEMENT; UNITED-STATES; HOSPICE; PAIN		Northeastern Univ, Bouve Coll Hlth Sci, Brigham & Womens Hosp, Ctr Excellence Nursing Practice,Sch Nursing, Boston, MA 02115 USA; Edith Nourse Rogers Mem Vet Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA	Harvard University; Brigham & Women's Hospital; Northeastern University; Geriatric Research Education & Clinical Center; Boston University	Hurley, AC (corresponding author), Northeastern Univ, Bouve Coll Hlth Sci, Brigham & Womens Hosp, Ctr Excellence Nursing Practice,Sch Nursing, 75 Francis St, Boston, MA 02115 USA.	Ahurley@partners.org	Volicer, Ladislav/K-7576-2019	Volicer, Ladislav/0000-0002-6939-7531	NIA NIH HHS [P30AG13846] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG013846] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahronheim JC, 1996, CLIN GERIATR MED, V12, P379; *ALZH ASS, 2002, STAT ALZH DIS; Benedetti F, 1999, PAIN, V80, P377, DOI 10.1016/S0304-3959(98)00228-0; Berger JT, 2000, J CLIN ETHIC, V11, P304; BIRKS JS, 1997, DONEPEZIL MILD MODER; BLASI ZV, 2002, J AM MED DIR ASSOC, V13, P57; Brown J., 1988, CLIN MANAGEMENT ALZH, P29; Casarett D, 2002, ALZ DIS ASSOC DIS, V16, P116, DOI 10.1097/00002093-200204000-00009; Cook AKR, 1999, INT J GERIATR PSYCH, V14, P421, DOI 10.1002/(SICI)1099-1166(199906)14:6<421::AID-GPS932>3.0.CO;2-Y; Doody RS, 2001, ARCH NEUROL-CHICAGO, V58, P449, DOI 10.1001/archneur.58.3.449; Dooneief G, 1996, NEUROLOGY, V46, P1746, DOI 10.1212/WNL.46.6.1746; DRICKAMER MA, 1992, NEW ENGL J MED, V326, P947, DOI 10.1056/NEJM199204023261410; EPPIS L, 1999, HOME CARE FINANC FAL, P207; FABISZEWSKI KJ, 1990, JAMA-J AM MED ASSOC, V263, P3168, DOI 10.1001/jama.263.23.3168; FELD MJ, 1997, APPROACHING DEATH IM; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried TR, 1997, J AM GERIATR SOC, V45, P302, DOI 10.1111/j.1532-5415.1997.tb00944.x; FRISSONI GB, 1998, SPR S ETH LAW AG, P48; Gaugler JE, 2000, J GERONTOL B-PSYCHOL, V55, pP247, DOI 10.1093/geronb/55.4.P247; HANRAHAN P, 1995, J AM GERIATR SOC, V43, P56, DOI 10.1111/j.1532-5415.1995.tb06243.x; Hebert LE, 2001, ALZ DIS ASSOC DIS, V15, P169, DOI 10.1097/00002093-200110000-00002; HELMES E, 1995, ARCH NEUROL-CHICAGO, V52, P306, DOI 10.1001/archneur.1995.00540270102026; HIRATADULAS CAI, 1991, J AM GERIATR SOC, V39, P979, DOI 10.1111/j.1532-5415.1991.tb04044.x; Huang ZB, 2000, CLIN GERIATR MED, V16, P313, DOI 10.1016/S0749-0690(05)70058-6; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; HURLEY A, 1996, FED PRACTITIONER, V13, P16; HURLEY AC, 1993, ADV NURS SCI, V16, P21, DOI 10.1097/00012272-199309000-00004; Hurley AC, 1996, ALZ DIS ASSOC DIS, V10, P5, DOI 10.1097/00002093-199601010-00003; HURLEY AC, 1992, RES NURS HEALTH, V15, P369, DOI 10.1002/nur.4770150506; Hurley AC, 1999, ALZ DIS ASSOC DIS, V13, pS6, DOI 10.1097/00002093-199904001-00004; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; Kayser-Jones J, 1996, J Gerontol Nurs, V22, P26; Komaromy C, 2000, Int J Palliat Nurs, V6, P192; Kovach CR, 2001, APPL NURS RES, V14, P193, DOI 10.1053/apnr.2001.26784; Kovach CR, 1999, J PAIN SYMPTOM MANAG, V18, P412, DOI 10.1016/S0885-3924(99)00094-9; KOVACH CR, 1998, SPR S ETH LAW AG, P276; KUKULL WA, 1994, J AM GERIATR SOC, V42, P723, DOI 10.1111/j.1532-5415.1994.tb06531.x; Leff B, 2001, J GERONTOL A-BIOL, V56, pM603, DOI 10.1093/gerona/56.10.M603; Leff B, 2000, J AM GERIATR SOC, V48, P943, DOI 10.1111/j.1532-5415.2000.tb06892.x; Luchins DJ, 1997, J AM GERIATR SOC, V45, P1054, DOI 10.1111/j.1532-5415.1997.tb05966.x; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Lynn J, 2001, WESTERN J MED, V175, P299, DOI 10.1136/ewjm.175.5.299; Mahoney E. K., 2000, MANAGEMENT CHALLENGI; Mahoney EK, 2000, MANAGEMENT CHALLENGI, P155; MAHONEY M, 1992, FAMILY DECISION MAKI; MAHONEY MA, 1998, SPR S ETH LAW AG, P169; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; McConnell S, 1999, GENERATIONS, V23, P69; *MED EC CO INC, 2002, PHYS DESK REF; Meier DE, 2001, ARCH INTERN MED, V161, P594, DOI 10.1001/archinte.161.4.594; Menzin J, 1999, AM J GERIAT PSYCHIAT, V7, P300; MITTELMAN MS, 1993, GERONTOLOGIST, V33, P730, DOI 10.1093/geront/33.6.730; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MOSS MS, 2000, ANN REV GERONTOLOGY, P224; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; *NAT I AG, 2000, 2000 PROGR REP ALZH; Ostbye T, 1999, NEUROLOGY, V53, P521, DOI 10.1212/WNL.53.3.521; PAN CX, 2000, ANN REV GERONTOLOGY, P273; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; Rempusheski V F, 2000, J Gerontol Nurs, V26, P27; RHEAUME YL, 1998, SPR S ETH LAW AG, P189; Rice DP, 2001, AM J MANAG CARE, V7, P809; Robinson E M, 2000, J Nurs Law, V7, P21; ROBINSON EM, 1998, FED PRACT, V15, P26; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rovner B W, 1992, J Geriatr Psychiatry Neurol, V5, P102; Ryan AA, 2000, J ADV NURS, V32, P1187, DOI 10.1046/j.1365-2648.2000.01589.x; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Smith GE, 2001, NEUROLOGY, V57, P1467, DOI 10.1212/WNL.57.8.1467; SMITH SJ, 1998, SPR S ETH LAW AG, P247; SPECTOR WD, 2000, CHARACTERISTICS LONG; Stern Y, 1997, JAMA-J AM MED ASSOC, V277, P806, DOI 10.1001/jama.277.10.806; STUART B, 1995, MED GUIDELINES DETER; Teno JM, 2002, JAMA-J AM MED ASSOC, V287, P3211, DOI 10.1001/jama.287.24.3211; Teno JM, 2001, JAMA-J AM MED ASSOC, V285, P2081, DOI 10.1001/jama.285.16.2081-a; Thompson R S, 1997, J Am Board Fam Pract, V10, P82; VOLICER BJ, 1993, J AM GERIATR SOC, V41, P535, DOI 10.1111/j.1532-5415.1993.tb01891.x; VOLICER L, 1994, J GERIATR PSYCH NEUR, V7, P227, DOI 10.1177/089198879400700406; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; Volicer L, 1998, HOSPICE CARE PATIENT; VOLICER L, 1990, AM J ALZHEIMERS CARE, V5, P22; VOLICER L, 1989, J GERIATR PSYCHIAT, V2, P169; VOLICER L, 1998, SPR S ETH LAW AG, P29; VOLICER L, 1996, LATE STAGE DEMENTIA, P125; WARDEN VJ, 1989, GERIATR NURS, V10, P210; Wilson SA, 1996, GERIATR NURS, V17, P6, DOI 10.1016/S0197-4572(96)80004-8; Wolfson C, 2001, NEW ENGL J MED, V344, P1111, DOI 10.1056/NEJM200104123441501; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090	90	35	35	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2324	2331		10.1001/jama.288.18.2324	http://dx.doi.org/10.1001/jama.288.18.2324			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	614JZ	12425711				2022-12-28	WOS:000179186400033
J	Edwards, JE; McQuay, HJ				Edwards, JE; McQuay, HJ			Dipyrone and agranulocytosis: what is the risk?	LANCET			English	Editorial Material									Univ Oxford, Oxford Radcliffe Hosp NHS Trust, Pain Res & Nuffield Dept Anaesthet, Oxford OX3 7LJ, England	Oxford University Hospitals NHS Foundation Trust; University of Oxford	Edwards, JE (corresponding author), Univ Oxford, Oxford Radcliffe Hosp NHS Trust, Pain Res & Nuffield Dept Anaesthet, S Parks Rd, Oxford OX3 7LJ, England.							Bensenor I M, 2001, Sao Paulo Med J, V119, P190; Hedenmalm K, 2002, EUR J CLIN PHARMACOL, V58, P265, DOI 10.1007/s00228-002-0465-2; KRAMER MS, 1987, J CHRON DIS, V40, P1073, DOI 10.1016/0021-9681(87)90073-7; Shapiro S, 1999, AM J TROP MED HYG, V60, P573, DOI 10.4269/ajtmh.1999.60.573; The International Agranulocytosis and Aplastic Anemia Study, 1986, JAMA-J AM MED ASSOC, V256, P1749; Tramer MR, 2000, PAIN, V85, P169, DOI 10.1016/S0304-3959(99)00267-5; Tramer MR, 1997, BRIT J ANAESTH, V78, P642, DOI 10.1093/bja/78.6.642; van der Klauw MM, 1999, ARCH INTERN MED, V159, P369, DOI 10.1001/archinte.159.4.369	8	43	45	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1438	1438		10.1016/S0140-6736(02)11489-9	http://dx.doi.org/10.1016/S0140-6736(02)11489-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433507				2022-12-28	WOS:000179186000004
J	Dickson, JAD				Dickson, JAD			Fossil echinoderms as monitor of the Mg/Ca ratio of phanerozoic oceans	SCIENCE			English	Article							SEAWATER CHEMISTRY; CALCITE; REEF; MG; TEMPERATURE; MAGNESIUM; CEMENTS; TRANSFORMATION; OSCILLATIONS; LIMESTONES	Opinion has long been divided as to whether the Mg/Ca ratio of seawater remained constant during the Phanerozoic or underwent substantial secular change. Existing empirical evidence for the Mg/Ca of ancient seawater provides a poorly resolved and often controversial signal. Echinoderm fossils that have retained their bulk original chemistry, despite micrometer-scale changes, preserve a record of seawater Mg/Ca and confirm that major changes in Mg/Ca occurred during the Phanerozoic. Echinoderms from the Cambrian and from the Carboniferous to the Triassic indicate a seawater Mg/Ca of 3.3, whereas echinoderms from the Jurassic to the Cretaceous indicate a Mg/Ca of 1.4. The present seawater Mg/Ca is 5.	Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England	University of Cambridge	Dickson, JAD (corresponding author), Univ Cambridge, Dept Earth Sci, Downing St, Cambridge CB2 3EQ, England.	jadd1@esc.cam.ac.uk						ALEXANDERSSON T, 1974, J SEDIMENT PETROL, V44, P7; ANDREWS JE, 1988, SCOT J GEOL, V24, P233, DOI 10.1144/sjg24030233; Burns SJ, 2000, SEDIMENTOLOGY, V47, P49, DOI 10.1046/j.1365-3091.2000.00004.x; BURTON EA, 1993, CHEM GEOL, V105, P163, DOI 10.1016/0009-2541(93)90124-2; Carpenter S.J., 1991, GEOCHIM COSMOCHIM AC, V55; CHAVE KE, 1954, J GEOL, V62, P266, DOI 10.1086/626162; de Villiers S, 1999, SCIENCE, V285, P721, DOI 10.1126/science.285.5428.721; Dickson JAD, 2001, GEOCHIM COSMOCHIM AC, V65, P443, DOI 10.1016/S0016-7037(00)00547-0; Dickson JAD, 2001, J SEDIMENT RES, V71, P764, DOI 10.1306/2DC40966-0E47-11D7-8643000102C1865D; DICKSON JAD, 1965, NATURE, V205, P587, DOI 10.1038/205587a0; GINSBURG RN, 1973, SEDIMENTOLOGY, V20, P575, DOI 10.1111/j.1365-3091.1973.tb01633.x; GREGOR CB, 1988, CHEM CYCLES EVOLUTIO; Hardie LA, 1996, GEOLOGY, V24, P279, DOI 10.1130/0091-7613(1996)024<0279:SVISCA>2.3.CO;2; Hartley G, 1996, GEOCHIM COSMOCHIM AC, V60, P315, DOI 10.1016/0016-7037(95)00388-6; Holland H. D., 1978, CHEM ATMOSPHERE OCEA; Holland HD, 2000, INT GEOL REV, V42, P481, DOI 10.1080/00206810009465093; Holland HD, 1998, GEOLOGY, V26, P92; Holland HD, 1996, GEOLOGY, V24, P993, DOI 10.1130/0091-7613(1996)024<0993:OTSVIT>2.3.CO;2; JAMES NP, 1983, J SEDIMENT PETROL, V53, P1051; JAMES NP, 1976, J SEDIMENT PETROL, V46, P523; Lowenstein TK, 2001, SCIENCE, V294, P1086, DOI 10.1126/science.1064280; MACINTYRE IG, 1977, J SEDIMENT PETROL, V47, P503; MACKENZIE FT, 1992, GEOCHIM COSMOCHIM AC, V56, P3281, DOI 10.1016/0016-7037(92)90305-3; MCKENZIE JA, 1982, TECTONOPHYSICS, V86, P149, DOI 10.1016/0040-1951(82)90065-8; MILLIMAN JD, 1973, SEDIMENTOLOGY, V20, P29, DOI 10.1111/j.1365-3091.1973.tb01605.x; MORSE JW, 1990, CHEM GEOL, V82, P265, DOI 10.1016/0009-2541(90)90085-L; Morse JW, 1997, GEOLOGY, V25, P85, DOI 10.1130/0091-7613(1997)025<0085:IOTAMC>2.3.CO;2; Muller J., 1974, INT ASS SEDIMENTOLOG, V1, P235; PIGOTT JD, 1986, MAR CHEM, V19, P355, DOI 10.1016/0304-4203(86)90056-3; Rimstidt JD, 1998, GEOCHIM COSMOCHIM AC, V62, P1851, DOI 10.1016/S0016-7037(98)00125-2; SANDBERG PA, 1983, NATURE, V305, P19, DOI 10.1038/305019a0; SCHLAGER W, 1978, SEDIMENTOLOGY, V25, P675, DOI 10.1111/j.1365-3091.1978.tb00325.x; Stanley SM, 1998, PALAEOGEOGR PALAEOCL, V144, P3, DOI 10.1016/S0031-0182(98)00109-6; WEBER JN, 1973, J GEOL, V81, P543, DOI 10.1086/627906; WILKINSON BH, 1989, AM J SCI, V289, P1158, DOI 10.2475/ajs.289.10.1158; WILKINSON BH, 1985, J SEDIMENT PETROL, V55, P171; Wilson PA, 2002, GEOLOGY, V30, P607, DOI 10.1130/0091-7613(2002)030<0607:TTCGHU>2.0.CO;2	37	183	192	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	2002	298	5596					1222	1224		10.1126/science.1075882	http://dx.doi.org/10.1126/science.1075882			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424375				2022-12-28	WOS:000179080400046
J	Ling, K; Doughman, RL; Firestone, AJ; Bunce, MW; Anderson, RA				Ling, K; Doughman, RL; Firestone, AJ; Bunce, MW; Anderson, RA			Type I gamma phosphatidylinositol phosphate kinase targets and regulates focal adhesions	NATURE			English	Article							4-PHOSPHATE 5-KINASE; TALIN; BINDING; DOMAIN; ACTIN; TYROSINE; ASSOCIATION; ACTIVATION; PROTEINS; VINCULIN	The ability of cells to form cell contacts, adhere to the extracellular matrix, change morphology, and migrate is essential for development, wound healing, metastasis, cell survival and the immune response. These events depend on the binding of integrin to the extracellular matrix, and assembly of focal adhesions, which are complexes comprising scaffolding and signalling proteins organized by adhesion to the extracellular matrix(1-3). Phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P-2) regulates interactions between these proteins, including the interaction of vinculin with actin and talin(4-9). The binding of talin to beta-integrin is strengthened by PtdIns(4,5)P-2, suggesting that the basis of focal adhesion assembly is regulated by this lipid mediator(9,10). Here we show that the type I phosphatidylinositol phosphate kinase isoform-gamma 661 (PIPKI-gamma661), an enzyme that makes PtdIns(4,5)P-2, is targeted to focal adhesions by an association with talin. PIPKIgamma661 is tyrosine phosphorylated by focal adhesion associated kinase signalling, increasing both the activity of phosphatidylinositol phosphate kinase and its association with talin. This defines a mechanism for spatial generation of PtdIns(4,5)P-2 at focal adhesions.	Univ Wisconsin, Sch Med, Dept Pharmacol, Program Mol & Cellular Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Anderson, RA (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Program Mol & Cellular Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	raanders@facstaff.wisc.edu		Anderson, Richard/0000-0001-6265-8359; Firestone, Ari/0000-0001-9902-443X				ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; CARY LA, 1999, FRONT BIOSCI, V4, P102; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; James P, 1996, GENETICS, V144, P1425; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	31	367	379	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	2002	420	6911					89	93		10.1038/nature01082	http://dx.doi.org/10.1038/nature01082			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422220				2022-12-28	WOS:000179068100042
J	Bonifati, V; Rizzu, P; van Baren, MJ; Schaap, O; Breedveld, GJ; Krieger, E; Dekker, MCJ; Squitieri, F; Ibanez, P; Joosse, M; van Dongen, JW; Vanacore, N; van Swieten, JC; Brice, A; Meco, G; van Duijn, CM; Oostra, BA; Heutink, P				Bonifati, V; Rizzu, P; van Baren, MJ; Schaap, O; Breedveld, GJ; Krieger, E; Dekker, MCJ; Squitieri, F; Ibanez, P; Joosse, M; van Dongen, JW; Vanacore, N; van Swieten, JC; Brice, A; Meco, G; van Duijn, CM; Oostra, BA; Heutink, P			Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism	SCIENCE			English	Article							ALPHA; LOCALIZATION; PROTEIN; STRESS	The DJ-1 gene encodes a ubiquitous, highly conserved protein. Here, we show that DJ-1 mutations are associated with PARK7, a monogenic form of human parkinsonism. The function of the DJ-1 protein remains unknown, but evidence suggests its involvement in the oxidative stress response. Our findings indicate that loss of DJ-1 function leads to neurodegeneration. Elucidating the physiological role of DJ-1 protein may promote understanding of the mechanisms of brain neuronal maintenance and pathogenesis of Parkinson's disease.	Erasmus MC, Dept Epidemiol & Biostat, Dept Clin Genet, Genet Epidemiol Unit, NL-3000 DR Rotterdam, Netherlands; Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy; Univ Med Ctr Nijmegen, Ctr Mol & Biomol Informat, NL-6525 GA Nijmegen, Netherlands; IRCCS INM Neuromed, Neurogenet Unit, I-86077 Pozzilli, Italy; Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France; Natl Inst Hlth, Epidemiol & Biostat Lab, I-00161 Rome, Italy; Erasmus MC, Dept Neurol, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Sapienza University Rome; Radboud University Nijmegen; IRCCS Neuromed; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Istituto Superiore di Sanita (ISS); Erasmus University Rotterdam; Erasmus MC	Bonifati, V (corresponding author), Erasmus MC, Dept Epidemiol & Biostat, Dept Clin Genet, Genet Epidemiol Unit, POB 1738, NL-3000 DR Rotterdam, Netherlands.	bonifati@kgen.fgg.eur.nl; heutink@kgen.fgg.eur.nl	Longo, Kenneth A/A-5631-2010; Brice, Alexis/A-2170-2009; brice, alexis/AAE-8275-2019; Squitieri, Ferdinando/N-1852-2019	brice, alexis/0000-0002-0941-3990; Squitieri, Ferdinando/0000-0002-7397-1727; Van Duijn, Cornelia/0000-0002-2374-9204; Heutink, Peter/0000-0001-5218-1737; van Swieten, John/0000-0001-6278-6844				Bonifati V, 2002, ANN NEUROL, V51, P253, DOI 10.1002/ana.10106; de Nobel H, 2001, YEAST, V18, P1413, DOI 10.1002/yea.793; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Kim MK, 1999, PROTEIN SCI, V8, P1492, DOI 10.1110/ps.8.7.1492; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Valente EM, 2001, AM J HUM GENET, V68, P895, DOI 10.1086/319522; Van Duijn CM, 2001, AM J HUM GENET, V69, P505; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	20	2009	2098	6	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 10	2003	299	5604					256	259		10.1126/science.1077209	http://dx.doi.org/10.1126/science.1077209			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	633LD	12446870				2022-12-28	WOS:000180284000041
J	Bergman, SJ				Bergman, SJ			Fiction as resistance	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Bergman, SJ (corresponding author), Capital 75 Bellevue St, Newton, MA 02458 USA.	sbergman@mpmcapital.com						CHEKHOV A, 1986, LETT A SUVORIN, P167; Clever LH, 2002, ANN INTERN MED, V136, P391, DOI 10.7326/0003-4819-136-5-200203050-00012; Collier VU, 2002, ANN INTERN MED, V136, P384, DOI 10.7326/0003-4819-136-5-200203050-00011; SALINGER JD, 1945, CATCHER RYE, V25; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; SHEM S, 1979, HOUSE GOD, P276; SHEM S, 1979, HOUSE GOD, P275; SHEM S, 1998, MOUNT MISERY, P497; STEVENS W, 1961, COLLECTED POEMS W ST, P165; Tolstoy L., 1930, WHAT IS ART WHAT IS, P123	10	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					934	937		10.7326/0003-4819-137-11-200212030-00022	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00022			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622GY	12459000				2022-12-28	WOS:000179639700015
J	Tan, LWH; Subramaniam, R				Tan, LWH; Subramaniam, R			Science and the student entrepreneur	SCIENCE			English	Editorial Material									Singapore Natl Acad Sci, Singapore 609081, Singapore		Tan, LWH (corresponding author), Singapore Natl Acad Sci, 15 Sci Ctr Rd, Singapore 609081, Singapore.							*MIN ED, 1998, LEARN THINK THINK LE	1	1	1	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1556	1556						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446891				2022-12-28	WOS:000179361600029
J	Check, E				Check, E			Fresh analyses put rice genomics on the map	NATURE			English	News Item																			0	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					259	259		10.1038/420259a	http://dx.doi.org/10.1038/420259a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447409	Bronze			2022-12-28	WOS:000179340400010
J	Gabbiani, F; Krapp, HG; Koch, C; Laurent, G				Gabbiani, F; Krapp, HG; Koch, C; Laurent, G			Multiplicative computation in a visual neuron sensitive to looming	NATURE			English	Article							SIGNALING IMPENDING COLLISION; OBJECT APPROACH; WIDE-FIELD; MOTION; ORGANIZATION; THRESHOLD; VARIABLES; CIRCUIT; LOCUST	Multiplicative operations are important in sensory processing(1-5), but their biophysical implementation remains largely unknown(5-10). We investigated an identified neuron ( the lobula giant movement detector, LGMD, of locusts) whose output firing rate in response to looming visual stimuli has been described by two models, one of which involves a multiplication. In this model, the LGMD multiplies postsynaptically two inputs ( one excitatory, one inhibitory) that converge onto its dendritic tree(11,12); in the other model, inhibition is presynaptic to the LGMD(13,14). By using selective activation and inactivation of pre- and postsynaptic inhibition, we show that postsynaptic inhibition has a predominant role, suggesting that multiplication is implemented within the neuron itself. Our pharmacological experiments and measurements of firing rate versus membrane potential also reveal that sodium channels act both to advance the response of the LGMD in time and to map membrane potential to firing rate in a nearly exponential manner. These results are consistent with an implementation of multiplication based on dendritic subtraction of two converging inputs encoded logarithmically, followed by exponentiation through active membrane conductances.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	California Institute of Technology; Baylor College of Medicine; University of Cambridge	Gabbiani, F (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.		Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X				ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; BARLOW HB, 1965, J PHYSIOL-LONDON, V178, P477, DOI 10.1113/jphysiol.1965.sp007638; Chance FS, 2002, NEURON, V35, P773, DOI 10.1016/S0896-6273(02)00820-6; Gabbiani F, 1999, J NEUROSCI, V19, P1122; Gabbiani F, 2001, J NEUROSCI, V21, P314, DOI 10.1523/JNEUROSCI.21-01-00314.2001; GALANT AR, 1987, NONLINEAR STAT MODEL; HATSOPOULOS N, 1995, SCIENCE, V270, P1000, DOI 10.1126/science.270.5238.1000; KOCH C, 1995, J COMPUT NEUROSCI, V2, P63, DOI 10.1007/BF00962708; Koch C., 1998, BIOPHYSICS COMPUTATI; McAdams CJ, 1999, J NEUROSCI, V19, P431, DOI 10.1523/JNEUROSCI.19-01-00431.1999; Mead C.A., 1989, ANALOG VLSI NEURAL S; OSHEA M, 1975, NATURE, V254, P53, DOI 10.1038/254053a0; Pena JL, 2001, SCIENCE, V292, P249, DOI 10.1126/science.1059201; RAUH JJ, 1990, TRENDS PHARMACOL SCI, V11, P325, DOI 10.1016/0165-6147(90)90236-2; REICHARDT W, 1957, Z NATURFORSCH PT B, V12, P448, DOI 10.1515/znb-1957-0707; Rind FC, 1998, J COMP NEUROL, V395, P405; Rind FC, 1996, J NEUROPHYSIOL, V75, P967, DOI 10.1152/jn.1996.75.3.967; Rind FC, 1996, J NEUROPHYSIOL, V75, P986, DOI 10.1152/jn.1996.75.3.986; RIND FC, 1992, J NEUROPHYSIOL, V68, P1654, DOI 10.1152/jn.1992.68.5.1654; ROBERTSON RM, 1993, NATURWISSENSCHAFTEN, V80, P176, DOI 10.1007/BF01226378; Rowell C.H.F., 1974, P87; ROWELL CHF, 1977, J EXP BIOL, V68, P157; SCHLOTTERER GR, 1977, CAN J ZOOL, V55, P1372, DOI 10.1139/z77-179; Sun HJ, 1998, NAT NEUROSCI, V1, P296, DOI 10.1038/1110; TORRE V, 1978, PROC R SOC SER B-BIO, V202, P409, DOI 10.1098/rspb.1978.0075; WAGNER H, 1982, NATURE, V297, P147, DOI 10.1038/297147a0; WARZECHA AK, 1993, J NEUROPHYSIOL, V69, P329, DOI 10.1152/jn.1993.69.2.329; Wicklein M, 2000, J COMP NEUROL, V424, P356; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4; Zanker JM, 1999, BIOL CYBERN, V80, P109, DOI 10.1007/s004220050509	30	269	270	2	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					320	324		10.1038/nature01190	http://dx.doi.org/10.1038/nature01190			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447440				2022-12-28	WOS:000179340400043
J	Tournier-Lasserve, E				Tournier-Lasserve, E			New players in the genetics of stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUTATIONS		Assistance Publ Hop Paris, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Tournier-Lasserve, E (corresponding author), Assistance Publ Hop Paris, F-75010 Paris, France.		Tournier-Lasserve, Elisabeth/N-7134-2017	Tournier-Lasserve, Elisabeth/0000-0002-3039-1677				Gretarsdottir S, 2002, AM J HUM GENET, V70, P593, DOI 10.1086/339252; Hassan A, 2000, BRAIN, V123, P1784, DOI 10.1093/brain/123.9.1784; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Laberge-le Couteulx S, 1999, NAT GENET, V23, P189, DOI 10.1038/13815; NATOWICZ M, 1987, ANN NEUROL, V22, P175, DOI 10.1002/ana.410220202; Onda H, 2001, AM J HUM GENET, V69, P804, DOI 10.1086/323614	6	34	35	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1711	1712		10.1056/NEJMcibr022035	http://dx.doi.org/10.1056/NEJMcibr022035			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444190				2022-12-28	WOS:000179339900014
J	Chen, WY; Colditz, GA; Rosner, B; Hankinson, SE; Hunter, DJ; Manson, JE; Stampfer, MJ; Willett, WC; Speizer, FE				Chen, WY; Colditz, GA; Rosner, B; Hankinson, SE; Hunter, DJ; Manson, JE; Stampfer, MJ; Willett, WC; Speizer, FE			Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer	ANNALS OF INTERNAL MEDICINE			English	Article							REPLACEMENT THERAPY; BEVERAGE CONSUMPTION; MEASUREMENT ERROR; WOMEN; ESTROGENS	Background: Physiologic evidence suggests that use of alcohol increases the risk for breast cancer through a hormonal mechanism, but the relationship among breast cancer, alcohol, and postmenopausal hormones (PMH) remains unclear. Objective: To examine the relation between concurrent use of alcohol and PMH and invasive breast cancer. Design: Prospective cohort study Setting: Nurses' Health Study. Participants: 44187 postmenopausal women. Measurements: Self-reported data on PMH use and breast cancer obtained from biennial questionnaires completed from 1980 to 1994 and average alcohol consumption in 1980, 1984, 1986, and 1990. Results: 1722 women developed invasive breast cancer. Risk for breast cancer was elevated in women who currently used PMH for 5 or more years and did not drink alcohol (relative risk, 1.32 [95% CI, 1.05 to 1.66]) and those who never used PMH but drank 20 or more g (1.5 to 2 drinks) of alcohol daily (relative risk, 1.28 [Cl, 0.97 to 1.69]). Current users of PMH for 5 or more years who consumed 20 or more g of alcohol daily had a relative risk for breast cancer nearly twice (1.99 [Cl, 1.42 to 2.79]) that of non-drinking nonusers of PMH. A hypothetical postmenopausal woman whose lifetime risk for breast cancer is 4% could increase her risk to 8% with 5 or more years of current PMH use and consumption of more than one alcoholic drink daily. Conclusions: Both alcohol consumption and PMH use were associated with an increased incidence of breast cancer. Women who are currently taking PMH may want to consider the added risks of regular alcohol consumption.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Chen, WY (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [5-R25-CA577011-08, CA40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Dawson D A, 1995, J Subst Abuse, V7, P331, DOI 10.1016/0899-3289(95)90026-8; Flanders W D, 1990, Epidemiology, V1, P239, DOI 10.1097/00001648-199005000-00010; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GAPSTUR SM, 1992, AM J EPIDEMIOL, V136, P1221, DOI 10.1093/oxfordjournals.aje.a116430; Ginsburg ES, 1996, JAMA-J AM MED ASSOC, V276, P1747, DOI 10.1001/jama.276.21.1747; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HARVEY EB, 1987, J NATL CANCER I, V78, P657; LONGNECKER MP, 1995, CANCER EPIDEM BIOMAR, V4, P721; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MIDANIK LT, 1994, AM J PUBLIC HEALTH, V84, P1218, DOI 10.2105/AJPH.84.8.1218; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; PAGANINIHILL A, 1983, LANCET, V2, P626; Pike MC, 1998, AM J EPIDEMIOL, V147, P718; REICHMAN ME, 1993, J NATL CANCER I, V85, P722, DOI 10.1093/jnci/85.9.722; Rockhill B, 2000, AM J EPIDEMIOL, V151, P404; ROSENBERG L, 1990, AM J EPIDEMIOL, V131, P6, DOI 10.1093/oxfordjournals.aje.a115486; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Rosner BA, 1996, STAT MED, V15, P293, DOI 10.1002/(SICI)1097-0258(19960215)15:3<293::AID-SIM166>3.0.CO;2-E; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; *USDA, 1997, USDA NUTR DAT STAND; WILLIAMS GD, 1992, BRIT J ADDICT, V87, P643; WILLIAMS RR, 1977, JNCI-J NATL CANCER I, V58, P525, DOI 10.1093/jnci/58.3.525	28	67	68	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					798	804		10.7326/0003-4819-137-10-200211190-00008	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616VE	12435216				2022-12-28	WOS:000179323400003
J	Leckman, JF				Leckman, JF			Tourette's syndrome	LANCET			English	Article							OBSESSIVE-COMPULSIVE DISORDER; DEFICIT HYPERACTIVITY DISORDER; DOUBLE-BLIND; TIC DISORDERS; STREPTOCOCCAL INFECTIONS; STRIATAL ANTIBODIES; CROSSOVER TRIAL; CHILDREN; PLACEBO; HALOPERIDOL	As our knowledge of Gilles de la Tourette's syndrome increases, so does our appreciation for the pathogenic complexity of this disorder and the challenges associated with its treatment. Advances in the neurosciences have led to new models of pathogenesis, whereas clinical studies have reinvigorated early hypotheses. The interdependent roles of genes and environment in disease formation have yet to be fully elucidated. Results of epidemiological studies have prompted debate on how best to characterise and diagnose this disorder. Absence of ideal anti-tic drugs, combined with knowledge that uncomplicated cases of childhood Tourette's syndrome frequently have a favourable outcome, has led to striking changes in care and treatment of patients. This seminar focuses on these changing views and offers a new perspective on our understanding of the pathogenesis of Tourette's syndrome and on principles for treatment of patients with this disorder.	Yale Univ, Ctr Child Study, New Haven, CT 06520 USA; Yale Univ, Dept Paediat, New Haven, CT 06520 USA; Yale Univ, Dept Psychiat, New Haven, CT 06520 USA; Yale Univ, Dept Psychol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Leckman, JF (corresponding author), Yale Univ, Ctr Child Study, New Haven, CT 06520 USA.	James.Leckman@yale.edu	Leckman, James/O-2426-2015					American Psychiatric Association, 2000, DIAGN STAT MAN MENT, P108; Anderson SA, 1997, SCIENCE, V278, P474, DOI 10.1126/science.278.5337.474; [Anonymous], 1999, Am J Hum Genet, V65, P1428; AZRIN NH, 1973, BEHAV RES THER, V11, P619, DOI 10.1016/0005-7967(73)90119-8; Blazquez PM, 2002, NEURON, V33, P973, DOI 10.1016/S0896-6273(02)00627-X; BLISS J, 1980, ARCH GEN PSYCHIAT, V37, P1343; Brown LL, 2002, J NEUROSCI, V22, P305, DOI 10.1523/JNEUROSCI.22-01-00305.2002; Bruggeman R, 2001, J CLIN PSYCHIAT, V62, P50, DOI 10.4088/JCP.v62n0111; Burd L, 1999, J PERINAT MED, V27, P295, DOI 10.1515/JPM.1999.042; Canales JJ, 2000, NAT NEUROSCI, V3, P377, DOI 10.1038/73949; Carter AS, 2000, J CHILD PSYCHOL PSYC, V41, P215, DOI 10.1111/1469-7610.00602; CHAPPELL P, 1994, BIOL PSYCHIAT, V36, P35, DOI 10.1016/0006-3223(94)90060-4; Chappell P, 1996, BIOL PSYCHIAT, V39, P776, DOI 10.1016/0006-3223(95)00221-9; Cohen D., 1991, CONT CONSTRUCTIONS C, P159; COHEN DJ, 1993, HDB TOURETTES SYNDRO, P461; Comings DE, 2001, ANN NY ACAD SCI, V931, P50; Costello EJ, 1996, ARCH GEN PSYCHIAT, V53, P1129; Dion Y, 2002, J CLIN PSYCHOPHARM, V22, P31, DOI 10.1097/00004714-200202000-00006; EGGERS C, 1988, EUR ARCH PSY CLIN N, V237, P223, DOI 10.1007/BF00449911; Elstner K, 2001, ACTA PSYCHIAT SCAND, V103, P52, DOI 10.1034/j.1600-0447.2001.00147.x; Fredericksen KA, 2002, NEUROLOGY, V58, P85, DOI 10.1212/WNL.58.1.85; Freeman RD, 2000, DEV MED CHILD NEUROL, V42, P436, DOI 10.1017/S0012162200000839; Garvey MA, 1999, BIOL PSYCHIAT, V45, P1564, DOI 10.1016/S0006-3223(99)00020-7; GEORGE MS, 1993, HUM PSYCHOPHARM CLIN, V8, P327, DOI 10.1002/hup.470080505; Gilbert DL, 2000, NEUROLOGY, V54, P1310, DOI 10.1212/WNL.54.6.1310; GOETZ CG, 1987, ANN NEUROL, V21, P307, DOI 10.1002/ana.410210313; Graybiel A M, 2001, Adv Neurol, V85, P123; Hallett JJ, 2000, J NEUROIMMUNOL, V111, P195, DOI 10.1016/S0165-5728(00)00320-9; Hornsey H, 2001, J CHILD PSYCHOL PSYC, V42, P1035, DOI 10.1111/1469-7610.00802; Jankovic J, 2001, NEW ENGL J MED, V345, P1184, DOI 10.1056/NEJMra010032; Jog MS, 1999, SCIENCE, V286, P1745, DOI 10.1126/science.286.5445.1745; KIESSLING LS, 1993, PEDIATRICS, V92, P39; Koos T, 1999, NAT NEUROSCI, V2, P467, DOI 10.1038/8138; Koos T, 2002, J NEUROSCI, V22, P529, DOI 10.1523/JNEUROSCI.22-02-00529.2002; Kurlan R, 1998, NEUROLOGY, V50, P1530, DOI 10.1212/WNL.50.6.1530; Kurlan R, 2002, NEUROLOGY, V58, P527; Kurlan R, 2001, NEUROLOGY, V57, P1383, DOI 10.1212/WNL.57.8.1383; Kushner Howard I., 1999, CURSING BRAIN HIST T; Leckman JF, 2000, NEURON, V28, P349, DOI 10.1016/S0896-6273(00)00114-8; Leckman JF, 1998, PEDIATRICS, V102, P14, DOI 10.1542/peds.102.1.14; LECKMAN JF, 1995, NEUROPSYCHOPHARMACOL, V12, P73, DOI 10.1016/0893-133X(94)00070-G; LECKMAN JF, 1991, ARCH GEN PSYCHIAT, V48, P324, DOI 10.1001/archpsyc.1991.01810280040006; LECKMAN JF, 1989, J AM ACAD CHILD PSY, V28, P566, DOI 10.1097/00004583-198907000-00015; Leckman JF, 1998, TOURETTES SYNDROME T, p[John Wiley and Sons, 23]; LECKMAN JF, IN PRESS AM J MED; LECKMAN JF, 1986, MOVEMENT DISORD, P257; LECKMAN JF, 1998, TOURETTES SYNDROME T, P285; Lin HQ, 2002, J AM ACAD CHILD PSY, V41, P1070, DOI 10.1097/00004583-200209000-00007; Marras C, 2001, NEUROLOGY, V56, P605, DOI 10.1212/WNL.56.5.605; McDougle CJ, 2000, ARCH GEN PSYCHIAT, V57, P794, DOI 10.1001/archpsyc.57.8.794; MCDOUGLE CJ, 1993, J CLIN PSYCHOPHARM, V13, P354; MCDOUGLE CJ, 1994, ARCH GEN PSYCHIAT, V51, P302; Merette C, 2000, AM J HUM GENET, V67, P1008, DOI 10.1086/303093; Morshed SA, 2001, BIOL PSYCHIAT, V50, P566, DOI 10.1016/S0006-3223(01)01096-4; Muller-Vahl KR, 2000, J NEUROL, V247, P514, DOI 10.1007/PL00007806; Perlmutter SJ, 1999, LANCET, V354, P1153, DOI 10.1016/S0140-6736(98)12297-3; Peterson BS, 1998, BIOL PSYCHIAT, V44, P1337, DOI 10.1016/S0006-3223(98)00176-0; Peterson BS, 1998, J CLIN PSYCHOPHARM, V18, P324, DOI 10.1097/00004714-199808000-00013; Peterson BS, 2001, J AM ACAD CHILD PSY, V40, P685, DOI 10.1097/00004583-200106000-00014; PETERSON BS, 1992, PSYCHONEUROENDOCRINO, V17, P553, DOI 10.1016/0306-4530(92)90015-Y; Peterson BS, 2001, ARCH GEN PSYCHIAT, V58, P427, DOI 10.1001/archpsyc.58.5.427; Peterson BS, 1998, ARCH GEN PSYCHIAT, V55, P326, DOI 10.1001/archpsyc.55.4.326; Piacentini J, 2001, Adv Neurol, V85, P319; Raz A, 1996, J NEUROPHYSIOL, V76, P2083, DOI 10.1152/jn.1996.76.3.2083; Robertson MM, 1999, NEUROLOGY, V53, P2108, DOI 10.1212/WNL.53.9.2108; Robertson MM, 2000, BRAIN, V123, P425, DOI 10.1093/brain/123.3.425; ROBERTSON MM, 1990, CLIN NEUROPHARMACOL, V13, P229, DOI 10.1097/00002826-199006000-00005; Sallee FR, 2000, J AM ACAD CHILD PSY, V39, P292, DOI 10.1097/00004583-200003000-00010; Sallee FR, 1997, AM J PSYCHIAT, V154, P1057; Scahill L, 2001, AM J PSYCHIAT, V158, P1067, DOI 10.1176/appi.ajp.158.7.1067; SCAHILL L, IN PRESS NEUROLOGY; SHAPIRO AK, 1984, J AM ACAD CHILD PSY, V23, P161, DOI 10.1097/00004583-198403000-00007; SHAPIRO E, 1989, ARCH GEN PSYCHIAT, V46, P722; SILVA RR, 1995, J CHILD PSYCHOL PSYC, V36, P305, DOI 10.1111/j.1469-7610.1995.tb01826.x; Silver AA, 2001, J CLIN PSYCHIAT, V62, P707, DOI 10.4088/JCP.v62n0908; Silver AA, 2001, J AM ACAD CHILD PSY, V40, P1103, DOI 10.1097/00004583-200109000-00020; Simonic I, 1998, AM J HUM GENET, V63, P839, DOI 10.1086/302002; Simonic I, 2001, AM J MED GENET, V105, P163, DOI 10.1002/ajmg.1192; Singer HS, 1998, NEUROLOGY, V50, P1618, DOI 10.1212/WNL.50.6.1618; SINGER HS, 1995, PEDIATRICS, V95, P74; Singer HS, 2000, PEDIATR NEUROL, V22, P380, DOI 10.1016/S0887-8994(00)00131-4; Spencer T, 1998, J CHILD PSYCHOL PSYC, V39, P1037, DOI 10.1017/S0021963098002984; Suzuki T, 2001, J NEUROSCI, V21, P6492, DOI 10.1523/JNEUROSCI.21-17-06492.2001; Swedo SE, 1998, AM J PSYCHIAT, V155, P264; Swerdlow N R, 2001, Adv Neurol, V85, P151; Swerdlow NR, 2001, BIOL PSYCHIAT, V50, P578, DOI 10.1016/S0006-3223(01)01164-7; Taylor JR, 2002, AM J PSYCHIAT, V159, P657, DOI 10.1176/appi.ajp.159.4.657; Vandewalle V, 1999, LANCET, V353, P724, DOI 10.1016/S0140-6736(98)05964-9; Walkup JT, 1996, AM J HUM GENET, V59, P684; Wendlandt JT, 2001, J NEUROIMMUNOL, V119, P106, DOI 10.1016/S0165-5728(01)00370-8; Whitaker AH, 1997, ARCH GEN PSYCHIAT, V54, P847; Wolf SS, 1996, SCIENCE, V273, P1225, DOI 10.1126/science.273.5279.1225; World Health Organisation (WHO), 1998, MICR, P43; Zhang HP, 2002, AM J HUM GENET, V70, P896, DOI 10.1086/339520; Zheng T, 2002, J NEUROPHYSIOL, V87, P1007, DOI 10.1152/jn.00519.2001; Ziemann U, 1997, AM J PSYCHIAT, V154, P1277	96	417	435	1	77	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2002	360	9345					1577	1586		10.1016/S0140-6736(02)11526-1	http://dx.doi.org/10.1016/S0140-6736(02)11526-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443611				2022-12-28	WOS:000179292400029
J	Strater, R; Becker, S; von Eckardstein, A; Heinecke, A; Gutsche, S; Junker, R; Kurnik, K; Schobess, R; Nowak-Gottl, U				Strater, R; Becker, S; von Eckardstein, A; Heinecke, A; Gutsche, S; Junker, R; Kurnik, K; Schobess, R; Nowak-Gottl, U			Prospective assessment of risk factors for recurrent stroke during childhood - a 5-year follow-up study	LANCET			English	Article							FACTOR-V-LEIDEN; ARTERIAL ISCHEMIC STROKE; ANTIPHOSPHOLIPID ANTIBODIES; CHILDREN; LIPOPROTEIN; PROTHROMBIN; THROMBOPHILIA; PLASMINOGEN; MOYAMOYA; FEATURES	Background Risk factors for arterial stroke in children include congenital heart malformations, vasculopathies, infectious diseases, collagen tissue diseases, and metabolic disorders. Results of previous case-control studies have shown an association between ischaemic stroke and hereditary prothrombotic risk factors: factor V G1691A and factor II G20210A mutations, raised lipoprotein (a), and deficiencies in antithrombin, protein C, and protein S. The relevance of these factors to a second ischaemic stroke event is not known. Methods We assessed the risk of a second arterial ischaemic stroke associated with these prothrombotic risk factors, with underlying diseases or stroke comorbidities, and with stroke subtypes (cardiac, vascular, infectious, idiopathic). 167 boys and 134 girls aged between 6 months and 18 years of age (median 7 years) with a first episode of ischaemic stroke were followed-up prospectively for a median of 44 months (range 20-56). Findings Recurrent ischaemic stroke was diagnosed in 20 of 301 children who survived (6.6%) at a median of 5 months (range 1.5-36) after first stroke onset. The relative risk of having a second stroke was significantly increased in patients with raised lipoprotein (a) (relative risk 4.4, 95% Cl 1.9-10.5) and in children with familial protein C deficiency (3.5, 1.1-10.9). Additionally, survival analysis showed that a first ischaemic stroke of vascular origin was significantly associated with having a second stroke (odds ratio 3.9, 95% Cl 1.4-10.6). Interpretation Raised lipoprotein (a), protein C deficiency, and stroke of vascular origin are risk factors for recurrent arterial ischaemic stroke in childhood.	Univ Munster, Dept Paediat, D-48149 Munster, Germany; Univ Munster, Inst Clin Chem, D-48149 Munster, Germany; Univ Munster, Inst Arteriosclerosis Res, D-48149 Munster, Germany; Univ Munster, Inst Med Informat & Biomath, D-48149 Munster, Germany; Goethe Univ Frankfurt, Dept Paediat, D-6000 Frankfurt, Germany; Univ Lubeck, Dept Paediat, Lubeck, Germany; Univ Munich, Dept Paediat, Munich, Germany; Univ Halle Wittenberg, Dept Paediat, Halle An Der Saale, Germany	University of Munster; University of Munster; University of Munster; University of Munster; Goethe University Frankfurt; University of Lubeck; University of Munich; Martin Luther University Halle Wittenberg	Nowak-Gottl, U (corresponding author), Univ Munster, Dept Paediat Haematol & Oncol, D-48149 Munster, Germany.	leagottl@uni-muenster.de	Junker, Ralf/M-2358-2013					Askalan R, 2001, STROKE, V32, P1257, DOI 10.1161/01.STR.32.6.1257; Bonduel M, 1999, ARCH NEUROL-CHICAGO, V56, P967, DOI 10.1001/archneur.56.8.967; Chabrier S, 2000, J CHILD NEUROL, V15, P290, DOI 10.1177/088307380001500504; Delsing BJP, 2001, PEDIATR NEUROL, V24, P283, DOI 10.1016/S0887-8994(01)00245-4; deVeber G, 2001, STROKE, V32, P1791; Dobson SR, 2002, BLOOD, V99, P3144, DOI 10.1182/blood.V99.9.3144; EDELBERT JM, 1989, BIOCHEMISTRY-US, V28, P2370, DOI 10.1021/bi00432a004; Ehrenforth S, 1999, EUR J PEDIATR, V158, pS97, DOI 10.1007/PL00014359; Ganesan V, 1996, LANCET, V347, P260, DOI 10.1016/S0140-6736(96)90434-1; Gunther G, 2000, STROKE, V31, P2437, DOI 10.1161/01.STR.31.10.2437; Heller C, 1999, EUR J PEDIATR, V158, pS117, DOI 10.1007/PL00014333; ISLER W, 1984, EUR NEUROL, V23, P421, DOI 10.1159/000115724; Junker R, 1999, ARTERIOSCL THROM VAS, V19, P2568, DOI 10.1161/01.ATV.19.10.2568; Kenet G, 2000, STROKE, V31, P1283, DOI 10.1161/01.STR.31.6.1283; Kirkham FJ, 2000, J CHILD NEUROL, V15, P299, DOI 10.1177/088307380001500506; KORTE W, 1994, NEUROPEDIATRICS, V25, P290, DOI 10.1055/s-2008-1073042; Lanthier S, 2000, NEUROLOGY, V54, P371, DOI 10.1212/WNL.54.2.371; Manceau E, 1997, CHILD NERV SYST, V13, P595, DOI 10.1007/s003810050148; MATHEWS KD, 1994, STROKE CHILDREN YOUN, P15; McColl MD, 1999, THROMB HAEMOSTASIS, V81, P690; Milionis HJ, 2000, J CLIN PATHOL, V53, P487, DOI 10.1136/jcp.53.7.487; Nicolaides P, 1996, DEV MED CHILD NEUROL, V38, P172; Nowak-Gottl U, 1999, BLOOD, V94, P3678, DOI 10.1182/blood.V94.11.3678.423k34_3678_3682; SCHOENBERG BS, 1978, NEUROLOGY, V28, P763, DOI 10.1212/WNL.28.8.763; Sebire G, 1999, ANN NEUROL, V45, P679, DOI 10.1002/1531-8249(199905)45:5<679::AID-ANA22>3.0.CO;2-E; SIMON DI, 1991, BIOCHEMISTRY-US, V30, P6671, DOI 10.1021/bi00241a006; Strater R, 2001, STROKE, V32, P2554, DOI 10.1161/hs1101.097379; Williams LS, 1997, NEUROLOGY, V49, P1541, DOI 10.1212/WNL.49.6.1541; Wityk RJ, 2000, ATHEROSCLEROSIS, V150, P389, DOI 10.1016/S0021-9150(99)00388-3; Zenz W, 1998, THROMB HAEMOSTASIS, V80, P763	30	246	254	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2002	360	9345					1540	1545		10.1016/S0140-6736(02)11520-0	http://dx.doi.org/10.1016/S0140-6736(02)11520-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443591				2022-12-28	WOS:000179292400009
J	Warhurst, DC; Craig, JC; Adagu, IS				Warhurst, DC; Craig, JC; Adagu, IS			Lysosomes and drug resistance in malaria	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM; CHLOROQUINE RESISTANCE; MOLECULAR MARKER		Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of London; London School of Hygiene & Tropical Medicine; University of California System; University of California San Francisco	Warhurst, DC (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.		warhurst, david c/C-3428-2013					Bray PG, 1996, MOL PHARMACOL, V50, P1559; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; FITCH CD, 1970, SCIENCE, V169, P289, DOI 10.1126/science.169.3942.289; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0; KIRSCH GE, 1995, BIOPHYS J, V68, P1804, DOI 10.1016/S0006-3495(95)80357-7; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; MARTINEY JA, 1991, J EXP MED, V173, P961; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; Sidhu ABS, 2002, SCIENCE, V298, P210, DOI 10.1126/science.1074045; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; Warhurst DC, 2001, NEW ENGL J MED, V344, P299, DOI 10.1056/NEJM200101253440411; WARHURST DC, 2002, COST B9 M ANT CHEM L; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; ZHANG H, 2002, J BIOL CHEM     0925	18	52	52	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1527	1529		10.1016/S0140-6736(02)11577-7	http://dx.doi.org/10.1016/S0140-6736(02)11577-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443586				2022-12-28	WOS:000179292400004
J	Lee, M; Katz, HE; Erben, C; Gill, DM; Gopalan, P; Heber, JD; McGee, DJ				Lee, M; Katz, HE; Erben, C; Gill, DM; Gopalan, P; Heber, JD; McGee, DJ			Broadband modulation of light by using an electro-optic polymer	SCIENCE			English	Article							GHZ	A major challenge to increasing bandwidth in optical telecommunications is to encode electronic signals onto a lightwave carrier by modulating the light up to very fast rates. Polymer electro-optic materials have the necessary properties to function in photonic devices beyond the 40-GHz bandwidth currently available. An appropriate choice of polymers is shown to effectively eliminate the factors contributing to an optical modulator's decay in the high-frequency response. The resulting device modulates light with a bandwidth of 150 to 200 GHz and produces detectable modulation signal at 1.6 THz. These rates are faster than anticipated bandwidth requirements for the foreseeable future.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Lee, M (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Heber, Joerg/AAU-2993-2020; Katz, Howard E/A-3352-2010	Heber, Joerg/0000-0002-6370-4254				Burns WK, 1998, IEEE PHOTONIC TECH L, V10, P805, DOI 10.1109/68.681490; Chen DT, 1997, APPL PHYS LETT, V70, P3335, DOI 10.1063/1.119162; COX CH, 1990, IEEE T MICROW THEORY, V38, P501, DOI 10.1109/22.54917; HAHN KH, 1994, ELECTRON LETT, V30, P1220, DOI 10.1049/el:19940809; Lee M, 2002, APPL PHYS LETT, V81, P1474, DOI 10.1063/1.1499767; Lee M, 2001, APPL PHYS LETT, V79, P1342, DOI 10.1063/1.1399305; Ma H, 2001, ADV MATER, V13, P1201, DOI 10.1002/1521-4095(200108)13:15<1201::AID-ADMA1201>3.0.CO;2-F; Noguchi K, 1998, J LIGHTWAVE TECHNOL, V16, P615, DOI 10.1109/50.664072; Shi YQ, 2000, SCIENCE, V288, P119, DOI 10.1126/science.288.5463.119; TENG CC, 1992, APPL PHYS LETT, V60, P1538, DOI 10.1063/1.107482; TUMOLILLO TA, 1992, IEEE PHOTONIC TECH L, V4, P142, DOI 10.1109/68.122342; WANG WS, 1995, IEEE PHOTONIC TECH L, V7, P638, DOI 10.1109/68.388749; Yariv A., 1989, QUANTUM ELECT; Zhang C, 2001, CHEM MATER, V13, P3043, DOI 10.1021/cm010463j	14	525	546	8	146	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1401	1403		10.1126/science.1077446	http://dx.doi.org/10.1126/science.1077446			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434054				2022-12-28	WOS:000179223100045
J	Rabow, MW; Markowitz, AJ				Rabow, MW; Markowitz, AJ			Responding to requests for physician-assisted suicide - "These are uncharted waters for both of us ..."	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Bascom PB, 2002, JAMA-J AM MED ASSOC, V288, P91, DOI 10.1001/jama.288.1.91	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2332	2332		10.1001/jama.288.18.2332	http://dx.doi.org/10.1001/jama.288.18.2332			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425712				2022-12-28	WOS:000179186400034
J	Benson, T				Benson, T			Why general practitioners use computers and hospital doctors do not - Part 2: scalability	BRITISH MEDICAL JOURNAL			English	Article									Abies Ltd, London NW3 1RX, England		Benson, T (corresponding author), Abies Ltd, 24 Carlingford Rd, London NW3 1RX, England.			Benson, Tim/0000-0002-2101-1353				Audit Commission, 2002, DAT REM IMPR QUAL PA; Benson T, 1998, INT J MED INFORM, V48, P133, DOI 10.1016/S1386-5056(97)00118-4; BENSON T, 1991, MED INFORMATICS REPO, P33; BLOIS SM, 1984, INFORMATION MED NATU; CHISHOLM J, 1990, BRIT MED J, V300, P1090; Department of Health, 2002, DEL 21 CENT IT SUPP; *GP2GP CONS, 2002, GP2GP IMPL GUID VERS; Hammond WE, 2001, J AM MED INFORM ASSN, V8, P222; *I MED, 2000, TO ERR IS HUM BUILD; NHS Management Executive, 1990, CAR CARD EV EXM PROJ; *OFF E ENV, 2002, GOV GAT; *OFF E ENV, 2002, E GOV INT FRAM VERS; *PERF INN UN, 2002, PRIV DAT SHAR WAY FO; *RCGP HLTH INF TAS, 1999, EL PAT REC SCOP STUD; Read J, 1986, BRIT J HEALTHC COMP, V3, P22; Simpson K, 1998, BRIT MED J, V316, P1655, DOI 10.1136/bmj.316.7145.1655; Slack W, 1997, CYBERMEDICINE COMPUT; SLEE V., 2000, ENDANGERED MED RECOR; *SOC SURV GALL POL, 1993, COMP IS GP PRACT 199; Tang P.C., 2001, MED INFORM COMPUTER, P327; WEED LL, 1968, NEW ENGL J MED, V278, P593, DOI 10.1056/NEJM196803142781105; Wyatt JC, 2001, CLIN KNOWLEDGE PRACT	22	41	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2002	325	7372					1090	1093		10.1136/bmj.325.7372.1090	http://dx.doi.org/10.1136/bmj.325.7372.1090			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424172	Bronze, Green Published			2022-12-28	WOS:000179415700025
J	Berger, A				Berger, A			Science commentary: What does zinc do?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; DEVELOPING-COUNTRIES; POOLED ANALYSIS; SUPPLEMENTATION; CHILDREN; PREGNANCY; MORBIDITY; DIARRHEA; INFANTS; GROWTH											Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7; Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516; Black RE, 2001, BRIT J NUTR, V85, pS125, DOI 10.1079/BJN2000304; Caulfield LE, 1998, AM J CLIN NUTR, V68, p499S, DOI 10.1093/ajcn/68.2.499S; Fortes C, 1998, J AM GERIATR SOC, V46, P19, DOI 10.1111/j.1532-5415.1998.tb01008.x; GIBSON RS, 1989, AM J CLIN NUTR, V49, P1266, DOI 10.1093/ajcn/49.6.1266; Girodon F, 1999, ARCH INTERN MED, V159, P748, DOI 10.1001/archinte.159.7.748; GOLDENBERG RL, 1995, JAMA-J AM MED ASSOC, V274, P463, DOI 10.1001/jama.274.6.463; Institute of Medicine Subcommittee on Nutritional Status Weight Gain During Pregnancy Subcommittee on Dietary Intake and Nutrient Supplements During Pregnancy, 1990, NUTR PREGN 1; Keen CL, 1998, AM J CLIN NUTR, V67, p1003S, DOI 10.1093/ajcn/67.5.1003S; Osendarp SJM, 2001, LANCET, V357, P1080, DOI 10.1016/S0140-6736(00)04260-4; Sazawal S, 2001, PEDIATRICS, V108, P1280, DOI 10.1542/peds.108.6.1280; Shankar AH, 2000, AM J TROP MED HYG, V62, P663, DOI 10.4269/ajtmh.2000.62.663	13	21	24	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2002	325	7372					1062	1063		10.1136/bmj.325.7372.1062	http://dx.doi.org/10.1136/bmj.325.7372.1062			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424163	Bronze, Green Published			2022-12-28	WOS:000179415700016
J	Malyutina, S; Bobak, M; Kurilovitch, S; Gafarov, V; Simonova, G; Nikitin, Y; Marmot, M				Malyutina, S; Bobak, M; Kurilovitch, S; Gafarov, V; Simonova, G; Nikitin, Y; Marmot, M			Relation between heavy and binge drinking and all-cause and cardiovascular mortality in Novosibirsk, Russia: a prospective cohort study	LANCET			English	Article							CORONARY-HEART-DISEASE; ALCOHOL-CONSUMPTION; RISK-FACTORS; MEN; POPULATION; PATTERN; BEER; US	Background Moderate alcohol consumption is associated with reduced cardiovascular mortality, but binge drinking is thought to be detrimental. We examined effects of heavy and binge drinking in a population with high rates of binge drinking. Methods We did a prospective cohort study in Novosibirsk, Russia, in 6502 men aged 25-64 years at baseline who were examined in WHO MONICA (monitoring trends and determinants in cardiovascular disease surveys) in 1985/86, 1988/89, and 1994/95, and in a pilot study in 1984. We assessed alcohol intake and drinking pattern by questionnaire; binge drinking was defined as consumption of 160 g or greater of pure alcohol on a typical occasion. Participants were followed-up for a median of 9.5 years (range 3.1-15.2). Findings There were 836 deaths in the cohort, 395 of which resulted from cardiovascular diseases. Prevalence of binge drinking at baseline was 16% (n=1005). Adjusted relative risks for binge drinking at least once a month (compared with consumption of <80 g pure alcohol) were 1.05 (95% CI 0.80-1.36) for deaths from all causes, 0.99 (0.66-1.50) for deaths from cardiovascular disease, 1.27 (0.81-1.99) for deaths from coronary heart disease, and 2.08 (1.08-3.99) for death from external causes. Risk of total and cardiovascular mortality was raised in a small group of frequent heavy drinkers (5% [264] of all drinkers); for this group, adjusted relative risks were 1.61 (1.04-2.50) for total mortality and 2.05 (1.09-3.86) for deaths from cardiovascular disease. Interpretation The risk of death from cardiovascular disease seems to be increased in frequent heavy drinkers, but is not necessarily associated with episodic binge drinking.	UCL, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, London WC1E 6BT, England; Russian Acad Med Sci, Inst Internal Med, Siberian Branch, Novosibirsk, Russia	University of London; University College London; Russian Academy of Medical Sciences; Russian Academy of Sciences	Marmot, M (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, 1-19 Torrington Pl, London WC1E 6BT, England.	michael@public-health.ucl.ac.uk	Marmot, M G/Y-3920-2019; Malyutina, Sofia/J-1651-2018; Gafarov, Valeriy V/O-9502-2015; Simonova, Galina I./AAT-4345-2021; Nikitin, Yuri/D-2774-2018	Marmot, M G/0000-0002-2431-6419; Malyutina, Sofia/0000-0001-6539-0466; Bobak, Martin/0000-0002-2633-6851; Nikitin, Yuri/0000-0002-3932-2299	Medical Research Council [G8802774, G0100222, G19/35] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bobak M, 1998, SOC SCI MED, V47, P269, DOI 10.1016/S0277-9536(98)00095-1; Bobak M, 1999, ADDICTION, V94, P857, DOI 10.1046/j.1360-0443.1999.9468579.x; Bobak M, 1999, ANN EPIDEMIOL, V9, P335; Britton A, 2000, J EPIDEMIOL COMMUN H, V54, P328, DOI 10.1136/jech.54.5.328; Carlson P, 1998, EUR J PUBLIC HEALTH, V8, P280, DOI 10.1093/eurpub/8.4.280; Carlson Per., 2000, UNHEALTHY DECADE SOC; Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360-0443.2000.951015056.x; Deev A, 1998, ANN EPIDEMIOL, V8, P147, DOI 10.1016/S1047-2797(98)00004-0; DYER AR, 1977, CIRCULATION, V56, P1067, DOI 10.1161/01.CIR.56.6.1067; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; *ICAP, 2002, 2 ICAP; Kauhanen J, 1997, EPIDEMIOLOGY, V8, P310, DOI 10.1097/00001648-199705000-00014; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; Malyutina S, 2001, ADDICTION, V96, P987, DOI 10.1046/j.1360-0443.2001.9679877.x; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; Mazzaglia G, 2001, ADDICTION, V96, P1743, DOI 10.1046/j.1360-0443.2001.961217434.x; Nemtsov AV, 2000, DRUG ALCOHOL DEPEN, V58, P133, DOI 10.1016/S0376-8716(99)00069-1; Poikolainen K, 1998, ADDICTION, V93, P1757, DOI 10.1046/j.1360-0443.1998.931217571.x; POIKOLAINEN K, 1983, INT J EPIDEMIOL, V12, P151, DOI 10.1093/ije/12.2.151; Puddey IB, 1999, ADDICTION, V94, P649, DOI 10.1046/j.1360-0443.1999.9456493.x; Rehm J, 1998, ALCOHOL CLIN EXP RES, V22, p4S, DOI 10.1111/j.1530-0277.1998.tb04368.x; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; ROSENGREN A, 1987, ACTA MED SCAND, V222, P201; RYAN M, 1995, BRIT MED J, V310, P646; Shkolnikov V. M., 1997, PREMATURE DEATH NEW, P239; Single E., 1998, DRINKING PATTERNS TH, P7; Tchernina Natalia, 2000, MORTALITY CRISIS TRA, P151; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; WANNAMETHEE G, 1992, BRIT HEART J, V68, P443; *WHO, 1987, MULT MON TRENDS DET	32	171	185	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	2002	360	9344					1448	1454		10.1016/S0140-6736(02)11470-X	http://dx.doi.org/10.1016/S0140-6736(02)11470-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	614JV	12433511				2022-12-28	WOS:000179186000008
J	Rassi, E				Rassi, E			C-reactive protein and progressive atherosclerosis	LANCET			English	Editorial Material							CARDIAC ALLOGRAFT VASCULOPATHY; CORONARY-ARTERY DISEASE; PRAVASTATIN; INFLAMMATION		Catholic Univ, Inst Cardiol, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Rassi, E (corresponding author), Catholic Univ, Inst Cardiol, Rome, Italy.							Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; ARDEHALI A, 1993, AM HEART J, V126, P1498, DOI 10.1016/0002-8703(93)90576-U; Cantin B, 2001, CIRCULATION, V104, P2615, DOI 10.1161/hc4601.099398; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Eisenberg MS, 2000, CIRCULATION, V102, P2100, DOI 10.1161/01.CIR.102.17.2100; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; MILLER LW, 1992, J HEART LUNG TRANSPL, V11, pS1; Pethig K, 2000, CIRCULATION, V102, P233; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401	11	7	7	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1436	1437		10.1016/S0140-6736(02)11486-3	http://dx.doi.org/10.1016/S0140-6736(02)11486-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433505				2022-12-28	WOS:000179186000002
J	Singh, RB; Dubnov, G; Niaz, MA; Ghosh, S; Singh, R; Rastogi, SS; Manor, O; Pella, D; Berry, EM				Singh, RB; Dubnov, G; Niaz, MA; Ghosh, S; Singh, R; Rastogi, SS; Manor, O; Pella, D; Berry, EM			Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial	LANCET			English	Article							POLYUNSATURATED FATTY-ACIDS; ACUTE MYOCARDIAL-INFARCTION; SOCIAL-CLASS; CHOLESTEROL; FISH; ATHEROSCLEROSIS; ASSOCIATION; STYLE; OIL	Background The rapid emergence of coronary artery disease (CAD) in south Asian people is not explained by conventional risk factors. In view of card ioprotective effects of a Mediterranean style diet rich in alpha-linolenic acid, we assessed the benefits of this diet for patients at high risk of CAD. Methods We did a randomised, single-blind trial in 1000 patients with angina pectoris, myocardial infarction, or surrogate risk factors for CAD. 499 patients were allocated to a diet rich in whole grains, fruits, vegetables, walnuts, and almonds. 501 controls consumed a local diet similar to the step I National Cholesterol Education Program (NCEP) prudent diet. Findings The intervention group consumed more fruits, vegetables, legumes, walnuts, and almonds than did controls (573 g [SD 127] vs 231 g [19] per day p<0.001). The intervention group had an increased intake of whole grains and mustard or soy bean oil. The mean intake of alpha-linolenic acid was two-fold greater in the intervention group (1.8 g [SD 0.4] vs 0.8 g [0.2] per day, p<0.001). Total cardiac end points were significantly fewer in the intervention group than the controls (39 vs 76 events, p<0.001). Sudden cardiac deaths were also reduced (6 vs 16, p=0.015), as were non-fatal myocardial infarctions (21 vs 43, p<0.001). We noted a significant reduction in serum cholesterol concentration and other risk factors in both groups; but especially in the intervention diet group. In the treatment group, patients with pre-existing CAD had significantly greater benefits compared with such patients in the control group. Interpretation An Indo-Mediterranean diet that is rich in alpha-linolenic acid might be more effective in primary and secondary prevention of CAD than the conventional step I NCEP prudent diet.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel; Med Hosp & Res Ctr, Ctr Nutr & Heart, Moradabad, India; Hebrew Univ Jerusalem, Hadassah Med Sch, Sch Publ Hlth & Community Med, IL-91120 Jerusalem, Israel; Safarik Univ, Kosice, Slovakia	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Pavol Jozef Safarik Kosice	Berry, EM (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel.	berry@md.huji.ac.il	Dubnov-Raz, Gal/L-3297-2016	Dubnov-Raz, Gal/0000-0003-1469-8043				[Anonymous], 1968, LANCET, V2, P693; Berry EM, 1999, MED HYPOTHESES, V53, P397, DOI 10.1054/mehy.1998.0786; Berry EM, 2001, NUTR METAB CARDIOVAS, V11, P181; BURR ML, 1989, LANCET, V2, P757; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Indian Consensus Group, 1996, J NUTR ENV MED, V6, P309, DOI DOI 10.3109/13590849609007257; JACOBSON MS, 1987, LANCET, V2, P656, DOI 10.1016/S0140-6736(87)92443-3; Janus ED, 1996, CIRCULATION, V94, P2671, DOI 10.1161/01.CIR.94.11.2671; Johansen O, 1999, ARTERIOSCL THROM VAS, V19, P1681, DOI 10.1161/01.ATV.19.7.1681; Joshipura KJ, 2001, ANN INTERN MED, V134, P1106, DOI 10.7326/0003-4819-134-12-200106190-00010; Kris-Etherton P, 2001, CIRCULATION, V103, P1823, DOI 10.1161/01.CIR.103.13.1823; Mori TA, 1997, ARTERIOSCL THROM VAS, V17, P279, DOI 10.1161/01.ATV.17.2.279; NASINGARAO BS, 1989, NUTR COMPOSITION IND; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333; REGNSTROM J, 1992, LANCET, V339, P1183, DOI 10.1016/0140-6736(92)91129-V; Robertson RM, 2001, CIRCULATION, V103, P1821, DOI 10.1161/01.CIR.103.13.1821; Rose G, 1982, CARDIOVASCULAR SURVE; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; Singh R. B., 2001, Journal of Nutritional and Environmental Medicine (Abingdon), V11, P43, DOI 10.1080/13590840020030258; Singh RB, 2000, ASIA PAC J CLIN NUTR, V9, P298, DOI 10.1046/j.1440-6047.2000.00177.x; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; Singh RB, 1997, CARDIOVASC DRUG THER, V11, P485, DOI 10.1023/A:1007757724505; Singh RB, 1999, LANCET, V353, P154, DOI 10.1016/S0140-6736(05)76196-1; SINGH RB, 1995, AM J CARDIOL, V76, P1233, DOI 10.1016/S0002-9149(99)80348-8; SINGH RB, 1995, LANCET, V346, P778, DOI 10.1016/S0140-6736(95)91537-0; SINGH RB, 1992, AM J CARDIOL, V70, P869, DOI 10.1016/0002-9149(92)90729-I; Singh RB, 1997, J ASSOC PHYSICIAN I, V45, P603; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; VANHANDEL E, 1957, J LAB CLIN MED, V50, P152; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; WILSON DE, 1973, J LAB CLIN MED, V82, P473; World Health Organization Study Group, 1990, DIET NUTR PREV CHRON; Yusuf S, 2000, NEW ENGL J MED, V342, P145	35	396	416	0	43	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	2002	360	9344					1455	1461		10.1016/S0140-6736(02)11472-3	http://dx.doi.org/10.1016/S0140-6736(02)11472-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433513				2022-12-28	WOS:000179186000010
J	Di Paolo, G; Pellegrini, L; Letinic, K; Cestra, G; Zoncu, R; Voronov, S; Chang, SH; Guo, J; Wenk, MR; De Camilli, P				Di Paolo, G; Pellegrini, L; Letinic, K; Cestra, G; Zoncu, R; Voronov, S; Chang, SH; Guo, J; Wenk, MR; De Camilli, P			Recruitment and regulation of phosphatidylinositol phosphate kinase type 1 gamma by the FERM domain of talin	NATURE			English	Article							SH3 DOMAIN; MEMBRANE; PHOSPHOINOSITIDES; ADHESION; BINDING; DISRUPTION; MOLECULES	Membrane phosphoinositides control a variety of cellular processes through the recruitment and/or regulation of cytosolic proteins(1-4). One mechanism ensuring spatial specificity in phosphoinositide signalling is the targeting of enzymes that mediate their metabolism to specific subcellular sites. Phosphatidylinositol phosphate kinase type 1gamma (PtdInsPKIgamma) is a phosphatidylinositol-4-phosphate 5-kinase that is expressed at high levels in brain, and is concentrated at synapses(5,6). Here we show that the predominant brain splice variant of PtdInsPKIg (PtdInsPKIgamma-90) binds, by means of a short carboxy-terminal peptide, to the FERM domain of talin, and is strongly activated by this interaction. Talin, a principal component of focal adhesion plaques 7,is also present at synapses. PtdInsPKIgamma-90 is expressed in non-neuronal cells, albeit at much lower levels than in neurons, and is concentrated at focal adhesion plaques, where phosphatidylinositol-4,5-bisphosphate has an important regulatory role. Overexpression of PtdInsPKIgamma-90, or expression of its C-terminal domain, disrupts focal adhesion plaques, probably by local disruption of normal phosphoinositide balance. These findings define an interaction that has a regulatory role in cell adhesion and suggest new similarities between molecular interactions underlying synaptic junctions and general mechanisms of cell adhesion.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.	pietro.decamilli@yale.edu	Wenk, Markus Rene/D-1441-2014; Chang, Sunghoe/J-2784-2012; cestra, gianluca/AAL-4736-2021		Fondazione Telethon Funding Source: Custom; Telethon [485/B] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); Telethon(Fondazione Telethon)		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Chavis P, 2001, NATURE, V411, P317, DOI 10.1038/35077101; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Merilainen J, 1997, J BIOL CHEM, V272, P23278, DOI 10.1074/jbc.272.37.23278; Monkley SJ, 2001, BIOCHEM BIOPH RES CO, V286, P880, DOI 10.1006/bbrc.2001.5497; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Sechi AS, 2000, J CELL SCI, V113, P3685; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	30	360	368	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	2002	420	6911					85	89		10.1038/nature01147	http://dx.doi.org/10.1038/nature01147			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422219				2022-12-28	WOS:000179068100041
J	Wacker, M; Linton, D; Hitchen, PG; Nita-Lazar, M; Haslam, SM; North, SJ; Panico, M; Morris, HR; Dell, A; Wren, BW; Aebi, M				Wacker, M; Linton, D; Hitchen, PG; Nita-Lazar, M; Haslam, SM; North, SJ; Panico, M; Morris, HR; Dell, A; Wren, BW; Aebi, M			N-linked glycosylation in Campylobacter jejuni and its functional transfer into E-coli	SCIENCE			English	Article							PROTEIN GLYCOSYLATION; GLYCOPROTEIN; PILIN	N-linked protein glycosylation is the most abundant posttranslation modification of secretory proteins in eukaryotes. A wide range of functions are attributed to glycan structures covalently linked to asparagine residues within the asparagine-X-serine/threonine consensus sequence (Asn-Xaa-Ser/Thr). We found an N-linked glycosylation system in the bacterium Campylobacter jejuni and demonstrate that a functional N-linked glycosylation pathway could be transferred into Escherichia coli. Although the bacterial N-glycan differs structurally from its eukaryotic counterparts, the cloning of a universal N-linked glycosylation cassette in E. coli opens up the possibility of engineering permutations of recombinant glycan structures for research and industrial applications.	Swiss Fed Inst Technol, Dept Biol, Inst Microbiol, CH-8092 Zurich, Switzerland; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England; M SCAN Mass Spectrometry Res & Training Ctr, Ascot SL5 7PZ, Berks, England	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Aebi, M (corresponding author), Swiss Fed Inst Technol, Dept Biol, Inst Microbiol, CH-8092 Zurich, Switzerland.	aebi@micro.biol.ethz.ch	nita-lazar, m/V-4259-2019; Mihai, Nita-Lazar/Q-2206-2016	Mihai, Nita-Lazar/0000-0002-5099-1311; Linton, Dennis/0000-0002-4717-5428				BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Doolittle WF, 1999, TRENDS CELL BIOL, V15, P5, DOI DOI 10.1016/S0168-9525(99)01877-6; ERICKSON PR, 1993, J BIOL CHEM, V268, P23780; Fry BN, 1998, MICROBIOL-SGM, V144, P2049, DOI 10.1099/00221287-144-8-2049; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7944, DOI 10.1021/ja00046a069; Karaoglu D, 2001, BIOCHEMISTRY-US, V40, P12193, DOI 10.1021/bi0111911; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOTYCZKA P, UNPUB; Linton D, 2002, MOL MICROBIOL, V43, P497, DOI 10.1046/j.1365-2958.2002.02762.x; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Power PM, 2000, MICROBIOL-UK, V146, P967, DOI 10.1099/00221287-146-4-967; Schaffer C, 2001, PROTEOMICS, V1, P248; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	21	581	647	5	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1790	1793		10.1126/science.298.5599.1790	http://dx.doi.org/10.1126/science.298.5599.1790			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459590				2022-12-28	WOS:000179494800046
J	Bogdanovich, S; Krag, TOB; Barton, ER; Morris, LD; Whittemore, LA; Ahima, RS; Khurana, TS				Bogdanovich, S; Krag, TOB; Barton, ER; Morris, LD; Whittemore, LA; Ahima, RS; Khurana, TS			Functional improvement of dystrophic muscle by myostatin blockade	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; MDX MOUSE; MICE; GENE; EXPRESSION; PHENOTYPE; TRANSGENE; MYOPATHY; PROTEIN	Mice(1,2) and cattle(3) with mutations in the myostatin (GDF8) gene show a marked increase in body weight and muscle mass, indicating that this new member of the TGF-beta superfamily is a negative regulator of skeletal muscle growth. Inhibition of the myostatin gene product is predicted to increase muscle mass and improve the disease phenotype in a variety of primary and secondary myopathies. We tested the ability of inhibition of myostatin in vivo to ameliorate the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD)(4-8). Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies for three months resulted in an increase in body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration and concentrations of serum creatine kinase. The functional improvement of dystrophic muscle by myostatin blockade provides a novel, pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD, and circumvents the major problems associated with conventional gene therapy in these disorders.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Muscle Inst, Philadelphia, PA 19104 USA; Wyeth Res, Musculoskeletal Sci Dept, Cambridge, MA 02140 USA; Univ Penn, Sch Med, Div Endocrinol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pfizer; University of Pennsylvania	Khurana, TS (corresponding author), Univ Penn, Sch Med, Dept Physiol, 3700 Hamilton Walk,Richards A-601, Philadelphia, PA 19104 USA.		Ahima, Rexford/W-1394-2019; Krag, Thomas/AAD-3307-2021	Krag, Thomas/0000-0001-9330-668X				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Brown SE, 1997, DYSTROPHIN GENE PROT; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; Ebihara S, 2000, PHYSIOL GENOMICS, V3, P133, DOI 10.1152/physiolgenomics.2000.3.3.133; Engel A., 1994, MYOLOGY; Fischer MD, 2002, PHYSIOL GENOMICS, V9, P71, DOI 10.1152/physiolgenomics.00115.2001; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Guyton A., 1995, TXB MED PHYSL; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; Jalenak M, 2002, J NEUROL SCI, V199, pS83; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lozier JN, 2002, HUM GENE THER, V13, P113, DOI 10.1089/10430340152712665; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; McLoon LK, 2002, MUSCLE NERVE, V25, P348, DOI 10.1002/mus.10056; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; Moustakas A, 2001, J CELL SCI, V114, P4359; MUNTONI F, 1993, J NEUROL SCI, V120, P71, DOI 10.1016/0022-510X(93)90027-V; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Thies RS, 2001, GROWTH FACTORS, V18, P251; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	30	621	744	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					418	421		10.1038/nature01154	http://dx.doi.org/10.1038/nature01154			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459784				2022-12-28	WOS:000179494700040
J	Jacobs, S				Jacobs, S			An oral drug for leishmaniasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	3	4	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1737	1738		10.1056/NEJMbtr020156	http://dx.doi.org/10.1056/NEJMbtr020156			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456848				2022-12-28	WOS:000179468600002
J	Cleland, JGF; Cohen-Solal, A; Aguilar, JC; Dietz, R; Eastaugh, J; Follath, F; Freemantle, N; Gavazzi, A; van Gilst, WH; Hobbs, FDR; Korewicki, J; Madeira, HC; Preda, I; Swedberg, K; Widimsky, J				Cleland, JGF; Cohen-Solal, A; Aguilar, JC; Dietz, R; Eastaugh, J; Follath, F; Freemantle, N; Gavazzi, A; van Gilst, WH; Hobbs, FDR; Korewicki, J; Madeira, HC; Preda, I; Swedberg, K; Widimsky, J		IMPROVEMENT Heart Failure Progra; Study Grp Diagnosis Working Grp He	Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey	LANCET			English	Article							ACE-INHIBITORS; MYOCARDIAL-INFARCTION; BETA-BLOCKERS; DIAGNOSIS; ETIOLOGY; PATTERNS	Background Heart failure is a prevalent condition that is generally treated in primary care. The aim of this study was to assess how primary-care physicians think that heart failure should be managed, how they implement their knowledge, and whether differences exist in practice between countries. Methods The survey was undertaken in 15 countries that had membership of the European Society of Cardiology (ESC) between Sept 1, 1999, and May 31, 2000. Primary-care physicians' knowledge and perceptions about the management of heart failure were assessed with a perception survey and how a representative sample of patients was managed with an actual practice survey. Findings 1363 physicians provided data for 11062 patients, of whom 54% were older than 70 years and 45% were women. 82% of patients had had an echocardiogram but only 51% of these showed left ventricular systolic dysfunction. Ischaemic heart disease, hypertension, diabetes mellitus, atrial fibrillation, and major valve disease were all common. Physicians gave roughly equal priority to improvement of symptoms and prognosis. Most were aware of the benefits of ACE inhibitors and beta blockers. 60% of patients were prescribed ACE inhibitors, 34% beta blockers but only 20% received these drugs in combination. Doses given. were about 50% of targets suggested in the ESC guidelines. If systolic dysfunction was documented, ACE inhibitors were more likely and beta blockers less likely to be prescribed than when there was no evidence of systolic dysfunction. Interpretation Results from this survey suggest that most patients with heart failure are appropriately investigated, although this finding might be as a result of high rates of hospital admissions. However, treatment seems to be less than optimum, and there are substantial variations in practice between countries. The inconsistencies between physicians' knowledge and the treatment that they deliver suggests that improved organisation of care for heart failure is required.	Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull HU16 5JQ, Yorks, England; Hop Beaujon, Dept Cardiol, Clichy, France; Hosp La Fe, E-46009 Valencia, Spain; Humboldt Univ, Max Delbruck Centrum, Franz Volhard Klin, Berlin, Germany; Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham, W Midlands, England; Univ Zurich Hosp, CH-8091 Zurich, Switzerland; Osped Riuniti Bergamo, Unita Operat Cardiol, Dipartimento Cardiovasc, I-24100 Bergamo, Italy; Univ Groningen, Dept Clin Pharmacol, Groningen, Netherlands; Natl Inst Cardiol, Warsaw, Poland; Fac Med Lisbon, Cadeira Med 3, Lisbon, Portugal; Semmelweis Univ, Dept Cardiol & Internal Med, Budapest, Hungary; Sahlgrens Univ Hosp, Dept Med, S-41345 Gothenburg, Sweden; Postgrad Med Sch, Dept Cardiol, Prague, Czech Republic	University of Hull; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Hospital Universitari i Politecnic La Fe; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; University of Birmingham; University of Zurich; University Zurich Hospital; Ospedali Riuniti di Bergamo; University of Groningen; Institute of Cardiology - Poland; Universidade de Lisboa; Semmelweis University; Sahlgrenska University Hospital	Cleland, JGF (corresponding author), Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull HU16 5JQ, Yorks, England.	j.g.cleland@hull.ac.uk	Swedberg, Karl/B-2475-2008; van Gilst, Wiek/R-1806-2019; Cleland, John G./AAZ-4185-2020; van Gilst, Wiek H/C-3828-2008	van Gilst, Wiek/0000-0003-2968-8585; Cleland, John G./0000-0002-1471-7016; Freemantle, Nick/0000-0001-5807-5740; hobbs, richard/0000-0001-7976-7172; Madeira, Hugo/0000-0003-4291-2289				Caruana L, 2000, BRIT MED J, V321, P215, DOI 10.1136/bmj.321.7255.215; Clark AL, 2000, POSTGRAD MED J, V76, P289, DOI 10.1136/pmj.76.895.289; CLARK AL, 1995, BRIT MED J, V310, P973, DOI 10.1136/bmj.310.6985.973; CLELAND JG, 1995, EUR HEART J, V16, P741; Cleland JGF, 1999, EUR J HEART FAIL, V1, P211, DOI 10.1016/S1388-9842(99)00039-2; Cleland JGF, 1999, BRIT MED J, V318, P824, DOI 10.1136/bmj.318.7187.824; Cleland JGF, 1998, LANCET, V352, P19; Cleland JGF, 1999, J CARDIOVASC RISK, V6, P131; Cleland JGF, 2001, EUR HEART J, V22, P623, DOI 10.1053/euhj.2000.2493; Cleland JGF, 1999, CARDIOLOGY, V92, P10, DOI 10.1159/000047289; Cleland JGF, 1999, EUR J HEART FAIL, V1, P139; Cleland JGF, 1999, EUR J HEART FAIL, V1, P229, DOI 10.1016/S1388-9842(99)00032-X; Collett D., 1991, MODELLING BINARY DAT; Cowie MR, 1997, EUR HEART J, V18, P208; Cowie MR, 1999, EUR HEART J, V20, P421, DOI 10.1053/euhj.1998.1280; DAVIE AP, 1995, CORONARY ARTERY DIS, V6, P315, DOI 10.1097/00019501-199504000-00008; Davie AP, 1999, POSTGRAD MED J, V75, P219, DOI 10.1136/pgmj.75.882.219; Follath F, 1998, J AM COLL CARDIOL, V32, P1167, DOI 10.1016/S0735-1097(98)00400-8; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Hillis GS, 1996, HEART, V76, P427, DOI 10.1136/hrt.76.5.427; Hjalmarson A, 1999, LANCET, V353, P2001; Hobbs FDR, 2000, EUR HEART J, V21, P1877, DOI 10.1053/euhj.2000.2170; Houghton T, 2000, EUR J HEART FAIL, V2, P333, DOI 10.1016/S1388-9842(00)00100-8; Lechat P, 1999, LANCET, V353, P9; Philbin EF, 1996, AM J CARDIOL, V77, P832, DOI 10.1016/S0002-9149(97)89177-1; Philbin EF, 1998, CLIN CARDIOL, V21, P103, DOI 10.1002/clc.4960210208; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Rothman K, 1986, MODERN EPIDEMIOLOGY; *TAS FORC WORK GRO, 1997, EUR HEART J, V18, P736; Toal M, 2000, EUR J HEART FAIL, V2, P201, DOI 10.1016/S1388-9842(00)00071-4; Vasan RS, 2001, NEW ENGL J MED, V344, P56, DOI 10.1056/NEJM200101043440111; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	33	427	448	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2002	360	9346					1631	1639		10.1016/S0140-6736(02)11601-1	http://dx.doi.org/10.1016/S0140-6736(02)11601-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457785				2022-12-28	WOS:000179393900007
J	Ashton, HA; Buxton, MJ; Day, NE; Kim, LG; Marteau, TM; Scott, RAP; Thomspon, SG; Walker, NM				Ashton, HA; Buxton, MJ; Day, NE; Kim, LG; Marteau, TM; Scott, RAP; Thomspon, SG; Walker, NM		Multicentre Aneurysm Screening Stu	The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial	LANCET			English	Article							PSYCHOLOGICAL MORBIDITY; MANAGEMENT; BENEFITS; ANXIETY; STATE; SCALE; RISKS	Background Opposing views have been published on the importance of ultrasound screening for abdominal aortic aneurysms. The Multicentre Aneurysm Screening Study was designed to assess whether or not such screening is beneficial. Methods A population-based sample of men (n=67 800) aged 65-74 years was enrolled, and each individual randomly allocated to either, receive an invitation for an abdominal ultrasound scan (invited group, n=33 839) or not (control group, n=33 961). Men in whom abdominal aortic aneurysms (greater than or equal to3 cm in diameter) were detected were followed-up with repeat ultrasound scans for a mean of 4.1 years. Surgery was considered on specific criteria (diameter greater than or equal to5.5 cm, expansion greater than or equal to1 cm per year, symptoms). Mortality data were obtained from the Office of National Statistics, and an intention-to-treat analysis was based on cause of death. Quality of life was assessed with four standardised scales. The primary outcome measure was mortality related to abdominal aortic aneurysm. Findings 27 147 of 33 839 (80%) men in the invited group accepted the invitation to screening, and 1333 aneurysms were detected. There were 65 aneurysm-related deaths (absolute risk 0.19%) in the invited group, and 113 (0.33%) in the control group (risk reduction 42%, 95% Cl 22-58; p=0.0002), with a 53% reduction (95% Cl 30-64) in those who attended screening. 30-day mortality was 6% (24 of 414) after elective surgery for an aneurysm, and 37% (30 of 81) after emergency surgery. Interpretation Our results provide reliable evidence of benefit from screening for abdominal aortic aneurysms.	St Richards Hosp, CMEC, Scott Res Unit, Chichester PO19 4SE, England		Scott, RAP (corresponding author), St Richards Hosp, CMEC, Scott Res Unit, Chichester PO19 4SE, England.			Walker, Neil/0000-0001-9796-7688; Marteau, Theresa/0000-0003-3025-1129; Kim, Lois/0000-0002-4552-3820				BERNSTEIN EF, 1984, ANN SURG, V200, P255, DOI 10.1097/00000658-198409000-00003; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Couto E, 2002, J MED SCREEN, V9, P40, DOI 10.1136/jms.9.1.40; Forbes JF, 1998, LANCET, V352, P1656; Heather BP, 2000, BRIT J SURG, V87, P750, DOI 10.1046/j.1365-2168.2000.01476.x; Khaira HS, 1998, ANN ROY COLL SURG, V80, P341; Kniemeyer HW, 2000, EUR J VASC ENDOVASC, V19, P190, DOI 10.1053/ejvs.1999.0980; Law M R, 1994, J Med Screen, V1, P110; Lederle FA, 2002, NEW ENGL J MED, V346, P1437, DOI 10.1056/NEJMoa012573; Lindholt JS, 1999, EUR J VASC ENDOVASC, V17, P472, DOI 10.1053/ejvs.1999.0835; Lindholt JS, 2000, EUR J VASC ENDOVASC, V20, P79, DOI 10.1053/ejvs.1999.1087; Lindholt JS, 2002, EUR J VASC ENDOVASC, V23, P55, DOI 10.1053/ejvs.2001.1534; LOEYES T, IN PRESS BIOMETRICS; Lucarotti ME, 1997, EUR J VASC ENDOVASC, V14, P499, DOI 10.1016/S1078-5884(97)80131-1; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; MASON JM, 1993, J PUBLIC HEALTH MED, V15, P154; *MULT AN SCREEN ST, IN PRESS BMJ; Noble M., 2000, INDICES DEPRIVATION; Norman PE, 1998, BMJ-BRIT MED J, V317, P852, DOI 10.1136/bmj.317.7162.852; Powell JT, 1998, LANCET, V352, P1649; SCOTT RAP, 1995, BRIT J SURG, V82, P1066, DOI 10.1002/bjs.1800820821; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; Scott RAP, 2001, EUR J VASC ENDOVASC, V21, P535, DOI 10.1053/ejvs.2001.1368; Scott RAP, 2002, BRIT J SURG, V89, P283, DOI 10.1046/j.0007-1323.2001.02014.x; Shaw C, 1999, SOC SCI MED, V49, P1571, DOI 10.1016/S0277-9536(99)00244-0; StLeger AS, 1996, EUR J VASC ENDOVASC, V11, P183, DOI 10.1016/S1078-5884(96)80049-9; Vardulaki KA, 2000, BRIT J SURG, V87, P195, DOI 10.1046/j.1365-2168.2000.01353.x; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895-4356(98)00081-X; Wilmink TBM, 1999, J VASC SURG, V30, P203, DOI 10.1016/S0741-5214(99)70129-1; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	869	895	2	43	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1531	1539		10.1016/S0140-6736(02)11522-4	http://dx.doi.org/10.1016/S0140-6736(02)11522-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443589				2022-12-28	WOS:000179292400007
J	Paulson, RJ; Boostanfar, R; Saadat, P; Mor, E; Tourgeman, DE; Slater, CC; Francis, MM; Jain, JK				Paulson, RJ; Boostanfar, R; Saadat, P; Mor, E; Tourgeman, DE; Slater, CC; Francis, MM; Jain, JK			Pregnancy in the sixth decade of life - Obstetric outcomes in women of advanced reproductive age	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OOCYTE DONATION; IN-VITRO; INFANTS	Context As a result of oocyte donation, women in their sixth decade of life are now able to conceive and carry pregnancies to term. However, little is known about pregnancy outcomes in this population. Objective To describe pregnancy outcomes in women aged 50 years or older who conceived after in vitro fertilization with donor oocytes. Design and Setting Retrospective analysis of cycles conducted at a US university assisted reproduction program during calendar years 1991-2001. Patients Seventy-seven postmenopausal women with no chronic medical conditions (mean [SDI age, 52.8 [2.91 years; range, 50-63 years) who underwent 121 embryo transfer procedures (89 fresh and 32 frozen). Pregnancy outcomes were ascertained by chart review and telephone follow-up. Main Outcome Measures Maternal and neonatal outcomes. Results There were 55 clinical pregnancies for a total pregnancy rate of 45.5%. The live birth rate was 37.2%. Of the 45 live births, 31 were singletons, 12 were twins, and 2 were triplets, for which the mean (SD) gestational ages at delivery were 38.4 (2.1) weeks, 35.8 (2.8) weeks, and 32.2 weeks, respectively. Mean (SD) birth weights were 3039 g (703 g), 2254 g (581 g), and 1913 g, respectively. Apgar scores at 1 and 5 minutes were 8.2 (0.9) and 9.1 (0.5), respectively. Of singletons, 68% were delivered by cesarean, and all multiples were delivered by cesarean. Mild preeclampsia was noted in 25% of patients and severe preeclampsia in 10%. Gestational diabetes required diet modification in 17.5%, and 2.5% required insulin. Conclusions Appropriately screened women aged 50 years or older can successfully conceive via oocyte donation and experience similar pregnancy rates, multiple gestation rates, and spontaneous abortion rates as younger recipients. During pregnancy, they appear at increased risk of preeclampsia and gestational diabetes. A majority can expect to deliver via cesarean. However, there does not appear to be any definitive medical reason for excluding these women from attempting pregnancy on the basis of age alone.	Univ So Calif, Womens & Childrens Hosp, Dept Obstet & Gynecol, Keck Sch Med,Div Reprod Endocrinol & Infertil, Los Angeles, CA 90033 USA	Children's Hospital Los Angeles; University of Southern California	Paulson, RJ (corresponding author), Univ So Calif, Womens & Childrens Hosp, Dept Obstet & Gynecol, Keck Sch Med,Div Reprod Endocrinol & Infertil, 1240 N Mission Rd,Room 8K9, Los Angeles, CA 90033 USA.	rpaulson@usc.edu						ANTINORI S, 1993, HUM REPROD, V8, P1487, DOI 10.1093/oxfordjournals.humrep.a138284; Behr B, 1999, HUM REPROD, V14, P454, DOI 10.1093/humrep/14.2.454; Cunningham FG, 2001, WILLIAMS OBSTET, V23rd; Gardner DK, 1997, HUM REPROD UPDATE, V3, P367, DOI 10.1093/humupd/3.4.367; Hansen M, 2002, NEW ENGL J MED, V346, P725, DOI 10.1056/NEJMoa010035; KIRZ DS, 1985, AM J OBSTET GYNECOL, V152, P7, DOI 10.1016/S0002-9378(85)80166-6; LEHMANN DK, 1987, AM J OBSTET GYNECOL, V157, P738, DOI 10.1016/S0002-9378(87)80041-8; MESTMAN JH, 1980, DIABETES CARE, V3, P447, DOI 10.2337/diacare.3.3.447; NARAYAN H, 1992, EUR J OBSTET GYN R B, V47, P47, DOI 10.1016/0028-2243(92)90213-I; NEWMAN RB, 1989, AM J OBSTET GYNECOL, V161, P547, DOI 10.1016/0002-9378(89)90354-2; PANTOS K, 1993, HUM REPROD, V8, P488, DOI 10.1093/oxfordjournals.humrep.a138077; Paulson RJ, 1997, FERTIL STERIL, V67, P949, DOI 10.1016/S0015-0282(97)81413-6; Paulson RJ, 2001, FERTIL STERIL, V75, P14, DOI 10.1016/S0015-0282(00)01719-2; Paulson RJ, 1997, HUM REPROD, V12, P835, DOI 10.1093/humrep/12.4.835; Salha O, 1999, HUM REPROD, V14, P2268, DOI 10.1093/humrep/14.9.2268; SAUER MV, 1993, LANCET, V341, P321, DOI 10.1016/0140-6736(93)90132-Z; SAUER MV, 1992, JAMA-J AM MED ASSOC, V268, P1275, DOI 10.1001/jama.268.10.1275; SAUER MV, 1995, FERTIL STERIL, V64, P111, DOI 10.1016/S0015-0282(16)57665-1; Sauer MV, 1996, HUM REPROD, V11, P2540; SAUER MV, 1990, NEW ENGL J MED, V323, P1157, DOI 10.1056/NEJM199010253231702; Schieve LA, 2002, NEW ENGL J MED, V346, P731, DOI 10.1056/NEJMoa010806; SERHAL PF, 1989, LANCET, V1, P1185; SPELLACY WN, 1990, OBSTET GYNECOL, V75, P168; SPELLACY WN, 1986, OBSTET GYNECOL, V68, P452; Ventura S J, 2000, Natl Vital Stat Rep, V48, P1; Zeitz J, 2002, FERTIL STERIL, V77, P18	26	165	175	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2320	2323		10.1001/jama.288.18.2320	http://dx.doi.org/10.1001/jama.288.18.2320			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425710	Bronze			2022-12-28	WOS:000179186400032
J	Hempstead, BL; Salzer, JL				Hempstead, BL; Salzer, JL			A glial spin on neurotrophins	SCIENCE			English	Editorial Material							IN-VITRO; MYELINATION; CELLS; PROLIFERATION; BDNF; P75		Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; NYU, Sch Med, Dept Neurol, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Cornell University; New York University; New York University	Hempstead, BL (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA.			Salzer, James/0000-0001-9126-7197				Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Bentley CA, 2000, J NEUROSCI, V20, P7706; Cellerino A, 1997, MOL CELL NEUROSCI, V9, P397, DOI 10.1006/mcne.1997.0641; Chan JR, 2001, P NATL ACAD SCI USA, V98, P14661, DOI 10.1073/pnas.251543398; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; Mirsky R, 1999, BRAIN PATHOL, V9, P293; NICKOLS JC, 2002, SOC NEUR ABSTR, V819, P15; PrugininBluger M, 1997, MECH DEVELOP, V61, P99, DOI 10.1016/S0925-4773(96)00623-5; SCHERER SS, 2001, GLIAL CELL DEV, P299; Syroid DE, 2000, J NEUROSCI, V20, P5741, DOI 10.1523/JNEUROSCI.20-15-05741.2000; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Yan HL, 2000, J NEUROSCI RES, V62, P329, DOI 10.1002/1097-4547(20001101)62:3<329::AID-JNR2>3.0.CO;2-C; Zhang JY, 2000, EUR J NEUROSCI, V12, P4171, DOI 10.1046/j.1460-9568.2000.01312.x	17	15	22	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1184	1186		10.1126/science.1078709	http://dx.doi.org/10.1126/science.1078709			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424359				2022-12-28	WOS:000179080400028
J	Snow, CD; Nguyen, N; Pande, VS; Gruebele, M				Snow, CD; Nguyen, N; Pande, VS; Gruebele, M			Absolute comparison of simulated and experimental protein-folding dynamics	NATURE			English	Article							TERTIARY STRUCTURE; MODEL; APOMYOGLOBIN; MECHANICS; SECONDARY; PATHWAYS; KINETICS; PEPTIDE; DESIGN	Protein folding is difficult to simulate with classical molecular dynamics. Secondary structure motifs such as alpha-helices and beta-hairpins can form in 0.1-10 mus (ref. 1), whereas small proteins have been shown to fold completely in tens of microseconds(2). The longest folding simulation to date is a single 1-mus simulation of the villin headpiece(3); however, such single runs may miss many features of the folding process as it is a heterogeneous reaction involving an ensemble of transition states(4,5). Here, we have used a distributed computing implementation to produce tens of thousands of 5-20-ns trajectories (700 mus) to simulate mutants of the designed mini-protein BBA5. The fast relaxation dynamics these predict were compared with the results of laser temperature-jump experiments. Our computational predictions are in excellent agreement with the experimentally determined mean folding times and equilibrium constants. The rapid folding of BBA5 is due to the swift formation of secondary structure. The convergence of experimentally and computationally accessible timescales will allow the comparison of absolute quantities characterizing in vitro and in silico (computed) protein folding(6).	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Stanford Univ, Biophys Program, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; Stanford University; Stanford University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Pande, VS (corresponding author), Univ Illinois, Dept Chem, 1209 W Calif St, Urbana, IL 61801 USA.		Snow, Christopher/L-5624-2013; Pande, Vijay/ABE-8145-2020	Snow, Christopher/0000-0002-7690-3519; 				ANDERSEN HC, 1983, J COMPUT PHYS, V52, P24, DOI 10.1016/0021-9991(83)90014-1; Ballew RM, 1996, P NATL ACAD SCI USA, V93, P5759, DOI 10.1073/pnas.93.12.5759; Bieri O, 1999, P NATL ACAD SCI USA, V96, P9597, DOI 10.1073/pnas.96.17.9597; CHANDLER D, 1978, J CHEM PHYS, V68, P2959, DOI 10.1063/1.436049; Daura X, 1998, J MOL BIOL, V280, P925, DOI 10.1006/jmbi.1998.1885; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740; Eaton WA, 1998, ACCOUNTS CHEM RES, V31, P745, DOI 10.1021/ar9700825; Ervin J, 2000, J PHOTOCH PHOTOBIO B, V54, P1, DOI 10.1016/S1011-1344(00)00002-6; Ferrara P, 2000, J PHYS CHEM B, V104, P5000, DOI 10.1021/jp994157t; Ferrara P, 2000, P NATL ACAD SCI USA, V97, P10780, DOI 10.1073/pnas.190324897; FERSHT AR, 1992, J MOL BIOL, V224, P771, DOI 10.1016/0022-2836(92)90561-W; FLETCHER R, 1963, COMPUT J, V6, P163, DOI 10.1093/comjnl/6.2.163; Gilmanshin R, 1997, P NATL ACAD SCI USA, V94, P3709, DOI 10.1073/pnas.94.8.3709; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOEHL P, 1994, J MOL BIOL, V239, P249, DOI 10.1006/jmbi.1994.1366; Lapidus LJ, 2000, P NATL ACAD SCI USA, V97, P7220, DOI 10.1073/pnas.97.13.7220; Mayor U, 2000, P NATL ACAD SCI USA, V97, P13518, DOI 10.1073/pnas.250473497; MOORE S, 1951, J BIOL CHEM, V192, P663; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; PONDER JW, 1987, J COMPUT CHEM, V8, P1016, DOI 10.1002/jcc.540080710; Qiu D, 1997, J PHYS CHEM A, V101, P3005, DOI 10.1021/jp961992r; Shea JE, 2001, ANNU REV PHYS CHEM, V52, P499, DOI 10.1146/annurev.physchem.52.1.499; Shirts M, 2000, SCIENCE, V290, P1903, DOI 10.1126/science.290.5498.1903; Struthers M, 1998, FOLD DES, V3, P95, DOI 10.1016/S1359-0278(98)00015-7; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; Zagrovic B, 2001, J MOL BIOL, V313, P151, DOI 10.1006/jmbi.2001.5033	29	573	579	0	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					102	106		10.1038/nature01160	http://dx.doi.org/10.1038/nature01160			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422224				2022-12-28	WOS:000179068100045
J	Weiger, WA; Smith, M; Boon, H; Richardson, MA; Kaptchuk, TJ; Eisenberg, DM				Weiger, WA; Smith, M; Boon, H; Richardson, MA; Kaptchuk, TJ; Eisenberg, DM			Advising patients who seek complementary and alternative medical therapies for cancer	ANNALS OF INTERNAL MEDICINE			English	Review							STRUCTURED PSYCHIATRIC INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; CHINESE HERBAL PREPARATION; VITAMIN-E SUPPLEMENTATION; METASTATIC BREAST-CANCER; PINEAL HORMONE MELATONIN; MANUAL LYMPH-DRAINAGE; DIETARY-FAT INTAKE; CELL LUNG-CANCER; ST-JOHNS WORT	Many patients with cancer use complementary and alternative medical (CAM) therapies. Physicians need authoritative information on CAM therapies to responsibly advise patients who seek these interventions. This article summarizes current evidence on the efficacy and safety of selected CAM therapies that are commonly used by patients with cancer. The following major categories of interventions are covered: dietary modification and supplementation, herbal products and other biological agents, acupuncture, massage, exercise, and psychological and mind-body therapies. Two categories of evidence on efficacy are considered: possible effects on disease progression and survival and possible palliative effects. In evaluating evidence on safety, two types of risk are considered: the risk for direct adverse effects and the risk for interactions with conventional treatments. For each therapy, the current balance of evidence on efficacy and safety points to whether the therapy may be reasonably recommended, accepted (for example, dietary fat reduction in well-nourished patients with breast or prostate cancer), or discouraged (for example, high-dose vitamin A supplementation). This strategy allows the development of an approach for providing responsible, evidence-based, patient-centered advice to persons with cancer who seek CAM therapies.	Harvard Univ, Sch Med, Landmark Ctr,Osher Inst, Div Res & Educ Complementary & Integrat Med Thera, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Canadian Col Naturopath Med, Toronto, ON, Canada; Univ Toronto, Toronto, ON, Canada; NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Weiger, WA (corresponding author), Harvard Univ, Sch Med, Landmark Ctr,Osher Inst, Div Res & Educ Complementary & Integrat Med Thera, 2nd Floor W,Suite 22A,401 Pk Dr, Boston, MA 02215 USA.	wendy_weiger@hms.harvard.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR 43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADLERCREUTZ CHT, 1995, J NUTR, V125, pS757, DOI 10.1093/jn/125.3_Suppl.757S; ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; Ahles TA, 1999, J PAIN SYMPTOM MANAG, V18, P157, DOI 10.1016/S0885-3924(99)00061-5; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Alimi D, 2000, J PAIN SYMPTOM MANAG, V19, P81, DOI 10.1016/S0885-3924(99)00140-2; Allred CD, 2001, CANCER RES, V61, P5045; Amato P, 2002, MENOPAUSE, V9, P145, DOI 10.1097/00042192-200203000-00010; [Anonymous], 1993, CA-CANCER J CLIN, V43, P309; [Anonymous], 2001, Institute of Medicine (US) Panel on Micronutrients; [Anonymous], 2001, MED EC; Awad AB, 2001, EUR J CANCER PREV, V10, P507, DOI 10.1097/00008469-200112000-00005; Bairati I, 1998, J UROLOGY, V159, P1271, DOI 10.1016/S0022-5347(01)63579-1; BAIRD DD, 1995, J CLIN ENDOCR METAB, V80, P1685, DOI 10.1210/jc.80.5.1685; BATIST G, 1995, ALTERNATIVE COMPLEME, V1, P243; BINDEMANN S, 1991, EUR J CANCER, V27, P170, DOI 10.1016/0277-5379(91)90480-2; Bogliun G, 1996, INT J GYNECOL CANCER, V6, P415, DOI 10.1046/j.1525-1438.1996.06050415.x; Bonham M, 2002, CANCER RES, V62, P3920; BOON H, 1999, BOT PHARM PHARM 47 C; BORDIA A, 1985, CLIN CARDIOL, V8, P552, DOI 10.1002/clc.4960081012; BORDIA AK, 1980, ATHEROSCLEROSIS, V35, P181, DOI 10.1016/0021-9150(80)90083-0; BOWMAN BB, 1984, J CLIN ONCOL, V2, P702, DOI 10.1200/JCO.1984.2.6.702; BROWN V, 1985, MACROBIOTIC MIRACLE; Calzada C, 1997, ATHEROSCLEROSIS, V128, P97, DOI 10.1016/S0021-9150(96)05974-6; CARTER JP, 1993, J AM COLL NUTR, V12, P209; Cascinu S, 2002, J CLIN ONCOL, V20, P3478, DOI 10.1200/JCO.2002.07.061; CASCINU S, 1995, J CLIN ONCOL, V13, P26, DOI 10.1200/JCO.1995.13.1.26; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; CHLEBOWSKI RT, 1992, BREAST CANCER RES TR, V20, P73; Classen C, 2001, ARCH GEN PSYCHIAT, V58, P494, DOI 10.1001/archpsyc.58.5.494; Cohen MH, 2002, ANN INTERN MED, V136, P596, DOI 10.7326/0003-4819-136-8-200204160-00009; CONNORS T. A., 1966, EUR J CANCER, V2, P293, DOI 10.1016/0014-2964(66)90042-9; CREAGAN ET, 1979, NEW ENGL J MED, V301, P687, DOI 10.1056/NEJM197909273011303; Cunningham AJ, 1998, PSYCHO-ONCOL, V7, P508, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<508::AID-PON376>3.0.CO;2-7; CURTIES D, 1998, MASSAGE THERAPY CANC; Darzynkiewicz Z, 2000, INT J ONCOL, V17, P729; Davis NB, 2002, J UROLOGY, V167, P1793, DOI 10.1016/S0022-5347(05)65209-3; de la Taille A, 1999, BJU INT, V84, P845; De la Taille A, 2000, J UROLOGY, V164, P1229, DOI 10.1097/00005392-200010000-00021; DeVita VT, 1997, CANC PRINCIPLES PRAC; Dimeo F, 1997, BLOOD, V90, P3390, DOI 10.1182/blood.V90.9.3390; Dimeo FC, 1999, CANCER, V85, P2273, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2273::AID-CNCR24>3.0.CO;2-B; DiPaola RS, 1998, NEW ENGL J MED, V339, P785, DOI 10.1056/NEJM199809173391201; Duda RB, 1999, J SURG ONCOL, V72, P230, DOI 10.1002/(SICI)1096-9098(199912)72:4<230::AID-JSO9>3.0.CO;2-2; Duncan AM, 1999, J CLIN ENDOCR METAB, V84, P192, DOI 10.1210/jc.84.1.192; Duncan AM, 1999, J CLIN ENDOCR METAB, V84, P3479, DOI 10.1210/jc.84.10.3479; DUNDEE JW, 1987, LANCET, V1, P1083; DVORKIN L, 2000, SHARK CARTILAGE; Edelman S, 1999, PSYCHO-ONCOL, V8, P474, DOI 10.1002/(SICI)1099-1611(199911/12)8:6<474::AID-PON427>3.0.CO;2-A; Edelman S, 1999, PSYCHO-ONCOL, V8, P295, DOI 10.1002/(SICI)1099-1611(199907/08)8:4<295::AID-PON386>3.3.CO;2-P; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; Ernst E, 2002, ARCH SURG-CHICAGO, V137, P316, DOI 10.1001/archsurg.137.3.316; EVANS BAJ, 1995, J ENDOCRINOL, V147, P295, DOI 10.1677/joe.0.1470295; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720; FILSHIE J, 1985, EUR J SURG ONCOL, V11, P389; FILSHIE J, 1988, CANCER SURV, V7, P161; FLETCHER RH, 2001, VITAMIN SUPPLEMANTAT; *FOOD NUTR BOARD I, 2002, DIET REF INT TABL; FORESTER B, 1985, AM J PSYCHIAT, V142, P22; Fotsis T, 1997, CANCER RES, V57, P2916; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; FREI B, 1994, AM J MED, V97, pS5, DOI 10.1016/0002-9343(94)90292-5; Frei B, 1994, AM J MED, V97, p22S; Fukui S, 2000, CANCER, V89, P1026, DOI 10.1002/1097-0142(20000901)89:5<1026::AID-CNCR12>3.0.CO;2-5; Giese S, 1998, PLAST RECONSTR SURG, V102, P1778, DOI 10.1097/00006534-199810000-00101; Goldman P, 2001, ANN INTERN MED, V135, P594, DOI 10.7326/0003-4819-135-8_Part_1-200110160-00010; Goodwin PJ, 2001, NEW ENGL J MED, V345, P1719, DOI 10.1056/NEJMoa011871; Grealish L, 2000, CANCER NURS, V23, P237, DOI 10.1097/00002820-200006000-00012; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Gutendorf B, 2001, TOXICOLOGY, V166, P79, DOI 10.1016/S0300-483X(01)00437-1; Habito RC, 2000, BRIT J NUTR, V84, P557, DOI 10.1017/S0007114500001872; Halicka HD, 1997, INT J ONCOL, V11, P437; Hargreaves DF, 1999, J CLIN ENDOCR METAB, V84, P4017, DOI 10.1210/jc.84.11.4017; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HERSKOVITZ S, 1992, MUSCLE NERVE, V15, P1215; Holmes MD, 1999, CANCER, V86, P826, DOI 10.1002/(SICI)1097-0142(19990901)86:5&lt;826::AID-CNCR19&gt;3.0.CO;2-0; HOPKINS MP, 1988, AM J OBSTET GYNECOL, V159, P1121, DOI 10.1016/0002-9378(88)90426-7; Hospers GAP, 1999, BRIT J CANCER, V80, P629, DOI 10.1038/sj.bjc.6690404; Hsieh TC, 1998, INT J ONCOL, V13, P1199; Hsieh TC, 1997, BIOCHEM MOL BIOL INT, V42, P535; Ikezoe T, 2001, PROSTATE, V49, P285, DOI 10.1002/pros.10024; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Johansson K, 1999, LYMPHOLOGY, V32, P103; Johansson K, 1998, LYMPHOLOGY, V31, P56; Ju YH, 2002, CANCER RES, V62, P2474; KAGERUD A, 1981, ACTA RADIOL ONCOL, V20, P97; Kane GC, 2000, MAYO CLIN PROC, V75, P933, DOI 10.4065/75.9.933; Kaptchuk TJ, 2001, ANN INTERN MED, V135, P196, DOI 10.7326/0003-4819-135-3-200108070-00012; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010; Kerr H D, 1997, WMJ, V96, P57; Kim DJ, 2000, CANCER CAUSE CONTROL, V11, P65, DOI 10.1023/A:1008913620344; Kristal AR, 2002, CANCER EPIDEM BIOMAR, V11, P719; Kubota T, 2000, PROSTATE, V42, P163; KUCERA H, 1982, FORTSCHR MED, V100, P760; Kuchler T, 1999, HEPATO-GASTROENTEROL, V46, P322; Kumar NB, 2002, CANCER-AM CANCER SOC, V94, P1166, DOI 10.1002/cncr.10320; KUSHI M, 1983, CANC PREVENTION DIET; KUSHI M, 1991, MACROBIOTIC APPROACH; Labriola D, 1999, ONCOLOGY-NY, V13, P1003; Labriola D, 1999, ONCOLOGY HUNTINGT, V13, P1008; Lamson D W, 1999, Altern Med Rev, V4, P304; LAWVERE S, 2002, MASSAGE THERAPY EVID, P57; Leitner S. P., 1998, P AN M AM SOC CLIN, V17, pA; Li DH, 1999, J NUTR, V129, P1075, DOI 10.1093/jn/129.5.1075; LINN MW, 1982, CANCER, V49, P1048, DOI 10.1002/1097-0142(19820301)49:5<1048::AID-CNCR2820490534>3.0.CO;2-G; Lissoni P, 1997, J PINEAL RES, V23, P15, DOI 10.1111/j.1600-079X.1997.tb00329.x; Lissoni P, 1999, EUR J CANCER, V35, P1688, DOI 10.1016/S0959-8049(99)00159-8; Lissoni P, 1996, ONCOLOGY, V53, P43; Lund EL, 1998, FOLIA MICROBIOL, V43, P505, DOI 10.1007/BF02820805; MACKINNON S, 2000, EVERYDAY REFERENCE H, P191; MacPherson H, 1999, J ALTERN COMPLEM MED, V5, P47, DOI 10.1089/acm.1999.5.47; MACVICAR MG, 1989, NURS RES, V38, P348; MANN F, 1973, LANCET, V2, P57; MARCUS R, 1996, PHARMACOL BASIS THER, P1573; MARKOVITS J, 1989, CANCER RES, V49, P5111; Martini MC, 1999, NUTR CANCER, V34, P133, DOI 10.1207/S15327914NC3402_2; Mathijssen RHJ, 2002, J NATL CANCER I, V94, P1247, DOI 10.1093/jnci/94.16.1247; MCMILLAN C, 1991, BRIT J CANCER, V64, P971, DOI 10.1038/bjc.1991.439; Messina MJ, 2001, J NUTR, V131, p3095S, DOI 10.1093/jn/131.11.3095S; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; Meyer F, 1999, CANCER CAUSE CONTROL, V10, P245, DOI 10.1023/A:1008913307947; Mikhail A, 1997, NEPHROL DIAL TRANSPL, V12, P797, DOI 10.1093/ndt/12.4.797; Miller DR, 1998, J CLIN ONCOL, V16, P3649, DOI 10.1200/JCO.1998.16.11.3649; MILLS EED, 1988, BRIT J CANCER, V57, P416, DOI 10.1038/bjc.1988.94; Mock V, 1997, Oncol Nurs Forum, V24, P991; MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301; MOUSAVI Y, 1993, STEROIDS, V58, P301, DOI 10.1016/0039-128X(93)90088-5; Moyad MA, 1999, UROLOGY, V54, P319, DOI 10.1016/S0090-4295(99)00216-2; MYERS C, 1983, SEMIN ONCOL, V10, P53; Nagata C, 2001, CANCER EPIDEM BIOMAR, V10, P179; Nagata C, 1998, JNCI-J NATL CANCER I, V90, P1830, DOI 10.1093/jnci/90.23.1830; *OFF TECHN ASS, 1990, OTAH405 OFF TECHN AS; Oh MK, 2001, UROLOGY, V57, P122, DOI 10.1016/S0090-4295(00)00986-9; Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; Pearl ML, 1999, CANCER NURS, V22, P307, DOI 10.1097/00002820-199908000-00008; Peng A T, 1974, Am Surg, V40, P50; Persky VW, 2002, AM J CLIN NUTR, V75, P145, DOI 10.1093/ajcn/75.1.145; Petrakis NL, 1996, CANCER EPIDEM BIOMAR, V5, P785; Peuker ET, 1999, ARCH FAM MED, V8, P553, DOI 10.1001/archfami.8.6.553; Pfeifer BL, 2000, BJU INT, V85, P481, DOI 10.1046/j.1464-410x.2000.00476.x; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; PRICE H, 1991, COMPLEMENT MED RES, V5, P93; PUNNONEN R, 1980, BRIT MED J, V281, P1110, DOI 10.1136/bmj.281.6248.1110; Rafi MM, 2000, ANTICANCER RES, V20, P2653; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; RATCLIFFE MA, 1995, PSYCHO-ONCOL, V4, P39, DOI 10.1002/pon.2960040105; RICHARDSON JL, 1990, J CLIN ONCOL, V8, P356, DOI 10.1200/JCO.1990.8.2.356; RICO RC, 1982, J MED, V13, P247; Riviere M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P46; Rosenbluth R. J., 1999, P ANN M AM SOC CLIN, V18, pA; SAKAMOTO K, 1973, BRIT J RADIOL, V46, P538, DOI 10.1259/0007-1285-46-547-538; Santell RC, 2000, J NUTR, V130, P1665, DOI 10.1093/jn/130.7.1665; Santibanez JF, 1997, ANTICANCER RES, V17, P1199; SATTILARO A, 1982, RECALLED LIFE; Segal R, 2001, J CLIN ONCOL, V19, P657, DOI 10.1200/JCO.2001.19.3.657; SHEN J, 1997, P AN M AM SOC CLIN, V16, pA148; Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755; SINGH CV, 1978, J INDIAN MED ASSOC, V11, P108; Sloman R, 1994, Contemp Nurse, V3, P6; Small EJ, 2000, J CLIN ONCOL, V18, P3595, DOI 10.1200/JCO.2000.18.21.3595; SMALL EJ, 2002, P AN M AM SOC CLIN, V21, pA709; Smith M, 1999, PATIENT EDUC COUNS, V38, P109, DOI 10.1016/S0738-3991(99)00058-0; Smyth JF, 1997, ANN ONCOL, V8, P569, DOI 10.1023/A:1008211226339; Sovak M, 2002, J NATL CANCER I, V94, P1275, DOI 10.1093/jnci/94.17.1275; Speca M, 2000, PSYCHOSOM MED, V62, P613, DOI 10.1097/00006842-200009000-00004; Speyer J, 1998, SEMIN ONCOL, V25, P525; SPIEGEL D, 1989, LANCET, V2, P888; SPIEGEL D, 1981, ARCH GEN PSYCHIAT, V38, P527; SPIEGEL D, 1983, PSYCHOSOM MED, V45, P333, DOI 10.1097/00006842-198308000-00007; STELLING K, 2000, EVERYDAY REFERENCE H, P110; SYRJALA KL, 1995, PAIN, V63, P189, DOI 10.1016/0304-3959(95)00039-U; SYRJALA KL, 1992, PAIN, V48, P137, DOI 10.1016/0304-3959(92)90049-H; TEICHER BA, 1994, CANCER CHEMOTH PHARM, V34, P235; TELCH CF, 1986, J CONSULT CLIN PSYCH, V54, P802, DOI 10.1037/0022-006X.54.6.802; Trotter JF, 1999, NEW ENGL J MED, V341, P2019, DOI 10.1056/NEJM199912233412616; Upmalis DH, 2000, MENOPAUSE, V7, P236, DOI 10.1097/00042192-200007040-00005; *US PREV SERV TASK, 1989, GUID CLIN PREV SERV, P388; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; WALKER C, 1998, PC WEEK, V15, P34; Walker LG, 1999, BRIT J CANCER, V80, P262, DOI 10.1038/sj.bjc.6690349; Walker LG, 1999, EUR J CANCER, V35, P1783, DOI 10.1016/S0959-8049(99)00169-0; Wang CF, 1998, NUTR CANCER, V31, P90, DOI 10.1080/01635589809514686; Wang CF, 1997, NUTR CANCER, V28, P236, DOI 10.1080/01635589709514582; Weinerman, 1994, ANNU ROYAL COLL PHYS, V27, P93; Weinrobe MC, 2001, NEW ENGL J MED, V345, P1213, DOI 10.1056/NEJM200110183451616; Weitzman S, 1998, INT J CANCER, V78, P69; WEN HL, 1977, MOD MED ASIA, V0013, P00012; WIERNIK PH, 1992, CANCER INVEST, V10, P1, DOI 10.3109/07357909209032783; Wilkie D J, 2000, Hosp J, V15, P31; Wilkinson IB, 1999, J CARDIOVASC PHARM, V34, P690, DOI 10.1097/00005344-199911000-00010; Williams JC, 1997, INT J EXP PATHOL, V78, P259, DOI 10.1046/j.1365-2613.1997.260359.x; Williams JK, 1998, CORONARY ARTERY DIS, V9, P759, DOI 10.1097/00019501-199809110-00009; Wiseman H, 1996, BIOCHEM SOC T, V24, P795, DOI 10.1042/bst0240795; WISSEL PS, 1987, EUR J CLIN PHARMACOL, V33, P403, DOI 10.1007/BF00637638; Wu AH, 1999, J NATL CANCER I, V91, P529, DOI 10.1093/jnci/91.6.529; Yeo T. C., 1994, Singapore Medical Journal, V35, P319; Yip I, 1996, ADV EXP MED BIOL, V399, P173; Zava DT, 1997, NUTR CANCER, V27, P31, DOI 10.1080/01635589709514498; 1999, CATILAGE; 2000, ESSIAC 1999	205	143	147	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					889	903		10.7326/0003-4819-137-11-200212030-00010	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00010			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	622GY	12458989				2022-12-28	WOS:000179639700005
J	Boehm, M; Nabel, EG				Boehm, M; Nabel, EG			Angiotensin-converting enzyme 2 - A new cardiac regulator	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARBOXYPEPTIDASE		NHLBI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Boehm, M (corresponding author), NHLBI, Bldg 10, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200	3	100	122	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1795	1797		10.1056/NEJMcibr022472	http://dx.doi.org/10.1056/NEJMcibr022472			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456857				2022-12-28	WOS:000179468600011
J	Bonduriansky, R; Brassil, CE				Bonduriansky, R; Brassil, CE			Rapid and costly ageing in wild male flies	NATURE			English	Article							EVOLUTIONARY; SENESCENCE; MORTALITY		Univ Toronto, Dept Zool, Evolutionary Ecol Grp, Toronto, ON M5S 3G5, Canada	University of Toronto	Bonduriansky, R (corresponding author), Univ Toronto, Dept Zool, Evolutionary Ecol Grp, Toronto, ON M5S 3G5, Canada.	russell.bonduriansky@utoronto.ca	Brassil, Chad E/A-1193-2008; Brassil, Chad/AAD-5244-2022	Brassil, Chad E/0000-0002-9611-7283; Brassil, Chad/0000-0002-9611-7283; Bonduriansky, Russell/0000-0002-5786-6951				ABRAMS PA, 1991, EVOL ECOL, V5, P343, DOI 10.1007/BF02214152; Bonduriansky R, 1997, CAN ENTOMOL, V129, P827, DOI 10.4039/Ent129827-5; Bonduriansky R, 1998, CAN ENTOMOL, V130, P399, DOI 10.4039/Ent130399-4; Hayflick L, 2000, NATURE, V408, P267, DOI 10.1038/35041709; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Partridge L, 1996, P ROY SOC B-BIOL SCI, V263, P1365, DOI 10.1098/rspb.1996.0200; PROMISLOW DEL, 1991, EVOLUTION, V45, P1869, DOI 10.1111/j.1558-5646.1991.tb02693.x; Prowse N, 1997, J INSECT PHYSIOL, V43, P501, DOI 10.1016/S0022-1910(97)00014-0; Roach DA, 2001, EXP GERONTOL, V36, P687, DOI 10.1016/S0531-5565(00)00235-7; Service PM, 2000, AM NAT, V156, P1, DOI 10.1086/303371; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x	11	114	125	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	2002	420	6914					377	377		10.1038/420377a	http://dx.doi.org/10.1038/420377a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459773				2022-12-28	WOS:000179494700027
J	Fried, SI; Munch, TA; Werblin, FS				Fried, SI; Munch, TA; Werblin, FS			Mechanisms and circuitry underlying directional selectivity in the retina	NATURE			English	Article							STARBURST AMACRINE CELLS; RABBIT RETINA; GANGLION-CELLS; MAMMALIAN RETINA; ACETYLCHOLINE; IMMUNOREACTIVITY; IDENTIFICATION; COMPUTATION; MORPHOLOGY; RESPONSES	In the retina, directionally selective ganglion cells respond with robust spiking to movement in their preferred direction, but show minimal response to movement in the opposite, or null, direction(1,2). The mechanisms and circuitry underlying this computation have remained controversial(3). Here we show, by isolating the excitatory and inhibitory inputs to directionally selective cells and measuring direct connections between these cells and presynaptic neurons, that a presynaptic interneuron, the starburst amacrine cell, delivers direct inhibition to directionally selective cells. The processes of starburst cells are connected asymmetrically to directionally selective cells: those pointing in the null direction deliver inhibition; those pointing in the preferred direction do not. Starburst cells project inhibition laterally ahead of a stimulus moving in the null direction. In addition, starburst inhibition is itself directionally selective: it is stronger for movement in the null direction. Excitation in response to null direction movement is reduced by an inhibitory signal acting at a site that is presynaptic to the directionally selective cell. The interplay of these components generates reduced excitation and enhanced inhibition in the null direction, thereby ensuring robust directional selectivity.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Werblin, FS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 145 LSA, Berkeley, CA 94720 USA.		Fried, Shelley/S-7954-2016	Fried, Shelley/0000-0001-6456-8656; Munch, Thomas/0000-0002-8884-6961				BARLOW HB, 1963, SCIENCE, V139, P412, DOI 10.1126/science.139.3553.412; BARLOW HB, 1965, J PHYSIOL-LONDON, V178, P477, DOI 10.1113/jphysiol.1965.sp007638; Borg-Graham L.J., 1992, SINGLE NEURON COMPUT, P347; Borg-Graham LJ, 2001, NAT NEUROSCI, V4, P176, DOI 10.1038/84007; BRECHA N, 1988, P NATL ACAD SCI USA, V85, P6187, DOI 10.1073/pnas.85.16.6187; CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P277, DOI 10.1113/jphysiol.1978.sp012233; Euler T, 2002, NATURE, V418, P845, DOI 10.1038/nature00931; FAMIGLIETTI EV, 1983, BRAIN RES, V261, P138, DOI 10.1016/0006-8993(83)91293-3; FAMIGLIETTI EV, 1985, J NEUROSCI, V5, P562; FAMIGLIETTI EV, 1991, J COMP NEUROL, V309, P40, DOI 10.1002/cne.903090105; FAMIGLIETTI EV, 1992, J COMP NEUROL, V324, P322, DOI 10.1002/cne.903240303; He SG, 1997, NATURE, V389, P378, DOI 10.1038/38723; Kittila CA, 1997, J NEUROPHYSIOL, V77, P675, DOI 10.1152/jn.1997.77.2.675; LINN DM, 1991, J NEUROSCI, V11, P111; MASLAND RH, 1976, J NEUROPHYSIOL, V39, P1220, DOI 10.1152/jn.1976.39.6.1220; MASLAND RH, 1979, J CELL BIOL, V83, P159, DOI 10.1083/jcb.83.1.159; MASLAND RH, 1984, PROC R SOC SER B-BIO, V223, P79, DOI 10.1098/rspb.1984.0084; MILLS SL, 1992, J COMP NEUROL, V321, P133, DOI 10.1002/cne.903210112; OMALLEY DM, 1992, J NEUROSCI, V12, P1394; Peters BN, 1996, J NEUROPHYSIOL, V75, P469, DOI 10.1152/jn.1996.75.1.469; POZNANSKI RR, 1992, B MATH BIOL, V54, P905; Roska B, 2001, NATURE, V410, P583, DOI 10.1038/35069068; Taylor WR, 2000, SCIENCE, V289, P2347, DOI 10.1126/science.289.5488.2347; Vaney D.I., 1990, PROGR RETINAL RES, V9, P49, DOI [10.1016/0278-4327(90)90004-2, DOI 10.1016/0278-4327(90)90004-2]; Vaney DI, 2000, J COMP NEUROL, V421, P1; Vaney DI, 2001, MOTION VISION, P13; VANEY DI, 1988, BRAIN RES, V438, P369, DOI 10.1016/0006-8993(88)91366-2; Yoshida K, 2001, NEURON, V30, P771, DOI 10.1016/S0896-6273(01)00316-6	28	270	277	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					411	414		10.1038/nature01179	http://dx.doi.org/10.1038/nature01179			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459782				2022-12-28	WOS:000179494700038
J	Thomas, JH; Weiss, NO; Tobias, SM; Brummell, NH				Thomas, JH; Weiss, NO; Tobias, SM; Brummell, NH			Downward pumping of magnetic flux as the cause of filamentary structures in sunspot penumbrae	NATURE			English	Article							STRATIFIED CONVECTION; INFRARED LINES; EVERSHED FLOW; FIELDS; TRANSPORT; FEATURES; GEOMETRY; PROBES	The structure of a sunspot is determined by the local interaction between magnetic fields and convection near the Sun's surface(1,2). The dark central umbra is surrounded by a filamentary penumbra, whose complicated fine structure has only recently been revealed by high-resolution observations(3-14). The penumbral magnetic field has an intricate and unexpected interlocking-comb structure and some field lines, with associated outflows of gas(15), dive back down below the solar surface at the outer edge of the spot. These field lines might be expected to float quickly back to the surface because of magnetic buoyancy, but they remain submerged. Here we show that the field lines are kept submerged outside the spot by turbulent, compressible convection, which is dominated by strong, coherent, descending plumes(16,17). Moreover, this downward pumping of magnetic flux explains the origin of the interlocking-comb structure of the penumbral magnetic field, and the behaviour of other magnetic features near the sunspot.	Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England; Univ Rochester, Dept Phys & Astron, Rochester, NY 14627 USA; Univ Rochester, Dept Mech Engn, Rochester, NY 14627 USA; Univ Leeds, Dept Appl Math, Leeds LS2 9JT, W Yorkshire, England; Univ Colorado, JILA, Boulder, CO 80309 USA; Univ Colorado, Dept Astrophys & Planetary Sci, Boulder, CO 80309 USA	University of Cambridge; University of Rochester; University of Rochester; University of Leeds; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Thomas, JH (corresponding author), Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England.	thomas@me.rochester.edu		Tobias, Steven/0000-0003-0205-7716				Brandenburg A, 1996, J FLUID MECH, V306, P325, DOI 10.1017/S0022112096001322; Brummell NH, 2002, ASTROPHYS J, V570, P825, DOI 10.1086/339626; DEGENHARDT D, 1991, ASTRON ASTROPHYS, V252, P821; Dorch SBF, 2001, ASTRON ASTROPHYS, V365, P562, DOI 10.1051/0004-6361:20000141; HARVEY K, 1973, SOL PHYS, V28, P61, DOI 10.1007/BF00152912; LITES BW, 1993, ASTROPHYS J, V418, P928, DOI 10.1086/173450; Montesinos B, 1997, NATURE, V390, P485, DOI 10.1038/37307; NORDLUND A, 1992, ASTROPHYS J, V392, P647, DOI 10.1086/171465; Pillet VM, 2000, ASTRON ASTROPHYS, V361, P734; Plaza CW, 1997, NATURE, V389, P47, DOI 10.1038/37933; Plaza CW, 2001, ASTROPHYS J, V547, P1148, DOI 10.1086/318377; RIMMELE TR, 1995, ASTROPHYS J, V445, P511, DOI 10.1086/175716; RUCKLIDGE AM, 1995, MON NOT R ASTRON SOC, V273, P491, DOI 10.1093/mnras/273.2.491; Ruedi I, 1999, ASTRON ASTROPHYS, V348, pL37; Schlichenmaier R, 1998, ASTROPHYS J, V493, pL121, DOI 10.1086/311137; Schlichenmaier R, 2000, ASTRON ASTROPHYS, V358, P1122; SCHMIEDER B, 1997, ASTRONOMICAL SOC PAC, V118; SHINE RA, 2001, ENCY ASTRONOMY ASTRO, P03209; SOLANKI SK, 1994, ASTRON ASTROPHYS, V283, P221; SOLANKI SK, 1993, ASTRON ASTROPHYS, V275, P283; Stanchfield DCH, 1997, ASTROPHYS J, V477, P485, DOI 10.1086/303704; THOMAS JH, 1992, NATO ASI C, V375; TILDESLEY MJ, UNPUB MON NOT R ASTR; TITLE AM, 1993, ASTROPHYS J, V403, P780, DOI 10.1086/172249; Tobias SM, 1998, ASTROPHYS J, V502, pL177, DOI 10.1086/311501; Tobias SM, 2001, ASTROPHYS J, V549, P1183, DOI 10.1086/319448	27	98	99	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	2002	420	6914					390	393		10.1038/nature01174	http://dx.doi.org/10.1038/nature01174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459777	Green Accepted			2022-12-28	WOS:000179494700031
J	Wiest, FC; Ferris, TG; Gokhale, M; Campbell, EG; Weissman, JS; Blumenthal, D				Wiest, FC; Ferris, TG; Gokhale, M; Campbell, EG; Weissman, JS; Blumenthal, D			Preparedness of internal medicine and family practice residents for treating common conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTITIONERS SELF-ASSESSMENT; PRIMARY-CARE; AUSCULTATORY SKILLS; KNOWLEDGE; OUTCOMES; VALIDITY; PREFERENCES; PHYSICIANS; TRAINEES; FEMALE	Context Although both internal medicine (IM) and family practice (FP) physicians frequently provide care for the same common adult conditions, IM. and FP residency programs differ in their training emphases. Objective To assess differences in IM and FP residents' self-perceived preparedness to diagnose and treat common adult medical conditions. Design, Setting, and Participants Cross-sectional analysis of a national survey administered in the spring of 1998 to residents in their final year of residency at US academic health centers. A total of 279 IM residents in 25 programs and 326 FP residents in 75 programs responded to the survey. Main Outcome Measures Residents' self-rated preparedness to diagnose and treat 4 inpatient conditions (acute myocardial infarction, diabetic ketoacidosis, acute asthma, and acute renal failure) and 8 outpatient conditions (diabetes, hypertension, low back pain, vaginitis, headache, depression, upper respiratory tract infection, and hyperlipidemia), controlling for resident sex, race/ethnicity, US medical school graduate status, intent to subspecialize, and estimates of exposure to patients in inpatient and outpatient settings. Results Internal medicine residents were more likely to report being very prepared for all 4 inpatient conditions (Pless than or equal to.001), while FP residents were more likely to report being very prepared for 5 of 8 outpatient conditions (Pless than or equal to.05). Differences between IM and FP residents persisted in multivariate Analyses for all inpatient conditions and some outpatient conditions. Exposure to patients in inpatient and outpatient settings varied by specialty and was significantly associated with resident self-report of preparedness for a majority of conditions investigated. Conclusions Internal medicine and FP residents report differences in preparedness to manage common adult conditions. These differences were consistent with the emphasis on an inpatient setting for IM residents and on off ice-based care for FP residents.	Massachusetts Gen Hosp, Div Gen Med, Inst Hlth Policy, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Dept Med, Seattle, WA USA; Dept Vet Affairs Puget Sound Healthcare Syst, Robert Wood Johnson Clin Scholars Program, Seattle, WA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle	Ferris, TG (corresponding author), Massachusetts Gen Hosp, Div Gen Med, Inst Hlth Policy, 50 Staniford St, Boston, MA 02114 USA.				PHS HHS [00850] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*ACCR COUNC GRAD M, 2001, PROGR REQ RES ED INT; *ACCR COUNC GRAD M, 1997, GRAD MED ED DIR PROG; *ACCR COUNC GRAD M, 2001, PROGR REQ RES ED FAM; *AM MED ASS, 1996, GRAD MED ED DAT 1996; Bertakis K D, 1999, Fam Med, V31, P187; Bertakis KD, 1998, MED CARE, V36, P879, DOI 10.1097/00005650-199806000-00011; BIRO FM, 1993, PEDIATR RES, V34, P555, DOI 10.1203/00006450-199311000-00001; Blumenthal D, 2001, JAMA-J AM MED ASSOC, V286, P1027, DOI 10.1001/jama.286.9.1027; Camp BW, 1997, ARCH PEDIAT ADOL MED, V151, P78, DOI 10.1001/archpedi.1997.02170380082013; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; Edwards A, 1998, BRIT MED J, V316, P1609, DOI 10.1136/bmj.316.7144.1609; FINCHER RME, 1993, ACAD MED, V68, pS47, DOI 10.1097/00001888-199302000-00030; GORDON MJ, 1991, ACAD MED, V66, P762, DOI 10.1097/00001888-199112000-00012; Hawkins RE, 1999, AM J MED, V106, P206, DOI 10.1016/S0002-9343(98)00392-1; KIEL DP, 1991, J GEN INTERN MED, V6, P544, DOI 10.1007/BF02598225; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LINN LS, 1986, J MED EDUC, V61, P293; Lurie N, 1997, J GEN INTERN MED, V12, P34; Lurie N, 1998, ARCH FAM MED, V7, P134, DOI 10.1001/archfami.7.2.134; MANDEL JH, 1988, ARCH INTERN MED, V148, P853, DOI 10.1001/archinte.148.4.853; Mangione S, 1999, AM J RESP CRIT CARE, V159, P1119, DOI 10.1164/ajrccm.159.4.9806083; Mangione S, 1997, JAMA-J AM MED ASSOC, V278, P717, DOI 10.1001/jama.278.9.717; MEENAN RF, 1988, J RHEUMATOL, V15, P1693; Phillips D, 1998, FAM PRACT, V15, P543, DOI 10.1093/fampra/15.6.543; Schmittdiel J, 1999, J WOMEN HEALTH GEN-B, V8, P825, DOI 10.1089/152460999319147; Schubert A, 1999, ANESTHESIOLOGY, V91, P288, DOI 10.1097/00000542-199907000-00037; Tracey JM, 1997, BRIT MED J, V315, P1426, DOI 10.1136/bmj.315.7120.1426; Wickstrom GC, 2000, J GEN INTERN MED, V15, P361, DOI 10.1046/j.1525-1497.2000.04118.x; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zinn WM, 1998, J GEN INTERN MED, V13, P186, DOI 10.1046/j.1525-1497.1998.00055.x; Zonia SC, 2000, ACAD MED, V75, P742, DOI 10.1097/00001888-200007000-00020	31	72	73	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2002	288	20					2609	2614		10.1001/jama.288.20.2609	http://dx.doi.org/10.1001/jama.288.20.2609			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AL	12444870	Bronze			2022-12-28	WOS:000179394500031
J	Hedley, AJ; Wong, CM; Thach, TQ; Ma, S; Lam, TH; Anderson, HR				Hedley, AJ; Wong, CM; Thach, TQ; Ma, S; Lam, TH; Anderson, HR			Cardiorespiratory and all-cause mortality after restrictions on sulphur content of fuel in Hong Kong: an intervention study	LANCET			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; AIR-POLLUTION INTERVENTION; TIME-SERIES; HOSPITAL ADMISSIONS; RESPIRATORY HEALTH; CITIES; PARTICLES; CHILDREN; DIOXIDE; DEATHS	Background In July, 1990, a restriction was introduced over one weekend that required all power plants and road vehicles in Hong Kong to use fuel oil with a sulphur content of not more than 0.5% by weight. This intervention led to an immediate fall in ambient sulphur dioxide (SO2). We assessed the effect of this intervention on mortality over the next 5 years. Methods Changes in trends in deaths were estimated by a Poisson regression model of deaths each month between 1985 and 1995. Changes in seasonal deaths immediately after the intervention were measured by the increase in deaths from warm to cool season. We also estimated the annual proportional change in number of deaths before and after the intervention. We used age-specific death rates to estimate person-years of life gained. Findings In the first 12 months after introduction of the restriction, a substantial reduction in seasonal deaths was noted, followed by a peak in the cool-season death rate between 13 and 24 months, returning to the expected pattern during years 3-5. Compared with predictions, the intervention led to a significant decline in the average annual trend in deaths from all causes (2.1%; p=0.001), respiratory (3.9%; p=0.0014) and cardiovascular (2.0%; p=0.0214) diseases, but not from other causes. The average gain in life expectancy per year of exposure to the lower pollutant concentration was 20 days (females) to 41 days (males). Interpretation Pollution resulting from sulphur-rich fuels has an effect on death rates, especially respiratory and cardiovascular deaths. The outcome of the Hong Kong intervention provides direct evidence that control of this pollution has immediate and long-term health benefits.	Univ Hong Kong, Dept Community Med, Pokfulam, Hong Kong, Peoples R China; Univ London, St Georges Hosp Med Sch, Dept Publ Hlth Sci, London, England	University of Hong Kong; St Georges University London; University of London	Hedley, AJ (corresponding author), Univ Hong Kong, Dept Community Med, 5-F Acad & Adm Block,Fac Med Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	commed@hkucc.hku.hk	Wong, Chit Ming/C-4438-2009; Thach, Thuan-Quoc/C-4416-2009; Hedley, Anthony J/A-9113-2013; Anderson, Hugh R/A-7417-2016; Hedley, Anthony/C-4305-2009; Lam, Tai Hing/C-4317-2009	Thach, Thuan-Quoc/0000-0003-3404-3888; Lam, Tai Hing/0000-0002-2033-9971				Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373, DOI 10.1164/ajrccm.159.2.9806020; ANDERSON HR, 1999, AIR POLLUTION HLTH, P461; ANDERSON HR, 1976, BRIT MED J, V312, P649; Atkinson RW, 1999, ARCH ENVIRON HEALTH, V54, P398, DOI 10.1080/00039899909603371; BARRON WF, 1995, CONTEMP ECON POLICY, V13, P105, DOI 10.1111/j.1465-7287.1995.tb00736.x; Brunekreef B, 2000, AM J EPIDEMIOL, V151, P449; Brunekreef B, 1997, OCCUP ENVIRON MED, V54, P781, DOI 10.1136/oem.54.11.781; Buringh E, 2000, INHAL TOXICOL, V12, P55, DOI 10.1080/0895-8378.1987.11463181; DERRIENNIC F, 1989, INT J EPIDEMIOL, V18, P186, DOI 10.1093/ije/18.1.186; Gemmell I, 2000, INT J EPIDEMIOL, V29, P274, DOI 10.1093/ije/29.2.274; HEDLEY AJ, LANCET; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658, DOI 10.1136/bmj.314.7095.1658; KUHN L, 1994, AM J EPIDEMIOL, V140, P943, DOI 10.1093/oxfordjournals.aje.a117183; Kunzli N, 2001, AM J EPIDEMIOL, V153, P1050, DOI 10.1093/aje/153.11.1050; McMichael AJ, 1998, INT J EPIDEMIOL, V27, P450, DOI 10.1093/ije/27.3.450; OSTRO BD, 1999, AIR POLLUTION HLTH, P899; Peters J, 1996, INT J EPIDEMIOL, V25, P821, DOI 10.1093/ije/28.5.859; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; POPE CA, 1995, INHAL TOXICOL, V7, P1, DOI 10.3109/08958379509014267; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Schlesinger R.B., 1999, AIR POLLUTION HLTH, P585, DOI [10.1016/B978-012352335-8/50101-0., DOI 10.1016/B978-012352335-8/50101-0]; Schwartz J, 2000, AM J EPIDEMIOL, V151, P440, DOI 10.1093/oxfordjournals.aje.a010228; Schwartz J, 2000, OCCUP ENVIRON MED, V57, P692, DOI 10.1136/oem.57.10.692; Spengler JD, 1996, ENVIRON HEALTH PERSP, V104, P492, DOI 10.2307/3432989; Wong CM, 2002, ENVIRON HEALTH PERSP, V110, P67, DOI 10.1289/ehp.0211067; Wong CM, 2001, ENVIRON HEALTH PERSP, V109, P335, DOI 10.2307/3454891; Wong CM, 1998, J EPIDEMIOL COMMUN H, V52, P571, DOI 10.1136/jech.52.9.571; Zeger SL, 1999, EPIDEMIOLOGY, V10, P171, DOI 10.1097/00001648-199903000-00015	28	212	217	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2002	360	9346					1646	1652		10.1016/S0140-6736(02)11612-6	http://dx.doi.org/10.1016/S0140-6736(02)11612-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457788				2022-12-28	WOS:000179393900010
J	Wang, XC; Yang, CL; Chai, JJ; Shi, YG; Xue, D				Wang, XC; Yang, CL; Chai, JJ; Shi, YG; Xue, D			Mechanisms of AIF-mediated apoptotic DNA degradation in Caenorhabditis elegans	SCIENCE			English	Article							PROGRAMMED CELL DEATHS; CYTOCHROME-C RELEASE; SERINE-PROTEASE; ENDONUCLEASE-G; MITOCHONDRIA; IDENTIFICATION; ACTIVATION; MUTATIONS; INDUCTION; INTERACTS	Apoptosis-inducing factor (AIF), a mitochondrial oxidoreductase, is released into the cytoplasm to induce cell death in response to apoptotic signals. However, the mechanisms underlying this process have not been resolved. We report that inactivation of the Caenorhabditis elegans AIF homolog wah-1 by RNA interference delayed the normal progression of apoptosis and caused a defect in apoptotic DNA degradation. WAH-1 localized in C. elegans mitochondria and was released into the cytosol and nucleus by the BH3-domain protein EGL-1 in a caspase (CED-3)-dependent manner. In addition, WAH-1 associated and cooperated with the mitochondrial endonuclease CPS-6/endonuclease G (EndoG) to promote DNA degradation and apoptosis. Thus, AIF and EndoG de. ne a single, mitochondria-initiated apoptotic DNA degradation pathway that is conserved between C. elegans and mammals.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of Colorado System; University of Colorado Boulder; Princeton University	Xue, D (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	ding.xue@colorado.edu		Chai, Jijie/0000-0001-7591-3873; XUE, DING/0000-0002-8429-8136; Shi, Yigong/0000-0003-2030-168X				Arnoult D, 2001, MOL BIOL CELL, V12, P3016, DOI 10.1091/mbc.12.10.3016; CAI J, UNPUB; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Horvitz HR, 1999, CANCER RES, V59, p1701S; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; SAVAGE C, 1994, J CELL SCI, V107, P2165; Song ZW, 1999, TRENDS CELL BIOL, V9, pM49, DOI 10.1016/S0968-0004(99)01485-1; Stanfield GM, 2000, MOL CELL, V5, P423, DOI 10.1016/S1097-2765(00)80437-2; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; WANG X, UNPUB; Wang XD, 2001, GENE DEV, V15, P2922; Wu YC, 2000, GENE DEV, V14, P536	33	316	343	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1587	1592		10.1126/science.1076194	http://dx.doi.org/10.1126/science.1076194			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446902				2022-12-28	WOS:000179361600040
J	Dalton, R				Dalton, R			Dinosaur curators plot mating game	NATURE			English	News Item																			0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					259	259		10.1038/420259b	http://dx.doi.org/10.1038/420259b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447410	Bronze			2022-12-28	WOS:000179340400011
J	Acuin, J				Acuin, J			Extracts from "Concise Clinical Evidence" - Chronic suppurative otitis media	BRITISH MEDICAL JOURNAL			English	Article									De La Salle Univ, Cavite, Philippines	De La Salle University; De La Salle University Dasmarinas	Acuin, J (corresponding author), De La Salle Univ, Cavite, Philippines.								0	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2002	325	7373					1159	1160		10.1136/bmj.325.7373.1159	http://dx.doi.org/10.1136/bmj.325.7373.1159			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433769	Green Published			2022-12-28	WOS:000179443100025
J	Guan, ZH; Giustetto, M; Lomvardas, S; Kim, JH; Miniaci, MC; Schwartz, JH; Thanos, D; Kandel, ER				Guan, ZH; Giustetto, M; Lomvardas, S; Kim, JH; Miniaci, MC; Schwartz, JH; Thanos, D; Kandel, ER			Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure	CELL			English	Article							LOCAL PROTEIN-SYNTHESIS; MOTOR SYNAPSES; IN-VIVO; FACILITATION; APLYSIA; CELL; FORM; IMMUNOPRECIPITATION; ACTIVATOR; TRANSIENT	Excitatory and inhibitory inputs converge on single neurons and are integrated into a coherent output. Although much is known about short-term integration, little is known about how neurons sum opposing signals for long-term synaptic plasticity and memory storage. In Aplysia, we find that when a sensory neuron simultaneously receives inputs from the facilitatory transmitter 5-HT at one set of synapses and the inhibitory transmitter FMRFamide at another, long-term facilitation is blocked and synapse-specific long-term depression dominates. Chromatin immunoprecipitation assays show that 5-HT induces the downstream gene C/EBP by activating CREB1, which recruits CBP for histone acetylation, whereas FMRFa leads to CREB1 displacement by CREB2 and recruitment of HDAC5 to deacetylate histones. When the two transmitters are applied together, facilitation is blocked because CREB2 and HDAC5 displace CREB1-CBP, thereby deacetylating histones.	Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; New York State Psychiatry Institute; Columbia University	Kandel, ER (corresponding author), Columbia Univ, Howard Hughes Med Inst, 1051 Riverside Dr, New York, NY 10032 USA.		Thanos, Dimitris/AAE-5720-2019; giustetto, maurizio/D-6606-2011; Schwartz, John/AAO-8158-2021	giustetto, maurizio/0000-0003-1323-4060; Schwartz, John/0000-0002-1660-8681; Miniaci, Maria/0000-0003-3844-0581; Lomvardas, Stavros/0000-0002-7668-3026	NIMH NIH HHS [MH48850] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Goodman RH, 2000, GENE DEV, V14, P1553; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lee JA, 2001, LEARN MEMORY, V8, P220, DOI 10.1101/lm.40201; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MONTAROLO PG, 1988, NATURE, V333, P171, DOI 10.1038/333171a0; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; SCHACHER S, 1983, J NEUROSCI, V3, P2403; Sherff CM, 1999, SCIENCE, V285, P1911, DOI 10.1126/science.285.5435.1911; Sherrington C, 1906, INTEGRATIVE ACTION N; Wagner BL, 2000, J BIOL CHEM, V275, P8263, DOI 10.1074/jbc.275.12.8263; Yamamoto N, 1999, J NEUROCHEM, V73, P2415, DOI 10.1046/j.1471-4159.1999.0732415.x	23	379	399	0	27	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 15	2002	111	4					483	493		10.1016/S0092-8674(02)01074-7	http://dx.doi.org/10.1016/S0092-8674(02)01074-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437922	Bronze			2022-12-28	WOS:000179346900002
J	Halloran, ME; Longini, IM; Nizam, A; Yang, Y				Halloran, ME; Longini, IM; Nizam, A; Yang, Y			Containing bioterrorist smallpox	SCIENCE			English	Article							TRANSMISSION	The need for a planned response to a deliberate introduction of smallpox has recently become urgent. We constructed a stochastic simulator of the spread of smallpox in structured communities to compare the effectiveness of mass vaccination versus targeted vaccination of close contacts of cases. Mass vaccination before smallpox introduction or immediately after the first cases was more effective than targeted vaccination in preventing and containing epidemics if there was no prior herd immunity (that is, no prior immunologic protection within the population). The effectiveness of postrelease targeted and mass vaccinations increased if we assumed that there was residual immunity in adults vaccinated before 1972, but the effectiveness of targeted vaccination increased more than that of mass vaccination. Under all scenarios, targeted vaccination prevented more cases per dose of vaccine than did mass vaccination. Although further research with larger-scale structured models is needed, our results suggest that increasing herd immunity, perhaps with a combination of preemptive voluntary vaccination and vaccination of first responders, could enhance the effectiveness of postattack intervention. It could also help targeted vaccination be more competitive with mass vaccination at both preventing and containing a deliberate introduction of smallpox.	Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA	Emory University; Rollins School Public Health	Halloran, ME (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032042] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI32042] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bailey NTJ, 1957, MATH THEORY EPIDEMIC; Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357; BROAD WJ, 2002, NY TIMES A      0615, P1; CHIN J, 2000, CONTROL COMMUNICABLE; DIECKMANN O, 1990, J MATH BIOL, V28, P365; ELVEBACK LR, 1976, AM J EPIDEMIOL, V103, P152, DOI 10.1093/oxfordjournals.aje.a112213; Fauci AS, 2002, NEW ENGL J MED, V346, P1319, DOI 10.1056/NEJM200204253461711; Frelinger JA, 2002, NEW ENGL J MED, V347, P689; Gani R, 2001, NATURE, V414, P748, DOI 10.1038/414748a; Halloran ME, 1997, AM J EPIDEMIOL, V146, P789; Halloran ME, 2002, VACCINE, V20, P3254; HENDERSO.RH, 1969, AM J EPIDEMIOL, V90, P423, DOI 10.1093/oxfordjournals.aje.a121088; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; Jezek Z, 1988, HUMAN MONKEYPOX; Kaplan EH, 2002, P NATL ACAD SCI USA, V99, P10935, DOI 10.1073/pnas.162282799; MACK TM, 1972, J INFECT DIS, V125, P161, DOI 10.1093/infdis/125.2.161; THOMAS DB, 1971, AM J EPIDEMIOL, V93, P373, DOI 10.1093/oxfordjournals.aje.a121270	17	221	229	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1428	1432		10.1126/science.1074674	http://dx.doi.org/10.1126/science.1074674			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434061				2022-12-28	WOS:000179223100054
J	Hivon, E; Kamionkowski, M				Hivon, E; Kamionkowski, M			A new window to the early universe	SCIENCE			English	Editorial Material							POWER SPECTRUM; GRAVITY-WAVES; MICROWAVE; POLARIZATION		CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Hivon, E (corresponding author), CALTECH, Pasadena, CA 91125 USA.	efh@ipac.caltech.edu; kamion@tapir.caltech.edu	Hivon, Eric/C-4298-2014	Hivon, Eric/0000-0003-1880-2733; Kamionkowski, Marc/0000-0001-7018-2055				de Bernardis P, 2000, NATURE, V404, P955, DOI 10.1038/35010035; Halverson NW, 2002, ASTROPHYS J, V568, P38, DOI 10.1086/338879; Hanany S, 2000, ASTROPHYS J, V545, pL5, DOI 10.1086/317322; Kamionkowski M, 1997, PHYS REV LETT, V78, P2058, DOI 10.1103/PhysRevLett.78.2058; Kamionkowski M, 1999, ANNU REV NUCL PART S, V49, P77, DOI 10.1146/annurev.nucl.49.1.77; Miller AD, 1999, ASTROPHYS J, V524, pL1, DOI 10.1086/312293; PEEBLES PJE, 1970, ASTROPHYS J, V162, P815, DOI 10.1086/150713; REES MJ, 1968, ASTROPHYS J, V153, pL1, DOI 10.1086/180208; Seljak U, 1997, PHYS REV LETT, V78, P2054, DOI 10.1103/PhysRevLett.78.2054; Seljak U, 1999, PHYS REV LETT, V82, P2636, DOI 10.1103/PhysRevLett.82.2636; SUNYAEV RA, 1970, ASTROPHYS SPACE SCI, V7, P3; 2002, COSM 02 INT WORKSH P	12	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1349	1350		10.1126/science.1078736	http://dx.doi.org/10.1126/science.1078736			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434043				2022-12-28	WOS:000179223100031
J	Li, C; Thompson, CB				Li, C; Thompson, CB			DNA damage, deamidation, and death	SCIENCE			English	Editorial Material							APOPTOSIS; PROTEINS		Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Li, C (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA.							Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; Lindner H, 2001, EXP GERONTOL, V36, P1551, DOI 10.1016/S0531-5565(01)00140-1; Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P944, DOI 10.1073/pnas.98.3.944; Schmitt CA, 1999, J PATHOL, V187, P127; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	10	20	21	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1346	1347		10.1126/science.1079168	http://dx.doi.org/10.1126/science.1079168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434041				2022-12-28	WOS:000179223100029
J	Sauer, FG; Pinkner, JS; Waksman, G; Hultgren, SJ				Sauer, FG; Pinkner, JS; Waksman, G; Hultgren, SJ			Chaperone priming of pilus subunits facilitates a topological transition that drives fiber formation	CELL			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; PAPD-LIKE CHAPERONES; STRUCTURAL BASIS; P-PILI; URINARY-TRACT; BIOGENESIS; PROTEIN; ADHESIN; RECOGNITION; EXPRESSION	Periplasmic chaperones direct the assembly of adhesive, multi-subunit pilus fibers that play critical roles in bacterial pathogenesis. Pilus assembly occurs via a donor strand exchange mechanism in which the N-terminal extension of one subunit replaces the chaperone G(1) strand that transiently occupies a groove in the neighboring subunit. Here, we show that the chaperone primes the subunit for assembly by holding the groove in an open, activated conformation. During donor strand exchange, the subunit undergoes a topological transition that triggers the closure of the groove and seals the N-terminal extension in place. It is this topological transition, made possible only by the priming action of the chaperone that drives subunit assembly into the fiber.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63105 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63105 USA; UCL, Ludwig Inst Canc Res, London W1W 7BS, England; Univ London Birkbeck Coll, London WC1E 7HX, England	Washington University (WUSTL); Washington University (WUSTL); Ludwig Institute for Cancer Research; University of London; University College London; University of London; Birkbeck University London	Waksman, G (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63105 USA.	waksman@biochem.wustl.edu		Pinkner, Jerome/0000-0002-7389-7440	NIAID NIH HHS [R01AI48689, R01AI49950, R01AI29549] Funding Source: Medline; NIDDK NIH HHS [R01DK51406] Funding Source: Medline; NIGMS NIH HHS [R01GM54033, R01GM60231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049950, R01AI029549, R01AI048689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054033, R01GM060231] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barnhart MM, 2000, P NATL ACAD SCI USA, V97, P7709, DOI 10.1073/pnas.130183897; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; Dodson KW, 2001, CELL, V105, P733, DOI 10.1016/S0092-8674(01)00388-9; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hooton TM, 2000, URINARY TRACT INFECT, P1; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; HULTGREN SJ, 1996, ESCHERICHIA COLI SAL, P2730; Hung DL, 1996, EMBO J, V15, P3792, DOI 10.1002/j.1460-2075.1996.tb00753.x; Hung DL, 2001, EMBO J, V20, P1508, DOI 10.1093/emboj/20.7.1508; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; Jones CH, 1997, EMBO J, V16, P6394, DOI 10.1093/emboj/16.21.6394; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LUND B, 1987, P NATL ACAD SCI USA, V84, P5898, DOI 10.1073/pnas.84.16.5898; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; MUHLDORFER I, 2001, MOL MED MICROBIOLOGY, P1515; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Sauer FG, 2000, SEMIN CELL DEV BIOL, V11, P27, DOI 10.1006/scdb.1999.0348; Saulino ET, 2000, P NATL ACAD SCI USA, V97, P9240, DOI 10.1073/pnas.160070497; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; STANTON SL, 2000, URINARY TRACT INFECT, pR11; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073; STRIKER R, 1994, J BIOL CHEM, V269, P12233; SUSSMAN M, 2001, MOL MED MICROBIOLOGY, P1507; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; Warren John W., 1996, P3	45	210	214	0	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 15	2002	111	4					543	551		10.1016/S0092-8674(02)01050-4	http://dx.doi.org/10.1016/S0092-8674(02)01050-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437927	Bronze			2022-12-28	WOS:000179346900007
J	Sutherland, RL; Musgrove, EA				Sutherland, RL; Musgrove, EA			Cyclin E and prognosis in patients with breast cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Garvan Inst Med Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research	Sutherland, RL (corresponding author), Garvan Inst Med Res, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008						0	15	17	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2002	347	20					1546	1547		10.1056/NEJMNEJMp020124	http://dx.doi.org/10.1056/NEJMNEJMp020124			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614KL	12432040				2022-12-28	WOS:000179187800001
J	Kolar, CS; Lodge, DM				Kolar, CS; Lodge, DM			Ecological predictions and risk assessment for alien fishes in North America	SCIENCE			English	Article							BIOLOGICAL INVADERS; INVASIONS	Methods of risk assessment for alien species, especially for nonagricultural systems, are largely qualitative. Using a generalizable risk assessment approach and statistical models of fish introductions into the Great Lakes, North America, we developed a quantitative approach to target prevention efforts on species most likely to cause damage. Models correctly categorized established, quickly spreading, and nuisance fishes with 87 to 94% accuracy. We then identified fishes that pose a high risk to the Great Lakes if introduced from unintentional ( ballast water) or intentional pathways ( sport, pet, bait, and aquaculture industries).	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	University of Notre Dame	Kolar, CS (corresponding author), US Geol Survey, Upper Midwest Environm Sci Ctr, 2630 Fanta Reed Rd, La Crosse, WI 54603 USA.		Lodge, David Michael/AAX-1781-2021; Ebersole, Joseph L/A-8371-2009					*COMM ENV NAT RES, 1999, CENR599001 NAT SCI T; *COMM SCI BAS PRED, 2002, PRED INV NON PLANTS; CUDMOREVOKEY B, 2000, 2550 CAN DEP FISH OC; Enserink M, 1999, SCIENCE, V285, P1834, DOI 10.1126/science.285.5435.1834; GODDARD CI, 1997, COMMUNICATION   0708; GRAFEN A, 1989, PHILOS T R SOC B, V326, P119, DOI 10.1098/rstb.1989.0106; Groves RH, 2001, WEED RISK ASSESSMENT; ILLIES J, 1978, LIMNOFAUNA EUROPEA; Kolar CS, 2001, TRENDS ECOL EVOL, V16, P199, DOI 10.1016/S0169-5347(01)02101-2; Krebs C.J., 2014, ECOLOGICAL METHODOLO; LODGE DM, 1993, TRENDS ECOL EVOL, V8, P133, DOI 10.1016/0169-5347(93)90025-K; Mooney H.A., 2000, INVASIVE SPECIES CHA; MOYLE PB, 1996, INTRO ICHTHYOLOGY; *NAT INV SPEC COUN, 2001, NATL MAN PLAN M INV; Pimentel D, 2000, BIOSCIENCE, V50, P53, DOI 10.1641/0006-3568(2000)050[0053:EAECON]2.3.CO;2; Rahel FJ, 2000, SCIENCE, V288, P854, DOI 10.1126/science.288.5467.854; Reichard SH, 1997, CONSERV BIOL, V11, P193, DOI 10.1046/j.1523-1739.1997.95473.x; Rejmanek M, 1996, ECOLOGY, V77, P1655, DOI 10.2307/2265768; Ricciardi A, 2000, TRENDS ECOL EVOL, V15, P62, DOI 10.1016/S0169-5347(99)01745-0; Ricciardi A, 1998, CAN J FISH AQUAT SCI, V55, P1759, DOI 10.1139/cjfas-55-7-1759; Risk Assessment and Management Committee, 1996, GEN NON AQ ORG RISK; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; SHARP E, 2002, DETROIT FREE PR 0411; Smith C.S., 1999, Biological Invasions, V1, P89, DOI 10.1023/A:1010091918466; U.S. Congress O.T.A., 1993, HARMF NON SPEC US; USFWS (U.S. Fish and Wildlife Service), 2002, FED REGISTER, V67, P49280	26	593	637	12	277	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1233	1236		10.1126/science.1075753	http://dx.doi.org/10.1126/science.1075753			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424378				2022-12-28	WOS:000179080400050
J	Ting, AY; Endy, D				Ting, AY; Endy, D			Decoding NF-kappa B signaling	SCIENCE			English	Editorial Material									MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Div Biol Engn, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Ting, AY (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.			Endy, Drew/0000-0001-6952-8098				BLOCK SM, 1982, CELL, V31, P215, DOI 10.1016/0092-8674(82)90421-4; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Han YQ, 1997, J BIOL CHEM, V272, P9825; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Samoilov M, 2002, J PHYS CHEM A, V106, P10205, DOI 10.1021/jp025846z; ZHANG J, IN PRESS NATURE REV	7	50	60	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1189	1190		10.1126/science.1079331	http://dx.doi.org/10.1126/science.1079331			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424362				2022-12-28	WOS:000179080400031
J	Barratt, PL; Seymour, MT; Stenning, SP; Georgiades, I; Walker, C; Birbeck, K; Quirke, P				Barratt, PL; Seymour, MT; Stenning, SP; Georgiades, I; Walker, C; Birbeck, K; Quirke, P		UKCCCR AXIS Trial Collaborators	DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study	LANCET			English	Article							MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; ALLELIC LOSS; GENETIC ALTERATIONS; IN-VITRO; SURVIVAL; MUTATION; CHEMOTHERAPY; PROGNOSIS; TUMORS	Background Present clinical algorithms assign adjuvant chemotherapy according to prognosis, but clinical decision-making would be greatly improved if reliable predictive markers were available to identify which subsets of patients benefit most from treatment. We examined molecular markers in preserved tissue from patients with Dukes' B or C colon cancer randomised to receive, or not, adjuvant fluorouracil, and assessed each marker's prognostic and predictive value. Methods Formalin-fixed paraffin-embedded paired normal and tumour samples were obtained from 393 patients with colon cancer from the UK AXIS trial of postoperative portal vein infusion fluorouracil versus control. We measured loss of heterozygosity (LOH) and microsatellite instability at four loci: P53 (17p13), D18S61 (18q22.3), D18S851 (18q21.1), and DP1 (5q21). The prognostic value of each marker was assessed with the log-rank test, and the predictive value by comparison of treatment hazard ratios with the chi(2) test for heterogeneity (CSH). Findings In 228 (58%) patients informative for LOH at D18S61, this marker was significantly predictive: benefit from fluorouracil was significantly greater in patients retaining heterozygosity than in those with LOH (CSH p=0.02). Conversely, LOH at D18S61 was a significant prognostic marker of improved outcome in untreated patients. 314 (80%) patients were informative for LOH at at least one of the three 17p and 18q sites, of whom half retained heterozygosity at one or more site. The effect of chemotherapy in these patients was striking (hazard ratio 0.45, 95% CI 0.28-0.73), whereas chemotherapy had no effect in patients with no retained heterozygosity (0.91; 0.56-1.48), CSH p=0.039. Interpretation Retention of heterozygosity at one or more 17p or 18q sites was associated with the ability to benefit from adjuvant fluorouracil. These results support the principle of developing molecular markers as predictive factors in treatment decisions.	Cookridge Hosp, Canc Res UK Clin Ctr, Leeds LS16 6QB, W Yorkshire, England; Univ Leeds, Sch Med, Acad Unit Pathol, Leeds LS2 9JT, W Yorkshire, England; Canc Div, MRC, Clin Trials Unit, London NW1, England; Leeds Teaching Hosp NHS Trust, Dept Histopathol & Mol Pathol, Leeds, W Yorkshire, England	Cancer Research UK; Cookridge Hospital; University of Leeds; University of Leeds; Medical Research Council Clinical Trials Unit; University of Leeds	Seymour, MT (corresponding author), Cookridge Hosp, Canc Res UK Clin Ctr, Leeds LS16 6QB, W Yorkshire, England.	Matt.Seymour@leedsth.nhs.uk	Quirke, Philip/AAI-1362-2019	Quirke, Philip/0000-0002-3597-5444; Seymour, Matthew/0000-0002-2441-9629				Aebi S, 1997, CLIN CANCER RES, V3, P1763; Ahnen DJ, 1998, CANCER RES, V58, P1149; Arango D, 2001, CANCER RES, V61, P4910; Augenlicht LH, 1997, CANCER RES, V57, P1769; BARDI G, 1993, CANCER, V71, P306, DOI 10.1002/1097-0142(19930115)71:2<306::AID-CNCR2820710207>3.0.CO;2-C; Barratt PL, 1998, BRIT J CANCER, V78, P27; Bast RC, 2001, J CLIN ONCOL, V19, P1865, DOI 10.1200/JCO.2001.19.6.1865; BENNETT MA, 1998, J CLIN PATHOL, V48, pM310; Boland CR, 1998, CANCER RES, V58, P5248; Carethers JM, 1999, GASTROENTEROLOGY, V117, P123, DOI 10.1016/S0016-5085(99)70558-5; Carethers JM, 1998, GASTROENTEROLOGY, V114, P1188, DOI 10.1016/S0016-5085(98)70424-X; CAWKWELL L, 1993, BRIT J CANCER, V67, P1262, DOI 10.1038/bjc.1993.236; Edler D, 2002, J CLIN ONCOL, V20, P1721, DOI 10.1200/JCO.2002.07.039; Elsaleh H, 2000, LANCET, V355, P1745, DOI 10.1016/S0140-6736(00)02261-3; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; Gonzalez-Garcia I, 2000, JNCI-J NATL CANCER I, V92, P544, DOI 10.1093/jnci/92.7.544; Halling KC, 1999, JNCI-J NATL CANCER I, V91, P1295, DOI 10.1093/jnci/91.15.1295; Hayes DF, 1998, BREAST CANCER RES TR, V52, P305, DOI 10.1023/A:1006197805041; Hayes DF, 1996, JNCI-J NATL CANCER I, V88, P1456, DOI 10.1093/jnci/88.20.1456; JAMES RD, 1999, P AN M AM SOC CLIN, V18, pA264; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; Malkhosyan S, 1998, P NATL ACAD SCI USA, V95, P10170, DOI 10.1073/pnas.95.17.10170; MARMOUNAS E, 1999, J CLIN ONCOL, V17, P1349; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Risques RA, 2001, LAB INVEST, V81, P307, DOI 10.1038/labinvest.3780239; Salahshor S, 1999, BRIT J CANCER, V81, P190, DOI 10.1038/sj.bjc.6690676; *SIX AXIS STEER GR, 1994, BRIT J SURG, V81, P1672; Soong R, 1997, CLIN CANCER RES, V3, P1405; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; *UK DEP HLTH, 1997, GUID COMM CANC SERV, P86; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Watatani M, 1996, CANCER, V77, P1688, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1688::AID-CNCR16>3.0.CO;2-U; Zhou W, 2002, LANCET, V359, P219, DOI 10.1016/S0140-6736(02)07448-2	37	166	170	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 2	2002	360	9343					1381	1391		10.1016/S0140-6736(02)11402-4	http://dx.doi.org/10.1016/S0140-6736(02)11402-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423985				2022-12-28	WOS:000179081600012
J	Shen, XT; Xiao, H; Ranallo, R; Wu, WH; Wu, C				Shen, XT; Xiao, H; Ranallo, R; Wu, WH; Wu, C			Modulation of ATP-dependent chromatin-remodeling complexes by inositol polyphosphates	SCIENCE			English	Article							MESSENGER-RNA EXPORT; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; PHOSPHATES; EXPRESSION; BINDING; KINASE; CELLS; GENES; NURF	Eukaryotes use adenosine triphosphate (ATP)-dependent chromatin-remodeling complexes to regulate gene expression. Here, we show that inositol polyphosphates can modulate the activities of several chromatin-remodeling complexes in vitro. Inositol hexakisphosphate (IP6) inhibits nucleosome mobilization by NURF, ISW2, and INO80 complexes. In contrast, nucleosome mobilization by the yeast SWI/SNF complex is stimulated by inositol tetrakisphosphate (IP4) and inositol pentakisphosphate (IP5). We demonstrate that mutations in genes encoding inositol polyphosphate kinases that produce IP4, IP5, and IP6 impair transcription in vivo. These results provide a link between inositol polyphosphates, chromatin remodeling, and gene expression.	NCI, Ctr Canc Res, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wu, C (corresponding author), NCI, Ctr Canc Res, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.			Shen, Xuetong/0000-0002-4267-5298	NATIONAL CANCER INSTITUTE [Z01BC005263, ZIABC005263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUNCE CM, 1993, BIOCHEM J, V289, P667, DOI 10.1042/bj2890667; Campbell S, 2001, P NATL ACAD SCI USA, V98, P10875, DOI 10.1073/pnas.191224698; Ebbert R, 1999, MOL MICROBIOL, V32, P741, DOI 10.1046/j.1365-2958.1999.01390.x; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FRENCH PJ, 1991, P ROY SOC B-BIOL SCI, V245, P193, DOI 10.1098/rspb.1991.0109; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Majumder AL, 1997, BBA-LIPID LIPID MET, V1348, P245, DOI 10.1016/S0005-2760(97)00122-7; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Shears SB, 2000, BIOESSAYS, V22, P786, DOI 10.1002/1521-1878(200009)22:9<786::AID-BIES3>3.3.CO;2-S; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Shen X., UNPUB; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	29	274	280	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 3	2003	299	5603					112	114		10.1126/science.1078068	http://dx.doi.org/10.1126/science.1078068			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	631JZ	12434013	Green Published			2022-12-28	WOS:000180165800046
J	Steger, DJ; Haswell, ES; Miller, AL; Wente, SR; O'Shea, EK				Steger, DJ; Haswell, ES; Miller, AL; Wente, SR; O'Shea, EK			Regulation of chromatin remodeling by inositol polyphosphates	SCIENCE			English	Article							TRANSCRIPTION FACTOR PHO4; MESSENGER-RNA EXPORT; SACCHAROMYCES-CEREVISIAE; YEAST; COMPLEX; KINASE; PHOSPHORYLATION; PROMOTER; DOMAIN; RECRUITMENT	Chromatin remodeling is required for efficient transcription of eukaryotic genes. In a genetic selection for budding yeast mutants that were defective in induction of the phosphate-responsive PHO5 gene, we identified mutations in ARG82/IPK2, which encodes a nuclear inositol polyphosphate kinase. In arg82 mutant strains, remodeling of PHO5 promoter chromatin is impaired, and the adenosine triphosphate-dependent chromatin-remodeling complexes SWI/SNF and INO80 are not efficiently recruited to phosphate-responsive promoters. These results suggest a role for the small molecule inositol polyphosphate in the regulation of chromatin remodeling and transcription.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37212 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Vanderbilt University	O'Shea, EK (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Haswell, Elizabeth/AAE-9370-2021	Haswell, Elizabeth/0000-0002-4246-065X	NIGMS NIH HHS [GM51219, GM51377, R01 GM051377] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051219, R01GM051377, R01GM051219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; Dubois E, 2000, FEBS LETT, V486, P300, DOI 10.1016/S0014-5793(00)02318-8; El Bakkoury M, 2000, MOL MICROBIOL, V35, P15, DOI 10.1046/j.1365-2958.2000.01665.x; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Tran HG, 2000, EMBO J, V19, P2323, DOI 10.1093/emboj/19.10.2323; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369	24	300	308	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 3	2003	299	5603					114	116		10.1126/science.1078062	http://dx.doi.org/10.1126/science.1078062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	631JZ	12434012	Green Accepted			2022-12-28	WOS:000180165800047
J	Bachilo, SM; Strano, MS; Kittrell, C; Hauge, RH; Smalley, RE; Weisman, RB				Bachilo, SM; Strano, MS; Kittrell, C; Hauge, RH; Smalley, RE; Weisman, RB			Structure-assigned optical spectra of single-walled carbon nanotubes	SCIENCE			English	Article							RAMAN-SCATTERING; ELECTRONIC-PROPERTIES; CHIRALITY DEPENDENCE; ROPES	Spectrofluorimetric measurements on single-walled carbon nanotubes (SWNTs) isolated in aqueous surfactant suspensions have revealed distinct electronic absorption and emission transitions for more than 30 different semiconducting nanotube species. By combining these fluorimetric results with resonance Raman data, each optical transition has been mapped to a specific (n,m) nanotube structure. Optical spectroscopy can thereby be used to rapidly determine the detailed composition of bulk SWNT samples, providing distributions in both tube diameter and chiral angle. The measured transition frequencies differ substantially from simple theoretical predictions. These deviations may reflect combinations of trigonal warping and excitonic effects.	Rice Univ, Dept Chem, Ctr Nanoscale Sci & Technol, Houston, TX 77005 USA; Rice Univ, Dept Chem, Ctr Biol & Environm Nanotechnol, Houston, TX 77005 USA; Rice Univ, Dept Phys, Houston, TX 77005 USA	Rice University; Rice University; Rice University	Weisman, RB (corresponding author), Rice Univ, Dept Chem, Ctr Nanoscale Sci & Technol, 6100 Main St, Houston, TX 77005 USA.	weisman@rice.edu	Hauge, Robert H/A-7008-2011; Bachilo, Sergei/ABC-4606-2020	Hauge, Robert H/0000-0002-3656-0152; Bachilo, Sergei/0000-0001-5236-1383; Weisman, R. Bruce/0000-0001-8546-9980				Alvarez L, 2000, CHEM PHYS LETT, V316, P186, DOI 10.1016/S0009-2614(99)01291-9; Ando T, 1997, J PHYS SOC JPN, V66, P1066, DOI 10.1143/JPSJ.66.1066; Bandow S, 1998, PHYS REV LETT, V80, P3779, DOI 10.1103/PhysRevLett.80.3779; Cowley JM, 1997, CHEM PHYS LETT, V265, P379, DOI 10.1016/S0009-2614(96)01442-X; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Dresselhaus MS, 2002, CARBON, V40, P2043, DOI 10.1016/S0008-6223(02)00066-0; Duesberg GS, 1999, CHEM PHYS LETT, V310, P8, DOI 10.1016/S0009-2614(99)00594-1; Ichida M, 1999, J PHYS SOC JPN, V68, P3131, DOI 10.1143/JPSJ.68.3131; Kataura H, 1999, SYNTHETIC MET, V103, P2555, DOI 10.1016/S0379-6779(98)00278-1; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Odom TW, 2000, J PHYS CHEM B, V104, P2794, DOI 10.1021/jp993592k; Qin LC, 1997, CHEM PHYS LETT, V269, P65, DOI 10.1016/S0009-2614(97)00258-3; Rao AM, 1997, SCIENCE, V275, P187, DOI 10.1126/science.275.5297.187; Reich S, 2000, PHYS REV B, V62, P4273, DOI 10.1103/PhysRevB.62.4273; Reich S, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.035412; Saito R, 2000, PHYS REV B, V61, P2981, DOI 10.1103/PhysRevB.61.2981; Saito R., 1998, PHYS PROPERTIES CARB; Sauvajol JL, 2002, CARBON, V40, P1697, DOI 10.1016/S0008-6223(02)00010-6; SAUVE G, 1995, J PHYS CHEM-US, V99, P2162, DOI 10.1021/j100007a055; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Venkateswaran UD, 1999, PHYS REV B, V59, P10928, DOI 10.1103/PhysRevB.59.10928; Yu ZH, 2001, J PHYS CHEM B, V105, P6831, DOI 10.1021/jp010853t	22	2594	2655	23	903	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 20	2002	298	5602					2361	2366		10.1126/science.1078727	http://dx.doi.org/10.1126/science.1078727			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	627DG	12459549				2022-12-28	WOS:000179915900048
J	Molinari, F; Rio, M; Meskenaite, V; Encha-Razavi, F; Auge, J; Bacq, D; Briault, S; Vekemans, M; Munnich, A; Attie-Bitach, T; Sonderegger, P; Colleaux, L				Molinari, F; Rio, M; Meskenaite, V; Encha-Razavi, F; Auge, J; Bacq, D; Briault, S; Vekemans, M; Munnich, A; Attie-Bitach, T; Sonderegger, P; Colleaux, L			Truncating neurotrypsin mutation in autosomal recessive nonsyndromic mental retardation	SCIENCE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; SERINE-PROTEASE; CHROMOSOMAL LOCALIZATION; GENE; POTENTIATION	A 4-base pair deletion in the neuronal serine protease neurotrypsin gene was associated with autosomal recessive nonsyndromic mental retardation (MR). In situ hybridization experiments on human fetal brains showed that neurotrypsin was highly expressed in brain structures involved in learning and memory. Immunoelectron microscopy on adult human brain sections revealed that neurotrypsin is located in presynaptic nerve endings, particularly over the presynaptic membrane lining the synaptic cleft. These findings suggest that neurotrypsin-mediated proteolysis is required for normal synaptic function and suggest potential insights into the pathophysiological bases of mental retardation.	INSERM, U393, Unite Rech Handicaps Genet Enfant, Paris, France; Hop Necker Enfants Malad, Dept Genet, Paris, France; Univ Zurich, Inst Biochem, CH-8006 Zurich, Switzerland; Ctr Natl Genotypage, Evry, France; Hop Bretonneau, CHU Tours, Serv Genet, Tours, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Zurich; CEA; UDICE-French Research Universities; Universite Paris Saclay; CHU Tours	Colleaux, L (corresponding author), INSERM, U393, Unite Rech Handicaps Genet Enfant, Paris, France.	colleaux@necker.fr	Molinari, Florence/M-7683-2016; COLLEAUX, LAURENCE/AAA-8144-2022; COLLEAUX, Laurence/H-6455-2017; ATTIE-BITACH, Tania/K-1453-2017	Molinari, Florence/0000-0001-5111-7215; COLLEAUX, LAURENCE/0000-0002-0987-7648; ATTIE-BITACH, Tania/0000-0002-1155-3626; Rio, Marlene/0000-0003-2049-5058				Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Carrie A, 1999, NAT GENET, V23, P25, DOI 10.1038/12623; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; Frey U, 1996, J NEUROSCI, V16, P2057; GEZC J, 1996, NAT GENET, V13, P105; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; HIRATA A, 2000, CELL NEUROSCI, V17, P600; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Kutsche K, 2000, NAT GENET, V26, P247, DOI 10.1038/80002; LAN Q, 1994, BBA-GENE STRUCT EXPR, V1218, P460, DOI 10.1016/0167-4781(94)90206-2; Luthi A, 1997, J NEUROSCI, V17, P4688; Meloni I, 2002, NAT GENET, V30, P436, DOI 10.1038/ng857; Merienne K, 1999, NAT GENET, V22, P13, DOI 10.1038/8719; MOLINARI F, UNPUB; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Roeleveld N, 1997, DEV MED CHILD NEUROL, V39, P125, DOI 10.1111/j.1469-8749.1997.tb07395.x; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Stromme P, 2000, DEV MED CHILD NEUROL, V42, P76, DOI 10.1017/S0012162200000165; Tiso N, 1996, BIOCHEM BIOPH RES CO, V225, P983, DOI 10.1006/bbrc.1996.1282; Tombes RM, 1997, BBA-MOL CELL RES, V1355, P281, DOI 10.1016/S0167-4889(96)00141-3; TSE WT, 1991, GENOMICS, V10, P858, DOI 10.1016/0888-7543(91)90173-C; Wolfer DP, 2001, MOL CELL NEUROSCI, V18, P407, DOI 10.1006/mcne.2001.1029; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; Yamamura Y, 1997, BIOCHEM BIOPH RES CO, V239, P386, DOI 10.1006/bbrc.1997.7417; Yoshida S, 1999, INT J MOL MED, V3, P405; Zemni R, 2000, NAT GENET, V24, P167, DOI 10.1038/72829; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	30	151	161	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1779	1781		10.1126/science.1076521	http://dx.doi.org/10.1126/science.1076521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459588				2022-12-28	WOS:000179494800042
J	Pellizzoni, L; Yong, J; Dreyfuss, G				Pellizzoni, L; Yong, J; Dreyfuss, G			Essential role for the SMN complex in the specificity of snRNP assembly	SCIENCE			English	Article							SPINAL MUSCULAR-ATROPHY; SPLICEOSOMAL-U-SNRNP; DISEASE GENE-PRODUCT; FUNCTIONAL-ANALYSIS; PROTEINS ASSEMBLE; RNA-BINDING; CORE DOMAIN; M3G CAP; IDENTIFICATION; COMPONENT	The Survival of Motor Neurons (SMN) protein, the product of the spinal muscular atrophy-determining gene, is part of a large macromolecular complex (SMN complex) that functions in the assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs). Using cell extracts and purified components, we demonstrated that the SMN complex is necessary and sufficient to mediate the ATP-dependent assembly of the core of seven Sm proteins on uridine-rich, small nuclear ribonucleic acids (U snRNAs). In vitro experiments revealed strict requirements for ordered binding of the Sm proteins and the U snRNAs to the SMN complex. Importantly, the SMN complex is necessary to ensure that Sm cores assemble only on correct RNA targets and prevent their otherwise promiscuous association with other RNAs. Thus, the SMN complex functions as a specificity factor essential for the efficient assembly of Sm proteins on U snRNAs and likely protects cells from illicit, and potentially deleterious, nonspecific binding of Sm proteins to RNAs.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774; Pellizzoni, Livio/0000-0002-9168-5628				Achsel T, 2001, P NATL ACAD SCI USA, V98, P3685, DOI 10.1073/pnas.071033998; Baccon J, 2002, J BIOL CHEM, V277, P31957, DOI 10.1074/jbc.M203478200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; KLEINSCHMIDT AM, 1989, NUCLEIC ACIDS RES, V17, P4817, DOI 10.1093/nar/17.12.4817; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Melki J, 1997, CURR OPIN NEUROL, V10, P381, DOI 10.1097/00019052-199710000-00005; Palfi Z, 2000, P NATL ACAD SCI USA, V97, P8967, DOI 10.1073/pnas.150236097; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2002, J BIOL CHEM, V277, P7540, DOI 10.1074/jbc.M110141200; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; SUMPTER V, 1992, MOL BIOL REP, V16, P229, DOI 10.1007/BF00419662; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Urlaub H, 2001, EMBO J, V20, P187, DOI 10.1093/emboj/20.1.187; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; YONG J, UNPUB; Yong JS, 2002, EMBO J, V21, P1188, DOI 10.1093/emboj/21.5.1188	43	416	426	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1775	1779		10.1126/science.1074962	http://dx.doi.org/10.1126/science.1074962			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459587				2022-12-28	WOS:000179494800041
J	Rogina, B; Helfand, SL; Frankel, S				Rogina, B; Helfand, SL; Frankel, S			Longevity regulation by Drosophila Rpd3 deacetylase and caloric restriction	SCIENCE			English	Article							HISTONE DEACETYLASE; LIFE-SPAN		Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, New Haven, CT 06536 USA; Univ Connecticut, Ctr Hlth, Sch Med, Dept Genet & Dev Biol, Farmington, CT 06030 USA	Yale University; University of Connecticut	Frankel, S (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, 295 Congress Ave, New Haven, CT 06536 USA.	stewart.frankel@yale.edu		Rogina, Blanka/0000-0003-1195-905X	NIA NIH HHS [R37 AG016667] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG016667] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; DORN R, 1986, CHROMOSOMA, V93, P398, DOI 10.1007/BF00285820; Kang HL, 2002, P NATL ACAD SCI USA, V99, P838, DOI 10.1073/pnas.022631999; Kim S, 1999, MOL BIOL CELL, V10, P3125, DOI 10.1091/mbc.10.10.3125; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; PLETCHER S, COMMUNICATION; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3	9	209	227	3	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1745	1745		10.1126/science.1078986	http://dx.doi.org/10.1126/science.1078986			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459580				2022-12-28	WOS:000179494800032
J	Turnbull, MM; Landee, CP				Turnbull, MM; Landee, CP			Porous materials with a difference	SCIENCE			English	Editorial Material							SPIN-CROSSOVER; FRAMEWORK		Clark Univ, Dept Chem, Worcester, MA 01610 USA; Clark Univ, Dept Phys, Worcester, MA 01610 USA	Clark University; Clark University	Turnbull, MM (corresponding author), Clark Univ, Dept Chem, Worcester, MA 01610 USA.	mturnbull@clarku.edu; clandee@clarku.edu		Turnbull, Mark/0000-0002-0232-8224				Beauvais LG, 2002, J AM CHEM SOC, V124, P12096, DOI 10.1021/ja027768z; Corma A, 1997, CHEM REV, V97, P2373, DOI 10.1021/cr960406n; Desiraju GR, 2002, ACCOUNTS CHEM RES, V35, P565, DOI 10.1021/ar010054t; Du M, 2002, INORG CHEM, V41, P4904, DOI 10.1021/ic025559+; Eddaoudi M, 2002, SCIENCE, V295, P469, DOI 10.1126/science.1067208; Gutlich P, 2000, CHEM SOC REV, V29, P419, DOI 10.1039/b003504l; Halder GJ, 2002, SCIENCE, V298, P1762, DOI 10.1126/science.1075948; Min KS, 2000, J AM CHEM SOC, V122, P6834, DOI 10.1021/ja000642m; Noro S, 2000, ANGEW CHEM INT EDIT, V39, P2082; REAL JA, 1995, SCIENCE, V268, P265, DOI 10.1126/science.268.5208.265; Seo JS, 2000, NATURE, V404, P982, DOI 10.1038/35010088; SUBRAMANIAN S, 1995, ANGEW CHEM INT EDIT, V37, P1461; Suh MP, 2002, J AM CHEM SOC, V124, P10976, DOI 10.1021/ja017560y; Yaghi OM, 1998, ACCOUNTS CHEM RES, V31, P474, DOI 10.1021/ar970151f	14	15	16	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1723	1724		10.1126/science.1078560	http://dx.doi.org/10.1126/science.1078560			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459571				2022-12-28	WOS:000179494800024
J	del Giorgio, PA; Duarte, CM				del Giorgio, PA; Duarte, CM			Respiration in the open ocean	NATURE			English	Review							DISSOLVED ORGANIC NITROGEN; PLANKTON RESPIRATION; OXYGEN UTILIZATION; BACTERIAL-GROWTH; CARBON FLUX; METABOLISM; PACIFIC; BALANCE; MATTER; MARINE	A key question when trying to understand the global carbon cycle is whether the oceans are net sources or sinks of carbon. This will depend on the production of organic matter relative to the decomposition due to biological respiration. Estimates of respiration are available for the top layers, the mesopelagic layer, and the abyssal waters and sediments of various ocean regions. Although the total open ocean respiration is uncertain, it is probably substantially greater than most current estimates of particulate organic matter production. Nevertheless, whether the biota act as a net source or sink of carbon remains an open question.	Univ Quebec, Dept Sci Biol, Montreal, PQ H3C 3P8, Canada; UIB, CSIC, IMEDEA, Esporles 07190, Islas Baleares, Spain	University of Quebec; University of Quebec Montreal; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Mediterraneo de Estudios Avanzados (IMEDEA); Universitat de les Illes Balears	del Giorgio, PA (corresponding author), Univ Quebec, Dept Sci Biol, CP 8888,Succ Ctr Ville, Montreal, PQ H3C 3P8, Canada.	del_giorgio.paul@uqam.ca	Duarte, Carlos M/A-7670-2013; Duarte Quesada, Carlos Manuel/ABD-6208-2021; del Giorgio, Paul/AAD-1315-2019	Duarte, Carlos M/0000-0002-1213-1361; del Giorgio, Paul/0000-0003-1866-8159				ARISTEGUI J, IN PRESS AQUAT MICRO; BAINES SB, 1991, LIMNOL OCEANOGR, V36, P1078, DOI 10.4319/lo.1991.36.6.1078; Balkanski Y, 1999, GLOBAL BIOGEOCHEM CY, V13, P257, DOI 10.1029/98GB02312; Bauer JE, 1998, NATURE, V392, P482, DOI 10.1038/33122; BAUER JE, 1992, NATURE, V357, P667, DOI 10.1038/357667a0; Bender M, 1996, GLOBAL BIOGEOCHEM CY, V10, P9, DOI 10.1029/95GB03295; Biddanda B, 1997, DEEP-SEA RES PT I, V44, P2069, DOI 10.1016/S0967-0637(97)00045-9; Boyd PW, 1999, DEEP-SEA RES PT II, V46, P2761, DOI 10.1016/S0967-0645(99)00083-1; Calbet A, 2001, LIMNOL OCEANOGR, V46, P1824, DOI 10.4319/lo.2001.46.7.1824; Carlson CA, 1998, LIMNOL OCEANOGR, V43, P375, DOI 10.4319/lo.1998.43.3.0375; Cherrier J, 1999, LIMNOL OCEANOGR, V44, P730, DOI 10.4319/lo.1999.44.3.0730; CHRISTENSEN JP, 1976, ESTUAR COAST MAR SCI, V4, P339, DOI 10.1016/0302-3524(76)90065-7; CHRISTENSEN JP, 1994, CONT SHELF RES, V14, P547, DOI 10.1016/0278-4343(94)90103-1; COLE JJ, 1988, MAR ECOL PROG SER, V43, P1, DOI 10.3354/meps043001; CORNELL S, 1995, NATURE, V376, P243, DOI 10.1038/376243a0; Del Giorgio P.A., 2000, MICROBIAL ECOLOGY OC, P289, DOI DOI 10.1146/ANNUREV.ECOLSYS.29.1.503; delGiorgio PA, 1997, NATURE, V385, P148, DOI 10.1038/385148a0; Doval MD, 2000, MAR CHEM, V68, P249, DOI 10.1016/S0304-4203(99)00081-X; Duarte CM, 1998, SCIENCE, V281, P234, DOI 10.1126/science.281.5374.234; Duarte CM, 1996, LIMNOL OCEANOGR, V41, P1758, DOI 10.4319/lo.1996.41.8.1758; DUARTE CM, 1999, SCIENCE, V284, pB1735; Duarte MC, 2001, LIMNOL OCEANOGR, V46, P425, DOI 10.4319/lo.2001.46.2.0425; Duce RA, 1991, GLOBAL BIOGEOCHEM CY, V5, P193, DOI 10.1029/91GB01778; DUCKLOW HW, 1995, REV GEOPHYS, V33, P1271, DOI 10.1029/95RG00130; Emerson S, 1997, NATURE, V389, P951, DOI 10.1038/40111; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; FIADEIRO ME, 1978, J MAR RES, V36, P323; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; GARFIELD PC, 1983, J MAR RES, V41, P747, DOI 10.1357/002224083788520496; Gattuso JP, 1998, ANNU REV ECOL SYST, V29, P405, DOI 10.1146/annurev.ecolsys.29.1.405; Gonzalez N, 2001, LIMNOL OCEANOGR, V46, P946, DOI 10.4319/lo.2001.46.4.0946; Hansell DA, 1998, NATURE, V395, P263, DOI 10.1038/26200; Harrison WG, 2001, DEEP-SEA RES PT II, V48, P2241, DOI 10.1016/S0967-0645(00)00181-8; Hernandez-Leon Santiago, 1999, Journal of Oceanography, V55, P471, DOI 10.1023/A:1007822921434; HOLLIGAN PM, 1984, MAR ECOL PROG SER, V17, P201, DOI 10.3354/meps017201; Hoppe HG, 2002, NATURE, V416, P168, DOI 10.1038/416168a; Jahnke RA, 1996, GLOBAL BIOGEOCHEM CY, V10, P71, DOI 10.1029/95GB03525; JENKINS WJ, 1985, J MAR RES, V43, P465, DOI 10.1357/002224085788438702; JOIRIS C, 1982, NETH J SEA RES, V16, P260, DOI 10.1016/0077-7579(82)90035-7; Karl DM, 1998, LIMNOL OCEANOGR, V43, P1270, DOI 10.4319/lo.1998.43.6.1270; KING FD, 1978, DEEP-SEA RES, V25, P689, DOI 10.1016/0146-6291(78)90624-0; KUMAR N, 1995, NATURE, V378, P675, DOI 10.1038/378675a0; Lefevre D, 1996, J MARINE SYST, V7, P281, DOI 10.1016/0924-7963(95)00003-8; Lefevre N, 2002, DEEP-SEA RES PT I, V49, P539, DOI 10.1016/S0967-0637(01)00064-4; LONGHURST A, 1995, J PLANKTON RES, V17, P1245, DOI 10.1093/plankt/17.6.1245; Mackenzie FT, 1998, GEOLOGY, V26, P423, DOI 10.1130/0091-7613(1998)026<0423:ROTCMI>2.3.CO;2; MENZEL DW, 1968, DEEP-SEA RES, V15, P327, DOI 10.1016/0011-7471(68)90009-0; MEYBECK M, 1982, AM J SCI, V282, P401, DOI 10.2475/ajs.282.4.401; MOPPER K, 1991, NATURE, V353, P60, DOI 10.1038/353060a0; Morel A, 2002, SCIENCE, V296, P1980, DOI 10.1126/science.1072561; MORIARTY DJW, 1995, MAR ECOL PROG SER, V119, P291, DOI 10.3354/meps119291; NOVOSELOV AA, 1962, OKEANOLOGIYA, V2, P84; PACKARD TT, 1981, OCEANOL ACTA, V4, P351; PACKARD TT, 1979, J MAR RES, V37, P711; PAULY D, 1995, NATURE, V374, P255, DOI 10.1038/374255a0; POMEROY LR, 1968, DEEP-SEA RES, V15, P381, DOI 10.1016/0011-7471(68)90014-4; POMEROY LR, 1991, MAR ECOL PROG SER, V75, P143, DOI 10.3354/meps075143; Raich JW, 2002, GLOBAL CHANGE BIOL, V8, P800, DOI 10.1046/j.1365-2486.2002.00511.x; Rivkin RB, 2001, SCIENCE, V291, P2398, DOI 10.1126/science.291.5512.2398; Robinson C, 2002, DEEP-SEA RES PT I, V49, P787, DOI 10.1016/S0967-0637(01)00083-8; SAMBROTTO RN, 1993, NATURE, V363, P248, DOI 10.1038/363248a0; Schlesinger WH., 1998, BIOGEOCHEMISTRY ANAL, V73, P353, DOI 10.1016/0016-7037(92)90106-s; Serret P, 2001, LIMNOL OCEANOGR, V46, P1642, DOI 10.4319/lo.2001.46.7.1642; SMITH EM, 1995, MAR ECOL PROG SER, V116, P217, DOI 10.3354/meps116217; SUESS E, 1980, NATURE, V288, P260, DOI 10.1038/288260a0; SUNDQUIST ET, 1993, SCIENCE, V259, P934, DOI 10.1126/science.259.5097.934; Takahashi T, 2002, DEEP-SEA RES PT II, V49, P1601, DOI 10.1016/S0967-0645(02)00003-6; Vidal M, 1999, LIMNOL OCEANOGR, V44, P106, DOI 10.4319/lo.1999.44.1.0106; Williams PJL, 1998, NATURE, V394, P55; WILLIAMS PJL, 1981, OCEANOL ACTA, V4, P359; Woodwell GM, 1998, CLIMATIC CHANGE, V40, P495, DOI 10.1023/A:1005345429236; WYRTKI K, 1962, DEEP-SEA RES, V9, P11, DOI 10.1016/0011-7471(62)90243-7	72	394	402	7	143	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	2002	420	6914					379	384		10.1038/nature01165	http://dx.doi.org/10.1038/nature01165			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459775				2022-12-28	WOS:000179494700029
J	Verghese, J; Lipton, RB; Hall, CB; Kuslansky, G; Katz, MJ; Buschke, H				Verghese, J; Lipton, RB; Hall, CB; Kuslansky, G; Katz, MJ; Buschke, H			Abnormality of gait as a predictor of non-Alzheimer's dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VASCULAR DEMENTIA; DIAGNOSTIC-CRITERIA; CLINICAL-DIAGNOSIS; DISEASE; DISORDERS; DIFFERENTIATION; DISTURBANCES; PREVALENCE; DECLINE; MATTER	Background: Neurologic abnormalities affecting gait occur early in several types of non-Alzheimer's dementias, but their value in predicting the development of dementia is uncertain. Methods: We analyzed the relation between neurologic gait status at base line and the development of dementia in a prospective study involving 422 subjects older than 75 years of age who lived in the community and did not have dementia at base line. Cox proportional-hazards regression analysis was used to calculate hazard ratios with adjustment for potential confounding demographic, medical, and cognitive variables. Results: At enrollment, 85 subjects had neurologic gait abnormalities of the following types: unsteady gait (in 31 subjects), frontal gait (in 12 subjects), hemiparetic gait (in 11 subjects), neuropathic gait (in 11 subjects), ataxic gait (in 10 subjects), parkinsonian gait (in 8 subjects), and spastic gait (in 2 subjects). During follow-up (median duration, 6.6 years), there were 125 newly diagnosed cases of dementia, 70 of them cases of Alzheimer's disease and 55 cases of non-Alzheimer's dementia (47 of which involved vascular dementia and 8 of which involved other types of dementia). Subjects with neurologic gait abnormalities had a greater risk of development of dementia (hazard ratio, 1.96 [95 percent confidence interval, 1.30 to 2.96]). These subjects had an increased risk of non-Alzheimer's dementia (hazard ratio, 3.51 [95 percent confidence interval, 1.98 to 6.24]), but not of Alzheimer's dementia (hazard ratio, 1.07 [95 percent confidence interval, 0.57 to 2.02]). Of non-Alzheimer's dementias, abnormal gait predicted the development of vascular dementia (hazard ratio, 3.46 [95 percent confidence interval, 1.86 to 6.42]). Among the types of abnormal gait, unsteady gait predicted vascular dementia (hazard ratio, 2.61), as did frontal gait (hazard ratio, 4.32) and hemiparetic gait (hazard ratio, 13.13). Conclusions: The presence of neurologic gait abnormalities in elderly persons without dementia at base line is a significant predictor of the risk of development of dementia, especially non-Alzheimer's dementia.	Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA; Innovat Med Res & Ctr Healthier Aging Adv PCS, Hunt Valley, MD USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Verghese, J (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, 1165 Morris Pk Ave, Bronx, NY 10461 USA.	jverghes@aecom.yu.edu	Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011; Hall, Charles B./AAX-8216-2020	Hall, Charles/0000-0001-9982-8120	NIA NIH HHS [AGO3949-15] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG003949] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALA TA, 1995, ALZ DIS ASSOC DIS, V9, P152; Alexander NB, 1996, CLIN GERIATR MED, V12, P689; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; ARONSON MK, 1990, NEUROLOGY, V40, P1102, DOI 10.1212/WNL.40.7.1102; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Bloem B R, 1992, J Geriatr Psychiatry Neurol, V5, P78; BRAAK H, 1989, NEUROPATH APPL NEURO, V15, P13, DOI 10.1111/j.1365-2990.1989.tb01146.x; Carmelli D, 2000, J GERONTOL A-BIOL, V55, pM103; Chui H, 2000, NEUROL CLIN, V18, P951, DOI 10.1016/S0733-8619(05)70234-6; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; Chui HC, 2000, ARCH NEUROL-CHICAGO, V57, P191, DOI 10.1001/archneur.57.2.191; COX DR, 1972, J R STAT SOC B, V34, P187; Crystal HA, 2000, ARCH NEUROL-CHICAGO, V57, P713, DOI 10.1001/archneur.57.5.713; DAWSON D, 1987, NATIONAL CTR HLTH ST, V133, P1; Elias MF, 2000, ARCH NEUROL-CHICAGO, V57, P808, DOI 10.1001/archneur.57.6.808; Esiri MM, 2000, ANN NY ACAD SCI, V903, P239, DOI 10.1111/j.1749-6632.2000.tb06373.x; Fleiss J, 1981, STAT METHODS RATES P, P38; Fratiglioni L, 1999, DRUG AGING, V15, P365, DOI 10.2165/00002512-199915050-00004; Fuh J L, 1994, J Geriatr Psychiatry Neurol, V7, P89; FULD PA, 1990, J CLIN EXP NEUROPSYC, V12, P520, DOI 10.1080/01688639008400998; Fuld PA., 1978, ALZHEIMERS DIS SENIL, V7, P185; Grober E, 1999, NEUROBIOL AGING, V20, P573, DOI 10.1016/S0197-4580(99)00063-9; Groves WC, 2000, J NEUROPSYCH CLIN N, V12, P305, DOI 10.1176/appi.neuropsych.12.3.305; Hall CB, 2000, STAT MED, V19, P1555, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1555::AID-SIM445>3.0.CO;2-3; HENNERICI MG, 1994, DEMENTIA, V5, P197, DOI 10.1159/000106723; Henon H, 2001, NEUROLOGY, V57, P1216, DOI 10.1212/WNL.57.7.1216; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Ikeda M, 2001, NEUROLOGY, V57, P839, DOI 10.1212/WNL.57.5.839; ISAACS B, 1973, BRIT J PSYCHIAT, V123, P467, DOI 10.1192/bjp.123.4.467; Jorm AF, 1998, NEUROLOGY, V51, P728, DOI 10.1212/WNL.51.3.728; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; KOTSORIS H, 1987, STROKE, V18, P138, DOI 10.1161/01.STR.18.1.138; Looi JCL, 1999, NEUROLOGY, V53, P670, DOI 10.1212/WNL.53.4.670; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; National Collaborative Group for the Revision of the Wechsler Adult Intelligence Scale, 1983, MANUAL WECHSLER ADUL, V03, P362; NUTT JG, 1993, NEUROLOGY, V43, P268, DOI 10.1212/WNL.43.2.268; RAVEN JC, 1977, GUIDE STANDARD PROGR; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; Skoog I, 1998, NEUROEPIDEMIOLOGY, V17, P2, DOI 10.1159/000026147; SUDARSKY L, 1990, NEW ENGL J MED, V322, P1441; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; Tiffin J., 1948, PURDUE PEGBOARD TEST; Verghese J, 1999, NEUROLOGY, V53, P1974, DOI 10.1212/WNL.53.9.1974; Waite LM, 2001, J NEUROL NEUROSUR PS, V71, P296, DOI 10.1136/jnnp.71.3.296; Whitman GT, 2001, NEUROLOGY, V57, P1942; ZUNG WWK, 1967, PSYCHOSOMATICS, V8, P287	50	463	477	2	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1761	1768		10.1056/NEJMoa020441	http://dx.doi.org/10.1056/NEJMoa020441			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456852				2022-12-28	WOS:000179468600006
J	Parker, M; Lucassen, A				Parker, M; Lucassen, A			Working towards ethical management of genetic testing	LANCET			English	Article							DISCLOSURE	Developments in genetic testing and increased public awareness of inherited disease have led to increasing interest in and concern about the ethical issues raised by clinical genetics. We looked at methods for ethical management of genetic testing, and investigated the advantages and limitations of use of ethical guidelines in clinical genetics. We believe that a key element in successful management of genetic testing in addition to guidelines will be availability of ethics training and support for geneticists, nurses, and counsellors. Clinical ethics committees and clinical ethicists can act as a useful focus for such training and advice if their role is seen to be genuinely supportive by health professionals and patients. We also argue that increased public involvement at the national level in policy debate about control of genetic testing is needed.	Univ Oxford, Inst Hlth Sci, Ethox Ctr, Oxford OX3 7LF, England; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England	University of Oxford	Parker, M (corresponding author), Univ Oxford, Inst Hlth Sci, Ethox Ctr, Oxford OX3 7LF, England.	Michael.parker@ethox.ox.ac.uk	Lucassen, Anneke/D-7764-2017	Lucassen, Anneke/0000-0003-3324-4338				Bergmark A, 2000, J MED ETHICS, V26, P312, DOI 10.1136/jme.26.5.312; CLARKE A, 1994, J MED GENET, V31, P785, DOI 10.1136/jmg.31.10.785; *COMM HLTH COUNC N, 1989, HER SCI SOC; Daniels N, 2000, BMJ-BRIT MED J, V321, P1300, DOI 10.1136/bmj.321.7272.1300; Donnai D, 2001, BRIT MED J, V322, P1048, DOI 10.1136/bmj.322.7293.1048; *GEN MED COUNC, 2002, CONF PROT PROV INF D; *HUM EMBR FERT AUT, 1999, JOINT PUBL CONS PREI; *HUM GEN COMM, 2000, WHOS HANDS YOUR GEN; Human Genetics Commission, 2002, INS INF BAL INT US P; Julian-Reynier C, 2000, AM J MED GENET, V94, P13, DOI 10.1002/1096-8628(20000904)94:1<13::AID-AJMG4>3.0.CO;2-T; Knoppers B. M., 1995, American Journal of Human Genetics, V57, pA296; Knoppers BM, 1998, AM J HUM GENET, V62, P474; Lucassen AM, 2000, J MED GENET, V37, P157, DOI 10.1136/jmg.37.2.157; National Health and Medical Research Council, 2000, ETH ASP HUM GEN TEST; *NUFF COUNC BIOETH, 2001, GEN HUM BEH ETH CONT; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS; *ROYAL COLL PHYS, 1996, CLIN GEN SDERV 21 CE; Secretary's Advisory Committee on Genetic Testing (SACGT), 2000, ENH OV GEN TESTS REC; Slowther A, 2001, CLIN ETHICS SUPPORT; The Genetic Interest Group, 1998, CONF MED GEN	20	18	18	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2002	360	9346					1685	1688		10.1016/S0140-6736(02)11608-4	http://dx.doi.org/10.1016/S0140-6736(02)11608-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457805				2022-12-28	WOS:000179393900027
J	Chen, P; Xiong, ZT; Luo, JZ; Lin, JY; Tan, KL				Chen, P; Xiong, ZT; Luo, JZ; Lin, JY; Tan, KL			Interaction of hydrogen with metal nitrides and imides	NATURE			English	Article							WALLED CARBON NANOTUBES; STORAGE	The pursuit of a clean and healthy environment has stimulated much effort in the development of technologies for the utilization of hydrogen-based energy. A critical issue is the need for practical systems for hydrogen storage, a problem that remains unresolved after several decades of exploration. In this context, the possibility of storing hydrogen in advanced carbon materials has generated considerable interest. But confirmation and a mechanistic understanding of the hydrogen-storage capabilities of these materials still require much work(1-5). Our previously published work on hydrogen uptake by alkali-doped carbon nanotubes cannot be reproduced by others(6-8). It was realized by us and also demonstrated by Pinkerton et al.(8) that most of the weight gain was due to moisture, which the alkali oxide picked up from the atmosphere. Here we describe a different material system, lithium nitride, which shows potential as a hydrogen storage medium. Lithium nitride is usually employed as an electrode, or as a starting material for the synthesis of binary or ternary nitrides(9,10). Using a variety of techniques, we demonstrate that this compound can also reversibly take up large amounts of hydrogen. Although the temperature required to release the hydrogen at usable pressures is too high for practical application of the present material, we suggest that more investigations are needed, as the metal-N-H system could prove to be a promising route to reversible hydrogen storage.	Natl Univ Singapore, Dept Phys, Singapore 119260, Singapore	National University of Singapore	Chen, P (corresponding author), Natl Univ Singapore, Dept Phys, 10 Kent Ridge Crescent, Singapore 119260, Singapore.		Chen, Ping/D-1456-2011; 李, 莹/C-5680-2012	Chen, Ping/0000-0002-0625-0639; Yang, Shuman/0000-0002-9638-0890				Chen Z., 1993, International Journal of Modern Physics E, V2, P285, DOI 10.1142/S021830139300011X; Dafert F.W., 1910, MONATSH CHEM, VCXVIII, P981; Dillon AC, 1997, NATURE, V386, P377, DOI 10.1038/386377a0; Hirscher M, 2001, APPL PHYS A-MATER, V72, P129, DOI 10.1007/s003390100816; *INT CTR DIFFR DAT, 1999, POW DIFFR FIL TM DAT; JUNG F, 1990, CLIN OXYGEN PRESSURE, V2, P15; JUZA R, 1951, Z ANORG ALLG CHEM, V266, P313, DOI 10.1002/zaac.19512660606; Liu C, 1999, SCIENCE, V286, P1127, DOI 10.1126/science.286.5442.1127; Meregalli V, 2001, APPL PHYS A-MATER, V72, P143, DOI 10.1007/s003390100789; MEYER RJ, 1960, LITHIUM GMELINS HDB, P273; O'Loughlin JL, 2001, INORG CHEM, V40, P2240, DOI 10.1021/ic001265h; Pinkerton FE, 2000, J PHYS CHEM B, V104, P9460, DOI 10.1021/jp000957o; SCHENK PW, 1963, NITROGEN HDB PREPARA, P464; Shodai T, 1997, J POWER SOURCES, V68, P515, DOI 10.1016/S0378-7753(97)02597-4; Yang RT, 2000, CARBON, V38, P623, DOI 10.1016/S0008-6223(99)00273-0; Ye Y, 1999, APPL PHYS LETT, V74, P2307, DOI 10.1063/1.123833	16	1413	1458	22	520	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					302	304		10.1038/nature01210	http://dx.doi.org/10.1038/nature01210			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447436				2022-12-28	WOS:000179340400038
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Woolf, SH		US Preventive Services Task Force	Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale	ANNALS OF INTERNAL MEDICINE			English	Article							ESTROGEN-PROGESTIN REPLACEMENT; BREAST-CANCER; ESTROGEN/PROGESTIN REPLACEMENT; PLUS PROGESTIN; OVARIAN-CANCER; FOLLOW-UP; RISK; WOMEN; METAANALYSIS; DISEASE	This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations for use of hormone replacement therapy for the primary prevention of chronic conditions in postmenopausal women and updates the 1996 USPSTF recommendations on this topic. The complete information on which this statement is based, including evidence tables and references, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov) and through the National Guideline Clearinghouse (www.guideline.gov) The USPSTF reviewed the evidence on the use of postmenopausal hormone replacement therapy and the following outcomes: cardiovascular disease, including CHD and stroke; osteoporosis and fractures; thromboembolism; dementia and cognitive function; breast, colon, ovarian, and endometrial cancer; and cholecystitis. The USPSTF also reviewed evidence of the effects of hormone replacement therapy on phytoestrogens and osteoporosis and cardiovascular disease. The use of hormone replacement therapy for relieving active symptoms of menopause, such as hot flashes, urogenital symptoms, and mood and sleep disturbances, among others, is outside the scope of these USPSTF recommendations, and literature on this topic was not reviewed. Sources for estimates of benefits and harms cited in this Recommendation statement are described in the summary of the evidence available from the Agency for Healthcare Research and Quality.	US Prevent Serv Task Force, Agcy Hlth Care Res & Qual Publicat Clearinghouse, Rockville, MD USA		Berg, AO (corresponding author), US Prevent Serv Task Force, Agcy Hlth Care Res & Qual Publicat Clearinghouse, Rockville, MD USA.							*AM ASS CLIN END, 1999, ENDOCR PRACT, V5, P355; *AM COLL OBST GYN, 2002, GUID WOM HLTH CAR, P130; *AM HEART ASS, Q A HORM REPL THER; American Cancer Society, 2002, CANC FACTS FIG; *CAN TASK FORC PER, HLTH CAN; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; HUMPHREY L, 2002, SYSTEMATIC EVIDENCE; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; LEBLANC E, 2002, SYSTEMATIC EVIDENCE; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Miller J, 2002, SYSTEMATIC EVIDENCE, V11; *N AM MEN SOC, REP NAMS ADV PAN POS; Nawaz H, 1999, AM J PREV MED, V17, P250; Nelson HD, 2002, POSTMENOPAUSAL HORMO; Persson I, 1996, INT J CANCER, V67, P327, DOI 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.CO;2-T; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SADOVSKY R, 2002, RECENT ANAL HORMONE; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; STEINBERG KK, 1994, EPIDEMIOLOGY, V5, P415, DOI 10.1097/00001648-199407000-00007; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534	30	109	112	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 19	2002	137	10					834	839		10.7326/0003-4819-137-10-200211190-00013	http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00013			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616VE	12435221				2022-12-28	WOS:000179323400007
J	Harkins, L; Volk, AL; Samanta, M; Mikolaenko, I; Britt, WJ; Bland, KI; Cobbs, CS				Harkins, L; Volk, AL; Samanta, M; Mikolaenko, I; Britt, WJ; Bland, KI; Cobbs, CS			Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer	LANCET			English	Article							IE2 PROTEINS; INFECTION; EXPRESSION; COLON; ADENOCARCINOMA; INHIBITION; APOPTOSIS; PROMOTER; LESSONS; BCL-2	Background Colorectal cancer is the second most frequent cause of death from cancer in the USA, and most tumours arise sporadically with no clear cause or genetic predisposition. Human cytomegalovirus is a beta-herpesvirus that is endemic in the human population and can cause life-threatening disease in immunosuppressed adults. In vitro, human cytomegalovirus can transform cells and dysregulate many cellular pathways relevant to colon adenocarcinoma pathogenesis, especially those affecting the cell cycle, mutagenesis, apoptosis, angiogenesis, and cyclo-oxygenase2 (COX-2) expression. We aimed to assess whether gene products of human cytomegalovirus could be detected in colorectal cancers. Methods We obtained formalin-fixed, paraffin-embedded pathological specimens of colorectal polyps, adenocarcinomas, and adjacent normal mucosa from 29 patients. To detect human cytomegalovirus proteins and nucleic acids, we used immunohistochemistry with two different monoclonal antibodies, in-situ hybridisation, and PCR with DNA sequencing. Findings Human cytomegalovirus proteins lE1-72 and pp65 were detected in a tumour cell-specific pattern in 14 (82%) of 17 and seven (78%) of nine colorectal polyps, respectively, and 12 (80%) of 15 and 11 (92%) of 12 adenocarcinomas, respectively, but not in adjacent non-neoplastic colon biopsy samples from the same patients (none of seven and none of two, respectively). Human cytomegalovirus infection of colon-cancer cells (Caco-2) in vitro resulted in specific induction of Bcl-2 and cyclo-oxygenase-2 proteins, both of which are thought to contribute to progression of colon cancer. Interpretation Human cytomegalovirus nucleic acids and proteins can be found that, specifically localise to neoplastic cells in human colorectal polyps and adenocarcinomas, and virus infection can induce important oncogenic pathways in colon-cancer cells.	Birmingham Vet Affairs Hosp, Pathol Serv, Birmingham, AL USA; Birmingham Vet Affairs Hosp, Surg Serv, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Pathol, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Paediat, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Surg, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Cobbs, CS (corresponding author), UAB Med Ctr, Dept Surg, MEB 519,1813 6th Ave S, Birmingham, AL 35294 USA.	cscobbs@uabmc.edu						BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; Bresnahan WA, 1998, J BIOL CHEM, V273, P22075, DOI 10.1074/jbc.273.34.22075; Britt W J, 1996, VIROLOGY, V3, P2493; Castillo JP, 2000, J VIROL, V74, P8028, DOI 10.1128/JVI.74.17.8028-8037.2000; Chen ZP, 2001, J VIROL, V75, P3613, DOI 10.1128/JVI.75.8.3613-3625.2001; Cinatl J, 1998, CANCER RES, V58, P367; Cinatl J, 1996, INTERVIROLOGY, V39, P259, DOI 10.1159/000150527; Cobbs CS, 2002, CANCER RES, V62, P3347; Doniger J, 1999, CLIN MICROBIOL REV, V12, P367, DOI 10.1128/CMR.12.3.367; FEARON ER, 2001, CANC PRINCIPLES PRAC, P1037; HAGEMEIER C, 1992, J GEN VIROL, V73, P2385, DOI 10.1099/0022-1317-73-9-2385; HART H, 1982, GUT, V23, P21, DOI 10.1136/gut.23.1.21; HASHIRO GM, 1979, INTERVIROLOGY, V12, P84, DOI 10.1159/000149072; Howley PM, 2001, CANC PRINCIPLES PRAC, P168; HUANG ES, 1978, LANCET, V1, P957, DOI 10.1016/s0140-6736(78)90248-9; Jarvis MA, 1999, J VIROL, V73, P4552, DOI 10.1128/JVI.73.6.4552-4560.1999; JAULT FM, 1995, J VIROL, V69, P6697, DOI 10.1128/JVI.69.11.6697-6704.1995; Johnson RA, 2000, J VIROL, V74, P1158, DOI 10.1128/JVI.74.3.1158-1167.2000; Johnson RA, 2001, J VIROL, V75, P6022, DOI 10.1128/JVI.75.13.6022-6032.2001; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KUHN JE, 1995, J MED VIROL, V47, P70, DOI 10.1002/jmv.1890470114; Loenen WAM, 2001, SEMIN IMMUNOL, V13, P41, DOI 10.1006/smim.2001.0294; MERRITT AJ, 1995, J CELL SCI, V108, P2261; Muralidhar S, 1996, J VIROL, V70, P8691, DOI 10.1128/JVI.70.12.8691-8700.1996; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; RUGER R, 1985, KLIN WOCHENSCHR, V63, P405, DOI 10.1007/BF01733665; Shen YQ, 1997, P NATL ACAD SCI USA, V94, P3341, DOI 10.1073/pnas.94.7.3341; Sheng HM, 1998, CANCER RES, V58, P362; Sturzl M, 2001, ADV CANCER RES, V81, P125, DOI 10.1016/S0065-230X(01)81004-6; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995; ZHU H, 1995, J VIROL, V69, P7960, DOI 10.1128/JVI.69.12.7960-7970.1995; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470; Zhu H, 2002, P NATL ACAD SCI USA, V99, P3932, DOI 10.1073/pnas.052713799	36	274	284	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2002	360	9345					1557	1563		10.1016/S0140-6736(02)11524-8	http://dx.doi.org/10.1016/S0140-6736(02)11524-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443594				2022-12-28	WOS:000179292400012
J	Rothman, SM				Rothman, SM			Stroke in children: Freud's first analysis	LANCET			English	Editorial Material							ARTERIAL ISCHEMIC STROKE; RISK-FACTORS; DISORDERS; HEMIPLEGIA; CHILDHOOD		Washington Univ, St Louis Childrens Hosp, Dept Neurol, St Louis, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL)	Rothman, SM (corresponding author), Washington Univ, St Louis Childrens Hosp, Dept Neurol, St Louis, MO 63110 USA.							Becker S, 1998, LANCET, V352, P1756, DOI 10.1016/S0140-6736(05)79830-5; Bonduel M, 1999, ARCH NEUROL-CHICAGO, V56, P967, DOI 10.1001/archneur.56.8.967; deVeber G, 1998, ARCH NEUROL-CHICAGO, V55, P1539, DOI 10.1001/archneur.55.12.1539; Freud S., 1968, INFANTILE CEREBRAL P; Golomb MR, 2001, ANN NEUROL, V50, P163, DOI 10.1002/ana.1078; HILAL SK, 1971, RADIOLOGY, V99, P71, DOI 10.1148/99.1.71; Lynch JK, 2002, PEDIATRICS, V109, P116, DOI 10.1542/peds.109.1.116; Nowak-Gottl U, 1999, BLOOD, V94, P3678, DOI 10.1182/blood.V94.11.3678.423k34_3678_3682; SOLOMON GE, 1970, BRAIN, V93, P107, DOI 10.1093/brain/93.1.107; TAYLOR J, 1905, PARALYSIS OTHER DIS; WEST C, 1871, NERVOUS SYSTEM CHILD	11	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1526	1527		10.1016/S0140-6736(02)11576-5	http://dx.doi.org/10.1016/S0140-6736(02)11576-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443585				2022-12-28	WOS:000179292400003
J	Thijssens, K; Hoff, C; Meyerink, J				Thijssens, K; Hoff, C; Meyerink, J			Tackers on the diaphragm	LANCET			English	Editorial Material									Med Centrum Leeuworden, Dept Surg, NL-8934 AD Leeuworden, Netherlands	Medical Center Leeuwarden	Thijssens, K (corresponding author), Med Centrum Leeuworden, Dept Surg, Henri Dunantweg 2, NL-8934 AD Leeuworden, Netherlands.								0	16	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1586	1586		10.1016/S0140-6736(02)11530-3	http://dx.doi.org/10.1016/S0140-6736(02)11530-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443612				2022-12-28	WOS:000179292400030
J	Kitano, H				Kitano, H			Computational systems biology	NATURE			English	Editorial Material							FUNCTIONAL GENOMICS; CIRCADIAN-RHYTHMS; DRUG DISCOVERY; CELL-CYCLE; IN-SILICO; ROBUSTNESS; MODEL; COMPLEXITY; DROSOPHILA; ORGANIZATION	To understand complex biological systems requires the integration of experimental and computational research - in other words a systems biology approach. Computational biology, through pragmatic modelling and theoretical exploration, provides a powerful foundation from which to address critical scientific questions head-on. The reviews in this Insight cover many different aspects of this energetic field, although all, in one way or another, illuminate the functioning of modular circuits, including their robustness, design and manipulation. Computational systems biology addresses questions fundamental to our understanding of life, yet progress here will lead to practical innovations in medicine, drug discovery and engineering.	Sony Comp Sci Labs Inc, Tokyo 1410022, Japan; Japan Sci & Technol Corp, ERATO, Kitano Symbiot Syst Project, Tokyo 1500001, Japan; Syst Biol Inst, Tokyo 1500001, Japan; Keio Univ, Sch Fundamental Sci & Technol, Kohoku Ku, Kanagawa 2238522, Japan; CALTECH, Pasadena, CA 91125 USA	Sony Corporation; Japan Science & Technology Agency (JST); Keio University; California Institute of Technology	Kitano, H (corresponding author), Sony Comp Sci Labs Inc, 3-14-13 Higashi Gotanda, Tokyo 1410022, Japan.	kitano@scl.sony.co.jp	Eils, Roland/B-6121-2009	Eils, Roland/0000-0002-0034-4036; Kitano, Hiroaki/0000-0002-3589-1953				Adamic LA, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.046135; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; [Anonymous], 1968, GEN SYSTEM THEORY; Bailey JE, 1999, NAT BIOTECHNOL, V17, P616, DOI 10.1038/10794; Bailey JE, 2001, METAB ENG, V3, P111, DOI 10.1006/mben.2001.0184; BALDI P, 2001, BIOINFORMATICS MACHI; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Bassingthwaighte JB, 2000, ANN BIOMED ENG, V28, P1043, DOI 10.1114/1.1313771; Beresford AP, 2002, DRUG DISCOV TODAY, V7, P109; BERRIDGE MJ, 1979, J EXP BIOL, V81, P217; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Borisuk MT, 1998, J THEOR BIOL, V195, P69, DOI 10.1006/jtbi.1998.0781; Butina D, 2002, DRUG DISCOV TODAY, V7, pS83, DOI 10.1016/S1359-6446(02)02288-2; Carlson JM, 1999, PHYS REV E, V60, P1412, DOI 10.1103/PhysRevE.60.1412; Cascante M, 2002, NAT BIOTECHNOL, V20, P243, DOI 10.1038/nbt0302-243; Chang DE, 2002, MOL MICROBIOL, V45, P289, DOI 10.1046/j.1365-2958.2002.03001.x; Chen KC, 2000, MOL BIOL CELL, V11, P369, DOI 10.1091/mbc.11.1.369; Edelman GM, 2001, P NATL ACAD SCI USA, V98, P13763, DOI 10.1073/pnas.231499798; Edwards JS, 2000, BIOTECHNOL PROGR, V16, P927, DOI 10.1021/bp0000712; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Ekins S, 2000, J PHARMACOL TOX MET, V44, P251, DOI 10.1016/S1056-8719(00)00109-X; Ekins Sean, 2002, J Mol Graph Model, V20, P305, DOI 10.1016/S1093-3263(01)00127-9; Eldar A, 2002, NATURE, V419, P304, DOI 10.1038/nature01061; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Fell D., 1997, UNDERSTANDING CONTRO; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Goldbeter A., 1996, BIOCH OSCILLATIONS C; Gonze D, 2002, P NATL ACAD SCI USA, V99, P673, DOI 10.1073/pnas.022628299; Guet CC, 2002, SCIENCE, V296, P1466, DOI 10.1126/science.1067407; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HIGGINS J, 1967, IND ENG CHEM, V59, P18, DOI 10.1021/ie50689a006; HUCKA M, 1908, PAC S BIOC, P450; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Ideker T E, 2000, Pac Symp Biocomput, P305; Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233; Jamshidi N, 2001, BIOINFORMATICS, V17, P286, DOI 10.1093/bioinformatics/17.3.286; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kitano H, 2002, NAT BIOTECHNOL, V20, P337, DOI 10.1038/nbt0402-337a; Kitano Hiroaki, 2001, P1; Leloup JC, 1999, J BIOL RHYTHM, V14, P433, DOI 10.1177/074873099129000948; LEVINE K, 1995, PROGR CELL CYCLE RES, P101; Li Albert P, 2002, Drug Discov Today, V7, P25, DOI 10.1016/S1359-6446(01)02117-1; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Little JW, 1999, EMBO J, V18, P4299, DOI 10.1093/emboj/18.15.4299; Morohashi M, 2002, J THEOR BIOL, V216, P19, DOI 10.1006/jtbi.2002.2537; Ni TC, 1996, J BIOL CHEM, V271, P7927, DOI 10.1074/jbc.271.14.7927; Ni TC, 1996, J THEOR BIOL, V179, P329, DOI 10.1006/jtbi.1996.0072; Noble D, 2002, SCIENCE, V295, P1678, DOI 10.1126/science.1069881; Novak B, 1998, BIOPHYS CHEM, V72, P185, DOI 10.1016/S0301-4622(98)00133-1; Onami Shuichi, 2001, P59; Podani J, 2001, NAT GENET, V29, P54, DOI 10.1038/ng708; Rudy Y, 2000, ANN BIOMED ENG, V28, P945, DOI 10.1114/1.1308484; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; SHENORR SS, 2000, NAT GENET, V31, P64; Tyson J.J., 2002, INTERD APPL, P230, DOI 10.1007/978-0-387-22459-6_9; Tyson JJ, 2001, J THEOR BIOL, V210, P249, DOI 10.1006/jtbi.2001.2293; Ueda HR, 2001, J THEOR BIOL, V210, P401, DOI 10.1006/jtbi.2000.2226; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; Weng GZ, 1999, SCIENCE, V284, P92, DOI 10.1126/science.284.5411.92; Wiener Norbert, 1948, CYBERNETICS CONTROL; Yi TM, 2000, P NATL ACAD SCI USA, V97, P4649, DOI 10.1073/pnas.97.9.4649	69	1341	1402	7	241	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					206	210		10.1038/nature01254	http://dx.doi.org/10.1038/nature01254			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432404				2022-12-28	WOS:000179200900056
J	Koonin, EV; Wolf, YI; Karev, GP				Koonin, EV; Wolf, YI; Karev, GP			The structure of the protein universe and genome evolution	NATURE			English	Review							GENE-TRANSFER; ATP-BINDING; FOLDS; CLASSIFICATION; FAMILIES; DATABASE; NUMBER; DOMAINS; SUPERFAMILIES; ORGANIZATION	Despite the practically unlimited number of possible protein sequences, the number of basic shapes in which proteins fold seems not only to be finite, but also to be relatively small, with probably no more than 10,000 folds in existence. Moreover, the distribution of proteins among these folds is highly non-homogeneous some folds and superfamilies are extremely abundant, but most are rare. Protein folds and families encoded in diverse genomes show similar size distributions with notable mathematical properties, which also extend to the number of connections between domains in multidomain proteins. All these distributions follow asymptotic power laws, such as have been identified in a wide variety of biological and physical systems, and which are typically associated with scale-free networks. These findings suggest that genome evolution is driven by extremely general mechanisms based on the preferential attachment principle.	Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Koonin, EV (corresponding author), Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.	koonin@ncbi.nlm.nih.gov		Wolf, Yuri/0000-0002-0247-8708				Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; ALEXANDROV NN, 1994, PROTEIN SCI, V3, P866; Anantharaman V, 2002, NUCLEIC ACIDS RES, V30, P1427, DOI 10.1093/nar/30.7.1427; Anantharaman V, 2001, J MOL BIOL, V307, P1271, DOI 10.1006/jmbi.2001.4508; Apic G, 2001, Bioinformatics, V17 Suppl 1, pS83; Aravind L, 2000, GENOME RES, V10, P1074, DOI 10.1101/gr.10.8.1074; Aravind L, 2002, CURR OPIN STRUC BIOL, V12, P392, DOI 10.1016/S0959-440X(02)00334-2; Barabasi A. L., 2002, FORMULA UNIVERSAL LA; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bilke S, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.036106; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Branden C., 1999, INTRO PROTEIN STRUCT; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; Coulson AFW, 2002, PROTEINS, V46, P61, DOI 10.1002/prot.10011; DAYHOFF MO, 1976, FED PROC, V35, P2132; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Doolittle WE, 1998, TRENDS GENET, V14, P307; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; Doolittle WF, 1999, TRENDS CELL BIOL, V15, P5, DOI DOI 10.1016/S0168-9525(99)01877-6; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Fitch WM, 2000, TRENDS GENET, V16, P227, DOI 10.1016/S0168-9525(00)02005-9; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Galperin MY, 2000, NAT BIOTECHNOL, V18, P609, DOI 10.1038/76443; Galperin MY, 1998, GENOME RES, V8, P779, DOI 10.1101/gr.8.8.779; Gisiger T, 2001, BIOL REV, V76, P161, DOI 10.1017/S1464793101005607; Gould SJ, 2002, STRUCTURE EVOLUTIONA; Govindarajan S, 1999, PROTEINS, V35, P408, DOI 10.1002/(SICI)1097-0134(19990601)35:4<408::AID-PROT4>3.0.CO;2-A; Harrison PM, 2002, J MOL BIOL, V318, P1155, DOI 10.1016/S0022-2836(02)00109-2; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huynen MA, 1998, MOL BIOL EVOL, V15, P583, DOI 10.1093/oxfordjournals.molbev.a025959; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Jordan IK, 2001, GENOME RES, V11, P555, DOI 10.1101/gr.GR-1660R; KAREV GP, IN PRESS BMC EVOL BI; KAREV GP, IN PRESS COMPUTATION; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; Koonin EV, 2000, CELL, V101, P573, DOI 10.1016/S0092-8674(00)80867-3; Koonin EV, 2001, ANNU REV MICROBIOL, V55, P709, DOI 10.1146/annurev.micro.55.1.709; KUZNETSOV VA, 2002, COMPUTATIONAL STAT M, P125; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lespinet O, 2002, GENOME RES, V12, P1048, DOI 10.1101/gr.174302; Li H, 1998, P NATL ACAD SCI USA, V95, P4987, DOI 10.1073/pnas.95.9.4987; Li H, 1996, SCIENCE, V273, P666, DOI 10.1126/science.273.5275.666; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; MARCHANT CD, 1983, PEDIATR CLIN N AM, V30, P281; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Martin AC, 1998, STRUCTURE, V6, P875, DOI 10.1016/S0969-2126(98)00089-6; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Orengo CA, 2002, PROTEOMICS, V2, P11; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; Pareto, 1897, COURS EC POLITIQUE; Qian J, 2001, J MOL BIOL, V313, P673, DOI 10.1006/jmbi.2001.5079; Ragan MA, 2001, CURR OPIN GENET DEV, V11, P620, DOI 10.1016/S0959-437X(00)00244-6; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Rost B, 2002, CURR OPIN STRUC BIOL, V12, P409, DOI 10.1016/S0959-440X(02)00337-8; Rzhetsky A, 2001, BIOINFORMATICS, V17, P988, DOI 10.1093/bioinformatics/17.10.988; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Todd AE, 2001, J MOL BIOL, V307, P1113, DOI 10.1006/jmbi.2001.4513; Vitkup D, 2001, NAT STRUCT BIOL, V8, P559, DOI 10.1038/88640; Wang ZX, 1998, PROTEIN ENG, V11, P621, DOI 10.1093/protein/11.8.621; Wolf YI, 1999, GENOME RES, V9, P17; Wolf YI, 2000, J MOL BIOL, V299, P897, DOI 10.1006/jmbi.2000.3786; Wuchty S, 2001, MOL BIOL EVOL, V18, P1694, DOI 10.1093/oxfordjournals.molbev.a003957; Yule GU, 1925, PHILOS T R SOC LON B, V213, P21, DOI 10.1098/rstb.1925.0002; Zhang C, 2001, CELL MOL LIFE SCI, V58, P72, DOI 10.1007/PL00000779; Zhang CO, 1998, J MOL BIOL, V284, P1301, DOI 10.1006/jmbi.1998.2282; Zhang CT, 1997, PROTEIN ENG, V10, P757, DOI 10.1093/protein/10.7.757; Zipf G. K., 1949, HUMAN BEHAV PRINCIPL; ZUCKERKANDL E, 1975, J MOL EVOL, V7, P1, DOI 10.1007/BF01732178	76	413	420	3	49	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					218	223		10.1038/nature01256	http://dx.doi.org/10.1038/nature01256			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432406				2022-12-28	WOS:000179200900058
J	Yamey, G				Yamey, G			WHO in 2002 - Have the latest reforms reversed WHO's decline?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WORLD-HEALTH; PUBLIC-HEALTH; EQUITY		BMJ Unified, London WC1H 9JR, England		Yamey, G (corresponding author), BMJ Unified, London WC1H 9JR, England.	gyamey@bmj.com						Abbasi K, 1999, BMJ-BRIT MED J, V318, P1003, DOI 10.1136/bmj.318.7189.1003; AlMazrou Y, 1997, LANCET, V350, P750; Anand S, 1998, WORLD DEV, V26, P307, DOI 10.1016/S0305-750X(97)10019-5; [Anonymous], 2001, MACR HLTH INV HLTH E; [Anonymous], 1999, WORLD HLTH REPORT 19; Braveman P, 2001, BRIT MED J, V323, P678, DOI 10.1136/bmj.323.7314.678; Frenk J, 1997, BRIT MED J, V314, P1404; Garrett L., 2000, BETRAYAL TRUST COLLA; GEAR HS, 1946, S AFR MED J, V20, P515; Lucas A, 1997, COOPERATION HLTH DEV; SMITH R, 1995, BRIT MED J, V310, P543, DOI 10.1136/bmj.310.6979.543; Taylor AL, 2000, B WORLD HEALTH ORGAN, V78, P920; VAUGHN P, 1995, COOPERATION HLTH DEV; WHO, 1999, ROLL BACK MAL; *WHO, 2001, HLTH SYST PERF ASS R; *WHO, 2001, PROP PROGR BUDG 2002; *WHO, 2002, IMPR WHO PERF COUNTR; *WHO, 1998, GH BRUNDTL DIR GEN E; *WHO, 1993, REP EX BOARD WORK GR; *WHO, 1999, CORP STRAT WHO SECR; Williams A, 2001, HEALTH ECON, V10, P93, DOI 10.1002/hec.594; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 2000, WORLD HLTH REP 2000; Yamey G, 2001, BMJ-BRIT MED J, V322, P1191, DOI 10.1136/bmj.322.7296.1191; 2002, ACHIEVING IMPACT ROO	25	15	15	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2002	325	7372					1107	1112		10.1136/bmj.325.7372.1107	http://dx.doi.org/10.1136/bmj.325.7372.1107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424177	Green Published			2022-12-28	WOS:000179415700030
J	McCave, IN				McCave, IN			A poisoned chalice?	SCIENCE			English	Editorial Material							NORTH-ATLANTIC; ARGENTINE BASIN; TRANSPORT; SEDIMENT; PARTICLE		Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England	University of Cambridge	McCave, IN (corresponding author), Univ Cambridge, Dept Earth Sci, Downing St, Cambridge CB2 3EQ, England.		McCave, Nick N/G-7323-2016; McCave, I. Nick/O-3992-2018	McCave, Nick N/0000-0002-4702-5489; McCave, I. Nick/0000-0002-4702-5489				ANDERSON RF, 1994, DEEP-SEA RES PT II, V41, P669, DOI 10.1016/0967-0645(94)90040-X; Balsam WL, 1987, PALEOCEANOGRAPHY, V2, P531, DOI 10.1029/PA002i005p00531; BALSAM WL, 1993, MAR GEOL, V112, P23, DOI 10.1016/0025-3227(93)90159-S; Benthien A, 2000, DEEP-SEA RES PT I, V47, P2369, DOI 10.1016/S0967-0637(00)00030-3; KEIGWIN LD, 1996, SCIENCE, V274, P1503, DOI DOI 10.1126/SCIENCE.274.5292.1503; LAINE EP, 1981, MAR GEOL, V39, P277, DOI 10.1016/0025-3227(81)90076-1; LEDBETTER MT, 1986, NATURE, V321, P423, DOI 10.1038/321423a0; McCave I. N., 1984, GEOL SOC SPEC PUBL, V15, P35, DOI DOI 10.1144/GSL.SP.1984.015.01.03; MCCAVE IN, 1986, W N ATLANTIC REGION, VM, P451; Ohkouchi N, 2002, SCIENCE, V298, P1224, DOI 10.1126/science.1075287; Sachs JP, 1999, SCIENCE, V286, P756, DOI 10.1126/science.286.5440.756; SCHMITZ WJ, 1993, REV GEOPHYS, V31, P29, DOI 10.1029/92RG02583; WEAVER PPE, 1994, SEDIMENTOLOGY, V41, P1025, DOI 10.1111/j.1365-3091.1994.tb01438.x	13	23	23	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1186	1187		10.1126/science.1076960	http://dx.doi.org/10.1126/science.1076960			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424360				2022-12-28	WOS:000179080400029
J	Wang, KC; Kim, JA; Sivasankaran, R; Segal, R; He, ZG				Wang, KC; Kim, JA; Sivasankaran, R; Segal, R; He, ZG			p75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp	NATURE			English	Article							NEUROTROPHIN RECEPTOR; AXON REGENERATION; RHO; PROTEIN; GROWTH; CNS; IDENTIFICATION; EXPRESSION; INHIBITION; OUTGROWTH	In inhibiting neurite outgrowth, several myelin components, including the extracellular domain of Nogo-A (Nogo-66)(1), oligodendrocyte myelin glycoprotein (OMgp)(2) and myelin-associated glycoprotein (MAG)(3,4), exert their effects through the same Nogo receptor (NgR). The glycosyl phosphatidylinositol (GPI)-anchored nature of NgR indicates the requirement for additional transmembrane protein(s) to transduce the inhibitory signals into the interior of responding neurons. Here, we demonstrate that p75, a transmembrane protein known to be a receptor for the neurotrophin family of growth factors(5,6), specifically interacts with NgR. p75 is required for NgR-mediated signalling, as neurons from p75 knockout mice are no longer responsive to myelin and to each of the known NgR ligands. Blocking the p75-NgR interaction also reduces the activities of these inhibitors. Moreover, a truncated p75 protein lacking the intracellular domain, when overexpressed in primary neurons, attenuates the same set of inhibitory activities, suggesting that p75 is a signal transducer of the NgR-p75 receptor complex. Thus, interfering with p75 and its downstream signalling pathways may allow lesioned axons to overcome most of the inhibitory activities associated with central nervous system myelin.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	He, ZG (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.			Wang, Kevin/0000-0002-5305-6791				Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tomoda T, 1999, NEURON, V24, P833, DOI 10.1016/S0896-6273(00)81031-4; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vinson M, 2001, J BIOL CHEM, V276, P20280, DOI 10.1074/jbc.M100345200; Walsh GS, 1999, J NEUROSCI, V19, P4155; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9	25	659	713	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					74	78		10.1038/nature01176	http://dx.doi.org/10.1038/nature01176			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422217				2022-12-28	WOS:000179068100039
J	Collier, J; Iheanacho, I				Collier, J; Iheanacho, I			The pharmaceutical industry as an informant	LANCET			English	Article							CLINICAL RESEARCH; TRIALS; DRUGS	The pharmaceutical industry spends more time and resources on generation, collation, and dissemination of medical information than it does on production of medicines. This information is essential as a resource for development of medicines, but is also needed to satisfy licensing requirements, protect patents, promote sales, and advise patients, prescribers, and dispensers. Such information is of great commercial value, and most of it is confidential, protected by regulations about intellectual property rights. Through their generation and dissemination of information, transnational companies can greatly influence clinical practice. Sometimes, their commercially determined goals represent genuine advances in health-care provision, but most often they are implicated in excessive and costly production of information that is largely kept secret, often duplicated, and can risk undermining the best interests of patients and society.	St George Hosp, Sch Med, Dept Pharmacol & Clin Pharmacol, Med Policy Unit, London SW17 0RE, England; Consumers Assoc, London NW1 4DF, England	St Georges University London	Collier, J (corresponding author), St George Hosp, Sch Med, Dept Pharmacol, Med Policy Unit, London SW17 0RE, England.							*ABPI, 2002, PHARM IND ISS RES SC; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 2001, PHARM J, V267, P361; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; Chalmers I, 2002, NATL I CLIN EXCELLEN, VII; Danzon Patricia M., 1997, TRADE PRICE DIFFEREN; Davidoff F, 2001, LANCET, V358, P854, DOI 10.1016/S0140-6736(01)06035-4; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; *DEP HLTH, 2002, CHIEF MED OFF WITHDR; *EUR FED PHARM IND, 2001, 2001 2002 YEAR REV; *GLOB FLOR HLTH RE, 2001, 10 90 REP HLTH RES 2; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Jackson T, 2001, BRIT MED J, V322, P1312, DOI 10.1136/bmj.322.7297.1312; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; KJAEGARD LL, 2002, BRIT MED J, V325, P349; LAING R, 2002, PHARM CO REPORTS; MCKEE M, IN PRESS IMPACT EU L, V39; MINTZES B, 2002, BLURRING BOUNDARIES; Montaner JSG, 2001, LANCET, V358, P1893, DOI 10.1016/S0140-6736(01)06891-X; Nathan DG, 1999, LANCET, V353, P771, DOI 10.1016/S0140-6736(99)00072-0; O'Reilly B, 2000, FORTUNE, V142, P258; *PHARM IND COMP TA, 2003, TERMS REF; *PHARM MARK, 2001, 6 PHARM MARK; *PHARM RES MAN AM, 1908, GOV RX IND COOP BEN; QUICK J, 2001, B WORLD HEALTH ORGAN, V79, P13; Ramsay S, 2001, LANCET, V358, P1348, DOI 10.1016/S0140-6736(01)06465-0; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Schieppati A, 2001, LANCET, V358, P1638, DOI 10.1016/S0140-6736(01)06658-2; Sigworth SK, 2001, JAMA-J AM MED ASSOC, V286, P1024, DOI 10.1001/jama.286.9.1024-a; Smith R, 2001, BRIT MED J, V323, P588, DOI 10.1136/bmj.323.7313.588; Spurgeon D, 2001, BRIT MED J, V323, P1085, DOI 10.1136/bmj.323.7321.1085; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Sweet M, 2001, BRIT MED J, V323, P1258; VILLANUEVA P, IN PRESS LANCET; *WHO, 1985, ETH CRIT MED DRUG PR; 2001, SCRIP, V2072, P15; 1997, DRUG THERAPIES B NAT; 2000, PRACTICAL GUIDE NUMB; 2001, DTB, V39, P25; 2002, PHARM MARKETING  JAN, P1311; 2001, LANCET, V357, P1141; 2002, CANADAS RES BASED PH	44	62	64	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1405	1409		10.1016/S0140-6736(02)11394-8	http://dx.doi.org/10.1016/S0140-6736(02)11394-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12424005				2022-12-28	WOS:000179081600031
J	Adkins, JF; McIntyre, K; Schrag, DP				Adkins, JF; McIntyre, K; Schrag, DP			The salinity, temperature, and delta O-18 of the glacial deep ocean	SCIENCE			English	Article							OXYGEN ISOTOPIC COMPOSITION; PORE FLUID CONSTRAINTS; SEA-LEVEL; YOUNGER DRYAS; MAXIMUM; WATER; RECORD; ATLANTIC; AGES; CIRCULATION	We use pore fluid measurements of the chloride concentration and the oxygen isotopic composition from Ocean Drilling Program cores to reconstruct salinity and temperature of the deep ocean during the Last Glacial Maximum (LGM). Our data show that the temperatures of the deep Pacific, Southern, and Atlantic oceans during the LGM were relatively homogeneous and within error of the freezing point of seawater at the ocean's surface. Our chloride data show that the glacial strati. cation was dominated by salinity variations, in contrast with the modern ocean, for which temperature plays a primary role. During the LGM the Southern Ocean contained the saltiest water in the deep ocean. This reversal of the modern salinity contrast between the North and South Atlantic implies that the freshwater budget at the poles must have been quite different. A strict conversion of mean salinity at the LGM to equivalent sea-level change yields a value in excess of 140 meters. However, the storage of fresh water in ice shelves and/or groundwater reserves implies that glacial salinity is a poor predictor of mean sea level.	CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	California Institute of Technology; Harvard University	Adkins, JF (corresponding author), CALTECH, Dept Geol & Planetary Sci, MS 100-23, Pasadena, CA 91125 USA.		Adkins, Jess/GYI-8778-2022	Mc Intyre, Katherine/0000-0001-6627-2920				Adkins JF, 1997, PALEOCEANOGRAPHY, V12, P337, DOI 10.1029/97PA00379; Adkins JF, 2001, GEOPHYS RES LETT, V28, P771, DOI 10.1029/2000GL011597; BARD E, 1990, NATURE, V346, P456, DOI 10.1038/346456a0; Boudreau B. P., 1997, MODELLING TRANSPORT, V171, DOI 10.1016/s0264-8172(98)80005-6; BOYLE EA, 1992, ANNU REV EARTH PL SC, V20, P245, DOI 10.1146/annurev.ea.20.050192.001333; BOYLE EA, 1995, PALEOCEANOGRAPHY, V10, P881, DOI 10.1029/95PA01625; Broecker WS, 1990, GLOBAL BIOGEOCHEM CY, V4, P103, DOI 10.1029/GB004i001p00103; BROECKER WS, 1986, QUATERNARY RES, V26, P121, DOI 10.1016/0033-5894(86)90087-6; Brumsack H., 1991, ODP TECHNICAL NOTE, V15; CHAPPELL J, 1986, NATURE, V324, P137, DOI 10.1038/324137a0; DANSGAARD W, 1969, SCIENCE, V166, P499, DOI 10.1126/science.166.3904.499; Denton G. H., 1981, LAST GREAT ICE SHEET, P437; DOMENICO PA, 1990, PHYSICAL CHEM HYDROL; Drewry DJ., 1983, ANTARCTICA GLACIOLOG; Duplessy JC, 1988, PALEOCEANOGRAPHY, V3, P343, DOI 10.1029/PA003i003p00343; DUPLESSY JC, 1989, RADIOCARBON, V31, P493; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; Elderfield H, 2000, NATURE, V405, P442, DOI 10.1038/35013033; FAIRBANKS RG, 1978, QUATERNARY RES, V10, P181, DOI 10.1016/0033-5894(78)90100-X; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; Keeling RF, 2001, PALEOCEANOGRAPHY, V16, P112, DOI 10.1029/2000PA000529; Kim ST, 1997, GEOCHIM COSMOCHIM AC, V61, P3461, DOI 10.1016/S0016-7037(97)00169-5; LABEYRIE LD, 1987, NATURE, V327, P477, DOI 10.1038/327477a0; Lambeck K, 2001, SCIENCE, V292, P679, DOI 10.1126/science.1059549; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Lynch-Stieglitz J, 1999, NATURE, V402, P644, DOI 10.1038/45204; Martin JB, 1999, GEOCHIM COSMOCHIM AC, V63, P383, DOI 10.1016/S0016-7037(99)00036-8; Paul HA, 2001, EARTH PLANET SC LETT, V192, P1, DOI 10.1016/S0012-821X(01)00437-X; PEACOCK S, 2000, AM GEOPHYS UNION MON, V114; RAYMO ME, 1990, EARTH PLANET SC LETT, V97, P353, DOI 10.1016/0012-821X(90)90051-X; Rohling EJ, 1998, NATURE, V394, P162, DOI 10.1038/28134; Rosenthal Y, 2000, PALEOCEANOGRAPHY, V15, P135, DOI 10.1029/1999PA000415; SARNTHEIN M, 1994, PALEOCEANOGRAPHY, V9, P209, DOI 10.1029/93PA03301; Schrag DP, 2002, QUATERNARY SCI REV, V21, P331, DOI 10.1016/S0277-3791(01)00110-X; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; SCHRAG DP, 1993, PALEOCEANOGRAPHY, V8, P1, DOI 10.1029/92PA02796; SHACKLETON N, 1967, NATURE, V215, P15, DOI 10.1038/215015a0; SHACKLETON NJ, 1983, EARTH PLANET SC LETT, V65, P233, DOI 10.1016/0012-821X(83)90162-0; SHACKLETON NJ, 1988, NATURE, V335, P708, DOI 10.1038/335708a0; STUIVER M, 1983, SCIENCE, V219, P849, DOI 10.1126/science.219.4586.849; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; TOGGWEILER JR, 1995, J PHYS OCEANOGR, V25, P1980, DOI 10.1175/1520-0485(1995)025<1980:EOSIOT>2.0.CO;2; WEISS RF, 1979, DEEP-SEA RES, V26, P1093, DOI 10.1016/0198-0149(79)90059-1; WORTHINGTON LV, 1970, DEEP-SEA RES, V17, P77, DOI 10.1016/0011-7471(70)90088-4; Yokoyama Y, 2000, NATURE, V406, P713, DOI 10.1038/35021035	46	490	501	2	158	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1769	1773		10.1126/science.1076252	http://dx.doi.org/10.1126/science.1076252			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459585				2022-12-28	WOS:000179494800039
J	Annas, GJ				Annas, GJ			Moral progress, mental retardation, and the death penalty	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CAPITAL-PUNISHMENT; PARTICIPATION		Boston Univ, Sch Publ Hlth, Dept Hlth Law, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				ALLEN DF, 1979, ETHICAL ISSUES MENTA, P17; ANNAS GJ, 1985, AM J PUBLIC HEALTH, V75, P1096, DOI 10.2105/AJPH.75.9.1096; BERTHOFF W, 1966, GREAT SHORT WORKS H, P419; *BRIT MED ASS, 2001, MED PROF HUM RIGHTS, P163; CURRAN WJ, 1980, NEW ENGL J MED, V302, P226, DOI 10.1056/NEJM198001243020410; FRADY M, 1993, NEW YORKER      0222, P132; Glover J, 2000, HUMANITY MORAL HIST; KAMINER W, 2002, NY TIMES MAGAZI 0707, P7; LeGraw JM, 2002, HUM RIGHTS QUART, V24, P382, DOI 10.1353/hrq.2002.0027; Lichtblau E., 2002, NY TIMES, pA1; MAILER N, 1979, EXECUTIONERS SONG, P985; Olgiati C., 1993, GUARDIAN        1012, P18; ROOT J, 1909, FT WORTH STAR T 0413, P12; SHAPIRO B, 2002, NATION          0722, P14; TRUOG RD, 1993, NEW ENGL J MED, V329, P1346, DOI 10.1056/NEJM199310283291812	15	4	4	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1814	1818		10.1056/NEJMlim021990	http://dx.doi.org/10.1056/NEJMlim021990			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456866	Green Published			2022-12-28	WOS:000179468600033
J	McKinstry, BH				McKinstry, BH			Telephone consultations may not save time	BRITISH MEDICAL JOURNAL			English	Letter									Univ Edinburgh, Dept Community Hlth Sci, Edinburgh EH8 9ER, Midlothian, Scotland	University of Edinburgh	McKinstry, BH (corresponding author), Univ Edinburgh, Dept Community Hlth Sci, Edinburgh EH8 9ER, Midlothian, Scotland.			McKinstry, Brian/0000-0001-9581-0468				McKinstry B, 2002, BRIT J GEN PRACT, V52, P306; Oldham J, 2002, BRIT MED J, V325, P547, DOI 10.1136/bmj.325.7363.547	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 23	2002	325	7374					1242	1242		10.1136/bmj.325.7374.1242	http://dx.doi.org/10.1136/bmj.325.7374.1242			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446547	Green Published			2022-12-28	WOS:000179506200037
J	Savolainen, P; Zhang, YP; Luo, J; Lundeberg, J; Leitner, T				Savolainen, P; Zhang, YP; Luo, J; Lundeberg, J; Leitner, T			Genetic evidence for an East Asian origin of domestic dogs	SCIENCE			English	Article							WOLF	The origin of the domestic dog from wolves has been established, but the number of founding events, as well as where and when these occurred, is not known. To address these questions, we examined the mitochondrial DNA (mtDNA) sequence variation among 654 domestic dogs representing all major dog populations worldwide. Although our data indicate several maternal origins from wolf, >95% of all sequences belonged to three phylogenetic groups universally represented at similar frequencies, suggesting a common origin from a single gene pool for all dog populations. A larger genetic variation in East Asia than in other regions and the pattern of phylogeographic variation suggest an East Asian origin for the domestic dog, similar to15,000 years ago.	Royal Inst Technol KTH, Dept Biotechnol, S-10691 Stockholm, Sweden; Chinese Acad Sci, Kunming Inst Zool, Yunnan Lab Mol Biol Domest Anim, Kunming 650223, Peoples R China; Chinese Acad Sci, Kunming Inst Zool, Lab Mol Evolut & Genome Divers, Kunming 650223, Peoples R China; Swedish Inst Infect Dis Control, Dept Virol, S-17182 Solna, Sweden	Royal Institute of Technology; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; Kunming Institute of Zoology; Swedish Institute for Infectious Disease Control	Savolainen, P (corresponding author), Royal Inst Technol KTH, Dept Biotechnol, S-10691 Stockholm, Sweden.							BENECKE N, 1987, J ARCHAEOL SCI, V14, P31, DOI 10.1016/S0305-4403(87)80004-3; Clutton-Brock J., 1999, NATURAL HIST DOMESTI; Clutton-Brock Juliet, 1995, P7; CLUTTONBROCK J, 1990, J ARCHAEOL SCI, V17, P643, DOI 10.1016/0305-4403(90)90046-8; DAVIS SJM, 1978, NATURE, V276, P608, DOI 10.1038/276608a0; DEGERBOL M, 1961, P PREHIST SOC, V27, P35, DOI 10.1017/S0079497X0001598X; Fu YX, 1997, GENETICS, V147, P915; Kurten B., 1980, PLEISTOCENE MAMMALS; LAWRENCE BARBARA, 1967, Z SAUGETIERKUNDE, V32, P44; LI Q, 1990, CHIN J CYNOLOGY, V2, P25; NOBIS G, 1979, UMSCHAU, V79, P610; Okumura N, 1996, ANIM GENET, V27, P397, DOI 10.1111/j.1365-2052.1996.tb00506.x; Olsen S.J., 1985, ORIGINS DOMESTIC DOG; OLSEN SJ, 1977, SCIENCE, V197, P533, DOI 10.1126/science.197.4303.533; POSADA D, 2001, MODELTEST 3 06; Swofford D., 2002, PAUP 4 0B10; Tchernov E, 1997, J ARCHAEOL SCI, V24, P65, DOI 10.1006/jasc.1995.0096; Vila C, 1999, MOL ECOL, V8, P2089, DOI 10.1046/j.1365-294x.1999.00825.x; Vila C, 1997, SCIENCE, V276, P1687, DOI 10.1126/science.276.5319.1687; WAYNE RK, 1993, TRENDS GENET, V9, P218, DOI 10.1016/0168-9525(93)90122-X	20	597	640	9	244	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	2002	298	5598					1610	1613		10.1126/science.1073906	http://dx.doi.org/10.1126/science.1073906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446907				2022-12-28	WOS:000179361600046
J	Yu, MK; Wu, P; Widelitz, RB; Chuong, CM				Yu, MK; Wu, P; Widelitz, RB; Chuong, CM			The morphogenesis of feathers	NATURE			English	Article							INTEGUMENTARY STRUCTURES; ADHESION MOLECULES; DINOSAUR; ORIGIN; CHINA; EXPRESSION; EVOLUTION; INDUCTION	Feathers are highly ordered, hierarchical branched structures(1,2) that confer birds with the ability of flight(3-5). Discoveries of fossilized dinosaurs in China bearing 'feather-like' structures have prompted interest in the origin and evolution of feathers(6-14). However, there is uncertainty about whether the irregularly branched integumentary fibres on dinosaurs such as Sinornithosaurus are truly feathers(11), and whether an integumentary appendage with a major central shaft and notched edges is a non-avian feather or a proto-feather(8-10). Here, we use a developmental approach to analyse molecular mechanisms in feather-branching morphogenesis. We have used the replication-competent avian sarcoma retrovirus(15) to deliver exogenous genes to regenerating flight feather follicles of chickens. We show that the antagonistic balance between noggin and bone morphogenetic protein 4 (BMP4) has a critical role in feather branching, with BMP4 promoting rachis formation and barb fusion, and noggin enhancing rachis and barb branching. Furthermore, we show that sonic hedgehog (Shh) is essential for inducing apoptosis of the marginal plate epithelia, which results in spaces between barbs. Our analyses identify the molecular pathways underlying the topological transformation of feathers from cylindrical epithelia to the hierarchical branched structures, and provide insights on the possible developmental mechanisms in the evolution of feather forms.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA	University of Southern California	Chuong, CM (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol, 2011 Zonal Ave, Los Angeles, CA 90033 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042177] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR042177-07, R01 AR042177, R01 AR042177-05, R01 AR042177-06S1, R01 AR042177-07S1, R01 AR042177-06] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Calabretta R, 2000, ARTIF LIFE, V6, P69, DOI 10.1162/106454600568320; Chatterjee S., 1997, THE RISE OF BIRDS; Chen PJ, 1998, NATURE, V391, P147, DOI 10.1038/34356; Chuong C-M, 1998, MOL BASIS EPITHELIAL; CHUONG CM, 1985, J CELL BIOL, V101, P1027, DOI 10.1083/jcb.101.3.1027; CHUONG CM, 1993, BIOESSAYS, V15, P513, DOI 10.1002/bies.950150804; Chuong CM, 2001, EUR J DERMATOL, V11, P286; Chuong CM, 2000, CURR OPIN GENET DEV, V10, P449, DOI 10.1016/S0959-437X(00)00111-8; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Dudley AT, 2000, CURR OPIN GENET DEV, V10, P387, DOI 10.1016/S0959-437X(00)00101-5; Feduccia A., 1999, ORIGIN EVOLUTION BIR, V2; Gill FB, 1994, ORNITHOLOGY, V2nd; Harris MP, 2002, J EXP ZOOL, V294, P160, DOI 10.1002/jez.10157; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Ji Q, 2001, NATURE, V410, P1084, DOI 10.1038/35074079; Ji Q, 1998, NATURE, V393, P753, DOI 10.1038/31635; Jiang TX, 1999, DEVELOPMENT, V126, P4997; Jones TD, 2000, SCIENCE, V288, P2202, DOI 10.1126/science.288.5474.2202; Jung HS, 1998, DEV BIOL, V196, P11, DOI 10.1006/dbio.1998.8850; LUCAS AM, 1972, AGR HDB USDA, V362; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Norell M, 2002, NATURE, V416, P36, DOI 10.1038/416036a; Prum RO, 1999, J EXP ZOOL, V285, P291; Prum RO, 2001, J EXP ZOOL, V291, P30, DOI 10.1002/jez.4; Prum RO, 2001, SCIENCE, V291, P1899; REGAL PJ, 1975, Q REV BIOL, V50, P35, DOI 10.1086/408299; TingBerreth SA, 1996, DEV DYNAM, V207, P157, DOI 10.1002/(SICI)1097-0177(199610)207:2<157::AID-AJA4>3.0.CO;2-G; Xu X, 1999, NATURE, V399, P350, DOI 10.1038/20670; Xu X, 2001, NATURE, V410, P200, DOI 10.1038/35065589; Zhang FC, 2000, SCIENCE, V290, P1955, DOI 10.1126/science.290.5498.1955	30	164	175	2	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					308	312		10.1038/nature01196	http://dx.doi.org/10.1038/nature01196			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12442169	Green Accepted			2022-12-28	WOS:000179340400040
J	Jain, A; Brennan, F; Nanchahal, J				Jain, A; Brennan, F; Nanchahal, J			Treatment of rheumatoid tenosynovitis with cytokine inhibitors	LANCET			English	Article								Hand function depends on tendon integrity, but in rheumatoid arthritis tenosynovitis can result in tendon adhesions and rupture. Cytokine inhibitors have proved effective in rheumatoid joint disease; however, their effect on the tenosynovium is not well understood. We investigated the ability of inhibitors of tumour necrosis factor alpha and interleukin 1 to reduce production of collagenolytic matrix metalloproteinases 1 and 13 in tenosynovial tissue obtained from patients with rheumatoid arthritis. Our data show that cytokine blockade can reduce collagenase concentrations in tenosynovial tissue, suggesting cytokine inhibitors could be effective in reduction of tendon damage.	Imperial Coll Sch Med, Kennedy Inst Rheumatol, London W6 8LH, England; Imperial Coll Sch Med, Dept Musculoskeletal Surg, London W6 8LH, England	Imperial College London; University of Oxford; Imperial College London	Jain, A (corresponding author), Imperial Coll Sch Med, Kennedy Inst Rheumatol, Charing Cross Hosp Campus,Arthrit Res Campaign Bl, London W6 8LH, England.	AJainUK@aol.com		Nanchahal, Jagdeep/0000-0002-9579-9411				BROWN FE, 1988, J HAND SURG-AM, V13A, P704, DOI 10.1016/S0363-5023(88)80129-1; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Jain A, 2001, ARTHRITIS RHEUM, V44, P1754, DOI 10.1002/1529-0131(200108)44:8<1754::AID-ART310>3.0.CO;2-8; Kaiser MJ, 2002, ARTHRITIS RHEUM, V46, P559, DOI 10.1002/art.10082; Woessner J.F., 2000, PROTEIN PROFILE SER	5	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2002	360	9345					1565	1566		10.1016/S0140-6736(02)11529-7	http://dx.doi.org/10.1016/S0140-6736(02)11529-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443596				2022-12-28	WOS:000179292400014
J	Kraack, H; Ocko, BM; Pershan, PS; Sloutskin, E; Deutsch, M				Kraack, H; Ocko, BM; Pershan, PS; Sloutskin, E; Deutsch, M			Structure of a Langmuir film on a liquid metal surface	SCIENCE			English	Article							X-RAY-DIFFRACTION; MERCURY TUNNELING JUNCTIONS; PHASE-DIAGRAM; MONOLAYER FILMS; SCATTERING; ACID; CRYSTALLIZATION; REFLECTIVITY; TRANSITIONS	The structure of organic monolayers on liquid surfaces depends sensitively on the details of the molecular interactions. The structure of a stearic acid film on a mercury surface was measured as a function of coverage with angstrom resolution. Unlike monolayers on water, the molecules were found here to undergo a transition from surface-parallel to surface-normal orientation with increasing coverage. At high coverage, two condensed hexatic phases of standing-up molecules were found. At low coverage, a two-dimensional (2D) gas phase and condensed single- and double-layered phases of flat-lying molecular dimers were revealed, exhibiting a 1D longitudinal positional order. This system should provide a broader tunability range for nanostructure construction than solid-supported self-assembled monolayers.	Bar Ilan Univ, Dept Phys, IL-52900 Ramat Gan, Israel; Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Harvard Univ, Div Appl Sci, Cambridge, MA 02138 USA	Bar Ilan University; United States Department of Energy (DOE); Brookhaven National Laboratory; Harvard University; Harvard University	Deutsch, M (corresponding author), Bar Ilan Univ, Dept Phys, IL-52900 Ramat Gan, Israel.	deutsch@mail.biu.ac.il						ALSNIELSEN J, 1994, PHYS REP, V246, P252; BARTON SW, 1988, LANGMUIR, V4, P233, DOI 10.1021/la00079a042; Boulas C, 1996, PHYS REV LETT, V76, P4797, DOI 10.1103/PhysRevLett.76.4797; BRASLAU A, 1985, PHYS REV LETT, V54, P114, DOI 10.1103/PhysRevLett.54.114; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; Daillant J, 2000, REP PROG PHYS, V63, P1725, DOI 10.1088/0034-4885/63/10/203; DEUTSCH M, 1998, THIN FILMS SELF ASSE, P179; DiMasi E, 1998, PHYS REV B, V58, P13419, DOI 10.1103/PhysRevB.58.R13419; DUTTA P, 1987, PHYS REV LETT, V58, P2228, DOI 10.1103/PhysRevLett.58.2228; Fradin C, 2000, NATURE, V403, P871, DOI 10.1038/35002533; Gaines GL, 1966, INSOLUBLE MONOLAYERS; GANGULY P, 1993, J PHYS CHEM-US, V97, P11965, DOI 10.1021/j100148a020; Gibaud A., 1999, XRAY NEUTRON REFLECT, P87, DOI [10.1007/3-540-48696-8_3, DOI 10.1007/3-540-48696-8_3]; HARAN A, 1994, SCIENCE, V263, P948, DOI 10.1126/science.263.5149.948; Harzallah B, 1996, J CHIM PHYS PCB, V93, P1202, DOI 10.1051/jcp/1996931202; Hatzor A, 2001, SCIENCE, V291, P1019; Hazra S, 2000, PHYSICA B, V283, P45, DOI 10.1016/S0921-4526(99)01889-X; JORTNER JR, 1997, MOL ELECT; KAGANER VM, 1993, PHYS REV LETT, V71, P2599, DOI 10.1103/PhysRevLett.71.2599; Kaganer VM, 1999, REV MOD PHYS, V71, P779, DOI 10.1103/RevModPhys.71.779; Kasemo B, 2002, SURF SCI, V500, P656, DOI 10.1016/S0039-6028(01)01809-X; KJAER K, 1987, PHYS REV LETT, V58, P2224, DOI 10.1103/PhysRevLett.58.2224; Kuzmenko I, 2001, CHEM REV, V101, P1659, DOI 10.1021/cr990038y; LIN B, 1990, PHYS REV LETT, V65, P191, DOI 10.1103/PhysRevLett.65.191; Maeda Y, 2001, APPL PHYS LETT, V79, P1181, DOI 10.1063/1.1396630; MAGNUSSEN OM, 1995, PHYS REV LETT, V74, P4444, DOI 10.1103/PhysRevLett.74.4444; Magnussen OM, 1996, NATURE, V384, P250, DOI 10.1038/384250a0; OVERBECK GA, 1993, J PHYS CHEM-US, V97, P7999, DOI 10.1021/j100132a032; Peterson IR, 1998, J PHYS CHEM B, V102, P9437, DOI 10.1021/jp981941p; Popescu M, 1997, THIN SOLID FILMS, V304, P323, DOI 10.1016/S0040-6090(97)00073-4; Rampi MA, 1998, APPL PHYS LETT, V72, P1781, DOI 10.1063/1.121183; Rayleigh L., 1891, NATURE, V43, P437, DOI DOI 10.1038/043437B0; Slowinski K, 2000, J ELECTROANAL CHEM, V491, P139, DOI 10.1016/S0022-0728(00)00305-3; Slowinski K, 1999, J AM CHEM SOC, V121, P7257, DOI 10.1021/ja991613i; SMALL DM, 1986, PHYSICAL CHEM LIPIDS; SMITH T, 1972, ADV COLLOID INTERFAC, V3, P161; Trigg G.L, 1998, ENCY APPL PHYS, P479; WEAST RC, 1986, HDB CHEM PHYSICS, pF174; WOLF SG, 1987, NATURE, V328, P63, DOI 10.1038/328063a0; WU XZ, 1993, PHYS REV LETT, V70, P958, DOI 10.1103/PhysRevLett.70.958	40	49	50	4	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1404	1407		10.1126/science.1078372	http://dx.doi.org/10.1126/science.1078372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434055	Green Submitted			2022-12-28	WOS:000179223100046
J	LaBarge, MA; Blau, HM				LaBarge, MA; Blau, HM			Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury	CELL			English	Article							SATELLITE CELL; CARDIAC-MUSCLE; X-IRRADIATION; SKELETAL; REGENERATION; EXPRESSION; TRANSPLANTATION; MYOBLASTS; PROLIFERATION; PURIFICATION	Adult bone marrow-derived cells (BMDC) are shown to contribute to muscle tissue in a step-wise biological progression. Following irradiation-induced damage, transplanted GFP-labeled BMDC become satellite cells: membrane-ensheathed mononucleate muscle stem cells. Following a subsequent exercise-induced damage, GFP-labeled multinucleate myofibers are detected. Isolated GFP-labeled satellite cells are heritably myogenic. They express three characteristic muscle markers, are karyotypically diploid, and form clones that can fuse into multinucleate cells in culture or into myofibers; after injection into mouse muscles. These results suggest that two temporally distinct injury-related signals first induce BMDC to occupy the muscle stem cell niche and then to help regenerate mature muscle fibers. The stress-induced progression of BMDC to muscle satellite cell to muscle fiber results in a contribution to as many as 3.5% of muscle fibers and is due to developmental plasticity in response to environmental cues.	Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Blau, HM (corresponding author), Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, CCSR 4215, Stanford, CA 94305 USA.	hblau@stanford.edu	LaBarge, Mark A/E-2621-2013	LaBarge, Mark/0000-0003-2405-4719	NHLBI NIH HHS [HL65572] Funding Source: Medline; NIA NIH HHS [AG20961, AG00259, AG09521] Funding Source: Medline; NICHD NIH HHS [HD18179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020961, R37AG009521, R01AG009521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; BAO ZZ, 1993, J CELL SCI, V106, P579; Baroffio A, 1996, DIFFERENTIATION, V60, P47, DOI 10.1046/j.1432-0436.1996.6010047.x; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; BISCHOFF R, 1986, DEV BIOL, V115, P129, DOI 10.1016/0012-1606(86)90234-4; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Blanco-Bose WE, 2001, EXP CELL RES, V265, P212, DOI 10.1006/excr.2001.5191; Blaveri K, 1999, DEV DYNAM, V216, P244, DOI 10.1002/(SICI)1097-0177(199911)216:3<244::AID-DVDY3>3.0.CO;2-9; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Ferrari G, 2001, NATURE, V411, P1014, DOI 10.1038/35082631; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fukada S, 2002, J CELL SCI, V115, P1285; GOYER RA, 1967, RADIAT RES, V30, P301, DOI 10.2307/3572054; Grounds MD, 1999, CURR OPIN NEUROL, V12, P535, DOI 10.1097/00019052-199910000-00007; Grounds MD, 1998, ANN NY ACAD SCI, V854, P78, DOI 10.1111/j.1749-6632.1998.tb09894.x; GULATI AK, 1987, J NEUROL SCI, V78, P111, DOI 10.1016/0022-510X(87)90083-9; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Heslop L, 2000, J CELL SCI, V113, P2299; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kadi F, 2000, HISTOCHEM CELL BIOL, V113, P99, DOI 10.1007/s004180050012; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; ROSENBLATT JD, 1995, IN VITRO CELL DEV-AN, V31, P773; ROSENBLATT JD, 1994, MUSCLE NERVE, V17, P608, DOI 10.1002/mus.880170607; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2002, AM J PATHOL, V161, P565, DOI 10.1016/S0002-9440(10)64212-5; Warren S, 1943, ARCH PATHOL, V35, P304; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zammit PS, 2001, DIFFERENTIATION, V68, P193, DOI 10.1046/j.1432-0436.2001.680407.x	46	600	649	1	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	2002	111	4					589	601		10.1016/S0092-8674(02)01078-4	http://dx.doi.org/10.1016/S0092-8674(02)01078-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437931	Bronze			2022-12-28	WOS:000179346900011
J	Hahn, WC; Weinberg, RA				Hahn, WC; Weinberg, RA			Mechanisms of disease: Rules for making human tumor cells.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROTEIN PHOSPHATASE 2A; HUMAN-DIPLOID FIBROBLASTS; A-ALPHA SUBUNIT; SMALL-T-ANTIGEN; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; GENE-EXPRESSION; LIFE-SPAN; MALIGNANT-TRANSFORMATION; SUPPRESSOR GENE		Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge, England; MIT, Dept Biol, Cambridge, England	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	william_hahn@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [K01CA094223, R01CA078461] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Beug H, 1985, Haematol Blood Transfus, V29, P290; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BISHOP JM, 1996, MOL ONCOLOGY; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOS JL, 1990, CANCER RES, V50, P1352; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Colella S, 2001, INT J CANCER, V93, P798, DOI 10.1002/ijc.1423; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; DePinho RA, 2001, SEMIN CANCER BIOL, V11, P175, DOI 10.1006/scbi.2000.0369; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; EVA A, 1983, SCIENCE, V220, P955, DOI 10.1126/science.6302839; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fidler IJ, 2000, CANCER J, V6, pS225; Fidler MW, 2001, EUR SPINE J, V10, P69, DOI 10.1007/s005860000206; Folkman J, 1992, Semin Cancer Biol, V3, P65; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Garber ME, 2002, P NATL ACAD SCI USA, V99, P1098; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 2002, MOL CELL BIOL, V22, P3562, DOI 10.1128/MCB.22.10.3562.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hahn WC, 2001, ANN MED, V33, P123, DOI 10.3109/07853890109002067; Hakem R, 2001, ANNU REV GENET, V35, P209, DOI 10.1146/annurev.genet.35.102401.090432; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Ho GH, 2001, BREAST CANCER RES TR, V65, P225, DOI 10.1023/A:1010686518990; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kang KS, 1998, MOL CARCINOGEN, V21, P225, DOI 10.1002/(SICI)1098-2744(199804)21:4<225::AID-MC1>3.0.CO;2-J; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; KRONTIRIS TG, 1981, P NATL ACAD SCI-BIOL, V78, P1181, DOI 10.1073/pnas.78.2.1181; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOEB LA, 1991, CANCER RES, V51, P3075; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; Macera-Bloch L, 2002, J CELL PHYSIOL, V190, P332, DOI 10.1002/jcp.10062; Masters JRW, 2000, NAT REV MOL CELL BIO, V1, P233, DOI 10.1038/35043102; MCCORMICK F, 1991, ENVIRON HEALTH PERSP, V93, P17, DOI 10.2307/3431162; McCormick Frank, 1999, Trends in Cell Biology, V9, pM53, DOI 10.1016/S0962-8924(99)01668-2; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; Polsky D, 2001, CANCER RES, V61, P7642; PRESS MF, 1990, PROG CLIN BIOL RES, V354, P209; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; Rich JN, 2001, CANCER RES, V61, P3556; Ross JS, 1999, AM J CLIN PATHOL, V112, pS53; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; Sanchez-Aguilera A, 2002, BLOOD, V99, P1411, DOI 10.1182/blood.V99.4.1411; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; SHARPLESSNE, 1990, CURR OPIN GENE DEV, V9, P22; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUSSI T, 2002, P53 DATABASE; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang XD, 2001, GENE DEV, V15, P2922; Wong AK, 2000, CANCER METAST REV, V19, P121, DOI 10.1023/A:1026537423753; Yeang CH, 2001, BIOINFORMATICS S1, V17, pS316, DOI DOI 10.1093/BIOINFORMATICS/17.SUPPL_1.S316; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723; Zimonjic D, 2001, CANCER RES, V61, P8838; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	123	609	645	0	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2002	347	20					1593	1603		10.1056/NEJMra021902	http://dx.doi.org/10.1056/NEJMra021902			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614KL	12432047				2022-12-28	WOS:000179187800008
J	Feskanich, D; Willett, W; Colditz, G				Feskanich, D; Willett, W; Colditz, G			Walking and leisure-time activity and risk of hip fracture in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL DENSITY; RANDOMIZED CONTROLLED TRIAL; HORMONE REPLACEMENT THERAPY; PHYSICAL-ACTIVITY; OLDER WOMEN; FALL RISK; BODY-SIZE; EXERCISE; STRENGTH; BALANCE	Context Physical activity can reduce the risk of hip fractures in older women, although the required type and duration of activity have not been determined. Walking is the most common activity among older adults, and evidence suggests that it can increase femoral bone density and reduce fracture risk. Objective To assess the relationship of walking, leisure-time activity, and risk of hip fracture among postmenopausal women. Design, Setting, and Participants Prospective analysis begun in 1986 with 12 years of follow-up in the Nurses' Health Study cohort of registered nurses within 11 US states. A total of 61200 postmenopausal women (aged 40-77 years and 98% white) without diagnosis of cancer, heart disease, stroke, or osteoporosis at baseline. Main Outcome Measures Incident hip fracture resulting from low or moderate trauma, analyzed by intensity and duration of leisure-time activity and by time spent walking, sitting, and standing, measured at baseline and updated throughout follow-up. Results From 1986 to 1998, 415 incident hip fracture cases were identified. After controlling for age, body mass index, use of postmenopausal hormones, smoking, and dietary intakes in proportional hazards models, risk of hip fracture was lowered by 6% (95% confidence interval [CI], 4%-9%; P<.001) for each increase of 3 metabolic equivalent (MET)-hours per week of activity (equivalent to 1 h/wk of walking at an average pace). Active women with at least 24 MET-h/wk had a 55% lower risk of hip fracture (relative risk [RR], 0.45; 95% CI, 0.32-0.63) compared with sedentary women with less than 3 MET-h/wk. Even women with a lower risk of hip fracture due to higher body weight experienced a further reduction in risk with higher levels of activity. Risk of hip fracture decreased linearly with increasing level of activity among women not taking postmenopausal hormones (P<.001), but not among women taking hormones (P=.24). Among women who did no other exercise, walking for at least 4 h/wk was associated with a 41% lower risk of hip fracture (RR, 0.59; 95% CI, 0.37-0.94) compared with less than 1 h/wk. More time spent standing was also independently associated with lower risks. Conclusion Moderate levels of activity, including walking, are associated with substantially lower risk of hip fracture in postmenopausal women.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Feskanich, D (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA87969] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Buchner DM, 1997, J GERONTOL A-BIOL, V52, pM218, DOI 10.1093/gerona/52A.4.M218; Campbell AJ, 1999, AGE AGEING, V28, P513, DOI 10.1093/ageing/28.6.513; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P166; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Coupland CAC, 1999, INT J EPIDEMIOL, V28, P241, DOI 10.1093/ije/28.2.241; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Ebrahim S, 1997, AGE AGEING, V26, P253, DOI 10.1093/ageing/26.4.253; Ensrud KE, 1997, ARCH INTERN MED, V157, P857, DOI 10.1001/archinte.157.8.857; Farahmand BY, 2000, EPIDEMIOLOGY, V11, P214, DOI 10.1097/00001648-200003000-00022; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; Gregg EW, 2000, J AM GERIATR SOC, V48, P883, DOI 10.1111/j.1532-5415.2000.tb06884.x; Gregg EW, 1998, ANN INTERN MED, V129, P81, DOI 10.7326/0003-4819-129-2-199807150-00002; Hoidrup S, 2001, AM J EPIDEMIOL, V154, P60, DOI 10.1093/aje/154.1.60; Hoidrup S, 1999, AM J EPIDEMIOL, V150, P1085, DOI 10.1093/oxfordjournals.aje.a009933; Institute of Medicine Food and Nutrition Board, 2002, DIET REF INT EN CARB; Jette AM, 1999, AM J PUBLIC HEALTH, V89, P66, DOI 10.2105/AJPH.89.1.66; Joakimsen RM, 1997, OSTEOPOROSIS INT, V7, P503, DOI 10.1007/BF02652555; Kelley GA, 1998, AM J PHYS MED REHAB, V77, P76, DOI 10.1097/00002060-199801000-00015; Kerr D, 1996, J BONE MINER RES, V11, P218; KOHRT WM, 1995, J BONE MINER RES, V10, P1303, DOI 10.1002/jbmr.5650100906; Kohrt WM, 1998, J APPL PHYSIOL, V84, P1506, DOI 10.1152/jappl.1998.84.5.1506; Kohrt WM, 1997, J BONE MINER RES, V12, P1253, DOI 10.1359/jbmr.1997.12.8.1253; KRALL EA, 1994, AM J MED, V96, P20, DOI 10.1016/0002-9343(94)90111-2; LANYON LE, 1996, BONE S1, V18, P37; Layne JE, 1999, MED SCI SPORT EXER, V31, P25, DOI 10.1097/00005768-199901000-00006; LONGCOPE C, 1981, MATURITAS, V3, P215, DOI 10.1016/0378-5122(81)90028-1; Lord SR, 1996, ARCH PHYS MED REHAB, V77, P232, DOI 10.1016/S0003-9993(96)90103-3; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; Margolis KL, 2000, ANN INTERN MED, V133, P123, DOI 10.7326/0003-4819-133-2-200007180-00011; Michaelsson K, 1998, OSTEOPOROSIS INT, V8, P540, DOI 10.1007/s001980050096; NELSON ME, 1991, AM J CLIN NUTR, V53, P1304, DOI 10.1093/ajcn/53.5.1304; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; Paganini-Hill A, 1991, Epidemiology, V2, P16; Parkkari J, 1999, CALCIFIED TISSUE INT, V65, P183; PRINCE R, 1995, J BONE MINER RES, V10, P1068, DOI 10.1002/jbmr.5650100711; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; ShumwayCook A, 1997, PHYS THER, V77, P46, DOI 10.1093/ptj/77.1.46; SKELTON DA, 1995, J AM GERIATR SOC, V43, P1081, DOI 10.1111/j.1532-5415.1995.tb07004.x; Specker BL, 1996, J BONE MINER RES, V11, P1539; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Stevens JA, 1997, ANN EPIDEMIOL, V7, P54, DOI 10.1016/S1047-2797(96)00110-X; Taaffe DR, 1999, J AM GERIATR SOC, V47, P1208, DOI 10.1111/j.1532-5415.1999.tb05201.x; Weiss M, 1998, CALCIFIED TISSUE INT, V62, P47, DOI 10.1007/s002239900393; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; ZYLSTRA S, 1989, INT J SPORTS MED, V10, P181, DOI 10.1055/s-2007-1024897	49	290	304	0	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2300	2306		10.1001/jama.288.18.2300	http://dx.doi.org/10.1001/jama.288.18.2300			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425707	Bronze			2022-12-28	WOS:000179186400029
J	Warshaw, GA; Bragg, EJ; Shaull, RW; Lindsell, CJ				Warshaw, GA; Bragg, EJ; Shaull, RW; Lindsell, CJ			Academic geriatric programs in US allopathic and osteopathic medical schools	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPORT CARD	Context By 2030, 20% of the US population will be older than 65 years compared with 12.4% in 2000. The development of geriatric medicine research and training programs to prepare for this increasing number of older individuals is largely dependent on the successful establishment of academic geriatric medicine programs in medical schools. Objective To assess the structure, resources, and activities of academic geriatric medicine programs in US allopathic and osteopathic schools of medicine. Design, Setting, and Participants Survey distributed to the academic geriatric medicine leaders of the 144 US allopathic and osteopathic medical schools in March 2001. Main Outcome Measures Organizational structure, program information, curriculum, budgetary issues, and characteristics of academic geriatric medicine leaders. Results A total of 121 program directors (84%) responded. Most schools (87%) had an identifiable academic geriatric program structure, with 67% established after 1984. The greatest proportion of faculty and staff time (40%) was spent in clinical practice, followed by research and scholarship (12%), residency and fellowship education (10% each), and medical student education (7.8%). Clinical practice accounted for the greatest portion (27%) of revenue, and 25.7% of the programs had total annual budgets of less than $250000, while 11 % had budgets of greater than $5 million. The largest obstacles to achieving the goals of an academic geriatric medicine program were a lack of research faculty and fellows and poor clinical reimbursement. Conclusions Most US medical schools have an identifiable academic geriatric medicine program; most have been established within the last 15 years. Resources are needed to train faculty for roles as teachers and researchers and to develop medical school geriatric programs of the size and scope equivalent to other academic disciplines.	Univ Cincinnati, Off Geriatr Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Family Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Warshaw, GA (corresponding author), Univ Cincinnati, Off Geriatr Med, POB 670504, Cincinnati, OH 45267 USA.			Lindsell, Christopher/0000-0002-3297-2811				*ASS AM MED COLL, 2001, US MED SCH FAC; *ASS AM MED COLL D, 2001, 2001 MED SCH GRAD QU; *ASS AM MED COLL J, 2000, ENH GER GER MED ED U; Association of American Medical Colleges, 1998, CONT ISSUES MED ED, V1, P1; BOND E, 1987, J AM GERIATR SOC, V35, P773; *DW REYN FDN, COMPR PROGR STRENGTH; HAZZARD WR, 1991, ANN INTERN MED, V115, P229, DOI 10.7326/0003-4819-115-3-229; Hazzard WR, 2000, ANN INTERN MED, V133, P293, DOI 10.7326/0003-4819-133-4-200008150-00014; Hazzard WR, 2000, J AM GERIATR SOC, V48, P686, DOI 10.1111/j.1532-5415.2000.tb04730.x; *I MED, 1978, AG MED ED REP STUD; *I MED, 1991, NAT RES AG AG EXT LI; II. Graduate Medical Education, 2000, JAMA, V284, P1159; II. Graduate Medical Education, 1998, JAMA, V280, P836; II. Graduate Medical Education, 1999, JAMA, V282, P893; Institue of Medicine, 1993, STRENGTH TRAIN GER P; Medina-Walpole A, 2002, J AM GERIATR SOC, V50, P949, DOI 10.1046/j.1532-5415.2002.50225.x; O'Brien, 2000, NATL CRISIS NEED GER; REUBEN DB, 1993, J AM GERIATR SOC, V41, P560, DOI 10.1111/j.1532-5415.1993.tb01896.x; Reuben DB, 1997, J AM GERIATR SOC, V45, P112, DOI 10.1111/j.1532-5415.1997.tb00989.x; REUBEN DB, 1994, TRAINING PHYSICIANS; ROWE JW, 1987, NEW ENGL J MED, V316, P1425, DOI 10.1056/NEJM198705283162229; *SAS I INC, 1999, SAS STAT SOFTW REL 8; Schroeder SA, 2002, ACAD MED, V77, P767, DOI 10.1097/00001888-200208000-00003; *SPSS INC, 2001, SPSS WIND REL 10 1 0; *US DEP HHS, 1996, NAT AG GER ED WHIT P; *US DEP HHS, 2001, PROF OLD AM; Warshaw GA., 2002, GERIATRIC MED TRAINI; 2002, JAMA, V288, P1151; 1997, JAMA, V278, P775; 1996, JAMA, V276, P739; 2001, JAMA, V286, P1095; 1995, JAMA, V274, P755	32	35	36	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2313	2319		10.1001/jama.288.18.2313	http://dx.doi.org/10.1001/jama.288.18.2313			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425709	Bronze			2022-12-28	WOS:000179186400031
J	Hobbs, MR; Udhayakumar, V; Levesque, MC; Booth, J; Roberts, JM; Tkachuk, AN; Pole, A; Coon, H; Kariuki, S; Nahlen, BL; Mwaikambo, ED; Lal, AL; Granger, DL; Anstey, NM; Weinberg, JB				Hobbs, MR; Udhayakumar, V; Levesque, MC; Booth, J; Roberts, JM; Tkachuk, AN; Pole, A; Coon, H; Kariuki, S; Nahlen, BL; Mwaikambo, ED; Lal, AL; Granger, DL; Anstey, NM; Weinberg, JB			A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children	LANCET			English	Article							TRANSCRIPTIONAL REGULATION; FALCIPARUM-MALARIA; INTERFERON-GAMMA; CEREBRAL MALARIA; DISEASE SEVERITY; SYNTHASE GENE; TRANSMISSION; INDUCTION; GENOME; MICE	Background Nitric oxide (NO) is a mediator of immunity to malaria, and genetic polymorphisms in the promoter of the inducible NO synthase gene (NOS2) could modulate production of NO. We postulated that NOS2 promoter polymorphisms would affect resistance to severe malaria. Methods We assessed genomic DNA from healthy children and from those diagnosed with malaria from Tanzania (n=47 and n=138, respectively) and Kenya (n=1106) for polymorphisms by single-stranded conformational polymorphism (SSCP) analysis and sequencing. We also measured in-vivo NO production in Tanzanian children. Findings We identified a novel single nucleotide polymorphism, -1173 C-->T, in the NOS2 promoter that was significantly associated with protection from symptomatic malaria (odds ratio 0.12, 95% CI 0.03-0.48, p=0.0006) in 179 Tanzanian children, and significantly associated with protection from severe malarial anaemia (adjusted relative risk 0.25, 95% CI 0.09-0.66, p=0.0005) in 1106 Kenyan children studied over 5 years. The risk of parasitaemia was not significantly different in wild-type or -1173 C-->T individuals. -1173 C-->T protection in Tanzanians was independent of the previously recognised NOS2-954 G-->C polymorphism. The (CCTTT)(n) NOS2 polymorphism (Tanzania and Kenya) was not associated with severe malaria outcomes. -1173 C-->T was associated with increased fasting urine and plasma NO metabolite concentrations in Tanzanian children, suggesting that the polymorphism was functional in vivo. Interpretation The NOS2 promoter -1173 C-->T single nucleotide polymorphism is associated with protection against cerebral malaria and severe malarial anaemia. Increased NO production in individuals with the -1173 C-->T polymorphism lends support to a protective role for NO against these syndromes. Targeted interventions to increase NO delivery or production could provide novel preventive and therapeutic strategies against these major causes of mortality in African children.	Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; VA Med Ctr, Salt Lake City, UT USA; Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA; VA & Duke Univ Med Ctr, Dept Med, Durham, NC USA; Univ Utah, Dept Psychiat, Salt Lake City, UT USA; WHO, Rollback Malaria Program, CH-1211 Geneva, Switzerland; Hubert Kairuki Mem Univ, Dept Paediat & Child Hlth, Dar Es Salaam, Tanzania; Menzies Sch Hlth Res, Div Infect Dis, Darwin, NT, Australia; Flinders Univ No Terr Clin Sch, Darwin, NT, Australia	Utah System of Higher Education; University of Utah; Centers for Disease Control & Prevention - USA; Duke University; Utah System of Higher Education; University of Utah; World Health Organization; Charles Darwin University; Menzies School of Health Research; Flinders University South Australia	Weinberg, JB (corresponding author), VA & Duke Med Ctr, 508 Fulton St, Durham, NC 27705 USA.		Nahlen, Bernard/AAH-2051-2021	Coon, Hilary/0000-0002-8877-5446; Tkachuk, Ariana/0000-0001-8991-9643	NCI NIH HHS [5P30CA42014] Funding Source: Medline; NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NIAID NIH HHS [R01 AI041764, AI41764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI041764, R01AI041764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aidoo M, 2002, LANCET, V359, P1311, DOI 10.1016/S0140-6736(02)08273-9; Akanmori BD, 2000, EUR CYTOKINE NETW, V11, P113; ALLEY EW, 1995, GENE, V158, P247, DOI 10.1016/0378-1119(94)00892-V; [Anonymous], 1996, Wkly Epidemiol Rec, V71, P17; Anstey NM, 1997, AM J TROP MED HYG, V57, P187, DOI 10.4269/ajtmh.1997.57.187; Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557; ANSTEY NM, 1999, NITRIC OXIDE INFECT, P311; Bloland PB, 1999, AM J TROP MED HYG, V60, P635, DOI 10.4269/ajtmh.1999.60.635; Burgner D, 1998, LANCET, V352, P1193, DOI 10.1016/S0140-6736(05)60531-4; Clark I, 2002, CRIT CARE MED, V30, pS263, DOI 10.1097/00003246-200205001-00015; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DE CR, 1995, J CLIN INVEST, V96, P60; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128; FLORQUIN S, 1994, J EXP MED, V180, P1153, DOI 10.1084/jem.180.3.1153; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; Kun JF, 2001, J INFECT DIS, V184, P330, DOI 10.1086/322037; Kun JFJ, 1998, LANCET, V351, P265, DOI 10.1016/S0140-6736(05)78273-8; Levesque M. C., 2001, Sepsis, V4, P217, DOI 10.1023/A:1012913023602; Levesque MC, 1999, J INFECT DIS, V180, P1994, DOI 10.1086/315140; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; Morahan G, 2002, GENES IMMUN, V3, P414, DOI 10.1038/sj.gene.6363909; Ohashi J, 2002, J INFECT DIS, V186, P578, DOI 10.1086/341779; Pance A, 2002, FASEB J, V16, P631, DOI 10.1096/fj.01-0450fje; Perkins DJ, 1999, INFECT IMMUN, V67, P4977, DOI 10.1128/IAI.67.9.4977-4981.1999; Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; RUST S, 1993, NUCLEIC ACIDS RES, V21, P3623, DOI 10.1093/nar/21.16.3623; SEGUIN MC, 1994, J EXP MED, V180, P353, DOI 10.1084/jem.180.1.353; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Turner G, 1997, BRAIN PATHOL, V7, P569, DOI 10.1111/j.1750-3639.1997.tb01075.x; Xu WM, 1997, GENE, V204, P165, DOI 10.1016/S0378-1119(97)00538-6; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	35	149	156	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1468	1475		10.1016/S0140-6736(02)11474-7	http://dx.doi.org/10.1016/S0140-6736(02)11474-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433515				2022-12-28	WOS:000179186000012
J	Raine, R; Haines, A; Sensky, T; Hutchings, A; Larkin, K; Black, N				Raine, R; Haines, A; Sensky, T; Hutchings, A; Larkin, K; Black, N			Systematic review of mental health interventions for patients with common somatic symptoms: can research evidence from secondary care be extrapolated to primary care?	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LOW-BACK-PAIN; IRRITABLE-BOWEL-SYNDROME; COGNITIVE-BEHAVIOR THERAPY; CHRONIC-FATIGUE-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; GRADED-EXERCISE; PSYCHOLOGICAL INTERVENTIONS; GENERAL-PRACTICE; EMG BIOFEEDBACK	Objectives To determine the strength of evidence for the effectiveness of mental health interventions for patients with three common somatic conditions (chronic fatigue syndrome, irritable bowel syndrome, and chronic back pain). To assess whether results obtained in secondary care can be extrapolated to primary care and suggest how future trials should be designed to provide more rigorous evidence. Design Systematic review. Data sources Five electronic databases, key texts, references in the articles identified, and citations from expert clinicians. Study selection Randomised controlled trials including participants with one of the three conditions for which no physical cause could be found. Two reviewers screened sources and independently extracted data and assessed quality. Results Sixty one studies were identified; 20 were classified as primary care and 41 as secondary care. For some interventions, such as brief psychodynamic interpersonal therapy, little research was identified. However, results of meta-analyses and of randomised controlled trials suggest that cognitive behaviour therapy and behaviour therapy are effective for chronic back pain and chronic fatigue syndrome and that antidepressants are effective for irritable bowel syndrome. Cognitive behaviour therapy and behaviour therapy were effective in both primary and secondary care in patients with back pain, although the evidence is more consistent and the effect size larger for secondary care. Antidepressants seem effective in irritable bowel syndrome in both settings but ineffective in chronic fatigue syndrome. Conclusions Treatment seems to be more effective in patients in secondary care than in primary care. This may be because secondary care patients have more severe disease, they receive a different treatment regimen, or the intervention is more closely supervised. However, conclusions of effectiveness should be considered in the light of the methodological weaknesses of the studies. Large pragmatic trials are needed of interventions delivered in primary care by appropriately trained primary care staff.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England; W Middlesex Univ Hosp, Imperial Coll Sci Technol & Med, Dept Psychol Med, Isleworth TW7 6AF, Middx, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Raine, R (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.	rosalind.raine@lsthm.ac.uk		Haines, Andy/0000-0002-8053-4605; Hutchings, Andrew/0000-0003-0215-9923				ALEVIZOS B, 1989, CLIN NEUROPHARMACOL, V12, pS66, DOI 10.1097/00002826-198912002-00009; ALTMAIER EM, 1992, PAIN, V49, P329, DOI 10.1016/0304-3959(92)90240-C; Basler HD, 1997, PATIENT EDUC COUNS, V31, P113, DOI 10.1016/S0738-3991(97)00996-8; Bendix A E, 1998, Eur Spine J, V7, P111, DOI 10.1007/s005860050040; Bendix AF, 1998, SPINE, V23, P717, DOI 10.1097/00007632-199803150-00013; Bendix AF, 1996, CLEV CLIN J MED, V63, P62, DOI 10.3949/ccjm.63.1.62; Bendix AF, 1997, SCAND J REHABIL MED, V29, P81; BENNETT P, 1985, BRIT J CLIN PSYCHOL, V24, P215, DOI 10.1111/j.2044-8260.1985.tb01340.x; Black N, 2001, BRIT MED J, V323, P275, DOI 10.1136/bmj.323.7307.275; BLANCHARD EB, 1992, BEHAV RES THER, V30, P175, DOI 10.1016/0005-7967(92)90141-3; BLANCHARD EB, 1993, BIOFEEDBACK SELF-REG, V18, P125, DOI 10.1007/BF00999789; BRIDGES KW, 1985, J PSYCHOSOM RES, V29, P563, DOI 10.1016/0022-3999(85)90064-9; BRU E, 1994, PSYCHOL HEALTH, V9, P371, DOI 10.1080/08870449408407495; Chilvers C, 2001, BMJ-BRIT MED J, V322, P772, DOI 10.1136/bmj.322.7289.772; Chisholm D, 2001, BRIT J GEN PRACT, V51, P15; CORNEY RH, 1990, J PSYCHOSOM RES, V34, P483, DOI 10.1016/0022-3999(90)90022-V; Deale A, 1997, AM J PSYCHIAT, V154, P408; Deale A, 2001, AM J PSYCHIAT, V158, P2038, DOI 10.1176/appi.ajp.158.12.2038; Deeks J.J., 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; *DEP HLTH, 2001, TREATM CHOIC PSYCH T; DeRubeis RJ, 1998, J CONSULT CLIN PSYCH, V66, P37, DOI 10.1037/0022-006X.66.1.37; Donaldson S, 1994, J Occup Rehabil, V4, P23, DOI 10.1007/BF02109994; Evans K, 1999, PSYCHOL MED, V29, P19, DOI 10.1017/S003329179800765X; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; Goossens MEJB, 1998, HEALTH ECON, V7, P39, DOI 10.1002/(SICI)1099-1050(199802)7:1<39::AID-HEC323>3.3.CO;2-J; GREENBAUM DS, 1987, DIGEST DIS SCI, V32, P257, DOI 10.1007/BF01297051; GREENE B, 1994, J CONSULT CLIN PSYCH, V62, P576, DOI 10.1037/0022-006X.62.3.576; GUTHRIE E, 1993, BRIT J PSYCHIAT, V163, P315, DOI 10.1192/bjp.163.3.315; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; HEEFNER JD, 1978, PSYCHOSOMATICS, V19, P540; Hickie IB, 2000, J CLIN PSYCHIAT, V61, P643, DOI 10.4088/JCP.v61n0909; Jackle J, 2000, J PHYS IV, V10, P3, DOI 10.1051/jp4:2000701; Jackson JL, 2000, AM J MED, V108, P65, DOI 10.1016/S0002-9343(99)00299-5; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Jyvasjarvi S, 2001, J PSYCHOSOM RES, V50, P185, DOI 10.1016/S0022-3999(00)00217-8; Keefer L, 2001, BEHAV RES THER, V39, P801, DOI 10.1016/S0005-7967(00)00078-4; Kole-Snijders AMJ, 1999, J CONSULT CLIN PSYCH, V67, P931, DOI 10.1037/0022-006X.67.6.931; LANCASTERSMITH MJ, 1982, ACTA PSYCHIAT SCAND, V66, P33, DOI 10.1111/j.1600-0447.1982.tb00912.x; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; Linton SJ, 2000, SPINE, V25, P2825, DOI 10.1097/00007632-200011010-00017; LINTON SJ, 1989, PAIN, V36, P197, DOI 10.1016/0304-3959(89)90024-9; LLOYD AR, 1993, AM J MED, V94, P197, DOI 10.1016/0002-9343(93)90183-P; LOLDRUP D, 1989, PSYCHOPHARMACOLOGY, V99, P1, DOI 10.1007/BF00634443; LYNCH PM, 1989, BEHAV THER, V20, P509, DOI 10.1016/S0005-7894(89)80130-3; MAYOU R, 1995, TREATMENT SOMATIC SY; Mertz H, 1998, AM J GASTROENTEROL, V93, P160, DOI 10.1111/j.1572-0241.1998.00160.x; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Moore JE, 2000, PAIN, V88, P145, DOI 10.1016/S0304-3959(00)00314-6; MYREN J, 1982, SCAND J GASTROENTERO, V17, P871, DOI 10.3109/00365528209181108; MYREN J, 1984, SCAND J GASTROENTERO, V19, P835, DOI 10.1080/00365521.1984.12005817; Natelson BH, 1996, PSYCHOPHARMACOLOGY, V124, P226, DOI 10.1007/BF02246661; NEFF DF, 1987, BEHAV THER, V18, P70, DOI 10.1016/S0005-7894(87)80052-7; NEWTONJOHN TRO, 1995, BEHAV RES THER, V33, P691, DOI 10.1016/0005-7967(95)00008-L; NICHOLAS MK, 1991, BEHAV RES THER, V29, P225, DOI 10.1016/0005-7967(91)90112-G; NICHOLAS MK, 1992, PAIN, V48, P339, DOI 10.1016/0304-3959(92)90082-M; NOUWEN A, 1983, PAIN, V17, P353, DOI 10.1016/0304-3959(83)90166-5; PAYNE A, 1995, J CONSULT CLIN PSYCH, V63, P779, DOI 10.1037/0022-006X.63.5.779; PHEASANT H, 1983, SPINE, V8, P552, DOI 10.1097/00007632-198307000-00012; PHILIPS HC, 1987, BEHAV RES THER, V25, P365, DOI 10.1016/0005-7967(87)90014-3; Powell P, 2001, BMJ-BRIT MED J, V322, P387, DOI 10.1136/bmj.322.7283.387; Prins JB, 2001, LANCET, V357, P841, DOI 10.1016/S0140-6736(00)04198-2; Raine R, 2000, BRIT J GEN PRACT, V50, P620; Rajagopalan M, 1998, J GASTROEN HEPATOL, V13, P738, DOI 10.1111/j.1440-1746.1998.tb00723.x; Ridsdale L, 2001, BRIT J GEN PRACT, V51, P19; Rose MJ, 1997, SPINE, V22, P2246, DOI 10.1097/00007632-199710010-00009; RUMSEY N, 1991, CONFIDENT MANAGEMENT; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SHAW G, 1991, DIGESTION, V50, P36, DOI 10.1159/000200738; SHWARTZ D, 1976, J CHRON DIS, V20, P637; STEINHART MJ, 1981, INT J PSYCHIAT MED, V11, P45, DOI 10.2190/WFHG-GR7T-79D6-UQVD; Strong J, 1998, J OCCUP REHABIL, V8, P61, DOI 10.1023/A:1023008632131; SVEDLUND J, 1983, LANCET, V2, P589; SVEDLUND J, 1985, SCAND J GASTROENTERO, V20, P147, DOI 10.3109/00365528509103950; Tanum L, 1996, SCAND J GASTROENTERO, V31, P318, DOI 10.3109/00365529609006404; Tripathi B M, 1983, J Assoc Physicians India, V31, P201; TURNER JA, 1990, J CONSULT CLIN PSYCH, V58, P573, DOI 10.1037/0022-006X.58.5.573; TURNER JA, 1982, J CONSULT CLIN PSYCH, V50, P757, DOI 10.1037/0022-006X.50.5.757; TURNER JA, 1993, PAIN, V52, P169, DOI 10.1016/0304-3959(93)90128-C; TURNER JA, 1988, J CONSULT CLIN PSYCH, V56, P261, DOI 10.1037/0022-006X.56.2.261; vanDulmen AM, 1996, PSYCHOSOM MED, V58, P508, DOI 10.1097/00006842-199609000-00013; vanTulder M., 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; Vercoulen JHMM, 1996, LANCET, V347, P858, DOI 10.1016/S0140-6736(96)91345-8; VJI J, 1991, INDIAN J PSYCHIAT, V33, P243; VLAEYEN JWS, 1995, BRIT J CLIN PSYCHOL, V34, P95, DOI 10.1111/j.2044-8260.1995.tb01443.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wearden AJ, 1998, BRIT J PSYCHIAT, V172, P485, DOI 10.1192/bjp.172.6.485; Whitford DL, 2000, BRIT J GEN PRACT, V50, P573; Whiting P, 2001, JAMA-J AM MED ASSOC, V286, P1360, DOI 10.1001/jama.286.11.1360	89	90	91	1	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2002	325	7372					1082	1085		10.1136/bmj.325.7372.1082	http://dx.doi.org/10.1136/bmj.325.7372.1082			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	618JV	12424170	Bronze, Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000179415700023
J	Deveras, RAE; Kessler, CM				Deveras, RAE; Kessler, CM			Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate	ANNALS OF INTERNAL MEDICINE			English	Article							COAGULOPATHY	Background: Bleeding associated with warfarin anticoagulation correlates directly to duration and degree of international normalized ratio (INR) elevation above the therapeutic range. Safe and rapid reversal of excessive anticoagulation is occasionally needed to treat or avoid hemorrhagic complications. Objective: To evaluate the efficacy and safety of human recombinant factor VIIa (rFVIIa) concentrate in persons requiring rapid reversal of the effects of warfarin. Design: Uncontrolled case series. Setting: Academic medical center. Patients: 13 patients with critically increased INRs requiring immediate reversal of warfarin-induced anti coagulation. Measurements: Prothrombin time and INR were measured before and after administration of varying doses of rFVIIa. Results: Critically prolonged INR and bleeding complications were treated successively and rapidly in all patients, regardless of rFVIIa dose (range, 15 to 90 mug/kg of body weight). Indications for use of rFVIIa included an INR greater than 10 in high-risk persons (n = 5), clinical hemorrhage (n = 4), and diagnostic or therapeutic procedures (n = 4). Conclusion: Safe, rapid, and effective administration of rFVIIa corrects critically prolonged INRs; and can avert or reverse bleeding associated with warfarin anticoagulation.	Georgetown Univ, Med Ctr, Div Hematol & Oncol, Washington, DC 20007 USA	Georgetown University	Deveras, RAE (corresponding author), Georgetown Univ, Med Ctr, Div Hematol & Oncol, 3800 Reservoir Rd NW, Washington, DC 20007 USA.	rad@georgetown.edu						Abu-Hajir M, 2001, BLOOD, V98, p79B; Ansell J, 2001, CHEST, V119, p22S, DOI 10.1378/chest.119.1_suppl.22S; Berntorp E, 2000, BLOOD COAGUL FIBRIN, V11, pS113, DOI 10.1097/00001721-200004001-00021; Bird LA, 1998, S AFR MED J, V88, P1344; Crowther MA, 2000, LANCET, V356, P1551, DOI 10.1016/S0140-6736(00)03125-1; DINESS V, 1990, THROMB RES, V59, P921, DOI 10.1016/0049-3848(90)90116-T; FIHN SD, 1996, ANN INTERN MED; Girard P, 1998, THROMB HAEMOSTASIS, V80, P109; Hirsh J, 2001, CHEST, V119, p8S, DOI 10.1378/chest.119.1_suppl.8S; Hylck EM, 2000, ARCH INTERN MED, V160, P1612, DOI 10.1001/archinte.160.11.1612; Kessler CM, 2000, CURR OPIN HEMATOL, V7, P408, DOI 10.1097/00062752-200011000-00015; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LUSHER JM, 1991, SEMIN HEMATOL, V28, P3; *NOV NORD, 2002, NOV COAG FACT VIIA R; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Peerlinck K, 1999, THROMB HAEMOSTASIS, V82, P1775, DOI 10.1055/s-0037-1614918; Pindur G, 1999, THROMB RES, V95, pS57, DOI 10.1016/S0049-3848(99)00085-7; Seitz R, 1999, THROMB RES, V95, pS19, DOI 10.1016/S0049-3848(99)00080-8; SERLIN MJ, 1983, DRUGS, V25, P610, DOI 10.2165/00003495-198325060-00004; Shopnick RI, 2001, BLOOD, V98, p99B	20	181	186	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					884	888		10.7326/0003-4819-137-11-200212030-00009	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622GY	12458988				2022-12-28	WOS:000179639700004
J	Lakhani, M				Lakhani, M			GPs and the information revolution	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1309	1309		10.1136/bmj.325.7375.1309	http://dx.doi.org/10.1136/bmj.325.7375.1309			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458278	Green Published			2022-12-28	WOS:000179696300051
J	Stefanova, I; Dorfman, JR; Germain, RN				Stefanova, I; Dorfman, JR; Germain, RN			Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes	NATURE			English	Article							SINGLE-CELL ANALYSIS; TRANSGENIC MICE; DEFICIENT MICE; RECEPTOR; CD4; MOLECULES; RESPONSES; THRESHOLDS; ACTIVATION; SURVIVAL	Major histocompatibility complex (MHC) class I and II molecules are highly polymorphic proteins that bind and present foreign peptides to the clonally distributed alphabeta receptors (TCR) of T lymphocytes. As a population, the immature T lymphocytes generated in the thymus express a very diverse set of TCR specificities. A process of positive selection filters this broad repertoire to optimize peripheral T cells for antigen recognition in the context of available MHC products. Only those precursor T cells whose TCRs generate an adequate but not excessive signalling response to self-peptides bound to the expressed MHC proteins undergo successful maturation(1). Here we show that post-thymic self-recognition facilitates the antigen reactivity of mature T cells. Both experimental and physiological interruption of T-cell contact with self-peptide MHC ligands leads to a rapid decline in signalling and response sensitivity to foreign stimuli. Because the adaptive immune system must be recruited early in an infectious process when antigen is limiting(2), these findings suggest that positive selection ensures predictable T-cell recognition of available self-ligands, which in turn promotes efficient responses to pathogens.	NIAID, Lymphocyte Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Germain, RN (corresponding author), NIAID, Lymphocyte Biol Sect, Immunol Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	rgermain@nih.gov	Dorfman, Jeffrey R/M-4218-2017; Germain, Ronald/ABE-7090-2020; Dorfman, Jeffrey R/B-4854-2011; Germain, Ronald N./Z-1945-2019	Dorfman, Jeffrey R/0000-0001-9938-8911; 				Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; COHN M, 1990, IMMUNOL REV, V115, P7, DOI 10.1111/j.1600-065X.1990.tb00783.x; CRUMP AL, 1993, P NATL ACAD SCI USA, V90, P10739, DOI 10.1073/pnas.90.22.10739; DING L, 1993, J IMMUNOL, V151, P1224; Dittel BN, 1999, IMMUNITY, V11, P289, DOI 10.1016/S1074-7613(00)80104-1; Dorfman JR, 2000, NAT IMMUNOL, V1, P329, DOI 10.1038/79783; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; Gascoigne N R, 1993, Semin Immunol, V5, P13, DOI 10.1006/smim.1993.1003; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Gestwicki JE, 2002, NATURE, V415, P81, DOI 10.1038/415081a; Hemmer B, 1998, J IMMUNOL, V160, P5807; Itoh Y, 1997, J EXP MED, V186, P757, DOI 10.1084/jem.186.5.757; JANEWAY CA, 1984, J IMMUNOL, V132, P662; Kassiotis G, 2002, NAT IMMUNOL, V3, P244, DOI 10.1038/ni766; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kersh EN, 1999, J EXP MED, V190, P1627, DOI 10.1084/jem.190.11.1627; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Micheletti F, 2000, J IMMUNOL, V165, P4264, DOI 10.4049/jimmunol.165.8.4264; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; Saitoe M, 2001, SCIENCE, V293, P514, DOI 10.1126/science.1061270; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; Smith K, 2001, J EXP MED, V194, P1253, DOI 10.1084/jem.194.9.1253; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; Witherden D, 2000, J EXP MED, V191, P355, DOI 10.1084/jem.191.2.355; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741; Zell T, 2001, P NATL ACAD SCI USA, V98, P10805, DOI 10.1073/pnas.191567898	30	312	315	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	2002	420	6914					429	434		10.1038/nature01146	http://dx.doi.org/10.1038/nature01146			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459785	Green Published			2022-12-28	WOS:000179494700043
J	Silverman, ES; Muse, VV; Mark, EJ; Wain, JC				Silverman, ES; Muse, VV; Mark, EJ; Wain, JC			A 32-year-old man with hemoptysis of nearly three decades' duration - Idiopathic pulmonary hemosiderosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DIFFUSE ALVEOLAR HEMORRHAGE; SYSTEMIC AUTOIMMUNE-DISEASE; INTRAPULMONARY HEMORRHAGE; GOODPASTURES-SYNDROME; GRANULOMATOSIS; CAPILLARITIS; ANTIBODIES; DIAGNOSIS; SURVIVAL; MARKERS		Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health	Silverman, ES (corresponding author), Brigham & Womens Hosp, Boston, MA 02115 USA.							Ball JA, 1998, CLIN CHEST MED, V19, P777, DOI 10.1016/S0272-5231(05)70116-7; BALTER MS, 1997, DIAGNOSIS TREATMENT, P155; BRITTON RS, 1994, IRON METABOLISM HLTH, P317; BRONSON SM, 1960, AMER J ROENTGENOL RA, V83, P260; CAPRON F, 1996, SPENCERS PATHOLOGY L, P865; CASSIMOS CD, 1983, J PEDIATR-US, V102, P698, DOI 10.1016/S0022-3476(83)80236-4; Evans J, 1998, CLIN CHEST MED, V19, P613, DOI 10.1016/S0272-5231(05)70106-4; EWAN PW, 1976, NEW ENGL J MED, V295, P1391, DOI 10.1056/NEJM197612162952502; FANBURG BL, 1993, NEW ENGL J MED, V329, P2019; Fossati G, 1992, Pediatr Med Chir, V14, P203; Gertner E, 1999, J RHEUMATOL, V26, P805; Guillevin L, 1999, ARTHRITIS RHEUM-US, V42, P421, DOI 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6; Hirshberg B, 1997, CHEST, V112, P440, DOI 10.1378/chest.112.2.440; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Homer RJ, 1998, CLIN CHEST MED, V19, P627, DOI 10.1016/S0272-5231(05)70107-6; Jennings CA, 1997, AM J RESP CRIT CARE, V155, P1101, DOI 10.1164/ajrccm.155.3.9116994; Kiper N, 1999, PEDIATR PULM, V27, P180, DOI 10.1002/(SICI)1099-0496(199903)27:3<180::AID-PPUL5>3.3.CO;2-#; KJELLMAN B, 1984, ACTA PAEDIATR SCAND, V73, P584, DOI 10.1111/j.1651-2227.1984.tb09978.x; Mandel J, 2000, AM J RESP CRIT CARE, V162, P1964, DOI 10.1164/ajrccm.162.5.9912045; MARK EJ, 1988, HUM PATHOL, V19, P1065, DOI 10.1016/S0046-8177(88)80088-1; MARK EJ, 1985, ARCH PATHOL LAB MED, V109, P413; Milman N, 1998, RESP MED, V92, P902, DOI 10.1016/S0954-6111(98)90188-3; MORGAN PGM, 1981, BRIT J DIS CHEST, V75, P225, DOI 10.1016/0007-0971(81)90001-2; NAIDICH DP, 1990, RADIOLOGY, V177, P357, DOI 10.1148/radiology.177.2.2217769; OHGA S, 1995, EUR J PEDIATR, V154, P994, DOI 10.1007/BF01958645; PACHECO A, 1991, CHEST, V99, P1525, DOI 10.1378/chest.99.6.1525; Pina J, 2001, MIL MED, V166, P827, DOI 10.1093/milmed/166.9.827; READING R, 1987, ARCH DIS CHILD, V62, P513, DOI 10.1136/adc.62.5.513; ROSSI GA, 1992, PEDIATR PULM, V13, P176, DOI 10.1002/ppul.1950130310; Saeed MM, 1999, CHEST, V116, P721, DOI 10.1378/chest.116.3.721; SOERGEL KH, 1962, AM J MED, V32, P499, DOI 10.1016/0002-9343(62)90051-7; Specks U, 2001, CURR OPIN RHEUMATOL, V13, P12, DOI 10.1097/00002281-200101000-00003; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; THAELL JF, 1978, MAYO CLIN PROC, V53, P113; THOMAS HM, 1975, CHEST, V68, P483, DOI 10.1378/chest.68.4.483; TRAVIS WD, 1990, AM J SURG PATHOL, V14, P1112, DOI 10.1097/00000478-199012000-00003; WILSON CB, 1973, KIDNEY INT, V3, P74, DOI 10.1038/ki.1973.14; WRIGHT PH, 1981, Q J MED, V50, P95; Zamora MR, 1997, MEDICINE, V76, P192, DOI 10.1097/00005792-199705000-00005	39	7	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1693	1701		10.1056/NEJMcpc020020	http://dx.doi.org/10.1056/NEJMcpc020020			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444185				2022-12-28	WOS:000179339900009
J	Ashton, HA; Buxton, MJ; Campbell, HE; Day, NE; Kim, LG; Marteau, TM; Scott, RAP; Thompson, SG; Barker, P; Collin, J; Morris, G; Sutton, G; Wilson, NK; Bridgewater, S; Druce, PS; Hardy, EJ; Lodge, S; Pettifer, M; Woronowski, H; Dewbury, K; Jarvis, LJ; Langham-Brown, J; Lindsell, D; Page, A; Buxton, MJ; Campbell, HE; Colehan, J; Holland, J; Hankins, M; Marteau, TM; Couto, E; Day, NE; Duffy, SW; Kim, LG; Styles, M; Thompson, SG; Vardulaki, KA; Walker, NM; Collin, J; Hardy, EJ; Lodge, S; Cuzick, J; Parmar, MKB; Ruckley, CV; Warlow, C; Emmett, G; Kay, DN; Peake, J				Ashton, HA; Buxton, MJ; Campbell, HE; Day, NE; Kim, LG; Marteau, TM; Scott, RAP; Thompson, SG; Barker, P; Collin, J; Morris, G; Sutton, G; Wilson, NK; Bridgewater, S; Druce, PS; Hardy, EJ; Lodge, S; Pettifer, M; Woronowski, H; Dewbury, K; Jarvis, LJ; Langham-Brown, J; Lindsell, D; Page, A; Buxton, MJ; Campbell, HE; Colehan, J; Holland, J; Hankins, M; Marteau, TM; Couto, E; Day, NE; Duffy, SW; Kim, LG; Styles, M; Thompson, SG; Vardulaki, KA; Walker, NM; Collin, J; Hardy, EJ; Lodge, S; Cuzick, J; Parmar, MKB; Ruckley, CV; Warlow, C; Emmett, G; Kay, DN; Peake, J		Multicentre Aneurysm Screening Stu	Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELECTIVE SURGERY; SURVIVAL; BENEFITS	Objective To assess the cost effectiveness of ultrasound screening for abdominal aortic aneurysms. Design Primary analysis: four year cost effectiveness analysis based directly on results from a randomised controlled trial in which patients were individually allocated to invitation to ultrasound screening (intervention) or to a control group not offered screening. Secondary analysis: projection of the data, based on conservative assumptions, to indicate likely cost effectiveness at 10 years. Setting Four centres in the United Kingdom. Screening delivered in primary care settings with follow up and surgery offered in the main hospitals Participants Population based sample of 67 800 men aged 65-74 years. Main outcome measures Mortality from and costs (screening, follow up, elective and emergency surgery) related to abdominal aortic aneurysm; cost per life year gained. Results Over four years there were 47 fewer deaths related to abdominal aortic aneurysms in the screening group than in the control group, but the additional costs incurred were pound2.2m. After adjustment for censoring and discounted at 6% the mean additional cost of the screening programme was pound63.39 ($97.77, El 00.48) (95% confidence interval pound53.31 to pound73.48) per patient. The hazard ratio for abdominal aortic aneurysm was 0.58 (0.42 to 0.78). Over four years the mean incremental cost effectiveness ratio for screening was pound28 400 (pound15 000 to pound146 000) per life year gained, equivalent to about pound36 000 per quality adjusted life year. After 10 years this figure is estimated to fall to around pound8000 per life year gained. Conclusions Even at four years the cost effectiveness of screening for abdominal aortic aneurysms is at the margin of acceptability according to current NHS thresholds. Over a longer period the cost effectiveness will improve substantially, the predicted ratio at 10 years falling to around a quarter of the four year figure.	Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	Brunel University	Buxton, MJ (corresponding author), Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England.	martin.buxton@brunel.ac.uk		Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; *CHART I PUBL FIN, 2000, HLTH SERV FIN DAT CO; Cho JS, 1998, J VASC SURG, V27, P813, DOI 10.1016/S0741-5214(98)70260-5; Collett D, 1994, MODELLING SURVIVAL D; COLLIN J, 1990, CAUSES MANAGEMENT AN, P447; Couto E, 2002, J MED SCREEN, V9, P40, DOI 10.1136/jms.9.1.40; Forbes JF, 1998, LANCET, V352, P1656; FRAME PS, 1993, ANN INTERN MED, V119, P411, DOI 10.7326/0003-4819-119-5-199309010-00010; Gold MR, 1996, COST EFFECTIVENESS H; Heitjan DF, 2000, HEALTH ECON, V9, P327; Jepson RG, 1997, EUR J VASC ENDOVASC, V14, P143, DOI 10.1016/S1078-5884(97)80212-2; KIND P, 1999, 172 CHE; Law M R, 1994, J Med Screen, V1, P110; Lin DY, 1997, BIOMETRICS, V53, P419, DOI 10.2307/2533947; Lindholt JS, 2002, EUR J VASC ENDOVASC, V23, P55, DOI 10.1053/ejvs.2001.1534; MASON JM, 1993, J PUBLIC HEALTH MED, V15, P154; *NAT I CLIN EXC, 2001, TECHN APPR PROC SER, V5; NETTEN A, 2001, UNITS COSTS HLTH SOC; Norman PE, 1998, BMJ-BRIT MED J, V317, P852, DOI 10.1136/bmj.317.7162.852; Office for National Statistics, INT LIF TABL ENGL WA; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; *ROYAL PHARM SOC G, 1998, 35 BMA RPS; StLeger AS, 1996, EUR J VASC ENDOVASC, V11, P183, DOI 10.1016/S1078-5884(96)80049-9; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; Vardulaki KA, 2002, BRIT J SURG, V89, P861, DOI 10.1046/j.1365-2168.2002.02133.x; Willan AR, 2001, STAT MED, V20, P1563, DOI 10.1002/sim.789	27	168	170	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	2002	325	7373					1135	1138B						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433761				2022-12-28	WOS:000179443100016
J	Sharp, D				Sharp, D			Time to leave Otzi alone?	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Sharp, D (corresponding author), Lancet, London NW1 7BY, England.							BROTHWELL D, 1986, BOGMAN ARCHAEOLOGY P, P89; Glob PV, 1977, BOG PEOPLE IRON AGE; Rollo F, 2002, P NATL ACAD SCI USA, V99, P12594, DOI 10.1073/pnas.192184599; SPINDLER K, 1995, MAN ICE	4	2	2	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1530	1530		10.1016/S0140-6736(02)11579-0	http://dx.doi.org/10.1016/S0140-6736(02)11579-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443588				2022-12-28	WOS:000179292400006
J	Snoke, D				Snoke, D			Spontaneous Bose coherence of excitons and polaritons	SCIENCE			English	Article							COUPLED QUANTUM-WELLS; EINSTEIN CONDENSATION; STIMULATED SCATTERING; GROUND-STATE; PHASE-TRANSITION; COULOMB DRAG; MICROCAVITY; TRANSPORT; LUMINESCENCE; PARAEXCITONS	In the past decade, there has been an increasing number of experiments on spontaneous Bose coherence of excitons and polaritons. Four major areas of research are reviewed here: three-dimensional excitons in the bulk semiconductor Cu2O, two-dimensional excitons in coupled quantum wells, Coulomb drag experiments in coupled two-dimensional electron gases, and polaritons in semiconductor microcavities. The unifying theory of all these experiments is the effect of spontaneous symmetry breaking in the Bose-Einstein condensation phase transition.	Univ Pittsburgh, Dept Phys, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Snoke, D (corresponding author), Univ Pittsburgh, Dept Phys, 3941 OHara St, Pittsburgh, PA 15260 USA.							ALEXANDROU A, 1990, PHYS REV B, V42, P9225, DOI 10.1103/PhysRevB.42.9225; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Andrews MR, 1996, SCIENCE, V273, P84, DOI 10.1126/science.273.5271.84; Baumberg JJ, 2000, PHYS REV B, V62, P16247, DOI 10.1103/PhysRevB.62.R16247; BLATT JM, 1962, PHYS REV, V126, P1691, DOI 10.1103/PhysRev.126.1691; Butov LV, 1998, PHYS REV B, V58, P1980, DOI 10.1103/PhysRevB.58.1980; Butov LV, 2002, NATURE, V418, P751, DOI 10.1038/nature00943; Butov LV, 2001, PHYS REV LETT, V86, P5608, DOI 10.1103/PhysRevLett.86.5608; BUTOV LV, 1994, PHYS REV LETT, V73, P304, DOI 10.1103/PhysRevLett.73.304; Cao H, 1997, PHYS REV A, V55, P4632, DOI 10.1103/PhysRevA.55.4632; CHASE LL, 1979, PHYS REV LETT, V42, P1231, DOI 10.1103/PhysRevLett.42.1231; CHENG JP, 1995, PHYS REV LETT, V74, P450, DOI 10.1103/PhysRevLett.74.450; Chu H, 1996, PHYS REV B, V54, P5020, DOI 10.1103/PhysRevB.54.5020; Combescot M, 2001, EUROPHYS LETT, V55, P390, DOI 10.1209/epl/i2001-00427-7; COMTE C, 1982, J PHYS-PARIS, V43, P1069, DOI 10.1051/jphys:019820043070106900; Denev S, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.085211; DENG H, IN PRESS SCIENCE; Duan JM, 1997, PHYS REV LETT, V79, P2097, DOI 10.1103/PhysRevLett.79.2097; Eastham PR, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.235101; Fernandez-Rossier J, 1997, PHYS STATUS SOLIDI A, V164, P343, DOI 10.1002/1521-396X(199711)164:1<343::AID-PSSA343>3.0.CO;2-0; Fried DG, 1998, PHYS REV LETT, V81, P3811, DOI 10.1103/PhysRevLett.81.3811; FUKUZAWA T, 1990, PHYS REV LETT, V64, P3066, DOI 10.1103/PhysRevLett.64.3066; HANAMURA E, 1977, PHYS REP, V33, P209, DOI 10.1016/0370-1573(77)90012-6; HASUO M, 1993, PHYS REV LETT, V70, P1303, DOI 10.1103/PhysRevLett.70.1303; Hu BYK, 2000, PHYS REV LETT, V85, P820, DOI 10.1103/PhysRevLett.85.820; Huang R, 2000, PHYS REV B, V61, pR7854, DOI 10.1103/PhysRevB.61.R7854; HULIN D, 1980, PHYS REV LETT, V45, P1970, DOI 10.1103/PhysRevLett.45.1970; JEFFRIES CD, 1987, ELECT HOLE DROPLETS; JEROME D, 1967, PHYS REV, V158, P462, DOI 10.1103/PhysRev.158.462; Jolk A, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.245209; Karasawa T, 2000, J LUMIN, V87-9, P174, DOI 10.1016/S0022-2313(99)00254-9; KASH JA, 1991, PHYS REV LETT, V66, P2247, DOI 10.1103/PhysRevLett.66.2247; Keldysh L. V., 1968, ZH EKSP TEOR FIZ, V54, P978; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; Krivolapchuk VV, 1999, SOLID STATE COMMUN, V111, P49, DOI 10.1016/S0038-1098(99)00162-3; Larionov AV, 2000, J EXP THEOR PHYS+, V90, P1093, DOI 10.1134/1.559200; Lilly MP, 1998, PHYS REV LETT, V80, P1714, DOI 10.1103/PhysRevLett.80.1714; LIN JL, 1993, PHYS REV LETT, V71, P1222, DOI 10.1103/PhysRevLett.71.1222; LOVOVIK YE, 1999, JETP LETT, V69, P616; LOZOVIK YE, 1975, JETP LETT+, V22, P274; Moskalenko S. A., 2000, BOSE EINSTEIN CONDEN; MOSKALENKO SA, 2000, BOSE EINSEIN CONDENS; MOSKALENKO SA, 2000, BOSE EISNTEIN DONDEN; MOSKALENKO SA, 1962, FIZ TVERD TELA, V4, P276; Mysyrowicz A, 1996, PHYS REV LETT, V77, P896, DOI 10.1103/PhysRevLett.77.896; Naveh Y, 1996, PHYS REV LETT, V77, P900, DOI 10.1103/PhysRevLett.77.900; Negoita V, 1999, PHYS REV B, V60, P2661, DOI 10.1103/PhysRevB.60.2661; Negoita V, 2000, OPT LETT, V25, P572, DOI 10.1364/OL.25.000572; Negoita V, 1999, APPL PHYS LETT, V75, P2059, DOI 10.1063/1.124915; Pau, 1996, Phys Rev A, V54, pR1789, DOI 10.1103/PhysRevA.54.R1789; Senellart P, 2000, PHYS REV B, V62, P16263, DOI 10.1103/PhysRevB.62.R16263; Shen MY, 1997, PHYS REV B, V56, P13066, DOI 10.1103/PhysRevB.56.13066; SHI H, 1994, PHYS REV B, V50, P1119, DOI 10.1103/PhysRevB.50.1119; Snoke D, 2002, NATURE, V418, P754, DOI 10.1038/nature00940; Snoke DW, 1995, PHYS REV E, V52, P5796, DOI 10.1103/PhysRevE.52.5796; SNOKE DW, 1991, PHYS REV B, V44, P2991, DOI 10.1103/PhysRevB.44.2991; Stevenson RM, 2000, PHYS REV LETT, V85, P3680, DOI 10.1103/PhysRevLett.85.3680; Sun Y, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.125323; Tikhodeev SG, 2000, PHYS STATUS SOLIDI A, V178, P63, DOI 10.1002/1521-396X(200003)178:1<63::AID-PSSA63>3.0.CO;2-C; TRAUERNICHT DP, 1986, PHYS REV B, V34, P2561, DOI 10.1103/PhysRevB.34.2561; WACHTER P, 1995, PHYS REV B, V51, P5542, DOI 10.1103/PhysRevB.51.5542; Wang EG, 1995, J APPL PHYS, V78, P7099, DOI 10.1063/1.360417; Warren JT, 2000, PHYS REV B, V61, P8215, DOI 10.1103/PhysRevB.61.8215; Zhou F, 1999, PHYS REV B, V59, pR7825, DOI 10.1103/PhysRevB.59.R7825; ZIMMERMANN R, 1976, PHYS STATUS SOLIDI B, V76, P191, DOI 10.1002/pssb.2220760120	65	311	318	4	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1368	1372		10.1126/science.1078082	http://dx.doi.org/10.1126/science.1078082			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434051				2022-12-28	WOS:000179223100039
J	Matsubayashi, K; Maki, M; Tsuzuki, T; Nishioka, T; Sato, NK				Matsubayashi, K; Maki, M; Tsuzuki, T; Nishioka, T; Sato, NK			Magnetic properties - Parasitic ferromagnetism in a hexaboride?	NATURE			English	Article							CA1-XLAXB6		Nagoya Univ, Grad Sch Sci, Dept Phys, Nagoya, Aichi 4648602, Japan	Nagoya University	Matsubayashi, K (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Phys, Nagoya, Aichi 4648602, Japan.		Matsubayashi, Kazuyuki/F-7696-2013	Matsubayashi, Kazuyuki/0000-0002-8814-1910				CHIKAZUMI S, 1975, HDB MAGNETIC MAT; Kunii S, 2000, J PHYS SOC JPN, V69, P3789, DOI 10.1143/JPSJ.69.3789; Moriwaka T, 2001, J PHYS SOC JPN, V70, P341, DOI 10.1143/JPSJ.70.341; Taniguchi K, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.064407; Vonlanthen P, 2000, PHYS REV B, V62, P10076, DOI 10.1103/PhysRevB.62.10076; Young DP, 1999, NATURE, V397, P412, DOI 10.1038/17081	6	61	62	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					143	144		10.1038/420143b	http://dx.doi.org/10.1038/420143b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432381				2022-12-28	WOS:000179200900034
J	Shore, B				Shore, B			Grace notes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2231	2231		10.1001/jama.288.18.2231	http://dx.doi.org/10.1001/jama.288.18.2231			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425682				2022-12-28	WOS:000179186400001
J	Abraham, J				Abraham, J			The pharmaceutical industry as a political player	LANCET			English	Article							MEDICINES; TRIALS	The pharmaceutical industry has produced many drugs that have benefited man Political frameworks designed to govern the industry must maintain these benefits. However, regulation needs to be sufficiently robust to protect public health from drugs that are unsafe, ineffective, or unnecessary. The extent of industry influence over drug regulation, at the expense of other interested parties, suggests that the current system could be more robust. The many ways in which the pharmaceutical industry can influence governments and regulatory agencies are discussed, and methods by which this influence can be curbed are suggested.	Univ Sussex, Ctr Res Hlth & Med, Brighton BN1 9SN, E Sussex, England	University of Sussex	Abraham, J (corresponding author), Univ Sussex, Ctr Res Hlth & Med, Brighton BN1 9SN, E Sussex, England.	J.W.Abraham@sussex.ac.uk						*ABPI, 1971, ABPI ANN REP 1970 71; *ABPI, 1984, ABPI NEWS, V198, P3; *ABPI, 1981, ABPI ANN REP 1980 81, P6; Abraham J, 1999, SOC SCI MED, V48, P1655, DOI 10.1016/S0277-9536(99)00042-8; Abraham J, 1998, LANCET, V352, P480, DOI 10.1016/S0140-6736(97)11282-X; Abraham J, 2001, HEALTH RISK SOC, V3, P113, DOI 10.1080/713670172; Abraham J, 1997, SCI TECHNOL HUM VAL, V22, P139, DOI 10.1177/016224399702200201; Abraham J, 1996, SCI POLITICS PHARM I; ABRHAM J, 2000, REGULATING MED EUROP; ANDERSSON F, 1992, INT J HEALTH SERV, V22, P53, DOI 10.2190/9Y32-X86Y-M3F0-JQFC; Anon, 1989, SCRIP, V1374, P4; Bardelay D, 1996, Int J Risk Saf Med, V9, P151, DOI 10.3233/JRS-1996-9304; Braithwaite J, 1986, CORPORATE CRIME PHAR, P298; BROWN JS, 1996, DRUG INF J, V30, P17; Charatan F, 2001, BRIT MED J, V322, P1198; COLLIER J, 1985, LANCET, V2, P377; DELAMOTHE T, 1989, BRIT MED J, V299, P476; Department of Health, 1971, SAF DRUGS FIN REP JO, P8; Dukes M N, 1996, Int J Risk Saf Med, V9, P143, DOI 10.3233/JRS-1996-9303; Durrington PN, 2000, LANCET, V356, P339, DOI 10.1016/S0140-6736(05)73621-7; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; GARUTTI RJ, 1994, P 2 IND C HARM, P376; GORDON AJ, 1994, P 2 INT C HARM, P384; GRIFFIN JP, 1981, BRIT MED J, V283, P477, DOI 10.1136/bmj.283.6289.477; Horton R, 2001, LANCET, V358, P417, DOI 10.1016/S0140-6736(01)05565-9; ICH, 1995, GUID NEED CARC STUD; IDANPAANHEIKKIL.J, 1998, P 4 INT C HARM, P33; Kmietowicz Z, 2000, BRIT MED J, V320, P1362; MACINNES A, 1997, SCRIP, V2279, P60; *MED CONTR AG, 1997, MCA ANN REP 1996; *MED CONTR AG, 1991, COMM SAF QUAL EFF; *MED CONTR AG, 1993, SAF DRUGS GUID CONTR, P97; Montaner JSG, 2001, LANCET, V358, P1893, DOI 10.1016/S0140-6736(01)06891-X; Ollila E, 1996, Int J Risk Saf Med, V9, P161, DOI 10.3233/JRS-1996-9306; SMITH HL, 2002, REGULATION SCI TECHN, P11; 1993, SCRIP, V1790, P5; 2001, SCRIP, V2654, P6; 1993, SCRIP, V1872, P19; 2000, SCRIP, V2553, P15; 1992, SCRIP, V1778, P5; 2001, SCRIP, V2615, P3; 1997, SCRIP, V2212, P3; 2001, SCRIP, V2653, P26; 1988, SCRIP, V1279, P3; 2001, SCRIP, V2635, P3; 1956, PHARM J, V176, P1; 2001, SCRIP, V2634, P15; 1988, SCRIP, V1369, P1; 1994, REGUL AFF J      JUN, P481; 2001, SCRIP, V2638, P7; 1977, REV PANEL NEW DRUG R, P2; 1991, SCRIP, V1586, P5; 2001, SCRIP, V2607, P5; 1993, SCRIP, V1800, P5; 2001, SCRIP, V2653, P8; 2001, SCRIP, V2649, P2; 1993, SCRIP, V1788, P5	57	90	92	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	2002	360	9344					1498	1502		10.1016/S0140-6736(02)11477-2	http://dx.doi.org/10.1016/S0140-6736(02)11477-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433532				2022-12-28	WOS:000179186000029
J	Oden, A; Fahlen, M				Oden, A; Fahlen, M			Oral anticoagulation and risk of death: a medical record linkage study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROSTHETIC HEART-VALVES; DOSE ANTICOAGULATION; REPLACEMENT; WARFARIN; THERAPY; THROMBOEMBOLISM; THROMBOMODULIN; INTENSITIES; PREVENTION; PLASMA	Objective To study how mortality varies with different degrees of anticoagulation reflected by the international normalised ratio (INR). Design Record linkage analysis with death hazard estimated as a continuous function of INR. Data sources 46 anticoagulation clinics in Sweden with computerised medical records. Subjects Records for 42 451 patients, 3533 deaths, and 1.25 million INR measurements. Main outcome measures Mortality from all causes and from intracranial haemorrhage. Results Mortality from all causes of death was strongly related to level of INR. Minimum risk of death was attained at 2.2 INR for all patients and 2.3 INR for patients with mechanical heart valve prostheses. A high INR was associated with an excess mortality: with an increase of I unit of INR above 2.5, the risks of death from cerebral bleeding (149 deaths) and from any cause were about doubled. Among patients with an INR of greater than or equal to3.0, 1069 deaths occurred within 7 weeks; if the risk coincided with that with an INR of 2.9, the expected number of deaths would have been 569. Thus at least 500 deaths were associated with a high INR value, but not necessarily caused by the treatment. Conclusions The excess mortality associated with high INR values supports the use of less intensive treatment and a small therapeutic window, with INR close to 2.2-2.3 irrespective of the indication for anticoagulant treatment. More preventive actions should be taken to avoid episodes of high INR.			Oden, A (corresponding author), Valler 190, S-44292 Romelanda, Sweden.	anders.oden@mbox301.swipnet.se						Acar J, 1996, CIRCULATION, V94, P2107, DOI 10.1161/01.CIR.94.9.2107; ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427; Breslow NE., 1987, STAT METHODS CANC RE, P81; CHAN A, 1992, AUST NZ J MED, V22, P119, DOI 10.1111/j.1445-5994.1992.tb02789.x; DEFRANZO AJ, 1995, ANN PLAS SURG, V34, P203, DOI 10.1097/00000637-199502000-00017; HIRSH J, 1995, AM J CARDIOL, V75, pB39, DOI 10.1016/0002-9149(95)80009-H; Hylck EM, 2000, ARCH INTERN MED, V160, P1612, DOI 10.1001/archinte.160.11.1612; Jansson JH, 1997, CIRCULATION, V96, P2938, DOI 10.1161/01.CIR.96.9.2938; Jansson JH, 1996, EUR HEART J, V17, P1503; Katircioglu SF, 1997, J CARDIAC SURG, V12, P363, DOI 10.1111/j.1540-8191.1997.tb00152.x; Katircioglu SF, 1998, J HEART VALVE DIS, V7, P455; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; Lehmann AB, 1997, ARCH INTERN MED, V157, P1385, DOI 10.1001/archinte.1997.00440330129015; LEVINE M, 1994, LANCET, V343, P886, DOI 10.1016/S0140-6736(94)90008-6; Moinuddeen K, 1998, CIRCULATION, V98, pII95; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; Smith JK, 1999, ANN PHARMACOTHER, V33, P301, DOI 10.1345/aph.18171; Stein PD, 2001, CHEST, V119, p220S, DOI 10.1378/chest.119.1_suppl.220S; Tientadakul Panutsaya, 1997, Journal of the Medical Association of Thailand, V80, P81; Turpie AGG, 1997, POSTGRAD MED, V101, P85, DOI 10.3810/pgm.1997.03.182; TURPIE AGG, 1988, LANCET, V1, P1242	21	159	166	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2002	325	7372					1073	1075		10.1136/bmj.325.7372.1073	http://dx.doi.org/10.1136/bmj.325.7372.1073			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424167	Bronze, Green Published			2022-12-28	WOS:000179415700020
J	Tanner, K; Fitzsimmons, G; Carrol, ED; Flood, TJ; Clark, JE				Tanner, K; Fitzsimmons, G; Carrol, ED; Flood, TJ; Clark, JE			Lesson of the week - Haemophilus influenzae type b epiglottitis as a cause of acute upper airways obstruction in children	BRITISH MEDICAL JOURNAL			English	Review							VACCINATION		Dept Paediat Infect Dis & Immunol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England		Clark, JE (corresponding author), Dept Paediat Infect Dis & Immunol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.		Clark, Julia/A-8214-2012	Clark, Julia/0000-0001-7746-0599; Carrol, Enitan/0000-0001-8357-7726				*ADV LIF SUPP GROU, 2000, ADV PAED LIF SUPP; BUTT W, 1988, CRIT CARE MED, V16, P43, DOI 10.1097/00003246-198801000-00008; Gonzalez Valdepena H, 1995, Pediatrics, V96, P424; Heath PT, 2000, CLIN INFECT DIS, V31, P973, DOI 10.1086/318132; Heath PT, 2000, JAMA-J AM MED ASSOC, V284, P2334, DOI 10.1001/jama.284.18.2334; HOLMES SJ, 1992, J INFECT DIS, V165, pS121, DOI 10.1093/infdis/165-Supplement_1-S121; MCVERNON J, 2001, P 19 ANN M EUR SOC P, P26; Rosenstein NE, 2000, PEDIATR CLIN N AM, V47, P337, DOI 10.1016/S0031-3955(05)70210-8; Selvadurai H, 1998, J PAEDIATR CHILD H, V34, P306; Wagle A, 1999, PAEDIATR ANAESTH, V9, P549, DOI 10.1046/j.1460-9592.1999.00428.x	10	23	23	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2002	325	7372					1099	1100		10.1136/bmj.325.7372.1099	http://dx.doi.org/10.1136/bmj.325.7372.1099			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424174	Green Published			2022-12-28	WOS:000179415700027
J	Kind, R; Yuan, X; Saul, J; Nelson, D; Sobolev, SV; Mechie, J; Zhao, W; Kosarev, G; Ni, J; Achauer, U; Jiang, M				Kind, R; Yuan, X; Saul, J; Nelson, D; Sobolev, SV; Mechie, J; Zhao, W; Kosarev, G; Ni, J; Achauer, U; Jiang, M			Seismic images of crust and upper mantle beneath Tibet: Evidence for Eurasian plate subduction	SCIENCE			English	Article							SOUTHERN TIBET; PARTIAL MELT; TOMOGRAPHY; ANELASTICITY; TEMPERATURES; MODELS	Seismic data from central Tibet have been combined to image the subsurface structure and understand the evolution of the collision of India and Eurasia. The 410- and 660-kilometer mantle discontinuities are sharply defined, implying a lack of a subducting slab beneath the plateau. The discontinuities appear slightly deeper beneath northern Tibet, implying that the average temperature of the mantle above the transition zone is about 300degreesC hotter in the north than in the south. There is a prominent south-dipping converter in the uppermost mantle beneath northern Tibet that might represent the top of the Eurasian mantle lithosphere underthrusting the northern margin of the plateau.	Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; Free Univ Berlin, D-12249 Berlin, Germany; Syracuse Univ, Dept Earth Sci, Syracuse, NY 13244 USA; Russian Acad Sci, Inst Phys Earth, Moscow 128810, Russia; Chinese Acad Geol Sci, Beijing 100037, Peoples R China; New Mexico State Univ, Dept Phys, Las Cruces, NM 88003 USA; Univ Strasbourg 1, Ecole & Observ Sci Terre, F-67084 Strasbourg, France	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Free University of Berlin; Syracuse University; Russian Academy of Sciences; Schmidt Institute of Physics of the Earth of the Russian Academy of Sciences; Chinese Academy of Geological Sciences; New Mexico State University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kind, R (corresponding author), Geoforschungszentrum Potsdam, Telegrafenberg, D-14473 Potsdam, Germany.		Sobolev, Stephan V/G-3813-2011; Yuan, Xiaohui/G-5149-2010	Sobolev, Stephan V/0000-0002-3382-4028; Yuan, Xiaohui/0000-0002-2891-1354				Grand SP., 1997, GSA TODAY, V7, P1; Helffrich G, 2000, REV GEOPHYS, V38, P141, DOI 10.1029/1999RG000060; HIRN A, 1984, NATURE, V307, P23, DOI 10.1038/307023a0; HIRN A, 1995, NATURE, V375, P571, DOI 10.1038/375571a0; Jin Y, 1996, J GEOPHYS RES-SOL EA, V101, P11275, DOI 10.1029/96JB00531; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; Kind R, 1996, SCIENCE, V274, P1692, DOI 10.1126/science.274.5293.1692; Kosarev G, 1999, SCIENCE, V283, P1306, DOI 10.1126/science.283.5406.1306; MOLNAR P, 1988, PHILOS T R SOC A, V326, P33, DOI 10.1098/rsta.1988.0080; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; OWENS TJ, 1993, B SEISMOL SOC AM, V83, P1959; Owens TJ, 1997, NATURE, V387, P37, DOI 10.1038/387037a0; Partzsch GM, 2000, TECTONOPHYSICS, V317, P189, DOI 10.1016/S0040-1951(99)00320-0; Rodgers AJ, 1998, J GEOPHYS RES-SOL EA, V103, P7137, DOI 10.1029/97JB03535; Rodgers ATJ, 1997, GEOPHYS RES LETT, V24, P9, DOI 10.1029/96GL03774; Sobolev SV, 1997, TECTONOPHYSICS, V275, P143, DOI 10.1016/S0040-1951(97)00019-X; Sobolev SV, 1996, EARTH PLANET SC LETT, V139, P147, DOI 10.1016/0012-821X(95)00238-8; Tapponnier P, 2001, SCIENCE, V294, P1671, DOI 10.1126/science.105978; Van der Voo R, 1999, EARTH PLANET SC LETT, V171, P7, DOI 10.1016/S0012-821X(99)00131-4; Wei WB, 2001, SCIENCE, V292, P716, DOI 10.1126/science.1010580; WILLETT SD, 1994, NATURE, V369, P642, DOI 10.1038/369642a0; Wittlinger G, 1996, EARTH PLANET SC LETT, V139, P263, DOI 10.1016/0012-821X(95)00235-5; Yuan XH, 1997, J GEOPHYS RES-SOL EA, V102, P27491, DOI 10.1029/97JB02379; Zhao W, 2001, GEOPHYS J INT, V145, P486, DOI 10.1046/j.0956-540x.2001.01402.x	24	541	614	8	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1219	1221		10.1126/science.1078115	http://dx.doi.org/10.1126/science.1078115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424374				2022-12-28	WOS:000179080400045
J	Tauchi, H; Kobayashi, J; Morishima, K; van Gent, DC; Shiraishi, T; Verkaik, NS; vanHeems, D; Ito, E; Nakamura, A; Sonodo, E; Takata, M; Takeda, S; Matsuura, S; Komatsu, K				Tauchi, H; Kobayashi, J; Morishima, K; van Gent, DC; Shiraishi, T; Verkaik, NS; vanHeems, D; Ito, E; Nakamura, A; Sonodo, E; Takata, M; Takeda, S; Matsuura, S; Komatsu, K			Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells	NATURE			English	Article							STRAND BREAK REPAIR; GENE CONVERSION; HUMAN MRE11; COMPLEX; PROTEIN; YEAST; INTEGRATION; CLONING; ROLES	Double-strand breaks occur during DNA replication and are also induced by ionizing radiation. There are at least two pathways which can repair such breaks: non-homologous end joining and homologous recombination (HR). Although these pathways are essentially independent of one another, it is possible that the proteins Mre11, Rad50 and Xrs2 are involved in both pathways in Saccharomyces cerevisiae(1). In vertebrate cells, little is known about the exact function of the Mre11-Rad50-Nbs1 complex in the repair of double-strand breaks because Mre11-andRad50-null mutations are lethal(2). Here we show that Nbs1 is essential for HR-mediated repair in higher vertebrate cells. The disruption of Nbs1 reduces gene conversion and sister chromatid exchanges, similar to other HR-deficient mutants(3). In fact, a site-specific double-strand break repair assay showed a notable reduction of HR events following generation of such breaks in Nbs1-disrupted cells. The rare recombinants observed in the Nbs1-disrupted cells were frequently found to have aberrant structures, which possibly arise from unusual crossover events, suggesting that the Nbs1 complex might be required to process recombination intermediates.	Ibaraki Univ, Fac Sci, Dept Environm Sci, Mito, Ibaraki 3108512, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Biol, Minami Ku, Hiroshima 7348553, Japan; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Kyoto Univ, Fac Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Radiat Biol Res Ctr, Sakyo Ku, Kyoto 6068501, Japan; Kawasaki Med Sch, Okayama 7010192, Japan	Ibaraki University; Hiroshima University; Erasmus University Rotterdam; Kyoto University; Kyoto University; Kawasaki Medical School	Tauchi, H (corresponding author), Ibaraki Univ, Fac Sci, Dept Environm Sci, Bunkyo 2-1-1, Mito, Ibaraki 3108512, Japan.	htauchi@mx.ibaraki.ac.jp; komatsu@house.rbc.kyoto-u.ac.jp	Matsuura, Shinya/U-4182-2017; Kobayashi, Junya/AAX-6390-2021	Matsuura, Shinya/0000-0001-5294-081X; Kobayashi, Junya/0000-0003-4645-7500; Takata, Minoru/0000-0002-4926-3675; van Gent, Dik C./0000-0003-1473-8148; Tauchi, Hiroshi/0000-0003-4934-2944				Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Moreau S, 1999, MOL CELL BIOL, V19, P556; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; TAVASSOLI M, 1995, NUCLEIC ACIDS RES, V23, P383, DOI 10.1093/nar/23.3.383; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; VERKAIK NS, IN PRESS EUR J IMMUN; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	30	230	237	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	2002	420	6911					93	98		10.1038/nature01125	http://dx.doi.org/10.1038/nature01125			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422221				2022-12-28	WOS:000179068100043
J	Rudenko, G; Henry, L; Henderson, K; Ichtchenko, K; Brown, MS; Goldstein, JL; Deisenhofer, J				Rudenko, G; Henry, L; Henderson, K; Ichtchenko, K; Brown, MS; Goldstein, JL; Deisenhofer, J			Structure of the LDL receptor extracellular domain at endosomal pH	SCIENCE			English	Article							LOW-DENSITY-LIPOPROTEIN; DEPENDENT LIGAND DISSOCIATION; CYSTEINE-RICH REPEAT; NMR STRUCTURE; FAMILIAL HYPERCHOLESTEROLEMIA; 3-DIMENSIONAL STRUCTURE; APOLIPOPROTEIN B-100; BACKBONE DYNAMICS; BINDING MODULES; CALCIUM-BINDING	The low-density lipoprotein receptor mediates cholesterol homeostasis through endocytosis of lipoproteins. It discharges its ligand in the endosome at pH<6. In the crystal structure at pH=5.3, the ligand-binding domain (modules R2 to R7) folds back as an arc over the epidermal growth factor precursor homology domain (the modules A, B, beta propeller, and C). The modules R4 and R5, which are critical for lipoprotein binding, associate with the beta propeller via their calcium-binding loop. We propose a mechanism for lipoprotein release in the endosome whereby the beta propeller functions as an alternate substrate for the ligand-binding domain, binding in a calcium-dependent way and promoting lipoprotein release.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Ctr Struct Biol, Berkeley, CA 94720 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Deisenhofer, J (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd Y4-206, Dallas, TX 75390 USA.	Johann.Deisenhofer@UTSouthwestern.edu	Rudenko, Gabrielle (Gabby)/O-7938-2018	Rudenko, Gabrielle (Gabby)/0000-0002-7372-0530; Ichtchenko, Konstantin/0000-0002-2198-1325	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beglova N, 2001, BIOCHEMISTRY-US, V40, P2808, DOI 10.1021/bi0027276; Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1978, J SUPRAMOL STR CELL, V8, P223, DOI 10.1002/jss.400080302; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; CHATTERTON JE, 1995, J LIPID RES, V36, P2027; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Clayton D, 2000, FEBS LETT, V479, P118, DOI 10.1016/S0014-5793(00)01842-1; Cooper AD, 1997, J LIPID RES, V38, P2173; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DOI T, 1994, J BIOL CHEM, V269, P25598; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Gabriel JCP, 1997, J SOLID STATE CHEM, V129, P257, DOI 10.1006/jssc.1996.7230; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; INNERARITY TL, 1987, ACTA MED SCAND, P51; Jeon H, 2001, NAT STRUCT BIOL, V8, P499, DOI 10.1038/88556; Jeon H, 2000, J BIOL CHEM, V275, P30458, DOI 10.1074/jbc.M002583200; KEIDAR S, 1989, J LIPID RES, V30, P1331; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurniawan ND, 2001, J MOL BIOL, V311, P341, DOI 10.1006/jmbi.2001.4867; LESLIE AGW, 1992, JOINT CCP4 ESF EACBM; McNamara JR, 1996, J LIPID RES, V37, P1924; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mikhailenko I, 1999, J CELL SCI, V112, P3269; MIYAKE Y, 1989, J BIOL CHEM, V264, P16584; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; North CL, 2000, BIOCHEMISTRY-US, V39, P2564, DOI 10.1021/bi992087a; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raussens V, 2002, J BIOL CHEM, V277, P29172, DOI 10.1074/jbc.M204043200; RUDENKO G, UNPUB; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Saha S, 2001, STRUCTURE, V9, P451, DOI 10.1016/S0969-2126(01)00606-2; SCHNEIDER WJ, 1979, P NATL ACAD SCI USA, V76, P5577, DOI 10.1073/pnas.76.11.5577; Segrest JP, 2001, J LIPID RES, V42, P1346; Simmons T, 1997, J BIOL CHEM, V272, P25531, DOI 10.1074/jbc.272.41.25531; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toyota Y, 1999, ATHEROSCLEROSIS, V147, P77, DOI 10.1016/S0021-9150(99)00166-5; VANDERWESTHUYZEN DR, 1991, BIOCHEM J, V277, P677, DOI 10.1042/bj2770677; Wang XY, 2000, ARTERIOSCL THROM VAS, V20, P1301, DOI 10.1161/01.ATV.20.5.1301; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	48	365	398	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	2002	298	5602					2353	2358		10.1126/science.1078124	http://dx.doi.org/10.1126/science.1078124			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	627DG	12459547	Green Submitted			2022-12-28	WOS:000179915900046
J	Lichter, PR				Lichter, PR			Impact of intraocular pressure reduction on glaucoma progression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLLABORATIVE INITIAL GLAUCOMA; TRABECULECTOMY; QUALITY	Objective: To provide the results of the Early Manifest Glaucoma Trial, which compared the; effect of immediately lowering the intraocular pressure (IOP), Vs no-treatment or later treatment, on the progression of newly detected open-angle glaucoma. Design: Randomized clinical trial. Participants: Two hundred fifty-five patients aged 50 to 80 years (median, 68,years) with early glaucoma, visual field defects (median-mean deviation, -4 dB), and a median IOP of 20 mm Hg, mainly identified through a population screening. Patients with an IOP greater than 30 mm Hg or advanced visual field loss were ineligible. Interventions: Patients Were randomized to either laser trabeculoplasty plus topical betaxolol hydrochloride (n=129) or no initial treatment (n=126). Study visits included Humphrey Full Threshold 30-2 visual field tests and tonometry every 3 months, and optic disc photography every 6 months. Decisions regarding treatment were made jointly with the patient when progression occurred and thereafter. Main Outcome Measures: Glaucoma progression was defined by specific visual field and optic disc outcomes. Criteria for perimetric progression were computer based and defined as the same 3 or, more test point locations showing significant deterioration from baseline in glaucoma change probability maps from 3 consecutive tests. Optic disc progression was determined by masked graders using flicker chronoscopy plus side-by-side photogradings. Results: After a median follow-up period of 6 years (range, 51-102 months), retention was excellent, with only 6 patients lost to follow-up for reasons other than death. On average, treatment reduced the IOP by 5.1 mm Hg or 25%, a reduction maintained throughout follow-up. Progression was less frequent in the treatment group (58/129; 45%) than in controls (78/126; 62%) (P=.007) and occurred significantly later in treated Patients. Treatment effects were also evident when stratifying patients by median IOP, mean deviation, and age as well as exfoliation status. Although patients reported few systemic or ocular conditions, increases in clinical nuclear lens opacity gradings were associated with treatment (P=.002.). Conclusions: The Early Manifest Glaucoma Trial is the first adequately powered randomized trial with an untreated control arm to evaluate the effects of IOP reduction in patients with open-angle glaucoma who have elevated and normal IOP. Its intent to treat analysis showed considerable beneficial effects of treatment that significantly delayed progression. Whereas progression varied across patient categories, treatment effects were present in both older and younger patients, high and normal-tension glaucoma and eyes with less and greater visual field loss.	Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan	Lichter, PR (corresponding author), Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.	plichter@med.umich.edu		Lichter, Paul/0000-0001-8394-4813				EDDY DM, 1988, HEALTH AFFAIR, V7, P19, DOI 10.1377/hlthaff.7.1.19; Ederer F, 2001, AM J OPHTHALMOL, V132, P311; Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268; Janz NK, 2001, OPHTHALMOLOGY, V108, P1954, DOI 10.1016/S0161-6420(01)00874-0; JAY JL, 1988, BRIT J OPHTHALMOL, V72, P881, DOI 10.1136/bjo.72.12.881; Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701; Lichter PR, 2002, ARCH OPHTHALMOL-CHIC, V120, P1371, DOI 10.1001/archopht.120.10.1371; Lichter PR, 2001, OPHTHALMOLOGY, V108, P1943, DOI 10.1016/S0161-6420(01)00873-9; MIGDAL C, 1994, OPHTHALMOLOGY, V101, P1651; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429; WATSON PG, 1981, OPHTHALMOLOGY, V88, P175	12	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2002	288	20					2607	2608						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AL	12444875				2022-12-28	WOS:000179394500030
J	Lassere, M; Johnson, K				Lassere, M; Johnson, K			The power of the protocol	LANCET			English	Editorial Material							GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; TRIALS		St George Hosp, Dept Rheumatol, Kogarah, NSW 2217, Australia; M TAG, Chatswood, NSW, Australia	St George Hospital	Lassere, M (corresponding author), St George Hosp, Dept Rheumatol, Kogarah, NSW 2217, Australia.							Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 2002, INT C HARM TECHN REQ; *ARTHR ADV COMM, 2001, M ARTHR ADV COMM; Boers M, 2002, LANCET, V360, P100, DOI 10.1016/S0140-6736(02)09436-9; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Geis GS, 2002, BRIT MED J, V325, P161; Horton R, 2001, CONTROL CLIN TRIALS, V22, P593, DOI 10.1016/S0197-2456(01)00175-1; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; JUNI P, 2002, BRIT MED J, V325, P161; JUNI P, 2002, BMJ             0709; Meinart CL, 1986, CLIN TRIALS DESIGN C; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247	13	18	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 23	2002	360	9346					1620	1622		10.1016/S0140-6736(02)11652-7	http://dx.doi.org/10.1016/S0140-6736(02)11652-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457782				2022-12-28	WOS:000179393900004
J	Swanson, SJ; Hale, DA; Mannon, RB; Kleiner, DE; Cendales, LC; Chamberlain, CE; Polly, SM; Harlan, DM; Kirk, AD				Swanson, SJ; Hale, DA; Mannon, RB; Kleiner, DE; Cendales, LC; Chamberlain, CE; Polly, SM; Harlan, DM; Kirk, AD			Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy	LANCET			English	Article							TOLERANCE	Renal allograft recipients generally need to take several immunosuppressive agents for life. Calcineurin inhibitors and glucocorticosteroids are the mainstays of most regimens but have undesirable chronic effects. We postulated that aggressive T-cell depletion combined with the newer immunosuppressant sirolimus would permit transplantation without multidrug treatment. We therefore tested T-cell depletion with rabbit antithymocyte globulin followed by sirolimus monotherapy in 12 patients in an open-label study. This approach was tolerated well, and all patients achieved excellent renal function, and most did not need chronic steroid treatment or calcineurin inhibitors. Rejection was typically correlated with low concentrations of sirolimus, indicating continued dependence on maintenance immunosuppression.	Walter Reed Army Med Ctr, Organ Transplant Serv, Washington, DC 20307 USA; NIDDKD, Transplantat & Autoimmun Branch, NIH, Bethesda, MD 20892 USA; NCI, Dept Pharm, Ctr Clin, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kirk, AD (corresponding author), Room 11S-219,Bldg 10,Ctr Dr, Bethesda, MD 20892 USA.		Kleiner, David E/N-2770-2013; Mannon, Roslyn/X-1407-2019; Kirk, Allan D./B-6905-2012; Mannon, Roslyn Bernstein/AIB-6720-2022; Mannon, Roslyn/Q-9740-2019	Kleiner, David E/0000-0003-3442-4453; Mannon, Roslyn/0000-0003-1776-3680; Kirk, Allan/0000-0003-2004-5962	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK062005, Z01DK062008] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Calne R, 1998, LANCET, V351, P1701, DOI 10.1016/S0140-6736(05)77739-4; Gaston RS, 2001, AM J KIDNEY DIS, V38, pS25, DOI 10.1053/ajkd.2001.28923; KIRK AD, 2000, CURR OPIN ORGAN TRAN, V5, P108; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015	5	96	98	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 23	2002	360	9346					1662	1664		10.1016/S0140-6736(02)11606-0	http://dx.doi.org/10.1016/S0140-6736(02)11606-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457792	Green Submitted			2022-12-28	WOS:000179393900014
J	Bignami, GF				Bignami, GF			Gamma-ray astronomy with INTEGRAL	SCIENCE			English	Editorial Material							DISCOVERY; BURST		Univ Pavia, Dipartimento Fis Nucl & Teor, I-27100 Pavia, Italy	University of Pavia	Bignami, GF (corresponding author), Univ Pavia, Dipartimento Fis Nucl & Teor, Via U Bassi 6, I-27100 Pavia, Italy.	bignami@asi.it		Bignami, Giovanni/0000-0001-9582-2450				BIGNAMI GF, 1981, ASTRON ASTROPHYS, V93, P71; Costa E, 1997, NATURE, V387, P783, DOI 10.1038/42885; Gehrels N, 2000, P SOC PHOTO-OPT INS, V4140, P42, DOI 10.1117/12.409142; GEHRELS N, 1993, SCI AM, V269, P68, DOI 10.1038/scientificamerican1293-68; GOLDWURM A, 1992, ASTROPHYS J, V389, pL79, DOI 10.1086/186353; Hartman RC, 1999, ASTROPHYS J SUPPL S, V123, P79, DOI 10.1086/313231; LEISING MD, 1990, ASTROPHYS J, V357, P638, DOI 10.1086/168952; MAHONEY WA, 1984, ASTROPHYS J, V286, P578, DOI 10.1086/162632; MIRABEL IF, 1992, NATURE, V358, P215, DOI 10.1038/358215a0; Tavani M, 2001, AIP CONF PROC, V587, P729; Ubertini P, 2000, AIP CONF PROC, V510, P684; Vedrenne G, 1999, ASTROPHYS LETT COMM, V39, P793	12	0	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1560	1561		10.1126/science.1079330	http://dx.doi.org/10.1126/science.1079330			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446892				2022-12-28	WOS:000179361600031
J	Pellegrini, L; Yu, DS; Lo, T; Anand, S; Lee, M; Blundell, TL; Venkitaraman, AR				Pellegrini, L; Yu, DS; Lo, T; Anand, S; Lee, M; Blundell, TL; Venkitaraman, AR			Insights into DNA recombination from the structure of a RAD51-BRCA2 complex	NATURE			English	Article							BRC REPEATS; CANCER SUSCEPTIBILITY; RAD51 RECOMBINATION; PROTEIN; RECA; EXPRESSION; FILAMENT; EXCHANGE; REPAIR; CELLS	The breast cancer susceptibility protein BRCA2 controls the function of RAD51, a recombinase enzyme, in pathways for DNA repair by homologous recombination. We report here the structure of a complex between an evolutionarily conserved sequence in BRCA2 ( the BRC repeat) and the RecA-homology domain of RAD51. The BRC repeat mimics a motif in RAD51 that serves as an interface for oligomerization between individual RAD51 monomers, thus enabling BRCA2 to control the assembly of the RAD51 nucleoprotein filament, which is essential for strand-pairing reactions during DNA recombination. The RAD51 oligomerization motif is highly conserved among RecA-like recombinases, highlighting a common evolutionary origin for the mechanism of nucleoprotein filament formation, mirrored in the BRC repeat. Cancer-associated mutations that affect the BRC repeat disrupt its predicted interaction with RAD51, yielding structural insight into mechanisms for cancer susceptibility.	Univ Cambridge, CR UK Dept Oncol, Cambridge CB2 2XZ, England; Hutchison MRC Res Ctr, MRC, Canc Cell Unit, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge; University of Cambridge	Venkitaraman, AR (corresponding author), Univ Cambridge, CR UK Dept Oncol, Cambridge CB2 2XZ, England.	arv22@cam.ac.uk	Pellegrini, Luca/AAE-2312-2022; Lee, MiYoung/G-3748-2014	Pellegrini, Luca/0000-0002-9300-497X; 				Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Boggon TJ, 2000, STRUCTURE, V8, pR143, DOI 10.1016/S0969-2126(00)00168-4; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deacon AM, 1998, P NATL ACAD SCI USA, V95, P9284, DOI 10.1073/pnas.95.16.9284; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; MURSHUDOV GN, 1997, ACTA CRYSTALLOGR D, V54, P905; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Warren M, 2002, HUM MOL GENET, V11, P841, DOI 10.1093/hmg/11.7.841; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yu VPCC, 2000, GENE DEV, V14, P1400; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	35	507	527	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	2002	420	6913					287	293		10.1038/nature01230	http://dx.doi.org/10.1038/nature01230			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12442171				2022-12-28	WOS:000179340400034
J	Szabo, P; Scheuring, I; Czaran, T; Szathmary, E				Szabo, P; Scheuring, I; Czaran, T; Szathmary, E			In silico simulations reveal that replicators with limited dispersal evolve towards higher efficiency and fidelity	NATURE			English	Article							DNA-POLYMERASE; CRYSTAL-STRUCTURE; EVOLUTION; POLYMERIZATION; MECHANISMS; LIFE	The emergence of functional replicases, acting quickly and with high accuracy, was crucial to the origin of life(1). Although where the first RNA molecules came from is still unknown, it is nevertheless assumed that catalytic RNA enzymes (ribozymes) with replicase function emerged at some early stage of evolution(1). The fidelity of copying is especially important because the mutation load limits the length of replicating templates that can be maintained by natural selection(2). An increase in template length is disadvantageous for a fixed digit copying fidelity, however, longer molecules are expected to be better replicases. An iteration for longer molecules with better replicase function has been suggested(3,4) and analysed mathematically(5). Here we show that more efficient replicases can spread, provided they are adsorbed to a prebiotic mineral surface. A cellular automaton(6) simulation reveals that copying fidelity, replicase speed and template efficiency all increase with evolution, despite the presence of molecular parasites, essentially because of reciprocal atruism(7) ('within-species mutualism') on the surface(8), thus making a gradual improvement of replicase function more plausible.	Eotvos Lorand Univ, Dept Plant Taxon & Ecol, Res Grp Ecol & Theoret Biol, H-1117 Budapest, Hungary; Int Inst Appl Syst Anal, Adapt Dynam Network, A-2361 Laxenburg, Austria; Collegium Budapest Inst Adv Study, H-1014 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Centre for Agricultural Research; Eotvos Lorand University; International Institute for Applied Systems Analysis (IIASA)	Szathmary, E (corresponding author), Eotvos Lorand Univ, Dept Plant Taxon & Ecol, Res Grp Ecol & Theoret Biol, 1-C Pazmany P Setany, H-1117 Budapest, Hungary.	szathmary@colbud.hu	Szathmáry, Eörs/A-5007-2011; Szathmary, Eors/AAS-1202-2021; Czárán, Tamás/P-4297-2019; Scheuring, Istvan/A-5368-2011; Czárán, Tamás/A-1169-2008	Szathmary, Eors/0000-0001-5227-2997; Czárán, Tamás/0000-0002-2722-6208; Scheuring, Istvan/0000-0002-8108-8897; Czárán, Tamás/0000-0002-2722-6208; Szabo, Peter/0000-0002-0521-3094				BOERLIJST MC, 1991, PHYSICA D, V48, P17, DOI 10.1016/0167-2789(91)90049-F; Czaran T, 2000, GEOMETRY ECOLOGICAL, P116, DOI 10.1613/jair.301; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; Ferris JP, 1996, NATURE, V381, P59, DOI 10.1038/381059a0; Florentz Catherine, 1995, P141; GALAS DJ, 1978, J MOL BIOL, V124, P653, DOI 10.1016/0022-2836(78)90176-6; Goodman MF, 1998, GENETICS, V148, P1475; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; James KD, 1999, ORIGINS LIFE EVOL B, V29, P375, DOI 10.1023/A:1006544611320; Johnston WK, 2001, SCIENCE, V292, P1319, DOI 10.1126/science.1060786; Joyce G. F., 1993, COLD SPRING HARB SYM, V24, P49; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Luther A, 1998, NATURE, V396, P245, DOI 10.1038/24343; NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0; Orgel LE, 1998, ORIGINS LIFE EVOL B, V28, P227, DOI 10.1023/A:1006595411403; Poole A, 1999, BIOESSAYS, V21, P880, DOI 10.1002/(SICI)1521-1878(199910)21:10<880::AID-BIES11>3.0.CO;2-P; Scheuring I, 2000, SELECTION, V1, P135; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; SZATHMARY E, 1987, J THEOR BIOL, V128, P463, DOI 10.1016/S0022-5193(87)80191-1; SZATHMARY E, 1993, J THEOR BIOL, V164, P447, DOI 10.1006/jtbi.1993.1166; TOFFOLI T, 1987, CELLULAR AUTOMATA MA, P155; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; von Kiedrowski G., 2000, SELECTION, V1, P173, DOI DOI 10.1556/SELECT.1.2000.1-3.17); vonKiedrowski G, 1996, NATURE, V381, P20, DOI 10.1038/381020a0; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wolfram S., 2002, NEW KIND SCI	27	107	108	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					340	343		10.1038/nature01187	http://dx.doi.org/10.1038/nature01187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447445				2022-12-28	WOS:000179340400048
J	[Anonymous]				[Anonymous]			Physics guidelines drop equal-responsibility clause	NATURE			English	News Item																		2002, NATURE, V419, P419	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	2002	420	6913					258	258		10.1038/420258b	http://dx.doi.org/10.1038/420258b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447408	Bronze			2022-12-28	WOS:000179340400009
J	Morales, CP; Souza, RF; Spechler, SJ				Morales, CP; Souza, RF; Spechler, SJ			Hallmarks of cancer progression in Barrett's oesophagus	LANCET			English	Review							INCREASED EXPRESSION; E-CADHERIN; DYSPLASIA; ADENOCARCINOMA; METAPLASIA; APOPTOSIS; HYPERMETHYLATION; ANGIOGENESIS; EPITHELIUM; ADHESION		Vet Adm Med Ctr, Gastroenterol Div 111B1, Dept Med, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Morales, CP (corresponding author), Vet Adm Med Ctr, Gastroenterol Div 111B1, Dept Med, Dallas, TX 75216 USA.	cpmoral@swbell.net						Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Auvinen MI, 2002, J CLIN ONCOL, V20, P2971, DOI 10.1200/JCO.2002.09.011; Bailey T, 1998, AM J PATHOL, V152, P135; BRITO MJ, 1995, INT J CANCER, V60, P27, DOI 10.1002/ijc.2910600103; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Coppola D, 1997, LAB INVEST, V76, P298; Couvelard A, 2000, J PATHOL, V192, P14; Eads CA, 2000, CANCER RES, V60, P5021; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HAMELIN R, 1994, GASTROENTEROLOGY, V107, P1012, DOI 10.1016/0016-5085(94)90225-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; JANKOWSKI J, 1993, AM J GASTROENTEROL, V88, P402; Jankowski JA, 2002, GASTROENTEROLOGY, V122, P588, DOI 10.1053/gast.2002.31599; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Klump B, 1998, GASTROENTEROLOGY, V115, P1381, DOI 10.1016/S0016-5085(98)70016-2; Lord RVN, 2000, J GASTROINTEST SURG, V4, P135, DOI 10.1016/S1091-255X(00)80049-9; Morales CP, 1998, CANCER, V83, P652, DOI 10.1002/(SICI)1097-0142(19980815)83:4<652::AID-CNCR4>3.0.CO;2-M; Reid BJ, 2000, AM J GASTROENTEROL, V95, P1669, DOI 10.1111/j.1572-0241.2000.02196.x; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shureiqi I, 2001, CANCER RES, V61, P4879; Souza RF, 2001, ALIMENT PHARM THER, V15, P1087, DOI 10.1046/j.1365-2036.2001.01046.x; Spechler SJ, 2002, NEW ENGL J MED, V346, P836, DOI 10.1056/NEJMcp012118; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SWAMI S, 1995, AM J GASTROENTEROL, V90, P1808; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wijnhoven BPL, 2001, ANN SURG, V233, P322, DOI 10.1097/00000658-200103000-00005; Wilson KT, 1998, CANCER RES, V58, P2929; Younes M, 2000, HUM PATHOL, V31, P434, DOI 10.1053/hp.2000.6715; YOUNES M, 1993, GASTROENTEROLOGY, V105, P1637, DOI 10.1016/0016-5085(93)91058-P	30	115	117	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2002	360	9345					1587	1589		10.1016/S0140-6736(02)11569-8	http://dx.doi.org/10.1016/S0140-6736(02)11569-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443613				2022-12-28	WOS:000179292400031
J	Egorov, AV; Hamam, BN; Fransen, E; Hasselmo, ME; Alonso, AA				Egorov, AV; Hamam, BN; Fransen, E; Hasselmo, ME; Alonso, AA			Graded persistent activity in entorhinal cortex neurons	NATURE			English	Article							MEMORY; HIPPOCAMPAL; CONNECTIONS; RESPONSES; CHANNELS; NETWORK; MONKEY; CA1	Working memory represents the ability of the brain to hold externally or internally driven information for relatively short periods of time(1,2). Persistent neuronal activity is the elementary process underlying working memory but its cellular basis remains unknown. The most widely accepted hypothesis is that persistent activity is based on synaptic reverberations in recurrent circuits. The entorhinal cortex in the parahippocampal region is crucially involved in the acquisition, consolidation and retrieval of long-term memory traces for which working memory operations are essential(2). Here we show that individual neurons from layer V of the entorhinal cortex-which link the hippocampus to extensive cortical regions(3)-respond to consecutive stimuli with graded changes in firing frequency that remain stable after each stimulus presentation. In addition, the sustained levels of firing frequency can be either increased or decreased in an input-specific manner. This firing behaviour displays robustness to distractors; it is linked to cholinergic muscarinic receptor activation, and relies on activity-dependent changes of a Ca2+-sensitive cationic current. Such an intrinsic neuronal ability to generate graded persistent activity constitutes an elementary mechanism for working memory.	Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal, PQ H3A 2B4, Canada; Royal Inst Technol, Dept Numer Anal & Comp Sci, S-10044 Stockholm, Sweden; Boston Univ, Dept Psychol, Program Neurosci, Boston, MA 02215 USA; Boston Univ, Ctr Memory & Brain, Boston, MA 02215 USA	McGill University; McGill University; Royal Institute of Technology; Boston University; Boston University	Alonso, AA (corresponding author), Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	angel.alonso@mcgill.ca		Egorov, Alexei/0000-0003-4899-8407; Hasselmo, Michael/0000-0002-9925-6377				ALONSO JR, 1995, J COMP NEUROL, V355, P135, DOI 10.1002/cne.903550202; ANDRADE R, 1991, BRAIN RES, V548, P81, DOI 10.1016/0006-8993(91)91109-E; BOEIJINGA PH, 1989, BRAIN RES, V478, P257, DOI 10.1016/0006-8993(89)91506-0; BUNSEY M, 1993, BEHAV NEUROSCI, V107, P740, DOI 10.1037/0735-7044.107.5.740; Dickson CT, 1997, J NEUROSCI, V17, P6729; Fransen E, 2002, J NEUROSCI, V22, P1081, DOI 10.1523/JNEUROSCI.22-03-01081.2002; Fraser DD, 1996, J NEUROSCI, V16, P4113; Fuster JM, 1997, TRENDS NEUROSCI, V20, P451, DOI 10.1016/S0166-2236(97)01128-4; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; Haj-Dahmane S, 1998, J NEUROPHYSIOL, V80, P1197, DOI 10.1152/jn.1998.80.3.1197; Hamam BN, 2000, J COMP NEUROL, V418, P457; Hasselmo ME, 1999, TRENDS COGN SCI, V3, P351, DOI 10.1016/S1364-6613(99)01365-0; Higuchi S, 1996, P NATL ACAD SCI USA, V93, P739, DOI 10.1073/pnas.93.2.739; Insausti R, 1997, HIPPOCAMPUS, V7, P146, DOI 10.1002/(SICI)1098-1063(1997)7:2<146::AID-HIPO4>3.0.CO;2-L; INSAUSTI R, 1987, J COMP NEUROL, V264, P356, DOI 10.1002/cne.902640306; Klink R, 1997, J NEUROPHYSIOL, V77, P1813, DOI 10.1152/jn.1997.77.4.1813; KRNJEVIC K, 1993, PROG BRAIN RES, V98, P285; Lisman JE, 1998, NAT NEUROSCI, V1, P273, DOI 10.1038/1086; Marder E, 1996, P NATL ACAD SCI USA, V93, P13481, DOI 10.1073/pnas.93.24.13481; Naber PA, 2001, HIPPOCAMPUS, V11, P99, DOI 10.1002/hipo.1028; Partridge LD, 2000, BRAIN RES, V867, P143, DOI 10.1016/S0006-8993(00)02275-7; Rempel-Clower NL, 2000, CEREB CORTEX, V10, P851, DOI 10.1093/cercor/10.9.851; ROOM P, 1986, J COMP NEUROL, V251, P415, DOI 10.1002/cne.902510402; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Seung HS, 2000, NEURON, V26, P259, DOI 10.1016/S0896-6273(00)81155-1; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Stern CE, 2001, HIPPOCAMPUS, V11, P337; Suzuki WA, 1997, J NEUROPHYSIOL, V78, P1062, DOI 10.1152/jn.1997.78.2.1062; Wang XJ, 2001, TRENDS NEUROSCI, V24, P455, DOI 10.1016/S0166-2236(00)01868-3; Young BJ, 1997, J NEUROSCI, V17, P5183	30	564	572	3	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					173	178		10.1038/nature01171	http://dx.doi.org/10.1038/nature01171			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432392				2022-12-28	WOS:000179200900045
J	Harding, GKM; Zhanel, GG; Nicolle, LE; Cheang, M				Harding, GKM; Zhanel, GG; Nicolle, LE; Cheang, M		Manitoba Diabet Urinary Tract Infe	Antimicrobial treatment in diabetic women with asymptomatic bacteriuria.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URINARY-TRACT-INFECTION; RISK-FACTORS; PYELONEPHRITIS; SPECTRUM; ABSCESS; GAS	Background: Asymptomatic bacteriuria is common among women with diabetes, and the treatment of such infections has been recommended to prevent complications related to symptomatic urinary tract infection. Methods: We enrolled women (>16 years of age) with diabetes, bacteriuria (greater/equal 10(sup 5) colony-forming units of an organism per milliliter in cultures of two consecutive urine specimens), and no urinary symptoms; 50 were randomly assigned to receive placebo and 55 to receive antimicrobial therapy. For the first six weeks, which included the initial course of treatment, the study was placebo-controlled and double-blind. Subsequently, the women were screened for bacteriuria every three months for up to three years; antimicrobial therapy was provided to women in the antimicrobial-therapy group who had asymptomatic bacteriuria. Results: Four weeks after the end of the initial course of therapy, 78 percent of placebo recipients had bacteriuria, as compared with 20 percent of women who received antimicrobial agents (P<0.001). During a mean follow-up of 27 months, 20 of 50 women in the placebo group (40 percent) and 23 of 55 women in the antimicrobial-therapy group (42 percent) had at least one episode of symptomatic urinary tract infection. The time to a first symptomatic episode was similar in the placebo group and the antimicrobial-therapy group (P=0.67 by the log-rank test), as were the (+/-SD) rates of any symptomatic urinary tract infection (1.10+/-0.17 and 0.93+/-0.14 per 1000 days of follow-up, respectively; relative risk, 1.19; 95 percent confidence interval, 0.28 to 1.81), pyelonephritis (0.28+/-0.08 and 0.13+/-0.05 per 1000 days of follow-up; relative risk, 2.13; 95 percent confidence interval, 0.81 to 5.62), and hospitalization for urinary tract infection (0.10+/-0.36 and 0.06+/-0.22 per 1000 days of follow-up; relative risk, 1.93; 95 percent confidence interval, 0.47 to 7.89). The women in the antimicrobial-therapy group had almost five times as many days of antibiotic use for urinary tract infection as did the women in the placebo group (158.2+/-1.7 vs. 33.7+/-0.91 per 1000 days of follow-up; relative risk, 0.21; 95 percent confidence interval, 0.20 to 0.22). Conclusions: Treatment of asymptomatic bacteriuria in women with diabetes does not appear to reduce complications. Diabetes itself should not be an indication for screening for or treatment of asymptomatic bacteriuria.	Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada; Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	Nicolle, LE (corresponding author), Hlth Sci Ctr, Dept Internal Med, GG443 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lnicolle@hsc.mb.ca						ABRUTYN E, 1994, ANN INTERN MED, V121, P901, DOI 10.7326/0003-4819-121-11-199412010-00028; ABRUTYN E, 1994, ANN INTERN MED, V120, P827, DOI 10.7326/0003-4819-120-10-199405150-00003; [Anonymous], 1990, AM FAM PHYSICIAN, V42, P389; Best CD, 1999, J UROLOGY, V162, P1273, DOI 10.1016/S0022-5347(05)68263-8; CARDENAS DD, 1995, ARCH PHYS MED REHAB, V76, P272, DOI 10.1016/S0003-9993(95)80615-6; Carton J A, 1992, Eur J Med, V1, P281; EDELSTEIN H, 1988, MEDICINE, V67, P118, DOI 10.1097/00005792-198803000-00005; ELLENBOGEN P H, 1976, Urology, V8, P413, DOI 10.1016/0090-4295(76)90505-7; EVANOFF GV, 1987, AM J MED, V83, P149, DOI 10.1016/0002-9343(87)90511-0; FOXMAN B, 1990, AM J PUBLIC HEALTH, V80, P331, DOI 10.2105/AJPH.80.3.331; Geerlings SE, 2000, DIABETES CARE, V23, P1737, DOI 10.2337/diacare.23.12.1737; Geerlings SE, 2001, ARCH INTERN MED, V161, P1421, DOI 10.1001/archinte.161.11.1421; Hansson S, 1997, INFECT DIS CLIN N AM, V11, P499, DOI 10.1016/S0891-5520(05)70370-6; HARDING GKM, 1974, NEW ENGL J MED, V291, P597, DOI 10.1056/NEJM197409192911203; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; Nicolle L E, 1987, Infect Dis Clin North Am, V1, P793; Nicolle LE, 1996, CLIN INFECT DIS, V22, P1051, DOI 10.1093/clinids/22.6.1051; NICOLLE LE, 1983, NEW ENGL J MED, V309, P1420, DOI 10.1056/NEJM198312083092304; NICOLLE LE, 1987, AM J MED, V83, P27, DOI 10.1016/0002-9343(87)90493-1; Nicolle LE, 1994, CANADIAN GUIDE PREVE, P100; Patterson JE, 1997, INFECT DIS CLIN N AM, V11, P735, DOI 10.1016/S0891-5520(05)70383-4; QUINT HJ, 1992, J UROLOGY, V147, P134, DOI 10.1016/S0022-5347(17)37160-4; RUBIN RH, 1992, CLIN INFECT DIS, V15, pS216, DOI 10.1093/clind/15.Supplement_1.S216; Snydman DR, 2001, CLIN INFECT DIS, V33, pS22, DOI 10.1086/320900; Stein G, 1999, NEPHROL DIAL TRANSPL, V14, P1618, DOI 10.1093/ndt/14.7.1618; ZHANEL GG, 1991, REV INFECT DIS, V13, P150; ZHANEL GG, 1995, CLIN INFECT DIS, V21, P316, DOI 10.1093/clinids/21.2.316	27	146	153	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2002	347	20					1576	1583		10.1056/NEJMoa021042	http://dx.doi.org/10.1056/NEJMoa021042			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614KL	12432044				2022-12-28	WOS:000179187800005
J	Stixrude, L; Peacor, DR				Stixrude, L; Peacor, DR			First-principles study of illite-smectite and implications for clay mineral systems	NATURE			English	Article							INTERPARTICLE DIFFRACTION; MECHANISMS; RECTORITE; DIAGENESIS; SANDSTONES; ZONE	Illite-smectite interstratified clay minerals are ubiquitous in sedimentary basins and they have been linked to the maturation, migration and trapping of hydrocarbons(1), rock cementation(2), evolution of porewater chemistry during diagenesis(3) and the development of pore pressure(4). But, despite the importance of these clays, their structures are controversial. Two competing models exist, each with profoundly different consequences for the understanding of diagenetic processes: model A views such interstratified clays as a stacking of layers identical to endmember illite and smectite layers, implying discrete and independently formed units (fundamental particles)(5), whereas model B views the clays as composed of crystallites with a unique structure that maintains coherency over much greater distances, in line with local charge balance about interlayers(6). Here we use first-principles density-functional theory to explore the energetics and structures of these two models for an illite-smectite interstratified clay mineral with a ratio of 1:1 and a Reichweite parameter of 1. We find that the total energy of model B is 2.3 kJ atom(-1) mol(-1) lower than that of model A, and that this energy difference can be traced to structural distortions in model A due to local charge imbalance. The greater stability of model B requires re-evaluation of the evolution of the smectite-to-illite sequence of clay minerals, including the nature of coexisting species, stability relations, growth mechanisms and the model of fundamental particles.	Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Stixrude, L (corresponding author), Univ Michigan, Dept Geol Sci, 1006 CC Little Bldg, Ann Arbor, MI 48109 USA.		Stixrude, Lars/C-5625-2012	Stixrude, Lars/0000-0003-3778-2432				AHN JH, 1986, CLAY CLAY MINER, V34, P165; ALTANER SP, 1988, NATURE, V331, P699, DOI 10.1038/331699a0; Altaner SP, 1997, CLAY CLAY MINER, V45, P517, DOI 10.1346/CCMN.1997.0450404; Benincasa E, 2001, CLAY MINER, V36, P421, DOI 10.1180/000985501750539508; BERMAN RG, 1988, J PETROL, V29, P445, DOI 10.1093/petrology/29.2.445; BETHKE CM, 1986, J GEOPHYS RES-SOLID, V91, P6535, DOI 10.1029/JB091iB06p06535; BOLES JR, 1979, J SEDIMENT PETROL, V49, P55; BROWN G, 1984, PHILOS T R SOC A, V311, P221, DOI 10.1098/rsta.1984.0025; Brown KM, 2001, EARTH PLANET SC LETT, V194, P97, DOI 10.1016/S0012-821X(01)00546-5; Dong HL, 1997, AM MINERAL, V82, P379; Eberl DD, 1998, AM J SCI, V298, P499, DOI 10.2475/ajs.298.6.499; Essene EJ, 1995, CLAY CLAY MINER, V43, P540, DOI 10.1346/CCMN.1995.0430504; HOWER J, 1976, GEOL SOC AM BULL, V87, P725, DOI 10.1130/0016-7606(1976)87<725:MOBMOA>2.0.CO;2; JAKOBSEN HJ, 1995, AM MINERAL, V80, P247; Kasama T, 2001, AM MINERAL, V86, P105; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; MONKHORST HJ, 1976, PHYS REV B, V13, P5188, DOI 10.1103/PhysRevB.16.1746; NADEAU PH, 1985, MINERAL MAG, V49, P393, DOI 10.1180/minmag.1985.049.352.10; NADEAU PH, 1984, CLAY MINER, V19, P757, DOI 10.1180/claymin.1984.019.5.06; NADEAU PH, 1984, SCIENCE, V225, P923, DOI 10.1126/science.225.4665.923; ROBINSON K, 1971, SCIENCE, V172, P567, DOI 10.1126/science.172.3983.567; ROSSMAN GR, 1984, REV MINERAL, V13, P145; Rothbauer Von R, 1971, NEUES JB MINERALOGIE, V1971, P143; Schroeder PA, 1998, CLAY MINER, V33, P671; SHAU YH, 1990, CONTRIB MINERAL PETR, V105, P123, DOI 10.1007/BF00678980; Smyth J.R., 1988, CRYSTAL STRUCTURES C; SRODON J, 1986, CLAY CLAY MINER, V34, P368, DOI 10.1346/CCMN.1986.0340403; Srodon J, 1999, ANNU REV EARTH PL SC, V27, P19, DOI 10.1146/annurev.earth.27.1.19; STIXRUDE L, IN PRESS J GEOPHYS R; Weaver CE., 1960, AM ASSOC PETR GEOL B, V44, P1505	30	82	86	6	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					165	168		10.1038/nature01155	http://dx.doi.org/10.1038/nature01155			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432389	Green Published			2022-12-28	WOS:000179200900042
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Serv Task Force	Screening for prostate cancer: Recommendation and rationale	ANNALS OF INTERNAL MEDICINE			English	Article								This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendations on screening for prostate cancer and updates the 1996 recommendations on this topic. The complete USPSTF recommendation and rationale statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358- 9295; e-mail, ahrqpubs@ahrq.gov). The complete information on which this statement is based, including tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned.	Univ Washington, Seattle, WA 98195 USA; Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA; Univ Rochester, Sch Med, Rochester, NY 14627 USA; Natl Initiat Childrens Healthcare Qual, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Harvard Univ Pilgrim Hlth Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA; Robert Wood Johnson Fdn, Princeton, NJ 08540 USA; Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA; Univ Michigan, Ann Arbor, MI 48109 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Merck & Co Inc, West Point, PA USA; Columbia Univ, New York, NY 10032 USA; Virginia Commonwealth Univ, Fairfax, VA USA	University of Washington; University of Washington Seattle; University System of Maryland; University of Maryland Baltimore; University of Rochester; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Harvard University; Harvard Medical School; University of Texas System; University of Texas Health San Antonio; Robert Wood Johnson Foundation (RWJF); Women & Infants Hospital Rhode Island; University of Michigan System; University of Michigan; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Merck & Company; Columbia University; Virginia Commonwealth University	Berg, AO (corresponding author), Univ Washington, Seattle, WA 98195 USA.							*AM AC FAM PHYS, 2002, PER HLTH EX REV 5 3; *AM CANC SOC, 2001, CA-CANCER J CLIN, V51, P38; *AM MED ASS, 2001, REP 9 COUNC SCI AFF; *AM UR ASS AUA, 2002, ONCOLOGY, V14, P2167; *CAN TASK FORC PRE, 2002, SCREEN PROST CANC; Coley CM, 1997, ANN INTERN MED, V126, P480; Harris R, 2002, ANN INTERN MED, V137, P917, DOI 10.7326/0003-4819-137-11-200212030-00014; HARRIS RP, 2001, 290970011 U N CAR EV	8	152	154	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					915	916		10.7326/0003-4819-137-11-200212030-00013	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622GY	12458992				2022-12-28	WOS:000179639700007
J	Chan, ED; Iseman, MD				Chan, ED; Iseman, MD			Current medical treatment for tuberculosis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DIRECTLY OBSERVED THERAPY; SELF-ADMINISTERED THERAPY; MYCOBACTERIUM-TUBERCULOSIS; RESISTANT TUBERCULOSIS; PREVENTIVE THERAPY; COST-EFFECTIVENESS; PYRAZINAMIDE; PULMONARY; EPIDEMIOLOGY; SURVEILLANCE		Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	National Jewish Health	Chan, ED (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, K613E,1400 Jackson St, Denver, CO 80206 USA.	chane@njc.org			NHLBI NIH HHS [R01 HL066112, R01-HL66112-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066112] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM LUNG ASS, 2002, AM LUNG ASS FACT SHE; *AM THOR SOC, 2001, AM J RESP CRIT CARE, V164, P1319; Ass J.B. Jr., 1994, AM J RESP CRIT CARE, V149, P1359; BARNES PF, 1988, J INFECT DIS, V158, P366, DOI 10.1093/infdis/158.2.366; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Burman WJ, 1997, CHEST, V112, P57, DOI 10.1378/chest.112.1.57; Burman WJ, 1997, CHEST, V112, P63, DOI 10.1378/chest.112.1.63; BURWEN DR, 1995, ARCH INTERN MED, V155, P1281, DOI 10.1001/archinte.155.12.1281; CANTWELL MF, 1992, JAMA-J AM MED ASSOC, V272, P535; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P921; *CDC, 1994, COR CURR TUB 1994; *CDCP, 2000, REP TUB US 2000; *CDCP AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P185; Chaulk CP, 1998, JAMA-J AM MED ASSOC, V279, P943, DOI 10.1001/jama.279.12.943; Chaulk CP, 2000, INT J TUBERC LUNG D, V4, P201; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; Corbett EL, 2002, LANCET, V359, P2177, DOI 10.1016/S0140-6736(02)09095-5; DAVID HL, 1970, APPL MICROBIOL, V20, P810, DOI 10.1128/AEM.20.5.810-814.1970; Girling D. J., 1991, American Review of Respiratory Disease, V143, P700; *HONG KONG CHEST S, 1979, TUBERCLE, V60, P201; HORN DL, 1994, NEW ENGL J MED, V330, P1241, DOI 10.1056/NEJM199404283301718; Iseman MD, 2000, RESURG EMERGING INFE, V1, P175; Iseman MD, 1999, CLIN GUIDE TUBERCULO; ISEMAN MD, 2002, IN PRESS EUR RESP J; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; MITCHISON DA, 1998, MYCOBACTERIA, V2, P15; Moore RD, 1996, AM J RESP CRIT CARE, V154, P1013, DOI 10.1164/ajrccm.154.4.8887600; NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2; Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001; NUNN P, 1991, LANCET, V337, P627; Onyebujoh PC, 1999, LANCET, V354, P116, DOI 10.1016/S0140-6736(98)10448-8; Ormerod P, 2000, THORAX, V55, P887; PASSANNANTE MR, 1994, CHEST, V106, P431, DOI 10.1378/chest.106.2.431; Peloquin CA, 1996, ANN PHARMACOTHER, V30, P919, DOI 10.1177/106002809603000901; Pulido F, 1997, ARCH INTERN MED, V157, P227, DOI 10.1001/archinte.157.2.227; Raviglione MC, 2002, LANCET, V359, P775, DOI 10.1016/S0140-6736(02)07880-7; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; Ridzon R, 1997, CLIN INFECT DIS, V24, P1264, DOI 10.1093/clinids/24.6.1264; Sbarbaro J A, 1994, Semin Respir Infect, V9, P120; Sbarbaro JA, 1996, TUBERCLE LUNG DIS, V77, P491, DOI 10.1016/S0962-8479(96)90045-3; Schwoebel V, 2000, EUR RESPIR J, V16, P364, DOI 10.1034/j.1399-3003.2000.16b28.x; Wagner KR, 2001, AIDS, V15, pS203, DOI 10.1097/00002030-200100005-00024; *WHO, 2002, WHO REP 2002 GLOB TU	46	110	120	2	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	2002	325	7375					1282	1286		10.1136/bmj.325.7375.1282	http://dx.doi.org/10.1136/bmj.325.7375.1282			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458250	Green Published			2022-12-28	WOS:000179696300021
J	Levinger, NE				Levinger, NE			Water in confinement	SCIENCE			English	Editorial Material							AQUEOUS REVERSE MICELLES; MOLECULAR SIMULATION; SOLVATION DYNAMICS; LIQUID WATER; SOLVENTS; SIZE		Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA	Colorado State University	Levinger, NE (corresponding author), Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.							Boyd JE, 2002, J PHYS CHEM B, V106, P6346, DOI 10.1021/jp0255740; Boyd JE, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.147401; Bursing H, 2001, PHYS CHEM CHEM PHYS, V3, P2378, DOI 10.1039/b009301g; DE TK, 1995, ADV COLLOID INTERFAC, V59, P95, DOI 10.1016/0001-8686(95)80005-N; Faeder J, 2000, J PHYS CHEM B, V104, P1033, DOI 10.1021/jp993076u; Faeder J, 2001, J PHYS CHEM B, V105, P11148, DOI 10.1021/jp010632n; Luisi P.L., 1984, REVERSE MICELLES BIO; OWRUTSKY JC, 1991, CHEM PHYS LETT, V184, P368, DOI 10.1016/0009-2614(91)80002-F; Pileni MP, 1997, BER BUNSEN PHYS CHEM, V101, P1578, DOI 10.1002/bbpc.19971011105; Salaniwal S, 1999, LANGMUIR, V15, P5188, DOI 10.1021/la9904556; Salaniwal S, 2001, LANGMUIR, V17, P1773, DOI 10.1021/la000554f; Senapati S, 2002, LANGMUIR, V18, P7371, DOI 10.1021/la025952s; Silber JJ, 1999, ADV COLLOID INTERFAC, V82, P189, DOI 10.1016/S0001-8686(99)00018-4; Venables DS, 2001, J PHYS CHEM B, V105, P9132, DOI 10.1021/jp0112065; Zhong Q, 2002, LANGMUIR, V18, P7401, DOI 10.1021/la0260234	15	282	284	1	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1722	1723		10.1126/science.1079322	http://dx.doi.org/10.1126/science.1079322			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459570				2022-12-28	WOS:000179494800023
J	Ashley, SW; Lauwers, GY; Maher, MM; Baker, GP; Colvin, RB				Ashley, SW; Lauwers, GY; Maher, MM; Baker, GP; Colvin, RB			A 69-year-old man with painful cutaneous nodules, elevated lipase levels, and abnormal results on abdominal scanning - Acinar-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SUBCUTANEOUS FAT NECROSIS; RAS; PANCREAS; MUTATION		Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ashley, SW (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.							Abraham SC, 2002, AM J PATHOL, V160, P953, DOI 10.1016/S0002-9440(10)64917-6; Ashley Stanley W., 1993, P913; BOLOGNIA JL, 1998, HARRISONS PRINCIPLES, V1, P310; BURNS WA, 1974, CANCER, V33, P1002, DOI 10.1002/1097-0142(197404)33:4<1002::AID-CNCR2820330415>3.0.CO;2-R; CHIARI H, 1983, PRAG MED WOCHENSCHR, V8, P299; Chiari H, 1883, PRAG NED WOCHENSCHR, V8, P285; Cubilla AL, 1984, ATLAS TUMOR PATHOLOG; DHAWAN SS, 1990, AM J GASTROENTEROL, V85, P1025; GOOD AE, 1976, AM J DIG DIS, V21, P978, DOI 10.1007/BF01071911; HELGER C, 1930, VIRCHOWS ARCH PATHOL, V274, P784; Heykarts B, 1999, DERMATOLOGY, V198, P182, DOI 10.1159/000018107; HOORENS A, 1993, AM J PATHOL, V143, P685; IMMELMAN EJ, 1964, AM J MED, V36, P96, DOI 10.1016/0002-9343(64)90152-4; KLIMSTRA DS, 1992, AM J SURG PATHOL, V16, P815, DOI 10.1097/00000478-199209000-00001; Kloppel G., 1993, PANCREAS, P871; MACMAHON HE, 1965, GASTROENTEROLOGY, V49, P555; MULLIN GT, 1968, ANN INTERN MED, V68, P75, DOI 10.7326/0003-4819-68-1-75; MURPHY GF, 1999, ROBBINS PATHOLOGIC B, P1170; PELLEGATA NS, 1994, CANCER RES, V54, P1556; POTTS DE, 1975, AM J MED, V58, P417, DOI 10.1016/0002-9343(75)90608-7; RADIN DR, 1986, RADIOLOGY, V158, P67, DOI 10.1148/radiology.158.1.3940400; Rigaud G, 2000, INT J CANCER, V88, P772; ROBERTSON JC, 1970, BMJ-BRIT MED J, V2, P708, DOI 10.1136/bmj.2.5711.708; SCHMID M, 1957, Z KLIN MED, V154, P439; TANNENBAUM H, 1975, J RHEUMATOL, V2, P14; Taruscio D, 2000, GENE CHROMOSOME CANC, V28, P294, DOI 10.1002/1098-2264(200007)28:3<294::AID-GCC7>3.0.CO;2-N; TERHUNE PG, 1994, MOL CARCINOGEN, V10, P110, DOI 10.1002/mc.2940100209; Terhune PG, 1998, PANCREAS, V16, P6, DOI 10.1097/00006676-199801000-00002; WEBB JN, 1977, J CLIN PATHOL, V30, P103, DOI 10.1136/jcp.30.2.103; ZELLER M, 1966, J AMER MED ASSOC, V195, P869, DOI 10.1001/jama.1966.03100100121045	30	20	20	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1783	1791		10.1056/NEJMcpc020019	http://dx.doi.org/10.1056/NEJMcpc020019			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456855				2022-12-28	WOS:000179468600009
J	Sheetz, MJ; King, GL				Sheetz, MJ; King, GL			Molecular understanding of hyperglycemia's adverse effects for diabetic complications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PROTEIN-KINASE-C; ENDOTHELIAL GROWTH-FACTOR; GLYCATION END-PRODUCTS; NERVE-CONDUCTION-VELOCITY; ALDOSE REDUCTASE INHIBITOR; EPITHELIUM-DERIVED FACTOR; VITAMIN-E SUPPLEMENTATION; ELEVATED GLUCOSE-LEVELS; NITRIC-OXIDE SYNTHASE; PKC-BETA INHIBITOR	Diabetic complications are the major cause of morbidity and mortality in persons with diabetes. Chronic hyperglycemia is a major initiator of diabetic microvascular complications (eg, retinopathy, neuropathy, nephropathy). Glucose,processing uses a variety of diverse metabolic pathways; hence, chronic hyperglycemia can induce multiple cellular changes leading to complications. Several predominant well-researched theories have been proposed to explain how hyperglycemia can produce the neural and vascular derangements that a re hallmarks of diabetes. These theories can be separated into those that emphasize the toxic effects of hyperglycemia and its pathophysiological derivatives (such as oxidants,,hyperosmolarity, or glycation products) on tissues directly and those that ascribe pathophysiological importance to a sustained alteration in cell signaling pathways (such as changes in phospholipids or kinases) induced by the products of glucose metabolism. This article summarizes these theories and the potential therapeutic interventions that may prevent diabetic complications in the presence of hyperglycemia, control of which is often difficult with current therapeutic options.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Lilly Res Labs, Indianapolis, IN USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Eli Lilly	King, GL (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl,Room 4504, Boston, MA 02215 USA.	george.king@joslin.harvard.edu	Mordwinkin, Nicholas M/A-4347-2010		NATIONAL EYE INSTITUTE [R01EY005110] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY05110] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aiello LP, 1996, ENDOCRIN METAB CLIN, V25, P271, DOI 10.1016/S0889-8529(05)70325-X; Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Araki S, 2000, DIABETOLOGIA, V43, P1540, DOI 10.1007/s001250051566; ASAHINA T, 1995, DIABETES, V44, P520, DOI 10.2337/diabetes.44.5.520; Babazono T, 1998, DIABETES, V47, P668, DOI 10.2337/diabetes.47.4.668; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Bohlen HG, 2001, AM J PHYSIOL-HEART C, V280, pH621, DOI 10.1152/ajpheart.2001.280.2.H621; BOLLINENI JS, 1993, DIABETES, V42, P1673, DOI 10.2337/diabetes.42.11.1673; BOULTON AJM, 1997, TXB DIABETES, P1; Bravi MC, 1997, METABOLISM, V46, P1194, DOI 10.1016/S0026-0495(97)90216-X; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; Bursell SE, 1996, INVEST OPHTH VIS SCI, V37, P886; Bursell SE, 1999, DIABETES CARE, V22, P1245, DOI 10.2337/diacare.22.8.1245; Buschhausen L, 2001, CARDIOVASC RES, V51, P463, DOI 10.1016/S0008-6363(01)00340-6; Cameron NE, 1996, J PHARMACOL EXP THER, V278, P1262; CAMERON NE, 1994, DIABETOLOGIA, V37, P449, DOI 10.1007/s001250050131; CAMERON NE, 1986, DIABETOLOGIA, V29, P168, DOI 10.1007/BF02427088; CAMERON NE, 1995, J CLIN INVEST, V96, P1159, DOI 10.1172/JCI118104; Cameron NE, 2001, DIABETOLOGIA, V44, P1973, DOI 10.1007/s001250100001; Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H; Chen SL, 2000, LAB INVEST, V80, P1311, DOI 10.1038/labinvest.3780139; Chibber R, 1999, CELL MOL BIOL, V45, P47; Cooper ME, 1999, DIABETES, V48, P2229, DOI 10.2337/diabetes.48.11.2229; CRAVEN PA, 1987, METABOLISM, V36, P95, DOI 10.1016/0026-0495(87)90070-9; Craven PA, 2001, DIABETES, V50, P2114, DOI 10.2337/diabetes.50.9.2114; Danis RP, 1998, INVEST OPHTH VIS SCI, V39, P171; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dekker LV, 2000, BIOCHEM J, V347, P285, DOI 10.1042/0264-6021:3470285; Devaraj S, 2001, CLIN CHEM, V47, P1974; DYCK PJ, 1985, P NATL ACAD SCI USA, V82, P2513, DOI 10.1073/pnas.82.8.2513; DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817; Dyck PJ, 1996, J NEUROPATH EXP NEUR, V55, P1181, DOI 10.1097/00005072-199612000-00001; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; Evans K, 1996, BRIT J OPHTHALMOL, V80, P763, DOI 10.1136/bjo.80.8.763; Fortune B, 1999, INVEST OPHTH VIS SCI, V40, P2638; Friedman EA, 1999, DIABETES CARE, V22, pB65; GABBAY KH, 1975, ANNU REV MED, V26, P521, DOI 10.1146/annurev.me.26.020175.002513; GANSEVOORT RT, 1995, NEPHROL DIAL TRANSPL, V10, P1963; GIARDINO I, 1994, J CLIN INVEST, V94, P110, DOI 10.1172/JCI117296; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; GOTO Y, 1995, BIOMED PHARMACOTHER, V49, P269, DOI 10.1016/0753-3322(96)82642-4; GREENE DA, 1992, DIABETES CARE, V15, P1902, DOI 10.2337/diacare.15.12.1902; GRIFFEY RH, 1988, JAMA-J AM MED ASSOC, V260, P2872, DOI 10.1001/jama.260.19.2872; Gupta S, 2000, KIDNEY INT, V58, P1389, DOI 10.1046/j.1523-1755.2000.00301.x; Ha HJ, 2000, KIDNEY INT, V58, pS19, DOI 10.1046/j.1523-1755.2000.07704.x; Hamada Y, 1996, BIOCHEM BIOPH RES CO, V228, P539, DOI 10.1006/bbrc.1996.1695; Hayden JM, 2000, CURR OPIN LIPIDOL, V11, P519, DOI 10.1097/00041433-200010000-00010; HENNEKENS, 1990, ARCH OPHTHALMOL-CHIC, V108, P1234; Hopfner RL, 1999, DIABETOLOGIA, V42, P1383, DOI 10.1007/s001250051308; HOTHERSALL JS, 1992, BIOCHEM INT, V27, P945; Hotta N, 2001, DIABETES CARE, V24, P1776, DOI 10.2337/diacare.24.10.1776; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; Ido Y, 2001, MICROCIRCULATION, V8, P251, DOI 10.1038/sj.mn.7800079; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Ishii H, 1998, J MOL MED, V76, P21, DOI 10.1007/s109-1998-8101-y; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Iwano M, 1996, KIDNEY INT, V49, P1120, DOI 10.1038/ki.1996.162; JAIN SK, 1994, METABOLISM, V43, P306, DOI 10.1016/0026-0495(94)90097-3; JENNINGS PE, 1987, DIABETES RES CLIN EX, V6, P151; KADOR PF, 1990, ARCH OPHTHALMOL-CHIC, V108, P1301, DOI 10.1001/archopht.1990.01070110117035; KARPEN CW, 1985, DIABETES, V34, P526, DOI 10.2337/diabetes.34.6.526; KIHARA M, 1995, EXP NEUROL, V132, P180; Kim YS, 2001, J LAB CLIN MED, V138, P59, DOI 10.1067/mlc.2001.115494; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KLEIN R, 1989, DIABETES METAB REV, V5, P559, DOI 10.1002/dmr.5610050703; KLEIN R, 1982, US DHS NIH PUBL, V13, P1; KOHNER EM, 1995, DIABETES, V44, P603, DOI 10.2337/diabetes.44.6.603; Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; KREISBERG JI, 1993, KIDNEY INT, V43, P109, DOI 10.1038/ki.1993.18; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Lal MA, 2000, DIABETES, V49, P1381, DOI 10.2337/diabetes.49.8.1381; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lee IK, 1999, DIABETES RES CLIN PR, V45, P183, DOI 10.1016/S0168-8227(99)00048-0; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOW PA, 1984, P NATL ACAD SCI-BIOL, V81, P6894, DOI 10.1073/pnas.81.21.6894; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Mackness MI, 1998, CURR OPIN LIPIDOL, V9, P319, DOI 10.1097/00041433-199808000-00006; MALIK RA, 1993, DIABETOLOGIA, V36, P454, DOI 10.1007/BF00402283; MAUER SM, 1989, DIABETES, V38, P839, DOI 10.2337/diabetes.38.7.839; Maxfield EK, 1997, J DIABETES COMPLICAT, V11, P47, DOI 10.1016/S1056-8727(96)00112-2; Meier M, 2000, VASC MED, V5, P173, DOI 10.1177/1358836X0000500307; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K; MIN W, 1993, VIRCHOWS ARCH A, V423, P201, DOI 10.1007/BF01614771; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MYERS RR, 1984, ANN NEUROL, V16, P587, DOI 10.1002/ana.410160510; NAGAMATSU M, 1995, DIABETES CARE, V18, P1160, DOI 10.2337/diacare.18.8.1160; Nagpala PG, 1996, J CELL PHYSIOL, V166, P249, DOI 10.1002/(SICI)1097-4652(199602)166:2<249::AID-JCP2>3.0.CO;2-P; Nakamura J, 1999, DIABETES, V48, P2090, DOI 10.2337/diabetes.48.10.2090; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Nonaka A, 2000, INVEST OPHTH VIS SCI, V41, P2702; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; Ogata N, 2001, AM J OPHTHALMOL, V132, P378, DOI 10.1016/S0002-9394(01)01008-X; OSTERBY R, 1988, DIABETOLOGIA, V31, P265; PERICO N, 1992, DIABETES, V41, P533, DOI 10.2337/diabetes.41.4.533; Ren S, 2000, AM J PHYSIOL-ENDOC M, V278, pE656, DOI 10.1152/ajpendo.2000.278.4.E656; Rippin JD, 2001, BEST PRACT RES CL EN, V15, P345, DOI 10.1053/beem.2001.0150; Ritz E, 1999, NEW ENGL J MED, V341, P1127, DOI 10.1056/NEJM199910073411506; ROBISON WG, 1989, INVEST OPHTH VIS SCI, V30, P2285; Samii A, 1999, NEUROSCI LETT, V262, P159, DOI 10.1016/S0304-3940(99)00064-6; Schiffrin EL, 1998, J CARDIOVASC PHARM, V32, pS2; Schleicher E, 1996, KIDNEY BLOOD PRESS R, V19, P305, DOI 10.1159/000174091; Schmidt AM, 2000, TRENDS ENDOCRIN MET, V11, P368, DOI 10.1016/S1043-2760(00)00311-8; Schratzberger P, 2001, J CLIN INVEST, V107, P1083, DOI 10.1172/JCI12188; SCHRODER S, 1991, AM J PATHOL, V139, P81; SENGER DR, 1986, CANCER RES, V46, P5629; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; SHEPRO D, 1993, FASEB J, V7, P1031, DOI 10.1096/fasebj.7.11.8370472; SHIBA T, 1993, AM J PHYSIOL, V265, pE783, DOI 10.1152/ajpendo.1993.265.5.E783; Shinoda K, 1999, BRIT J OPHTHALMOL, V83, P834, DOI 10.1136/bjo.83.7.834; Sima AAF, 1997, DIABETOLOGIA, V40, pB74, DOI 10.1007/BF03168192; Soriano FG, 2001, CIRC RES, V89, P684, DOI 10.1161/hh2001.097797; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Studer RK, 1997, METABOLISM, V46, P918, DOI 10.1016/S0026-0495(97)90080-9; Sugimoto K, 2000, DIABETES-METAB RES, V16, P408; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki S, 1999, DIABETES RES CLIN PR, V45, P161, DOI 10.1016/S0168-8227(99)00046-7; TAHER MM, 1993, ARCH BIOCHEM BIOPHYS, V303, P260, DOI 10.1006/abbi.1993.1281; TESFAMARIAM B, 1994, FREE RADICAL BIO MED, V16, P383, DOI 10.1016/0891-5849(94)90040-X; TESFAMARIAM B, 1994, J HYPERTENS, V12, P41; TESFAYE S, 1994, DIABETOLOGIA, V37, P847, DOI 10.1007/BF00400938; Tomlinson DR, 1999, DIABETOLOGIA, V42, P1271, DOI 10.1007/s001250051439; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; VANDENENDEN MK, 1995, INVEST OPHTH VIS SCI, V36, P1675; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; Williams B, 1997, DIABETES, V46, P1497, DOI 10.2337/diabetes.46.9.1497; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAN SD, 1994, J BIOL CHEM, V269, P9889; YUE DK, 1982, DIABETES, V31, P789, DOI 10.2337/diabetes.31.9.789; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	151	700	732	1	177	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2002	288	20					2579	2588		10.1001/jama.288.20.2579	http://dx.doi.org/10.1001/jama.288.20.2579			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AL	12444865				2022-12-28	WOS:000179394500025
J	Yamey, G				Yamey, G			WHO in 2002 - Faltering steps towards partnerships	BRITISH MEDICAL JOURNAL			English	Article							HEALTH; STRATEGY		BMJ Unified, London WC1H 9JR, England		Yamey, G (corresponding author), BMJ Unified, London WC1H 9JR, England.							BALE EH, 2002, WG43 COMM MACR HLTH; BELLAMY C, 2002, PUBLIC PRIVATE CIVIL; Brugha R, 2002, LANCET, V359, P435, DOI 10.1016/S0140-6736(02)07607-9; Buse K, 2001, B WORLD HEALTH ORGAN, V79, P748; FEACHEM R, 2002, ACHIEVING IMPACT ROL; Garner P, 2000, BMJ-BRIT MED J, V321, P129, DOI 10.1136/bmj.321.7254.129; GODLEE F, 1995, BRIT MED J, V310, P178, DOI 10.1136/bmj.310.6973.178a; OMARI AA, 2002, COCHRANE DB SYST REV; Reich M. R., 2002, PUBLIC PRIVATE PARTN, P1; RICHTER R, 2002, HLTH ACTION INT PUBL; *UNAIDS, 2002, UNAIDS BARC GLOB EST; Verheul E, 2001, BRIT MED J, V323, P120, DOI 10.1136/bmj.323.7305.120; *WHO, 1998, 51 WORLD HLTH ASS GE; *WHO, 2002, 203 WHO; *WHO, 2002, SOURC PRIC SEL DRUGS; *WHO, 2002, LAUNCH ROLL BACK MAL; *WHO, 2002, GUID WORK PRIV SECT; *WORLD BANK, 2002, HIPC IN; Yamey G, 2001, BRIT MED J, V322, P754; YAMEY G, 2000, BRIT MED J, V320, P228	20	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 23	2002	325	7374					1236	1240		10.1136/bmj.325.7374.1236	http://dx.doi.org/10.1136/bmj.325.7374.1236			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446545	Green Published			2022-12-28	WOS:000179506200032
J	Ridker, PM; Rifai, N; Rose, L; Buring, JE; Cook, NR				Ridker, PM; Rifai, N; Rose, L; Buring, JE; Cook, NR			Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; HORMONE REPLACEMENT THERAPY; PLASMA-CONCENTRATION; STATIN THERAPY; RISK-FACTORS; INFLAMMATION; HEALTH; ATHEROSCLEROSIS; HOMOCYSTEINE; STROKE	Background: Both C-reactive protein and low-density lipoprotein (LDL) cholesterol levels are elevated in persons at risk for cardiovascular events. However, population-based data directly comparing these two biologic markers are not available. Methods: C-reactive protein and LDL cholesterol were measured at base line in 27,939 apparently healthy American women, who were then followed for a mean of eight years for the occurrence of myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes. We assessed the value of these two measurements in predicting the risk of cardiovascular events in the study population. Results: Although C-reactive protein and LDL cholesterol were minimally correlated (r=0.08), base-line levels of each had a strong linear relation with the incidence of cardiovascular events. After adjustment for age, smoking status, the presence or absence of diabetes mellitus, categorical levels of blood pressure, and use or nonuse of hormone-replacement therapy, the relative risks of first cardiovascular events according to increasing quartiles of C-reactive protein, as compared with the women in the lowest quintile, were 1.4, 1.6, 2.0, and 2.3 (P<0.001), whereas the corresponding relative risks in increasing quintiles of LDL cholesterol, as compared with the lowest, were 0.9, 1.1, 1.3, and 1.5 (P<0.001). Similar effects were observed in separate analyses of each component of the composite end point and among users and nonusers of hormone-replacement therapy. Overall, 77 percent of all events occurred among women with LDL cholesterol levels below 160 mg per deciliter (4.14 mmol per liter), and 46 percent occurred among those with LDL cholesterol levels below 130 mg per deciliter (3.36 mmol per liter). By contrast, because C-reactive protein and LDL cholesterol measurements tended to identify different high-risk groups, screening for both biologic markers provided better prognostic information than screening for either alone. Independent effects were also observed for C-reactive protein in analyses adjusted for all components of the Framingham risk score. Conclusions: These data suggest that the C-reactive protein level is a stronger predictor of cardiovascular events than the LDL cholesterol level and that it adds prognostic information to that conveyed by the Framingham risk score.	Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Cardiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Ridker, PM (corresponding author), Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, 900 Commonwealth Ave E, Boston, MA 02215 USA.	pridker@partners.org			NHLBI NIH HHS [HL-43851, HL-58755, HL-63293] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851, R01HL058755, R01HL063293] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CM, 2002, CIRCULATION, V105, P2595, DOI 10.1161/01.CIR.0000017493.03108.1C; Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295; Centers for Disease Control/American Heart Association, 2002, AM HEART ASS WORKSH; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Ford ES, 2000, ARTERIOSCL THROM VAS, V20, P1052, DOI 10.1161/01.ATV.20.4.1052; Grundy SM, 2001, CIRCULATION, V104, P491, DOI 10.1161/01.CIR.104.4.491; HAINLINE A, 1982, MANUAL LAB OPERATION; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Meier-Ewert HK, 2001, CLIN CHEM, V47, P426; Mendall MA, 2000, EUR HEART J, V21, P1584, DOI 10.1053/euhj.1999.1982; Ockene IS, 2001, CLIN CHEM, V47, P444; Pradhan AD, 2002, JAMA-J AM MED ASSOC, V288, P980, DOI 10.1001/jama.288.8.980; Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007; Ridker PM, 1997, NEW ENGL J MED, V337, P356; Ridker PM, 1999, CIRCULATION, V100, P713, DOI 10.1161/01.CIR.100.7.713; Ridker PM, 2001, EUR HEART J, V22, P2135, DOI 10.1053/euhj.2001.2990; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Rifai N, 2002, ANN INTERN MED, V136, P529, DOI 10.7326/0003-4819-136-7-200204020-00010; Roberts WL, 2001, CLIN CHEM, V47, P980; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rost NS, 2001, STROKE, V32, P2575, DOI 10.1161/hs1101.098151; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	31	2644	2820	4	148	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2002	347	20					1557	1565		10.1056/NEJMoa021993	http://dx.doi.org/10.1056/NEJMoa021993			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614KL	12432042				2022-12-28	WOS:000179187800003
J	Zhang, JM; Xu, F; Hashimshony, T; Keshet, N; Cedar, H				Zhang, JM; Xu, F; Hashimshony, T; Keshet, N; Cedar, H			Establishment of transcriptional competence in early and late S phase	NATURE			English	Article							BETA-GLOBIN LOCUS; HISTONE ACETYLATION; DNA-REPLICATION; CHROMATIN STRUCTURE; ORIGINS; ACTIVATION; CHROMOSOME; INVITRO; REGION; CELLS	In animal cells, the process of DNA replication takes place in a programmed manner, with each gene region designated to replicate at a fixed time slot in S phase. Housekeeping genes undergo replication in the first half of S phase in all cell types, whereas the replication of many tissue specific genes is developmentally controlled, being late in most tissues but early in the tissue of expression(1). Here we employ nuclear DNA injection as an experimental system to test whether this phenomenon is due to differences in the ability to set up transcriptional competence during S phase(2,3). Our results show that, regardless of sequence, exogenous genes are a better template for transcription when injected into nuclei of cells in early as opposed to late S phase, and this expression state, once initiated, is preserved after cell division. DNA injected in late S phase is apparently repressed because it is packaged into chromatin containing deacetylated histones, and the same is true for late replicating chromosomal DNA. These findings suggest a mechanistic connection between replication timing and gene expression that might help to explain how epigenetic states can be maintained in vivo.	Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, Jerusalem, Israel	Hebrew University of Jerusalem	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, Jerusalem, Israel.							Allshire R, 2000, CELL, V102, P705, DOI 10.1016/S0092-8674(00)00058-1; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; Cimbora DM, 2000, MOL CELL BIOL, V20, P5581, DOI 10.1128/MCB.20.15.5581-5591.2000; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Kutsukake M, 2000, GENE, V245, P31, DOI 10.1016/S0378-1119(99)00569-7; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; OHE Y, 1995, HUM GENE THER, V6, P325, DOI 10.1089/hum.1995.6.3-325; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Simon I, 1999, NATURE, V401, P929, DOI 10.1038/44866; Simon I, 2001, EMBO J, V20, P6150, DOI 10.1093/emboj/20.21.6150; SIMON I, 1996, DNA REPLICATION EUKA, P387; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOLOMON MJ, 1987, MOL CELL BIOL, V7, P3822, DOI 10.1128/MCB.7.10.3822; WEINTRAUB H, 1979, NUCLEIC ACIDS RES, V7, P781, DOI 10.1093/nar/7.3.781; Wolffe A. P., 1996, DNA REPLICATION EUKA, P271; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	28	141	141	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					198	202		10.1038/nature01150	http://dx.doi.org/10.1038/nature01150			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432398				2022-12-28	WOS:000179200900051
J	Ball, K; Berch, DB; Helmers, KF; Jobe, JB; Leveck, MD; Marsiske, M; Morris, JN; Rebok, GW; Smith, DM; Tennstedt, SL; Unverzagt, FW; Willis, SL				Ball, K; Berch, DB; Helmers, KF; Jobe, JB; Leveck, MD; Marsiske, M; Morris, JN; Rebok, GW; Smith, DM; Tennstedt, SL; Unverzagt, FW; Willis, SL		ACTIVE Study Grp	Effects of cognitive training interventions with older adults - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI-MENTAL-STATE; MEMORY; AGE; PERFORMANCE; YOUNG; IMPAIRMENT; HEALTH; RECALL; CRASH; NORMS	Context Cognitive function in older adults is related to independent living and need for care. However, few studies have addressed whether improving cognitive functions might have short- or long-term effects on activities related to living independently: Objective To evaluate whether 3 cognitive training interventions improve mental abilities and daily functioning in older, independent-living adults. Design Randomized, controlled, single-blind trial with recruitment conducted from March 1998 to October 1999 and 2-year follow-up through December 2001. Setting and Participants Volunteer sample of 2832 persons aged 65 to 94 years recruited from senior housing, community centers, and hospital/clinics in 6 metropolitan areas in the United States. Interventions Participants were randomly assigned to 1 of 4 groups: 10-session group training for memory (verbal episodic memory; n=711), or reasoning (ability to solve problems that follow a serial pattern; n=705), or speed of processing (visual search and identification; n=712); or a no-contact control group (n=704). For the 3 treatment groups, 4-session booster training was offered to a 60% random sample 11 months later. Main Outcome Measures Cognitive function and cognitively demanding everyday functioning. Results Thirty participants were incorrectly randomized and were excluded from the analysis. Each intervention improved the targeted cognitive ability compared with baseline, durable to 2 years (P<.001 for all). Eighty-seven percent of speed-, 74% of reasoning-, and 26% of memory-trained participants demonstrated reliable cognitive improvement immediately after the intervention period. Booster training enhanced training gains in speed (P<.001) and reasoning (P<.001) interventions (speed booster, 92%; no booster, 68%; reasoning booster, 72%;. no booster, 49%), which were maintained at 2-year follow-up (P<.001 for both). No training effects on everyday functioning were detected at -2 years. Conclusions Results support the effectiveness and durability of the cognitive training interventions in improving targeted cognitive abilities: Training effects were of a magnitude equivalent to the amount of decline expected in elderly persons without dementia over 7- to 14-year intervals. Because of minimal functional decline across all groups, longer follow-up is likely required to observe training effects on everyday function.	Univ Alabama Birmingham, Dept Psychol, Ctr Res Appl Gerontol, Birmingham, AL 35294 USA; NIA, NIH, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Univ Florida, Inst Aging, Gainesville, FL USA; Univ Florida, Dept Hlth Policy & Epidemiol, Gainesville, FL USA; Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; Hebrew Rehabil Ctr Aged, Roslindale, MA USA; Johns Hopkins Univ, Dept Mental Hyg, Baltimore, MD USA; Indiana Univ, Sch Med, Dept Psychiat, Bloomington, IN USA; New England Res Inst, Watertown, MA 02172 USA; Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA	University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Johns Hopkins University; Maryland Department of Health & Mental Hygiene; Indiana University System; Indiana University Bloomington; HealthCore, Inc; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ball, K (corresponding author), Univ Alabama Birmingham, Dept Psychol, Ctr Res Appl Gerontol, 924 19th St S,101 Holley Mears Bldg, Birmingham, AL 35294 USA.	kball@uab.edu		Ball, Karlene/0000-0003-1811-9870; Marsiske, Michael/0000-0001-5973-2116	NATIONAL INSTITUTE OF NURSING RESEARCH [U01NR004508, U01NR004507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG014263, U01AG014289, U01AG014276, U01AG014260, U01AG014282] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; BALL K, 1988, Investigative Ophthalmology and Visual Science, V29, P448; Ball K., 2000, MOBILITY TRANSPORTAT, P213; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; Baltes P. B., 1982, AGING COGNITIVE PROC, P353, DOI DOI 10.1007/978-1-4684-4178-9_19; Blom G., 1958, STAT ESTIMATES TRANS; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Callahan CM, 1996, ARCH NEUROL-CHICAGO, V53, P134, DOI 10.1001/archneur.1996.00550020038013; CHURCHILL JD, IN PRESS NEUROBIOL A; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; COHEN GD, 1995, AM J GERIAT PSYCHIAT, V3, P1, DOI 10.1097/00019442-199524310-00001; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; DIEHL M, 1995, PSYCHOL AGING, V10, P478, DOI 10.1037/0882-7974.10.3.478; Diehl M, 1998, ANN M GER SOC AM NOV; DUDEK FJ, 1979, PSYCHOL BULL, V86, P335, DOI 10.1037/0033-2909.86.2.335; EDWARDS JD, IN PRESS GERONTOLOGY; Ekstrom R., 1976, MANUAL KIT FACTOR RE; *FED INT FOR AG RE, 2000, OLD AM 2000 KEY IND; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gonda J, 1985, SCHAIE THURSTONE MEN; GREENBERG C, 1987, ED GERONTOL, V12, P385; HOFLAND BF, 1981, J EDUC PSYCHOL, V73, P573, DOI 10.1037/0022-0663.73.4.573; Jobe JB, 2001, CONTROL CLIN TRIALS, V22, P453, DOI 10.1016/S0197-2456(01)00139-8; KLIEGL R, 1990, DEV PSYCHOL, V26, P894, DOI 10.1037/0012-1649.26.6.894; Krampe RT, 1996, J EXP PSYCHOL GEN, V125, P331, DOI 10.1037/0096-3445.125.4.331; LACHMAN ME, 1992, J GERONTOL, V47, pP293, DOI 10.1093/geronj/47.5.P293; LEIRER VO, 1988, J AM GERIATR SOC, V36, P877; LOWENTHAL MF, 1967, AGING MENTAL DISORDE; MCHORNEY CA, 1994, MED CARE, V32, P551, DOI 10.1097/00005650-199406000-00002; MORRIS J, 1997, MEASUREMENT ELDERLY; Morris JN, 1997, J AM GERIATR SOC, V45, P1017, DOI 10.1111/j.1532-5415.1997.tb02975.x; Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203; Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; OWSLEY C, IN PRESS GERONTOLOGY; Rasmusson DX, 1999, AGING NEUROPSYCHOL C, V6, P56, DOI 10.1076/anec.6.1.56.790; REBOK GW, 1989, DEV PSYCHOL, V25, P714, DOI 10.1037/0012-1649.25.5.714; RECANZONE GH, 2000, NEW COGNITIVE NEUROS, P237; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Schaie K. W., 1996, INTELLECTUAL DEV ADU; Small BJ, 1999, J GERONTOL B-PSYCHOL, V54, pP107, DOI 10.1093/geronb/54B.2.P107; Thurstone L. L., 1949, EXAMINER MANUAL SRA; WILLIS S, 1990, NEUROPSYCHOLOGY EVER, P183; Willis S L, 1986, Psychol Aging, V1, P239, DOI 10.1037/0882-7974.1.3.239; WILLIS SL, 1992, RES AGING, V14, P68, DOI 10.1177/0164027592141004; WILLIS SL, 1990, DEV PSYCHOL, V26, P905, DOI 10.1037/0012-1649.26.6.905; Willis SL., 1993, MANUAL EVERYDAY PROB; WILSON B, 1985, RIVER MEAD BEHAV MEM; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742; YESAVAGE JA, 1985, AM J PSYCHIAT, V142, P600; Zelinski EM, 1997, PSYCHOL AGING, V12, P503, DOI 10.1037/0882-7974.12.3.503	57	1298	1344	7	219	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2271	2281		10.1001/jama.288.18.2271	http://dx.doi.org/10.1001/jama.288.18.2271			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	614JZ	12425704	Green Accepted			2022-12-28	WOS:000179186400026
J	Boyce, M				Boyce, M			Observational study of 353 applications to London multicentre research ethics committee 1997-2000	BRITISH MEDICAL JOURNAL			English	Article									Cent Middlesex Hosp, Hammersmith Med Res, London NW10 7NS, England	Imperial College London	Boyce, M (corresponding author), Cent Middlesex Hosp, Hammersmith Med Res, London NW10 7NS, England.			Boyce, Malcolm/0000-0001-8807-612X				Alberti KGMM, 2000, BRIT MED J, V320, P1157, DOI 10.1136/bmj.320.7243.1157; Lux AL, 2000, BRIT MED J, V320, P1182, DOI 10.1136/bmj.320.7243.1182; Tully J, 2000, BRIT MED J, V320, P1179, DOI 10.1136/bmj.320.7243.1179	3	16	16	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2002	325	7372					1081	1081		10.1136/bmj.325.7372.1081	http://dx.doi.org/10.1136/bmj.325.7372.1081			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JV	12424169	Bronze, Green Published			2022-12-28	WOS:000179415700022
J	Slattery, MM; Morrison, JJ				Slattery, MM; Morrison, JJ			Preterm delivery	LANCET			English	Review							LOW-BIRTH-WEIGHT; BROAD-SPECTRUM ANTIBIOTICS; INFANTS BORN; CONTROLLED-TRIAL; ANTENATAL CORTICOSTEROIDS; MYOMETRIAL CONTRACTILITY; BACTERIAL VAGINOSIS; VAGINAL CLINDAMYCIN; GESTATIONAL-AGE; UNITED-STATES	Preterm delivery and its short-term and long-term sequelae constitute a serious problem in terms of mortality, disability, and cost to society. The incidence of preterm delivery, which has increased in recent years, is associated with various epidemiological and clinical risk factors. Results of randomised controlled trials suggest that attempts to reduce these risk factors by use of drugs are limited by side-effects and poor efficacy. An improved understanding of the physiological pathways that regulate uterine contraction and relaxation in animals and people has, however, helped to define the complex processes that underlie parturition (term and preterm), and has led to new scientific approaches for myometrial modulation. The continuing elucidation of the mechanisms that regulate preterm labour, combined with rigorous clinical assessment, offer hope for future solutions.	Natl Univ Ireland Univ Coll Galway, Univ Coll Hosp Galway, Inst Clin Sci, Dept Obstet & Gynaecol, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway	Morrison, JJ (corresponding author), Natl Univ Ireland Univ Coll Galway, Univ Coll Hosp Galway, Inst Clin Sci, Dept Obstet & Gynaecol, Galway, Ireland.	john.morrison@nuigalway.ie						Abdalla HI, 1998, BRIT J OBSTET GYNAEC, V105, P332, DOI 10.1111/j.1471-0528.1998.tb10096.x; Abramov Y, 2000, OBSTET GYNECOL, V95, P482, DOI 10.1016/S0029-7844(99)00578-5; ALI AF, 2000, OBSTET GYNECOL, V95, pS61; ALLEN MC, 1993, NEW ENGL J MED, V329, P1597, DOI 10.1056/NEJM199311253292201; Althuisius SM, 2000, AM J OBSTET GYNECOL, V183, P823, DOI 10.1067/mob.2000.108874; American College of Obstetricians and Gynecologists, 2001, Obstet Gynecol, V98, P709; Ananth CV, 2001, AM J EPIDEMIOL, V154, P657, DOI 10.1093/aje/154.7.657; Bajo AM, 2000, PEPTIDES, V21, P1383, DOI 10.1016/S0196-9781(00)00282-5; BAKKETEIG LS, 1979, AM J OBSTET GYNECOL, V135, P1086, DOI 10.1016/0002-9378(79)90742-7; Bernasko J, 1997, OBSTET GYNECOL, V89, P368, DOI 10.1016/S0029-7844(96)00527-3; BOER K, 1994, ACTA PAEDIATR, V83, P65, DOI 10.1111/j.1651-2227.1994.tb13386.x; Bohin S, 1996, ARCH DIS CHILD-FETAL, V74, pF110, DOI 10.1136/fn.74.2.F110; BROCKLEHURST P, 2000, COCHRANE LIB; BUNNINGPFAUE F, 2000, IR J MED SCI S4, V169, P71; Burke C, 2000, J PERINAT MED, V28, P49, DOI 10.1515/JPM.2000.007; CARRHILL RA, 1985, BRIT J OBSTET GYNAEC, V92, P921, DOI 10.1111/j.1471-0528.1985.tb03071.x; Challis JRG, 2000, OBSTET GYNECOL SURV, V55, P650, DOI 10.1097/00006254-200010000-00025; CHERUKURI R, 1988, OBSTET GYNECOL, V72, P147; CHEUNG YB, 2000, AM J EPIDEMIOL, V152, P1117; Costeloe K, 2000, PEDIATRICS, V106, P659, DOI 10.1542/peds.106.4.659; CREASY RK, 1993, AM J OBSTET GYNECOL, V168, P1223, DOI 10.1016/0002-9378(93)90373-Q; Demissie K, 2001, AM J EPIDEMIOL, V154, P307, DOI 10.1093/aje/154.4.307; Dennedy MC, 2001, BRIT J OBSTET GYNAEC, V108, P605, DOI 10.1016/S0306-5456(00)00147-9; DEPP R, 1993, AM J OBSTET GYNECOL, V169, P352; DINSMOOR MJ, 1994, AM J OBSTET GYNECOL, V171, P305, DOI 10.1016/S0002-9378(94)70027-3; Dirnberger DR, 2001, AM J PERINAT, V18, P267, DOI 10.1055/s-2001-16989; Dong YL, 1999, J CLIN INVEST, V104, P559, DOI 10.1172/JCI6324; EGARTER CH, 1992, BAILLIERE CLIN OB GY, V6, P755, DOI 10.1016/S0950-3552(05)80187-7; Ekerhovd E, 1999, OBSTET GYNECOL, V93, P987, DOI 10.1016/S0029-7844(99)00249-5; El-Metwally D, 2000, J PEDIATR-US, V137, P616, DOI 10.1067/mpd.2000.109143; Engstrom T, 2001, J ENDOCRINOL, V169, P33, DOI 10.1677/joe.0.1690033; FAN YD, 1987, AM J PERINAT, V4, P324, DOI 10.1055/s-2007-999800; Fergusson DM, 2002, BJOG-INT J OBSTET GY, V109, P21, DOI 10.1016/S1470-0328(02)01020-0; FERRARA TB, 1994, J PEDIATR-US, V124, P119, DOI 10.1016/S0022-3476(94)70266-7; Finnstrom O, 1997, ACTA PAEDIATR, V86, P503, DOI 10.1111/j.1651-2227.1997.tb08921.x; Fisch B, 1997, J Perinatol, V17, P473; FRASER AM, 1995, NEW ENGL J MED, V332, P1113, DOI 10.1056/NEJM199504273321701; GARDNER MO, 1995, OBSTET GYNECOL, V85, P553, DOI 10.1016/0029-7844(94)00455-M; Glinianaia S V, 1998, Twin Res, V1, P189, DOI 10.1375/twin.1.4.189; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; GOLDENBERG RL, 1993, OBSTET GYNECOL, V81, P444; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Goldenberg RL, 2001, OBSTET GYNECOL, V97, P316, DOI 10.1016/S0029-7844(00)01153-4; GOLDING J, 1995, EARLY HUM DEV, V43, P1, DOI 10.1016/0378-3782(95)01660-U; Grammatopoulos DK, 1999, LANCET, V354, P1546, DOI 10.1016/S0140-6736(99)03418-2; Guinn DA, 2001, JAMA-J AM MED ASSOC, V286, P1581, DOI 10.1001/jama.286.13.1581; Guise JM, 2001, AM J PREV MED, V20, P62, DOI 10.1016/S0749-3797(01)00256-2; Gyetvai K, 1999, OBSTET GYNECOL, V94, P869, DOI 10.1016/S0029-7844(99)00329-4; Hack M, 2002, NEW ENGL J MED, V346, P149, DOI 10.1056/NEJMoa010856; Hagan R, 1996, BRIT J OBSTET GYNAEC, V103, P239, DOI 10.1111/j.1471-0528.1996.tb09712.x; HANDLER A, 1991, AM J EPIDEMIOL, V133, P818, DOI 10.1093/oxfordjournals.aje.a115961; HANNAH ME, 1995, J SOC OBSTET GYNAECO, V17, P1089; Hansen M, 2002, NEW ENGL J MED, V346, P725, DOI 10.1056/NEJMoa010035; HATCH EE, 1986, AM J EPIDEMIOL, V124, P986, DOI 10.1093/oxfordjournals.aje.a114488; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; Health Canada, 2000, CAN PER HLTH REP; HILLIER SL, 1995, CLIN INFECT DIS, V20, pS276, DOI 10.1093/clinids/20.Supplement_2.S276; HOLTROP PC, 1994, AM J OBSTET GYNECOL, V170, P1266; Houlihan DD, 2002, AM J OBSTET GYNECOL, V186, P778, DOI 10.1067/mob.2002.122253; Iannucci TA, 1996, AM J OBSTET GYNECOL, V174, P1896, DOI 10.1016/S0002-9378(96)70226-0; Jalava J, 1996, BRIT J OBSTET GYNAEC, V103, P664, DOI 10.1111/j.1471-0528.1996.tb09835.x; Joseph KS, 1998, NEW ENGL J MED, V339, P1434, DOI 10.1056/NEJM199811123392004; Joseph KS, 2001, OBSTET GYNECOL, V98, P57, DOI 10.1016/S0029-7844(01)01394-1; Katz V L, 1993, J Perinatol, V13, P261; Kekki M, 2001, OBSTET GYNECOL, V97, P643, DOI 10.1016/S0029-7844(01)01321-7; KENYON S, 2000, COCHRANE LIB; Kenyon SL, 2001, LANCET, V357, P989, DOI 10.1016/S0140-6736(00)04234-3; Kenyon SL, 2001, LANCET, V357, P979, DOI 10.1016/S0140-6736(00)04233-1; Kilpatrick SJ, 1997, OBSTET GYNECOL, V90, P803, DOI 10.1016/S0029-7844(97)00483-3; KING J, 2000, COCHRANE LIB; Koniak-Griffin D, 2000, NURS RES, V49, P130, DOI 10.1097/00006199-200005000-00003; Koupilova I, 1998, PAEDIATR PERINAT EP, V12, P7; Kramer MS, 2001, PAEDIATR PERINAT EP, V15, P104, DOI 10.1046/j.1365-3016.2001.00012.x; Kramer MS, 1996, MATERNAL EXTRAUTERIN, P349; KRISTENSEN J, 1995, OBSTET GYNECOL, V86, P800, DOI 10.1016/0029-7844(95)00275-V; KROHN MA, 1995, J INFECT DIS, V171, P1475, DOI 10.1093/infdis/171.6.1475; Kurkinen-Raty M, 2000, BRIT J OBSTET GYNAEC, V107, P1427, DOI 10.1111/j.1471-0528.2000.tb11660.x; Kurtzman JT, 1999, AM J OBSTET GYNECOL, V181, P853, DOI 10.1016/S0002-9378(99)70313-3; Lees CC, 1999, OBSTET GYNECOL, V94, P403, DOI 10.1016/S0029-7844(99)00296-3; Lefebvre F, 1996, AM J OBSTET GYNECOL, V174, P833, DOI 10.1016/S0002-9378(96)70309-5; Leung TN, 1998, AUST NZ J OBSTET GYN, V38, P138, DOI 10.1111/j.1479-828X.1998.tb02986.x; LUMLEY J, 1993, BAILLIERE CLIN OB GY, V7, P477, DOI 10.1016/S0950-3552(05)80445-6; MACFARLANE A, 1988, BRIT MED BULL, V44, P861, DOI 10.1093/oxfordjournals.bmb.a072298; MACNAUGHTON MC, 1993, BRIT J OBSTET GYNAEC, V100, P516; MADINGER NE, 1989, AM J OBSTET GYNECOL, V161, P657, DOI 10.1016/0002-9378(89)90373-6; Mattison DR, 2001, PAEDIATR PERINAT EP, V15, P7, DOI 10.1046/j.1365-3016.2001.00004.x; McCormick MC, 2002, NEW ENGL J MED, V346, P197, DOI 10.1056/NEJM200201173460310; MCGRADY GA, 1992, AM J EPIDEMIOL, V136, P266, DOI 10.1093/oxfordjournals.aje.a116492; MEIS PJ, 1987, AM J OBSTET GYNECOL, V156, P1165, DOI 10.1016/0002-9378(87)90133-5; Mercer BM, 1996, AM J OBSTET GYNECOL, V174, P1885, DOI 10.1016/S0002-9378(96)70225-9; Miller JM, 1999, AM J OBSTET GYNECOL, V180, P1427, DOI 10.1016/S0002-9378(99)70030-X; MITCHELL MD, 1984, J DEV PHYSIOL, V6, P107; Monaghan SC, 2000, OBSTET GYNECOL, V95, P752, DOI 10.1016/S0029-7844(99)00630-4; Moran CJ, 2002, MOL HUM REPROD, V8, P196, DOI 10.1093/molehr/8.2.196; MORRISON JJ, 1993, AM J OBSTET GYNECOL, V169, P1277, DOI 10.1016/0002-9378(93)90294-S; Morrison JJ, 1997, BRIT J OBSTET GYNAEC, V104, P1341, DOI 10.1111/j.1471-0528.1997.tb11002.x; Morrison JJ, 1996, HUM REPROD, V11, P2285; MORRISON JJ, 1996, PROG OB GYN, V12, P67; Moutquin JM, 2000, AM J OBSTET GYNECOL, V182, P1191, DOI 10.1067/mob.2000.104950; MOUTQUIN JM, 1992, NEW ENGL J MED, V327, P308; MUELLERHEUBACH E, 1989, AM J OBSTET GYNECOL, V160, P1172, DOI 10.1016/0002-9378(89)90183-X; NEERHOF MG, 1989, AM J OBSTET GYNECOL, V161, P633, DOI 10.1016/0002-9378(89)90368-2; Offidani C, 1995, Minerva Ginecol, V47, P381; OLSEN P, 1995, AM J EPIDEMIOL, V142, P1184, DOI 10.1093/oxfordjournals.aje.a117577; Palmier B, 1999, J PHARMACOL EXP THER, V289, P1022; PAO CC, 1991, AM J OBSTET GYNECOL, V164, P1295, DOI 10.1016/0002-9378(91)90702-S; Perri T, 2001, J ASSIST REPROD GEN, V18, P245, DOI 10.1023/A:1016614217411; Peruzzi L, 1999, LANCET, V354, P1615, DOI 10.1016/S0140-6736(99)03105-0; Pharoah POD, 1998, ARCH DIS CHILD-FETAL, V79, pF21, DOI 10.1136/fn.79.1.F21; Rennie JM, 1996, ARCH DIS CHILD-FETAL, V74, pF214, DOI 10.1136/fn.74.3.F214; ROMERO R, 1990, AM J OBSTET GYNECOL, V163, P757, DOI 10.1016/0002-9378(90)91063-I; ROMERO R, 1988, CLIN OBSTET GYNECOL, V31, P553, DOI 10.1097/00003081-198809000-00006; Romero R, 2001, PAEDIATR PERINAT EP, V15, P41, DOI 10.1046/j.1365-3016.2001.00007.x; Romero R, 2000, AM J OBSTET GYNECOL, V182, P1173, DOI 10.1067/mob.2000.95834; Romero R, 1999, MED FETUS MOTHER, P1581; Rust OA, 2001, AM J OBSTET GYNECOL, V185, P1098, DOI 10.1067/mob.2001.118163; Rust OA, 2000, AM J OBSTET GYNECOL, V183, P830, DOI 10.1067/mob.2000.109040; Rydhstroem H, 2001, Twin Res, V4, P227, DOI 10.1375/twin.4.4.227; Sanborn BM, 2000, J SOC GYNECOL INVEST, V7, P4, DOI 10.1016/S1071-5576(99)00051-9; Sawdy R J, 1999, Curr Opin Obstet Gynecol, V11, P131, DOI 10.1097/00001703-199904000-00005; Schieve LA, 1996, OBSTET GYNECOL, V88, P356, DOI 10.1016/0029-7844(96)00203-7; Sebire NJ, 2001, MED HYPOTHESES, V56, P497, DOI 10.1054/mehy.2000.1204; SHIONO PH, 1995, AM J OBSTET GYNECOL, V172, P19, DOI 10.1016/0002-9378(95)90078-0; Slattery MM, 2001, BRIT J OBSTET GYNAEC, V108, P704; Slattery MM, 2001, OBSTET GYNECOL, V98, P563, DOI 10.1016/S0029-7844(01)01522-8; Slattery MM, 2001, AM J OBSTET GYNECOL, V184, P625, DOI 10.1067/mob.2001.110695; Smith GCS, 2001, BRIT MED J, V323, P476, DOI 10.1136/bmj.323.7311.476; Soderstrom-Anttila V, 1998, HUM REPROD, V13, P2009, DOI 10.1093/humrep/13.7.2009; Terrone DA, 2000, AM J OBSTET GYNECOL, V182, P1477, DOI 10.1067/mob.2000.107334; THORNTON S, 1992, CONT REV OBSTET GYNA, V4, P121; Tsatsaris V, 2001, OBSTET GYNECOL, V97, P840, DOI 10.1016/S0029-7844(00)01212-6; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; VENTURA SJ, 1999, BIRTHS FINAL DATA 19, V47; Vermeulen GM, 2001, BRIT J OBSTET GYNAEC, V108, P697, DOI 10.1016/S0306-5456(00)00175-3; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601; Worldwide Atosiban versus Beta-agonists Study Group, 2001, BJOG, V108, P133; WRAY S, 1993, AM J PHYSIOL, V264, pC1, DOI 10.1152/ajpcell.1993.264.1.C1; Zhou WJ, 1999, OBSTET GYNECOL, V94, P948, DOI 10.1016/S0029-7844(99)00440-8; [No title captured]	139	554	587	0	44	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	2002	360	9344					1489	1497		10.1016/S0140-6736(02)11476-0	http://dx.doi.org/10.1016/S0140-6736(02)11476-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433531				2022-12-28	WOS:000179186000028
J	Battie, MC; Videman, T; Gibbons, LE; Manninen, H; Gill, K; Pope, M; Kaprio, J				Battie, MC; Videman, T; Gibbons, LE; Manninen, H; Gill, K; Pope, M; Kaprio, J			Occupational driving and lumbar disc degeneration: a case-control study	LANCET			English	Article							WHOLE-BODY VIBRATION; LOW-BACK-PAIN; VITAMIN-D-RECEPTOR; INTERVERTEBRAL DISC; IDENTICAL-TWINS; DISEASE; RISK; VOLVO	Background Back problems are reported more by occupational drivers than by any other occupational group. One explanation is that whole-body vibration caused by the vehicle leads to accelerated disc degeneration, herniation, and associated symptoms. We aimed to investigate the effects of lifetime driving exposure on lumbar disc degeneration in monozygotic twins with very different histories of occupational driving during their life. Methods We assessed 45 male monozygotic twin pairs from the population-based Finnish Twin Cohort who had greatly different patterns of occupational driving during their life. Data were obtained for driving exposures and potential confounding factors through an extensive, structured interview. We assessed disc degeneration with lumbar MRI. Findings Disc degeneration did not differ between occupational drivers and their twin brothers. We also did not identify any overall tendency for greater degeneration or pathology in occupational drivers than their twin brothers. Interpretations Although driving may exacerbate symptoms of back problems, it does not damage the disc. Our inability to identify structural damage should be encouraging to those employed in occupations involving motorised vehicles and operation of heavy equipment.	Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA; Kuopio Univ Hosp, Dept Clin Radiol, SF-70210 Kuopio, Finland; SW Orthoped Inst, Dept Orthoped Surg, Dallas, TX USA; Univ Aberdeen, Dept Environm & Occupat Med, Aberdeen, Scotland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland	University of Alberta; University of Washington; University of Washington Seattle; Kuopio University Hospital; University of Eastern Finland; University of Aberdeen; University of Helsinki	Battie, MC (corresponding author), Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada.		Battie, Michele C/C-6155-2018; Kaprio, Jaakko/A-1820-2008	Battie, Michele C/0000-0001-8499-2040; Kaprio, Jaakko/0000-0002-3716-2455	NIAMS NIH HHS [R01 AR40857] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040857] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Annunen S, 1999, SCIENCE, V285, P409, DOI 10.1126/science.285.5426.409; BATTIE MC, 1991, SPINE, V16, P1015, DOI 10.1097/00007632-199109000-00001; Battie MC, 1995, SPINE, V20, P2601, DOI 10.1097/00007632-199512150-00001; Bijkerk C, 1999, ARTHRITIS RHEUM, V42, P1729, DOI 10.1002/1529-0131(199908)42:8<1729::AID-ANR23>3.0.CO;2-H; BOOS N, 1993, RADIOLOGY, V188, P351, DOI 10.1148/radiology.188.2.8327677; Bovenzi M, 1999, INT ARCH OCC ENV HEA, V72, P351, DOI 10.1007/s004200050387; Brinckmann P, 1998, CLIN BIOMECH, V13, pS1, DOI 10.1016/S0268-0033(98)00050-3; BRINCKMANN P, 1988, CLIN BIOMECH, V3, P1; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DUPUIS H, 1994, INT ARCH OCC ENV HEA, V66, P303, DOI 10.1007/BF00378362; DUPUIS H, 1986, EFFECTS WHOLE BODY V, P31; Frank JW, 1996, SPINE, V21, P2908, DOI 10.1097/00007632-199612150-00024; GERTLING PO, 1987, TRILLEN SCHOKKEN TIJ; HANSSON T, 1991, CLIN BIOMECH, V6, P173, DOI 10.1016/0268-0033(91)90030-T; HELIOVAARA M, 1987, J CHRON DIS, V40, P259, DOI 10.1016/0021-9681(87)90162-7; HOLM S, 1985, Orthopaedic Transactions, V9, P525; Hoogendoorn WE, 1999, SCAND J WORK ENV HEA, V25, P387, DOI 10.5271/sjweh.451; *INT ORG STAND, 1985, 26311 ISO; Jensen MV, 1996, SPINE, V21, P2352, DOI 10.1097/00007632-199610150-00009; Jones G, 1998, ANN RHEUM DIS, V57, P94, DOI 10.1136/ard.57.2.94; Keller M., 1988, Molecular Plant-Microbe Interactions, V1, P267, DOI 10.1094/MPMI-1-267; KELSEY JL, 1975, AM J EPIDEMIOL, V102, P63, DOI 10.1093/oxfordjournals.aje.a112135; KJELLBERG A, 1994, ARBETE HALSA, V41, P1; Kumar A, 1999, SPINE, V24, P2506, DOI 10.1097/00007632-199912010-00013; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lings S, 2000, INT ARCH OCC ENV HEA, V73, P290, DOI 10.1007/s004200000118; Luoma K, 1998, SCAND J WORK ENV HEA, V24, P358, DOI 10.5271/sjweh.356; MCLAIN RF, 1994, SPINE, V19, P1455, DOI 10.1097/00007632-199407000-00006; Portney L, 2000, FDN CLIN RES APPL PR, P565; Rantasalo, 1979, FINNISH TWIN REGISTR; Ronnemaa T, 1997, ANN INTERN MED, V126, P26, DOI 10.7326/0003-4819-126-1-199701010-00004; Videman T, 2000, CLIN BIOMECH, V15, P83, DOI 10.1016/S0268-0033(99)00047-9; Videman T, 1998, SPINE, V23, P2477, DOI 10.1097/00007632-199812010-00002; WUKASCH W, 1979, THESIS ZENTRALINSTIT	34	83	85	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1369	1374		10.1016/S0140-6736(02)11399-7	http://dx.doi.org/10.1016/S0140-6736(02)11399-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423982				2022-12-28	WOS:000179081600009
J	Powles, J; Day, N				Powles, J; Day, N			Interpreting the global burden of disease	LANCET			English	Editorial Material							ENERGY-EXPENDITURE; DISABILITY		Inst Publ Hlth, Cambridge CB2 2SR, England	University of Cambridge	Powles, J (corresponding author), Inst Publ Hlth, Cambridge CB2 2SR, England.			Powles, John/0000-0002-0766-7989				Black AE, 1996, EUR J CLIN NUTR, V50, P72; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Murray CJL, 1999, EPIDEMIOLOGY, V10, P594, DOI 10.1097/00001648-199909000-00029; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; *US DHHS CDCP, 1996, PHYS ACT HLTH REP SU; Wareham NJ, 2000, AM J EPIDEMIOL, V152, P132, DOI 10.1093/aje/152.2.132	7	11	14	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1342	1343		10.1016/S0140-6736(02)11412-7	http://dx.doi.org/10.1016/S0140-6736(02)11412-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423975				2022-12-28	WOS:000179081600002
J	Ridderinkhof, KR; de Vlugt, Y; Bramlage, A; Spaan, M; Elton, M; Snel, J; Band, GPH				Ridderinkhof, KR; de Vlugt, Y; Bramlage, A; Spaan, M; Elton, M; Snel, J; Band, GPH			Alcohol consumption impairs detection of performance errors in mediofrontal cortex	SCIENCE			English	Article							RESPONSE-INHIBITION; ERP COMPONENTS; POTENTIALS; ATTENTION; DOPAMINE; ACCURACY; ETHANOL; SPEED; TASK	The anterior cingulate cortex (ACC) is a critical component of the human mediofrontal neural circuit that monitors ongoing processing in the cognitive system for signs of erroneous outcomes. Here, we show that the consumption of alcohol in moderate doses induces a significant deterioration of the ability to detect the activation of erroneous responses as reflected in the amplitude of brain electrical activity associated with the ACC. This impairment was accompanied by failures to instigate performance adjustments after these errors. These findings offer insights into how the effects of alcohol on mediofrontal brain function may result in compromised performance.	Univ Amsterdam, Dept Psychol, NL-1018 WB Amsterdam, Netherlands; Leiden Univ, Dept Psychol, NL-2333 AK Leiden, Netherlands	University of Amsterdam; Leiden University; Leiden University - Excl LUMC	Ridderinkhof, KR (corresponding author), Univ Amsterdam, Dept Psychol, Roetersstr 15, NL-1018 WB Amsterdam, Netherlands.	richard@psy.uva.nl	Band, Guido/H-7659-2013	Snel, Jan/0000-0002-1778-605X; Band, Guido/0000-0003-0408-0039				Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Burle B, 2002, PSYCHOL RES-PSYCH FO, V66, P324, DOI 10.1007/s00426-002-0105-6; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Easdon CM, 2000, EXP CLIN PSYCHOPHARM, V8, P387, DOI 10.1037//1064-1297.8.3.387; Eckardt MJ, 1998, ALCOHOL CLIN EXP RES, V22, P998, DOI 10.1111/j.1530-0277.1998.tb03695.x; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; FERRARA SD, 1994, INT J LEGAL MED, V106, P169, DOI 10.1007/BF01371332; Fillmore MT, 2000, J STUD ALCOHOL, V61, P239, DOI 10.15288/jsa.2000.61.239; Finnigan F, 1992, HDB HUMAN PERFORMANC, V2, P73; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; Groeger J., 2000, UNDERSTANDING DRIVIN; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Howat P, 1991, Drug Alcohol Rev, V10, P151, DOI 10.1080/09595239100185211; JAASKELAINEN IP, 1995, ALCOHOL CLIN EXP RES, V19, P607, DOI 10.1111/j.1530-0277.1995.tb01555.x; JENNINGS JR, 1976, PERCEPT PSYCHOPHYS, V19, P85, DOI 10.3758/BF03199391; Kopp B, 1996, PSYCHOPHYSIOLOGY, V33, P282, DOI 10.1111/j.1469-8986.1996.tb00425.x; Luu P, 2000, J NEUROSCI, V20, P464, DOI 10.1523/JNEUROSCI.20-01-00464.2000; Marinkovic K, 2000, J STUD ALCOHOL, V61, P24, DOI 10.15288/jsa.2000.61.24; MAYLOR EA, 1987, ACTA PSYCHOL, V65, P147, DOI 10.1016/0001-6918(87)90024-2; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Nieuwenhuis S, 2002, COGN AFFECT BEHAV NE, V2, P19, DOI 10.3758/CABN.2.1.19; Ridderinkhof KR, 2002, PSYCHOL RES-PSYCH FO, V66, P312, DOI 10.1007/s00426-002-0104-7; Ridderinkhof KR, 2002, ATTENTION PERFORM, V19, P494; ROHRBAUGH JW, 1987, ALCOHOL, V4, P293, DOI 10.1016/0741-8329(87)90026-7; Ullsperger M, 2001, NEUROIMAGE, V14, P1387, DOI 10.1006/nimg.2001.0935; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837	28	256	264	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	2002	298	5601					2209	2211		10.1126/science.1076929	http://dx.doi.org/10.1126/science.1076929			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	624RA	12424384				2022-12-28	WOS:000179773700053
J	Komatitsch, D; Ritsema, J; Tromp, J				Komatitsch, D; Ritsema, J; Tromp, J			The spectral-element method, beowulf computing, and global seismology	SCIENCE			English	Review							SEISMIC-WAVE PROPAGATION; SYNTHETIC SEISMOGRAMS; EARTHS MANTLE; VELOCITY STRUCTURE; NORMAL-MODES; BOUNDARY; SIMULATIONS; ATTENUATION; COMPUTATION; ANISOTROPY	The propagation of seismic waves through Earth can now be modeled accurately with the recently developed spectral-element method. This method takes into account heterogeneity in Earth models, such as three-dimensional variations of seismic wave velocity, density, and crustal thickness. The method is implemented on relatively inexpensive clusters of personal computers, so-called Beowulf machines. This combination of hardware and software enables us to simulate broadband seismograms without intrinsic restrictions on the level of heterogeneity or the frequency content.	CALTECH, Seismol Lab, Pasadena, CA 91125 USA	California Institute of Technology	Komatitsch, D (corresponding author), CALTECH, Seismol Lab, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	komatits@gps.caltech.edu	Tromp, Jeroen/B-6185-2015; Komatitsch, Dimitri/E-7153-2012	Tromp, Jeroen/0000-0002-2742-8299; Komatitsch, Dimitri/0000-0003-2309-8269				Bassin C., 2000, EOS T AM GEOPHYS UN, V81, pF897; Becker TW, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000168; CAPDEVILLE Y, IN PRESS GEOPHYS J I; Cerveny V, 2001, SEISMIC RAY THEORY; Chaljub E, 1997, GEOPHYS RES LETT, V24, P2613, DOI 10.1029/97GL52693; Chaljub E., 2000, THESIS U PARIS 7; Cormier VF, 1999, GEOPHYS J INT, V136, P373, DOI 10.1046/j.1365-246X.1999.00736.x; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; FUCHS K, 1971, GEOPHYS J ROY ASTR S, V23, P417, DOI 10.1111/j.1365-246X.1971.tb01834.x; Furumura T, 1998, GEOPHYS J INT, V135, P845, DOI 10.1046/j.1365-246X.1998.00682.x; GELLER RJ, 1994, GEOPHYS J INT, V116, P421, DOI 10.1111/j.1365-246X.1994.tb01807.x; GILBERT F, 1971, GEOPHYS J ROY ASTR S, V22, P223, DOI 10.1111/j.1365-246X.1971.tb03593.x; Gropp W, 1996, PARALLEL COMPUT, V22, P789, DOI 10.1016/0167-8191(96)00024-5; HARA T, 1991, GEOPHYS J INT, V104, P523, DOI 10.1111/j.1365-246X.1991.tb05699.x; Igel H, 1996, GEOPHYS RES LETT, V23, P415, DOI 10.1029/96GL00422; Igel H, 1999, GEOPHYS J INT, V136, P559, DOI 10.1046/j.1365-246x.1999.00758.x; Komatitsch D, 1998, B SEISMOL SOC AM, V88, P368; Komatitsch D, 2002, GEOPHYS J INT, V149, P390, DOI 10.1046/j.1365-246X.2002.01653.x; Komatitsch D, 2002, GEOPHYS J INT, V150, P303, DOI 10.1046/j.1365-246X.2002.01716.x; LI XD, 1993, GEOPHYS J INT, V112, P92, DOI 10.1111/j.1365-246X.1993.tb01439.x; LOGNONNE P, 1990, GEOPHYS J INT, V102, P365, DOI 10.1111/j.1365-246X.1990.tb04472.x; Montagner JP, 1998, PURE APPL GEOPHYS, V151, P223, DOI 10.1007/s000240050113; Ni SD, 2002, SCIENCE, V296, P1850, DOI 10.1126/science.1070698; Nolet G, 2000, J GEOPHYS RES-SOL EA, V105, P19043, DOI 10.1029/2000JB900161; PARK J, 1986, J GEOPHYS RES-SOLID, V91, P6441, DOI 10.1029/JB091iB06p06441; PATERA AT, 1984, J COMPUT PHYS, V54, P468, DOI 10.1016/0021-9991(84)90128-1; PRIOLO E, 1994, J ACOUST SOC AM, V95, P681, DOI 10.1121/1.408428; Reid FJL, 2001, GEOPHYS J INT, V145, P615, DOI 10.1046/j.1365-246x.2001.01395.x; Ritsema J, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013831; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; Romanowicz B, 2002, SCIENCE, V296, P513, DOI 10.1126/science.1069404; Romanowicz B, 1998, PURE APPL GEOPHYS, V153, P257, DOI 10.1007/s000240050196; SADOURNY R, 1972, MON WEATHER REV, V100, P136, DOI 10.1175/1520-0493(1972)100<0136:CFAOTP>2.3.CO;2; Spetzler J, 2001, GEOPHYS RES LETT, V28, P2341, DOI 10.1029/2000GL012691; Wen LX, 2001, EARTH PLANET SC LETT, V189, P141, DOI 10.1016/S0012-821X(01)00365-X; WOODHOUSE JH, 1984, J GEOPHYS RES, V89, P5953, DOI 10.1029/JB089iB07p05953	36	165	187	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1737	1742		10.1126/science.1076024	http://dx.doi.org/10.1126/science.1076024			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459579				2022-12-28	WOS:000179494800031
J	Jiang, R; Manson, JE; Stampfer, MJ; Liu, SM; Willett, WC; Hu, FB				Jiang, R; Manson, JE; Stampfer, MJ; Liu, SM; Willett, WC; Hu, FB			Nut and peanut butter consumption and risk of type 2 diabetes in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; SATURATED FATTY-ACIDS; LOW-CARBOHYDRATE DIET; INSULIN SENSITIVITY; MONOUNSATURATED-FAT; GLUCOSE-TOLERANCE; GLYCEMIC LOAD; LIFE-STYLE; PLASMA-CHOLESTEROL; SERUM-LIPOPROTEIN	Context Nuts are high in unsaturated (polyunsaturated and monounsaturated) fat and other nutrients that may,improve glucose and insulin homeostasis. Objective To examine prospectively the relationship between nut consumption and risk of type 2 diabetes. Design, Setting, and Participants. Prospective cohort study of 83 818 women from 11 states in the Nurses' Health Study. The women were aged 34 to 59 years, had no history of diabetes, cardiovascular disease, or cancer, completed a validated dietary questionnaire at baseline in 1980, and were followed up for 16 years. Main Outcome Measure Incident cases of type 2 diabetes. Results We documented 3206 new cases of type 2 diabetes. Nut consumption was inversely associated with risk of type 2 diabetes after adjustment for age, body mass index (BMI), family history of diabetes, physical activity, smoking, alcohol use, and total energy intake. The multivariate relative risks (RRs) across categories of nut consumption (never/almost never, <once/week, 1-4 times/week, and >= 5 times/week) for a 28-g (1 oz) serving size were 1.0, 0.92 (95% confidence interval [CI], 0.85-1.00), 0.84 (0.95% CI, 0.76-0.93), and 0.73 (95% CI, 0.60-0.89) (P for trend <.001). Further adjustment for-intakes of dietary fats, cereal fiber, and other dietary factors did not appreciably change the results. The inverse association persisted within strata defined by levels of BMI, smoking, alcohol use, and other diabetes risk factors. Consumption of peanut butter was also inversely associated with type 2 diabetes. The multivariate RR was 0.79 (95% CI, 0.68-0.91; P for trend <.001) in women consuming peanut butter 5 times or more a week (equivalent to >= 140 g [5 oz] of peanuts/week) compared with those who never/almost never ate peanut butter. Conclusions Our findings suggest potential benefits of higher nut and peanut butter consumption in lowering risk of type 2 diabetes in women. To avoid increasing caloric intake, regular nut consumption can be recommended as a replacement for consumption of refined grain products or red or processed meats.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Prevent Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Jiang, R (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	rjiang@hsph.harvard.edu	Liu, Simin/GSN-4159-2022; Hu, Frank/C-1919-2013; Liu, Simin/I-3689-2014	Liu, Simin/0000-0003-2098-3844	NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058845] Funding Source: NIH RePORTER; NCI NIH HHS [CA87969] Funding Source: Medline; NIDDK NIH HHS [DK58845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBEY M, 1994, AM J CLIN NUTR, V59, P995, DOI 10.1093/ajcn/59.5.995; *AM DIAB ASS, 2002, DIAB FACTS FIG 2000; ANDERSON JW, 1987, J AM DIET ASSOC, V87, P1189; BORKMAN M, 1991, J CLIN ENDOCR METAB, V72, P432, DOI 10.1210/jcem-72-2-432; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; Christiansen E, 1997, DIABETES CARE, V20, P881, DOI 10.2337/diacare.20.5.881; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; Cox D. R., 1984, ANAL SURVIVAL DATA; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; FESKENS EJM, 1990, INT J EPIDEMIOL, V19, P953, DOI 10.1093/ije/19.4.953; FESKENS EJM, 1994, AM J EPIDEMIOL, V140, P350, DOI 10.1093/oxfordjournals.aje.a117257; FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437; FESKENS EJM, 1995, DIABETES CARE, V18, P1104, DOI 10.2337/diacare.18.8.1104; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; Fraser GE, 1997, EPIDEMIOLOGY, V8, P168, DOI 10.1097/00001648-199703000-00008; Gavin JR, 1997, DIABETES CARE, V20, P1183; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HARRIS M, 1979, DIABETES, V28, P1039; HEINE RJ, 1989, AM J CLIN NUTR, V49, P448, DOI 10.1093/ajcn/49.3.448; HOUTSMULLER AJ, 1980, NUTR METAB, V24, P105; HOWARD BV, 1991, DIABETES CARE, V14, P786, DOI 10.2337/diacare.14.9.786; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341; Hu FB, 2001, DIABETOLOGIA, V44, P805, DOI 10.1007/s001250100547; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Kleinbaum D, 1988, APPL REGRESSION ANAL; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Liu SM, 2000, AM J PUBLIC HEALTH, V90, P1409, DOI 10.2105/AJPH.90.9.1409; Louheranta AM, 1998, METABOLISM, V47, P529, DOI 10.1016/S0026-0495(98)90235-9; LUNDGREN H, 1989, AM J CLIN NUTR, V49, P708, DOI 10.1093/ajcn/49.4.708; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MARSHALL JA, 1991, AM J EPIDEMIOL, V134, P590, DOI 10.1093/oxfordjournals.aje.a116132; MayerDavis EJ, 1997, AM J CLIN NUTR, V65, P79, DOI 10.1093/ajcn/65.1.79; Meyer KA, 2000, AM J CLIN NUTR, V71, P921; OByrne DJ, 1997, LIPIDS, V32, P687, DOI 10.1007/s11745-997-0088-y; PAOLISSO G, 1989, DIABETES CARE, V12, P265, DOI 10.2337/diacare.12.4.265; PAOLISSO G, 1990, DIABETOLOGIA, V33, P511, DOI 10.1007/BF00404136; PAOLISSO G, 1992, AM J CLIN NUTR, V55, P1161, DOI 10.1093/ajcn/55.6.1161; PARILLO M, 1992, METABOLISM, V41, P1373, DOI 10.1016/0026-0495(92)90111-M; PRINEAS RJ, 1993, NEW ENGL J MED, V329, P359; RESNICK LM, 1993, AM J HYPERTENS, V6, pS123, DOI 10.1093/ajh/6.4S.123S; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIVELLESE A, 1980, LANCET, V2, P447; SABATE J, 1993, NEW ENGL J MED, V328, P603, DOI 10.1056/NEJM199303043280902; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545; Salmeron J, 2001, AM J CLIN NUTR, V73, P1019; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SCHWAB US, 1995, J NUTR, V125, P466; SIMPSON HCR, 1981, LANCET, V1, P1; SJOGREN A, 1988, MAGNESIUM, V7, P117; SPILLER GA, 1992, J AM COLL NUTR, V11, P126; Storlien LH, 1996, DIABETOLOGIA, V39, P621, DOI 10.1007/BF00418533; SWINBURN BA, 1991, J CLIN ENDOCR METAB, V73, P156, DOI 10.1210/jcem-73-1-156; TREVISAN M, 1990, JAMA-J AM MED ASSOC, V263, P688, DOI 10.1001/jama.263.5.688; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; *USDA, 1993, COMP FOODS RAW PROC; UUSITUPA M, 1994, AM J CLIN NUTR, V59, P1310, DOI 10.1093/ajcn/59.6.1310; van Dam RM, 2002, DIABETES CARE, V25, P417, DOI 10.2337/diacare.25.3.417; Vessby B, 2001, DIABETOLOGIA, V44, P312, DOI 10.1007/s001250051620; Willett W, 2002, AM J CLIN NUTR, V76, p274S, DOI 10.1093/ajcn/76.1.274S; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLETT WC, 1998, MODERN EPIDEMIOLOGY, P623	65	336	346	3	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2002	288	20					2554	2560		10.1001/jama.288.20.2554	http://dx.doi.org/10.1001/jama.288.20.2554			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AL	12444862	Bronze			2022-12-28	WOS:000179394500022
J	Basaria, S; de Beur, SJ				Basaria, S; de Beur, SJ			The white butterfly	LANCET			English	Editorial Material									Johns Hopkins Univ, Sch Med, Div Endocrinol & Metab, Baltimore, MD 21224 USA	Johns Hopkins University	Basaria, S (corresponding author), Johns Hopkins Univ, Sch Med, Div Endocrinol & Metab, Baltimore, MD 21224 USA.			Basaria, Shehzad/0000-0002-8533-2383; Basaria, Shehzad/0000-0003-1749-8549					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 23	2002	360	9346					1639	1639		10.1016/S0140-6736(02)11611-4	http://dx.doi.org/10.1016/S0140-6736(02)11611-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457786				2022-12-28	WOS:000179393900008
J	Bomford, A				Bomford, A			Genetics of haemochromatosis	LANCET			English	Review							AUTOSOMAL-DOMINANT HEMOCHROMATOSIS; VOLUNTARY BLOOD-DONORS; IRON-BINDING-CAPACITY; CLASS-I MOLECULE; HEREDITARY HEMOCHROMATOSIS; TRANSFERRIN RECEPTOR; HFE MUTATIONS; IDIOPATHIC HEMOCHROMATOSIS; PROTEIN HFE; CLINICAL EXPRESSION	After identification of the hereditary haemchromatosis gene HFE, and receipt of confirmation that most patients with the condition were homozygous for a single, founder mutation (C282Y), most assumed that C282Y would be a prevalent, highly penetrant mutation in a gene that plays a key part in the regulation of iron absorption and of whole-body iron homoeostasis. With carrier rates of between 10% and 15%, and a homozygote frequency of about one-in-150 in people of northern European descent, C282Y is certainly prevalent. However, it is not highly penetrant. The pronounced variation in phenotype in individuals with the same gene mutation has prompted the search for modifier genes at other loci, and foe environmental factors that might affect expression of the condition. Progress in our understanding of how HFE regulates the absorption of dietary iron has been slow, but much can be learnt from the study of the rare instances of haemochromatosis that involve mutations in newly-identified iron-metabolism genes, such as TFR2-a transferrin receptor isoform-and ferroportin1/IREG1/MTP1-an intestinal iron transporter. The availability of definitive information on penetrance and the identity of genetic modifiers will aid the debate on whether population screening for haemochromatosis should be undertaken or whether alternative strategies should be implemented to improve early detection.	Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Bomford, A (corresponding author), Kings Coll Hosp London, Inst Liver Studies, Denmark Hill, London SE5 9RS, England.		Bomford, Adrian/A-7462-2011					Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Adam D, 2001, NATURE, V414, P6, DOI 10.1038/35102234; Adams P, 2000, J HEPATOL, V33, P487, DOI 10.1016/S0168-8278(01)80874-6; Adams PC, 2000, HEPATOLOGY, V31, P1160, DOI 10.1053/he.2000.6984; Adams PC, 1999, AM J GASTROENTEROL, V94, P1593; Adams PC, 2000, GUT, V46, P301, DOI 10.1136/gut.46.3.301; Aguilar-Martinez P, 2001, GUT, V48, P836, DOI 10.1136/gut.48.6.836; Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; Ajioka RS, 2002, BLOOD, V100, P1465, DOI 10.1182/blood-2001-11-0037; Allen K, 2000, BRIT MED J, V320, P183, DOI 10.1136/bmj.320.7228.183; Andrikovics H, 2001, BLOOD CELL MOL DIS, V27, P334, DOI 10.1006/bcmd.2001.0384; Asberg A, 2001, SCAND J GASTROENTERO, V36, P1108; BACON BR, 1990, HEPATOLOGY, V11, P127, DOI 10.1002/hep.1840110122; Bacon BR, 2001, GASTROENTEROLOGY, V120, P718, DOI 10.1053/gast.2001.21913; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Bastin JM, 1998, BRIT J HAEMATOL, V103, P931, DOI 10.1046/j.1365-2141.1998.01102.x; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; Beutler E, 2002, LANCET, V359, P211, DOI 10.1016/S0140-6736(02)07447-0; Bhavnani M, 2000, GUT, V46, P707, DOI 10.1136/gut.46.5.707; Bonn D, 2000, LANCET, V355, P1526, DOI 10.1016/S0140-6736(05)74585-2; Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211; Bothwell TH, 1998, SEMIN HEMATOL, V35, P55; Brissot P, 1999, J HEPATOL, V30, P588, DOI 10.1016/S0168-8278(99)80188-3; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Burt MJ, 1998, GUT, V43, P830, DOI 10.1136/gut.43.6.830; Byrnes V, 2000, BLOOD CELL MOL DIS, V26, P2, DOI 10.1006/bcmd.2000.0270; Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534; Canonne-Hergaux F, 2001, BLOOD, V97, P1138, DOI 10.1182/blood.V97.4.1138; Cassanelli S, 2001, J HEPATOL, V34, P523, DOI 10.1016/S0168-8278(01)00035-6; Cogswell ME, 1998, ANN INTERN MED, V129, P971, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00008; Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7; Crawford DHG, 1998, GASTROENTEROLOGY, V114, P1003, DOI 10.1016/S0016-5085(98)70320-8; Crawford DHG, 2000, HEPATOLOGY, V31, P1192, DOI 10.1053/he.2000.7354; CRAWFORD DHG, 1995, AM J HUM GENET, V57, P362; Cullen LM, 1998, AM J HUM GENET, V62, P1403, DOI 10.1086/301878; Datz C, 1997, J HEPATOL, V27, P773, DOI 10.1016/S0168-8278(97)80312-1; Devalia V, 2002, BLOOD, V100, P695, DOI 10.1182/blood-2001-11-0132; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Dupic F, 2002, GASTROENTEROLOGY, V122, P745, DOI 10.1053/gast.2002.31877; EASON RJ, 1990, AUST NZ J MED, V20, P226, DOI 10.1111/j.1445-5994.1990.tb01024.x; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; Ehrlich R, 2000, IMMUNITY, V13, P585, DOI 10.1016/S1074-7613(00)00058-3; Fargion S, 2001, BLOOD, V97, P3707, DOI 10.1182/blood.V97.12.3707; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feeney GP, 2001, BBA-MOL CELL RES, V1538, P242, DOI 10.1016/S0167-4889(01)00075-1; FINCH C, 1994, BLOOD, V84, P1697; Fleming RE, 2001, P NATL ACAD SCI USA, V98, P2707, DOI 10.1073/pnas.051630898; Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143; Fletcher LM, 2002, GASTROENTEROLOGY, V122, P281, DOI 10.1053/gast.2002.30992; Frazer DM, 2001, AM J PHYSIOL-GASTR L, V281, pG931, DOI 10.1152/ajpgi.2001.281.4.G931; GAVIN MW, 1994, AM J CLIN NUTR, V59, P1376, DOI 10.1093/ajcn/59.6.1376; Gochee PA, 2002, GASTROENTEROLOGY, V122, P646, DOI 10.1016/S0016-5085(02)80116-0; Griffiths WJH, 2001, GASTROENTEROLOGY, V120, P1420, DOI 10.1053/gast.2001.24050; GROOTVELD M, 1989, J BIOL CHEM, V264, P4417; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hanson EH, 2001, AM J EPIDEMIOL, V154, P193, DOI 10.1093/aje/154.3.193; Hickman PE, 2000, GUT, V46, P405, DOI 10.1136/gut.46.3.405; Holtzman NA, 2000, NEW ENGL J MED, V343, P141, DOI 10.1056/NEJM200007133430213; Houglum K, 1997, HEPATOLOGY, V26, P605, DOI 10.1002/hep.510260311; Jackson HA, 2001, BRIT J HAEMATOL, V114, P474, DOI 10.1046/j.1365-2141.2001.02949.x; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jezequel P, 1998, HUM GENET, V102, P332, DOI 10.1007/s004390050701; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kato J, 2001, AM J HUM GENET, V69, P191, DOI 10.1086/321261; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Krawczak M, 2001, AM J HUM GENET, V69, P361, DOI 10.1086/321973; Le Gac G, 2000, BLOOD CELL MOL DIS, V26, P312, DOI 10.1006/bcmd.2000.0312; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lee HJ, 2001, INT J MULTIPHAS FLOW, V27, P783, DOI 10.1016/S0301-9322(00)00050-1; Lee PL, 2001, BLOOD CELL MOL DIS, V27, P285, DOI 10.1006/bcmd.2001.0381; Lee PL, 1999, BLOOD CELL MOL DIS, V25, P374, DOI 10.1006/bcmd.1999.0267; Levy JE, 2000, J CLIN INVEST, V105, P1209, DOI 10.1172/JCI9635; LOMBARD M, 1990, GASTROENTEROLOGY, V98, P976, DOI 10.1016/0016-5085(90)90022-S; Lombard M, 1997, GUT, V40, P435, DOI 10.1136/gut.40.4.435; Lucotte G, 2001, BLOOD CELL MOL DIS, V27, P549, DOI 10.1006/bcmd.2001.0417; LYNCH SR, 1989, BLOOD, V74, P2187; Mattman A, 2002, BLOOD, V100, P1075, DOI 10.1182/blood-2002-01-0133; McCullen MA, 2002, CLIN CHIM ACTA, V315, P169, DOI 10.1016/S0009-8981(01)00711-2; McDonnell SM, 1999, AM J MED, V106, P619, DOI 10.1016/S0002-9343(99)00120-5; McDonnell SM, 1999, AM J MED, V107, P30, DOI 10.1016/S0002-9343(99)00163-1; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; Merryweather-Clarke AT, 1998, BRIT J HAEMATOL, V101, P369, DOI 10.1046/j.1365-2141.1998.00736.x; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; Montosi G, 2000, BLOOD, V96, P1125, DOI 10.1182/blood.V96.3.1125.015k19_1125_1129; Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468; Mura C, 1999, BLOOD, V93, P2502, DOI 10.1182/blood.V93.8.2502.408k27_2502_2505; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Nielsen P, 1998, BRIT J HAEMATOL, V103, P842; Njajou OT, 2001, NAT GENET, V28, P213, DOI 10.1038/90038; OLSSON L, 1994, P NATL ACAD SCI USA, V91, P9086, DOI 10.1073/pnas.91.19.9086; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Parkkila S, 2001, GASTROENTEROLOGY, V121, P1489, DOI 10.1053/gast.2001.29617; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; Philpott CC, 2002, HEPATOLOGY, V35, P993, DOI 10.1053/jhep.2002.33466; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; Piperno A, 1996, HEPATOLOGY, V24, P43, DOI 10.1002/hep.510240109; Piperno A, 1998, GASTROENTEROLOGY, V114, P996, DOI 10.1016/S0016-5085(98)70319-1; Pointon JJ, 2000, GENET TEST, V4, P151, DOI 10.1089/10906570050114867; Powell LW, 2000, J HEPATOL, V32, P48, DOI 10.1016/S0168-8278(00)80415-8; Pratiwi R, 1999, J HEPATOL, V31, P39, DOI 10.1016/S0168-8278(99)80161-5; Provenzale Dawn, 2002, Gastrointest Endosc Clin N Am, V12, P93, DOI 10.1016/S1052-5157(03)00061-8; Ramalingam TS, 2000, NAT CELL BIOL, V2, P953, DOI 10.1038/35046611; Riedel HD, 1999, BLOOD, V94, P3915, DOI 10.1182/blood.V94.11.3915.423k27_3915_3921; Rochette J, 1999, AM J HUM GENET, V64, P1056, DOI 10.1086/302318; Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379; Roetto A, 2001, BLOOD, V97, P2555, DOI 10.1182/blood.V97.9.2555; Rolfs A, 2002, AM J PHYSIOL-GASTR L, V282, pG598, DOI 10.1152/ajpgi.00371.2001; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; Roy CN, 2000, BLOOD, V96, P4020, DOI 10.1182/blood.V96.13.4020.h8004020_4020_4027; Ryan E, 1998, BLOOD CELL MOL DIS, V24, P428, DOI 10.1006/bcmd.1998.0211; Sachot S, 2001, BLOOD CELL MOL DIS, V27, P518, DOI 10.1006/bcmd.2001.0394; Salter-Cid L, 1999, P NATL ACAD SCI USA, V96, P5434, DOI 10.1073/pnas.96.10.5434; Santos M, 1998, BLOOD, V91, P3059, DOI 10.1182/blood.V91.8.3059.3059_3059_3065; Simon M, 1980, Prog Med Genet, V4, P135; SIMON M, 1976, GUT, V17, P332, DOI 10.1136/gut.17.5.332; Sproule TJ, 2001, P NATL ACAD SCI USA, V98, P5170, DOI 10.1073/pnas.091088998; Steinberg KK, 2001, JAMA-J AM MED ASSOC, V285, P2216, DOI 10.1001/jama.285.17.2216; Tavill AS, 2001, HEPATOLOGY, V33, P1321, DOI 10.1053/jhep.2001.24783; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; Trinder D, 2002, P NATL ACAD SCI USA, V99, P5622, DOI 10.1073/pnas.082112299; *UK HAEM CONS, 1997, GUT, V44, P841; Van Vlierberghe H, 2001, J HEPATOL, V35, P707, DOI 10.1016/S0168-8278(01)00203-3; Vineis P, 2001, LANCET, V357, P709, DOI 10.1016/S0140-6736(00)04136-2; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Waheed A, 1999, P NATL ACAD SCI USA, V96, P1579, DOI 10.1073/pnas.96.4.1579; Waheed A, 2002, P NATL ACAD SCI USA, V99, P3117, DOI 10.1073/pnas.042701499; Walker AP, 1999, J MED GENET, V36, P537; Wallace DF, 2002, J HEPATOL, V36, P474, DOI 10.1016/S0168-8278(01)00304-X; Wallace DF, 2002, BLOOD, V100, P692, DOI 10.1182/blood.V100.2.692; West AP, 2000, J BIOL CHEM, V275, P38135, DOI 10.1074/jbc.C000664200; Whitfield JB, 2000, AM J HUM GENET, V66, P1246, DOI 10.1086/302862; WHITTAKER P, 1989, J CLIN INVEST, V83, P261, DOI 10.1172/JCI113868; WILLIAMS R, 1966, BMJ-BRIT MED J, V2, P78, DOI 10.1136/bmj.2.5505.78; Willis G, 2000, GUT, V46, P401, DOI 10.1136/gut.46.3.401; Willis G, 1999, LANCET, V354, P221, DOI 10.1016/S0140-6736(99)02195-9; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Yang QH, 1998, ANN INTERN MED, V129, P946, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00005; Zoller H, 2001, GASTROENTEROLOGY, V120, P1412, DOI 10.1053/gast.2001.24033; Zuccon L, 2000, HAEMATOLOGICA, V85, P346	145	89	96	1	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2002	360	9346					1673	1681		10.1016/S0140-6736(02)11607-2	http://dx.doi.org/10.1016/S0140-6736(02)11607-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457803				2022-12-28	WOS:000179393900025
J	Buchanan, G; Halligan, S; Williams, A; Cohen, CRG; Tarroni, D; Phillips, RKS; Bartram, CI				Buchanan, G; Halligan, S; Williams, A; Cohen, CRG; Tarroni, D; Phillips, RKS; Bartram, CI			Effect of MRI on clinical outcome of recurrent fistula-in-ano	LANCET			English	Article							ANAL FISTULAS; SURGERY	Recurrent fistula-in-ano is usually due to sepsis missed at surgery, which can be identified by MRI. We aimed to establish the therapeutic effect of MRI in patients with fistula-in-ano. We did MRI in 71 patients with recurrent fistula, with further surgery done at the discretion of the surgeon. Surgery and MRI agreed in 40 patients, five (13%) of whom had further recurrence, compared with 16 (52%) of 31 in whom surgery and MRI disagreed (p=0.0005). Further recurrence in all 16 was at the site predicted by MRI. For surgeons who always acted on MRI, further recurrences arose in four of 25 (16%) operations versus eight of 14 (57%) operations for those who ignored imaging (p=0.008). Surgery guided by MRI reduces further recurrence of fistula-in-ano by 75% and should be done in all patients with recurrent fistula.	St Marks Hosp, Intestinal Imaging Ctr, London HA1 3UJ, England; St Marks Hosp, Dept Surg, London HA1 3UJ, England	Imperial College London; Imperial College London	Halligan, S (corresponding author), St Marks Hosp, Intestinal Imaging Ctr, Northwick Pk, London HA1 3UJ, England.		Halligan, Steve/C-5875-2009	Halligan, Steve/0000-0003-0632-5108				Beets-Tan RGH, 2001, RADIOLOGY, V218, P75, DOI 10.1148/radiology.218.1.r01dc0575; GarciaAguilar J, 1996, DIS COLON RECTUM, V39, P723, DOI 10.1007/BF02054434; LUNNISS PJ, 1992, LANCET, V340, P394, DOI 10.1016/0140-6736(92)91472-K; Scholefield JH, 1997, INT J COLORECTAL DIS, V12, P276, DOI 10.1007/s003840050105; Spencer JA, 1998, AM J ROENTGENOL, V171, P403, DOI 10.2214/ajr.171.2.9694464	5	153	161	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 23	2002	360	9346					1661	1662		10.1016/S0140-6736(02)11605-9	http://dx.doi.org/10.1016/S0140-6736(02)11605-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618AE	12457791				2022-12-28	WOS:000179393900013
J	Ozaki, K; Spolski, R; Feng, CG; Qi, CF; Cheng, J; Sher, A; Morse, HC; Liu, CY; Schwartzberg, PL; Leonard, WJ				Ozaki, K; Spolski, R; Feng, CG; Qi, CF; Cheng, J; Sher, A; Morse, HC; Liu, CY; Schwartzberg, PL; Leonard, WJ			A critical role for IL-21 in regulating immunoglobulin production	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; B-CELL FUNCTION; LYMPHOID DEVELOPMENT; CYTOKINE RECEPTOR; NATURAL-KILLER; GAMMA-CHAIN; EXPRESSION; MEMORY; MICE; TRANSPLANTATION	The cytokine interleukin-21 (IL-21) is closely related to IL-2 and IL-15, and their receptors all share the common cytokine receptor gamma chain, gamma(c), which is mutated in humans with X-linked severe combined immunodeficiency disease (XSCID). We demonstrate that, although mice deficient in the receptor for IL-21 (IL-21R) have normal lymphoid development, after immunization, these animals have higher production of the immunoglobulin IgE, but lower IgG1, than wild-type animals. Mice lacking both IL-4 and IL-21R exhibited a significantly more pronounced phenotype, with dysgammaglobulinemia, characterized primarily by a severely impaired IgG response. Thus, IL-21 has a significant influence on the regulation of B cell function in vivo and cooperates with IL-4. This suggests that these gamma(c)-dependent cytokines may be those whose inactivation is primarily responsible for the B cell defect in humans with XSCID.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; NHLBI, Transgen Facil, NIH, Bethesda, MD 20892 USA; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NIAID, Immunopathol Lab, NIH, Bethesda, MD 20892 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 49,Room 4A38, Bethesda, MD 20892 USA.	wjl@helix.nih.gov	Leonard, Warren/AAA-1397-2022	feng, carl/0000-0003-4301-4640; Morse, Herbert/0000-0002-9331-3705	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL005401, Z01HL005401] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000123, Z01HG000123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000858, Z01AI000858] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asao H, 2001, J IMMUNOL, V167, P1, DOI 10.4049/jimmunol.167.1.1; BUCKLEY R, 1993, FASEB J, V7, pA95; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; BUCKLEY RH, COMMUNICATION; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CavazzanaCalvo M, 1996, BLOOD, V88, P3901, DOI 10.1182/blood.V88.10.3901.bloodjournal88103901; CONLEY ME, 1988, P NATL ACAD SCI USA, V85, P3090, DOI 10.1073/pnas.85.9.3090; CONLEY ME, 1991, CLIN IMMUNOL IMMUNOP, V61, pS94, DOI 10.1016/S0090-1229(05)80043-1; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Driver DJ, 2001, J IMMUNOL, V167, P1393, DOI 10.4049/jimmunol.167.3.1393; Feng C. J., UNPUB; FINKELMAN FD, 1987, J IMMUNOL, V138, P2826; GOUGEON ML, 1990, J IMMUNOL, V145, P2873; Haddad E, 1999, BLOOD, V94, P2923, DOI 10.1182/blood.V94.8.2923.420k44_2923_2930; Hartnett BJ, 2000, VET IMMUNOL IMMUNOP, V75, P121, DOI 10.1016/S0165-2427(00)00193-8; Kasaian MT, 2002, IMMUNITY, V16, P559, DOI 10.1016/S1074-7613(02)00295-9; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Leonard WJ, 2001, NAT REV IMMUNOL, V1, P200, DOI 10.1038/35105066; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; McHeyzer-Williams LJ, 2000, J EXP MED, V191, P1149, DOI 10.1084/jem.191.7.1149; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Ozaki K, 2000, P NATL ACAD SCI USA, V97, P11439, DOI 10.1073/pnas.200360997; OZAKI K, UNPUB; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; SMALL TN, 1989, HUM IMMUNOL, V25, P181, DOI 10.1016/0198-8859(89)90081-5; Suzuki Y, 1996, J IMMUNOL, V157, P2564; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; White H, 2000, EUR J IMMUNOL, V30, P732; Yap GS, 1999, IMMUNOBIOLOGY, V201, P240, DOI 10.1016/S0171-2985(99)80064-3	32	766	804	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1630	1634		10.1126/science.1077002	http://dx.doi.org/10.1126/science.1077002			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12446913	Green Published			2022-12-28	WOS:000179361600052
J	Hirosumi, J; Tuncman, G; Chang, LF; Gorgun, CZ; Uysal, KT; Maeda, K; Karin, M; Hotamisligil, GS				Hirosumi, J; Tuncman, G; Chang, LF; Gorgun, CZ; Uysal, KT; Maeda, K; Karin, M; Hotamisligil, GS			A central role for JNK in obesity and insulin resistance	NATURE			English	Article							C-JUN ACTIVATION; PROTEIN-KINASE; TNF-ALPHA; LIPID-METABOLISM; DIFFERENTIATION; APOPTOSIS; GLUCOSE; STRESS	Obesity is closely associated with insulin resistance and establishes the leading risk factor for type 2 diabetes mellitus, yet the molecular mechanisms of this association are poorly understood(1). The c-Jun amino-terminal kinases (JNKs) can interfere with insulin action in cultured cells(2) and are activated by inflammatory cytokines and free fatty acids, molecules that have been implicated in the development of type 2 diabetes(3,4). Here we show that JNK activity is abnormally elevated in obesity. Furthermore, an absence of JNK1 results in decreased adiposity, significantly improved insulin sensitivity and enhanced insulin receptor signalling capacity in two different models of mouse obesity. Thus, JNK is a crucial mediator of obesity and insulin resistance and a potential target for therapeutics.	Harvard Univ, Sch Publ Hlth, Div Biol Sci, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Diego	Hotamisligil, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Div Biol Sci, 665 Huntington Ave, Boston, MA 02115 USA.							Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hotamisligil G.S, 2000, DIABETES MELLITUS, P651; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; Rizzo MT, 1999, PROSTAG LEUKOTR ESS, V60, P187, DOI 10.1054/plef.1999.0024; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sethi JK, 1999, SEMIN CELL DEV BIOL, V10, P19, DOI 10.1006/scdb.1998.0273; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	26	2469	2630	2	221	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	2002	420	6913					333	336		10.1038/nature01137	http://dx.doi.org/10.1038/nature01137			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617BM	12447443				2022-12-28	WOS:000179340400046
J	Yamey, G				Yamey, G			WHO's management: struggling to transform a "fossilised bureaucracy"	BMJ-BRITISH MEDICAL JOURNAL			English	Article									BMJ Unified, London WC1H 9JR, England		Yamey, G (corresponding author), BMJ Unified, London WC1H 9JR, England.	gyamey@bmj.com						Anand S, 1998, WORLD DEV, V26, P307, DOI 10.1016/S0305-750X(97)10019-5; Braveman P, 2001, BRIT MED J, V323, P678, DOI 10.1136/bmj.323.7314.678; GODLEE F, 1994, BRIT MED J, V309, P1636, DOI 10.1136/bmj.309.6969.1636; GODLEE F, 1994, BRIT MED J, V309, P1566, DOI 10.1136/bmj.309.6968.1566; GODLEE F, 1994, BRIT MED J, V309, P1424, DOI 10.1136/bmj.309.6966.1424; Kapp C, 2002, LANCET, V359, P329, DOI 10.1016/S0140-6736(02)07562-1; Lerer L, 2001, INT J HEALTH SERV, V31, P415, DOI 10.2190/XE6N-XDKK-XY4C-57GV; SMITH R, 1995, BRIT MED J, V310, P543, DOI 10.1136/bmj.310.6979.543; *WHO, 2002, HUM RES ANN REP 2001; *WHO, 1999, 9910 WHO; *WHO, 1999, GH BRUNDTL HUM DEV W; *WHO, 1999, GH BRUNDTL WHO WAY A; *WHO, 2002, NEED INCR REPR DEV C; *WHO, 1978, ALM AT DECL PRIM HL; *WHO, 2002, ASS HLTH SYST PERF R; *WHO SAFF ASS, 2001, JOB SAT SURV RES; Williams A, 2001, HEALTH ECON, V10, P93, DOI 10.1002/hec.594; World Health Organization (WHO), 1981, GLOB STRAT HLTH ALL	18	10	10	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	2002	325	7373					1170	1173		10.1136/bmj.325.7373.1170	http://dx.doi.org/10.1136/bmj.325.7373.1170			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433772	Green Published			2022-12-28	WOS:000179443100032
J	Psaltis, D				Psaltis, D			Coherent optical information systems	SCIENCE			English	Article							STORAGE; TOMOGRAPHY; MEMORY	Coherent optical beams are used to communicate, store, and process information in a growing number of applications. The availability of coherent laser sources is of critical importance for the realization of such optical information systems. An incoherent source randomly populates the available temporal and spatial channels of the optical system, making it difficult to represent information. Coherent laser sources provide a stable carrier on which to encode information, making it possible to realize powerful information-processing techniques such as wavelength division multiplexing in fiber networks, gated holographic imaging, and three-dimensional optical data storage.	CALTECH, Dept Elect Engn, Pasadena, CA 91125 USA	California Institute of Technology	Psaltis, D (corresponding author), CALTECH, Dept Elect Engn, Pasadena, CA 91125 USA.							An X, 1999, APPL OPTICS, V38, P386, DOI 10.1364/AO.38.000386; Chinn SR, 1996, OPT LETT, V21, P899, DOI 10.1364/OL.21.000899; Chuang E, 1999, P IEEE, V87, P1931, DOI 10.1109/5.796355; Collier R., 1971, OPTICAL HOLOGRAPHY; Coufal H. J., 2000, HOLOGRAPHIC DATA STO; Denisyuk Y.N., 1962, DOKL PHYS, V7, P543; GABOR D, 1948, NATURE, V161, P777, DOI 10.1038/161777a0; Goodman J. W., 2000, STAT OPTICS, V1; GOODMAN JW, 1984, P IEEE, V72, P850, DOI 10.1109/PROC.1984.12943; GROVER A, 1976, J OPT SOC AM, V66, P306; HEE MR, 1993, OPT LETT, V18, P950, DOI 10.1364/OL.18.000950; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; HYDE SCW, 1995, OPT LETT, V20, P1331, DOI 10.1364/OL.20.001331; Ikuta M, 2002, APPL OPTICS, V41, P1882, DOI 10.1364/AO.41.001882; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; KAZOVSKY LG, 1996, OPTICAL FIBER COMMUN; Li GQ, 2002, APPL OPTICS, V41, P348, DOI 10.1364/AO.41.000348; Liu WH, 2002, OPT LETT, V27, P854, DOI 10.1364/OL.27.000854; Liu WH, 1999, OPT LETT, V24, P1340, DOI 10.1364/OL.24.001340; Madsen C.K., 1999, OPTICAL FILTER DESIG; Mandel L, 1995, OPTICAL COHERENCE QU; Marks DL, 1999, SCIENCE, V284, P2164, DOI 10.1126/science.284.5423.2164; Othonos A, 1997, REV SCI INSTRUM, V68, P4309, DOI 10.1063/1.1148392; PARTHENOPOULOS DA, 1989, SCIENCE, V245, P843, DOI 10.1126/science.245.4920.843; RAKULJIC GA, 1993, OPT LETT, V18, P459, DOI 10.1364/OL.18.000459; Saleh B.E.A., 2007, FUNDAMENTALS PHOTONI, V2nd; Steckman GJ, 2001, APPL OPTICS, V40, P3387, DOI 10.1364/AO.40.003387; Wang MM, 2000, APPL OPTICS, V39, P1826, DOI 10.1364/AO.39.001826	28	72	73	5	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1359	1363		10.1126/science.1078823	http://dx.doi.org/10.1126/science.1078823			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434049	Green Published			2022-12-28	WOS:000179223100037
J	Coey, JMD; Venkatesan, M; Fitzgerald, CB; Douvalis, AP; Sanders, IS				Coey, JMD; Venkatesan, M; Fitzgerald, CB; Douvalis, AP; Sanders, IS			Ferromagnetism of a graphite nodule from the Canyon Diablo meteorite	NATURE			English	Article							CARBON	There are recent reports of weak ferromagnetism in graphite(1,2) and synthetic carbon materials(3) such as rhombohedral C-60 (ref. 4), as well as a theoretical prediction of a ferromagnetic instability in graphene sheets(5). With very small ferromagnetic signals, it is difficult to be certain that the origin is intrinsic, rather than due to minute concentrations of iron-rich impurities. Here we take a different experimental approach to study ferromagnetism in graphitic materials, by making use of meteoritic graphite, which is strongly ferromagnetic at room temperature. We examined ten samples of extraterrestrial graphite from a nodule in the Canyon Diablo meteorite. Graphite is the major phase in every sample, but there are minor amounts of magnetite, kamacite, akaganeite, and other phases. By analysing the phase composition of a series of samples, we find that these iron-rich minerals can only account for about two-thirds of the observed magnetization. The remainder is somehow associated with graphite, corresponding to an average magnetization of 0.05 Bohr magnetons per carbon atom. The magnetic ordering temperature is near 570 K. We suggest that the ferromagnetism is a magnetic proximity effect induced at the interface with magnetite or kamacite inclusions.	Univ Dublin Trinity Coll, Dept Phys, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Geol, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	Coey, JMD (corresponding author), Univ Dublin Trinity Coll, Dept Phys, Dublin 2, Ireland.	jcoey@tcd.ie		Coey, John Michael David/0000-0003-0053-8452; Sanders, Ian/0000-0002-1125-5282				ALLEMAND PM, 1991, SCIENCE, V253, P301, DOI 10.1126/science.253.5017.301; Alphenaar BW, 2000, PHYSICA E, V6, P848, DOI 10.1016/S1386-9477(99)00233-7; Baskaran G, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.016402; BRETT R, 1969, GEOCHIM COSMOCHIM AC, V33, P1473, DOI 10.1016/0016-7037(69)90151-3; Coey JMD, 2002, J APPL PHYS, V91, P8345, DOI 10.1063/1.1447879; Esquinazi P, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.024429; Gonzalez J, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.134421; GRADY MM, 2000, CATALOGUE METEORITES, P89; Harigaya K, 2001, J PHYS-CONDENS MAT, V13, P1295, DOI 10.1088/0953-8984/13/6/309; Hohne R, 2002, ADV MATER, V14, P753, DOI 10.1002/1521-4095(20020517)14:10<753::AID-ADMA753>3.0.CO;2-D; KELLY BT, 1981, PHYSICS GRAPHITE; Makarova TL, 2001, NATURE, V413, P716, DOI 10.1038/35099527; MAKAROVA TL, IN PRESS STUDIES HIG, V44; Moehlecke S, 2002, PHILOS MAG B, V82, P1335, DOI 10.1080/13642810210146443; Mrzel A, 1998, CHEM PHYS LETT, V298, P329, DOI 10.1016/S0009-2614(98)01184-1; MURATA K, 1992, J CHEM SOC CHEM COMM, P567, DOI 10.1039/c39920000567; PAPIKE JJ, 1998, REV MINERALOGY, V35; Wakabayashi K, 2000, PHYSICA B, V280, P388, DOI 10.1016/S0921-4526(99)01778-0	18	168	169	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					156	159		10.1038/nature01100	http://dx.doi.org/10.1038/nature01100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432386	Green Submitted			2022-12-28	WOS:000179200900039
J	Jeffcoate, W				Jeffcoate, W			Rejection of new consultant contract is a vote of no confidence	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Jeffcoate, W (corresponding author), The Lancet, London NW1 7BY, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 9	2002	360	9344					1440	1440		10.1016/S0140-6736(02)11491-7	http://dx.doi.org/10.1016/S0140-6736(02)11491-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JV	12433509				2022-12-28	WOS:000179186000006
J	Yach, D				Yach, D			Unleashing the power of prevention to achieve global health-gains	LANCET			English	Editorial Material									WHO, CH-1211 Geneva, Switzerland	World Health Organization	Yach, D (corresponding author), WHO, CH-1211 Geneva, Switzerland.							[Anonymous], 1986, 1 INT C HLTH PROM; von Schirnding Y, 2002, REV SAUDE PUBL, V36, P379, DOI 10.1590/S0034-89102002000400001; *WHO, 2000, WHO REP 2002 RED RIS; WHO, 2002, INNOVATIVE CARE CHRO; *WHO, 2002, REP WHO M GEN 9 12 J; World Health Organization, 2002, NEW CHAIRS TEXT FRAM	6	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1343	1344		10.1016/S0140-6736(02)11413-9	http://dx.doi.org/10.1016/S0140-6736(02)11413-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423976				2022-12-28	WOS:000179081600003
J	Auerbach, AD; Wachter, RM; Katz, P; Showstack, J; Baron, RB; Goldman, L				Auerbach, AD; Wachter, RM; Katz, P; Showstack, J; Baron, RB; Goldman, L			Implementation of a voluntary hospitalist service at a community teaching hospital: Improved clinical efficiency and patient outcomes	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH MAINTENANCE ORGANIZATION; LIVER-TRANSPLANTATION; PROPENSITY SCORE; CARE; VOLUME; IMPACT; SYSTEM; EXPERIENCE; CANCER	Background: Previous investigations of the effect of the hospitalist model on resource use and patient outcomes have focused on academic medical centers or have used short follow-up periods. Objective: To determine the effects of hospitalist care on resource use and patient outcomes and whether these effects change over time. Design: Retrospective cohort study. Setting: Community-based, urban teaching hospital. Patients: 5308 patients cared for by community or hospitalist physicians in the 2 years after implementation of a voluntary hospitalist service. Measurements: Length of stay, costs, 10-day readmission rates, use of consultative services, in-hospital mortality rate, and mortality rate at 30 and 60 days. Results: Patients of hospitalists were younger than those of community physicians (65 years vs. 74 years; P < 0.001) and were more likely to be of black than of white ethnicity (33.3% vs.17.9%; P < 0.001), have Medicaid insurance (25.1 % vs. 10.2 %; P < 0.001), and receive intensive care (19.9% vs. 15.8%; P < 0.001). After adjustment in multivariable models, length of stay and costs were not different in the first year of the study. in year 2, patients of hospitalists had shorter stays (0.61 day shorter; P = 0.002) and lower costs ($822 lower; P = 0.002). Over the 2 years of this study, patients of hospitalists had lower risk for death in the hospital (adjusted relative hazard, 0.71 [95% Cl, 0.54 to 0.93]) and at 30 and 60 days of follow-up. Conclusions: A voluntary hospitalist service at a community based teaching hospital produced reductions in length of stay and costs that became statistically significant in the second year of use. A mortality benefit extending beyond hospitalization was noted in both years. Future investigations are needed to understand the ways in which hospitalists increase clinical efficiency and appear to improve the quality of care.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Auerbach, AD (corresponding author), Univ Calif San Francisco, Dept Med, Box 0120,505 Parnassus Ave, San Francisco, CA 94143 USA.	ada@medicine.ucsf.edu	Showstack, Jonathan/L-6556-2013	Showstack, Jonathan/0000-0002-1367-419X				Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Bellet PS, 2000, PEDIATRICS, V105, P478, DOI 10.1542/peds.105.3.478; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; Cebul RD, 1998, JAMA-J AM MED ASSOC, V279, P1282, DOI 10.1001/jama.279.16.1282; Craig DE, 1999, ANN INTERN MED, V130, P355, DOI 10.7326/0003-4819-130-4-199902161-00005; Diamond HS, 1998, ANN INTERN MED, V129, P197, DOI 10.7326/0003-4819-129-3-199808010-00006; Freese RB, 1999, ANN INTERN MED, V130, P350, DOI 10.7326/0003-4819-130-4-199902161-00004; Glasgow RE, 1999, ARCH SURG-CHICAGO, V134, P30, DOI 10.1001/archsurg.134.1.30; Hamilton BH, 1998, MED CARE, V36, P892, DOI 10.1097/00005650-199806000-00012; Katz PP, 1999, INT J TECHNOL ASSESS, V15, P366, DOI 10.1017/S0266462399015287; Manthous CA, 1997, MAYO CLIN PROC, V72, P391, DOI 10.4065/72.5.391; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SHOWSTACK J, 1989, NEW ENGL J MED, V321, P1086, DOI 10.1056/NEJM198910193211605; Showstack J, 1999, JAMA-J AM MED ASSOC, V281, P1381, DOI 10.1001/jama.281.15.1381; Showstack J, 1999, ANN INTERN MED, V130, P376, DOI 10.7326/0003-4819-130-4-199902161-00010; Sosa JA, 1998, ANN SURG, V228, P429, DOI 10.1097/00000658-199809000-00016; Stein MD, 1998, J GEN INTERN MED, V13, P774, DOI 10.1046/j.1525-1497.1998.00231.x; Wachter R M, 1999, Healthc Financ Manage, V53, P48; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487; Wachter RM, 1999, ANN INTERN MED, V130, P338, DOI 10.7326/0003-4819-130-4-199902161-00002; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	24	151	151	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 3	2002	137	11					859	865		10.7326/0003-4819-137-11-200212030-00006	http://dx.doi.org/10.7326/0003-4819-137-11-200212030-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622GY	12458985				2022-12-28	WOS:000179639700001
J	Greig, D; Louis, EJ; Borts, RH; Travisano, M				Greig, D; Louis, EJ; Borts, RH; Travisano, M			Hybrid speciation in experimental populations of yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; GENETIC MATERIAL; STERILITY; SELECTION; EVOLUTION	Most models of speciation require gradual change and geographic or ecological isolation for new species to arise. Homoploid hybrid speciation occurred readily between Saccharomyces cerevisiae and Saccharomyces paradoxus. Hybrids had high self-fertility (about 82%), low fertility when backcrossed to either parental species (about 7.5%), and vigorous growth under different thermal environments that favored one or the other of the parental species. Extensive karyotypic changes (tetrasomy) were observed in the hybrids, although genic incompatibilities accounted for 50% of the variation in self-fertility.	Univ Houston, Dept Biol, Houston, TX 77204 USA; UCL, Dept Biol, Galton Lab, London WC1E 6BT, England; Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England	University of Houston System; University of Houston; University of London; University College London; University of Leicester	Travisano, M (corresponding author), Univ Houston, Dept Biol, 4800 Calhoun Rd, Houston, TX 77204 USA.	mtrav@uh.edu	Greig, Duncan/AAW-3139-2020; Travisano, Michael/AAI-4809-2020; Louis, Edward/B-7920-2008	Greig, Duncan/0000-0002-8907-0253; Louis, Edward/0000-0003-1157-3608				BUSH GL, 1975, ANNU REV ECOL SYST, V6, P339, DOI 10.1146/annurev.es.06.110175.002011; Coyne JA, 1998, PHILOS T ROY SOC B, V353, P287, DOI 10.1098/rstb.1998.0210; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; Grant V, 1971, PLANT SPECIATION, V1st; Greig D, 2002, P ROY SOC B-BIOL SCI, V269, P1167, DOI 10.1098/rspb.2002.1989; Groth G, 1999, INT J SYST BACTERIOL, V49, P1933; Hunter N, 1996, EMBO J, V15, P1726, DOI 10.1002/j.1460-2075.1996.tb00518.x; Johnson PA, 1996, EVOL ECOL, V10, P187, DOI 10.1007/BF01241784; LOIDL J, 1995, GENETICS, V139, P1511; Marinoni G, 1999, J BACTERIOL, V181, P6488, DOI 10.1128/JB.181.20.6488-6496.1999; Masneuf I, 1998, APPL ENVIRON MICROB, V64, P3887; Mayr E., 1963, ANIMAL SPECIES EVOLU; Mortimer RK, 2000, GENOME RES, V10, P403, DOI 10.1101/gr.10.4.403; NAUMOV G I, 1987, Studies in Mycology, P469; Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401; Rieseberg LH, 1997, ANNU REV ECOL SYST, V28, P359, DOI 10.1146/annurev.ecolsys.28.1.359; Rieseberg LH, 2001, TRENDS ECOL EVOL, V16, P351, DOI 10.1016/S0169-5347(01)02187-5; Rundle HD, 2000, SCIENCE, V287, P306, DOI 10.1126/science.287.5451.306; Sebastiani F, 2002, RES MICROBIOL, V153, P53, DOI 10.1016/S0923-2508(01)01286-4; Taylor DR, 2002, P NATL ACAD SCI USA, V99, P3690, DOI 10.1073/pnas.072660299; TEMPLETON AR, 1981, ANNU REV ECOL SYST, V12, P23, DOI 10.1146/annurev.es.12.110181.000323; White M., 1978, MODELS SPECIATION	22	133	139	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1773	1775		10.1126/science.1076374	http://dx.doi.org/10.1126/science.1076374			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12459586				2022-12-28	WOS:000179494800040
J	Parry, CM; Hien, TT; Dougan, G; White, NJ; Farrar, JJ				Parry, CM; Hien, TT; Dougan, G; White, NJ; Farrar, JJ			Typhoid fever	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESISTANT SALMONELLA-TYPHI; COMPLETE GENOME SEQUENCE; ENTERICA SEROVAR TYPHI; VI-CAPSULAR POLYSACCHARIDE; PAPUA-NEW-GUINEA; MULTIDRUG-RESISTANT; RISK-FACTORS; BONE-MARROW; SEROTYPE-TYPHI; ENDEMIC AREA		Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ctr Mol Microbiol & Infect, London SW7 2AZ, England; Mahidol Univ, Fac Trop Med, Oxfrod Trop Med Res Programme, Wellcome Trust Mahidol Univ, Bangkok, Thailand	University of Oxford; Imperial College London; Mahidol University	Farrar, JJ (corresponding author), Univ Oxford, Clin Res Unit, Hosp Trop Dis, 190 Ben Ham Tu,Quan 5, Ho Chi Minh City, Vietnam.	jeremyjf@hcm.vnn.vn	White, Nick/AAC-6527-2019; Hasan, Rumina/F-4420-2015; thada, pawan kumar/AAF-9598-2022; White, Nicholas J/I-4629-2012; thada, pawan kumar/AEW-4993-2022; Farrar, Jeremy J./HGA-7610-2022	White, Nick/0000-0002-1897-1978; thada, pawan kumar/0000-0002-2085-8739; thada, pawan kumar/0000-0002-2085-8739; Farrar, Jeremy/0000-0002-2700-623X				ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; Ackers ML, 2000, JAMA-J AM MED ASSOC, V283, P2668, DOI 10.1001/jama.283.20.2668; [Anonymous], 1990, LANCET, V336, P1065; Bethell DB, 1996, ARCH DIS CHILD, V74, P44, DOI 10.1136/adc.74.1.44; Bhutta ZA, 1999, AM J TROP MED HYG, V61, P654, DOI 10.4269/ajtmh.1999.61.654; Bhutta ZA, 1997, J INFECTION, V35, P253, DOI 10.1016/S0163-4453(97)93004-8; Bhutta ZA, 1996, ARCH DIS CHILD, V75, P214, DOI 10.1136/adc.75.3.214; Bhutta ZA, 1997, J INFECTION, V35, P308, DOI 10.1016/S0163-4453(97)93460-5; BHUTTA ZA, 1992, J INFECTION, V25, P215, DOI 10.1016/0163-4453(92)94173-U; BITAR R, 1985, REV INFECT DIS, V7, P257; BLACK RE, 1985, B WORLD HEALTH ORGAN, V63, P899; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BODHIDATTA L, 1987, REV INFECT DIS, V9, P841; Brown JC, 1996, J ANTIMICROB CHEMOTH, V37, P891, DOI 10.1093/jac/37.5.891; Burkhardt JE, 1997, CLIN INFECT DIS, V25, P1196, DOI 10.1086/516119; BUTLER T, 1978, ARCH INTERN MED, V138, P407, DOI 10.1001/archinte.138.3.407; Butler T, 1999, J ANTIMICROB CHEMOTH, V44, P243, DOI 10.1093/jac/44.2.243; BUTLER T, 1993, ANTIMICROB AGENTS CH, V37, P2418, DOI 10.1128/AAC.37.11.2418; BUTLER T, 1991, REV INFECT DIS, V13, P85; Cao X T, 1999, Pediatr Infect Dis J, V18, P245; Chinh NT, 2000, ANTIMICROB AGENTS CH, V44, P1855, DOI 10.1128/AAC.44.7.1855-1859.2000; CLEGG A, 1994, ACTA TROP, V57, P255, DOI 10.1016/0001-706X(94)90071-X; Connerton P, 2000, J CLIN MICROBIOL, V38, P895, DOI 10.1128/JCM.38.2.895-897.2000; CREWEBROWN HH, 1998, P 12 WORLD AIDS C GE, P284; Doherty CP, 2000, ANN TROP PAEDIATR, V20, P297, DOI 10.1080/02724936.2000.11748151; Dunstan SJ, 2001, J INFECT DIS, V183, P1156, DOI 10.1086/319289; Dunstan SJ, 2001, J INFECT DIS, V183, P261, DOI 10.1086/317940; DUTTA P, 1993, ANTIMICROB AGENTS CH, V37, P1197, DOI 10.1128/AAC.37.5.1197; Engels EA, 1998, BRIT MED J, V316, P110, DOI 10.1136/bmj.316.7125.110; Everest P, 2001, TRENDS MICROBIOL, V9, P316, DOI 10.1016/S0966-842X(01)02067-4; FERRECCIO C, 1984, J PEDIATR-US, V104, P899, DOI 10.1016/S0022-3476(84)80492-8; FERRECCIO C, 1988, J INFECT DIS, V157, P1235, DOI 10.1093/infdis/157.6.1235; Frenck RW, 2000, CLIN INFECT DIS, V31, P1134, DOI 10.1086/317450; FUNJABI NH, 1988, PEDIATR INFECT DIS J, V7, P598; Gasem MH, 2001, TROP MED INT HEALTH, V6, P484, DOI 10.1046/j.1365-3156.2001.00734.x; GILMAN RH, 1975, LANCET, V1, P1211; Girgis NI, 1999, ANTIMICROB AGENTS CH, V43, P1441, DOI 10.1128/AAC.43.6.1441; GOTUZZO E, 1991, ARCH INTERN MED, V151, P381, DOI 10.1001/archinte.151.2.381; GOTUZZO E, 1994, INFECT DIS CLIN PRAC, V3, P345, DOI 10.1097/00019048-199409000-00004; GROSSMAN DA, 1995, J INFECT DIS, V171, P212, DOI 10.1093/infdis/171.1.212; Hermans PWM, 1996, J CLIN MICROBIOL, V34, P1373, DOI 10.1128/JCM.34.6.1373-1379.1996; HERZOG C, 1976, Infection, V4, P166, DOI 10.1007/BF01638944; Hoa NTT, 1998, T ROY SOC TROP MED H, V92, P503, DOI 10.1016/S0035-9203(98)90891-4; HOFFMAN SL, 1984, NEW ENGL J MED, V310, P82, DOI 10.1056/NEJM198401123100203; HOFFMAN SL, 1986, AM J TROP MED HYG, V35, P836, DOI 10.4269/ajtmh.1986.35.836; HORNICK RB, 1970, NEW ENGL J MED, V283, P739, DOI 10.1056/NEJM197010012831406; HORNICK RB, 1970, NEW ENGL J MED, V283, P686, DOI 10.1056/NEJM197009242831306; House D, 2001, J CLIN MICROBIOL, V39, P1002, DOI 10.1128/JCM.39.3.1002-1007.2001; House D, 2001, CURR OPIN INFECT DIS, V14, P573, DOI 10.1097/00001432-200110000-00011; HUCKSTEP RL, 1962, THYROID FEVER OTHER; Ivanoff B., 1995, SE ASIAN J TROP MED, V26, P1; Kariuki S, 2000, EMERG INFECT DIS, V6, P649, DOI 10.3201/eid0606.000616; KEUTER M, 1994, J INFECT DIS, V169, P1306, DOI 10.1093/infdis/169.6.1306; KLUGMAN KP, 1987, LANCET, V2, P1165; LANATA CF, 1983, LANCET, V2, P441; LEUNG D, 1995, LANCET, V346, P648, DOI 10.1016/S0140-6736(95)91488-9; LEVINE MM, 1987, LANCET, V1, P1049; LEVINE MM, 1982, J INFECT DIS, V146, P724, DOI 10.1093/infdis/146.6.724; Lin FYC, 2000, AM J TROP MED HYG, V62, P644, DOI 10.4269/ajtmh.2000.62.644; Lin FYC, 2001, NEW ENGL J MED, V344, P1263, DOI 10.1056/NEJM200104263441701; Loebstein R, 1998, ANTIMICROB AGENTS CH, V42, P1336, DOI 10.1128/AAC.42.6.1336; Luby SP, 1998, EPIDEMIOL INFECT, V120, P129, DOI 10.1017/S0950268897008558; Luxemburger C, 2001, T ROY SOC TROP MED H, V95, P19, DOI 10.1016/S0035-9203(01)90318-9; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Mehta G, 2001, EUR J CLIN MICROBIOL, V20, P760, DOI 10.1007/s100960100603; Memon IA, 1997, SOUTHERN MED J, V90, P1204, DOI 10.1097/00007611-199712000-00008; Mermin JH, 1999, J INFECT DIS, V179, P1416, DOI 10.1086/314766; Mirza S, 2000, J CLIN MICROBIOL, V38, P1449, DOI 10.1128/JCM.38.4.1449-1452.2000; Mirza SH, 1996, J MED MICROBIOL, V44, P317, DOI 10.1099/00222615-44-5-317; Osler W., 1912, PRINCIPLES PRACTICE, V8th, P1; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; Parry CM, 1999, J CLIN MICROBIOL, V37, P2882, DOI 10.1128/JCM.37.9.2882-2886.1999; REED RP, 1994, PEDIATR INFECT DIS J, V13, P774, DOI 10.1097/00006454-199409000-00004; ROGERSON SJ, 1991, T ROY SOC TROP MED H, V85, P113, DOI 10.1016/0035-9203(91)90180-7; RUBIN FA, 1990, J CLIN MICROBIOL, V28, P825, DOI 10.1128/JCM.28.4.825-827.1990; Saha SK, 1999, PEDIATR INFECT DIS J, V18, P387, DOI 10.1097/00006454-199904000-00018; SCHAAD UB, 1995, PEDIATR INFECT DIS J, V14, P1, DOI 10.1097/00006454-199501000-00001; SCHWALBE RS, 1990, ANTIMICROB AGENTS CH, V34, P161, DOI 10.1128/AAC.34.1.161; SEOUD M, 1988, OBSTET GYNECOL, V71, P711; Shanahan PMA, 2000, EPIDEMIOL INFECT, V124, P9, DOI 10.1017/S0950268899003453; Shanahan PMA, 1998, J CLIN MICROBIOL, V36, P1595, DOI 10.1128/JCM.36.6.1595-1600.1998; Sherburne CK, 2000, NUCLEIC ACIDS RES, V28, P2177, DOI 10.1093/nar/28.10.2177; SIMANJUNTAK CH, 1991, LANCET, V338, P1055, DOI 10.1016/0140-6736(91)91910-M; Sinha A, 1999, LANCET, V354, P734, DOI 10.1016/S0140-6736(98)09001-1; SONG JH, 1993, J CLIN MICROBIOL, V31, P1439, DOI 10.1128/JCM.31.6.1439-1443.1993; Sood S, 1999, LANCET, V353, P1241, DOI 10.1016/S0140-6736(99)00637-6; STUART BM, 1946, ARCH INTERN MED, V78, P629, DOI 10.1001/archinte.1946.00220060002001; Tarr PE, 1999, AM J TROP MED HYG, V61, P163, DOI 10.4269/ajtmh.1999.61.163; TAYLOR DE, 1985, ANTIMICROB AGENTS CH, V28, P452, DOI 10.1128/AAC.28.3.452; Thong KL, 2000, Int J Infect Dis, V4, P194, DOI 10.1016/S1201-9712(00)90108-5; Threlfall EJ, 1999, LANCET, V353, P1590, DOI 10.1016/S0140-6736(99)01001-6; THRELFALL EJ, 1992, EUR J CLIN MICROBIOL, V11, P990, DOI 10.1007/BF01967788; Threlfall EJ, 2001, J ANTIMICROB CHEMOTH, V48, P740, DOI 10.1093/jac/48.5.740; VALLENAS C, 1985, PEDIATR INFECT DIS J, V4, P496, DOI 10.1097/00006454-198509000-00011; VANBASTEN JP, 1994, TROP GEOGR MED, V46, P336; Vinh H, 1996, ANTIMICROB AGENTS CH, V40, P958, DOI 10.1128/AAC.40.4.958; WAHDAN MH, 1982, J INFECT DIS, V145, P292, DOI 10.1093/infdis/145.3.292; Wain J, 1999, J CLIN MICROBIOL, V37, P2466, DOI 10.1128/JCM.37.8.2466-2472.1999; Wain J, 1998, J CLIN MICROBIOL, V36, P1683, DOI 10.1128/JCM.36.6.1683-1687.1998; Wain J, 1997, CLIN INFECT DIS, V25, P1404, DOI 10.1086/516128; Wain J, 2001, J CLIN MICROBIOL, V39, P1571, DOI 10.1128/JCM.39.4.1571-1576.2001; White NJ, 1996, CURR OPIN INFECT DIS, V9, P298, DOI 10.1097/00001432-199610000-00003; WOODWARD TE, 1948, ANN INTERN MED, V29, P131, DOI 10.7326/0003-4819-29-1-131	103	836	876	3	72	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 28	2002	347	22					1770	1782		10.1056/NEJMra020201	http://dx.doi.org/10.1056/NEJMra020201			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619GU	12456854	Green Submitted, Bronze			2022-12-28	WOS:000179468600008
J	Bilsker, D; Goldner, EM				Bilsker, D; Goldner, EM			Routine outcome measurement by mental health-care providers: is it worth doing?	LANCET			English	Editorial Material									Univ British Columbia, Mental Hlth Evaluat & Community Consultat Unit, Vancouver, BC VGT 1WG, Canada	University of British Columbia	Bilsker, D (corresponding author), Univ British Columbia, Mental Hlth Evaluat & Community Consultat Unit, 2250 Wesbrook Mall, Vancouver, BC VGT 1WG, Canada.	dbilsker@interchange.ubc.ca						ANDREWS G, 2000, MEASUREMENT CONSUMER; Bond G., 2000, PSYCHIAT REHABILITAT; CALSYN RJ, 2002, MENT HLTH SERV RES, V2, P107; DICKEY B, 1994, J MENT HEALTH ADMIN, V21, P313, DOI 10.1007/BF02521337; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR, P39; Geddes J, 1997, BMJ-BRIT MED J, V315, P1483, DOI 10.1136/bmj.315.7121.1483; Gilbody SM, 2001, BRIT MED J, V322, P406, DOI 10.1136/bmj.322.7283.406; GOLDNER EM, 1995, CAN J PSYCHIAT, V40, P97; Jerrell JM, 1999, PSYCHIATR SERV, V50, P109, DOI 10.1176/ps.50.1.109; Lyons J.S., 1997, MEASUREMENT MANAGEME; Moncrieff J, 1998, BRIT J PSYCHIAT, V172, P227, DOI 10.1192/bjp.172.3.227; Remington G, 2001, PSYCHIATR SERV, V52, P96, DOI 10.1176/appi.ps.52.1.96; Sederer L I, 1995, Am J Med Qual, V10, P127, DOI 10.1177/0885713X9501000303; Slade M, 1999, SOC PSYCH PSYCH EPID, V34, P243, DOI 10.1007/s001270050139; Smith GR, 1997, PSYCHIATR SERV, V48, P364; Speer DC, 1996, CLIN PSYCHOL-SCI PR, V3, P105, DOI 10.1111/j.1468-2850.1996.tb00061.x; Speer DC., 1998, MENTAL HLTH OUTCOME; Torrey WC, 2001, PSYCHIAT SERV, V52, P45, DOI 10.1176/appi.ps.52.1.45; Walter G, 1998, J Qual Clin Pract, V18, P109	19	28	29	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2002	360	9346					1689	1690		10.1016/S0140-6736(02)11610-2	http://dx.doi.org/10.1016/S0140-6736(02)11610-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	618AE	12457807				2022-12-28	WOS:000179393900029
J	Newton, PJ; Newsholme, W; Brink, NS; Manji, H; Williams, IG; Miller, RF				Newton, PJ; Newsholme, W; Brink, NS; Manji, H; Williams, IG; Miller, RF			Lesson of the week - Acute meningoencephalitis and meningitis due to primary HIV infection	BRITISH MEDICAL JOURNAL			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ENCEPHALOPATHY; SEROCONVERSION; PROGRESSION; DIAGNOSIS; ANTIBODY; THERAPY; TYPE-1		UCL, Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England; Camden Primary Care Trust, Mortimer Market Ctr, London WC1E 6AU, England; UCL Hosp, Dept Virol, London W1T 4JF, England; Natl Hosp Neurol & Neurosurg, Dept Clin Neurol, London WC1N 3BG, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Miller, RF (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England.	rmiller@gum.ucl.ac.uk	Manji, Hadi/AAH-2748-2021	Miller, Robert/0000-0003-2067-4291				ABB J, 1987, INFECTION, V15, P425, DOI 10.1007/BF01647221; Berrey MM, 2001, J INFECT DIS, V183, P1466, DOI 10.1086/320189; BIGGAR RJ, 1986, BRIT MED J, V293, P1210, DOI 10.1136/bmj.293.6556.1210; BOUFASSA F, 1995, J INFECT DIS, V171, P1190, DOI 10.1093/infdis/171.5.1190; Carcelain G, 1999, AIDS, V13, P1077, DOI 10.1097/00002030-199906180-00011; CARNE CA, 1985, LANCET, V2, P1206; HARDY WD, 1991, REV INFECT DIS, V13, P745; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; Jeffery KJM, 1997, LANCET, V349, P313, DOI 10.1016/S0140-6736(96)08107-X; Lindback S, 2000, AIDS, V14, P2333, DOI 10.1097/00002030-200010200-00014; PATON P, 1990, RES VIROLOGY, V141, P427, DOI 10.1016/0923-2516(90)90043-I; Quinn TC, 1997, JAMA-J AM MED ASSOC, V278, P58, DOI 10.1001/jama.278.1.58; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; SCULLY RE, 1989, NEW ENGL J MED, V321, P454; Vanhems P, 1999, J ACQ IMMUN DEF SYND, V21, P99	15	23	23	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 23	2002	325	7374					1225	1226		10.1136/bmj.325.7374.1225	http://dx.doi.org/10.1136/bmj.325.7374.1225			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446542	Green Published			2022-12-28	WOS:000179506200025
J	Lee, JS; FitzGibbon, E; Butman, JA; Dufresne, CR; Kushner, H; Wientroub, S; Robey, PG; Collins, MT				Lee, JS; FitzGibbon, E; Butman, JA; Dufresne, CR; Kushner, H; Wientroub, S; Robey, PG; Collins, MT			Normal vision despite narrowing of the optic canal in fibrous dysplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MCCUNE-ALBRIGHT-SYNDROME; ACTIVATING G(S)ALPHA MUTATION; REVERSIBLE VISUAL-LOSS; STIMULATORY G-PROTEIN; NERVE DECOMPRESSION; SKULL BASE; BONE; GENE; BLINDNESS; CHILDHOOD	Background: Fibrous dysplasia of bone frequently involves the anterior base of the cranium and results in encasement of the optic-nerve canals. It has been assumed that such encasement leads to constriction and eventual blindness. There is controversy about whether patients should be regularly monitored or whether they should undergo prophylactic decompression of the optic nerve. This question is of particular concern in patients with normal vision, since the risks associated with surgical decompression include blindness. Methods: We studied 38 patients with fibrous dysplasia of the lesser wing of the sphenoid bone. The patients underwent a detailed neuro-ophthalmologic examination and computed tomography of the face and skull, reformatted to measure the extent of involvement of the optic canal and the area of the canals. The results were compared with those of 38 age- and sex-matched controls. Results: Of the 38 patients, 15 were male and 23 female, and their mean age was 26 years. Twelve had polyostotic fibrous dysplasia, and 26 had the McCune-Albright syndrome. Sixty-seven optic canals were affected by fibrous dysplasia; in 49 of them (73 percent) there was complete encasement. The mean (+/-SD) areas of the right and left canals were 9.6+/-3.8 mm(sup 2) and 9.9+/-3.6 mm(sup 2), respectively, in the patients, as compared with 12.0+/-2.9 mm(sup 2) and 11.9+/-2.7 mm(sup 2) in the controls (P=0.009 for the comparison of the right areas and P=0.03 for the comparison of the left areas by the paired t-test). In all but two of the patients, the results of neuro-ophthalmologic examination were normal. In the two patients with monocular visual impairment, the areas of the optic canals were similar on the normal and abnormal sides. Conclusions: Encasement of the optic canal in fibrous dysplasia causes narrowing of the canal, but that in itself does not result in visual loss. Therefore, prophylactic decompression of the optic nerve does not appear to be indicated on the basis of the presence of fibrous dysplasia on diagnostic images alone, since it does not correlate with visual loss.	NEI, Vraniofacial & Skeleton Dis Branch, Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA; NIH, Warren G Magnuson Clin Ctr, Dept Diagnost Radiol, Bethesda, MD 20892 USA; Georgetown Univ, Med Ctr, Div Plast Surg, Washington, DC 20007 USA; Biomed Comp Res Inst, Philadelphia, PA USA; Tel Aviv Med Ctr & Sch Med, Dana Childrens Hosp, Dept Pediat Orthoped Surg, IL-64239 Tel Aviv, Israel	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; Georgetown University; Tel Aviv University; Sackler Faculty of Medicine	Lee, JS (corresponding author), Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, 521 Parnassus Ave,C-522, San Francisco, CA 94143 USA.		Butman, John/J-2780-2013; Robey, Pamela Gehron/H-1429-2011; Dufresne, Craig R/B-2172-2019; Butman, John A/A-2694-2008	Butman, John/0000-0002-1547-9195; Robey, Pamela Gehron/0000-0002-5316-5576; Dufresne, Craig R/0000-0001-6051-348X; 	NATIONAL EYE INSTITUTE [ZIAEY000388, Z01EY000388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000649] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Albright F, 1937, NEW ENGL J MED, V216, P727, DOI 10.1056/NEJM193704292161701; Alman BA, 1996, J ORTHOPAED RES, V14, P311, DOI 10.1002/jor.1100140221; ARROYO JG, 1991, J CLIN NEURO-OPHTHAL, V11, P259; Bianco P, 2000, J BONE MINER RES, V15, P120, DOI 10.1359/jbmr.2000.15.1.120; Bocca G, 1998, ACTA PAEDIATR, V87, P599, DOI 10.1080/08035259850158371; Chen YR, 1997, PLAST RECONSTR SURG, V99, P22, DOI 10.1097/00006534-199701000-00004; DORFMAN HD, 1998, BONE TUMORS, P441; Edelstein C, 1998, AM J OPHTHALMOL, V126, P469, DOI 10.1016/S0002-9394(98)00118-4; Lichtenstein L, 1942, ARCH PATHOL, V33, P777; Marie PJ, 1997, AM J PATHOL, V150, P1059; McCune D, 1936, AM J DIS CHILD, V52, P743; Michael CB, 2000, J NEUROSURG, V92, P350, DOI 10.3171/jns.2000.92.2.0350; MOORE AT, 1985, OPHTHALMOLOGY, V92, P12; Papadopoulos MC, 1998, BRIT J NEUROSURG, V12, P159; PAPAY FA, 1995, J CRANIOFAC SURG, V6, P5, DOI 10.1097/00001665-199501000-00004; POSNICK JC, 1993, PEDIATR NEUROSURG, V19, P260, DOI 10.1159/000120742; Ricalde P, 2001, J ORAL MAXIL SURG, V59, P157, DOI 10.1053/joms.2001.20487; Riminucci M, 1999, J PATHOL, V187, P249, DOI 10.1002/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J; Riminucci M, 1997, AM J PATHOL, V151, P1587; SASSIN JF, 1968, ARCH NEUROL-CHICAGO, V18, P363, DOI 10.1001/archneur.1968.00470340049004; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; Seiff SR, 1997, PLAST RECONSTR SURG, V100, P1611, DOI 10.1097/00006534-199711000-00045; SHENKER A, 1994, J CLIN ENDOCR METAB, V79, P750, DOI 10.1210/jc.79.3.750; Spiegel AM, 1997, J INHERIT METAB DIS, V20, P113, DOI 10.1023/A:1005393501786; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WEISMAN JS, 1990, AM J OPHTHALMOL, V110, P244, DOI 10.1016/S0002-9394(14)76338-X	26	120	133	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1670	1676		10.1056/NEJMoa020742	http://dx.doi.org/10.1056/NEJMoa020742			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444181				2022-12-28	WOS:000179339900005
J	Steinhubl, SR; Berger, PB; Mann, JT; Fry, ETA; DeLago, A; Wilmer, C; Topol, EJ				Steinhubl, SR; Berger, PB; Mann, JT; Fry, ETA; DeLago, A; Wilmer, C; Topol, EJ		CREDO Investigators	Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE CARDIAC EVENTS; STENT IMPLANTATION; ISCHEMIC EVENTS; P-SELECTIN; CLOPIDOGREL; ASPIRIN; RISK; PRETREATMENT; ANTICOAGULATION; EXPRESSION	Context Following percutaneous coronary intervention (PCI), short-term clopidogrel therapy in addition to aspirin leads to greater protection from thrombotic complications than aspirin alone. However, the optimal duration of combination oral antiplatelet therapy is unknown. Also, although current clinical data suggest a benefit for beginning therapy with a clopidogrel loading dose prior to PCI, the practical application of this therapy has not been prospectively studied. Objectives To evaluate the benefit of long-term (12-month) treatment with clopidogrel after PCI and to determine the benefit of initiating clopidogrel with a preprocedure loading dose, both in addition to aspirin therapy. Design, Setting, and Participants The Clopidogrel for the Reduction of Events During Observation (CREDO) trial, a randomized, double-blind, placebo-controlled trial conducted among 2116 patients who were to undergo elective PCI or were deemed at high likelihood of undergoing PCI, enrolled at 99 centers in North America from June 1,999 through April 2001. Interventions Patients were randomly assigned to receive a 300-mg clopidogrel loading dose (n = 1053),or placebo (n = 1063) 3 to 24 hours before PCI. Thereafter, all patients received clopidogrel, 75 mg/d, through day 28. From day 29 through 12 months, patients in the loading-dose group received clopidogrel, 75 mg/d, and those in the control group received placebo. Both groups received aspirin throughout the study. Main Outcome Measures One-year incidence of the composite of death, myocardial infarction (MI), or stroke in the intent-to-treat population; 28-day incidence of the composite of death, MI, or urgent target vessel revascularization in the per-protocol population. Results At 1 year, long-term clopidogrel therapy was associated with a 26.9% relative reduction in the combined risk of death, MI, or stroke (95% confidence interval [CI], 3.9%-44.4%; P=.02; absolute reduction, 3%). Clopidogrel pretreatment did not significantly reduce the combined risk of death, MI, or urgent target vessel revascularization at 28 days (reduction, 18.5%; 95% CI, -14.2% to 41.8%; P=.23). However, in a prespecified subgroup analysis, patients who received clopidogrel at least 6 hours before PCI experienced a relative risk reduction of 38.6% (95% CI, -1.6% to 62.9%; P=.051) for this end point compared with no reduction with treatment less than 6 hours before PCI. Risk of major bleeding at 1 year increased, but not significantly (8.8% with clopidogrel vs 6.7% with placebo; P=.07). Conclusions Following PCI, long-term (1-year) clopidogrel therapy significantly reduced the risk of adverse ischemic events. A loading dose of clopidogrel given at least 3 hours before the procedure did not reduce events at 28 days, but subgroup analyses suggest that longer intervals between the loading dose and PCI may reduce events.	Univ N Carolina, Div Cardiol, Sch Med, Chapel Hill, NC 27599 USA; Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA; WakeMed, Raleigh, NC USA; St Vincent Hosp, Dept Cardiol, Indianapolis, IN USA; Albany Med Ctr, Div Cardiol, Albany, NY USA; Atlanta Med Ctr, Atlanta, GA USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Mayo Clinic; Albany Medical College; WellStar Atlanta Medical Center; Cleveland Clinic Foundation	Steinhubl, SR (corresponding author), Univ N Carolina, Div Cardiol, Sch Med, CB 7075,338 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.	steven_steinhubl@med.unc.edu	Fry, Edward/AAP-7004-2021	Topol, Eric/0000-0002-1478-4729				Berger PB, 2002, CIRCULATION, V106, P2284, DOI 10.1161/01.CIR.0000035924.70846.20; Bertrand ME, 1998, CIRCULATION, V98, P1597, DOI 10.1161/01.CIR.98.16.1597; Bhatt DL, 2002, AM J CARDIOL, V90, P625, DOI 10.1016/S0002-9149(02)02567-5; Bonz AW, 2002, J AM COLL CARDIOL, V40, P662, DOI 10.1016/S0735-1097(02)02014-4; Chew DP, 2001, AM J CARDIOL, V88, P672, DOI 10.1016/S0002-9149(01)01813-6; Chew DP, 2001, CIRCULATION, V104, P992, DOI 10.1161/hc3401.095074; Helft G, 2000, ARTERIOSCL THROM VAS, V20, P2316, DOI 10.1161/01.ATV.20.10.2316; Klinkhardt U, 2002, CLIN PHARMACOL THER, V71, P176, DOI 10.1067/mcp.2002.122018; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Muller I, 2001, HEART, V85, P92, DOI 10.1136/heart.85.1.92; Neumann FJ, 1997, CIRCULATION, V95, P2387, DOI 10.1161/01.CIR.95.10.2387; PAGE CP, 1989, IMMUNOPHARMACOLOGY, V17, P51, DOI 10.1016/0162-3109(89)90008-8; Peters RJG, 2002, EUR HEART J, V23, P510; Savcic M, 1999, SEMIN THROMB HEMOST, V25, P15; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Schuhlen H, 1998, CIRCULATION, V98, P104, DOI 10.1161/01.CIR.98.2.104; Seyfarth HJ, 2002, AM HEART J, V143, P118, DOI 10.1067/mhj.2002.119372; Steinhubl SR, 1998, J AM COLL CARDIOL, V32, P1366, DOI 10.1016/S0735-1097(98)00376-3; Steinhubl SR, 2001, CIRCULATION, V103, P1403, DOI 10.1161/01.CIR.103.10.1403; Thel MC, 2000, AM J CARDIOL, V85, P427, DOI 10.1016/S0002-9149(99)00767-5; Topol EJ, 2001, NEW ENGL J MED, V344, P1888, DOI 10.1056/NEJM200106213442502; Urban P, 1998, CIRCULATION, V98, P2126, DOI 10.1161/01.CIR.98.20.2126; van Domburg RT, 1999, HEART, V82, P27; Yusuf S, 2001, NEW ENGL J MED, V345, P494	25	2475	2618	0	67	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2002	288	19					2411	2420		10.1001/jama.288.19.2411	http://dx.doi.org/10.1001/jama.288.19.2411			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FB	12435254	Bronze			2022-12-28	WOS:000179292300024
J	Catherinot, E; Rivaud, E; Epardeau, B; Cahen, P; Condette-Auliac, S; Couderc, LJ				Catherinot, E; Rivaud, E; Epardeau, B; Cahen, P; Condette-Auliac, S; Couderc, LJ			A holiday in Canada	LANCET			English	Article							BLASTOMYCOSIS		Hop Foch, Serv Pneumol, F-92150 Suresnes, France; Hop Foch, Serv Anatomopathol, F-92150 Suresnes, France; Hop Foch, Microbiol Serv, F-92150 Suresnes, France; Hop Foch, Serv Neuroradiol, F-92150 Suresnes, France	Hospital Foch; Hospital Foch; Hospital Foch; Hospital Foch	Couderc, LJ (corresponding author), Hop Foch, Serv Pneumol, 40 Rue Worth, F-92150 Suresnes, France.							BRADSHER RW, 1992, CLIN INFECT DIS, V14, pS82, DOI 10.1093/clinids/14.Supplement_1.S82; Chapman SW, 2000, CLIN INFECT DIS, V30, P679, DOI 10.1086/313750; CHAPMAN SW, 1995, PRINCIPLES PRACTICE, P2353; Martynowicz MA, 2002, CHEST, V121, P768, DOI 10.1378/chest.121.3.768; Ostroff SM, 1998, INFECT DIS CLIN N AM, V12, P231, DOI 10.1016/S0891-5520(05)70420-7	5	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1564	1564		10.1016/S0140-6736(02)11523-6	http://dx.doi.org/10.1016/S0140-6736(02)11523-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443595				2022-12-28	WOS:000179292400013
J	Davis, RC; Hobbs, FDR; Kenkre, JE; Roalfe, AK; Hare, R; Lancashire, RJ; Davies, MK				Davis, RC; Hobbs, FDR; Kenkre, JE; Roalfe, AK; Hare, R; Lancashire, RJ; Davies, MK			Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; MORBIDITY; TRIAL; POPULATION; CAPTOPRIL	Objectives To determine the prevalence of left ventricular systolic dysfunction, and of heart failure due to different causes, in patients with risk factors for these conditions. Design Epidemiological study, including detailed clinical assessment, electrocardiography, and echocardiography. Setting 16 English general practices, representative for socioeconomic status and practice type. Participants 1062 patients (66% response rate) with previous myocardial infarction, angina, hypertension, or diabetes. Main outcome measures Prevalence of systolic dysfunction, both with and without symptoms, and of heart failure, in groups of patients with each of the risk factors. Results Definite systolic dysfunction (ejection fraction < 40%) was found in 54/244 (22.1%, 95% confidence interval 17.1% to 27.9%) patients with previous myocardial infarction, 26/321 (8.1%, 5.4% to 11.6%) with angina, 7/388 (1.8%, 0.7% to 3.7%) with hypertension, and 12/208 (5.8%, 3.0% to 9.9%) with diabetes. In each group, approximately half of these patients had symptoms of dyspnoea, and therefore had heart failure. Overall rates of heart failure, defined as symptoms of dyspnoea plus objective evidence of cardiac dysfunction (systolic dysfunction, atrial fibrillation, or clinically significant valve disease) were 16.0% (11.6% to 21.2%) in patients with previous myocardial infarction, 8.4% (5.6% to 12.0%) in those with angina, 2.8% (1.4% to 5.0%) in those with hypertension, and 7.7% (4.5% to 12.21%) in those with diabetes. Conclusion Many people with ischaemic heart disease or diabetes have systolic dysfunction or heart failure. The data support the need for trials of targeted echocardiographic screening, in view of the major benefits of modern treatment. In contrast, patients with uncomplicated hypertension have similar rates to the general population.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Selly Oak Hosp, Dept Cardiol, Birmingham B29 6JD, W Midlands, England	University of Birmingham; University of Birmingham	Davis, RC (corresponding author), Sandwell Gen Hosp, W Bromwich B71 4HJ, W Midlands, England.			hobbs, richard/0000-0001-7976-7172				Blue L, 2001, BRIT MED J, V323, P715, DOI 10.1136/bmj.323.7315.715; CLARKE KW, 1994, BRIT HEART J, V71, P584; CLELAND JG, 1995, EUR HEART J, V16, P741; Davie AP, 1997, EUR HEART J, V18, P981; Davies MK, 2001, LANCET, V358, P439, DOI 10.1016/S0140-6736(01)05620-3; Davis R. C., 1998, European Heart Journal, V19, P639; *DEP HLTH, 2000, NAT SERV FRAM COR HE; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Hjalmarson A, 1999, LANCET, V353, P2001; Hobbs FDR, 2000, EUR HEART J, V21, P1877, DOI 10.1053/euhj.2000.2170; Lechat P, 1999, LANCET, V353, P9; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; McMurray JV, 1998, EUR HEART J, V19, P842, DOI 10.1093/eurheartj/19.6.842; Mosterd A, 1999, NEW ENGL J MED, V340, P1221, DOI 10.1056/NEJM199904223401601; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; SUTTON GC, 1990, AM HEART J, V120, P1538, DOI 10.1016/0002-8703(90)90055-3; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WILSON JMG, 1968, WHO PUBLIC HLTH PAPE, V34, P14; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	23	45	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2002	325	7373					1156	1158A		10.1136/bmj.325.7373.1156	http://dx.doi.org/10.1136/bmj.325.7373.1156			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618XN	12433768	Bronze, Green Published			2022-12-28	WOS:000179443100024
J	Laing, GJ; Law, J; Levin, A; Logan, S				Laing, GJ; Law, J; Levin, A; Logan, S			Evaluation of a structured test and a parent led method for screening for speech and language problems: prospective population based study	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; CHILDREN; IMPAIRMENTS; OUTCOMES; THERAPY; DELAY; AGE	Objective To evaluate two methods for the identifying speech and language problems in preschool children. Design Prospective population based study. Setting Inner London. Participants and methods 37 health visitors were randomly assigned to use a structured screening test (18) or a parent led method (19). Of 623 eligible children aged 30-36 months, the parents of 582 agreed to participate (353 using the structured test and 229 the parent led method). Main outcome measures Children were assessed by a speech and language therapist blinded to the test result, using the Reynell developmental language scales. Children were classified as having "severe language problems" if the Reynell score was below the third centile for receptive language and as "needing therapy" if the Reynell score was below the seventh centile for receptive or expressive language and clinical opinion. Results Reference assessments and usable scores were obtained for 458 (97%) of the 474 children screened. 98 (21%) children had severe language problems and 131 (29%) needed therapy. The sensitivity and specificity for the structured screening test were 66% (95% confidence interval 53% to 76%) and 89% (85% to 93%) respectively for severe language problems and 54% (43% to 65%) and 90% (85% to 93%) for those needing therapy. The sensitivity and specificity for referral by the parent led method were 56% (40% to 71%) and 85% (78% to 90%) for severe language problems and 58% (44% to 71%) and 90% (83% to 94%) for those needing speech and language therapy. Conclusions Both approaches failed to detect a substantial proportion of children with severe language problems and led to over-referral for diagnostic assessments. Screening is likely to be an ineffective approach to the management of speech and language problems in preschool children in this population.	Peninsula Med Sch, Inst Hlth & Social Care Res, Exeter EX1 2LU, Devon, England; City Univ London, London EC1V OHB, England; St Leonards Hosp, City & Hackney Primary Care Trust, Dept Child Hlth, London N1 5LZ, England	University of Exeter; City University London	Logan, S (corresponding author), Peninsula Med Sch, Inst Hlth & Social Care Res, St Lukes Campus, Exeter EX1 2LU, Devon, England.		Law, James C/F-2116-2010	Logan, Stuart/0000-0002-9279-261X				ALBERMAN ED, 1970, BRIT J PREV SOC MED, V24, P129; [Anonymous], 1997, REYNELL DEV LANGUAGE; ARAM DM, 1980, J COMMUN DISORD, V13, P150; Bryant T, 2000, CONFIDENCE INTERVAL; COHEN NJ, 1991, CAN J BEHAV SCI, V23, P376, DOI 10.1037/h0079017; Conti-Ramsden G, 2001, INT J LANG COMM DIS, V36, P207, DOI 10.1080/13682820010019883; DEAN JA, 1995, EPIINFO V 6 03 WORD; DEWINTER M, 1995, SCREENING CHILD HLTH; Glascoe FP, 2000, CHILD CARE HLTH DEV, V26, P137, DOI 10.1046/j.1365-2214.2000.00173.x; Glascoe FP, 1997, AMBULATORY CHILD HLT, V2, P349; Glogowska M, 2000, BRIT MED J, V321, P923, DOI 10.1136/bmj.321.7266.923; HALL D, 2002, HLTH ALL CHILDREN; HALL D, 1991, HLTH ALL CHILDREN; Hall DMB, 1996, HLTH ALL CHILDREN; Johnson CJ, 1999, J SPEECH LANG HEAR R, V42, P744, DOI 10.1044/jslhr.4203.744; Law J, 2000, BRIT MED J, V321, P908, DOI 10.1136/bmj.321.7266.908; Law J, 1998, Health Technol Assess, V2, P1; LAW J, 1994, CHILD CARE HLTH DEV, V20, P295, DOI 10.1111/j.1365-2214.1994.tb00392.x; LAW J, PROMOTING SPEECH LAN; LAW J, 2001, PROMOTING SPEECH LAN; LAW J, 1992, CHILD ABUSE NEGLECT; MCRAE KM, 1991, DEV MED CHILD NEUROL, V33, P868; PAUL R, 1983, J AM ACAD CHILD PSY, V22, P525, DOI 10.1097/00004583-198311000-00002; PERRIN J, 1994, PEDIATRICS, V93, P863; SILVA PA, 1987, DEV MED CHILD NEUROL, V29, P630; SIRNEL DL, 1991, J CLIN EPIDEMIOL, V44, P323; Stothard SE, 1998, J SPEECH LANG HEAR R, V41, P407, DOI 10.1044/jslhr.4102.407	27	34	35	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2002	325	7373					1152	1154B		10.1136/bmj.325.7373.1152	http://dx.doi.org/10.1136/bmj.325.7373.1152			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	618XN	12433766	Green Published, Bronze			2022-12-28	WOS:000179443100022
J	Tulzer, G; Arzt, W; Franklin, RCG; Loughna, PV; Mair, R; Gardiner, HM				Tulzer, G; Arzt, W; Franklin, RCG; Loughna, PV; Mair, R; Gardiner, HM			Fetal pulmonary valvuloplasty for critical pulmonary stenosis or atresia with intact septum	LANCET			English	Article							VENTRICULAR SEPTUM	Progressive stenosis of the semilunar valves in utero can be life threatening. We treated two fetuses with complete or almost complete pulmonary atresia and imminent hydrops (increased cardiothoracic ratio, pericardial effusion, holosystolic tricuspid regurgitation extending into diastole, and abnormal venous Dopplers). We dilated the pulmonary valve of two fetuses in utero at 28 and 30 weeks' gestation, through the mothers' abdomens. After the procedure, the fetuses had decreased signs of circulatory failure and gestation continued until near term. In the neonatal period, we did a repeat valvuloplasty with systemic-to-pulmonary arterial shunt. Both children. (now aged 18 months and 12 months) now have biventricular circulation. Surgery on selected fetuses with semilunar valve stenosis or atresia, or both, can extend pregnancy and favourably change the postnatal surgical options.	Univ London Imperial Coll Sci Technol & Med, Queen Charlottes & Chelsea Hosp, Fac Med,Inst Reprod & Dev Biol, Div Paediat Obstet & Gynaecol, London W12 0NN, England; Childrens Hosp Linz, Childrnes Heart Ctr Linz, Linz, Austria; Matern Hosp, Dept Prenatal Med, Linz, Austria; Royal Brompton & Harefield NHS Trust, London, England; Natl Heart & Lung Inst, London, England	Imperial College London; Kepler University Hospital; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Imperial College London	Gardiner, HM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Queen Charlottes & Chelsea Hosp, Fac Med,Inst Reprod & Dev Biol, Div Paediat Obstet & Gynaecol, London W12 0NN, England.							BULL C, 1994, J THORAC CARDIOV SUR, V107, P359, DOI 10.1016/S0022-5223(94)70080-X; Daubeney PEF, 1998, CIRCULATION, V98, P562, DOI 10.1161/01.CIR.98.6.562; DELEVAL MR, 1985, CIRCULATION, V72, P1152; Huhta JC, 2001, J PERINAT MED, V29, P381, DOI 10.1515/JPM.2001.054; Kohl T, 2000, AM J CARDIOL, V85, P1230, DOI 10.1016/S0002-9149(00)00733-5	5	125	137	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1567	1568		10.1016/S0140-6736(02)11531-5	http://dx.doi.org/10.1016/S0140-6736(02)11531-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443597				2022-12-28	WOS:000179292400015
J	Yoshida, S; Shidoh, M; Matsumura, S; Ohyama, H				Yoshida, S; Shidoh, M; Matsumura, S; Ohyama, H			Superficial siderosis from spinal teratoma	LANCET			English	Editorial Material									Muroran City Gen Hosp, Dept Radiol, Muroran, Hokkaido 0518512, Japan; Muroran City Gen Hosp, Dept Neurosurg, Muroran, Hokkaido 0518512, Japan		Yoshida, S (corresponding author), Muroran City Gen Hosp, Dept Radiol, Yamate Chou 3-8-1, Muroran, Hokkaido 0518512, Japan.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 16	2002	360	9345					1539	1539		10.1016/S0140-6736(02)11521-2	http://dx.doi.org/10.1016/S0140-6736(02)11521-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	616FC	12443590				2022-12-28	WOS:000179292400008
J	Kerrick, D				Kerrick, D			Serpentinite seduction	SCIENCE			English	Editorial Material							METAMORPHIC DEVOLATILIZATION; SUBDUCTION; DEHYDRATION; SEISMICITY		Penn State Univ, Dept Geosci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Kerrick, D (corresponding author), Penn State Univ, Dept Geosci, University Pk, PA 16802 USA.	kerrick@geosc.psu.edu						Bostock MG, 2002, NATURE, V417, P536, DOI 10.1038/417536a; Dobson DP, 2002, SCIENCE, V298, P1407, DOI 10.1126/science.1075390; FRUEHGREEN GL, 1996, P ODP SCI RESULTS, V147, P255; Fryer P, 2000, GEOL S AM S, P35; Iwamori H, 2000, EARTH PLANET SC LETT, V181, P41, DOI 10.1016/S0012-821X(00)00180-1; Kerrick DM, 2001, EARTH PLANET SC LETT, V189, P19, DOI 10.1016/S0012-821X(01)00347-8; Kerrick DM, 2001, NATURE, V411, P293, DOI 10.1038/35077056; Kirby S. H., 1996, GEOPHYS MONOGR SER, V96, P195, DOI DOI 10.1029/GM096P0195; Muller MR, 1997, EARTH PLANET SC LETT, V148, P93, DOI 10.1016/S0012-821X(97)00030-7; OHanley D.S., 1996, SERPENTINITES RECORD; Omori S., 2002, B EARTHQ RES I TOKYO, V76, P455; Peacock SM, 2001, GEOLOGY, V29, P299, DOI 10.1130/0091-7613(2001)029<0299:ATLPOD>2.0.CO;2; Scambelluri M, 2001, EARTH PLANET SC LETT, V192, P457, DOI 10.1016/S0012-821X(01)00457-5; ULMER P, 1995, SCIENCE, V268, P858, DOI 10.1126/science.268.5212.858	14	56	58	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1344	1345		10.1126/science.298.5597.1344	http://dx.doi.org/10.1126/science.298.5597.1344			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12434039				2022-12-28	WOS:000179223100027
J	Volkman, BF; Prehoda, KE; Scott, JA; Peterson, FC; Lim, WA				Volkman, BF; Prehoda, KE; Scott, JA; Peterson, FC; Lim, WA			Structure of the N-WASP EVH1 domain-WIP complex: Insight into the molecular basis of Wiskott-Aldrich Syndrome	CELL			English	Article							SYNDROME PROTEIN WASP; ACTIN-DEPOLYMERIZING PROTEIN; PLECKSTRIN HOMOLOGY DOMAINS; X-LINKED THROMBOCYTOPENIA; CHEMICAL-SHIFT INDEX; ARP2/3 COMPLEX; T-CELL; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; FILOPODIUM FORMATION; SECONDARY STRUCTURE	Missense mutants that cause the immune disorder Wiskott-Aldrich Syndrome (WAS) map primarily to the Enabled/VASP homology 1 (EVH1) domain of the actin regulatory protein WASP. This domain has been implicated in both peptide and phospholipid binding. We show here that the N-WASP EVH1 domain does not bind phosphatidyl inositol-(4,5)-bisphosphate, as previously reported, but does specifically bind a 25 residue motif from the WASP Interacting Protein (WIP). The NMR structure of the complex reveals a novel recognition mechanism-the WIP ligand, which is far longer than canonical EVH1 ligands, wraps around the domain, contacting a narrow but extended surface. This recognition mechanism provides a basis for understanding the effects of mutations that cause WAS.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	University of California System; University of California San Francisco; Medical College of Wisconsin	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	wlim@itsa.ucsf.edu	Volkman, Brian F./ABE-7312-2020; Volkman, Brian F./ABE-7306-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179; Prehoda, Ken/0000-0003-4214-6158				Ball LJ, 2000, EMBO J, V19, P4903, DOI 10.1093/emboj/19.18.4903; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Barzik M, 2001, J MOL BIOL, V309, P155, DOI 10.1006/jmbi.2001.4640; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Callebaut I, 1998, FEBS LETT, V441, P181, DOI 10.1016/S0014-5793(98)01541-5; Cannon JL, 2001, IMMUNITY, V15, P249, DOI 10.1016/S1074-7613(01)00178-9; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Carlier MF, 1999, CHEM BIOL, V6, pR235, DOI 10.1016/S1074-5521(99)80107-0; Coppolino MG, 2001, J CELL SCI, V114, P4307; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DERRY JMJ, 1995, HUM MOL GENET, V4, P1127, DOI 10.1093/hmg/4.7.1127; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; El-Hakeh Jazmin, 2002, Hum Mutat, V19, P186, DOI 10.1002/humu.9013; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Greer WL, 1996, HUM GENET, V98, P685, DOI 10.1007/s004390050285; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Ho HYH, 2001, P NATL ACAD SCI USA, V98, P11306, DOI 10.1073/pnas.211420498; Imai K, 1999, CLIN IMMUNOL, V92, P128, DOI 10.1006/clim.1999.4746; Insall R, 1999, TRENDS CELL BIOL, V9, P211; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; KOLLURI R, 1995, HUM MOL GENET, V4, P1119, DOI 10.1093/hmg/4.7.1119; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Leverrier Y, 2001, J IMMUNOL, V166, P4831, DOI 10.4049/jimmunol.166.8.4831; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Markley JL, 1998, PURE APPL CHEM, V70, P117, DOI 10.1351/pac199870010117; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Millard TH, 2001, TRENDS BIOCHEM SCI, V26, P198, DOI 10.1016/S0968-0004(01)01788-1; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Naqvi SN, 1998, CURR BIOL, V8, P959, DOI 10.1016/S0960-9822(98)70396-3; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Renfranz PJ, 2002, CURR OPIN CELL BIOL, V14, P88, DOI 10.1016/S0955-0674(01)00299-X; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; SANTORO J, 1992, J MAGN RESON, V97, P202, DOI 10.1016/0022-2364(92)90250-B; Savoy DN, 2000, J IMMUNOL, V164, P2866, DOI 10.4049/jimmunol.164.6.2866; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; Snapper SB, 2001, NAT CELL BIOL, V3, P897, DOI 10.1038/ncb1001-897; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; Stewart DM, 1999, J IMMUNOL, V162, P5019; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zhu QL, 1997, BLOOD, V90, P2680, DOI 10.1182/blood.V90.7.2680.2680_2680_2689; Zicha D, 1998, BRIT J HAEMATOL, V101, P659, DOI 10.1046/j.1365-2141.1998.00767.x	72	125	132	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	2002	111	4					565	576		10.1016/S0092-8674(02)01076-0	http://dx.doi.org/10.1016/S0092-8674(02)01076-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	617DY	12437929	Bronze			2022-12-28	WOS:000179346900009
J	Hasty, J; McMillen, D; Collins, JJ				Hasty, J; McMillen, D; Collins, JJ			Engineered gene circuits	NATURE			English	Review							YEAST-CELL CYCLE; REGULATORY NETWORKS; CIRCADIAN-RHYTHMS; TRANSCRIPTIONAL REGULATORS; POSITIVE FEEDBACK; ESCHERICHIA-COLI; KINETIC-ANALYSIS; FISSION YEAST; GOOD EGG; MODEL	A central focus of postgenomic research will be to understand how cellular phenomena arise from the connectivity of genes and proteins. This connectivity generates molecular network diagrams that resemble complex electrical circuits, and a systematic understanding will require the development of a mathematical framework for describing the circuitry. From an engineering perspective, the natural path towards such a framework is the construction and analysis of the underlying submodules that constitute the network. Recent experimental advances in both sequencing and genetic engineering have made this approach feasible through the design and implementation of synthetic gene networks amenable to mathematical modelling and quantitative analysis. These developments have signalled the emergence of a gene circuit discipline, which provides a framework for predicting and evaluating the dynamics of cellular processes. Synthetic gene networks will also lead to new logical forms of cellular control, which could have important applications in functional genomics, nanotechnology, and gene and cell therapy.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Boston Univ, Ctr Biodynam, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	University of California System; University of California San Diego; Boston University; Boston University	Hasty, J (corresponding author), Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.	hasty@ucsd.edu		McMillen, David/0000-0003-2676-5450				Arkin A, 1998, GENETICS, V149, P1633; Aurell E, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.051914; Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; Bassler BL, 1999, CURR OPIN MICROBIOL, V2, P582, DOI 10.1016/S1369-5274(99)00025-9; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; Bialek W, 2001, ADV NEUR IN, V13, P103; Chen KC, 2000, MOL BIOL CELL, V11, P369, DOI 10.1091/mbc.11.1.369; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Ferrell JE, 1999, BIOESSAYS, V21, P866, DOI 10.1002/(SICI)1521-1878(199910)21:10<866::AID-BIES9>3.0.CO;2-1; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; GLASS L, 1973, J THEOR BIOL, V39, P103, DOI 10.1016/0022-5193(73)90208-7; GLASS L, 1975, J THEOR BIOL, V54, P85, DOI 10.1016/S0022-5193(75)80056-7; GLASS L, 1975, J CHEM PHYS, V63, P1325, DOI 10.1063/1.431518; Goodwin BC, 1976, ANAL PHYSL CELLS DEV; Guet CC, 2002, SCIENCE, V296, P1466, DOI 10.1126/science.1067407; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hasty J, 2000, P NATL ACAD SCI USA, V97, P2075, DOI 10.1073/pnas.040411297; Hasty J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.148101; Hasty J, 2001, NAT REV GENET, V2, P268, DOI 10.1038/35066056; Hasty J, 2001, CHAOS, V11, P207, DOI 10.1063/1.1345702; KAUFFMAN S, 1974, J THEOR BIOL, V44, P167, DOI 10.1016/S0022-5193(74)80037-8; KELLER AD, 1995, J THEOR BIOL, V172, P169, DOI 10.1006/jtbi.1995.0014; Kepler TB, 2001, BIOPHYS J, V81, P3116, DOI 10.1016/S0006-3495(01)75949-8; Lauffenburger DA, 2000, P NATL ACAD SCI USA, V97, P5031, DOI 10.1073/pnas.97.10.5031; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; Leloup JC, 2000, BIOESSAYS, V22, P84; McAdams HH, 2000, CURR BIOL, V10, pR318, DOI 10.1016/S0960-9822(00)00440-1; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; McMillen D, 2002, P NATL ACAD SCI USA, V99, P679, DOI 10.1073/pnas.022642299; MONOD J, 1961, COLD SPRING HARB SYM, V26, P389, DOI 10.1101/SQB.1961.026.01.048; Novak B, 1997, P NATL ACAD SCI USA, V94, P9147, DOI 10.1073/pnas.94.17.9147; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; PALSSON BO, 1985, J THEOR BIOL, V113, P279, DOI 10.1016/S0022-5193(85)80228-9; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Paulsson J, 2000, P NATL ACAD SCI USA, V97, P7148, DOI 10.1073/pnas.110057697; PTASHNE M, 1980, CELL, V19, P1, DOI 10.1016/0092-8674(80)90383-9; Ramachandra M, 2001, NAT BIOTECHNOL, V19, P1035, DOI 10.1038/nbt1101-1035; REINITZ J, 1990, J THEOR BIOL, V145, P295, DOI 10.1016/S0022-5193(05)80111-0; Roussel MR, 2000, J THEOR BIOL, V205, P321, DOI 10.1006/jtbi.2000.2072; SAVAGEAU MA, 1974, NATURE, V252, P546, DOI 10.1038/252546a0; SAVAGEAU MA, 1976, BIOCH SYSTEM ANAL; Simpson ML, 2001, TRENDS BIOTECHNOL, V19, P317, DOI 10.1016/S0167-7799(01)01691-2; SMITH H, 1987, J MATH BIOL, V25, P169, DOI 10.1007/BF00276388; Smolen P, 2000, NEURON, V26, P567, DOI 10.1016/S0896-6273(00)81194-0; SOMERS D, 1993, BIOL CYBERN, V68, P393, DOI 10.1007/BF00198772; Sveiczer A, 2000, P NATL ACAD SCI USA, V97, P7865, DOI 10.1073/pnas.97.14.7865; TEGNER J, UNPUB P NATL ACAD SC; Thattai M, 2001, P NATL ACAD SCI USA, V98, P8614, DOI 10.1073/pnas.151588598; Thattai M, 2002, BIOPHYS J, V82, P2943, DOI 10.1016/S0006-3495(02)75635-X; THOMAS R, 1995, B MATH BIOL, V57, P247, DOI 10.1007/BF02460618; THOMAS R, 1994, BER BUNSEN PHYS CHEM, V98, P1148, DOI 10.1002/bbpc.19940980916; Tyson J., 1978, PROG THEOR BIOL, V5, P1; Tyson JJ, 1999, BIOPHYS J, V77, P2411, DOI 10.1016/S0006-3495(99)77078-5; Vilar JMG, 2002, P NATL ACAD SCI USA, V99, P5988, DOI 10.1073/pnas.092133899; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG DL, 1993, PROCEEDINGS OF THE FIFTEENTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P1058; Weiss R., 2000, DNA6 6 INT M DNA BAS; WEISS R, 1 WORKSH NONS COMP; Weiss R, 2001, CELLULAR COMPUTATION	65	537	565	5	132	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	2002	420	6912					224	230		10.1038/nature01257	http://dx.doi.org/10.1038/nature01257			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432407				2022-12-28	WOS:000179200900059
J	Zhong, HM; Molday, LL; Molday, RS; Yau, KW				Zhong, HM; Molday, LL; Molday, RS; Yau, KW			The heteromeric cyclic nucleotide gated channel adopts a 3A : 1B stoichiometry	NATURE			English	Article							ROD PHOTORECEPTOR; ION CHANNELS; BETA-SUBUNIT; C-ELEGANS; SENSITIVITY; ARRANGEMENT; NEURONS; FAMILY; CAMP	Cyclic nucleotide-gated (CNG) channels are crucial for visual and olfactory transductions(1-4). These channels are tetramers and in their native forms are composed of A and B subunits(5), with a stoichiometry thought to be 2A:2B (refs 6, 7). Here we report the identification of a leucine-zipper(8)-homology domain named CLZ (for carboxy-terminal leucine zipper). This domain is present in the distal C terminus of CNG channel A subunits but is absent from B subunits, and mediates an inter-subunit interaction. With cross-linking, non-denaturing gel electrophoresis and analytical centrifugation, this CLZ domain was found to mediate a trimeric interaction. In addition, a mutant cone CNG channel A subunit with its CLZ domain replaced by a generic trimeric leucine zipper produced channels that behaved much like the wild type, but less so if replaced by a dimeric or tetrameric leucine zipper. This A-subunit-only, trimeric interaction suggests that heteromeric CNG channels actually adopt a 3A:1B stoichiometry. Biochemical analysis of the purified bovine rod CNG channel confirmed this conclusion. This revised stoichiometry provides a new foundation for understanding the structure and function of the CNG channel family.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Ophthalmol, Vancouver, BC V6T 1Z3, Canada; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	University of British Columbia; University of British Columbia; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.			Zhong, Haining/0000-0002-7109-4724	NATIONAL EYE INSTITUTE [R37EY006837] Funding Source: NIH RePORTER; NEI NIH HHS [R37 EY006837-14, R37 EY006837-15, R37 EY006837-15S1, R37 EY006837, R37 EY006837-13] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; Biel M, 1999, Rev Physiol Biochem Pharmacol, V135, P151, DOI 10.1007/BFb0033672; Bonigk W, 1999, J NEUROSCI, V19, P5332; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; Bradley J, 2001, SCIENCE, V294, P2095, DOI 10.1126/science.294.5549.2095; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; GORDON SE, 1995, P NATL ACAD SCI USA, V92, P10222, DOI 10.1073/pnas.92.22.10222; Gordon SE, 1996, BIOCHEMISTRY-US, V35, P3994, DOI 10.1021/bi952607b; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; He YJ, 2000, P NATL ACAD SCI USA, V97, P895, DOI 10.1073/pnas.97.2.895; Higgins MK, 2002, EMBO J, V21, P2087, DOI 10.1093/emboj/21.9.2087; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KAUPP UB, 1995, CURR OPIN NEUROBIOL, V5, P434, DOI 10.1016/0959-4388(95)80002-6; Kazmin D, 2002, ANAL BIOCHEM, V301, P91, DOI 10.1006/abio.2001.5488; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; Molday R S, 1999, Methods Enzymol, V294, P246; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; Poetsch A, 2001, J BIOL CHEM, V276, P48009, DOI 10.1074/jbc.M108941200; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; Sautter A, 1998, P NATL ACAD SCI USA, V95, P4696, DOI 10.1073/pnas.95.8.4696; Shammat IM, 1999, NEURON, V23, P809, DOI 10.1016/S0896-6273(01)80038-6; Shapiro MS, 1998, P NATL ACAD SCI USA, V95, P14546, DOI 10.1073/pnas.95.24.14546; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	31	180	187	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 14	2002	420	6912					193	198		10.1038/nature01201	http://dx.doi.org/10.1038/nature01201			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614QM	12432397	Green Accepted			2022-12-28	WOS:000179200900050
J	Gottlieb, JL				Gottlieb, JL			Age-related macular degeneration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; 5-YEAR INCIDENCE; MACULOPATHY; PREVALENCE; DRUSEN; RISK; TRANSLOCATION; ABNORMALITIES; PROGNOSIS; BLINDNESS		Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53717 USA	University of Wisconsin System; University of Wisconsin Madison	Gottlieb, JL (corresponding author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, 2870 Univ Ave,Suite 206, Madison, WI 53717 USA.	jlgottlieb@facstaff.wisc.edu						*AM AC OPHTH, 2000, COMPR AD EYE EV PREF; [Anonymous], 1994, Arch Ophthalmol, V112, P489; [Anonymous], 1991, Arch Ophthalmol, V109, P1109; [Anonymous], 1998, Ophthalmology, V105, P11; Arnold J, 2001, AM J OPHTHALMOL, V131, P541; Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198; BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006; Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329; BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1557, DOI 10.1001/archopht.1995.01100120087016; BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035; Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0; CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265; Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246; de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X; FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640; Fine SL, 2001, ARCH OPHTHALMOL-CHIC, V119, P275; GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206; Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1; HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200; HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522; HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207; KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659; Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6; KLEIN R, 1995, OPHTHALMOLOGY, V102, P371; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480; Maguire MG, 1999, AGE RELATED MACULAR, P17; Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171; MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048; MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450; Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6; Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1; SARKS SH, 2001, RETINA, P1064; SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500; SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953; Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0; SEDDON JM, 2001, RETINA, P1039; Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285; SUNNESS S, 1999, AGE RELATED MACULAR, P155; TIELSCH JA, 1994, PREVENT BLINDNESS AM; Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001; VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205; WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038; YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701	49	50	50	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2002	288	18					2233	2236		10.1001/jama.288.18.2233	http://dx.doi.org/10.1001/jama.288.18.2233			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JZ	12425683				2022-12-28	WOS:000179186400002
J	Hoffmann, A; Levchenko, A; Scott, ML; Baltimore, D				Hoffmann, A; Levchenko, A; Scott, ML; Baltimore, D			The I kappa B-NF-kappa B signaling module: Temporal control and selective gene activation	SCIENCE			English	Article							DEFICIENT MICE; ALPHA; MECHANISMS; EPSILON; FAMILY; BETA	Nuclear localization of the transcriptional activator NFkappa-B (nuclear factor kappaB) is controlled in mammalian cells by three isoforms of NF-kappaB inhibitor protein: IkappaBalpha, -beta, and -epsilon. Based on simplifying reductions of the IkappaB-NF-kappaB signaling module in knockout cell lines, we present a computational model that describes the temporal control of NF-kappaB activation by the coordinated degradation and synthesis of IkappaB proteins. The model demonstrates that IkappaBalpha is responsible for strong negative feedback that allows for a fast turn-off of the NF-kappaB response, whereas IkappaBbeta and -epsilon function to reduce the system's oscillatory potential and stabilize NF-kappaB responses during longer stimulations. Bimodal signal-processing characteristics with respect to stimulus duration are revealed by the model and are shown to generate specificity in gene expression.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	California Institute of Technology; Johns Hopkins University; Massachusetts Institute of Technology (MIT)	Baltimore, D (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	baltimo@caltech.edu	Levchenko, Andre/A-3328-2010; Hoffmann, Ary/R-2972-2019	Hoffmann, Ary/0000-0001-9497-7645				Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; HOFFMANN A, UNPUB; Kemler I, 1999, GLIA, V26, P212, DOI 10.1002/(SICI)1098-1136(199905)26:3<212::AID-GLIA3>3.0.CO;2-F; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Memet S, 1999, J IMMUNOL, V163, P5994; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; SCOTT M, UNPUB; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914	19	1392	1450	3	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	2002	298	5596					1241	1245		10.1126/science.1071914	http://dx.doi.org/10.1126/science.1071914			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424381				2022-12-28	WOS:000179080400053
J	Medalia, O; Weber, I; Frangakis, AS; Nicastro, D; Gerisch, G; Baumeister, W				Medalia, O; Weber, I; Frangakis, AS; Nicastro, D; Gerisch, G; Baumeister, W			Macromolecular architecture in eukaryotic cells visualized by cryoelectron tomography	SCIENCE			English	Article							AUTOMATIC ELECTRON TOMOGRAPHY; ARP2/3 COMPLEX; 26S PROTEASOME; F-ACTIN; DICTYOSTELIUM; CYTOKINESIS; FILAMENTS; MECHANISM; PROTEINS; PARTICLE	Electron tomography of vitrifed cells is a noninvasive three-dimensional imaging technique that opens up new vistas for exploring the supramolecular organization of the cytoplasm. We applied this technique to Dictyostelium cells, focusing on the actin cytoskeleton. In actin networks reconstructed without prior removal of membranes or extraction of soluble proteins, the cross-linking of individual micro laments, their branching angles, and membrane attachment sites can be analyzed. At a resolution of 5 to 6 nanometers, single macromolecules with distinct shapes, such as the 26S proteasome, can be identified in an unperturbed cellular environment.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Baumeister, W (corresponding author), Max Planck Inst Biochem, D-82152 Martinsried, Germany.		Weber, Igor/J-3947-2012	Weber, Igor/0000-0003-4296-3166; Frangakis, Achilleas/0000-0002-8067-6611; Medalia, Ohad/0000-0003-0994-2937; Nicastro, Daniela/0000-0002-0122-7173				Baumeister W, 1999, TRENDS CELL BIOL, V9, P81, DOI 10.1016/S0962-8924(98)01423-8; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; Bohm J, 2000, P NATL ACAD SCI USA, V97, P14245, DOI 10.1073/pnas.230282097; de Hostos EL, 1999, TRENDS CELL BIOL, V9, P345, DOI 10.1016/S0962-8924(99)01620-7; DIERKSEN K, 1992, ULTRAMICROSCOPY, V40, P71, DOI 10.1016/0304-3991(92)90235-C; DIERKSEN K, 1993, ULTRAMICROSCOPY, V49, P109, DOI 10.1016/0304-3991(93)90217-L; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Frangakis AS, 2002, P NATL ACAD SCI USA, V99, P14153, DOI 10.1073/pnas.172520299; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Grimm R, 1998, BIOPHYS J, V74, P1031, DOI 10.1016/S0006-3495(98)74028-7; Grimm R, 1997, BIOPHYS J, V72, P482, DOI 10.1016/S0006-3495(97)78689-2; Grimm R, 1996, J MICROSC-OXFORD, V183, P60, DOI 10.1046/j.1365-2818.1996.77441.x; GRUNEWALD R, IN PRESS BIOPHYS CHE; HART RG, 1968, SCIENCE, V159, P1464, DOI 10.1126/science.159.3822.1464; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HEGERL R, 1976, Z NATURFORSCH A, V31, P1717, DOI 10.1515/zna-1976-1241; HEUSER JE, 1980, J CELL BIOL, V86, P212, DOI 10.1083/jcb.86.1.212; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; Insall R, 2001, CELL MOTIL CYTOSKEL, V50, P115, DOI 10.1002/cm.10005; Koster AJ, 1997, J STRUCT BIOL, V120, P276, DOI 10.1006/jsbi.1997.3933; Lee EY, 2001, BBA-GEN SUBJECTS, V1525, P217, DOI 10.1016/S0304-4165(01)00107-6; MCEWEN BF, 1995, ULTRAMICROSCOPY, V60, P357, DOI 10.1016/0304-3991(95)00082-8; McEwen BF, 2001, J HISTOCHEM CYTOCHEM, V49, P553, DOI 10.1177/002215540104900502; McEwen BF, 2001, CURR OPIN NEUROBIOL, V11, P594, DOI 10.1016/S0959-4388(00)00255-5; Muller-Taubenberger A, 2001, EMBO J, V20, P6772, DOI 10.1093/emboj/20.23.6772; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Nicastro D, 2000, J STRUCT BIOL, V129, P48, DOI 10.1006/jsbi.1999.4204; Niewohner J, 1997, J CELL BIOL, V138, P349, DOI 10.1083/jcb.138.2.349; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Plitzko JM, 2002, TRENDS BIOTECHNOL, V20, pS40, DOI 10.1016/S0167-7799(02)02017-6; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Resch GP, 2002, J CELL SCI, V115, P1877; Schliwa M, 2002, NAT REV MOL CELL BIO, V3, P291, DOI 10.1038/nrm781; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; Tsujioka M, 1999, CURR BIOL, V9, P389, DOI 10.1016/S0960-9822(99)80169-9; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958	43	610	629	2	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1209	1213		10.1126/science.1076184	http://dx.doi.org/10.1126/science.1076184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424373				2022-12-28	WOS:000179080400042
J	Klein, M; Heimans, JJ; Aaronson, NK; van der Ploeg, HM; Grit, J; Muller, M; Postma, TJ; Mooij, JJ; Boerman, RH; Beute, GN; Ossenkoppele, GJ; van Imhoff, GW; Dekker, AW; Jolles, J; Slotman, BJ; Struikmans, H; Taphoorn, MJB				Klein, M; Heimans, JJ; Aaronson, NK; van der Ploeg, HM; Grit, J; Muller, M; Postma, TJ; Mooij, JJ; Boerman, RH; Beute, GN; Ossenkoppele, GJ; van Imhoff, GW; Dekker, AW; Jolles, J; Slotman, BJ; Struikmans, H; Taphoorn, MJB			Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study	LANCET			English	Article							QUALITY-OF-LIFE; RADIATION; ADULTS; CANCER; TRIAL	Background Because survival benefits of treatment with radiotherapy are questionable and such treatment can cause substantial damage to the brain over time, the optimum management strategy for low-grade gliomas remains controversial. We aimed to identify the specific effects of radiotherapy on objective and self-reported cognitive function, and on cognitive deterioration over time, in patients with low-grade gliomas treated with early radiotherapy. Methods 195 patients with low-grade glioma (of whom 104 had received radiotherapy 1-22 years previously) were compared with 100 low-grade haematological patients and 195 healthy controls. Our analyses aimed to differentiate between the effects of the tumour (eg, disease duration, lateralisation) and treatment effects (neurosurgery, radiotherapy, antiepileptic drugs) on cognitive function and on relative risk of cognitive disability. Findings Low-grade glioma patients had lower ability in all cognitive domains than did low-grade haematological patients, and did even less well by comparison with healthy controls. Use of radiotherapy was associated with poorer cognitive function; however, cognitive disability in the memory domain was found only in radiotherapy patients who received fraction doses exceeding 2 Gy. Antiepileptic drug use was strongly associated with disability in attentional and executive function. Interpretation Our findings suggest that the tumour itself has the most deleterious effect on cognitive function and that radiotherapy mainly results in additional long-term cognitive disability when high fraction doses are used.	Vrije Univ Amsterdam, Med Ctr, Dept Med Psychol, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Neurol, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Haematol, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Radiat Oncol, NL-1081 BT Amsterdam, Netherlands; Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, Amsterdam, Netherlands; Univ Groningen Hosp, Dept Neurosurg, Groningen, Netherlands; Univ Groningen Hosp, Dept Haematol, Groningen, Netherlands; Univ Nijmegen Hosp, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; St Elizabeth Hosp, Dept Neurosurg, Tilburg, Netherlands; Univ Med Ctr Utrecht, Dept Haematol, Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Neurol, Utrecht, Netherlands; Maastricht Univ, Dept Neuropsychol Neuropsychiat & Psychobiol, Maastricht, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; University of Groningen; University of Groningen; Radboud University Nijmegen; Elisabeth-TweeSteden Ziekenhuis (ETZ); Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Maastricht University	Klein, M (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Med Psychol, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		Klein, Martin/C-4192-2012; Aaronson, Neil K/AAV-8194-2021	Klein, Martin/0000-0003-4160-5746; Klein, Martin/0000-0001-5553-7911; Slotman, Ben/0000-0002-9902-4592				Abrey LE, 1998, J CLIN ONCOL, V16, P859, DOI 10.1200/JCO.1998.16.3.859; ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; [Anonymous], VULNERABLE BRAIN ENV; Bampoe J, 1999, J NEURO-ONCOL, V42, P259, DOI 10.1023/A:1006103010109; Bauman G, 1999, CAN J NEUROL SCI, V26, P18; CORN BW, 1994, CANCER, V74, P2828, DOI 10.1002/1097-0142(19941115)74:10<2828::AID-CNCR2820741014>3.0.CO;2-K; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Cull A, 1996, BRIT J CANCER, V74, P1674, DOI 10.1038/bjc.1996.608; DEANGELIS LM, 1989, NEUROLOGY, V39, P789, DOI 10.1212/WNL.39.6.789; Karim ABMF, 2002, INT J RADIAT ONCOL, V52, P316, DOI 10.1016/S0360-3016(01)02692-X; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; Kiebert GM, 1998, EUR J CANCER, V34, P1902, DOI 10.1016/S0959-8049(98)00268-8; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Leighton C, 1997, J CLIN ONCOL, V15, P1294, DOI 10.1200/JCO.1997.15.4.1294; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Olson JD, 2000, NEUROLOGY, V54, P1442, DOI 10.1212/WNL.54.7.1442; ORDER SE, 1968, RADIOLOGY, V91, P149, DOI 10.1148/91.1.149; PHILIPPON JH, 1993, NEUROSURGERY, V32, P554; Postma TJ, 2002, NEUROLOGY, V59, P121, DOI 10.1212/WNL.59.1.121; RECHT LD, 1992, ANN NEUROL, V31, P431, DOI 10.1002/ana.410310413; Schmand B, 1991, Tijdschr Gerontol Geriatr, V22, P15; Shaw E G, 1995, Clin Neurosurg, V42, P488; STEWART A, 1998, MEASURING FUNCTIONIN; Surma-aho O, 2001, NEUROLOGY, V56, P1285, DOI 10.1212/WNL.56.10.1285; TAPHOORN MJB, 1992, J NEUROL NEUROSUR PS, V55, P372, DOI 10.1136/jnnp.55.5.372; TAPHOORN MJB, 1994, ANN NEUROL, V36, P48, DOI 10.1002/ana.410360111; van Boxtel MPJ, 1998, J GERONTOL A-BIOL, V53, pM147; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; van der Sanden GAC, 1998, NEUROEPIDEMIOLOGY, V17, P247, DOI 10.1159/000026177; Wade D T, 1988, Int Disabil Stud, V10, P64; *WHO, 2001, ICIDH, V2	31	402	416	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1361	1368		10.1016/S0140-6736(02)11398-5	http://dx.doi.org/10.1016/S0140-6736(02)11398-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423981	Green Submitted			2022-12-28	WOS:000179081600008
J	Dioum, EM; Rutter, J; Tuckerman, JR; Gonzalez, G; Gilles-Gonzalez, MA; McKnight, SL				Dioum, EM; Rutter, J; Tuckerman, JR; Gonzalez, G; Gilles-Gonzalez, MA; McKnight, SL			NPAS2: A gas-responsive transcription factor	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; OXYGEN SENSOR; HEME PROTEIN; BINDING; LIGHT; CLOCK; RECEPTOR; DOMAINS; NEURONS; GENES	Neuronal PAS domain protein 2 (NPAS2) is a mammalian transcription factor that binds DNA as an obligate dimeric partner of BMAL1 and is implicated in the regulation of circadian rhythm. Here we show that both PAS domains of NPAS2 bind heme as a prosthetic group and that the heme status controls DNA binding in vitro. NPAS2-BMAL1 heterodimers, existing in either the apo (heme-free) or holo (heme-loaded) state, bound DNA avidly under favorably reducing ratios of the reduced and oxidized forms of nicotinamide adenine dinucleotide phosphate. Low micromolar concentrations of carbon monoxide inhibited the DNA binding activity of holo-NPAS2 but not that of apo-NPAS2. Upon exposure to carbon monoxide, inactive BMAL1 homodimers were formed at the expense of NPAS2-BMAL1 heterodimers. These results indicate that the heterodimerization of NPAS2, and presumably the expression of its target genes, are regulated by a gas through the heme-based sensor described here.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Plant Biol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Plant Biotechnol, Columbus, OH 43210 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilles-Gonzalez, MA (corresponding author), Ohio State Univ, Dept Biochem, 1060 Carmack Rd, Columbus, OH 43210 USA.	magg@biochem.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059388] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL640381] Funding Source: Medline; NIGMS NIH HHS [NIH5-T32-GM08-291-12] Funding Source: Medline; NIMH NIH HHS [R01 MH5938805] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; Appleby C. A., 1980, Methods for evaluating biological nitrogen fixation., P315; Ascoli F, 1981, Methods Enzymol, V76, P72; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Denison MS, 2002, CHEM-BIOL INTERACT, V141, P3, DOI 10.1016/S0009-2797(02)00063-7; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Gilles-Gonzalez MA, 2001, IUBMB LIFE, V51, P165, DOI 10.1080/152165401753544232; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Gonzalez G, 2002, BIOCHEMISTRY-US, V41, P8414, DOI 10.1021/bi025845x; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Ingi T, 1996, J NEUROSCI, V16, P5621; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; VINCENT SR, 1994, NEUROSCIENCE, V63, P223, DOI 10.1016/0306-4522(94)90018-3; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	27	366	379	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	2002	298	5602					2385	2387		10.1126/science.1078456	http://dx.doi.org/10.1126/science.1078456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	627DG	12446832				2022-12-28	WOS:000179915900055
J	Black, A				Black, A			Reconfiguring health systems	BRITISH MEDICAL JOURNAL			English	Article									Durrow, Machynlleth SY20 8WQ, Wales		Black, A (corresponding author), Durrow, POB 22, Machynlleth SY20 8WQ, Wales.							*DEP HLTH, CAP INV MAN; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; FITZPATRICK R, 1992, BRIT MED J, V305, P1074, DOI 10.1136/bmj.305.6861.1074; *HOUS COMM SEL COM, 2002, 1 HOUS COMM SEL COMM; Lathrop P. J., 1993, RESTRUCTURING HLTH C; *ROYAL COLL PHYS L, 2002, IS AC MED SERV; Scottish Office, 1998, AC SERV REV; Wanless, 2002, SECURING OUR FUTURE; *WORC HLTH AUTH, 1998, INV EXC; 2002, ECONOMIST       0622, P34	10	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1290	1293		10.1136/bmj.325.7375.1290	http://dx.doi.org/10.1136/bmj.325.7375.1290			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458253	Green Published			2022-12-28	WOS:000179696300023
J	Cappuccio, FP; Oakeshott, P; Strazzullo, P; Kerry, SM				Cappuccio, FP; Oakeshott, P; Strazzullo, P; Kerry, SM			Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study	BRITISH MEDICAL JOURNAL			English	Article							BRITISH-HYPERTENSION-SOCIETY; CARDIOVASCULAR RISK; CORONARY RISK; EUROPEAN POPULATIONS; CLINICAL-PRACTICE; BLOOD-PRESSURE; HEALTH SURVEY; MANAGEMENT; VALIDATION; GUIDELINES	Objective To compare the 10 year risk of coronary heart disease (CHD), stroke, and combined cardiovascular disease (CVD) estimated from the Framingham equations. Design Population based cross sectional survey. Setting Nine general practices in south London. Population 1386 men and women, age 40-59 years, with no history of CVD (475 white people, 447 south Asian people, and 464 people of African origin), and a subgroup of 1069 without known diabetes, left ventricular hypertrophy, peripheral vascular disease, renal impairment, or target organ damage. Main outcome measures 10 year risk estimates. Results People of African origin had the lowest 10 year risk estimate of CHD adjusted for age and sex (7.0%, 95% confidence interval 6.5 to 7.5.) compared with white people (8.8%, 8.2 to 9.5) and south Asians (9.2%, 8.6 to 9.9) and the highest estimated risk of stroke (1.7% (1.5 to 1.9),1.4% (1.3 to 1.6),1.6% (1.5 to 1.8), respectively). The estimate risk of combined CVD, however, was highest in south Asians (12.5%, 11.6 to 13.4) compared with white people (11.9%, 11.0 to 12.7) and people of African origin (10.5%, 9.7 to 11.2). In the subgroup of 1069, the probability that a risk of CHD greater than or equal to 15% would identify risk of combined CVD greater than or equal to 20% was 91% in white people and 81% in both south Asians and people of African origin. The use of thresholds for risk of CHD of 12% in south Asians and 10% in people of African origin would increase the probability of identifying those at risk to 100% and 97%, respectively. Conclusion Primary care doctors should use a lower threshold of CHD risk when treating mild uncomplicated hypertension in people of African or south Asian origin.	St George Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England; Univ Naples, Federico II Med Sch, Dept Clin & Expt Med, I-80131 Naples, Italy	St Georges University London; University of Naples Federico II	Cappuccio, FP (corresponding author), St George Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England.		Cappuccio, Francesco/D-3028-2009; Modesti, Pietro Amedeo/B-2638-2012	Modesti, Pietro Amedeo/0000-0002-9511-2173; Oakeshott, Pippa/0000-0003-2568-8211; Cappuccio, Francesco Paolo/0000-0002-7842-5493				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Cappuccio FP, 1997, J HUM HYPERTENS, V11, P571, DOI 10.1038/sj.jhh.1000516; Cappuccio FP, 1998, NUTR METAB CARDIOVAS, V8, P371; Cappuccio FP, 1997, HEART, V78, P555, DOI 10.1136/hrt.78.6.555; Chapman JN, 1999, AM J HYPERTENS, V12, P437, DOI 10.1016/S0895-7061(99)00027-8; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; Department of Health, 2000, NAT SERV FRAM COR HE, P1; Du XL, 1997, BMJ-BRIT MED J, V314, P272, DOI 10.1136/bmj.314.7076.272; Haq IU, 1999, HEART, V81, P40, DOI 10.1136/hrt.81.1.40; Harris T, 1999, BRIT MED J, V318, P531; Harris TJ, 2000, NUTR METAB CARDIOVAS, V10, P305; Hennekens C. H., 1987, EPIDEMIOLOGY MED, P1; Jackson R, 2000, BMJ-BRIT MED J, V320, P659, DOI 10.1136/bmj.320.7236.659; Jackson R, 2000, BMJ-BRIT MED J, V320, P709, DOI 10.1136/bmj.320.7236.709; LENG GC, 1992, J CLIN EPIDEMIOL, V45, P1101, DOI 10.1016/0895-4356(92)90150-L; Menotti A, 2000, HEART, V84, P238, DOI 10.1136/heart.84.3.238; Primatesta P, 2000, J HUM HYPERTENS, V14, P143, DOI 10.1038/sj.jhh.1000960; Primatesta P, 2001, HYPERTENSION, V38, P827, DOI 10.1161/hyp.38.4.827; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; ROSE GA, 1982, CARDIOVASCULAR SURVE, P123; Wallis EJ, 2000, BMJ-BRIT MED J, V320, P671, DOI 10.1136/bmj.320.7236.671; Wallis EJ, 2001, J HYPERTENS, V19, P691, DOI 10.1097/00004872-200104000-00005; Wood D, 1998, HEART, V80, pS1	25	109	113	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2002	325	7375					1271	1274B		10.1136/bmj.325.7375.1271	http://dx.doi.org/10.1136/bmj.325.7375.1271			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	623HB	12458243	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000179696300016
J	Bennett, IM; Farfano, HMV; Bogani, F; Primak, A; Liddell, PA; Otero, L; Sereno, L; Silber, JJ; Moore, AL; Moore, TA; Gust, D				Bennett, IM; Farfano, HMV; Bogani, F; Primak, A; Liddell, PA; Otero, L; Sereno, L; Silber, JJ; Moore, AL; Moore, TA; Gust, D			Active transport of Ca2+ by an artificial photosynthetic membrane	NATURE			English	Article							ELECTRON-TRANSFER; LIQUID MEMBRANES; DERIVATIVES	Transport of calcium ions across membranes and against a thermodynamic gradient is essential to many biological processes, including muscle contraction, the citric acid cycle, glycogen metabolism, release of neurotransmitters, vision, biological signal transduction and immune response. Synthetic systems that transport metal ions across lipid or liquid membranes are well known(1-6), and in some cases light has been used to facilitate transport(7). Typically, a carrier molecule located in a symmetric membrane binds the ion from aqueous solution on one side and releases it on the other. The thermodynamic driving force is provided by an ion concentration difference between the two aqueous solutions, coupling to such a gradient in an auxiliary species, or photomodulation of the carrier by an asymmetric photon flux(7). Here we report a different approach, in which active transport is driven not by concentration gradients, but by light-induced electron transfer in a photoactive molecule that is asymmetrically disposed across a lipid bilayer. The system comprises a synthetic, light-driven transmembrane Ca2+ pump based on a redox-sensitive, lipophilic Ca2+-binding shuttle molecule whose function is powered by an intramembrane artificial photosynthetic reaction centre. The resulting structure transports calcium ions across the bilayer of a liposome to develop both a calcium ion concentration gradient and a membrane potential, expanding Mitchell's concept of a redox loop mechanism for protons(8) to include divalent cations. Although the quantum yield is relatively low (similar to1 per cent), the Ca2+ electrochemical potential developed is significant.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA; Univ Natl Rio Cuarto, Dept Quim & Fis, Rio Cuarto, Argentina	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Universidad Nacional Rio Cuarto	Gust, D (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.			Otero, Luis/0000-0002-7347-8107; Silber, Juana/0000-0001-9395-9939				BARTSCH RA, 1996, CHEM SEPARATIONS LIQ; DADFARNIA S, 1993, J MEMBRANE SCI, V78, P115, DOI 10.1016/0376-7388(93)85253-S; de Gyves J, 1999, IND ENG CHEM RES, V38, P2182, DOI 10.1021/ie980374p; Hirose T, 1998, RRD PURE APPL CHEM, V2, P527; LAMRABTE A, 1991, PHOTOCHEM PHOTOBIOL, V54, P123, DOI 10.1111/j.1751-1097.1991.tb01994.x; Longin TL, 2001, CHEM INNOV, V31, P23; MINTA A, 1989, J BIOL CHEM, V264, P8171; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; Steinberg-Yfrach G, 1998, NATURE, V392, P479, DOI 10.1038/33116; SteinbergYfrach G, 1997, NATURE, V385, P239, DOI 10.1038/385239a0; Sullivan B.W., 1990, P45; ZHAO ZG, 1992, PHOTOCHEM PHOTOBIOL, V55, P611, DOI 10.1111/j.1751-1097.1992.tb04284.x	12	133	135	7	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					398	401		10.1038/nature01209	http://dx.doi.org/10.1038/nature01209			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459780				2022-12-28	WOS:000179494700034
J	Dixon, JE; Leist, L; Langmuir, C; Schilling, JG				Dixon, JE; Leist, L; Langmuir, C; Schilling, JG			Recycled dehydrated lithosphere observed in plume-influenced mid-ocean-ridge basalt	NATURE			English	Article							SHONA MANTLE PLUMES; ATLANTIC RIDGE; ISOTOPIC EVIDENCE; CONSTRAINTS; EVOLUTION; MAGMAS; HETEROGENEITY; SEAMOUNT; WATER; H2O	A substantial uncertainty in the Earth's global geochemical water cycle is the amount of water that enters the deep mantle through the subduction and recycling of hydrated oceanic lithosphere. Here we address the question of recycling of water into the deep mantle by characterizing the volatile contents of different mantle components as sampled by ocean island basalts and mid-ocean-ridge basalts. Although all mantle plume (ocean island) basalts seem to contain more water than mid-ocean-ridge basalts, we demonstrate that basalts associated with mantle plume components containing subducted lithosphere-'enriched-mantle' or 'EM-type' basalts-contain less water than those associated with a common mantle source. We interpret this depletion as indicating that water is extracted from the lithosphere during the subduction process, with greater than 92 per cent efficiency.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, MGG, Miami, FL 33149 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA	University of Miami; Harvard University; University of Rhode Island	Dixon, JE (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, MGG, 4600 Rickenbacker Causeway, Miami, FL 33149 USA.		Dixon, Jacqueline/B-5340-2012					Abe Y., 2000, ORIGIN EARTH MOON, P413; Allegre CJ, 1996, GEOPHYS RES LETT, V23, P3555, DOI 10.1029/96GL03373; ANDRES M, IN PRESS EARTH PLANE; Bell K., 2002, EOS T AM GEOPHYS UN, V83, P273, DOI [DOI 10.1029/2002E0000190, DOI 10.1029/2002EO000190]; Blichert-Toft J, 1999, SCIENCE, V285, P879, DOI 10.1126/science.285.5429.879; CHAUVEL C, 1995, CHEM GEOL, V126, P65, DOI 10.1016/0009-2541(95)00103-3; CHAUVEL C, 1992, EARTH PLANET SC LETT, V110, P99, DOI 10.1016/0012-821X(92)90042-T; Cheng QC, 1999, CONTRIB MINERAL PETR, V135, P225, DOI 10.1007/s004100050508; Danyushevsky LV, 2000, J PETROL, V41, P1329, DOI 10.1093/petrology/41.8.1329; Dixon JE, 1997, J PETROL, V38, P911, DOI 10.1093/petrology/38.7.911; Dixon JE, 2001, J PETROL, V42, P627, DOI 10.1093/petrology/42.3.627; DONNELLY K, 2001, EOS T AGU S, V82, pF1402; Dosso L, 1999, EARTH PLANET SC LETT, V170, P269, DOI 10.1016/S0012-821X(99)00109-0; Douglass J, 1999, J GEOPHYS RES-SOL EA, V104, P2941, DOI 10.1029/98JB02642; Douglass J, 2000, CHEM GEOL, V163, P1, DOI 10.1016/S0009-2541(99)00070-4; DOUGLASS J, 1995, GEOPHYS RES LETT, V22, P2893, DOI 10.1029/95GL02665; EILER JM, 2002, STABLE ISOTOPES IGNE; Gibson SA, 2002, EARTH PLANET SC LETT, V195, P59, DOI 10.1016/S0012-821X(01)00566-0; Hanan BB, 1996, SCIENCE, V272, P991, DOI 10.1126/science.272.5264.991; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; HAURI EH, 1994, J GEOPHYS RES-SOL EA, V99, P24275, DOI 10.1029/94JB01257; HIROSE K, 1995, EARTH PLANET SC LETT, V133, P463, DOI 10.1016/0012-821X(95)00096-U; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; HOFMANN AW, 1986, EARTH PLANET SC LETT, V79, P33, DOI 10.1016/0012-821X(86)90038-5; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; HOFMANN AW, 1986, CHEM GEOL, V57, P17, DOI 10.1016/0009-2541(86)90091-4; Kamenetsky VS, 2001, GEOLOGY, V29, P243, DOI 10.1130/0091-7613(2001)029<0243:ROGCLI>2.0.CO;2; Kingsley RH, 1998, J GEOPHYS RES-SOL EA, V103, P24159, DOI 10.1029/98JB01496; Langmuir C., 1992, LDEO923 COL U; LEROEX AP, 1987, GEOCHIM COSMOCHIM AC, V51, P541, DOI 10.1016/0016-7037(87)90068-8; LEROUX PJ, IN PRESS EARTH PLANE; MCKENZIE D, 1983, NATURE, V301, P229, DOI 10.1038/301229a0; MENZIES M, 1980, NATURE, V283, P634, DOI 10.1038/283634a0; MICHAEL P, 1995, EARTH PLANET SC LETT, V131, P301, DOI 10.1016/0012-821X(95)00023-6; Michael PJ, 1998, J GEOPHYS RES-SOL EA, V103, P18325, DOI 10.1029/98JB00791; MILLER DM, 1994, NATURE, V368, P514, DOI 10.1038/368514a0; NADEAU S, 1993, EARTH PLANET SC LETT, V114, P431, DOI 10.1016/0012-821X(93)90074-J; PEACOCK SM, 1990, SCIENCE, V248, P329, DOI 10.1126/science.248.4953.329; Plank T, 1998, CHEM GEOL, V145, P325, DOI 10.1016/S0009-2541(97)00150-2; RIDEOUT ML, 1985, INITIAL REP DEEP SEA, V82, P483; Sarda P, 2000, J GEOPHYS RES-SOL EA, V105, P5973, DOI 10.1029/1999JB900282; SCHILLING JG, 1980, PHILOS T R SOC A, V297, P147, DOI 10.1098/rsta.1980.0208; Schirmer J., 1992, Information Bulletin on Variable Stars, P1; Schmidt MW, 1998, EARTH PLANET SC LETT, V163, P361, DOI 10.1016/S0012-821X(98)00142-3; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; SHIREY SB, 1987, NATURE, V325, P217, DOI 10.1038/325217a0; SIMONS K, 2002, GEOCHEM GEOPHYS GEOS, V3; THOMPSON AB, 1992, NATURE, V358, P295, DOI 10.1038/358295a0; WEAVER BL, 1991, EARTH PLANET SC LETT, V104, P381, DOI 10.1016/0012-821X(91)90217-6; WHITE WM, 1985, GEOLOGY, V13, P115, DOI 10.1130/0091-7613(1985)13<115:SOOBRI>2.0.CO;2; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	51	378	398	5	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 28	2002	420	6914					385	389		10.1038/nature01215	http://dx.doi.org/10.1038/nature01215			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619TZ	12459776				2022-12-28	WOS:000179494700030
J	Richards, DA; Meakins, J; Tawfik, J; Godfrey, L; Dutton, E; Richardson, G; Russell, D				Richards, DA; Meakins, J; Tawfik, J; Godfrey, L; Dutton, E; Richardson, G; Russell, D			Nurse telephone triage for same day appointments in general practice: multiple interrupted time series trial of effect on workload and costs	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; PRIMARY-CARE; CONSULTATION	Objective To compare the workloads of general practitioners and nurses and costs of patient care for nurse telephone triage and standard management of requests for same day appointments in routine primary care. Design Multiple interrupted time series using sequential introduction of experimental triage system in different sites with repeated measures taken one week in every month for 12 months. Setting Three primary care sites in York. Participants 4685 patients: 1233 in standard management, 3452 in the triage system. All patients requesting same day appointments during study weeks were included in the trial. Main outcome measures Type of consultation (telephone, appointment, or visit), time taken for consultation, presenting complaints, use of services during the month after same day contact, and costs of drugs and same day, follow up, and emergency care. Results The triage system reduced appointments with general practitioner by 29-44%. Compared with standard management, the triage system had a relative risk (95% confidence interval) of 0.85 (0.72 to 1.00) for home visits, 2.41 (2.08 to 2.80) for telephone care, and 3.79 (3.21 to 4.48) for nurse care. Mean overall time in the triage system was 1.70 minutes longer, but mean general practitioner time was reduced by 2.45 minutes. Routine appointments and nursing time increased, as did out of hours and accident and emergency attendance. Costs did not differ significantly between standard management and triage: mean difference pound1.48 more per patient for triage (95% confidence interval -0.19 to 3.15). Conclusions Triage reduced the number of same day appointments with general practitioners but resulted in busier routine surgeries, increased nursing time, and a small but significant increase in out of hours and accident and emergency attendance. Consequently, triage does not reduce overall costs per patient for managing same day appointments.	Univ Manchester, Sch Nursing Midwifery & Hlth Visiting, Manchester M13 9PL, Lancs, England; Rawcliffe Surg, Priory Med Grp, York YO30 6ND, N Yorkshire, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England; Univ York, Dept Hlth Sci, York YO1 5DD, N Yorkshire, England	University of Manchester; University of York - UK; University of York - UK	Richards, DA (corresponding author), Univ Manchester, Sch Nursing Midwifery & Hlth Visiting, Manchester M13 9PL, Lancs, England.		Richards, David/B-4807-2009	Richards, David/0000-0002-8821-5027				*BRIT MED ASS, 1996, GEN MED SERV COMM ME; *DEP HLTH, 1989, GEN PRACT NAT HLTH S; Gallagher M, 1998, BRIT J GEN PRACT, V48, P1141; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; Jones K, 1998, BRIT J GEN PRACT, V48, P1303; Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054; Lattimer V, 1997, BRIT MED J, V314, P198; Thompson F, 1999, BMJ-BRIT MED J, V319, P1408, DOI 10.1136/bmj.319.7222.1408	8	53	54	2	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 23	2002	325	7374					1214	1217		10.1136/bmj.325.7374.1214	http://dx.doi.org/10.1136/bmj.325.7374.1214			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	619YU	12446539	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000179506200022
J	Hulscher, JBF; van Sandick, JW; de Boer, AGEM; Wijnhoven, BPL; Tijssen, JGP; Fockens, P; Stalmeier, PFM; ten Kate, FJW; van Dekken, H; Obertop, H; Tilanus, HW; van Lanschot, JJB				Hulscher, JBF; van Sandick, JW; de Boer, AGEM; Wijnhoven, BPL; Tijssen, JGP; Fockens, P; Stalmeier, PFM; ten Kate, FJW; van Dekken, H; Obertop, H; Tilanus, HW; van Lanschot, JJB			Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GASTRIC CARDIA; SURGICAL THERAPY; CARCINOMA	Background: Controversy exists about the best surgical treatment for esophageal carcinoma. Methods: We randomly assigned 220 patients with adenocarcinoma of the mid-to-distal esophagus or adenocarcinoma of the gastric cardia involving the distal esophagus either to transhiatal esophagectomy or to transthoracic esophagectomy with extended en bloc lymphadenectomy. Principal end points were overall survival and disease-free survival. Early morbidity and mortality, the number of quality-adjusted life-years gained, and cost effectiveness were also determined. Results: A total of 106 patients were assigned to undergo transhiatal esophagectomy, and 114 to undergo transthoracic esophagectomy. Demographic characteristics and characteristics of the tumor were similar in the two groups. Perioperative morbidity was higher after transthoracic esophagectomy, but there was no significant difference in in-hospital mortality (P=0.45). After a median follow-up of 4.7 years, 142 patients had died -- 74 (70 percent) after transhiatal resection and 68 (60 percent) after transthoracic resection (P=0.12). Although the difference in survival was not statistically significant, there was a trend toward a survival benefit with the extended approach at five years: disease-free survival was 27 percent in the transhiatal-esophagectomy group, as compared with 39 percent in the transthoracic-esophagectomy group (95 percent confidence interval for the difference, -1 to 24 percent [the negative value indicates better survival with transhiatal resection]), whereas overall survival was 29 percent as compared with 39 percent (95 percent confidence interval for the difference, -3 to 23 percent). Conclusions: Transhiatal esophagectomy was associated with lower morbidity than transthoracic esophagectomy with extended en bloc lymphadenectomy. Although median overall, disease-free, and quality-adjusted survival did not differ statistically between the groups, there was a trend toward improved long-term survival at five years with the extended transthoracic approach.	Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Psychol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Erasmus Univ, Hosp Rotterdam, Dept Surg, Rotterdam, Netherlands; Erasmus Univ, Hosp Rotterdam, Dept Pathol, Rotterdam, Netherlands; RADIAN, Nijmegen, Netherlands; Med Technol Assessment, Nijmegen, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus University Rotterdam	van Lanschot, JJB (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Surg, Suite G4-112,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Stalmeier, P.F.M./L-4666-2015; Hulscher, Jan/AAD-3026-2021; Wijnhoven, Bas/AAF-4838-2020	Hulscher, Jan/0000-0003-4491-486X; de Boer, Angela/0000-0003-1942-6848				*AM SOC AN, 2002, ASA PHYS STAT CLASS; [Anonymous], 1997, J CLIN PATHOL; BUNT AMG, 1995, J CLIN ONCOL, V13, P19, DOI 10.1200/JCO.1995.13.1.19; Chu KM, 1997, AM J SURG, V174, P320, DOI 10.1016/S0002-9610(97)00105-0; Fumagalli U, 1996, DIS ESOPHAGUS, V9, P30; Gold MR, 1996, COST EFFECTIVENESS H; GOLDMINC M, 1993, BRIT J SURG, V80, P367, DOI 10.1002/bjs.1800800335; Hulscher JBF, 2000, EUR J SURG, V166, P862, DOI 10.1080/110241500447245; Hulscher JBF, 2001, ANN THORAC SURG, V72, P306, DOI 10.1016/S0003-4975(00)02570-4; Hulscher JBF, 2001, BRIT J SURG, V88, P715, DOI 10.1046/j.1365-2168.2001.01746.x; Jacobi CA, 1997, EUR J CARDIO-THORAC, V11, P32, DOI 10.1016/S1010-7940(96)01106-2; Jansen SJT, 2000, MED DECIS MAKING, V20, P62, DOI 10.1177/0272989X0002000108; MULLER JM, 1990, BRIT J SURG, V77, P845, DOI 10.1002/bjs.1800770804; OOSTENBRINK JB, 2000, HANDLEIDING KOSTENON; Steup WH, 1996, J THORAC CARDIOV SUR, V111, P85, DOI 10.1016/S0022-5223(96)70404-X; Wijnhoven BPL, 1999, BRIT J SURG, V86, P529, DOI 10.1046/j.1365-2168.1999.01082.x	16	1156	1227	2	25	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	2002	347	21					1662	1669		10.1056/NEJMoa022343	http://dx.doi.org/10.1056/NEJMoa022343			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	617BL	12444180	Green Published			2022-12-28	WOS:000179339900004
J	Dong, F; Miller, RE				Dong, F; Miller, RE			Vibrational transition moment angles in isolated biomolecules: A structural tool	SCIENCE			English	Article							DOUBLE-RESONANCE SPECTROSCOPY; AB-INITIO; GAS-PHASE; ELECTRONIC-SPECTRA; MATRIX-ISOLATION; BASE-PAIRS; IR; DYNAMICS; CYTOSINE; TAUTOMERS	Infrared spectroscopy is used extensively in the study of isolated biomolecules, but it becomes less useful as it is applied to systems of increasing complexity. Even if the individual vibrational bands can be resolved spectroscopically, their assignment becomes problematic when they are more closely spaced than can be determined using ab initio methods. We describe a method that helps to alleviate this difficulty by measuring the direction of the vibrational transition moment for each vibrational band. The molecules of interest ( adenine and cytosine) are cooled to 0.37 kelvin in liquid helium nanodroplets and oriented in a large dc electric field. A polarized infrared laser is then used to determine the directions of the infrared transition moments relative to the permanent dipole moment. Comparisons with ab initio calculations provide detailed structural information, including experimental evidence for nonplanarity of adenine and three tautomers of cytosine.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Dong, F (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.							Borst DR, 2002, J PHYS CHEM A, V106, P4022, DOI 10.1021/jp0140769; Callegari C, 2001, J CHEM PHYS, V115, P10090, DOI 10.1063/1.1418746; Civcir PU, 2000, J MOL STRUC-THEOCHEM, V532, P157, DOI 10.1016/S0166-1280(00)00556-X; Dian BC, 2002, SCIENCE, V296, P2369, DOI 10.1126/science.1071563; Dkhissi A, 2000, J PHYS CHEM A, V104, P9785, DOI 10.1021/jp0013053; Frisch M. J., 1998, GAUSSIAN 98; HARTMANN M, 1995, PHYS REV LETT, V75, P1566, DOI 10.1103/PhysRevLett.75.1566; Hobza P, 1999, CHEM REV, V99, P3247, DOI 10.1021/cr9800255; Holmen A, 1997, J PHYS CHEM A, V101, P4361, DOI 10.1021/jp970381b; Kawahara S, 2002, J PHYS CHEM A, V106, P3207, DOI 10.1021/jp0139538; Kong W, 2001, INT J MOD PHYS B, V15, P3471, DOI 10.1142/S0217979201007816; KWIATKOWSKI JS, 1988, J AM CHEM SOC, V110, P2353, DOI 10.1021/ja00216a001; Lehmann KK, 1998, SCIENCE, V279, P2065, DOI 10.1126/science.279.5359.2065; Marsh D, 2000, BIOPHYS J, V78, P2499, DOI 10.1016/S0006-3495(00)76795-6; MICHL J, 1995, SPECTROSCOPY POLARIZ, P150; MILLER RE, 1988, SCIENCE, V240, P447, DOI 10.1126/science.240.4851.447; Mishra SK, 2000, SPECTROCHIM ACTA A, V56, P1355, DOI 10.1016/S1386-1425(99)00262-0; Mons M, 2002, J PHYS CHEM A, V106, P5088, DOI 10.1021/jp0139742; Nauta K, 1999, SCIENCE, V283, P1895, DOI 10.1126/science.283.5409.1895; Nauta K, 2001, SCIENCE, V292, P481, DOI 10.1126/science.1058896; Nir E, 2002, PHYS CHEM CHEM PHYS, V4, P732, DOI 10.1039/b107429f; Plutzer C, 2001, PHYS CHEM CHEM PHYS, V3, P5466, DOI 10.1039/b107997b; Pratt DW, 2002, SCIENCE, V296, P2347, DOI 10.1126/science.1073589; Radziszewski JG, 1996, J AM CHEM SOC, V118, P10275, DOI 10.1021/ja961668+; Snoek LC, 2002, PHYS CHEM CHEM PHYS, V4, P2130, DOI 10.1039/b200059h; SZCZESNIAK M, 1988, J AM CHEM SOC, V110, P8319, DOI 10.1021/ja00233a006; Zwier TS, 2001, J PHYS CHEM A, V105, P8827, DOI 10.1021/jp011659+	27	134	136	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	2002	298	5596					1227	1230		10.1126/science.1076947	http://dx.doi.org/10.1126/science.1076947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424376				2022-12-28	WOS:000179080400048
J	Vanderah, TA				Vanderah, TA			Talking ceramics	SCIENCE			English	Editorial Material							DIELECTRIC-PROPERTIES; MICROWAVE DIELECTRICS; FREQUENCY		Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA	Vanderah, TA (corresponding author), Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA.							Cava RJ, 2001, J MATER CHEM, V11, P54, DOI 10.1039/b003681l; Chappell WJ, 2001, IEEE MICROW WIREL CO, V11, P246, DOI 10.1109/7260.928927; CHRISTOFFERSEN R, 1994, J AM CERAM SOC, V77, P1441, DOI 10.1111/j.1151-2916.1994.tb09741.x; Cockayne E, 2000, PHYS REV B, V62, P3735, DOI 10.1103/PhysRevB.62.3735; Davies P.K., 1995, CERAMIC T, V53, P137; Davies PK, 1997, J AM CERAM SOC, V80, P1727, DOI 10.1111/j.1151-2916.1997.tb03046.x; Kamba S, 2001, J APPL PHYS, V89, P3900, DOI 10.1063/1.1351873; Levin I, 2001, J SOLID STATE CHEM, V156, P122, DOI 10.1006/jssc.2000.8971; NEGAS T, 1993, AM CERAM SOC BULL, V72, P80; NEGAS T, 1991, NIST SPECIAL PUBLICA, V804, P21; NEGAS T, COMMUNICATION; OBRYAN HM, 1974, J AM CERAM SOC, V57, P450, DOI 10.1111/j.1151-2916.1974.tb11380.x; Pendry J, 2001, PHYS WORLD, V14, P47; PENN S, 1999, HDB LOW HIGH DIELECT, V2, pCH10; REANEY IM, 1994, JPN J APPL PHYS 1, V33, P3984, DOI 10.1143/JJAP.33.3984; Reaney IM, 2001, PHILOS MAG A, V81, P501, DOI 10.1080/01418610108214318; Richtmyer RD, 1939, J APPL PHYS, V10, P391, DOI 10.1063/1.1707320; SNYDER WR, 1986, NBS SPEC PUB, V555; ZELEZNY V, IN PRESS PHYS REV B; ZURMUHLEN R, 1995, J APPL PHYS, V77, P5351, DOI 10.1063/1.359290	20	274	283	1	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1182	1184		10.1126/science.1078489	http://dx.doi.org/10.1126/science.1078489			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12424358				2022-12-28	WOS:000179080400027
J	de Caen, A				de Caen, A			Management of profound hypothermia in children without the use of extracorporeal life support therapy	LANCET			English	Article								Profound hypothermia is managed more and more with extracorporeal life support technology, especially when a patient's circulation is compromised. Many centres do not have rapid access to this service, however, and are still dependent on active internal rewarming techniques-eg, peritoneal and pleural lavage. Such interventions are invasive, and associated with inherent risk. Here, we report our successful experience with an active external rewarming technique in children with profound hypothermia (core temperature <20&DEG;C).	Stollery Childrens Hosp, Div Pediat Intens Care, Edmonton, AB, Canada	Stollery Children's Hospital	de Caen, A (corresponding author), 3A3-06 Walter C Mackenzie Ctr, Edmonton, AB T6G 2B7, Canada.							ANDERSON S, 1970, BRIT J ANAESTH, V42, P653, DOI 10.1093/bja/42.7.653; CURRIE AE, 1994, J ROY SOC MED, V87, P293; DANZL DF, 1994, NEW ENGL J MED, V331, P1756, DOI 10.1056/NEJM199412293312607; MAIR P, 1995, LANCET, V345, P1048; THOMPSON DA, 1994, ANN EMERG MED, V23, P1390, DOI 10.1016/S0196-0644(94)70369-8	5	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 2	2002	360	9343					1394	1395		10.1016/S0140-6736(02)11392-4	http://dx.doi.org/10.1016/S0140-6736(02)11392-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612ND	12423988				2022-12-28	WOS:000179081600015
